<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000833A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221220" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000833</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17474631</doc-number><date>20210914</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>4188</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>25</main-group><subgroup>24</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>12</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>4188</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>25</main-group><subgroup>24</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>205</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>12</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>16807385</doc-number><date>20200303</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>17474631</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>15725500</doc-number><date>20171005</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>10617676</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>16807385</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>62404798</doc-number><date>20161006</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>JANSSEN PHARMACEUTICA NV</orgname><address><city>Beerse</city><country>BE</country></address></addressbook><residence><country>BE</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Chrovian</last-name><first-name>Christa C.</first-name><address><city>La Jolla</city><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Letavic</last-name><first-name>Michael A.</first-name><address><city>San Diego</city><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Rech</last-name><first-name>Jason C.</first-name><address><city>Ann Arbor</city><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Rudolph</last-name><first-name>Dale A.</first-name><address><city>San Diego</city><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Soyode-Johnson</last-name><first-name>Akinola</first-name><address><city>San Diego</city><country>US</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>Stenne</last-name><first-name>Brice M.</first-name><address><city>La Jolla</city><country>US</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>Wall</last-name><first-name>Jessica L.</first-name><address><city>San Diego</city><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>JANSSEN PHARMACEUTICA NV</orgname><role>03</role><address><city>BEERSE</city><country>BE</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.</p></abstract><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">FIELD OF THE INVENTION</heading><p id="p-0002" num="0001">The present invention is related to compounds having NR2B modulating properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with NR2B receptor activity in animals, in particular humans.</p><heading id="h-0002" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0003" num="0002">Glutamate is one of the major excitatory neurotransmitters that is widely spread in the brain. First indication of its role as an excitatory messenger was in the 1950's when it was observed that intravenous administration of glutamate induces convulsions. However, the detection of the whole glutamatergic neurotransmitter system with its various receptors did not take place before the 1970's and 1980's when numerous antagonists were developed or, as in the case of PCP and ketamine, were identified as antagonists. Finally, in the 1990's molecular biology provided the tools for the classification of the glutamatergic receptors.</p><p id="p-0004" num="0003">N-methyl-D-aspartate (NMDA) receptors are a subtype of ionotropic glutamate receptors that mediate excitatory synaptic transmission in the brain. NMDA receptors are ubiquitously distributed thoroughout the brain and play a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. NMDA receptors are distinct from other major subtypes of ionotropic glutamate receptors (AMPA and kainate receptors) in that they are blocked by Mg<sup>2+</sup> at resting membrane potentials, are highly Ca<sup>2+</sup> permeable, and require co-activation by two distinct neurotransmitters: glutamate and glycine (or D-serine) (Traynelis S F et al., <i>Pharmacol Rev. </i>2010; 62(3):405-96). The influx of Ca<sup>2+</sup> through NMDA receptors triggers signaling cascades and regulates gene expression that is critical for different forms of synaptic plasticity including both long-term potentiation of synapse efficacy (LTP) (Berberich S et al., <i>Neuropharmacology </i>2007; 52(1):77-86) and long-term depression (LTD) (Massey, P V et al., <i>J Neurosci. </i>2004 Sep. 8; 24(36):7821-8).</p><p id="p-0005" num="0004">The vast majority of the mammalian NMDA receptors form a heterotetramer made of two obligatory GluN1 units and two variable GluN2 receptor subunits encoded by the GRIN1 gene and one of four GRIN2 genes, respectively. One or both GluN2 subunits can be potentially replaced by a GluN3A or a GluN3B subunit. The GRIN1 gene product has 8 splice variants while there are 4 different GRIN2 genes (GRIN2A-D) encoding four distinct GluN2 subunits. The glycine binding site is present on the GluN1 subunit and the glutamate binding site is present on the GluN2 subunit.</p><p id="p-0006" num="0005">The GluNR2 subunits play a dominant role in determining the functional and pharmacological properties of the NMDA receptor assembly and exhibit distinct distribution in different areas of the brain. For instance, GluN2B subunits are expressed primarily in the forebrain in the adult mammalian brain (Paoletti P et al., <i>Nat Rev Neurosci. </i>2013; 14(6):383-400; Watanabe M et al., <i>J Comp Neurol. </i>1993; 338(3):377-90) and are implicated in learning, memory processing, mood, attention, emotion and pain perception (Cull-Candy S et al., <i>Curr Opin Neurobiol. </i>2001; 11(3):327-35).</p><p id="p-0007" num="0006">Compounds that modulate GluN2B-containing NMDA receptor function can be useful in treatment of many neurological and psychiatric disorders including but not limited to bipolar disorder (Martucci L et al., <i>Schizophrenia Res, </i>2006; 84(2-3):214-21), major depressive disorder (Miller O H et al., <i>eLife. </i>2014; 3:e03581; Li N et al., <i>Biol Psychiatry. </i>2011; 69(8):754-61), treatment-resistant depression (Preskorn S H et al. <i>J Clin Psychopharmacol. </i>2008; 28(6):631-7) and ther mood disorders (including schizophrenia (Grimwood S et al., <i>Neuroreport. </i>1999; 10(3):461-5; Weickert C S et al. <i>Molecular Psychiatry </i>(2013) 18, 1185-1192), ante- and postpartum depression, seasonal affective disorder and the like), Alzheimer's disease (Hanson J E et al., <i>Neurobiol Dis. </i>2015; 74:254-62; Li S et al., <i>J Neurosci. </i>2011; 31(18):6627-38) and other dementias (Orgogozo J M et al. <i>Stroke </i>2002, 33: 1834-1839), Parkinson's disease (Duty S, <i>CNS Drugs. </i>2012; 26(12):1017-32; Steece-Collier K et al., <i>Exp Neurol. </i>2000; 163(1):239-43; Leaver K R et al. <i>Clin Exp Pharmacol Physiol. </i>2008; 35(11):1388-94), Huntington's chorea (Tang T S et al., <i>Proc Natl Acad Sci USA. </i>2005; 102(7):2602-7; Li L et al., <i>J Neurophysiol </i>2004; 92(5):2738-46), multiple sclerosis (Grasselli Get al., <i>Br J Pharmacol. </i>2013; 168(2):502-17; Farjam M et al., <i>Iran J Pharm Res. </i>2014; 13(2):695-705), cognitive impairment (Wang D et al. 2014, <i>Expert Opin Ther Targets Expert Opin Ther Targets. </i>2014; 18(10):1121-30), head injury (Bullock M R et al., <i>Ann N Y Acad Sci. </i>1999; 890:51-8), spinal cord injury, stroke (Yang Y et al., <i>J Neurosurg. </i>2003; 98(2):397-403), epilepsy (Naspolini A P et al., <i>Epilepsy Res. </i>2012 June; 100(1-2):12-9), movement disorders (e.g. dyskinesias) (Morissette M et al., <i>Mov Disord. </i>2006; 21(1):9-17), various neurodegenerative diseases (e.g. amyotrophic lateral sclerosis (Fuller P I et al., <i>Neurosci Lett. </i>2006; 399(1-2):157-61) or neurodegeneration associated with bacterial or chronic infections), glaucoma (Naskar R et al. <i>Semin Ophthalmol. </i>1999 September; 14(3):152-8), pain (e.g. chronic, cancer, post-operative and neuropathic pain (Wu L J and Zhuo M, <i>Neurotherapeutics. </i>2009; 6(4):693-702), diabetic neuropathy, migraine (Peeters M et al., <i>J Pharmacol Exp Ther. </i>2007; 321(2):564-72), cerebral ischemia (Yuan H et al., <i>Neuron. </i>2015; 85(6):1305-18), encephalitis (Dalmau J. et al., <i>Lancet Neurol. </i>2008; 7(12):1091-8.), autism and autism spectrum disorders (Won H. et al., <i>Nature. </i>2012; 486(7402):261-5), memory and learning disorders (Tang, Y. P. et al., <i>Nature. </i>1999; 401(6748):63-9), obsessive compulsive disorder (Arnold P D et al., <i>Psychiatry Res. </i>2009; 172(2):136-9.), attention deficit hyperactivity disorder (ADHD) (Dorval K M et al., <i>Genes Brain Behay. </i>2007; 6(5):444-52), PTSD (Haller J et al. <i>Behav Pharmacol. </i>2011; 22(2):113-21; Leaderbrand K et al. <i>Neurobiol Learn Mem. </i>2014; 113:35-40), tinnitus (Guitton M J, and Dudai Y, <i>Neural Plast. </i>2007; 80904; Hu S S et al. 2016; 273(2): 325-332), sleep disorders (like narcolepsy or excessive daytime sleepiness, patent WO 2009058261 A1), vertigo and nystagmus (Straube A. et al., <i>Curr Opin Neurol. </i>2005; 18(1):11-4; Starck M et al. <i>J Neurol. </i>1997 January; 244(1):9-16), anxiety autoimmunological disorders like neuropsychiatric systemic lupus erythematosus (Kowal C et al. <i>Proc. Natl. Acad. Sci. U.S.A. </i>2006; 103, 19854-19859) and addictive illnesses (e.g. alcohol addiction, drug addiction) (Nagy J, 2004, <i>Curr Drug Targets CNS Neurol Disord. </i>2004; 3(3):169-79.; Shen H et al., <i>Proc Natl Acad Sci USA. </i>2011; 108(48):19407-12).</p><p id="p-0008" num="0007">In view of the clinical importance of NR2B, the identification of compounds that modulate NR2B receptor function represents an attractive avenue into the development of new therapeutic agents. Such compounds are provided herein.</p><heading id="h-0003" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0009" num="0008">The invention is directed to the general and preferred embodiments defined, respectively, by the independent and dependent claims appended hereto, which are incorporated by reference herein. One aspect of this invention concerns compounds of Formula (I):</p><p id="p-0010" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="26.50mm" wi="55.29mm" file="US20230000833A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0011" num="0000">wherein<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0009">R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>; R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>alkyl, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; pyridinyl substituted with F, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>haloalkyl; thiazolyl; thiazolyl substituted with C<sub>1-6</sub>alkyl or C<sub>1-6</sub>haloalkyl; thienyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>3</sub>, and cyclopropyl;</li>        <li id="ul0002-0002" num="0010">R<sup>3 </sup>is H;</li>        <li id="ul0002-0003" num="0011">R<sup>4 </sup>is selected from the group consisting of:        <ul id="ul0003" list-style="none">            <li id="ul0003-0001" num="0012">(a)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0012" num="0000"><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="21.17mm" wi="20.83mm" file="US20230000833A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0013" num="0000">wherein ring A is a 4-6 membered heterocycle optionally containing an additional oxygen heteroatom selected from the group consisting of: azetidinyl; azetidinyl substituted with one or two members independently selected from the group consisting of: F, OH, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>haloalkyl, CH<sub>2</sub>OCH<sub>3</sub>, CN, and OCH<sub>3</sub>; pyrrolidinyl; pyrrolidinyl substituted two F members; morpholinyl; piperidinyl; piperazinyl substituted with C<sub>1-6</sub>alkyl; and (2,6-diazaspiro[3.3]heptan-6-yl);<ul id="ul0004" list-style="none">    <li id="ul0004-0001" num="0000">    <ul id="ul0005" list-style="none">        <li id="ul0005-0001" num="0000">        <ul id="ul0006" list-style="none">            <li id="ul0006-0001" num="0013">(b)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0014" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="20.66mm" wi="25.40mm" file="US20230000833A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0015" num="0000">wherein R<sup>4b </sup>is selected from the group consisting of: H; C<sub>1-6</sub>alkyl; CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>; C<sub>3-6</sub>cycloalkyl; C<sub>3-6</sub>cycloalkyl substituted substituted with two or three members independently selected from the group consisting of F or CH<sub>3</sub>; oxetanyl; oxetanyl substituted with CH<sub>3</sub>; and pyridinyl;<ul id="ul0007" list-style="none">    <li id="ul0007-0001" num="0000">    <ul id="ul0008" list-style="none">        <li id="ul0008-0001" num="0000">        <ul id="ul0009" list-style="none">            <li id="ul0009-0001" num="0014">(c)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0016" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="10.75mm" wi="16.17mm" file="US20230000833A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0017" num="0000">wherein R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;<ul id="ul0010" list-style="none">    <li id="ul0010-0001" num="0000">    <ul id="ul0011" list-style="none">        <li id="ul0011-0001" num="0000">        <ul id="ul0012" list-style="none">            <li id="ul0012-0001" num="0015">(d)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0018" num="0000"><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="15.66mm" wi="19.22mm" file="US20230000833A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0019" num="0000">wherein R<sup>4d </sup>is selected from the group consisting of: OH, C<sub>1-6</sub>alkyl, O&#x2014;C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, thienyl, and thiazolyl; and<ul id="ul0013" list-style="none">    <li id="ul0013-0001" num="0000">    <ul id="ul0014" list-style="none">        <li id="ul0014-0001" num="0000">        <ul id="ul0015" list-style="none">            <li id="ul0015-0001" num="0016">(e) C<sub>2-6</sub>alkyl substituted with one or two members independently selected from OH, OC<sub>1-6</sub>alkyl, or cyclopropyl; CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-6</sub>alkyl); CH<sub>2</sub>CH<sub>2</sub>NH(CH<sub>2</sub>CH<sub>2</sub>OH); CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>3-6</sub>cycloalkyl); and difluoro(3-pyridyl)methyl; and</li>        </ul>        </li>        <li id="ul0014-0002" num="0017">R<sup>1a </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>;<br/>and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides, or solvates of compounds of Formula (I).</li>    </ul>    </li></ul></p><p id="p-0020" num="0018">Further embodiments are provided by pharmaceutically acceptable salts of compounds of Formulas (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I).</p><p id="p-0021" num="0019">In certain embodiments, the compounds of Formula (I) are compounds selected from those species described or exemplified in the detailed description below.</p><p id="p-0022" num="0020">In a further aspect, the invention relates to enantiomers and diastereomers of the compounds of Formula (I), as well as the pharmaceutically acceptable salts.</p><p id="p-0023" num="0021">In a further aspect, the invention relates to pharmaceutical compositions for treating a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of Formula (I).</p><p id="p-0024" num="0022">Pharmaceutical compositions according to the invention may further comprise one or more pharmaceutically acceptable excipients.</p><p id="p-0025" num="0023">In another aspect, the chemical embodiments of the present invention are useful as NR2B receptor modulators. Thus, the invention is directed to a method for modulating NR2B receptor activity, including when such receptor is in a subject, comprising exposing NR2B receptor to an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I).</p><p id="p-0026" num="0024">In another aspect, the invention is directed to a method of treating a subject suffering from, or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to the subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I). Additional embodiments of methods of treatment are set forth in the detailed description.</p><p id="p-0027" num="0025">In another aspect, the method of studying isotopically labeled compounds in metabolic studies (preferably with <sup>14</sup>C), reaction kinetic studies (with, for example <sup>2</sup>H or <sup>3</sup>H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. For example, an <sup>18</sup>F or <sup>11</sup>C labeled compound may be particularly preferred for PET or SPECT studies.</p><p id="p-0028" num="0026">Additional embodiments of this invention include methods of making compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of Formula (I).</p><p id="p-0029" num="0027">An object of the present invention is to overcome or ameliorate at least one of the disadvantages of the conventional methodologies and/or prior art, or to provide a useful alternative thereto.</p><p id="p-0030" num="0028">Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0004" level="1">DETAILED DESCRIPTION OF INVENTION</heading><p id="p-0031" num="0029">In one aspect, provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides, or solvates thereof,</p><p id="p-0032" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="26.50mm" wi="55.29mm" file="US20230000833A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0033" num="0000">wherein<ul id="ul0016" list-style="none">    <li id="ul0016-0001" num="0000">    <ul id="ul0017" list-style="none">        <li id="ul0017-0001" num="0030">R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</li>        <li id="ul0017-0002" num="0031">R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; pyridinyl substituted with F, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>haloalkyl; thiazolyl; thiazolyl substituted with C<sub>1-6</sub>alkyl or C<sub>1-6</sub>haloalkyl; thienyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>3</sub>, and cyclopropyl;</li>        <li id="ul0017-0003" num="0032">R<sup>3 </sup>is H;</li>        <li id="ul0017-0004" num="0033">R<sup>4 </sup>is selected from the group consisting of:        <ul id="ul0018" list-style="none">            <li id="ul0018-0001" num="0034">(a)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0034" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="21.17mm" wi="20.83mm" file="US20230000833A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0035" num="0000">wherein ring A is a 4-6 membered heterocycle optionally containing an additional oxygen heteroatom selected from the group consisting of: azetidinyl; azetidinyl substituted with one or two members independently selected from the group consisting of: F, OH, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>haloalkyl, CH<sub>2</sub>OCH<sub>3</sub>, CN, and OCH<sub>3</sub>; pyrrolidinyl; pyrrolidinyl substituted two F members; morpholinyl; piperidinyl; piperazinyl substituted with C<sub>1-6</sub>alkyl; and (2,6-diazaspiro[3.3]heptan-6-yl);<ul id="ul0019" list-style="none">    <li id="ul0019-0001" num="0000">    <ul id="ul0020" list-style="none">        <li id="ul0020-0001" num="0000">        <ul id="ul0021" list-style="none">            <li id="ul0021-0001" num="0035">(b)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0036" num="0000"><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="20.66mm" wi="25.40mm" file="US20230000833A1-20230105-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0037" num="0000">wherein R<sup>4b </sup>is selected from the group consisting of: H; C<sub>1-6</sub>alkyl; CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>; C<sub>3-6</sub>cycloalkyl; C<sub>3-6</sub>cycloalkyl substituted substituted with two or three members independently selected from the group consisting of F or CH<sub>3</sub>; oxetanyl; oxetanyl substituted with CH<sub>3</sub>; and pyridinyl;<ul id="ul0022" list-style="none">    <li id="ul0022-0001" num="0000">    <ul id="ul0023" list-style="none">        <li id="ul0023-0001" num="0000">        <ul id="ul0024" list-style="none">            <li id="ul0024-0001" num="0036">(c)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0038" num="0000"><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="10.75mm" wi="16.17mm" file="US20230000833A1-20230105-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0039" num="0000">wherein R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;<ul id="ul0025" list-style="none">    <li id="ul0025-0001" num="0000">    <ul id="ul0026" list-style="none">        <li id="ul0026-0001" num="0000">        <ul id="ul0027" list-style="none">            <li id="ul0027-0001" num="0037">(d)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0040" num="0000"><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="15.66mm" wi="19.22mm" file="US20230000833A1-20230105-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0041" num="0000">wherein R<sup>4d </sup>is selected from the group consisting of: OH, C<sub>1-6</sub>alkyl, O&#x2014;C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, thienyl, and thiazolyl; and<ul id="ul0028" list-style="none">    <li id="ul0028-0001" num="0000">    <ul id="ul0029" list-style="none">        <li id="ul0029-0001" num="0000">        <ul id="ul0030" list-style="none">            <li id="ul0030-0001" num="0038">(e) C<sub>2-6</sub>alkyl substituted with one or two members independently selected from OH, OC<sub>1-6</sub>alkyl, or cyclopropyl; CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-6</sub>alkyl); CH<sub>2</sub>CH<sub>2</sub>NH(CH<sub>2</sub>CH<sub>2</sub>OH); CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>3-6</sub>cycloalkyl); and difluoro(3-pyridyl)methyl and</li>        </ul>        </li>        <li id="ul0029-0002" num="0039">R<sup>1a </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>.</li>    </ul>    </li></ul></p><p id="p-0042" num="0040">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>1 </sup>is H.</p><p id="p-0043" num="0041">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>1 </sup>is CH<sub>3</sub>.</p><p id="p-0044" num="0042">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>1a </sup>is H.</p><p id="p-0045" num="0043">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>2 </sup>is phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: Cl, F, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>alkyl, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; or pyridinyl substituted with CF<sub>3</sub>.</p><p id="p-0046" num="0044">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>2 </sup>is thiazolyl substituted with C<sub>1-6</sub>alkyl or CF<sub>3</sub>; thienyl; or thienyl substituted with one or two members each independently selected from the group consisting of: CI, F, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCD<sub>3</sub>, and cyclopropyl.</p><p id="p-0047" num="0045">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>1 </sup>is H or CH<sub>3</sub>, R<sup>2 </sup>is phenyl, wherein the phenyl is optionally substituted with one, two, or three members independently selected from: halo, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>haloalkyl; or thienyl, wherein the thienyl is optionally substituted with one or two members independently selected from: halo, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>haloalkyl; R<sup>3 </sup>is H, and R<sup>4 </sup>is</p><p id="p-0048" num="0000"><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="71.97mm" wi="56.22mm" file="US20230000833A1-20230105-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0049" num="0046">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>2 </sup>is phenyl; o-tolyl; m-tolyl; p-tolyl; 4-tert-butylphenyl; 3-(trifluoromethyl)phenyl; 4-fluorophenyl; 3-fluorophenyl; 3-cyanophenyl; 3-chlorophenyl; 4-chlorophenyl; 3-(difluoromethyl)phenyl; 3-methoxyphenyl; 3-(difluoromethoxy)phenyl; 4-methoxyphenyl; 3-(trifluoromethoxy)phenyl; 2-ethoxyphenyl; 3-ethoxyphenyl; 3-cyclopropylphenyl; 3-(dimethylamino)phenyl; 2,3-dichlorophenyl; 2,3-difluorophenyl; 2,3-dimethylphenyl; 2-fluoro-3-(trifluoromethyl)phenyl; 2,4-dimethoxyphenyl; 2,3-dimethoxyphenyl; 2,4-difluorophenyl; 3,4-difluorophenyl; 3,4-dichlorophenyl; 3-(difluoromethyl)-4-fluoro-phenyl; 5-(difluoromethyl)-2-fluorophenyl; 2,6-dimethylphenyl; 3,5-dimethylphenyl; 3,5-difluorophenyl; 3-fluoro-5-(trifluoromethyl)phenyl; 2-methyl-5-(trifluoromethyl)phenyl; 2-methyl-3-(trifluoromethyl)phenyl; 4-chloro-3-methyl-phenyl; 4-fluoro-3-(trifluoromethyl)phenyl; 4-chloro-3-(trifluoromethyl)phenyl; 2-ethoxy-5-fluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 2-chloro-4-methoxy-phenyl; 4-fluoro-2-methyl-phenyl; 4-fluoro-2-methoxy-phenyl; 2-fluoro-6-methoxy-phenyl; 3-fluoro-4-methoxy-phenyl; 3-fluoro-5-methyl-phenyl; 2-fluoro-3-methyl-phenyl; 4-fluoro-3-methyl-phenyl; 4-methoxy-3-methyl-phenyl; 4-fluoro-2,3-dimethyl-phenyl; 2,4-difluoro-3-methyl-phenyl; 2,3,4-trifluorophenyl; 3,4,5-trifluorophenyl; 3,4-difluoro-5-(trifluoromethyl)phenyl; 3-pyridyl; 2-(trifluoromethyl)-4-pyridyl; 2-thienyl; 5-methyl-2-thienyl; 5-ethyl-2-thienyl; 4-methyl-2-thienyl; 5-(trideuteriomethoxymethyl; 5-(hydroxymethyl)-2-thienyl; 5-fluoro-2-thienyl; 5-chloro-2-thienyl; 5-cyclopropyl-2-thienyl; 5-chloro-4-methyl-2-thienyl; 5-(difluoromethyl)-2-thienyl; 5-(difluoromethyl)-3-thienyl; 5-(trifluoromethyl)-2-thienyl; 5-(trifluoromethyl)-3-thienyl; 2-(trifluoromethyl)-3-thienyl; 4-(difluoromethyl)-2-thienyl; 5-(1,1,2,2,2-pentafluoroethyl)-2-thienyl; 4-methylthiazol-2-yl; 2-methylthiazol-5-yl; 2-(trifluoromethyl)thiazol-5-yl; or 2-(trifluoromethyl)thiazol-4-yl.</p><p id="p-0050" num="0047">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>3 </sup>is H.</p><p id="p-0051" num="0048">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>3 </sup>is D or T.</p><p id="p-0052" num="0049">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>4 </sup>is</p><p id="p-0053" num="0000"><chemistry id="CHEM-US-00012" num="00012"><img id="EMI-C00012" he="21.17mm" wi="21.84mm" file="US20230000833A1-20230105-C00012.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0054" num="0000">wherein ring A is</p><p id="p-0055" num="0000"><chemistry id="CHEM-US-00013" num="00013"><img id="EMI-C00013" he="101.01mm" wi="75.61mm" file="US20230000833A1-20230105-C00013.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0056" num="0050">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>4 </sup>is</p><p id="p-0057" num="0000"><chemistry id="CHEM-US-00014" num="00014"><img id="EMI-C00014" he="185.25mm" wi="75.18mm" file="US20230000833A1-20230105-C00014.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0058" num="0051">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>4 </sup>is</p><p id="p-0059" num="0000"><chemistry id="CHEM-US-00015" num="00015"><img id="EMI-C00015" he="250.19mm" wi="71.63mm" file="US20230000833A1-20230105-C00015.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0060" num="0052">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>4 </sup>is</p><p id="p-0061" num="0000"><chemistry id="CHEM-US-00016" num="00016"><img id="EMI-C00016" he="152.48mm" wi="75.52mm" file="US20230000833A1-20230105-C00016.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0062" num="0053">An additional embodiment of the invention is a compound of Formula (I) wherein R<sup>4 </sup>is</p><p id="p-0063" num="0000"><chemistry id="CHEM-US-00017" num="00017"><img id="EMI-C00017" he="156.72mm" wi="63.58mm" file="US20230000833A1-20230105-C00017.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0064" num="0000">wherein</p><p id="p-0065" num="0054">R<sup>a </sup>is independently selected from: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;</p><p id="p-0066" num="0055">R<sup>b </sup>is independently selected from: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>;</p><p id="p-0067" num="0056">R<sup>c </sup>is F or CH<sub>3</sub>;</p><p id="p-0068" num="0057">R<sup>d </sup>is OCH<sub>3</sub>;</p><p id="p-0069" num="0058">m is 0 or 1; and</p><p id="p-0070" num="0059">n is 0, 1, or 2.</p><p id="p-0071" num="0060">An additional embodiment of the invention is a compound of Formula (I) wherein<ul id="ul0031" list-style="none">    <li id="ul0031-0001" num="0000">    <ul id="ul0032" list-style="none">        <li id="ul0032-0001" num="0061">R<sup>1 </sup>is H or CH<sub>3</sub>;</li>        <li id="ul0032-0002" num="0062">R<sup>2 </sup>is phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, and OC<sub>1-6</sub>alkyl;</li>        <li id="ul0032-0003" num="0063">R<sup>3 </sup>is H; and</li>        <li id="ul0032-0004" num="0064">R<sup>4 </sup>is</li>    </ul>    </li></ul></p><p id="p-0072" num="0000"><chemistry id="CHEM-US-00018" num="00018"><img id="EMI-C00018" he="92.20mm" wi="75.69mm" file="US20230000833A1-20230105-C00018.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0073" num="0065">An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA):</p><p id="p-0074" num="0000"><chemistry id="CHEM-US-00019" num="00019"><img id="EMI-C00019" he="34.97mm" wi="58.93mm" file="US20230000833A1-20230105-C00019.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0075" num="0000">wherein R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;<ul id="ul0033" list-style="none">    <li id="ul0033-0001" num="0000">    <ul id="ul0034" list-style="none">        <li id="ul0034-0001" num="0066">R<sup>2 </sup>is phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, OC<sub>1-6</sub>alkyl; thiazolyl substituted with C<sub>1-6</sub>alkyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCD<sub>3</sub>, and cyclopropyl;</li>    </ul>    </li></ul></p><heading id="h-0005" level="2">R<sup>3 </sup>is H or T; and</heading><p id="p-0076" num="0067">ring A is</p><p id="p-0077" num="0000"><chemistry id="CHEM-US-00020" num="00020"><img id="EMI-C00020" he="90.93mm" wi="74.42mm" file="US20230000833A1-20230105-C00020.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0078" num="0000">and pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IA).</p><p id="p-0079" num="0068">An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA):</p><p id="p-0080" num="0000"><chemistry id="CHEM-US-00021" num="00021"><img id="EMI-C00021" he="34.97mm" wi="58.93mm" file="US20230000833A1-20230105-C00021.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0081" num="0000">wherein<ul id="ul0035" list-style="none">    <li id="ul0035-0001" num="0000">    <ul id="ul0036" list-style="none">        <li id="ul0036-0001" num="0069">R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</li>        <li id="ul0036-0002" num="0070">R<sup>2 </sup>is 3-(trifluoromethyl)phenyl, 4-fluoro-3-methyl-phenyl, 2,4-difluoro-3-methyl-phenyl, 5-(trifluoromethyl)-2-thienyl, 5-(difluoromethyl)-2-thienyl, or 5-chloro-4-methyl-2-thienyl;</li>        <li id="ul0036-0003" num="0071">R<sup>3 </sup>is H; and<br/>ring A is</li>    </ul>    </li></ul></p><p id="p-0082" num="0000"><chemistry id="CHEM-US-00022" num="00022"><img id="EMI-C00022" he="20.66mm" wi="66.46mm" file="US20230000833A1-20230105-C00022.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0083" num="0072">An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA):</p><p id="p-0084" num="0000"><chemistry id="CHEM-US-00023" num="00023"><img id="EMI-C00023" he="34.97mm" wi="58.93mm" file="US20230000833A1-20230105-C00023.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><ul id="ul0037" list-style="none">    <li id="ul0037-0001" num="0073">wherein R<sup>2 </sup>is m-tolyl, 3-fluorophenyl, 3-chlorophenyl, 3-(trifluoromethyl)phenyl, 5-methyl-2-thienyl, 5-ethyl-2-thienyl, 5-(hydroxymethyl)-2-thienyl, 5-cyclopropyl-2-thienyl, 5-(trideuteriomethoxymethyl)-2-thienyl, 5-(trifluoromethyl)-2-thienyl, 5-(trifluoromethyl)-3-thienyl, 2-(trifluoromethyl)-3-thienyl, pentafluoroethyl)-2-thienyl, 5-(trifluoromethyl)thiophen-2-yl, 5-fluoro-2-thienyl, 5-chloro-4-methyl-2-thienyl, 5-(difluoromethyl)-2-thienyl, 4-(difluoromethyl)-2-thienyl, 5-(difluoromethyl)-3-thienyl, 4-methylthiazol-2-yl, 2-methylthiazol-5-yl, 4-methoxyphenyl, 4-fluoro-2-methyl-phenyl, 2-fluoro-3-methyl-phenyl, 4-fluoro-3-methyl-phenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 2,4-difluoro-3-methyl-phenyl, 3,4,5-trifluorophenyl, 2-(trifluoromethyl)thiazol-5-yl, 2-(trifluoromethyl)thiazol-4-yl, 2-methyl-5-(trifluoromethyl)phenyl, 2-methyl-3-(trifluoromethyl)phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, or 4-fluoro-3-(trifluoromethyl)phenyl.</li></ul></p><p id="p-0085" num="0074">An additional embodiment of the invention is a compound of Formula (I) having the Formula (IB):</p><p id="p-0086" num="0000"><chemistry id="CHEM-US-00024" num="00024"><img id="EMI-C00024" he="36.15mm" wi="59.10mm" file="US20230000833A1-20230105-C00024.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0087" num="0000">wherein R<sup>1 </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>;<ul id="ul0038" list-style="none">    <li id="ul0038-0001" num="0000">    <ul id="ul0039" list-style="none">        <li id="ul0039-0001" num="0075">R<sup>2 </sup>is selected from the group consisting of: phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl OC<sub>1-6</sub>alkyl; pyridinyl; thiazolyl substituted with C<sub>1-6</sub>alkyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, and cyclopropyl;</li>        <li id="ul0039-0002" num="0076">R<sup>3 </sup>is H; and</li>        <li id="ul0039-0003" num="0077">R<sup>4b </sup>is H, C<sub>1-6</sub>alkyl, 2-methoxyethyl, C<sub>3-6</sub>cycloalkyl, 3,3-difluorocyclobutyl, 3,3-difluoro-1-methyl-cyclobutyl, cyclopentyl, oxetan-3-yl, 3-methyloxetan-3-yl, or 2-pyridyl;<br/>and pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IB).</li>    </ul>    </li></ul></p><p id="p-0088" num="0078">An additional embodiment of the invention is a compound of Formula (I) having the Formula (IB):</p><p id="p-0089" num="0000"><chemistry id="CHEM-US-00025" num="00025"><img id="EMI-C00025" he="36.15mm" wi="59.10mm" file="US20230000833A1-20230105-C00025.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0090" num="0000">wherein<ul id="ul0040" list-style="none">    <li id="ul0040-0001" num="0000">    <ul id="ul0041" list-style="none">        <li id="ul0041-0001" num="0079">R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</li>        <li id="ul0041-0002" num="0080">R<sup>1b </sup>is CH<sub>3</sub>;</li>        <li id="ul0041-0003" num="0081">R<sup>2 </sup>is 3-(trifluoromethyl)phenyl, 4-fluoro-3-methyl-phenyl, 2,4-difluoro-3-methyl-phenyl, 5-(trifluoromethyl)-2-thienyl, 5-(difluoromethyl)-2-thienyl, or 5-chloro-4-methyl-2-thienyl;</li>        <li id="ul0041-0004" num="0082">R<sup>3 </sup>is H; and</li>        <li id="ul0041-0005" num="0083">R<sup>4b </sup>is CH<sub>3</sub>.</li>    </ul>    </li></ul></p><p id="p-0091" num="0084">An additional embodiment of the invention is a compound of Formula (I) having the Formula (IB):</p><p id="p-0092" num="0000"><chemistry id="CHEM-US-00026" num="00026"><img id="EMI-C00026" he="36.15mm" wi="59.10mm" file="US20230000833A1-20230105-C00026.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><ul id="ul0042" list-style="none">    <li id="ul0042-0001" num="0085">wherein R<sup>2 </sup>is 3-pyridyl, 5-methyl-2-thienyl, 4-methyl-2-thienyl, 5-cyclopropyl-2-thienyl, 5-ethyl-2-thienyl, 5-chloro-2-thienyl, 5-(hydroxymethyl)-2-thienyl, 5-(trifluoromethyl)-2-thienyl, 5-(trifluoromethyl)-3-thienyl, 2-(trifluoromethyl)-3-thienyl, 5-(difluoromethyl)-2-thienyl, 5-(difluoromethyl)-3-thienyl, 5-chloro-4-methyl-2-thienyl, 5-fluoro-2-thienyl, 5-fluoro-2-thienyl, 2-methylthiazol-5-yl, 3,5-dimethylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-fluoro-2-methyl-phenyl, 2-fluoro-3-methyl-phenyl, 4-fuoro-3-methyl-phenyl, 4-chlorophenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-methoxy-3-methyl-phenyl, 4-fluoro-2-methoxy-phenyl, 2-fluoro-6-methoxy-phenyl, 2,4-difluoro-3-methyl-phenyl, 3-(difluoromethyl)phenyl, 3-chloro-4-fluoro-phenyl, 2,4-dimethoxyphenyl, 2-ethoxy-5-fluoro-phenyl, 2-chloro-4-methoxy-phenyl, 3-(trifluoromethyl)phenyl, 2-(trifluoromethyl)thiazol-5-yl, 2-(trifluoromethyl)thiazol-4-yl, 2-fluoro-3-(trifluoromethyl)phenyl, or 3,4-difluoro-5-(trifluoromethyl)phenyl.</li></ul></p><p id="p-0093" num="0086">An additional embodiment of the invention is a compound of Formula (I) having the Formula (IC):</p><p id="p-0094" num="0000"><chemistry id="CHEM-US-00027" num="00027"><img id="EMI-C00027" he="24.64mm" wi="56.30mm" file="US20230000833A1-20230105-C00027.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0095" num="0000">wherein R<sup>1 </sup>is H or CH<sub>3</sub>;<ul id="ul0043" list-style="none">    <li id="ul0043-0001" num="0000">    <ul id="ul0044" list-style="none">        <li id="ul0044-0001" num="0087">R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>alkyl, OC<sub>1-6</sub>haloalkyl, and N(CH<sub>3</sub>)<sub>2</sub>; pyridinyl substituted with CF<sub>3</sub>; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>haloalkyl; and</li>        <li id="ul0044-0002" num="0088">R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;<br/>and pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IC).</li>    </ul>    </li></ul></p><p id="p-0096" num="0089">An additional embodiment of the invention is a compound of Formula (I) having the Formula (ID):</p><p id="p-0097" num="0000"><chemistry id="CHEM-US-00028" num="00028"><img id="EMI-C00028" he="29.55mm" wi="57.91mm" file="US20230000833A1-20230105-C00028.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0098" num="0000">wherein R<sup>1 </sup>is H or CH<sub>3</sub>;<ul id="ul0045" list-style="none">    <li id="ul0045-0001" num="0000">    <ul id="ul0046" list-style="none">        <li id="ul0046-0001" num="0090">R<sup>2 </sup>is m-tolyl, 3-(trifluoromethyl)phenyl, 4-chlorophenyl, 2,4-difluoro-3-methyl-phenyl, 3,4-difluorophenyl, 4-fuoro-3-methyl-phenyl, 3-cyclopropylphenyl, 3-fluoro-4-methoxy-phenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-methoxyphenyl, 2-ethoxy-5-fluoro-phenyl, 4-fluoro-2-methoxy-phenyl, or 3-chloro-4-fluoro-phenyl; and Rod is OH, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, 2-thienyl, or thiazol-2-yl; and pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (ID).</li>    </ul>    </li></ul></p><p id="p-0099" num="0091">A further embodiment of the current invention is a compound as shown below in Table 1.</p><p id="p-0100" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="21pt" align="center"/><colspec colname="2" colwidth="245pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry>Ex #</entry><entry>Compound Name</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="21pt" align="char" char="."/><colspec colname="2" colwidth="245pt" align="left"/><tbody valign="top"><row><entry>1</entry><entry>6-(4-Methoxyphenyl)-1-(2-morpholino-2-oxo-ethyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>2</entry><entry>6-(4-Fluoro-2-methyl-phenyl)-1-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>3</entry><entry>N-Ethyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>4</entry><entry>(S*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>5</entry><entry>(R*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>6</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>7</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>8</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(5-methylisoxazol-3-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>9</entry><entry>2-[6-(5-Chloro-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry></row><row><entry/><entry>dimethyl-acetamide;</entry></row><row><entry>10</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>11</entry><entry>1-[(5-Methylisoxazol-3-yl)methyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>12</entry><entry>6-(4-Fluorophenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>13</entry><entry>6-(4-Fluorophenyl)-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>14</entry><entry>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(4-methyl-2-</entry></row><row><entry/><entry>thienyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>15</entry><entry>6-(4-Fluorophenyl)-1-[(1-methylpyrazol-4-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>16</entry><entry>1-[(1,5-Dimethylpyrazol-3-yl)methyl]-6-(4-fluorophenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>17</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>18</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>19</entry><entry>1-[(5-Methylisoxazol-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>20</entry><entry>N-Cyclopropyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>21</entry><entry>1-[(3-Chlorophenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>22</entry><entry>1-[(2-Methoxy-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>23</entry><entry>1-(Pyrimidin-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>24</entry><entry>(R/S)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>25</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>26</entry><entry>N,N-Dimethyl-2-[2-oxo-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>27</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>28</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>29</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>30</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>31</entry><entry>(R/S)-1-(2-Cyclopropyl-2-hydroxy-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>32</entry><entry>1-[(2-Oxo-1H-pyridin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>33</entry><entry>(R/S)-6-(4-Fluoro-2-methyl-phenyl)-3-methyl-1-(oxetan-2-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>34</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>35</entry><entry>6-(4-Methoxyphenyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>36</entry><entry>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>37</entry><entry>2-[6-(2-Chloro-4-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-</entry></row><row><entry/><entry>cyclopropyl-acetamide;</entry></row><row><entry>38</entry><entry>N-Cyclopropyl-2-[6-(4-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>39</entry><entry>N-Cyclopropyl-2-[6-(3,5-dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>40</entry><entry>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]-N-methyl-acetamide;</entry></row><row><entry>41</entry><entry>N-Cyclopropyl-2-[6-(4-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]-N-methyl-acetamide;</entry></row><row><entry>42</entry><entry>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>43</entry><entry>(R*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>44</entry><entry>(S*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>45</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>46</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>47</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>48</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>49</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>50</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>51</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>52</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>53</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>54</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>55</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>56</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>57</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>58</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>59</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>60</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>61</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>62</entry><entry>6-(3,4-difluorophenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>63</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>64</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>65</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-2-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>66</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>67</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>68</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>69</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-5-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>70</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>71</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>72</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-4-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>73</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>74</entry><entry>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>75</entry><entry>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>76</entry><entry>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>77</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>78</entry><entry>N,N-Dimethyl-2-[3-methyl-6-(5-methyl-2-thienyl)-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>79</entry><entry>2-[6-(5-Ethyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry></row><row><entry/><entry>dimethyl-acetamide;</entry></row><row><entry>80</entry><entry>N,N-Dimethyl-2-[3-methyl-6-(4-methyl-2-thienyl)-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>81</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-fluoro-2-thienyl)-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>82</entry><entry>2-[6-(5-Fluoro-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry></row><row><entry/><entry>dimethyl-acetamide;</entry></row><row><entry>83</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(5-fluoro-2-thienyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>84</entry><entry>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>85</entry><entry>6-(5-Fluoro-2-thienyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>86</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(4-methylthiazol-2-</entry></row><row><entry/><entry>yl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>87</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-ethyl-2-thienyl)-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>88</entry><entry>6-(5-Ethyl-2-thienyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>89</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(hydroxymethyl)-2-thienyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>90</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-(hydroxymethyl)-2-thienyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>91</entry><entry>2-[6-[5-(Hydroxymethyl)-2-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>92</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)-3-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>93</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(difluoromethyl)-2-thienyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>94</entry><entry>2-[6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>95</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)-3-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>96</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)-3-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>97</entry><entry>2-[6-[5-(Difluoromethyl)-3-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>98</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(difluoromethyl)-3-thienyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>99</entry><entry>6-[5-(Difluoromethyl)-3-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>100</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>101</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-3-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>102</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-3-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>103</entry><entry>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[5-(trifluoromethyl)-3-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>104</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-3-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>105</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-cyclopropyl-2-thienyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>106</entry><entry>6-(5-Cyclopropyl-2-thienyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>107</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-4-</entry></row><row><entry/><entry>yl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>108</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)thiazol-4-</entry></row><row><entry/><entry>yl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>109</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-</entry></row><row><entry/><entry>(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>110</entry><entry>2-[6-(5-Cyclopropyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-</entry></row><row><entry/><entry>N,N-dimethyl-acetamide;</entry></row><row><entry>111</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(1,1,2,2,2-pentafluoroethyl)-</entry></row><row><entry/><entry>2-thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>112</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(2-methylthiazol-5-</entry></row><row><entry/><entry>yl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>113</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(2-methylthiazol-5-</entry></row><row><entry/><entry>yl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>114</entry><entry>N,N-Dimethyl-2-[3-methyl-6-(2-methylthiazol-5-yl)-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>115</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-5-</entry></row><row><entry/><entry>yl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>116</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-</entry></row><row><entry/><entry>(trifluoromethyl)thiazol-5-yl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>117</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-(difluoromethyl)-2-thienyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>118</entry><entry>6-[4-(Difluoromethyl)-2-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>119</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)thiazol-5-</entry></row><row><entry/><entry>yl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>120</entry><entry>1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-</entry></row><row><entry/><entry>yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one-7-D;</entry></row><row><entry>121</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trideuteriomethoxymethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>122</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trideuteriomethoxymethyl)-</entry></row><row><entry/><entry>2-thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>123</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-</entry></row><row><entry/><entry>(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>124</entry><entry>1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-</entry></row><row><entry/><entry>yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one-7-T;</entry></row><row><entry>125</entry><entry>1-[(5-Methylisoxazol-3-yl)methyl]-6-(4-methyl-2-thienyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>126</entry><entry>1-[(5-Methylisoxazol-3-yl)methyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>127</entry><entry>1-[(3-Methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(4-methyl-2-thienyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>128</entry><entry>6-(4-Fluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>129</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>130</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>131</entry><entry>6-(3,4-Difluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>132</entry><entry>6-(2,4-Difluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>133</entry><entry>(R/S)-3-methyl-1-(oxetan-2-ylmethyl)-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>134</entry><entry>Ethyl 2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetate;</entry></row><row><entry>135</entry><entry>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetic</entry></row><row><entry/><entry>acid;</entry></row><row><entry>136</entry><entry>Ethyl 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>1-yl]acetate;</entry></row><row><entry>137</entry><entry>2-[3-Methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetic acid;</entry></row><row><entry>138</entry><entry>1-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>139</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrazin-2-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>140</entry><entry>6-(4-Fluorophenyl)-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>141</entry><entry>6-(4-Fluorophenyl)-1-[(1-methyl-1,2,4-triazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>142</entry><entry>6-(4-Fluorophenyl)-1-[(1-methyltriazol-4-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>143</entry><entry>6-(3,4-Difluorophenyl)-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>144</entry><entry>6-(3,4-Difluorophenyl)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>145</entry><entry>6-(3,4-Difluorophenyl)-1-[[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]-</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>146</entry><entry>1-(2-Pyrrolidin-1-ylethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>147</entry><entry>1-[2-(3-Hydroxyazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>148</entry><entry>1-[2-(Cyclopropylamino)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>149</entry><entry>1-[2-(3-Methoxyazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>150</entry><entry>1-[2-(Cyclobutylamino)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>151</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>152</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>153</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>154</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>155</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[2-(trifluoromethyl)-4-pyridyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>156</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-3-methyl-phenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>157</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(2,6-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>158</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(3-chlorophenyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>159</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(3,5-difluorophenyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>160</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[3-(trifluoromethoxy)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>161</entry><entry>1-[2-(1-Piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>162</entry><entry>1-[2-(4-Fluoro-1-piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>163</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>164</entry><entry>1-[2-(3-Methylpyrrolidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>165</entry><entry>1-[2-(4-Hydroxy-1-piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>166</entry><entry>1-[2-[3-(Trifluoromethyl)azetidin-1-yl]ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>167</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>168</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>169</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(2,3-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>170</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(3,5-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>171</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-2,3-dimethyl-phenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>172</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>173</entry><entry>6-(3,5-Difluorophenyl)-1-[2-(2-hydroxyethylamino)ethyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>174</entry><entry>6-(3,5-Difluorophenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>175</entry><entry>6-(3,5-Difluorophenyl)-1-[2-(3-hydroxypyrrolidin-1-yl)ethyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>176</entry><entry>6-(3,5-Difluorophenyl)-1-[2-(3-methoxypyrrolidin-1-yl)ethyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>177</entry><entry>6-(4-Fluoro-2-methyl-phenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>178</entry><entry>6-(2,6-Dimethylphenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>179</entry><entry>6-(o-Tolyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>180</entry><entry>6-Phenyl-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>181</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>182</entry><entry>6-(2,3-Dimethylphenyl)-1-[2-(3-fluoroazetidin-1-yl)ethyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>183</entry><entry>6-(3,5-Dimethylphenyl)-1-[2-(3-fluoroazetidin-1-yl)ethyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>184</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(4-fluoro-2,3-dimethyl-phenyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>185</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>186</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>187</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>188</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>189</entry><entry>6-(3,5-Difluorophenyl)-1-[2-(propylamino)ethyl]-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>190</entry><entry>N-Cyclobutyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>191</entry><entry>1-[2-(3-Methoxyazetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>192</entry><entry>N-(Oxetan-3-yl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>193</entry><entry>1-[2-(4-Methylpiperazin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>194</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>195</entry><entry>N-(3,3-Difluorocyclobutyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>196</entry><entry>1-[2-(3,3-Difluoropyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>197</entry><entry>3-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>198</entry><entry>N-(3,3-Difluoro-1-methyl-cyclobutyl)-2-[3-methyl-2-oxo-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>199</entry><entry>N-(3-Methyloxetan-3-yl)-2-[3-methyl-2-oxo-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>200</entry><entry>N-(3,3-Difluorocyclobutyl)-2-[3-methyl-2-oxo-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>201</entry><entry>1-(2-Oxo-2-pyrrolidin-1-yl-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>202</entry><entry>(R/S)&#x2014;N-Cyclopropyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]propanamide;</entry></row><row><entry>203</entry><entry>(R/S)-1-[2-(Azetidin-1-yl)-1-methyl-2-oxo-ethyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>204</entry><entry>1-(2-Morpholino-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>205</entry><entry>N-Cyclopentyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>206</entry><entry>1-[2-Oxo-2-(1-piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>207</entry><entry>1-[2-(2,6-Diazaspiro[3.3]heptan-6-yl)-2-oxo-ethyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>208</entry><entry>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-</entry></row><row><entry/><entry>pyridyl)acetamide;</entry></row><row><entry>209</entry><entry>N-(3,3-Difluoro-1-methyl-cyclobutyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>210</entry><entry>1-[(6-Methoxy-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>211</entry><entry>1-(Cyclopropylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>212</entry><entry>3-[[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>213</entry><entry>2-[[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>214</entry><entry>1-[2-Oxo-2-(2-thienyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>215</entry><entry>1-(2-Oxo-2-thiazol-2-yl-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>216</entry><entry>(R/S)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>217</entry><entry>(R/S)-1-(Morpholin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>218</entry><entry>(R/S)-1-(Tetrahydropyran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>219</entry><entry>6-[3-(Trifluoromethyl)phenyl]-1-[[4-(trifluoromethyl)phenyl]methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>220</entry><entry>1-[(3-Fluoro-4-methoxy-phenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>221</entry><entry>1-[(4-Fluoro-3-methyl-phenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>222</entry><entry>1-[(3-Fluorophenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>223</entry><entry>(R*)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>224</entry><entry>(S*)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>225</entry><entry>(R/S)-1-[(2,2-Difluorocyclopropyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>226</entry><entry>1-[(3-Fluorooxetan-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>227</entry><entry>1-(Pyrimidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>228</entry><entry>1-(2-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>229</entry><entry>1-(4-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>230</entry><entry>1-(3-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>231</entry><entry>1-[(2-Methylpyrimidin-5-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>232</entry><entry>1-(Pyridazin-3-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>233</entry><entry>1-[(3-Methoxy-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>234</entry><entry>1-[(3-Fluoro-5-methyl-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>235</entry><entry>1-[(6-Methyl-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>236</entry><entry>1-(2H-Tetrazol-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>237</entry><entry>1-[Difluoro(3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>238</entry><entry>1-[(6-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>239</entry><entry>1-(2-Cyclopropyl-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>240</entry><entry>1-(2-Oxobutyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>241</entry><entry>1-(3-Methyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>242</entry><entry>1-[(5-Methyl-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>243</entry><entry>1-(Thiadiazol-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>244</entry><entry>1-[(6-Oxo-1H-pyridin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>245</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-3-methyl-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>246</entry><entry>3-Methyl-1-(pyrimidin-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>247</entry><entry>3-Methyl-1-(pyrimidin-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>248</entry><entry>3-Methyl-1-[(2-methylpyrimidin-4-yl)methyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>249</entry><entry>3-Methyl-1-(pyrazin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>250</entry><entry>3-Methyl-1-(4-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>251</entry><entry>3-Methyl-1-(2-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>252</entry><entry>1-[(6-Methoxypyridazin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>253</entry><entry>1-(Pyrazin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>254</entry><entry>1-[(2-Methylpyrimidin-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>255</entry><entry>1-(Pyrimidin-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>256</entry><entry>1-[(5-Fluoropyrimidin-2-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>257</entry><entry>6-[3-(Trifluoromethyl)phenyl]-1-[[6-(trifluoromethyl)-3-pyridyl]methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>258</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>259</entry><entry>6-[3-(Trifluoromethyl)phenyl]-1-[[5-(trifluoromethyl)-3-pyridyl]methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>260</entry><entry>6-[3-(Trifluoromethyl)phenyl]-1-[[4-(trifluoromethyl)-3-pyridyl]methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>261</entry><entry>3-Methyl-1-(pyrimidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>262</entry><entry>1-(2-cyclobutyl-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>263</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>264</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-[2-fluoro-3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>265</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>266</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>267</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-[4-fluoro-3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>268</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-(2,3-dichlorophenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>269</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>270</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>271</entry><entry>(R/S)-6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-(oxetan-2-ylmethyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>272</entry><entry>6-(3,4-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>273</entry><entry>6-(3-Chlorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>274</entry><entry>6-(3-Fluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>275</entry><entry>6-(3,4-Difluorophenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>276</entry><entry>6-(3-Fluorophenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>277</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>278</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>279</entry><entry>6-(3,4-Difluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>280</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>281</entry><entry>6-(3-Fluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>282</entry><entry>6-(3-Chlorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>283</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>284</entry><entry>6-(3,4-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>285</entry><entry>6-(3-Fluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>286</entry><entry>6-(4-Fluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>287</entry><entry>6-[3-(Difluoromethyl)phenyl]-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>288</entry><entry>6-(3-Methoxyphenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>289</entry><entry>6-(p-Tolyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>290</entry><entry>6-(3-fluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>291</entry><entry>6-[3-(Difluoromethyl)phenyl]-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>292</entry><entry>6-(3,4-Difluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>293</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>294</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>295</entry><entry>6-(4-Fluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>296</entry><entry>6-(3-Chlorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>297</entry><entry>6-(m-Tolyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>298</entry><entry>6-(3,4-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>299</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>300</entry><entry>6-[3-(Difluoromethoxy)phenyl]-1-(3-pyridylmethyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>301</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>302</entry><entry>6-[3-(Difluoromethyl)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>303</entry><entry>6-(2,3-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>304</entry><entry>6-[3-(Difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>305</entry><entry>6-(3-Chlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>306</entry><entry>6-(4-Chloro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>307</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethoxy)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>308</entry><entry>1-[(5-Methyl-3-pyridyl)methyl]-6-(3,4,5-trifluorophenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>309</entry><entry>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[(5-methyl-3-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>310</entry><entry>6-(2,3-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>311</entry><entry>6-(3,5-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>312</entry><entry>1-[(4-Methyl-3-pyridyl)methyl]-6-(3,4,5-trifluorophenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>313</entry><entry>1-[(4-Methyl-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>314</entry><entry>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[(4-methyl-3-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>315</entry><entry>1-[(3-Methyl-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>316</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>317</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>318</entry><entry>6-(3,5-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>319</entry><entry>6-(2,3-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>320</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>321</entry><entry>2-[6-(5-Chloro-4-methyl-2-thienyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-</entry></row><row><entry/><entry>N,N-dimethyl-acetamide;</entry></row><row><entry>322</entry><entry>2-[6-(5-Chloro-4-methyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>323</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>324</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>325</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>326</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(5-methyl-2-</entry></row><row><entry/><entry>thienyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>327</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>328</entry><entry>3-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>329</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>330</entry><entry>6-(3,4-Difluorophenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>331</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>332</entry><entry>6-(m-Tolyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>333</entry><entry>(R/S)-6-(3,4-Difluorophenyl)-1-(2-hydroxybutyl)-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>334</entry><entry>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>335</entry><entry>(R/S)-1-(2-Hydroxybutyl)-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>336</entry><entry>(R/S)-6-(2,4-difluoro-3-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>337</entry><entry>(R/S)-1-(2-Hydroxybutyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>338</entry><entry>(R/S)-1-(2-Hydroxy-3-methyl-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>339</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>340</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>341</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>342</entry><entry>6-[3-(Difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>343</entry><entry>6-(3,4-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>344</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(3,4,5-</entry></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>345</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-[3-</entry></row><row><entry/><entry>(trifluoromethoxy)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>346</entry><entry>6-(2,3-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>347</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(2,3,4-</entry></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>348</entry><entry>6-(3-Chlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>349</entry><entry>6-(3-Chloro-2-fluoro-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>350</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(m-tolyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>351</entry><entry>6-(3,4-Dichlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>352</entry><entry>6-(2-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>353</entry><entry>3-Methyl-1-(3-pyridylmethyl)-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>354</entry><entry>6-(3,5-Difluorophenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>355</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>356</entry><entry>3-Methyl-6-(m-tolyl)-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>357</entry><entry>6-(2-Fluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>358</entry><entry>6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(3-</entry></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>359</entry><entry>6-(3-Chloro-2-fluoro-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>360</entry><entry>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(3-</entry></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>361</entry><entry>3-Methyl-1-(3-pyridylmethyl)-6-(2,3,4-trifluorophenyl)imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>362</entry><entry>3-Methyl-1-(3-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>363</entry><entry>6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>364</entry><entry>3-Methyl-1-(3-pyridylmethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>365</entry><entry>6-(5-Chloro-4-methyl-2-thienyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>366</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>367</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>368</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>369</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(3,4-difluorophenyl)-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>370</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-(3,4,5-</entry></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>371</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(2-fluoro-3-methyl-phenyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>372</entry><entry>6-(5-Chloro-4-methyl-2-thienyl)-1-[(5-chloro-3-pyridyl)methyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>373</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>374</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-(m-tolyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>375</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(2,3-difluorophenyl)-3-methyl-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>376</entry><entry>6-(3-Chlorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>377</entry><entry>6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>378</entry><entry>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>379</entry><entry>3-Methyl-6-(m-tolyl)-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>380</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>381</entry><entry>6-(3-Fluoro-5-methyl-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>382</entry><entry>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>383</entry><entry>6-[3-Fluoro-5-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>384</entry><entry>6-[4-Chloro-3-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>387</entry><entry>6-[3,4-Difluoro-5-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>388</entry><entry>3-Methyl-1-(2-oxobutyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>389</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>390</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>391</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>392</entry><entry>6-(3-Cyclopropylphenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>393</entry><entry>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-1-(2-hydroxy-4-methoxy-butyl)-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>394</entry><entry>(R/S)-6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(oxetan-2-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>395</entry><entry>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(oxetan-2-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>396</entry><entry>(R/S)-6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(oxetan-2-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>397</entry><entry>(R/S)-6-(3-Chlorophenyl)-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>398</entry><entry>(R/S)-3-Methyl-6-[2-methyl-3-(trifluoromethyl)phenyl]-1-(oxetan-2-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>399</entry><entry>(R/S)-1-(2,4-Dihydroxybutyl)-3-methyl-6-[2-methyl-3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>400</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>401</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>402</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(3,4,5-</entry></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>403</entry><entry>6-(3,4-Difluorophenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>404</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(m-tolyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>405</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2-fluoro-3-methyl-phenyl)-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>406</entry><entry>6-(3-Chlorophenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>407</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[4-fluoro-3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>408</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>409</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>410</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>411</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(3,4,5-</entry></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>412</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(3,5-difluorophenyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>413</entry><entry>1-(2-(3,3-Difluoroazetidin-1-yl)-2-oxoethyl)-6-(4-fluoro-3-methylphenyl)-3-</entry></row><row><entry/><entry>methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;</entry></row><row><entry>414</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-</entry></row><row><entry/><entry>phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>415</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[2-fluoro-3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>416</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(3,4-difluorophenyl)-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>417</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(3-fluorophenyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>418</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2-fluoro-3-methyl-phenyl)-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>419</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>420</entry><entry>2-[6-(4-Fuoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-</entry></row><row><entry/><entry>N,N-dimethyl-acetamide;</entry></row><row><entry>421</entry><entry>2-[6-(3,4-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry></row><row><entry/><entry>dimethyl-acetamide;</entry></row><row><entry>422</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(3,4-difluorophenyl)-3-methyl-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>423</entry><entry>2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>424</entry><entry>2-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>425</entry><entry>2-[6-(2,3-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry></row><row><entry/><entry>dimethyl-acetamide;</entry></row><row><entry>426</entry><entry>2-[6-[3-(Difluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-</entry></row><row><entry/><entry>N,N-dimethyl-acetamide;</entry></row><row><entry>427</entry><entry>2-[6-(2-Fluoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-</entry></row><row><entry/><entry>N,N-dimethyl-acetamide;</entry></row><row><entry>428</entry><entry>2-[6-(3,5-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry></row><row><entry/><entry>dimethyl-acetamide;</entry></row><row><entry>429</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-(3-pyridyl)imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>430</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-</entry></row><row><entry/><entry>2-thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>431</entry><entry>2-[6-[3,4-Difluoro-5-(trifluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>432</entry><entry>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>433</entry><entry>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>434</entry><entry>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>435</entry><entry>N-Methyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>436</entry><entry>2-[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-</entry></row><row><entry/><entry>acetamide;</entry></row><row><entry>437</entry><entry>2-[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-</entry></row><row><entry/><entry>methyl-acetamide;</entry></row><row><entry>438</entry><entry>2-[6-(3,5-Dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-</entry></row><row><entry/><entry>acetamide;</entry></row><row><entry>439</entry><entry>2-[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-</entry></row><row><entry/><entry>methyl-acetamide;</entry></row><row><entry>440</entry><entry>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-</entry></row><row><entry/><entry>methyl-acetamide;</entry></row><row><entry>441</entry><entry>2-[6-(2-Ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-</entry></row><row><entry/><entry>acetamide;</entry></row><row><entry>442</entry><entry>N-(2-Methoxyethyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>443</entry><entry>2-[6-(2-Ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-</entry></row><row><entry/><entry>methoxyethyl)acetamide;</entry></row><row><entry>444</entry><entry>N-(2-Methoxyethyl)-2-[6-(4-methoxyphenyl)-2-oxo-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>445</entry><entry>N-(2-Methoxyethyl)-2-[2-oxo-6-(3-pyridyl)-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>446</entry><entry>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-</entry></row><row><entry/><entry>(2-methoxyethyl)acetamide;</entry></row><row><entry>447</entry><entry>N-Cyclopropyl-2-[6-(3,5-difluorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>448</entry><entry>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-</entry></row><row><entry/><entry>cyclopropyl-acetamide;</entry></row><row><entry>449</entry><entry>N-Cyclopropyl-2-[6-(3-ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>450</entry><entry>N-Cyclopropyl-2-[6-(3-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>451</entry><entry>N-Cyclopropyl-2-[6-(4-methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>452</entry><entry>N-Cyclopropyl-2-[6-(4-fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>453</entry><entry>2-[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-</entry></row><row><entry/><entry>acetamide;</entry></row><row><entry>454</entry><entry>N-Cyclopropyl-2-[6-(2,4-dimethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>1-yl]acetamide;</entry></row><row><entry>455</entry><entry>N-Cyclopropyl-2-[6-(2-fluoro-6-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>456</entry><entry>N-Cyclopropyl-2-[6-(2-ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>457</entry><entry>6-(3-Fluoro-4-methoxy-phenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>458</entry><entry>6-(2-Ethoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>459</entry><entry>6-(4-Chlorophenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>460</entry><entry>6-(2-Ethoxy-5-fluoro-phenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>461</entry><entry>6-(4-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>462</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>463</entry><entry>6-(3-Ethoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>464</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>465</entry><entry>1-(Cyclopropylmethyl)-6-(2,4-dimethoxyphenyl)-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>466</entry><entry>1-(Cyclopropylmethyl)-6-(2-ethoxy-5-fluoro-phenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>467</entry><entry>1-(Cyclopropylmethyl)-6-(4-fluoro-2-methoxy-phenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>468</entry><entry>1-(Cyclopropylmethyl)-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>469</entry><entry>1-(Cyclopropylmethyl)-6-(3-fluoro-4-methoxy-phenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>470</entry><entry>1-(Cyclopropylmethyl)-6-(3,5-difluorophenyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>471</entry><entry>1-(Cyclopropylmethyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>472</entry><entry>1-(Cyclopropylmethyl)-6-(2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>473</entry><entry>1-(Cyclopropylmethyl)-6-[3-(dimethylamino)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>474</entry><entry>1-(Cyclopropylmethyl)-6-(3,5-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>475</entry><entry>6-(3-Methoxyphenyl)-1-(tetrahydrofuran-2-ylmethyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>476</entry><entry>4-[[6-(4-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>477</entry><entry>3-[[6-(4-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>478</entry><entry>3-[[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>479</entry><entry>3-[[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>480</entry><entry>3-[[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>481</entry><entry>2-[[6-(2-Fluoro-6-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>482</entry><entry>2-[[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>483</entry><entry>2-[[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>484</entry><entry>2-[[6-(2-Ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>485</entry><entry>2-[[6-(3-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>486</entry><entry>2-[[6-(3-Cyanophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>487</entry><entry>2-[[6-(2,4-Dimethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>488</entry><entry>2-[[6-(3,5-Dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>489</entry><entry>2-[[6-(2-Ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>490</entry><entry>2-[[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>491</entry><entry>2-[[6-(3-Fluoro-4-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>492</entry><entry>6-(4-Fluoro-2-methyl-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>493</entry><entry>6-(2,3-Dimethoxyphenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>494</entry><entry>6-(2-Ethoxy-5-fluoro-phenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>495</entry><entry>6-(3,5-Dimethylphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>496</entry><entry>6-(2,4-Dimethoxyphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>497</entry><entry>6-(2-Ethoxyphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>498</entry><entry>1-[(3-Fluorophenyl)methyl]-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>499</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>500</entry><entry>6-[3-(Dimethylamino)phenyl]-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>501</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>502</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>503</entry><entry>6-(2-Ethoxyphenyl)-1-[(2-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>504</entry><entry>1-[(3-Chlorophenyl)methyl]-6-(3,5-difluorophenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>505</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[(3-methoxyphenyl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>506</entry><entry>1-[(3-Methoxyphenyl)methyl]-6-(3-pyridyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>507</entry><entry>1-[(3-Methoxyphenyl)methyl]-6-(4-methyl-2-thienyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>508</entry><entry>6-(3,5-Difluorophenyl)-1-[(4-methoxyphenyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>509</entry><entry>1-[(3,5-Dimethoxyphenyl)methyl]-6-(2-fluoro-6-methoxy-phenyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>510</entry><entry>1-[(3,5-Dimethoxyphenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>511</entry><entry>6-(4-Chlorophenyl)-1-[(4-isopropylphenyl)methyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>512</entry><entry>6-(4-tert-Butylphenyl)-1-[(3,4-dimethoxy-2-pyridyl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>513</entry><entry>3-[1-[(3,5-Dimethylisoxazol-4-yl)methyl]-2-oxo-3H-imidazo[4,5-b]pyridin-6-</entry></row><row><entry/><entry>yl]benzonitrile;</entry></row><row><entry>514</entry><entry>1-[(3,5-Dimethylisoxazol-4-yl)methyl]-6-(2-ethoxy-5-fluoro-phenyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>515</entry><entry>6-(4-Methoxy-3-methyl-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>516</entry><entry>6-(3,5-Dimethylphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>517</entry><entry>6-(2-Ethoxyphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>518</entry><entry>6-(2,4-Dimethoxyphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>519</entry><entry>6-(3-Fluoro-4-methoxy-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>520</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>521</entry><entry>6-(2-Ethoxy-5-fluoro-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>522</entry><entry>6-(4-Fluoro-2-methyl-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>523</entry><entry>6-(3,5-Difluorophenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>532</entry><entry>N-(3-Chloropropyl)-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>533</entry><entry>2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>534</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>535</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(2-fluoroethyl)-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>536</entry><entry>1-[2-[3-(2-Fluoroethyl)azetidin-1-yl]-2-oxo-ethyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>537</entry><entry>6-(6-Fluoro-2-pyridyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>538</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-(2-fluoroethoxy)-3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>539</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>540</entry><entry>1-[2-(3-<sup>18</sup>F-Fluoranylazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-</entry></row><row><entry/><entry>phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>541</entry><entry>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>542</entry><entry>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>543</entry><entry>6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-1-(pyridazin-3-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>544</entry><entry>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>545</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(thiadiazol-4-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>546</entry><entry>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>547</entry><entry>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>548</entry><entry>3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>549</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>550</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(1-methylpyrazol-4-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>551</entry><entry>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>552</entry><entry>3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[3-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>553</entry><entry>3-Methyl-6-(5-methyl-2-thienyl)-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>554</entry><entry>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-(5-methyl-2-</entry></row><row><entry/><entry>thienyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>555</entry><entry>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-(5-methyl-2-</entry></row><row><entry/><entry>thienyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>556</entry><entry>3-Methyl-6-(5-methyl-2-thienyl)-1-(thiadiazol-4-ylmethyl)imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>557</entry><entry>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(5-methyl-2-</entry></row><row><entry/><entry>thienyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>558</entry><entry>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(5-methyl-2-</entry></row><row><entry/><entry>thienyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>559</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-methyltriazol-4-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>560</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>561</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-methylpyrazol-4-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>562</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-(thiadiazol-4-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>563</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>564</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-methylisoxazol-3-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>565</entry><entry>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>566</entry><entry>3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>567</entry><entry>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>568</entry><entry>3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>569</entry><entry>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>570</entry><entry>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>571</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-methylisoxazol-3-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>572</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-methylpyrazol-4-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>573</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>574</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-methyltriazol-4-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>575</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-</entry></row><row><entry/><entry>yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>576</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(thiadiazol-4-</entry></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>577</entry><entry>N-(2-Fluoroethyl)-N-methyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</entry></row><row><entry>578</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>579</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>580</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(m-tolyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>581</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(m-</entry></row><row><entry/><entry>tolyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>582</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>583</entry><entry>N,N-Dimethyl-2-[3-methyl-6-(m-tolyl)-2-oxo-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]acetamide;</entry></row><row><entry>584</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethyl)-4-fluoro-phenyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>585</entry><entry>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-</entry></row><row><entry/><entry>ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>586</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethyl)-4-fluoro-</entry></row><row><entry/><entry>phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>587</entry><entry>2-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>588</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>589</entry><entry>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-</entry></row><row><entry/><entry>ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>590</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethoxy)-4-fluoro-</entry></row><row><entry/><entry>phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>591</entry><entry>2-[6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>592</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-chloro-3-(difluoromethoxy)phenyl]-3-</entry></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>593</entry><entry>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-</entry></row><row><entry/><entry>ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>594</entry><entry>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3,3-difluoroazetidin-1-yl)-2-</entry></row><row><entry/><entry>oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>595</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-</entry></row><row><entry/><entry>(fluoromethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>596</entry><entry>2-[3-(Fluoromethyl)-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>597</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)-6-[5-</entry></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>598</entry><entry>3-(Fluoromethyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-</entry></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>599</entry><entry>2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-(fluoromethyl)-2-oxo-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]-N,N-dimethyl-acetamide;</entry></row><row><entry>600</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry></row><row><entry/><entry>(fluoromethyl)imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>601</entry><entry>1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one;</entry></row><row><entry>602</entry><entry>6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>603</entry><entry>1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxy-3-methyl-phenyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>604</entry><entry>1-Isobutyl-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>605</entry><entry>6-(2-Ethoxyphenyl)-1-[(3-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-</entry></row><row><entry/><entry>2-one;</entry></row><row><entry>606</entry><entry>6-(2-Ethoxyphenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry></row><row><entry/><entry>one;</entry></row><row><entry>607</entry><entry>N-Cyclopropyl-2-[6-(2-ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry></row><row><entry>608</entry><entry>2-[[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-</entry></row><row><entry/><entry>yl]methyl]benzonitrile;</entry></row><row><entry>609</entry><entry>1-(3,3-Dimethyl-2-oxo-butyl)-6-(3-fluoro-4-methoxy-phenyl)-3H-</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry></row><row><entry>610</entry><entry>2-[6-(3,5-Difluorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-</entry></row><row><entry/><entry>methoxyethyl)acetamide;</entry></row><row><entry>611</entry><entry>1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry></row><row><entry/><entry>b]pyridin-2-one; and</entry></row><row><entry>612</entry><entry>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-</entry></row><row><entry/><entry>methoxyethyl)acetamide;</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/>and pharmaceutically acceptable salts, N-oxides, or solvates thereof.</p><p id="p-0101" num="0092">A further embodiment of the current invention is a compound selected from the group consisting of:<ul id="ul0047" list-style="none">    <li id="ul0047-0001" num="0000">    <ul id="ul0048" list-style="none">        <li id="ul0048-0001" num="0093">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0048-0002" num="0094">N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</li>        <li id="ul0048-0003" num="0095">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0048-0004" num="0096">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0048-0005" num="0097">1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0048-0006" num="0098">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0048-0007" num="0099">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0048-0008" num="0100">1-(2-(3,3-Difluoroazetidin-1-yl)-2-oxoethyl)-6-(4-fluoro-3-methylphenyl)-3-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;</li>        <li id="ul0048-0009" num="0101">1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one; and</li>        <li id="ul0048-0010" num="0102">2-[6-(4-Fuoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;<br/>and pharmaceutically acceptable salts, solvates, or N-oxides thereof.</li>    </ul>    </li></ul></p><p id="p-0102" num="0103">A further embodiment of the current invention is a compound selected from the group consisting of:<ul id="ul0049" list-style="none">    <li id="ul0049-0001" num="0000">    <ul id="ul0050" list-style="none">        <li id="ul0050-0001" num="0104">6-(5-(Difluoromethyl)-2-fluorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0050-0002" num="0105">6-(5-(Difluoromethyl)-2-fluorophenyl)-3-methyl-1-(pyridin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0050-0003" num="0106">N-(3-Chloropropyl)-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</li>        <li id="ul0050-0004" num="0107">2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</li>        <li id="ul0050-0005" num="0108">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0050-0006" num="0109">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(2-fluoroethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0050-0007" num="0110">1-[2-[3-(2-Fluoroethyl)azetidin-1-yl]-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0050-0008" num="0111">6-(6-Fluoro-2-pyridyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0050-0009" num="0112">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0050-0010" num="0113">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0050-0011" num="0114">1-[2-(3-<sup>18</sup>F-Fluoranylazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</li>        <li id="ul0050-0012" num="0115">6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one;</li>    </ul>    </li></ul></p><p id="p-0103" num="0116">6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;<ul id="ul0051" list-style="none">    <li id="ul0051-0001" num="0000">    <ul id="ul0052" list-style="none">        <li id="ul0052-0001" num="0117">6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0002" num="0118">6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0003" num="0119">6-(3,4-Difluorophenyl)-3-methyl-1-(thiadiazol-4-ylmethypimidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0004" num="0120">6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0005" num="0121">6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0006" num="0122">3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0007" num="0123">6-(3,4-Difluorophenyl)-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0008" num="0124">6-(3,4-Difluorophenyl)-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0009" num="0125">3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0010" num="0126">3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0011" num="0127">3-Methyl-6-(5-methyl-2-thienyl)-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0012" num="0128">3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0013" num="0129">3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0014" num="0130">3-Methyl-6-(5-methyl-2-thienyl)-1-(thiadiazol-4-ylmethypimidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0015" num="0131">3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0016" num="0132">3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0017" num="0133">6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0018" num="0134">6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0019" num="0135">6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0020" num="0136">6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-(thiadiazol-4-ylmethypimidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0021" num="0137">6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0022" num="0138">6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0023" num="0139">3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0024" num="0140">3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0025" num="0141">3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0026" num="0142">3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0027" num="0143">3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0028" num="0144">3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0029" num="0145">6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0030" num="0146">6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0031" num="0147">6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0032" num="0148">6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0033" num="0149">6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0034" num="0150">6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(thiadiazol-4-ylmethypimidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0035" num="0151">N-(2-Fluoroethyl)-N-methyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</li>        <li id="ul0052-0036" num="0152">1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0037" num="0153">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0038" num="0154">1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0039" num="0155">1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(m-tolypimidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0040" num="0156">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0041" num="0157">N,N-Dimethyl-2-[3-methyl-6-(m-tolyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</li>        <li id="ul0052-0042" num="0158">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethyl)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0043" num="0159">6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0044" num="0160">1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethyl)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0045" num="0161">2-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</li>        <li id="ul0052-0046" num="0162">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0047" num="0163">6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0048" num="0164">1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0049" num="0165">2-[6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</li>        <li id="ul0052-0050" num="0166">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-chloro-3-(difluoromethoxy)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0051" num="0167">6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0052" num="0168">6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0053" num="0169">1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-(fluoromethyl)imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0054" num="0170">2-[3-(Fluoromethyl)-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</li>        <li id="ul0052-0055" num="0171">1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0056" num="0172">3-(Fluoromethyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0057" num="0173">2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-(fluoromethyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</li>        <li id="ul0052-0058" num="0174">6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethypimidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0059" num="0175">1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0060" num="0176">6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0061" num="0177">1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0062" num="0178">1-Isobutyl-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0063" num="0179">6-(2-Ethoxyphenyl)-1-[(3-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0064" num="0180">6-(2-Ethoxyphenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0065" num="0181">N-Cyclopropyl-2-[6-(2-ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</li>        <li id="ul0052-0066" num="0182">2-[[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</li>        <li id="ul0052-0067" num="0183">1-(3,3-Dimethyl-2-oxo-butyl)-6-(3-fluoro-4-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</li>        <li id="ul0052-0068" num="0184">2-[6-(3,5-Difluorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide;</li>        <li id="ul0052-0069" num="0185">1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one; and</li>        <li id="ul0052-0070" num="0186">2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide;<br/>and pharmaceutically acceptable salts, solvates, or N-oxides thereof.</li>    </ul>    </li></ul></p><p id="p-0104" num="0187">A further embodiment of the current invention is a compound selected from the group consisting of:</p><p id="p-0105" num="0188">and pharmaceutically acceptable salts, solvates, or N-oxides thereof.<ul id="ul0053" list-style="none">    <li id="ul0053-0001" num="0000">    <ul id="ul0054" list-style="none">        <li id="ul0054-0001" num="0189">1-(2-Oxo-2-(pyrrolidin-1-yl)ethyl)-6-(thiazol-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</li>        <li id="ul0054-0002" num="0190">1-(2-(3-hydroxy-3-methylazetidin-1-yl)-2-oxoethyl)-6-(5-methylpyridin-3-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</li>        <li id="ul0054-0003" num="0191">1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(6-fluoropyridin-3-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</li>        <li id="ul0054-0004" num="0192">1-(2-(2-Oxo-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetyl)azetidine-3-carbonitrile;</li>        <li id="ul0054-0005" num="0193">1-Benzyl-6-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</li>        <li id="ul0054-0006" num="0194">1-(2-(3-Methylazetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</li>        <li id="ul0054-0007" num="0195">1-(2-(3-(Methoxymethyl)azetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; and</li>        <li id="ul0054-0008" num="0196">6-(2-Fluoro-3-methylphenyl)-1-(2-oxo-2-(3-(trifluoromethyl)azetidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; and<br/>pharmaceutically acceptable salts, solvates, or N-oxides thereof.</li>    </ul>    </li></ul></p><p id="p-0106" num="0197">An additional embodiment of the invention is a pharmaceutical composition comprising:</p><p id="p-0107" num="0198">(A) an effective amount of at least one compound selected from compounds of Formula (I):</p><p id="p-0108" num="0000"><chemistry id="CHEM-US-00029" num="00029"><img id="EMI-C00029" he="26.50mm" wi="55.29mm" file="US20230000833A1-20230105-C00029.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0109" num="0000">wherein<ul id="ul0055" list-style="none">    <li id="ul0055-0001" num="0000">    <ul id="ul0056" list-style="none">        <li id="ul0056-0001" num="0199">R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</li>        <li id="ul0056-0002" num="0200">R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; pyridinyl substituted with F, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>haloalkyl; thiazolyl; thiazolyl substituted with C<sub>1-6</sub>alkyl or C<sub>1-6</sub>haloalkyl; thienyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>3</sub>, and cyclopropyl;</li>        <li id="ul0056-0003" num="0201">R<sup>3 </sup>is H;</li>        <li id="ul0056-0004" num="0202">R<sup>4 </sup>is selected from the group consisting of:        <ul id="ul0057" list-style="none">            <li id="ul0057-0001" num="0203">(a)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0110" num="0000"><chemistry id="CHEM-US-00030" num="00030"><img id="EMI-C00030" he="21.00mm" wi="21.08mm" file="US20230000833A1-20230105-C00030.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0111" num="0000">wherein ring A is a 4-6 membered heterocycle optionally containing an additional oxygen heteroatom selected from the group consisting of: azetidinyl; azetidinyl substituted with one or two members independently selected from the group consisting of: F, OH, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>haloalkyl, CH<sub>2</sub>OCH<sub>3</sub>, CN, and OCH<sub>3</sub>; pyrrolidinyl; pyrrolidinyl substituted two F members; morpholinyl; piperidinyl; piperazinyl substituted with C<sub>1-6</sub>alkyl; and (2,6-diazaspiro[3.3]heptan-6-yl);<ul id="ul0058" list-style="none">    <li id="ul0058-0001" num="0000">    <ul id="ul0059" list-style="none">        <li id="ul0059-0001" num="0000">        <ul id="ul0060" list-style="none">            <li id="ul0060-0001" num="0204">(b)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0112" num="0000"><chemistry id="CHEM-US-00031" num="00031"><img id="EMI-C00031" he="20.66mm" wi="25.23mm" file="US20230000833A1-20230105-C00031.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0113" num="0000">wherein R<sup>4b </sup>is selected from the group consisting of: H; C<sub>1-6</sub>alkyl; CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>; C<sub>3-6</sub>cycloalkyl; C<sub>3-6</sub>cycloalkyl substituted substituted with two or three members independently selected from the group consisting of F or CH<sub>3</sub>; oxetanyl; oxetanyl substituted with CH<sub>3</sub>; and pyridinyl;<ul id="ul0061" list-style="none">    <li id="ul0061-0001" num="0000">    <ul id="ul0062" list-style="none">        <li id="ul0062-0001" num="0000">        <ul id="ul0063" list-style="none">            <li id="ul0063-0001" num="0205">(c)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0114" num="0000"><chemistry id="CHEM-US-00032" num="00032"><img id="EMI-C00032" he="10.75mm" wi="16.00mm" file="US20230000833A1-20230105-C00032.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0115" num="0000">wherein R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;<ul id="ul0064" list-style="none">    <li id="ul0064-0001" num="0000">    <ul id="ul0065" list-style="none">        <li id="ul0065-0001" num="0000">        <ul id="ul0066" list-style="none">            <li id="ul0066-0001" num="0206">(d)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0116" num="0000"><chemistry id="CHEM-US-00033" num="00033"><img id="EMI-C00033" he="15.58mm" wi="19.05mm" file="US20230000833A1-20230105-C00033.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0117" num="0000">wherein R<sup>4d </sup>is selected from the group consisting of: OH, C<sub>1-6</sub>alkyl, O&#x2014;C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, thienyl, and thiazolyl; and<ul id="ul0067" list-style="none">    <li id="ul0067-0001" num="0000">    <ul id="ul0068" list-style="none">        <li id="ul0068-0001" num="0000">        <ul id="ul0069" list-style="none">            <li id="ul0069-0001" num="0207">(e) C<sub>2-6</sub>alkyl substituted with one or two members independently selected from OH, OC<sub>1-6</sub>alkyl, or cyclopropyl; CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-6</sub>alkyl); CH<sub>2</sub>CH<sub>2</sub>NH(CH<sub>2</sub>CH<sub>2</sub>OH); CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>3-6</sub>cycloalkyl); and difluoro(3-pyridyl)methyl; and</li>        </ul>        </li>        <li id="ul0068-0002" num="0208">R<sup>1a </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>;<br/>and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides or solvates of compounds of Formula (I);</li>    </ul>    </li></ul></p><p id="p-0118" num="0209">and (B) at least one pharmaceutically acceptable excipient.</p><p id="p-0119" num="0210">An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IA), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IA), pharmaceutically acceptable prodrugs of compounds of Formula (IA), and pharmaceutically active metabolites of Formula (IA); and at least one pharmaceutically acceptable excipient.</p><p id="p-0120" num="0211">An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IB), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IB), pharmaceutically acceptable prodrugs of compounds of Formula (IB), and pharmaceutically active metabolites of Formula (IB); and at least one pharmaceutically acceptable excipient.</p><p id="p-0121" num="0212">An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IC), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IC), pharmaceutically acceptable prodrugs of compounds of Formula (IC), and pharmaceutically active metabolites of Formula (IC); and at least one pharmaceutically acceptable excipient.</p><p id="p-0122" num="0213">An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (ID), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (ID), pharmaceutically acceptable prodrugs of compounds of Formula (ID), and pharmaceutically active metabolites of Formula (ID); and at least one pharmaceutically acceptable excipient.</p><p id="p-0123" num="0214">An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound in Table 1, as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Table 1, pharmaceutically acceptable prodrugs of compounds of Table 1, and pharmaceutically active metabolites of Table 1; and at least one pharmaceutically acceptable excipient.</p><p id="p-0124" num="0215">Also within the scope of the invention are enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), and pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)).</p><p id="p-0125" num="0216">Also within the scope of the invention are isotopic variations of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), such as, e.g., deuterated compounds of Formula (I). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), and pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)).</p><p id="p-0126" num="0217">An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I):</p><p id="p-0127" num="0000"><chemistry id="CHEM-US-00034" num="00034"><img id="EMI-C00034" he="26.42mm" wi="55.12mm" file="US20230000833A1-20230105-C00034.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0128" num="0000">wherein<ul id="ul0070" list-style="none">    <li id="ul0070-0001" num="0000">    <ul id="ul0071" list-style="none">        <li id="ul0071-0001" num="0218">R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</li>        <li id="ul0071-0002" num="0219">R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>alkyl, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; pyridinyl substituted with F, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>haloalkyl; thiazolyl; thiazolyl substituted with C<sub>1-6</sub>alkyl or C<sub>1-6</sub>haloalkyl; thienyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>3</sub>, and cyclopropyl;</li>        <li id="ul0071-0003" num="0220">R<sup>3 </sup>is H;</li>        <li id="ul0071-0004" num="0221">R<sup>4 </sup>is selected from the group consisting of:        <ul id="ul0072" list-style="none">            <li id="ul0072-0001" num="0222">(a)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0129" num="0000"><chemistry id="CHEM-US-00035" num="00035"><img id="EMI-C00035" he="20.40mm" wi="22.18mm" file="US20230000833A1-20230105-C00035.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0130" num="0000">wherein ring A is a 4-6 membered heterocycle optionally containing an additional oxygen heteroatom selected from the group consisting of: azetidinyl; azetidinyl substituted with one or two members independently selected from the group consisting of: F, OH, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>haloalkyl, CH<sub>2</sub>OCH<sub>3</sub>, CN, and OCH<sub>3</sub>; pyrrolidinyl; pyrrolidinyl substituted two F members; morpholinyl; piperidinyl; piperazinyl substituted with C<sub>1-6</sub>alkyl; and (2,6-diazaspiro[3.3]heptan-6-yl);<ul id="ul0073" list-style="none">    <li id="ul0073-0001" num="0000">    <ul id="ul0074" list-style="none">        <li id="ul0074-0001" num="0000">        <ul id="ul0075" list-style="none">            <li id="ul0075-0001" num="0223">(b)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0131" num="0000"><chemistry id="CHEM-US-00036" num="00036"><img id="EMI-C00036" he="20.57mm" wi="25.40mm" file="US20230000833A1-20230105-C00036.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0132" num="0000">wherein R<sup>4b </sup>is selected from the group consisting of: H; C<sub>1-6</sub>alkyl; CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>; C<sub>3-6</sub>cycloalkyl; C<sub>3-6</sub>cycloalkyl substituted substituted with two or three members independently selected from the group consisting of F or CH<sub>3</sub>; oxetanyl; oxetanyl substituted with CH<sub>3</sub>; and pyridinyl;<ul id="ul0076" list-style="none">    <li id="ul0076-0001" num="0000">    <ul id="ul0077" list-style="none">        <li id="ul0077-0001" num="0000">        <ul id="ul0078" list-style="none">            <li id="ul0078-0001" num="0224">(c)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0133" num="0000"><chemistry id="CHEM-US-00037" num="00037"><img id="EMI-C00037" he="10.75mm" wi="16.00mm" file="US20230000833A1-20230105-C00037.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0134" num="0000">wherein R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;<ul id="ul0079" list-style="none">    <li id="ul0079-0001" num="0000">    <ul id="ul0080" list-style="none">        <li id="ul0080-0001" num="0000">        <ul id="ul0081" list-style="none">            <li id="ul0081-0001" num="0225">(d)</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0135" num="0000"><chemistry id="CHEM-US-00038" num="00038"><img id="EMI-C00038" he="15.66mm" wi="19.05mm" file="US20230000833A1-20230105-C00038.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0136" num="0000">wherein R<sup>4d </sup>is selected from the group consisting of: OH, C<sub>1-6</sub>alkyl, O&#x2014;C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, thienyl, and thiazolyl; and<ul id="ul0082" list-style="none">    <li id="ul0082-0001" num="0000">    <ul id="ul0083" list-style="none">        <li id="ul0083-0001" num="0000">        <ul id="ul0084" list-style="none">            <li id="ul0084-0001" num="0226">(e) C<sub>2-6</sub>alkyl substituted with one or two members independently selected from OH, OC<sub>1-6</sub>alkyl, or cyclopropyl; CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-6</sub>alkyl); CH<sub>2</sub>CH<sub>2</sub>NH(CH<sub>2</sub>CH<sub>2</sub>OH); CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>3-6</sub>cycloalkyl); and difluoro(3-pyridyl)methyl; and</li>        </ul>        </li>        <li id="ul0083-0002" num="0227">R<sup>1a </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>;<br/>and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides, or solvates thereof, to a subject in need thereof.</li>    </ul>    </li></ul></p><p id="p-0137" num="0228">An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), enantiomers and diastereromers of the compounds of Formula (I), isotopic variations of the compounds of Formula (I), and pharmaceutically acceptable salts of all of the foregoing.</p><p id="p-0138" num="0229">In preferred embodiments of the inventive method, the disease, disorder, or medical condition is selected from: neurologic and psychiatric disorders including, but not limited to: (1) mood disorders and mood affective disorders; (2) neurotic, stress-related and somatoform disorders including anxiety disorders; (3) disorders of psychological development; (4) behavioral syndromes associated with physiological disturbances and physical factors; (5) extrapyramidal and movement disorders; (6) episodic and paroxysmal disorders, epilepsy; (7) pain; (8) forms of neurodegeneration; (9) cerebrovascular diseases, acute and chronic; and any sequelae of cerebrovascular diseases.</p><p id="p-0139" num="0230">Examples of mood disorders and mood affective disorders that can be treated according to the present invention include, but are not limited to, bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, depressive disorder with postpartum onset, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder. In specific embodiments, the mood disorders and mood affective disorders that can be treated according to the present invention are major depressive disorder, treatment-resistant depression and bipolar disorder.</p><p id="p-0140" num="0231">Examples of disorders belonging to the neurotic, stress-related and somatoform disorders that can be treated according to the present invention include, but are not limited to, anxiety disorders, general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post-traumatic stress disorder (PTSD); other neurotic disorders such as depersonalisation-derealisation syndrome.</p><p id="p-0141" num="0232">Examples of disorders of psychological development that can be treated according to the present invention include, but are not limited to pervasive developmental disorders, including but not limited to Asperger's syndrome and Rett's syndrome, autistic disorders, childhood autism and overactive disorder associated with mental retardation and stereotyped movements, specific developmental disorder of motor function, specific developmental disorders of scholastic skills.</p><p id="p-0142" num="0233">Examples of behavioral syndromes associated with physiological disturbances and physical factors according to the present invention include, but are not limited to mental and behavioural disorders associated with childbirth, including but not limited to postnatal (postpartum) and prenatal depression; eating disorders, including but not limited to anorexia nervosa, bulimia nervosa, pica and binge eating disporder.</p><p id="p-0143" num="0234">Examples of extrapyramidal and movement disorders that can be treated according to the present invention include, but are not limited to Parkinson's disease; second Parkinsonism, such as postencephalitic Parkinsonism; Parkinsonism comprised in other disorders; Lewis body disease; degenerative diseases of the basal ganglia; other extrapyramidal and movement disorders including but not limited to tremor, essential tremor and drug-induced tremor, myoclonus, chorea and drug-induced chorea, drug-induced tics and tics of organic origin, drug-induced acute dystonia, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia; neuroleptic-induced movement disorders including but not limited to neuroleptic malignant syndrome (NMS), neuroleptic induced parkinsonism, neuroleptic-induced early onset or acute dyskinesia, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, neuroleptic-induced tremor; restless leg syndrome, Stiff-man syndrome.</p><p id="p-0144" num="0235">Further examples of movement disorders with malfunction and/or degeneration of basal ganglia that can be treated according to the present invention include, but are not limited to dystonia including but not limited to focal dystonia, multiple-focal or segmental dystonia, torsion dystonia, hemispheric, generalised and tardive dystonia (induced by psychopharmacological drugs). Focal dystonia include cervical dystonia (torticolli), blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in the extremities, like the writer's cramp), oromandibular dystonia and spasmodic dysphonia (cramp of the vocal cord);</p><p id="p-0145" num="0236">Examples for episodic and paroxysmal disorders that can be treated according to the present invention include, but are not limited to epilepsy, including localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, generalized idiopathic epilepsy and epileptic syndromes including but not limited to myoclonic epilepsy in infancy, neonatal convulsions (familial), childhood absence epilepsy (pyknolepsy), epilepsy with grand mal seizures on awakening, absence epilepsy, myoclonic epilepsy (impulsive petit mal) and nonspecific atonic, clonic, myoclonic, tonic, tonic-clonic epileptic seizures.</p><p id="p-0146" num="0237">Further examples of epilepsy that can be treated according to the present invention include, but are not limited to epilepsy with myoclonic absences, myoclonic-astatic seizures, infantile spasms, Lennox-Gastaut syndrome, Salaam attacks, symptomatic early myoclonic encephalopathy, West's syndrome, petit and grand mal seizures; status epilepticus.</p><p id="p-0147" num="0238">Examples of pain include, but are not limited to pain disorders related to psychological factors, such as persistent somatoform disorders; acute, chronic and chronic intractable pain, headache; acute and chronic pain related to physiological processes and physical disorders including but not limited to back pain, tooth pain, abdominal pain, low back pain, pain in joints; acute and chronic pain that is related to diseases of the musculoskeletal system and connective tissue including, but not limited to rheumatism, myalgia, neuralgia and fibromyalgia; acute and chronic pain that is related to nerve, nerve root and plexus disorders, such as trigeminal pain, postzoster neuralgia, phantom limb syndrome with pain, carpal tunnel syndrome, lesion of sciatic nerve, diabetic mononeuropathy; acute and chronic pain that is related to polyneuropathies and other disorders of the peripheral nervous system, such as hereditary and idiopathic neuropathy, inflammatory polyneuropathy, polyneuropathy induced by drugs, alcohol or toxic agents, polyneuropathy in neoplastic disease, diabetic polyneuropathy.</p><p id="p-0148" num="0239">Examples of diseases that include forms of neurodegeneration include, but are not limited to, acute neurodegeneration, such as intracranial brain injuries, such as stroke, diffuse and local brain injuries, epidural, subdural and subarachnoid haemorrhage, and chronic neurodegeneration, such as Alzheimer's disease, Huntington's disease, multiple sclerosis and ALS.</p><p id="p-0149" num="0240">Examples of cerebrovascular diseases include, but are not limited to, subarachnoid haemorrhage, intracerebral haemorrhage and other nontraumatic intracranial haemorrhage, cerebral infarction, stroke, occlusion and stenosis or precerebral and cerebral arteries, not resulting in cerebral infarction, dissection of cerebral arteries, cerebral aneurysm, cerebral atherosclerosis, progressive vascular leukoencephalopathy, hypertensive encephalopathy, nonpyogenic thrombosis of intracranial venous system, cerebral arteritis, cerebral amyloid angiopathy and sequelae of cerebrovascular diseases.</p><p id="p-0150" num="0241">In some embodiments, administration of a compound of the invention, or pharmaceutically acceptable salt thereof, is effective in preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.</p><p id="p-0151" num="0242">Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.</p><p id="p-0152" num="0243">The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. For the sake of brevity, the disclosures of the publications, including patents, cited in this specification are herein incorporated by reference.</p><p id="p-0153" num="0244">As used herein, the terms &#x201c;including&#x201d;, &#x201c;containing&#x201d; and &#x201c;comprising&#x201d; are used herein in their open, non-limiting sense.</p><p id="p-0154" num="0245">The term &#x201c;alkyl&#x201d; refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Examples of alkyl groups include methyl (Me, which also may be structurally depicted by the symbol, &#x201c;/&#x201d;), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples. The term C<sub>1-4</sub>alkyl as used here refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain. The term C<sub>1-6</sub>alkyl as used here refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain.</p><p id="p-0155" num="0246">The term &#x201c;alkoxy&#x201d; includes a straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on.</p><p id="p-0156" num="0247">The term &#x201c;aryl&#x201d; refers to a monocyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having 6 atoms per ring. (Carbon atoms in the aryl groups are sp<sup>2 </sup>hybridized.)</p><p id="p-0157" num="0248">The term &#x201c;phenyl&#x201d; represents the following moiety:</p><p id="p-0158" num="0000"><chemistry id="CHEM-US-00039" num="00039"><img id="EMI-C00039" he="11.60mm" wi="11.18mm" file="US20230000833A1-20230105-C00039.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0159" num="0249">The term &#x201c;thienyl&#x201d; represents the following moiety:</p><p id="p-0160" num="0000"><chemistry id="CHEM-US-00040" num="00040"><img id="EMI-C00040" he="9.74mm" wi="10.67mm" file="US20230000833A1-20230105-C00040.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0161" num="0250">The term &#x201c;heteroaryl&#x201d; refers to a monocyclic or fused bicyclic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 9 ring atoms per heterocycle. Illustrative examples of heteroaryl groups include the following entities, in the form of properly bonded moieties:</p><p id="p-0162" num="0000"><chemistry id="CHEM-US-00041" num="00041"><img id="EMI-C00041" he="68.92mm" wi="70.95mm" file="US20230000833A1-20230105-C00041.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0163" num="0251">Those skilled in the art will recognize that the species of heteroaryl, cycloalkyl, aryl and heterocycloalkyl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.</p><p id="p-0164" num="0252">A &#x201c;heterocycloalkyl&#x201d; refers to a monocyclic ring structure that is saturated or partially saturated and has from 4 to 7 ring atoms per ring structure selected from carbon atoms and up to two heteroatoms selected from nitrogen, oxygen, and sulfur. The ring structure may optionally contain up to two oxo groups on sulfur ring members. Illustrative entities, in the form of properly bonded moieties, include:</p><p id="p-0165" num="0000"><chemistry id="CHEM-US-00042" num="00042"><img id="EMI-C00042" he="37.00mm" wi="74.00mm" file="US20230000833A1-20230105-C00042.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0166" num="0253">The term &#x201c;cyano&#x201d; refers to the group &#x2014;CN.</p><p id="p-0167" num="0254">The term &#x201c;cycloalkyl&#x201d; refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:</p><p id="p-0168" num="0000"><chemistry id="CHEM-US-00043" num="00043"><img id="EMI-C00043" he="31.16mm" wi="64.18mm" file="US20230000833A1-20230105-C00043.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0169" num="0255">The term &#x201c;halo&#x201d; represents chloro, fluoro, bromo or iodo.</p><p id="p-0170" num="0256">The term &#x201c;perhaloalkyl&#x201d; or &#x201c;haloalkyl&#x201d; refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens. The term &#x201c;C<sub>1-4</sub>haloalkyl&#x201d; as used here refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain, optionally substituting hydrogens with halogens. The term &#x201c;C<sub>1-6</sub>haloalkyl&#x201d; as used here refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain, optionally substituting hydrogens with halogens. Examples of &#x201c;perhaloalkyl&#x201d;, &#x201c;haloalkyl&#x201d; groups include trifluoromethyl (CF<sub>3</sub>), difluoromethyl (CF<sub>2</sub>H), monofluoromethyl (CH<sub>2</sub>F), pentafluoroethyl (CF<sub>2</sub>CF<sub>3</sub>), tetrafluoroethyl (CHFCF<sub>3</sub>), monofluoroethyl (CH<sub>2</sub>CH<sub>2</sub>F), trifluoroethyl (CH<sub>2</sub>CF<sub>3</sub>), tetrafluorotrifluoromethylethyl (&#x2014;CF(CF<sub>3</sub>)<sub>2</sub>), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.</p><p id="p-0171" num="0257">The term &#x201c;perhaloalkoxy&#x201d; or &#x201c;haloalkoxy&#x201d; refers to a straight- or branched-chain alkoxy group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens. Examples of perhaloalkoxy groups include trifluoromethoxy (OCF<sub>3</sub>), difluoromethoxy (OCF<sub>2</sub>H), monofluoromethoxy (OCH<sub>2</sub>F), monofluoroethoxy (OCH<sub>2</sub>CH<sub>2</sub>F), pentafluoroethoxy (OCF<sub>2</sub>CF<sub>3</sub>), tetrafluoroethoxy (OCHFCF<sub>3</sub>), trifluoroethoxy (OCH<sub>2</sub>CF<sub>3</sub>), tetrafluorotrifluoromethylethoxy (&#x2014;OCF(CF<sub>3</sub>)<sub>2</sub>), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.</p><p id="p-0172" num="0258">The term &#x201c;substituted&#x201d; means that the specified group or moiety bears one or more substituents. The term &#x201c;unsubstituted&#x201d; means that the specified group bears no substituents. The term &#x201c;optionally substituted&#x201d; means that the specified group is unsubstituted or substituted by one or more substituents. Where the term &#x201c;substituted&#x201d; is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.</p><p id="p-0173" num="0259">The terms &#x201c;para&#x201d;, &#x201c;meta&#x201d;, and &#x201c;ortho&#x201d; have the meanings as understood in the art. Thus, for example, a fully substituted phenyl group has substituents at both &#x201c;ortho&#x201d;(o) positions adjacent to the point of attachment of the phenyl ring, both &#x201c;meta&#x201d; (m) positions, and the one &#x201c;para&#x201d; (p) position across from the point of attachment. To further clarify the position of substituents on the phenyl ring, the 2 different ortho positions will be designated as ortho and ortho' and the 2 different meta positions as meta and meta' as illustrated below.</p><p id="p-0174" num="0000"><chemistry id="CHEM-US-00044" num="00044"><img id="EMI-C00044" he="24.30mm" wi="29.13mm" file="US20230000833A1-20230105-C00044.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0175" num="0260">When referring to substituents on a pyridyl group, the terms &#x201c;para&#x201d;, &#x201c;meta&#x201d;, and &#x201c;ortho&#x201d; refer to the placement of a substituent relative to the point of attachment of the pyridyl ring. For example the structure below is described as 3-pyridyl with the X<sup>1 </sup>substituent in the ortho position, the X<sup>2 </sup>substituent in the meta position, and X<sup>3 </sup>substituent in the para position:</p><p id="p-0176" num="0000"><chemistry id="CHEM-US-00045" num="00045"><img id="EMI-C00045" he="21.84mm" wi="26.92mm" file="US20230000833A1-20230105-C00045.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0177" num="0261">To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term &#x201c;about&#x201d;. It is understood that, whether the term &#x201c;about&#x201d; is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value. Whenever a yield is given as a percentage, such yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be obtained under the particular stoichiometric conditions. Concentrations that are given as percentages refer to mass ratios, unless indicated differently.</p><p id="p-0178" num="0262">The terms &#x201c;buffered&#x201d; solution or &#x201c;buffer&#x201d; solution are used herein interchangeably according to their standard meaning. Buffered solutions are used to control the pH of a medium, and their choice, use, and function is known to those of ordinary skill in the art. See, for example, G. D. Considine, ed., Van Nostrand's Encyclopedia of Chemistry, p. 261, 5<sup>th </sup>ed. (2005), describing, inter alia, buffer solutions and how the concentrations of the buffer constituents relate to the pH of the buffer. For example, a buffered solution is obtained by adding MgSO<sub>4 </sub>and NaHCO<sub>3 </sub>to a solution in a 10:1 w/w ratio to maintain the pH of the solution at about 7.5.</p><p id="p-0179" num="0263">Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof. Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers.</p><p id="p-0180" num="0264">It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed &#x201c;isomers.&#x201d;</p><p id="p-0181" num="0265">Stereoisomers that are not mirror images of one another are termed &#x201c;diastereomers&#x201d; and those that are non-superimposable mirror images of each other are termed &#x201c;enantiomers.&#x201d; When a compound has an asymmetric center, for example, it is bonded to four different groups, and a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R-and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+)- or (&#x2212;)-isomers respectively). A chiral compound can exist as either an individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a &#x201c;racemic mixture.&#x201d;</p><p id="p-0182" num="0266">&#x201c;Tautomers&#x201d; refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of 7 electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci-and nitro-forms of phenyl nitromethane, that are likewise formed by treatment with acid or base.</p><p id="p-0183" num="0267">Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.</p><p id="p-0184" num="0268">The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof.</p><p id="p-0185" num="0269">Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.</p><p id="p-0186" num="0270">Certain examples contain chemical structures that are depicted as an absolute enantiomer but are intended to indicate enatiopure material that is of unknown configuration. In these cases (R*) or (S*) is used in the name to indicate that the absolute stereochemistry of the corresponding stereocenter is unknown. Thus, a compound designated as (R*) refers to an enantiopure compound with an absolute configuration of either (R) or (S). In cases where the absolute stereochemistry has been confirmed, the structures are named using (R) and (S).</p><p id="p-0187" num="0271">The symbols <img id="CUSTOM-CHARACTER-00001" he="3.22mm" wi="10.58mm" file="US20230000833A1-20230105-P00001.TIF" alt="custom-character" img-content="character" img-format="tif"/> and <img id="CUSTOM-CHARACTER-00002" he="3.22mm" wi="10.24mm" file="US20230000833A1-20230105-P00002.TIF" alt="custom-character" img-content="character" img-format="tif"/> are used as meaning the same spatial arrangement in chemical structures shown herein. Analogously, the symbols <img id="CUSTOM-CHARACTER-00003" he="3.22mm" wi="10.92mm" file="US20230000833A1-20230105-P00003.TIF" alt="custom-character" img-content="character" img-format="tif"/> and <img id="CUSTOM-CHARACTER-00004" he="3.22mm" wi="11.26mm" file="US20230000833A1-20230105-P00004.TIF" alt="custom-character" img-content="character" img-format="tif"/> are used as meaning the same spatial arrangement in chemical structures shown herein.</p><p id="p-0188" num="0272">Additionally, any formula given herein is intended to refer also to hydrates, solvates, and polymorphs of such compounds, and mixtures thereof, even if such forms are not listed explicitly. Certain compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), or pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) may be obtained as solvates. Solvates include those formed from the interaction or complexation of compounds of the invention with one or more solvents, either in solution or as a solid or crystalline form. In some embodiments, the solvent is water and the solvates are hydrates. In addition, certain crystalline forms of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) or pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) may be obtained as co-crystals. In certain embodiments of the invention, compounds of Formula (I) were obtained in a crystalline form. In other embodiments, crystalline forms of compounds of Formula (I) were cubic in nature. In other embodiments, pharmaceutically acceptable salts of compounds of Formula (I) were obtained in a crystalline form. In still other embodiments, compounds of Formula (I) were obtained in one of several polymorphic forms, as a mixture of crystalline forms, as a polymorphic form, or as an amorphous form. In other embodiments, compounds of Formula (I) convert in solution between one or more crystalline forms and/or polymorphic forms.</p><p id="p-0189" num="0273">Reference to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named. For example, reference herein to a compound such as R&#x2014;COOH, encompasses reference to any one of, for example, R&#x2014;COOH<sub>(s)</sub>, R&#x2014;COOH<sub>(sol)</sub>, and R&#x2014;COO<sup>&#x2212;</sup><sub>(sol)</sub>. In this example, R&#x2014;COOH<sub>(s) </sub>refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation; R&#x2014;COOH<sub>(sol) </sub>refers to the undissociated form of the compound in a solvent; and R&#x2014;COO<sup>&#x2212;</sup><sub>(sol) </sub>refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R&#x2014;COOH, from a salt thereof, or from any other entity that yields R&#x2014;COO<sup>&#x2212;</sup> upon dissociation in the medium being considered. In another example, an expression such as &#x201c;exposing an entity to compound of formula R&#x2014;COOH&#x201d; refers to the exposure of such entity to the form, or forms, of the compound R&#x2014;COOH that exists, or exist, in the medium in which such exposure takes place. In still another example, an expression such as &#x201c;reacting an entity with a compound of formula R&#x2014;COOH&#x201d; refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R&#x2014;COOH that exists, or exist, in the medium in which such reacting takes place. In this regard, if such entity is for example in an aqueous environment, it is understood that the compound R&#x2014;COOH is in such same medium, and therefore the entity is being exposed to species such as R&#x2014;COOH<sub>(aq) </sub>and/or R&#x2014;COO<sup>&#x2212;</sup><sub>(aq)</sub>, where the subscript &#x201c;(aq)&#x201d; stands for &#x201c;aqueous&#x201d; according to its conventional meaning in chemistry and biochemistry. A carboxylic acid functional group has been chosen in these nomenclature examples; this choice is not intended, however, as a limitation but it is merely an illustration. It is understood that analogous examples can be provided in terms of other functional groups, including but not limited to hydroxyl, basic nitrogen members, such as those in amines, and any other group that interacts or transforms according to known manners in the medium that contains the compound. Such interactions and transformations include, but are not limited to, dissociation, association, tautomerism, solvolysis, including hydrolysis, solvation, including hydration, protonation, and deprotonation. No further examples in this regard are provided herein because these interactions and transformations in a given medium are known by any one of ordinary skill in the art.</p><p id="p-0190" num="0274">In another example, a zwitterionic compound is encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form. Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name identification CHEBI:27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities. As generally well known, a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term &#x201c;inner salts&#x201d;. Other sources refer to these compounds as &#x201c;dipolar ions&#x201d;, although the latter term is regarded by still other sources as a misnomer. As a specific example, am inoethanoic acid (the amino acid glycine) has the formula H<sub>2</sub>NCH<sub>2</sub>COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion <sup>+</sup>H<sub>3</sub>NCH<sub>2</sub>COO<sup>&#x2212;</sup>. Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this invention are given explicitly herein. They are, however, part of the embodiments of this invention. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.</p><p id="p-0191" num="0275">Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine such as <sup>2</sup>H, <sup>3</sup>H, <sup>11</sup>C, <sup>13</sup>C, <sup>14</sup>C, <sup>15</sup>N, <sup>18</sup>O, <sup>17</sup>O, <sup>31 </sup>P, <sup>32</sup>P, <sup>35</sup>S, <sup>18</sup>F, <sup>36</sup>Cl, <sup>125</sup>I, respectively. Such isotopically labeled compounds are useful in metabolic studies (preferably with <sup>14</sup>C), reaction kinetic studies (with, for example deuterium (i.e., D or <sup>2</sup>H); or tritium (i.e., T or <sup>3</sup>H)), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an <sup>18</sup>F or <sup>11</sup>C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., <sup>2</sup>H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.</p><p id="p-0192" num="0276">When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.</p><p id="p-0193" num="0277">According to the foregoing interpretive considerations on assignments and nomenclature, it is understood that explicit reference herein to a set implies, where chemically meaningful and unless indicated otherwise, independent reference to embodiments of such set, and reference to each and every one of the possible embodiments of subsets of the set referred to explicitly.</p><p id="p-0194" num="0278">By way of a first example on substituent terminology, if substituent S<sup>1</sup><sub>example </sub>is one of S<sub>1 </sub>and S<sub>2</sub>, and substituent S<sup>2</sup><sub>example </sub>is one of S<sub>3 </sub>and S<sub>4</sub>, then these assignments refer to embodiments of this invention given according to the choices S<sup>1</sup><sub>example </sub>is S<sub>1 </sub>and S<sup>2</sup><sub>example </sub>is S<sub>3</sub>; S<sup>1</sup><sub>example </sub>is S<sub>1 </sub>and S<sup>2</sup><sub>example </sub>is S<sub>4</sub>; S<sup>1</sup><sub>example </sub>is S<sub>2 </sub>and S<sup>2</sup><sub>example </sub>is S<sub>3</sub>; S<sup>1</sup><sub>example </sub>is S<sub>2 </sub>and S<sup>2</sup><sub>example </sub>is S<sub>4</sub>; and equivalents of each one of such choices. The shorter terminology &#x201c;S<sup>1</sup><sub>example </sub>is one of S<sub>1 </sub>and S<sub>2</sub>, and S<sup>2</sup><sub>example </sub>is one of S<sub>3 </sub>and S<sub>4</sub>&#x201d; is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to members such as R<sup>1</sup>, R<sup>1a</sup>, R<sup>1b</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>4b</sup>, R<sup>4c</sup>, R<sup>4d</sup>, R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup>, Het<sup>1</sup>, HAL<sup>1</sup>, PG, Y, and ring A, and any other generic substituent symbol used herein.</p><p id="p-0195" num="0279">Furthermore, when more than one assignment is given for any member or substituent, embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof. By way of a second example on substituent terminology, if it is herein described that substituent S<sub>example </sub>is one of S<sub>1</sub>, S<sub>2</sub>, and S<sub>3</sub>, this listing refers to embodiments of this invention for which S<sub>example </sub>is S<sub>1</sub>; S<sub>example </sub>is S<sub>2</sub>; S<sub>example </sub>is S<sub>3</sub>; S<sub>example </sub>is one of S<sub>1 </sub>and S<sub>2</sub>; S<sub>example </sub>is one of S<sub>1 </sub>and S<sub>3</sub>S<sub>example </sub>is one of S<sub>2 </sub>and S<sub>3</sub>; S<sub>example </sub>is one of S<sub>1</sub>, S<sub>2 </sub>and S<sub>3</sub>; and S<sub>example </sub>is any equivalent of each one of these choices. The shorter terminology &#x201c;S<sub>example </sub>is one of S<sub>1</sub>, S<sub>2</sub>, and S<sub>3</sub>&#x201d; is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing second example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to members such as R<sup>1</sup>, R<sup>1a</sup>, R<sup>1b</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>4b</sup>, R<sup>4c</sup>, R<sup>4d</sup>, R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup>, Het<sup>1</sup>, HAL<sup>1</sup>, PG, Y, and ring A, and any other generic substituent symbol used herein.</p><p id="p-0196" num="0280">The nomenclature &#x201c;C<sub>i-j</sub>&#x201d; with j&#x3e;i, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized. By way of example, the term C<sub>1-4 </sub>refers independently to embodiments that have one carbon member (C<sub>1</sub>), embodiments that have two carbon members (C<sub>2</sub>), embodiments that have three carbon members (C<sub>3</sub>), and embodiments that have four carbon members (C<sub>4</sub>).</p><p id="p-0197" num="0281">The term C<sub>n-m</sub>alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n&#x2264;N&#x2264;m, with m&#x3e;n. Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed. For example, reference to disubstituent &#x2014;A&#x2014;B&#x2014;, where A&#x2260;B, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.</p><p id="p-0198" num="0282">The invention includes also pharmaceutically acceptable salts of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), preferably of those described above and of the specific compounds exemplified herein, and methods of treatment using such salts.</p><p id="p-0199" num="0283">The term &#x201c;pharmaceutically acceptable&#x201d; means approved or approvable by a regulatory agency of Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U. S. Pharmcopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.</p><p id="p-0200" num="0284">A &#x201c;pharmaceutically acceptable salt&#x201d; is intended to mean a salt of a free acid or base of compounds represented by Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) that are non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. It should possess the desired pharmacological activity of the parent compound. See, generally, G. S. Paulekuhn, et al., &#x201c;Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database&#x201d;, <i>J. Med. Chem., </i>2007, 50:6665-72, S. M. Berge, et al., &#x201c;Pharmaceutical Salts&#x201d;, <i>J Pharm Sci., </i>1977, 66:1-19, and <i>Handbook of Pharmaceutical Salts, Properties, Selection, </i>and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Examples of pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. A compound of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.</p><p id="p-0201" num="0285">Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, &#x3b3;-hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.</p><p id="p-0202" num="0286">When the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) contain a basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art. For example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palm itic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid, glutaric acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.</p><p id="p-0203" num="0287">When the compound of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) is an acid, such as a carboxylic acid or sulfonic acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology. Illustrative examples of suitable salts include organic salts derived from amino acids, such as N-methyl-D-glucamine, lysine, choline, glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.</p><p id="p-0204" num="0288">The invention also relates to pharmaceutically acceptable prodrugs of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), and treatment methods employing such pharmaceutically acceptable prodrugs. The term &#x201c;prodrug&#x201d; means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I). A &#x201c;pharmaceutically acceptable prodrug&#x201d; is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in &#x201c;<i>Design of Prodrugs&#x201d;</i>, ed. H. Bundgaard, Elsevier, 1985.</p><p id="p-0205" num="0289">Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxyl, or carboxylic acid group of a compound of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Examples of amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-am inobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.</p><p id="p-0206" num="0290">Additional types of prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) as amides or alkyl esters. Examples of amides include those derived from ammonia, primary C<sub>1-6</sub>alkyl amines and secondary di(C<sub>1-6</sub>alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties. Examples of amides include those that are derived from ammonia, C<sub>1-3</sub>alkyl primary amines, and di(C<sub>1-2</sub>alkyl)amines. Examples of esters of the invention include C<sub>1-7</sub>alkyl, C<sub>5-7</sub>cycloalkyl, phenyl, and phenyl(C<sub>1-6</sub>alkyl) esters. Preferred esters include methyl esters. Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Fleisher et al., <i>Adv. Drug Delivery Rev. </i>1996, 19, 115-130. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs. Prodrugs of this type may be prepared as described in Robinson et al., <i>J Med Chem. </i>1996, 39 (1), 10-18. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.</p><p id="p-0207" num="0291">The present invention also relates to pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), which may also be used in the methods of the invention. A &#x201c;pharmaceutically active metabolite&#x201d; means a pharmacologically active product of metabolism in the body of a compound of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID) as applicable) or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini, et al., <i>J Med Chem. </i>1997, 40, 2011-2016; Shan, et al., <i>J Pharm Sci. </i>1997, 86 (7), 765-767; Bagshawe, <i>Drug Dev Res. </i>1995, 34, 220-230; Bodor, <i>Adv Drug Res. </i>1984, 13, 224-331; Bundgaard, <i>Design of Prodrugs </i>(Elsevier Press, 1985); and Larsen, <i>Design and Application of Prodrugs, Drug Design and Development </i>(Krogsgaard-Larsen, et al., eds., Harwood Academic Publishers, 1991).</p><p id="p-0208" num="0292">The compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of the present invention are useful as modulators of the NR2B receptor in the methods of the invention. As such modulators, the compounds may act as antagonists, agonists, or inverse agonists. The term &#x201c;modulators&#x201d; include both inhibitors and activators, where &#x201c;inhibitors&#x201d; refer to compounds that decrease, prevent, inactivate, desensitize, or down-regulate the NR2B receptor expression or activity, and &#x201c;activators&#x201d; are compounds that increase, activate, facilitate, sensitize, or up-regulate NR2B receptor expression or activity.</p><p id="p-0209" num="0293">The term &#x201c;treat&#x201d;, &#x201c;treatment&#x201d; or &#x201c;treating&#x201d;, as used herein, is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of affecting a therapeutic or prophylactic benefit through modulation of NR2B receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of NR2B receptor activity. The term &#x201c;subject&#x201d; refers to a mammalian patient in need of such treatment, such as a human.</p><p id="p-0210" num="0294">Accordingly, the invention relates to methods of using the compounds described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated by NR2B receptor activity, such as: bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, depressive disorder with postpartum onset, disruptive mood dysregulation disorder, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder; anxiety disorders, general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post traumatic stress disorder (PTSD); other neurotic disorders such as depersonalisation-derealisation syndrome; pervasive developmental disorders, including but not limited to Asperger's syndrome and Rett's syndrome, autistic disorders, childhood autism and overactive disorder associated with mental retardation and stereotyped movements, specific developmental disorder of motor function, specific developmental disorders of scholastic skills; postnatal (postpartum) and prenatal depression; eating disorders, including but not limited to anorexia nervosa, bulimia nervosa, pica and binge eating disorder; Parkinson's disease; second Parkinsonism, such as postencephalitic Parkinsonism; Parkinsonism comprised in other disorders; Lewis body disease; degenerative diseases of the basal ganglia; other extrapyramidal and movement disorders including but not limited to tremor, essential tremor and drug-induced tremor, myoclonus, chorea and drug-induced chorea, drug-induced tics and tics of organic origin, drug-induced acute dystonia, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia; neuroleptic-induced movement disorders including but not limited to neuroleptic malignant syndrome (NMS), neuroleptic induced parkinsonism, neuroleptic-induced early onset or acute dyskinesia, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, neuroleptic-induced tremor; restless leg syndrome, Stiff-man syndrome; dystonia including but not limited to focal dystonia, multiple-focal or segmental dystonia, torsion dystonia, hemispheric, generalised and tardive dystonia (induced by psychopharmacological drugs). Focal dystonia include cervical dystonia (torticolli), blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in the extremities, like the writer's cramp), oromandibular dystonia and spasmodic dysphonia (cramp of the vocal cord); epilepsy, including localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, generalized idiopathic epilepsy and epileptic syndromes including but not limited to myoclonic epilepsy in infancy, neonatal convulsions (familial), childhood absence epilepsy (pyknolepsy), epilepsy with grand mal seizures on awakening, absence epilepsy, myoclonic epilepsy (impulsive petit mal) and nonspecific atonic, clonic, myoclonic, tonic, tonic-clonic epileptic seizures; epilepsy with myoclonic absences, myoclonic-astatic seizures, infantile spasms, Lennox-Gastaut syndrome, Salaam attacks, symptomatic early myoclonic encephalopathy, West's syndrome, petit and grand mal seizures; status epilepticus; persistent somatoform disorders; acute, chronic and chronic intractable pain, headache; acute and chronic pain related to physiological processes and physical disorders including but not limited to back pain, tooth pain, abdominal pain, low back pain, pain in joints; acute and chronic pain that is related to diseases of the musculoskeletal system and connective tissue including, but not limited to rheumatism, myalgia, neuralgia and fibromyalgia; acute and chronic pain that is related to nerve, nerve root and plexus disorders, such as trigeminal pain, postzoster neuralgia, phantom limb syndrome with pain, carpal tunnel syndrome, lesion of sciatic nerve, diabetic mononeuropathy; acute and chronic pain that is related to polyneuropathies and other disorders of the peripheral nervous system, such as hereditary and idiopathic neuropathy, inflammatory polyneuropathy, polyneuropathy induced by drugs, alcohol or toxic agents, polyneuropathy in neoplastic disease, diabetic polyneuropathy; and acute neurodegeneration, such as intracranial brain injuries, such as stroke, diffuse and local brain injuries, epidural, subdural and subarachnoid haemorrhage, and chronic neurodegeneration, such as Alzheimer's disease, Huntington's disease, multiple sclerosis, and ALS; subarachnoid haemorrhage, intracerebral haemorrhage and other nontraumatic intracranial haemorrhage, cerebral infarction, stroke, occlusion and stenosis or precerebral and cerebral arteries, not resulting in cerebral infarction, dissection of cerebral arteries, cerebral aneurysm, cerebral atherosclerosis, progressive vascular leukoencephalopathy, hypertensive encephalopathy, nonpyogenic thrombosis of intracranial venous system, cerebral arteritis, cerebral amyloid angiopathy and sequelae of cerebrovascular diseases; glaucoma and other neuopathies; dementias, vascular demensia, Lewy body dementia, frontotemporal dementia, and HIV-dementia; vertigo and nystagmus; tinnitus; neuropsychiatric systemic lupus erythematosus; disruptive mood dysregulation disorder; schizophrenia spectrum disorder; and sleep/wake disorders. In specific embodiments, subjects that can be treated according to the present invention are diagnosed with or suffering from major depressive disorder, treatment-resistant depression and bipolar disorder.</p><p id="p-0211" num="0295">In treatment methods according to the invention, an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. An &#x201c;effective amount&#x201d; means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.</p><p id="p-0212" num="0296">Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.</p><p id="p-0213" num="0297">In addition, the active agents of the invention may be used in combination with additional active ingredients in the treatment of the above conditions. The additional active ingredients may be co-administered separately with an active agent of compounds of Table 1 or included with such an agent in a pharmaceutical composition according to the invention. In an exemplary embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by NR2B activity, such as another NR2B modulator or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.</p><p id="p-0214" num="0298">The active agents of the invention are used, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of at least one active agent in accordance with the invention; and (b) a pharmaceutically acceptable excipient.</p><p id="p-0215" num="0299">A &#x201c;pharmaceutically acceptable excipient&#x201d; refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.</p><p id="p-0216" num="0300">Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.</p><p id="p-0217" num="0301">The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.</p><p id="p-0218" num="0302">For oral administration, the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the compounds may be formulated to yield a dosage of, e.g., from about 0.05 to about 100 mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily. For example, a total daily dosage of about 5 mg to 5 g daily may be accomplished by dosing once, twice, three, or four times per day.</p><p id="p-0219" num="0303">Oral tablets may include a compound according to the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.</p><p id="p-0220" num="0304">Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.</p><p id="p-0221" num="0305">Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.</p><p id="p-0222" num="0306">The active agents of this invention may also be administered by non-oral routes. For example, the compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the compounds of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses may range from about 1 to 1000 &#x3bc;g/kg/minute of compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.</p><p id="p-0223" num="0307">For topical administration, the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery.</p><p id="p-0224" num="0308">Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.</p><p id="p-0225" num="0309">Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Unless otherwise specified, the variables are as defined above in reference to Formula (I). Reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0&#xb0; C. and the reflux temperature of the solvent. Reactions may be heated employing conventional heating or microwave heating. Reactions may also be conducted in sealed pressure vessels above the normal reflux temperature of the solvent.</p><p id="p-0226" num="0310">Abbreviations and acronyms used herein include the following:</p><p id="p-0227" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="161pt" align="left"/><colspec colname="2" colwidth="56pt" align="left"/><thead><row><entry namest="1" nameend="2" rowsep="1">TABLE 2</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry>Term</entry><entry>Acronym</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Acetonitrile</entry><entry>ACN</entry></row><row><entry>Aqueous</entry><entry>aq</entry></row><row><entry>Atmosphere</entry><entry>atm</entry></row><row><entry>Gold(III) chloride</entry><entry>Au(III)Cl<sub>3</sub></entry></row><row><entry>tert-Butylcarbamoyl</entry><entry>Boc</entry></row><row><entry>Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium</entry><entry>BOP</entry></row><row><entry>hexafluorophosphate</entry><entry/></row><row><entry>Broad</entry><entry>br</entry></row><row><entry>1,1&#x2032;-Carbonyldiimidazole</entry><entry>CDI</entry></row><row><entry>Diatomaceous Earth</entry><entry>Celite&#x2009;&#xae;</entry></row><row><entry>Diethylaminosulfur trifluoride</entry><entry>DAST</entry></row><row><entry>1,8-Diazabicyclo[5.4.0]undec-7-ene</entry><entry>DBU</entry></row><row><entry>N,N&#x2032;-Dicyclohexylcarbodiimide</entry><entry>DCC</entry></row><row><entry>Dichloroethane</entry><entry>DCE</entry></row><row><entry>Dichloromethane</entry><entry>DCM</entry></row><row><entry>Bis(2-methoxyethyl)aminosulfur trifluoride</entry><entry>Deoxo-Fluor&#x2009;&#xae;</entry></row><row><entry>Diisopropylethylamine</entry><entry>DIPEA, DIEA, or</entry></row><row><entry/><entry>Hunig's base</entry></row><row><entry>4-Dimethylaminopyridine</entry><entry>DMAP</entry></row><row><entry>1,2-Dimethoxyethane</entry><entry>DME</entry></row><row><entry>N,N-Dimethylformamide</entry><entry>DMF</entry></row><row><entry>Dimethylsulfoxide</entry><entry>DMSO</entry></row><row><entry>1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide</entry><entry>EDCI, EDAC, or</entry></row><row><entry/><entry>EDC</entry></row><row><entry>Diethyl ether</entry><entry>Ether, Et<sub>2</sub>O</entry></row><row><entry>Ethyl Acetate</entry><entry>EtOAc, or EA</entry></row><row><entry>Ethanol</entry><entry>EtOH</entry></row><row><entry>Electrospray ionization</entry><entry>ESI</entry></row><row><entry>Normal-phase silica gel chromatography</entry><entry>FCC</entry></row><row><entry>Grams</entry><entry>g</entry></row><row><entry>Hours</entry><entry>h</entry></row><row><entry>1-[Bis(dimethylamino)methylene]-1H-1,2,3-</entry><entry>HATU</entry></row><row><entry>triazolo[4,5-b]pyridinium 3-oxid</entry><entry/></row><row><entry>hexafluorophosphate</entry><entry/></row><row><entry>N,N,N&#x2032;,N&#x2032;-Tetramethyl-O-(1H-benzotriazol-1-</entry><entry>HBTU</entry></row><row><entry>yl)uronium hexafluorophosphate</entry><entry/></row><row><entry>Hydroxybenzotriazole</entry><entry>HOBt</entry></row><row><entry>High-pressure liquid chromatography</entry><entry>HPLC</entry></row><row><entry>Hertz</entry><entry>Hz</entry></row><row><entry>Isopropyl alcohol</entry><entry>iPrOH, IPA</entry></row><row><entry>Liquid chromatography and mass spectrometry</entry><entry>LCMS</entry></row><row><entry>Lithium bis(trimethylsilyl)amide</entry><entry>LHMDS</entry></row><row><entry>Molar</entry><entry>M</entry></row><row><entry>Mass to charge ratio</entry><entry>m/z</entry></row><row><entry>meta-Chloroperoxybenzoic acid</entry><entry>mCPBA</entry></row><row><entry>Methyl Iodide</entry><entry>MeI</entry></row><row><entry>Methanol</entry><entry>MeOH</entry></row><row><entry>Milligrams</entry><entry>mg</entry></row><row><entry>Minute</entry><entry>min</entry></row><row><entry>Milliliter</entry><entry>mL</entry></row><row><entry>Microliter</entry><entry>&#x3bc;L</entry></row><row><entry>Millimoles</entry><entry>mmol</entry></row><row><entry>Mass spectrometry</entry><entry>MS</entry></row><row><entry>Normal</entry><entry>N</entry></row><row><entry>N-Bromosuccinimide</entry><entry>NBS</entry></row><row><entry>N-Chlorosuccinimide</entry><entry>NCS</entry></row><row><entry>N-Iodosuccinimide</entry><entry>NIS</entry></row><row><entry>Nuclear magnetic resonance</entry><entry>NMR</entry></row><row><entry>CF<sub>3</sub>SO<sub>3</sub>&#x2014; or triflate</entry><entry>OTf</entry></row><row><entry>Palladium(II)bis(triphenylphosphine) dichloride</entry><entry>Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub></entry></row><row><entry>Tetrakis(triphenylphosphine)palladium(0)</entry><entry>Pd(PPh<sub>3</sub>)<sub>4</sub></entry></row><row><entry>[1,1&#x2032;-Bis(di-tert-</entry><entry>PdCl<sub>2</sub>(dtbpf) or</entry></row><row><entry>butylphosphino)ferrocene]dichloropalladium(II)</entry><entry>Pd(dtbpf)<sub>2</sub>Cl<sub>2</sub></entry></row><row><entry>[1,1&#x2032;-Bis(diphenylphosphino)ferrocene]dichloro-</entry><entry>PdCl<sub>2</sub>(dppf) or</entry></row><row><entry>palladium(II)</entry><entry>Pd(dppf)<sub>2</sub>Cl<sub>2</sub></entry></row><row><entry>Parts per million</entry><entry>ppm</entry></row><row><entry>Precipitate</entry><entry>ppt</entry></row><row><entry>Polytetrafluoroethylene</entry><entry>PTFE</entry></row><row><entry>Bromotripyrrolidinophosphonium hexafluorophosphate</entry><entry>PyBroP&#x2009;&#xae;</entry></row><row><entry>Retention time</entry><entry>R<sub>t</sub></entry></row><row><entry>Room temperature</entry><entry>rt</entry></row><row><entry>Saturated</entry><entry>sat</entry></row><row><entry>1-Chloromethyl-4-fluoro-1,4-</entry><entry>Selectfluor&#x2009;&#xae;</entry></row><row><entry>diazoniabicyclo[2.2.2]octane</entry><entry/></row><row><entry>bis(tetrafluoroborate)</entry><entry/></row><row><entry>[2-(Trimethylsilyl)ethoxy]methyl acetal</entry><entry>SEM</entry></row><row><entry>Supercritical Fluid Chromatography</entry><entry>SFC</entry></row><row><entry>Temperature</entry><entry>T</entry></row><row><entry>Triphenylmethyl</entry><entry>Trityl</entry></row><row><entry>Tetra-n-butylammonium fluoride</entry><entry>TBAF</entry></row><row><entry>Triethylamine</entry><entry>TEA</entry></row><row><entry>Trifluoroacetic acid</entry><entry>TFA</entry></row><row><entry>2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-</entry><entry>T<sub>3</sub>P</entry></row><row><entry>2,4,6-trioxide</entry><entry/></row><row><entry>Tetrahydrofuran</entry><entry>THF</entry></row><row><entry>Thin layer chromatography</entry><entry>TLC</entry></row><row><entry>Volume in milliliters of solvent per gram of substrate</entry><entry>V, or volumes</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0006" level="1">PREPARATIVE EXAMPLES</heading><p id="p-0228" num="0311">Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples to follow.</p><p id="p-0229" num="0000"><chemistry id="CHEM-US-00046" num="00046"><img id="EMI-C00046" he="13.97mm" wi="43.35mm" file="US20230000833A1-20230105-C00046.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0230" num="0312">According to SCHEME 1, a compound of formula (IV), where Y is a suitable leaving group such as Cl or &#x2014;OSO<sub>2</sub>CH<sub>3</sub>and Het<sup>1 </sup>is a suitably substituted heteroaryl such as pyrimidinyl, pyrazinyl, pyridinyl, is prepared from a compound of formula (III), under conditions known to one skilled in the art. For example, a compound of formula (III) is reacted with a base such as TEA, methanesulfonyl chloride, in a solvent such as DCM, a temperatures ranging from 0&#xb0; C. to rt, to afford a compound of formula (IV), where Y is &#x2014;OSO<sub>2</sub>CH<sub>3</sub>. A compound of formula (III), where Het<sup>1 </sup>is pyrazinyl, pyridazinyl, pyrimidinyl and the like, is reacted under chlorination conditions, for example, reaction with thionyl chloride, and the like, in a solvent such as DCM, a temperatures ranging from 0&#xb0; C. to rt, to afford a compound of formula (IV), where Y is Cl.</p><p id="p-0231" num="0000"><chemistry id="CHEM-US-00047" num="00047"><img id="EMI-C00047" he="53.68mm" wi="66.63mm" file="US20230000833A1-20230105-C00047.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0232" num="0313">According to SCHEME 2, 2-bromoacetyl chloride is reacted with a commercially available or synthetically accessible suitably substituted heterocycloalkylamine of formula (V), where A is a fully saturated or partially saturated 3-6 membered ring optionally containing additional S, N, or O atoms, or suitably substituted amine of formula (VI), where R<sup>4b </sup>and R<sup>1b </sup>are as defined in Formula (I), in the presence of a suitable base such as Et<sub>3</sub>N (TEA), in a solvent such as acetonitrile (ACN), at temperatures ranging from &#x2212;78&#xb0; C. to rt, to provide a compound of formula (VII) or (VIII).</p><p id="p-0233" num="0000"><chemistry id="CHEM-US-00048" num="00048"><img id="EMI-C00048" he="91.10mm" wi="75.95mm" file="US20230000833A1-20230105-C00048.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0234" num="0314">According to SCHEME 3, a compound of formula (Xa) is prepared from a compound of formula (IX), where HAL<sup>1 </sup>is Cl or Br, by reaction with an amine such as methylamine, benzhydrylamine and the like, with or without a base such as DIPEA, in a solvent such as THF, EtOH, and the like, at temperatures ranging from 0&#xb0; C. to the reflux temperature of the solvent, for a period of 3 to 24 h to provide a compound of formula (Xa), where R<sup>a </sup>is CH<sub>3 </sub>or benzhydryl. Reduction of the nitro compound of formula (Xa), where R<sup>a </sup>is H, CH<sub>3</sub>, or a suitable nitrogen protecting group such as benzhydryl, employing conditions known to one skilled in the art, provides a diamine compound of formula (XI). For example, reduction with zinc in the presence of NH<sub>4</sub>Cl, in a solvent such as acetone/water, for a period of 24 to 72 h; or reduction with Pt/C, aq. H<sub>3</sub>PO<sub>2</sub>, NH<sub>4</sub>VO<sub>3</sub>, under H<sub>2</sub>, at temperatures ranging from 20 to 45&#xb0; C., for a period of 1-3 h; or reduction with Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, NH<sub>3 </sub>in H<sub>2</sub>O, in a solvent such as THF, water, or a mixture thereof, provides a compound of formula (XI), where R<sup>a </sup>is H, CH<sub>3 </sub>or benzhydryl and R<sup>c </sup>is H.</p><p id="p-0235" num="0315">A compound of formula (Xb) is prepared from in two steps from 4-chloro-3-nitropyridin-2-amine. In the first step, 4-chloro-3-nitropyridin-2-amine is halogenated with a halogenating agent such as N-bromosuccinimide (NBS), in a solvent such as ACN, at temperatures ranging from rt to 80&#xb0; C. In the second step, 5-bromo-4-chloro-3-nitropyridin-2-amine is protected with a suitable nitrogen protecting group (PG) such as BOC, and the like, under conditions known to one skilled in the art, to provide a compound of formula (Xb).</p><p id="p-0236" num="0316">A compound of formula (XI), where R<sup>a </sup>is CH<sub>3 </sub>and R<sup>c </sup>is Cl, is prepared in three steps from a compound of formula (Xb). In the first step, alkylation with an alkylating agent such as Mel, in a solvent such as DMF, THF and the like, at temperatures ranging from 0&#xb0; C. to rt, for a period of 3 to 16 h. In the second step, deprotection of the tert-butylcarbamate protecting group (PG), is achieved by reaction with an acid such as TFA, in a solvent such as DCM, and the like, at rt. In the third step, reduction of the nitro group employing reduction conditions previously described, affords a compound of formula (XI), where R<sup>a </sup>is CH<sub>3 </sub>and R<sup>c </sup>is Cl.</p><p id="p-0237" num="0317">Cyclization of a commercially available or synthetically accessible compound of formula (XI), where R<sup>a </sup>is H; a suitable nitrogen protecting group such as benzhydryl; or CH<sub>3</sub>; and R<sup>c </sup>is H or Cl, in the presence of CDI, in a solvent such as ACN, DMF, THF and the like, at a temperature ranging from 5&#xb0; C. to 60&#xb0; C., for a period of 1-16 h, provides a compound of formula (XII), where R<sup>a </sup>is H, a suitable nitrogen protecting group such as benzhydryl, or CH<sub>3</sub>.</p><p id="p-0238" num="0000"><chemistry id="CHEM-US-00049" num="00049"><img id="EMI-C00049" he="88.05mm" wi="75.86mm" file="US20230000833A1-20230105-C00049.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0239" num="0318">According to SCHEME 4, a compound of formula (Xa), where R<sup>a </sup>is H, CH<sub>3 </sub>or a suitable nitrogen protecting group such as BOC, benzhydryl, and the like, is reacted in a metal mediated cross coupling reaction to provide a compound of formula (XIII), where R<sup>2 </sup>is a suitably substituted phenyl, pyridinyl, or thienyl. For example, a compound of formula (Xa), where R<sup>a </sup>is H, CH<sub>3</sub>, or BOC, is reacted with a suitably substituted commercially available or synthetically accessible aryl or heteroaryl boronic acid, boronate ester, and the like, in the presence of a palladium catalyst such as PdCl<sub>2</sub>(dtbpf), Pd(PPh<sub>3</sub>)<sub>4</sub>, PdCl<sub>2</sub>(dppf), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, and the like, a base such as K<sub>3</sub>PO<sub>4</sub>, aq. Na<sub>2</sub>CO<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, and the like, in a suitable solvent such as 1,2-dimethoxyethane, 1,4-dioxane, DMF, water, or a mixture thereof, at a temperature ranging from 60 to 180&#xb0; C., employing microwave or conventional heating, for a period of about 30 min to 16 h, to provide a compound of formula (XIII). Reduction of the nitro group, under hydrogenation conditions, for example, Pd/C, in a solvent such as EtOH, and the like, at a temperature ranging from 25-35&#xb0; C., under an atmosphere of H<sub>2</sub>, provides a compound of formula (XIV).</p><p id="p-0240" num="0319">A compound of formula (XIV) is also prepared from a compound of formula (XI), where R<sup>a </sup>and R<sup>c </sup>are H, employing a metal mediated cross coupling reaction as previously described. Cyclization of a compound of formula (XIV), employing CDI conditions previously described provides a compound of formula (XV).</p><p id="p-0241" num="0000"><chemistry id="CHEM-US-00050" num="00050"><img id="EMI-C00050" he="67.23mm" wi="75.86mm" file="US20230000833A1-20230105-C00050.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0242" num="0320">According to SCHEME 5, a compound of formula (XII), where R<sup>a </sup>is H, CH<sub>3</sub>, or a suitable nitrogen protecting group such as 4-methoxybenzyl, benzhydryl, trityl, and the like, is alkylated with a suitable alkylating agent, employing a base such as NaH, K<sub>2</sub>CO<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub>, TEA, and the like, in a suitable solvent such as DMF, ACN, DCM, at temperatures ranging from 0&#xb0; C. to 85&#xb0; C., to afford a compound of formula (XVI).</p><p id="p-0243" num="0321">Alkylation with a compound of formula (IV); where Y is CI, Br or OSO<sub>2</sub>CH<sub>3 </sub>and Het<sup>1 </sup>is an appropriately substituted heteroaryl, or heterocycloalkyl such as pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, oxadiazolyl, oxetanyl, and the like, affords a compound of formula (XVI), where R<sup>b </sup>is &#x2014;CH<sub>2</sub>R<sup>4c</sup>.</p><p id="p-0244" num="0322">Alkylation with a compound of formula (VII); where Y is Cl, and ring A is a suitably substituted heterocycloalkylamine such as azetidin-1-yl, 3-fluoroazetidin-1-yl, pyrrolidinyl, and the like, affords a compound of formula (XVI), where R<sup>b </sup>is</p><p id="p-0245" num="0000"><chemistry id="CHEM-US-00051" num="00051"><img id="EMI-C00051" he="14.99mm" wi="26.59mm" file="US20230000833A1-20230105-C00051.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0246" num="0323">Alkylation with a compound of formula (VIII); where Y is Cl, R<sup>1b </sup>is H or CH<sub>3</sub>, and R<sup>4b </sup>is as defined in Formula (I) affords a compound of formula (XVI), where R<sup>b </sup>is</p><p id="p-0247" num="0000"><chemistry id="CHEM-US-00052" num="00052"><img id="EMI-C00052" he="15.92mm" wi="27.77mm" file="US20230000833A1-20230105-C00052.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0248" num="0324">Alkylation with 2-bromo-1-cyclopropylethanone, tert-butyl bromoacetate, ethyl bromoacetate, and the like, affords a compound of formula (XVI), where R<sup>b </sup>is</p><p id="p-0249" num="0000"><chemistry id="CHEM-US-00053" num="00053"><img id="EMI-C00053" he="11.68mm" wi="23.03mm" file="US20230000833A1-20230105-C00053.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0250" num="0000">where R<sup>4d </sup>is C<sub>1-6</sub>alkyl, OC<sub>1-6</sub>alkyl, or C<sub>3-6</sub>cycloalkyl. Further reduction of a compound of formula (XVI), where R<sup>4d </sup>is C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl, with a reducing agent such as NaBH<sub>4</sub>, in a suitable solvent such as EtOH, provides a compound of formula (XVI) where R<sup>b </sup>is CH<sub>2</sub>CH(OH)C<sub>1-6</sub>alkyl or CH<sub>2</sub>CH(OH)C<sub>3-6</sub>cycloalkyl. Reduction of a compound of formula (XVI), where R<sup>4d </sup>is OC<sub>1-6</sub>alkyl, with a reducing agent such as LiBH<sub>4</sub>, provides a compound of formula (XVI), where R<sup>b </sup>is CH<sub>2</sub>CH<sub>2</sub>OH. Subsequent oxidation, employing an oxidizing agent such as Dess-Martin Periodinane, provides a compound of formula (XVI), where R<sup>b </sup>is CH<sub>2</sub>(C&#x2550;O)H.</p><p id="p-0251" num="0325">A compound of formula (XVI), where R<sup>b </sup>is CH<sub>2</sub>(C&#x2550;O)H, is reacted under reductive amination conditions, for example, reaction with a suitably substituted amine such as azetidine, pyrrolidine, piperidine, cyclopropylamine, cyclobutyl amine, ethanolamine, and the like, a reducing agent such as NaBH(OAc)<sub>3</sub>, NaCNBH<sub>3</sub>, NaBH<sub>4</sub>, and the like, in a suitable solvent such as DCM, and the like, for a period of 12-24 h.</p><p id="p-0252" num="0326">Alkylation of a compound of formula (XII) with an alkylating agent such as ethyl pyridin-2-yl carbonate provides a compound of formula (XVI), where R<sup>a </sup>is H, R<sup>b </sup>is CO<sub>2</sub>Et. Alkylation with 1-bromo-2-methoxyethane provides a compound of formula (XVI), where R<sup>a </sup>is trityl, and R<sup>b </sup>is CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>.</p><p id="p-0253" num="0327">A compound of formula (XVI), where R<sup>a </sup>is H, and R<sup>b </sup>is CO<sub>2</sub>Et, is further alkylated with an alkylating agent such as trityl chloride, under conditions previously described, for a period of 24-28 h, at rt, to provide a compound of formula (XVI), where R<sup>a </sup>is the trityl protecting group. Subsequent removal of the carboxylate, with isopropylamine, in THF, affords a compound of formula (XVI), where R<sup>a </sup>is trityl and R<sup>b </sup>is H. A compound of formula (XVI), where R<sup>a </sup>is trityl and R<sup>b </sup>is H, is alkylated under conditions described for SCHEME 5.</p><p id="p-0254" num="0328">A compound of formula (XVI), where R<sup>a </sup>is trityl and R<sup>b </sup>is CH<sub>2</sub>CO<sub>2</sub>C<sub>1-6</sub>alkyl, is saponified, employing conditions known to one skilled in the art, to provide an acid compound formula (XVI), where R<sup>a </sup>is trityl and R<sup>b </sup>is CH<sub>2</sub>CO<sub>2</sub>H.</p><p id="p-0255" num="0329">Deprotection of protecting group on a compound of formula (XVI), where R<sup>a </sup>is benzhydryl, is achieved in TFA, in the presence of thioanisole, at 80&#xb0; C., for a period of 1 h, to afford a compound of formula (XVI), where R<sup>a </sup>is H.</p><p id="p-0256" num="0000"><chemistry id="CHEM-US-00054" num="00054"><img id="EMI-C00054" he="67.23mm" wi="75.86mm" file="US20230000833A1-20230105-C00054.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0257" num="0330">According to Scheme 7, a compound of formula (XII), where R<sup>a </sup>is a suitable nitrogen protecting group such as 4-methoxybenzyl, trityl, and the like, is coupled in a metal mediated cross coupling reaction using conditions previously described, to provide a compound of formula (XV), where R<sup>2 </sup>is a suitably substituted phenyl or pyridyl.</p><p id="p-0258" num="0000"><chemistry id="CHEM-US-00055" num="00055"><img id="EMI-C00055" he="67.23mm" wi="75.86mm" file="US20230000833A1-20230105-C00055.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0259" num="0331">According to SCHEME 8, a compound of formula (XVI), where R<sup>a </sup>is H, CH<sub>3</sub>, or a suitable nitrogen protecting group such as trityl, is reacted in a metal mediated cross coupling reaction with a commercially available or synthetically accessible boronic acid or boronate ester, as previously described to provide a compound of Formula (I), where R<sup>2 </sup>is suitably substitued phenyl, pyridinyl or thienyl. Boronate esters are also prepared in-situ, under conditions known to one skilled in the art, in a one pot coupling reaction.</p><p id="p-0260" num="0332">When R<sup>a </sup>is a protecting group such as trityl, a deprotection step, employing an acid such as TFA, in a solvent such as DCM, provides a compound of Formula (I), where R<sup>1 </sup>is H.</p><p id="p-0261" num="0333">A compound of Formula (I) is also prepared from a compound of formula (XVI) in two steps. In a first step, a compound of formula (XVI) is converted into the boronate ester, by reaction with bis(pinacolato)diboron, KOAc, and PdCl<sub>2</sub>(dppf), in a suitable solvent such as 1,4-dioxane, at a temperature of about 130&#xb0; C., for period of about 2 h. In a second step, the boronate ester is reacted in a metal mediated cross coupling reaction, as previously described, with suitably substituted phenyl, to provide a compound of Formula (I).</p><p id="p-0262" num="0000"><chemistry id="CHEM-US-00056" num="00056"><img id="EMI-C00056" he="80.77mm" wi="75.86mm" file="US20230000833A1-20230105-C00056.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0263" num="0334">According to SCHEME 9, a compound of Formula (I), is prepared from a compound of formula (XV). A compound of formula (XV) where R<sup>a </sup>is H, CH<sub>3</sub>, or a protecting group such as 4-methoxybenzyl or trityl, R<sup>c </sup>is H, and R<sup>2 </sup>is a suitably substituted phenyl or thienyl, is alkylated according to methods described in SCHEME 5. For example, alkylation with an electrophile such as ethyl 2-bromoacetate, tert-butyl 2-bromoacetate, 2-(chloromethyl)pyridine, 3-(chloromethyl)-5-methylisoxazole, 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole, 1-(bromomethyl)-3-chlorobenzene, pyrimidin-4-ylmethyl methanesulfonate, 2-bromo-1-cyclopropylethanone, and the like, a base such as NaH, K<sub>2</sub>CO<sub>3</sub>, and the like, in a suitable solvent such as ACN, DMF, and the like, at temperatures ranging from 0 to 85&#xb0; C., provides a compound of Formula (I), where R<sup>4 </sup>is CH<sub>2</sub>CO<sub>2</sub>C<sub>1-6</sub>alkyl, CH<sub>2</sub>pyridine, and the like. Where R<sup>a </sup>is a protecting group such as 4-methoxybenzyl, or trityl, a deprotection step is employed to provide a compound of Formula (I), where R<sup>1 </sup>is H.</p><p id="p-0264" num="0335">A compound of formula (XII) is reacted under Mitsonobu conditions to form a compound of Formula (I), where R<sup>4 </sup>is CH<sub>2</sub>&#x2014;R<sup>4c</sup>, where R<sup>4c </sup>is pyrimidinyl. For example, a compound of formula (XII), where R<sup>2 </sup>is a suitably substituted phenyl or thienyl, R<sup>a </sup>is CH<sub>3</sub>, and R<sup>c </sup>is H, is reacted with a compound of formula (III), where Het<sup>1 </sup>is pyrimidinyl, using triphenylphosphine and di-tent-butyl azodicarboxylate, in a solvent such as ACN, and the like, at a temperature ranging from 90 to 110&#xb0; C., to provide a compound of Formula (I), where R<sup>4 </sup>is CH<sub>2</sub>&#x2014;R<sup>4c</sup>, where R<sup>4c </sup>is pyrimidinyl, R<sup>1 </sup>is CH<sub>3 </sub>and R<sup>2 </sup>is H.</p><p id="p-0265" num="0336">Saponification of an ester compound of Formula (I) under basic conditions such as LiOH, and the like, in a solvent such as THF and water, at a temperature of about rt, affords a compound of Formula (I), where R<sup>4 </sup>is CH<sub>2</sub>CO<sub>2</sub>H.</p><p id="p-0266" num="0337">Alkylation of a compound of Formula (I), where R<sup>1 </sup>is H, with a base such as NaH, an alkylating agent such as Mel, in a suitable solvent such as DMF, affords a compound of Formula (I) where R<sup>1 </sup>is CH<sub>3</sub>.</p><p id="p-0267" num="0338">Reduction of a compound of Formula (I), where R<sup>1 </sup>is H, R<sup>2 </sup>is a suitably substituted phenyl or thienyl, R<sup>3 </sup>is H and R<sup>4 </sup>is CH<sub>2</sub>C(&#x2550;O)cyclopropyl, CH<sub>2</sub>C(&#x2550;O)C<sub>1-6</sub>alkyl, and the like, using a reducing agent such as NaBH<sub>4</sub>, in a suitable solvent such as MeOH, provides a compound of Formula (I), where R<sup>4 </sup>is C<sub>1-6</sub>alkyl substituted with one or two members independently selected from OH or cyclopropyl.</p><p id="p-0268" num="0000"><chemistry id="CHEM-US-00057" num="00057"><img id="EMI-C00057" he="131.91mm" wi="75.86mm" file="US20230000833A1-20230105-C00057.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0269" num="0339">According to SCHEME 10, a compound of Formula (IA) or (IB), where R<sup>a </sup>is H, CH<sub>3</sub>, or a suitable nitrogen protecting group such as trityl, and R<sup>2 </sup>is a suitably substituted phenyl or thienyl, is prepared by conventional amide bond forming techniques such as coupling reactions which are well known to those skilled in the art. For example, reaction of a suitably substitued heterocycloalkyl amine of formula (V) or amine of formula (IV) where R<sup>1b </sup>is H or CH<sub>3 </sub>and R<sup>4b </sup>is C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, with an acid compound of formula (XX11), where the acid is activated with an appropriate activating reagent, for example a carbodiimide, such as DCC or EDCI optionally in the presence of HOBt and/or a catalyst such as DMAP; a halotrisaminophosphonium salt such as BOP, or PyBroP; a suitable pyridinium salt such as 2-chloro-1-methyl pyridinium chloride; or another suitable coupling agent such as HBTU, HATU, 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (T3P&#xae;) and the like. Coupling reactions are conducted in a suitable solvent such as DCM, THF, DMF and the like, optionally in the presence of a tertiary amine such as N-methylmorpholine, N-ethyldiisopropylamine (DIEA, DIPEA), or triethylamine (TEA), at a temperature ranging from about 0&#xb0; C. to rt, to provide compound a of Formula (IA) or Formula (IB). Deprotection, in instances where R<sup>a </sup>is a protecting group, employing conditions known to one skilled in the art provides a compound of Formula (IA) or Formula (IB).</p><p id="p-0270" num="0000"><chemistry id="CHEM-US-00058" num="00058"><img id="EMI-C00058" he="157.90mm" wi="75.86mm" file="US20230000833A1-20230105-C00058.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0271" num="0340">According to SCHEME 11, a compound of formula (XVIII) where R<sup>a </sup>and R<sup>c </sup>are H, is reacted under a two step reductive amination reaction, with a suitably substituted aldehyde such as 5-methylisoxazole-3-carbaldehyde. In a first step, the imine is formed by reaction of the aldehyde with an amine compound of formula (XVIII), in the presence of molecular sieves, at a temperature of about 70&#xb0; C., for a period of 16-24 h. In a second step, reduction of the imine, with a reducing agent such as NaBH<sub>4</sub>, in a suitable solvent such as EtOH, and the like, provides a compound of formula (XIX), where R<sup>4c </sup>is a suitably substituted heteroaryl such as 5-methylisoxazole. Coupling of a compound of formula (XIX), under conditions previously described provides a compound of formula (XX). Cyclization of a compound of formula (XX), under conditions previously described, such as reation with CDI, provides a compound of Formula (IC).</p><p id="p-0272" num="0000"><chemistry id="CHEM-US-00059" num="00059"><img id="EMI-C00059" he="114.22mm" wi="75.86mm" file="US20230000833A1-20230105-C00059.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0273" num="0341">According to SCHEME 12, an amine compound of formula (XIV), where R<sup>a </sup>is a protecting group such as BOC, and R<sup>c </sup>is H, and R<sup>2 </sup>is an appropriately substituted phenyl, is reacted under reductive amination conditions with an aldehyde such as 1,5-dimethyl-1h-pyrazole-3-carbaldehyde, AcOH, in a solvent such as DCE, and a reducing agent such as NaBH(OAc)<sub>3</sub>, to provide a compound of formula (XX). Deprotection of a compound of formula (XX), where R<sup>a </sup>is BOC, and R<sup>c </sup>is H, with an acid such as TFA, in a solvent such as DCM, at room temperature, afforded the cyclized compound of Formula (IC).</p><p id="p-0274" num="0342">A compound of formula (XXI), where R<sup>a </sup>is H, and R<sup>4c </sup>is 5-methylisoxazol-3-yl, and the like, is cyclized under CDI conditions previously described, to provide a compound of Formula (IC).</p><p id="p-0275" num="0343">Compounds of Formula (I) may be converted to their corresponding salts using methods known to one of ordinary skill in the art. For example, an amine of Formula (I) is treated with trifluoroacetic acid, HCl, or citric acid in a solvent such as Et<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, THF, MeOH, chloroform, or isopropanol to provide the corresponding salt form. Alternately, trifluoroacetic acid or formic acid salts are obtained as a result of reverse phase HPLC purification conditions. Cyrstalline forms of pharmaceutically acceptable salts of compounds of Formula (I) may be obtained in crystalline form by recrystallization from polar solvents (including mixtures of polar solvents and aqueous mixtures of polar solvents) or from non-polar solvents (including mixtures of non-polar solvents).</p><p id="p-0276" num="0344">Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.</p><p id="p-0277" num="0345">Compounds prepared according to the schemes described above may be obtained as single forms, such as single enantiomers, by form-specific synthesis, or by resolution. Compounds prepared according to the schemes above may alternately be obtained as mixtures of various forms, such as racemic (1:1) or non-racemic (not 1:1) mixtures. Where racemic and non-racemic mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one of ordinary skill in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation. Where regioisomeric or diastereomeric mixtures are obtained, as applicable, single isomers may be separated using conventional methods such as chromatography or crystallization.</p><p id="p-0278" num="0346">The following specific examples are provided to further illustrate the invention and various preferred embodiments.</p><heading id="h-0007" level="1">EXAMPLES</heading><p id="p-0279" num="0347">In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.</p><p id="p-0280" num="0348">Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were &#x201c;dried,&#x201d; they were generally dried over a drying agent such as Na<sub>2</sub>SO<sub>4 </sub>or MgSO<sub>4</sub>. Where mixtures, solutions, and extracts were &#x201c;concentrated&#x201d;, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM (Microwave Reactor) Discover instrument.</p><p id="p-0281" num="0349">For the reactions conducted under continuous flow conditions, &#x201c;flowed through a LTF-VS mixer&#x201d; refers to the use of a Chemyx Fusion 100 Touch Syringe Pump that is in line via 1/16&#x2033; PTFE tubing to a LTF-VS mixer (Little Things Factory GmbH (http://www.ltf-gmbh.com), unless otherwise indicated.</p><p id="p-0282" num="0350">Normal-phase silica gel chromatography (FCC) was performed on silica gel (SiO<sub>2</sub>) using prepacked cartridges.</p><p id="p-0283" num="0351">Preparative reverse-phase high performance liquid chromatography (RP HPLC) was performed on either:</p><p id="p-0284" num="0352">METHOD A. An Agilent HPLC with an Xterra Prep RP18 column (5 &#x3bc;M, 30&#xd7;100 or 50&#xd7;150mm) or an XBridge C<sub>18 </sub>OBD column (5 &#x3bc;M, 30&#xd7;100 or 50&#xd7;150mm), and a mobile phase of 5% ACN in 20 mM NH<sub>4</sub>OH was held for 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 40 or 80 mL/min.</p><p id="p-0285" num="0353">or</p><p id="p-0286" num="0354">METHOD B. A Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 pm, 30&#xd7;100mm, T=45&#xb0; C.), mobile phase of 5% ACN in H<sub>2</sub>O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 6 min, then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.</p><p id="p-0287" num="0355">or</p><p id="p-0288" num="0356">METHOD C. A Shimadzu LC-8A Series HPLC with an XBridge C<sub>18 </sub>OBD column (5 &#x3bc;m, 50&#xd7;100 mm), mobile phase of 5% ACN in H<sub>2</sub>O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.</p><p id="p-0289" num="0357">or</p><p id="p-0290" num="0358">METHOD D. A Gilson HPLC with an XBridge C<sub>18 </sub>column (5 &#x3bc;m, 100&#xd7;50 mm), mobile phase of 5-99% ACN in 20 mM NH<sub>4</sub>OH over 10 min and then hold at 99 ACN for 2 min, at a flow rate of 80 mL/min.</p><p id="p-0291" num="0359">Preparative supercritical fluid high performance liquid chromatography (SFC) was performed either on a Jasco preparative SFC system, an APS 1010 system from Berger instruments, or a SFC-PICLAB-PREP 200 (PIC SOLUTION, Avignon, France). The separations were conducted at 100 to 150 bar with a flow rate ranging from 40 to 60 mL/min. The column was heated to 35 to 40&#xb0; C.</p><p id="p-0292" num="0360">Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.</p><p id="p-0293" num="0361">Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. Definitions for multiplicity are as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad. It will be understood that for compounds comprising an exchangeable proton, said proton may or may not be visible on an NMR spectrum depending on the choice of solvent used for running the NMR spectrum and the concentration of the compound in the solution.</p><p id="p-0294" num="0362">Chemical names were generated using Chem Draw Ultra 12.0, Chem Draw Ultra 14.0 (CambridgeSoft Corp., Cambridge, Mass.) or ACD/Name Version 10.01 (Advanced Chemistry).</p><p id="p-0295" num="0363">Compounds designated as R* or S* are enantiopure compounds where the absolute configuration was not determined.</p><heading id="h-0008" level="1">Intermediate 1: 2-(Chloromethyl)Pyrazine</heading><p id="p-0296" num="0364"><chemistry id="CHEM-US-00060" num="00060"><img id="EMI-C00060" he="13.12mm" wi="21.17mm" file="US20230000833A1-20230105-C00060.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0297" num="0365">To a solution of 2-pyrazinylmethanol (500 mg, 4.54 mmol) in DCM (15 mL) at 0&#xb0; C. was added thionyl chloride (0.66 mL, 9.1 mmol). The reaction mixture was stirred at 0&#xb0; C. for 3 h. The reaction mixture was concentrated in vacuo. The crude reaction mixture was triturated with Et<sub>2</sub>O to yield the title compound as a black solid (749 mg, 4.54 mmol, 99.9%), which was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 4.87 (s, 2H), 8.63-8.69 (m, 2H), 8.82 (d, J=1.39 Hz, 1H).</p><heading id="h-0009" level="1">Intermediate 2: 3-(Chloromethyl)pyridazine hydrochloride</heading><p id="p-0298" num="0366"><chemistry id="CHEM-US-00061" num="00061"><img id="EMI-C00061" he="12.36mm" wi="22.01mm" file="US20230000833A1-20230105-C00061.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0299" num="0367">Method A: 3-(Chloromethyl)pyridazine hydrochloride. The title compound was prepared in a manner analogous to Intermediate 1. MS (ESI): mass calcd. for C<sub>5</sub>H<sub>5</sub>ClN<sub>2</sub>, 128.0; m/z found, 129.0 [M+H]<sup>+</sup>.</p><p id="p-0300" num="0368">Method B: 3-(Chloromethyl)pyridazine. Trichloroisocyanuric acid (148 mg, 0.6 mmol) was added in portions to a mixture of 3-methylpyridazine (145 &#x3bc;L, 1.6 mmol) in CHC<sub>3 </sub>at reflux. The mixture was stirred at reflux overnight. After cooling, the mixture was filtered, and the filtrate was diluted with DCM, washed with an aqueous solution of 1M NaOH followed by brine, dried (MgSO<sub>4</sub>) and concentrated under reduced pressure to yield title compound (205 mg, 80%). MS (ESI): mass calcd. for C<sub>5</sub>H<sub>5</sub>ClN<sub>2</sub>, 128.0; m/z found, 129 [M+H]<sup>+</sup>.</p><heading id="h-0010" level="1">Intermediate 3: 5-(Chloromethyl)pyrimidine hydrochloride</heading><p id="p-0301" num="0369"><chemistry id="CHEM-US-00062" num="00062"><img id="EMI-C00062" he="12.28mm" wi="22.01mm" file="US20230000833A1-20230105-C00062.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0302" num="0370">The title compound was prepared in a manner analogous to Intermediate 1. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 4.85 (s, 2H) 8.90 (s, 2H) 9.16 (s, 1H).</p><heading id="h-0011" level="1">Intermediate 4: 2-Bromo-N,N-dimethylacetamide</heading><p id="p-0303" num="0371"><chemistry id="CHEM-US-00063" num="00063"><img id="EMI-C00063" he="14.31mm" wi="21.84mm" file="US20230000833A1-20230105-C00063.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0304" num="0372">Under an atmosphere of nitrogen, 2-bromoacetyl chloride (1.3 mL, 16 mmol) was added to a mixture of TEA (2.2 mL, 16 mmol) and dimethylamine (8 mL, 16 mmol) in MeCN (20 mL) at &#x2212;78&#xb0; C. The stirred reaction mixture was then allowed to slowly warm to room temperature. After stirring for 2 hours, water was added (30 mL) and the mixture was extracted with DCM (3&#xd7;40 mL). The combined organic layers were dried, and concentrated under vacuum to afford the desired product (2.03 g, 76%) which was carried forward as crude material. MS (ESI): mass calcd. for C<sub>4</sub>H<sub>8</sub>BrNO, 166.1. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 4.35 (s, 2H), 2.99 (s, 3H), 2.85 (s, 3H).</p><heading id="h-0012" level="1">Intermediate 5: 1-(Azetidin-1-yl)-2-bromoethan-1-one</heading><p id="p-0305" num="0373"><chemistry id="CHEM-US-00064" num="00064"><img id="EMI-C00064" he="14.99mm" wi="23.88mm" file="US20230000833A1-20230105-C00064.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0306" num="0374">The title compound was prepared in a manner analogous to 2-bromo-N,N-dimethylacetamide (Intermediate 4), using azetidine. MS (ESI): mass calcd. for C<sub>5</sub>H<sub>8</sub>BrNO, 178.1 <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 4.35-4.29 (m, 2H), 4.14-4.09 (m, 2H), 3.91-3.88 (s, 2H), 2.38-2.31 (m, 2H).</p><heading id="h-0013" level="1">Intermediate 6: 2-Bromo-1-(3-fluoroazetidin-1-yl)ethan-1-one</heading><p id="p-0307" num="0375"><chemistry id="CHEM-US-00065" num="00065"><img id="EMI-C00065" he="17.02mm" wi="29.29mm" file="US20230000833A1-20230105-C00065.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0308" num="0376">The title compound was prepared in a manner analogous to 2-bromo-N,N-dimethylacetamide (Intermediate 4) using 3-fluoroazetidine.HCI. MS (ESI): mass calcd. for C<sub>5</sub>H<sub>7</sub>BrFNO, 196.1.<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 5.50-5.29 (m, 1H), 4.57-4.45 (m, 1H), 4.32-4.14 (m, 2H), 4.01-3.86 (m, 3H).</p><heading id="h-0014" level="1">Intermediate 7: Potassium trimethoxy(trifluoromethyl)borate</heading><p id="p-0309" num="0377"><chemistry id="CHEM-US-00066" num="00066"><img id="EMI-C00066" he="20.74mm" wi="18.46mm" file="US20230000833A1-20230105-C00066.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0310" num="0378">To a three-necked round-bottom flask equipped with a thermometer and nitrogen inlet/outlet adapter were added KF (1000 g, 17.2 mol, 1.0 equiv.) and anhydrous THF(15 L). The mixture was stirred at 23&#xb1;2&#xb0; C. under a nitrogen flow. B(OMe)<sub>3 </sub>(1860 g, 17.9 mol, 1.04 equiv.) was added to the mixture while a slight temperature drop was observed. F<sub>3</sub>CTMS (2690 g, 18.9 mol, 1.1 equiv.) was added to the mixture while a slight temperature drop was observed. The mixture was stirred at 23&#xb1;2&#xb0; C. for 20 hours under a nitrogen flow until the solid was completely dissolved. The resulting mixture was concentrated to 6 L under reduced pressure, then hexane 12 L was added to the mixture and the mixture was stirred for 20 min. The precipitated solid was collected by filtration followed by washing with hexane 2L&#xd7;2. The wet solid was dried under vacuum to give the title compound (3840 g, 94.5%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) 3.22 (s, 9H). <sup>19</sup>F NMR (376 MHz, D<sub>2</sub>O) &#x3b4; &#x2212;74.83 (dd, J=59.1, 28.5 Hz).</p><heading id="h-0015" level="1">Intermediate 8: 2-(2,4-difluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane</heading><p id="p-0311" num="0379"><chemistry id="CHEM-US-00067" num="00067"><img id="EMI-C00067" he="29.89mm" wi="33.87mm" file="US20230000833A1-20230105-C00067.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0312" num="0380">To a solution a 3-bromo-2,6-difluorotoluene (0.95 mL, 7.2 mmol), 4,4,4&#x2032;,4&#x2032;,5,5,5&#x2032;,5&#x2032;-octamethyl-2,2&#x2032;-bi-1,3,2-dioxaborolane (3.68 g, 14.5 mmol) and KOAc (1.07 g, 10.9 mmol) in 1,4-dioxane (38 mL) was added PdCl<sub>2</sub>(dppf) (265 mg, 0.362 mmol). The reaction mixture was stirred at 120&#xb0; C. for 16 h. Then, the crude reaction mixture was cooled, filtered through Celite&#xae; and concentrated in vacuo. The crude product was purified (FCC, SiO<sub>2</sub>, 0-20% EtOAc in hexanes) to yield the title compound (1.8 g, 98%).</p><heading id="h-0016" level="1">Intermediate 9: Ethyl 6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate</heading><p id="p-0313" num="0381"><chemistry id="CHEM-US-00068" num="00068"><img id="EMI-C00068" he="25.82mm" wi="36.07mm" file="US20230000833A1-20230105-C00068.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0314" num="0382">Step A: 6-Bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 2,3-diamino-5-bromopyridine (5 g, 27 mmol) in THF (87 mL) was added CDI (3.02 g, 18.6 mmol), and the reaction mixture was stirred at 80&#xb0; C. for 16 h. Then, water was added, and the mixture was filtered. The solids were collected by filtration, washed with water and Et<sub>2</sub>O, and dried under vacuum to afford the title compound (5.3 g, 25 mmol, 93%), which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>6</sub>H<sub>4</sub>BrN<sub>3</sub>O, 212.95; m/z found, 214 [M+H]<sup>+</sup>.</p><p id="p-0315" num="0383">Step B: Ethyl 6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate. A mixture of 6-bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (5.3 g, 25 mmol), ethyl pyridin-2-yl carbonate (5.36 g, 27.2 mmol) and K<sub>2</sub>CO<sub>3 </sub>(3.77 g, 27.2 mmol) in DMF (245 mL) was heated to 75&#xb0; C. for 3 h. The crude reaction mixture was concentrated in vacuo and diluted with water and 1 M HCl until the mixture reached pH 1. The solution was filtered and triturated with Et<sub>2</sub>O to afford the title compound (6.6 g, 23 mmol, 93%), which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>9</sub>H<sub>8</sub>BrN<sub>3</sub>O<sub>3</sub>, 284.97; m/z found, 286 [M+H]<sup>+</sup>.</p><heading id="h-0017" level="1">Intermediate 10: 6-Bromo-3-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-0316" num="0384"><chemistry id="CHEM-US-00069" num="00069"><img id="EMI-C00069" he="25.82mm" wi="49.45mm" file="US20230000833A1-20230105-C00069.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0317" num="0385">To a solution of ethyl 6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate (11.48 g, 40.21 mmol), and K<sub>2</sub>CO<sub>3 </sub>(6.65 g, 48.1 mmol), in DMF (120 mL) was added 4-methoxybenzylchloride (6.01 mL, 44.1 mmol) dropwise. The reaction mixture was heated to 50&#xb0; C. for 6 h. The reaction mixture was cooled to rt, and isopropylamine (3.4 mL, 40.1 mmol) was added, the reaction mixture was stirred at rt for 1 h. Water and EtOAc were added. The organic layer was separated, dried (MgSO4), filtered and concentrated under reduced pressure. Purification (FCC, SiO<sub>2</sub>, EtOAc in DCM from 0% to 35%) afforded the title compound as a cream solid. Trituration with Et<sub>2</sub>O to afforded the title compound (6.9 g, 51%). MS (ESI): m/z found [M+H]=334.</p><heading id="h-0018" level="1">Intermediate 11: 6-Bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0318" num="0386"><chemistry id="CHEM-US-00070" num="00070"><img id="EMI-C00070" he="16.85mm" wi="32.00mm" file="US20230000833A1-20230105-C00070.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0319" num="0387">Method A:</p><p id="p-0320" num="0388">Step A: 5-Bromo-N-methyl-3-nitropyridin-2-amine. To a solution of 5-bromo-2-chloro-3-nitropyridine (15 g, 63 mmol) in THF (570 mL) at 0&#xb0; C. was added a solution of methylamine (40% in H<sub>2</sub>O, 10.9 mL, 126 mmol). The reaction mixture was stirred at room temperature for 16 h. Upon completion, the reaction mixture was extracted with EtOAc (3&#xd7;500 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under reduced pressure to yield the title compound as a yellow solid (14.6 g, 62.7 mmol, 99%), which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>6</sub>H<sub>6</sub>BrN<sub>3</sub>O<sub>2</sub>, 230.96; m/z found, 232 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.54 (d, J=2.3 Hz, 1H), 8.46 (d, J=2.3 Hz, 1H), 8.17 (br s, 1H), 3.16 (d, J=4.9 Hz, 3H).</p><heading id="h-0019" level="1">Step B: 5-Bromo-N<sup>2</sup>-methylpyridine-2,3-diamine</heading><p id="p-0321" num="0389">To a stirred suspension of 5-bromo-N-methyl-3-nitropyridin-2-amine (14.6 g, 62.7 mmol) and zinc (41 g, 627 mmol) in a mixture of water (29 mL) and acetone (291 mL) was added NH<sub>4</sub>Cl (33.6 g, 627 mmol). The reaction mixture was stirred at room temperature for 72 h. Upon completion the mixture was filtered through Celite&#xae; and rinsed with DCM. The filtrate was washed with water and the aqueous layer was extracted with DCM (3&#xd7;). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under reduced pressure to yield the title compound as an oil (12.7 g, 69.3 mmol), which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>6</sub>H<sub>8</sub>BrN<sub>3</sub>, 200.99; m/z found, 202 [M+H]<sup>+</sup>.</p><p id="p-0322" num="0390">Step C: 6-Bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 5-bromo-N<sup>2</sup>-methylpyridine-2,3-diamine (14 g, 69 mmol) in DMF (702 mL) at room temperature was added CDI (29 g, 180 mmol). The reaction mixture was stirred for 16 h. LCMS analysis of the crude reaction mixture showed that the reaction was not complete, and the resultant residue was re-dissolved in THF and CDI (11.2, 69 mmol) was added. The reaction mixture was stirred at 60&#xb0; C. for 16 h. The reaction mixture was quenched with water and diluted with Et<sub>2</sub>O. The suspension was filtered and the resulting solid was washed with Et<sub>2</sub>O and dried under vacuum to yield the title compound as a black solid (15.8 g, 35.7 mmol), which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>7</sub>H<sub>6</sub>BrN<sub>3</sub>O, 226.97; m/z found, 227.0 [M+H]<sup>+</sup>.</p><p id="p-0323" num="0391">Method B:</p><p id="p-0324" num="0392">Step A: 5-Bromo-N-methyl-3-nitropyridin-2-amine. Into a 20 L four-necked flask were charged with EtOH (10.5 L) and 2,5-dibromo-3-nitropyridine (1500 g, 5.32 mol). The mixture was heated to 50&#xb0; C. followed by addition of aq. MeNH<sub>2 </sub>(40% w/w, 1032.5 g, 13.3 mol) during 1 h. After stirring at 55 to 65&#xb0; C. for 2 h, the reaction mixture was cooled 20&#xb0; C. and filtered. The cake was washed with EtOH/H<sub>2</sub>O (V/V=1/1, 1 L) followed by slurring in water (8 L) at room temperature for 1.5 h. Then the suspension was filtered and the cake was washed with water (1 L). The cake was collected and dried at room temperature overnight to give the title compound (1198 g, 97%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.55 (d, J=2.3 Hz, 1H), 8.48 (d, J=2.3 Hz, 1H), 8.20 (bs, 1H), 3.18 (d, J=8.0 Hz, 3H).</p><p id="p-0325" num="0393">Step B: 5-Bromo-N<sup>2</sup>-methylpyridine-2,3-diamine. Into a pressure reactor was charged with Pt/C (5% wt, 78.7 g, 10.6% w/w), aq. H<sub>3</sub>PO<sub>2</sub>(50% wt, 5.8 g), NH<sub>4</sub>VO<sub>3 </sub>(2.1 g), THF/EtOH (V/V=1/1, 12.1 L) and 5-bromo-N-methyl-3-nitropyridin-2-amine (740 g, 3.19 mol). The reactor was purged with hydrogen and pressurized to 20 atm followed by stirring at 20 to 30&#xb0; C. for about 0.5 h. Then the mixture was re-pressurized to 20 atm with hydrogen and stirred at 30 to 45&#xb0; C. for 1 h. The reaction mixture was cooled to room temperature and filtered through a pad of Celite&#xae; followed by washing the cake with THF (1 L). The combined filtrate was concentrated at 40 to 45&#xb0; C. under vacuum. Solvent chasing distillation by n-heptane (1 L&#xd7;2) and dilution with ACN (3 L) afforded a dark solution of the title compound in ACN which was used in the next step without further purification.</p><p id="p-0326" num="0394">Step C: 6-Bromo-3-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one. Into a 5 L three-necked flask was charged with a solution of 5-bromo-N<sup>2</sup>-methylpyridine-2,3-diamine (in ACN (3.05 L). The mixture was cooled to 5&#xb0; C. followed by addition of CDI (564.55 g, 3.48 mol) in portions. The mixture was stirred at 5 to 25&#xb0; C. for 3 h followed by concentration until about 2 L of solvent was left. The resulting mixture was filtered and the cake was slurried with H<sub>2</sub>O (3.5 L) at 20 to 25&#xb0; C. for 3 h. The suspension was filtered and the cake was dried at 20 to 25&#xb0; C. for 48 h to give the title compound (680 g, 87.9%, over two steps). <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.30 (s, 1H), 8.06 (d, J=3.0 Hz, 1H), 7.49 (d, J=3.0 Hz, 1H), 3.29 (s, 3H).</p><heading id="h-0020" level="1">Intermediate 12: Ethyl 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate</heading><p id="p-0327" num="0395"><chemistry id="CHEM-US-00071" num="00071"><img id="EMI-C00071" he="29.89mm" wi="32.00mm" file="US20230000833A1-20230105-C00071.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0328" num="0396">To a mixture of 6-bromo-3-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one (Intermediate 11, 350.0 g, 1.535 mol) and ACN (4800 mL) was charged with K<sub>2</sub>CO<sub>3 </sub>(318.2 g). The resulting mixture was warmed to 45 to 50&#xb0; C. followed by dropwise addition of ethyl 2-bromoacetate (281.9 g, 1.688 mol) at 50 to 60&#xb0; C. Then the reaction mixture was warmed to 80 to 85&#xb0; C. and kept at this temperature for 7.5 h. Additional ethyl 2-bromoacetate (25.6 g, 0.153 mol) was charged into the reaction mixture. After stirring at 80 to 85&#xb0; C. for 3 h, the mixture was cooled to room temperature naturally and stirred overnight. The mixture was warmed to 80 to 85&#xb0; C. followed by addition of ethyl 2-bromoacetate (51.2 g, 0.306 mmol) and K<sub>2</sub>CO<sub>3 </sub>(42.4 g). Another portion of K<sub>2</sub>CO<sub>3 </sub>(106.0 g) was added into the mixture after stirring for 3.5 h. The reaction was cooled to 65 to 70&#xb0; C. followed by filtration. The cake was washed with ACN (1400 mL) and the combined filtrate was concentrated at 40 to 45&#xb0; C. until about 2.8 volume of ACN was left. HCl (0.08 N, 2500 mL) was poured into the residue and the resulting suspension was stirred at 20 to 25&#xb0; C. for 30 min followed by filtration. The cake was collected and dried at 45&#xb0; C. vacuum oven for 14 h to give the title compound (438 g, 91%).<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.12 (d, J=1.9 Hz, 1H), 7.23 (d, J=1.9 Hz, 1H), 4.61 (s, 2H), 4.25 (q, J=7.5 Hz, 2H), 3.49 (s, 3H), 1.30 (t, J=7.5 Hz, 3H).</p><heading id="h-0021" level="1">Intermediate 13: 2-(6-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid. Lithium Salt</heading><p id="p-0329" num="0397"><chemistry id="CHEM-US-00072" num="00072"><img id="EMI-C00072" he="27.35mm" wi="35.73mm" file="US20230000833A1-20230105-C00072.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0330" num="0398">Step A: Ethyl 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate. Under a nitrogen atmosphere was added 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11, 5 g, 21.9 mmol) to a suspension of sodium hydride (60% dispersion in mineral oil, 1.3 g, 32.9 mmol) in DMF (171 mL) at room temperature. After 10 minutes ethyl bromoacetate (3.2 mL, 28.5 mmol) was added and the reaction was stirred at room temperature. After 4 h, complete conversion was observed. The reaction was cooled to 0&#xb0; C. and water was added (200 mL). The precipitates were collected by filtration and washed with water to give the title compound (6.1 g, 88%).MS (ESI): mass calcd. for C<sub>11</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>, 313.0; m/z found, 313.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.14 (d, J=2.0 Hz, 1H), 7.92 (d, J=2.0 Hz, 1H), 4.76 (s, 2H), 4.16 (q, J=7.1 Hz, 2H), 3.35 (s, 3H), 1.22 (t, J=7.1 Hz, 3H).</p><p id="p-0331" num="0399">Step B: 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid. Lithium hydroxide (2M, 1.2 mL, 2.3 mmol) was added to a mixture of ethyl 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (612 mg, 1.9 mmol) in THF (23 mL) at room temperature. The precipitates were collected by filtration and washed with THF to give the title compound (465 mg, 83%). MS (ESI): mass calcd. for C<sub>9</sub>H<sub>8</sub>BrN<sub>3</sub>O3, 285.0; m/z found, 286.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.02 (d, J=2.0 Hz, 1H), 7.46 (d, J=2.0 Hz, 1H), 4.03 (s, 2H), 3.31 (s, 3H).</p><heading id="h-0022" level="1">Intermediate 14: 2-(6-Bromo-7-chloro-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic Acid and its Trifluoroacetic Acid Salt</heading><p id="p-0332" num="0400"><chemistry id="CHEM-US-00073" num="00073"><img id="EMI-C00073" he="27.35mm" wi="34.04mm" file="US20230000833A1-20230105-C00073.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0333" num="0401">Step A. 5-Bromo-4-chloro-3-nitropyridin-2-amine. A solution of 4-chloro-3-nitropyridin-2-amine (2 g, 11.5 mmol) and N-bromosuccinimide (2.5 g, 13.8 mmol) in ACN (125 mL) was heated at 80&#xb0; C. After 1 h, the reaction mixture was cooled was cooled to room temperature and volatiles were removed under reduced pressure. Purification (FCC, SiO<sub>2</sub>, 0-5% EtOAc in DCM), afforded the title compound (2.9 g, 99%). MS (ESI): mass calcd. for C<sub>5</sub>H<sub>3</sub>BrClN<sub>3</sub>O<sub>2</sub>, 250.9; m/z found, 251.8 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.42 (s, 1H), 7.37 (br s, 2H).</p><p id="p-0334" num="0402">Step B: tert-Butyl (5-bromo-4-chloro-3-nitropyridin-2-yl)carbamate. To a mixture of 5-bromo-4-chloro-3-nitropyridin-2-amine (2.9 g, 11.4 mmol) in THF (200 mL) at room temperature, under a nitrogen atmosphere was added sodium hydride (60% dispersion in mineral oil, 1.1 g, 27.4 mmol) in small batches. After 30 minutes, BOC-anhydride (2.4 mL, 11.4 mmol) was added to the reaction mixture. After 16 h, water (5 mL) was added to the reaction mixture and volatiles were removed. The residue was partitioned between water (100 mL) and EtOAc (150 mL). The organic layer was collected. The aqueous layer was washed with EtOAc (3&#xd7;150 mL). The combined organics were dried (MgSO<sub>4</sub>), filtered and concentrated under vacuum. Purification (FCC, SiO<sub>2</sub>, 0-5% EtOAc in DCM), afforded the title compound (3.0 g, 75%). MS (ESI): mass calcd. for C<sub>10 </sub>H<sub>11</sub>BrClN<sub>3</sub>O<sub>4</sub>, 351.0; m/z found, 295.9 [M-tBu]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 10.62 (s, 1H), 8.89 (s, 1H), 1.42 (s, 9H).</p><p id="p-0335" num="0403">Step C: tert-Butyl (5-bromo-4-chloro-3-nitropyridin-2-yl)(methyl)carbamate. To a mixture of tert-butyl (5-bromo-4-chloro-3-nitropyridin-2-yl)carbamate (3.0 g, 8.6 mmol) in DMF (140 mL) at room temperature, under a nitrogen atmosphere was added sodium hydride (60% dispersion in mineral oil, 445 mg, 11.1 mmol) in small batches. After 30 minutes, iododmethane (0.64 mL, 10.3 mmol) was added to the reaction mixture at 0&#xb0; C. After 16 h, EtOAc (200 mL) was added to the reaction mixture. The mixture was washed with brine (1&#xd7;350 mL). The organic was dried (MgSO<sub>4</sub>), filtered and concentrated under vacuum to give the title compound (3.1 g, 99%). MS (ESI): mass calcd. for C<sub>11</sub>H<sub>13</sub>BrClN<sub>3</sub>O<sub>4</sub>, 365.0; m/z found, 309.9 [M-tBu]<sup>+</sup>.</p><p id="p-0336" num="0404">Step D: 5-Bromo-4-chloro-N-methyl-3-nitropyridin-2-amine, TFA Salt. To a solution of tert-butyl (5-bromo-4-chloro-3-nitropyridin-2-yl)(methyl)carbamate (3.1 g, 8.6 mmol) in DCM (100 mL) at room temperature was added TFA (13 mL, 171 mmol). After completion, volatiles were removed. The solid was dissolved in EtOAc (200 mL). The mixture was washed with brine (2&#xd7;300 mL). The organic was dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to give the title compound (2.3 g, 99%). MS (ESI): mass calcd. for C<sub>6</sub>H<sub>5</sub>BrClN<sub>3</sub>O<sub>2</sub>, 265.0; m/z found, 265.8 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.53 (s, 1H), 7.60-7.52 (m, 1H), 2.86 (d, J=4.5 Hz, 3H).</p><p id="p-0337" num="0405">Step E: 5-Bromo-4-chloro-N<sup>2</sup>-methylpyridine-2,3-diamine. To a stirred suspension of 5-bromo-4-chloro-N-methyl-3-nitropyridin-2-amine (500 mg, 1.9 mmol) and zinc (1.2 g, 18.8 mmol) in a mixture of water (0.9 mL) and acetone (8.7 mL) was slowly added ammonium chloride (1 g, 18.8 mmol) at 0&#xb0; C. Upon completion, the mixture was filtered through Celite&#xae; and rinsed with MeOH. The volatiles were removed and the material was partitioned between water (40 mL) and EtOAc (40 mL). The organic layer was collected. The aqueous layer was washed with EtOAc (3&#xd7;60 mL). The combined organics were dried (MgSO<sub>4</sub>), filtered and concentrated under vacuum. Purification (FCC, SiO<sub>2</sub>, 0-10% MeOH in DCM), afforded the title compound (280 mg, 63%). MS (ESI): mass calcd. for C<sub>6</sub>H<sub>7</sub>BrClN<sub>3</sub>, 235.0; m/z found, 235.8 [M+H]<sup>+</sup>.</p><p id="p-0338" num="0406">Step F: 6-Bromo-7-chloro-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a mixture of 5-bromo-4-chloro-N<sup>2</sup>-methylpyridine-2,3-diamine (210 mg, 0.9 mmol) in DMF (7 mL), under a nitrogen atmosphere, at room temperature was added CDI (432 mg, 2.7 mmol). After 16 h, additional CDI (432 mg, 2.7 mmol) was added to the reaction mixture. The reaction mixture was heated at 70&#xb0; C. Upon complete conversion, the reaction mixture was slowly poured into ice. The resulting mixture was extracted using EtOAc (3&#xd7;). The combined organics were washed with 1N HCl (1&#xd7;), dried (MgSO<sub>4</sub>), filtered and concentrated under vacuum to afford title product which was used crude without further purification. MS (ESI): mass calcd. for C<sub>7</sub>H<sub>5</sub>BrClN<sub>3</sub>O, 260.9; m/z found, 261.8 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.98 (s, 1H), 8.21 (s, 1H), 3.28 (s, 3H).</p><p id="p-0339" num="0407">Step G: tert-Butyl 2-(6-bromo-7-chloro-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate. To a suspension of sodium hydride (60% dispersion in mineral oil, 38 mg, 1.0 mmol) in DMF (5 mL), under a nitrogen atmosphere, at room temperature was added 6-bromo-7-chloro-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (170 mg, 0.6 mmol). After 10 min, tert-butyl bromoacetate (0.12 mL, 0.84 mmol) was added to the reaction mixture. After 16 h, water (50 mL) was added to the mixture. After 30 minutes, the resulting precipitates were filtered off and washed with water to give title compound, which was used crude without further purification. MS (ESI): mass calcd. for C<sub>13</sub>H<sub>15</sub>BrClN<sub>3</sub>O<sub>3</sub>, 375.0; m/z found, 375.8 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.33 (s, 1H), 4.80 (s, 2H), 3.37 (s, 3H), 1.43 (s, 9H).</p><p id="p-0340" num="0408">Step H: 2-(6-Bromo-7-chloro-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid and its trifluoroacetic acid salt. To a solution of tert-butyl 2-(6-bromo-7-chloro-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (126 mg, 0.3 mmol) in DCM (3.8 mL) at room temperature was added TFA (0.26 mL, 3.3 mmol). After completion, volatiles were removed. The resulting solid was triturated in MeOH. The solids were collected by filtration and washed with MeOH to give the title compound (112 mg, 77%). MS (ESI): mass calcd. for C<sub>9</sub>H<sub>7</sub>BrClN<sub>3</sub>O<sub>3</sub>, 318.9; m/z found, 319.8 [M+H]<sup>+</sup>.</p><heading id="h-0023" level="1">Intermediate 15: 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide</heading><p id="p-0341" num="0409"><chemistry id="CHEM-US-00074" num="00074"><img id="EMI-C00074" he="30.56mm" wi="36.07mm" file="US20230000833A1-20230105-C00074.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0342" num="0410">To a solution of 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11, 600 mg, 2.6 mmol) in DMF (20 mL) was added NaH (72 mg, 3.2 mmol). Upon addition of NaH vigorous bubbling occurred. After 30 min of stirring at room temperature, bubbling had ceased and 2-bromo-N,N-dimethylacetamide (Intermediate 4, 618 mg, 3.7 mmol) was added. The resulting reaction mixture was stirred at room temperature then diluted with ethyl acetate and quenched with water. The combined organic layers were dried using Mg<sub>2</sub>SO<sub>4 </sub>and concentrated under reduced pressure to yield a yellow oil which was purified (FCC, SiO<sub>2</sub>, 0-7% 2M NH<sub>3</sub>/MeOH in DCM) to provide the title compound (504 mg, 61%) as a beige solid. MS (ESI): mass calcd. for C<sub>11</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>2</sub>, 313.1; m/z found, 314.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.12-8.08 (d, J=2.0 Hz, 1H), 7.81-7.77 (d, J=2.0 Hz, 1H), 4.83-4.75 (s, 2H), 3.35-3.33 (s, 3H), 3.08-3.06 (s, 3H), 2.85-2.83 (s, 3H).</p><heading id="h-0024" level="1">Intermediate 16: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one.</heading><p id="p-0343" num="0411"><chemistry id="CHEM-US-00075" num="00075"><img id="EMI-C00075" he="34.29mm" wi="35.56mm" file="US20230000833A1-20230105-C00075.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0344" num="0412">The title compound was prepared in a manner analogous to 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N, N-dimethylacetamide (Intermediate 15), using 1-(azetidin-1-yl)-2-bromoethan-1-one (Intermediate 5). MS (ESI): mass calcd. for C<sub>11</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>2</sub>, 325.1; m/z found, 326.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.10 (d, J=2.0 Hz, 1H), 7.78 (d, J=2.0 Hz, 1H), 4.55 (s, 2H), 4.27 (t, J=7.6 Hz, 2H), 3.91 (t, J=7.7 Hz, 2H), 3.33 (s, 3H), 2.32-2.24 (m, 2H).</p><heading id="h-0025" level="1">Intermediate 17: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-bromo-7-chloro-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0345" num="0413"><chemistry id="CHEM-US-00076" num="00076"><img id="EMI-C00076" he="34.29mm" wi="35.56mm" file="US20230000833A1-20230105-C00076.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0346" num="0414">A mixture of 2-(6-bromo-7-chloro-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid TFA salt (Intermediate 14, 112 mg, 0.3 mmol), azetidine (0.03 mL, 0.5 mmol), DIPEA (0.15 mL, 0.9 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (50% solution in DCM, 0.7 mL, 1.2 mmol) in DMF (3.4 mL) was stirred at room temperature. After 3 days, azetidine (0.03 mL, 0.5 mmol), DIPEA (0.15 mL, 0.9 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (50% solution in DCM, 0.7 mL, 1.2 mmol) were added again. After 16 h, a saturated aqueous solution NaHCO<sub>3 </sub>(20 mL) was added. The mixture was extracted using DCM (3&#xd7;30 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to give the title compound (92 mg, 0.3 mmol, 99%) which was used crude without further purification. MS (ESI): mass calcd. for C<sub>12</sub>H<sub>12</sub>BrClN<sub>4</sub>O<sub>2</sub>, 358.0; m/z found, 358.8 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3b4; 8.10 (s, 1H), 4.54 (s, 2H), 4.08 (t, J=7.6 Hz, 2H), 3.71 (t, J=7.7 Hz, 2H), 3.17 (s, 3H), 2.15-2.05 (m, 2H).</p><heading id="h-0026" level="1">Intermediate 18: 6-Bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0347" num="0415"><chemistry id="CHEM-US-00077" num="00077"><img id="EMI-C00077" he="41.06mm" wi="35.56mm" file="US20230000833A1-20230105-C00077.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0348" num="0416">The title compound was prepared in a manner analogous to 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15), using 2-bromo-1-(3-fluoroazetidin-1-yl)ethan-1-one (Intermediate 6) . MS (ESI): mass calcd. for C<sub>12</sub>H<sub>12</sub>BrFN<sub>4</sub>O<sub>2</sub>, 343.1; m/z found, 344.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.11 (d, J=2.0 Hz, 1H), 7.79 (d, J=2.0 Hz, 1H), 5.55-5.37 (m, 1H), 4.68-4.56 (m, 3H), 4.45-4.34 (m, 1H), 4.30-4.19 (m, 1H), 4.02-3.91 (m, 1H), 3.34 (s, 3H).</p><heading id="h-0027" level="1">Intermediate 19: 6-Bromo-3-methyl-1-(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0349" num="0417"><chemistry id="CHEM-US-00078" num="00078"><img id="EMI-C00078" he="28.62mm" wi="40.13mm" file="US20230000833A1-20230105-C00078.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0350" num="0418">The title compound was prepared in a manner analogous to Intermediate 15, using 3-(chloromethyl)pyridazine (Intermediate 2). MS (ESI): mass calcd. for C<sub>12</sub>H<sub>10</sub>BrN<sub>5</sub>O, 320.1; m/z found, 321.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; .9.16 (dd, J=4.6, 2.0 Hz, 1H), 8.13 (d, J=1.9 Hz, 1H), 7.82 (d, J=2.0 Hz, 1H), 7.72-7.65 (m, 2H), 5.41 (s, 2H), 3.36 (s, 3H).</p><heading id="h-0028" level="1">Intermediate 20: 6-Bromo-3-methyl-1-(pyrimidin-4-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0351" num="0419"><chemistry id="CHEM-US-00079" num="00079"><img id="EMI-C00079" he="28.62mm" wi="40.98mm" file="US20230000833A1-20230105-C00079.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0352" num="0420">To a cooled (0&#xb0; C.) solution of 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11, 65 mg, 0.28 mmol), triphenylphosphine (149 mg, 0.57 mmol), and pyrimidin-4-ylmethanol (31 mg, 0.28 mmol) in ACN (1.6 mmL) was added (E)-di-tert-butyl diazene-1,2-dicarboxylate (98 mg, 0.43 mmol). The reaction mixture was heated under microwave irradiation at 110&#xb0; C. for 15 minutes. The reaction mixture was cooled to rt, and concentrated under reduced pressure. Purification (Reverse phase HPLC;Stationary phase: C<sub>18 </sub>XBridge 30&#xd7;100 mm 5 um; gradient 81% 10 mM NH<sub>4</sub>CO<sub>3</sub>H pH 9 solution in Water, 19% CH<sub>3</sub>CN to 64% 10mM NH<sub>4</sub>CO<sub>3</sub>H pH 9 solution in Water, 36% CH<sub>3</sub>CN) afforded the title compound as a white solid (28 mg, 31%).</p><heading id="h-0029" level="1">Intermediate 21: 6-Bromo-3-methyl-1-(pyrazin-2-ylmethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-0353" num="0421"><chemistry id="CHEM-US-00080" num="00080"><img id="EMI-C00080" he="29.38mm" wi="40.13mm" file="US20230000833A1-20230105-C00080.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0354" num="0422">The title compound was prepared in a manner analogous to Intermediate 20, using pyrazin-2-ylmethanol.</p><heading id="h-0030" level="1">Intermediate 22: 6-Bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one.</heading><p id="p-0355" num="0423"><chemistry id="CHEM-US-00081" num="00081"><img id="EMI-C00081" he="30.56mm" wi="40.81mm" file="US20230000833A1-20230105-C00081.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0356" num="0424">To a solution of 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11, 600 mg, 2.63 mmol) in DMF (8 mL) at 0&#xb0; C. was added NaH (60% dispersion in mineral oil, 137 mg, 3.42 mmol), and the reaction mixture was stirred at room temperature for 10 min. Then, 3-chloromethyl-5-methylisoxazole (288 &#x3bc;L, 2.63 mmol) was added at 0&#xb0; C., and the mixture was stirred at room temperature overnight. The crude reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The residue was purified (FCC, SiO<sub>2</sub>, 0-40% EtOAc in heptanes) to yield the title compound (850 mg, 83%). MS (ESI): mass calcd. for C<sub>12</sub>H<sub>11</sub>BrN<sub>4</sub>O<sub>2</sub>, 322.0; m/z found, 323 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.12 (d, J=1.2 Hz, 1H), 7.79 (d, J=1.3 Hz, 1H), 6.18 (s, 1H), 5.14 (s, 2H), 3.34 (s, 3H), 2.35 (s, 3H).</p><heading id="h-0031" level="1">Intermediate 23: 6-Bromo-3-methyl-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0357" num="0425"><chemistry id="CHEM-US-00082" num="00082"><img id="EMI-C00082" he="30.56mm" wi="40.81mm" file="US20230000833A1-20230105-C00082.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0358" num="0426">The title compound was prepared in a manner analogous to Intermediate 22: 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one using 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole.</p><heading id="h-0032" level="1">Intermediate 24: 6-Bromo-3-methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0359" num="0427"><chemistry id="CHEM-US-00083" num="00083"><img id="EMI-C00083" he="27.69mm" wi="43.69mm" file="US20230000833A1-20230105-C00083.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0360" num="0428">The title compound was prepared in a manner analogous to Intermediate 22: 6-bromo-3-methyl-14(5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one using 5-(chloromethyl)-3-methyl-1,2,4-oxadiazole. MS (ESI): m/z found, 325.9 [M+H], <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) d 8.17 (d, J=1.7 Hz, 1H), 7.96 (d, J=1.7 Hz, 1H), 5.48 (s, 2H), 3.36 (s, 3H), 2.29 (s, 3H).</p><heading id="h-0033" level="1">Intermediate 25: 6-Bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0361" num="0429"><chemistry id="CHEM-US-00084" num="00084"><img id="EMI-C00084" he="26.59mm" wi="36.91mm" file="US20230000833A1-20230105-C00084.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0362" num="0430">The title compound was prepared in a manner analogous to Intermediate 22, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 2-(bromomethyl)oxetane. MS (ESI): mass calcd. for C<sub>11</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>2</sub>, 297.0; m/z found, 298.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.10 (d, J=2.0 Hz, 1H), 7.83 (d, J=2.0 Hz, 1H), 5.02-4.96 (m, 1H), 4.45 (ddd, J=8.6, 7.1, 5.7 Hz, 1H), 4.32 (dt, J=9.0, 6.0 Hz, 1H), 4.19-4.01 (m, 2H), 3.34 (s, 3H), 2.69-2.61 (m, 1H), 2.46-2.38 (m, 1H).</p><heading id="h-0034" level="1">Intermediate 26: 3-Methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0363" num="0431"><chemistry id="CHEM-US-00085" num="00085"><img id="EMI-C00085" he="31.33mm" wi="39.79mm" file="US20230000833A1-20230105-C00085.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><heading id="h-0035" level="1">Step A: N-Methyl-3-nitro-5-(3-(trifluoromethyl)phenyl)pyridin-2-amine</heading><p id="p-0364" num="0432">A mixture of 5-bromo-N-methyl-3-nitropyridin-2-amine (Intermediate 11, product from Step A, 2.2 g, 9.5 mmol), 3-(trifluoromethyl)phenylboronic acid (2.7 g, 14.2 mmol), 1,1&#x2032;-bis(diphenylphosphino)ferrocene palladium(II)dichloride dichloromethane complex (542 mg, 0.66 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(6.2 g, 19.0 mmol), dioxane (87 mL) and H<sub>2</sub>O (17 mL) was heated to 90&#xb0; C. using an oil bath. After 16 h, the reaction mixture was cooled to room temperature and volatiles were removed. The crude material was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in hexanes), to give the title compound (2.6 g, 91%).</p><heading id="h-0036" level="1">Step B: N<sup>2</sup>-Methyl-5-(3-(trifluoromethyl)phenyl)pyridine-2,3-diamine</heading><p id="p-0365" num="0433">A mixture of N-methyl-3-nitro-5-(3-(trifluoromethyl)phenyl)pyridin-2-amine (2.6 g, 8.6 mmol) and 10% palladium on carbon (0.46 g, 0.43 mmol) in EtOH (80 mL) was allowed to stir at room temperature under a hydrogen atmosphere (1 atm, balloon). After 16 h, the reaction was filtered through a pad of Celite&#xae; and the filtrate was concentrated under vacuum. The material was dissolved in a minimum amount of MeOH and filtered through an acrodisc syringe filter and the filtrate was concentrated under vacuum to give the title compound (2.3 g, 99%), which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>13</sub>H<sub>12</sub>F<sub>3</sub>N<sub>3</sub>, 267.1; m/z found, 268.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.04 (d, J=2.1 Hz, 1H), 7.74-7.71 (m, 1H), 7.70-7.66 (m, 1H), 7.56-7.48 (m, 2H), 7.09 (d, J=2.1 Hz, 1H), 4.37-4.26 (m, 1H), 3.29 (s, 2H), 3.08 (d, J=5.1 Hz, 3H).</p><p id="p-0366" num="0434">Step C: 3-Methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a mixture of N<sup>2</sup>-methyl-5-(3-(trifluoromethyl)phenyl)pyridine-2,3-diamine (2.3 g, 8.6 mmol) in DMF (87 mL), under a nitrogen atmosphere, at room temperature was added CDI (1.7 g, 10.3 mmol). After 16 h, conversion was not complete and additional CDI (2.1 g, 12.9 mmol) was added to the reaction mixture. After 3 h, complete conversion was observed and water (200 mL) was added. The precipitates were collected by filtration, washed with water and dried under vacuum to give the title compound (2.2 g, 87%). MS (ESI): mass calcd. for C<sub>14</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O, 293.1; m/z found, 294.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3b4; 11.29 (s, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.05-7.94 (m, 2H), 7.77-7.67 (m, 2H), 7.63 (d, J=2.0 Hz, 1H), 3.34 (s, 3H).</p><heading id="h-0037" level="1">Intermediate 27: 6-(4-Fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0367" num="0435"><chemistry id="CHEM-US-00086" num="00086"><img id="EMI-C00086" he="29.89mm" wi="45.21mm" file="US20230000833A1-20230105-C00086.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0368" num="0436">To a solution a 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11, 75 mg, 0.29 mmol), (4-fluoro-3-methylphenyl)boronic acid (1.01 g, 6.58 mmol) and a saturated aqueous solution of NaHCO<sub>3 </sub>(10 mL) in 1,4-dioxane (20 mL) was added Pd(Ph<sub>3</sub>)<sub>4 </sub>(253 mg, 0.219 mmol). The reaction mixture was stirred at 120&#xb0; C. for 20 min under microwave irradiation. Then, the crude reaction mixture cooled, diluted with EtOAc and washed with water. The organic layer was separated, dried Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was triturated with Et<sub>2</sub>O and filtered to yield the title compound as a black solid (1.1 g, 4.28 mmol), which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>14</sub>H<sub>12</sub>FN<sub>3</sub>O, 257.1; m/z found, 258.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.31 (d, J=1.44 Hz, 3H), 7.18-7.25 (m, 1H), 7.49 (d, J=2.02 Hz, 1H), 7.49-7.52 (m, 1H), 7.60 (dd, J=7.37, 1.88 Hz, 1H), 8.22 (d, J=2.02 Hz, 1H), 11.17 (s, 1H).</p><heading id="h-0038" level="1">Intermediate 28: 6-(3-Fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0369" num="0437"><chemistry id="CHEM-US-00087" num="00087"><img id="EMI-C00087" he="30.73mm" wi="39.79mm" file="US20230000833A1-20230105-C00087.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0370" num="0438">To a solution a 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11, 1 g, 4.4 mmol), (3-fluorophenyl)boronic acid (920 mg, 6.58 mmol) and Na<sub>2</sub>CO<sub>3 </sub>(10 mL) in 1,4-dioxane (20 mL) was added PdCl<sub>2</sub>(dppf) (449 mg, 0.614 mmol). The reaction mixture was stirred at 170&#xb0; C. for 15 min under microwave irradiation. Then, the crude reaction mixture was cooled, diluted with water and extracted with EtOAc. The organic layer was separated, dried Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified (FCC, SiO<sub>2</sub>, 0-4% 7 M solution of NH<sub>3</sub>/MeOH in DCM) to yield the title compound as a brown solid (460 mg, 43%). MS (ESI): mass calcd. for C<sub>13</sub>H<sub>10</sub>FN<sub>3</sub>O, 243.1; m/z found, 244.1 [M+H]<sup>+</sup>.</p><heading id="h-0039" level="1">Intermediate 29: 6-(3,4-Difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0371" num="0439"><chemistry id="CHEM-US-00088" num="00088"><img id="EMI-C00088" he="30.65mm" wi="45.21mm" file="US20230000833A1-20230105-C00088.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0372" num="0440">The title compound was prepared in a manner analogous to Intermediate 28: 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one using (3,4-difluorophenyl)boronic acid. MS (ESI): mass calcd. for C<sub>13</sub>H<sub>9</sub>F<sub>2</sub>N<sub>3</sub>O, 261.1; m/z found, 262.1 [M+H]<sup>+</sup>.</p><heading id="h-0040" level="1">Intermediate 30: 6-(2,4-Difluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0373" num="0441"><chemistry id="CHEM-US-00089" num="00089"><img id="EMI-C00089" he="29.89mm" wi="45.21mm" file="US20230000833A1-20230105-C00089.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0374" num="0442">The title compound was prepared in a manner analogous to Intermediate 27: 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one using Intermediate 8: 2-(2,4-difluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C<sub>14</sub>H<sub>11</sub>F<sub>2</sub>N<sub>3</sub>O, 275.1; m/z found, 276.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.22 (s, 3H) 3.33 (s, 3H) 7.17 (t, J=8.67 Hz, 1H) 7.40 (s, 1H) 7.36-7.46 (m, 1H) 8.07 (s, 1H) 11.20 (br s, 1H).</p><heading id="h-0041" level="1">Intermediate 31: N-Benzhydryl-5-bromo-3-nitropyridin-2-amine</heading><p id="p-0375" num="0443"><chemistry id="CHEM-US-00090" num="00090"><img id="EMI-C00090" he="34.88mm" wi="36.41mm" file="US20230000833A1-20230105-C00090.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0376" num="0444">A solution of 5-bromo-2-chloro-3-nitropyridine (71.2 g, 300 mmol), benzhydrylamine (60 g, 330 mmol), and DIPEA (78 g, 600 mmol) in EtOH (600 mL) was heated to reflux overnight. Then solvent was removed in vacuo. Cold EtOH (1000 mL) was added to the crude residue and the mixture was stirred in an ice bath for 30 minutes upon which time a precipitate formed. The precipitate was filtered, collected and washed with cold EtOH to afford the title compound (93 g, 81%).</p><heading id="h-0042" level="1">Intermediate 32: 6-Bromo-1-(2-methoxyethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0377" num="0445"><chemistry id="CHEM-US-00091" num="00091"><img id="EMI-C00091" he="25.82mm" wi="36.07mm" file="US20230000833A1-20230105-C00091.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0378" num="0446">Step A: N<sup>2</sup>-benzhydryl-5-bromopyridine-2,3-diamine. To a solution of 28% NH<sub>3 </sub>in H<sub>2</sub>O (60 mL), THF (300 mL) and water (300 mL) was added N-benzhydryl-5-bromo-3-nitropyridin-2-amine (Intermediate 31, 60 g, 156 mmol). Then, Na<sub>2</sub>S<sub>2</sub>O<sub>4 </sub>(81.5 g, 468 mmol) was added portion-wise to the reaction mixture, and the mixture was stirred at room temperature overnight. The crude reaction mixture was extracted with EtOAc (3&#xd7;300 mL) and washed with water (300 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to yield the title compound (40 g, 73%), which was used in the next step without further purification.</p><p id="p-0379" num="0447">Step B: 3-Benzhydryl-6-bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A solution of N<sup>2</sup>-benzhydryl-5-bromopyridine-2,3-diamine (50 g, 141 mmol) and CDI (45.7 g, 282 mmol) in 1,4-dioxane (500 mL) was refluxed for 5 h. Then, the solvent was evaporated and the resultant solid was washed with water and dried to yield the title compound (54 g, 99%), which was used in the next step without further purification.</p><p id="p-0380" num="0448">Step C: 3-Benzhydryl-6-bromo-1-(2-methoxyethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A solution of 3-benzhydryl-6-bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (4 g, 11 mmol), 1-bromo-2-methoxyethane (3 g, 21 mmol and K<sub>2</sub>CO<sub>3 </sub>(4.3 g, 32 mmol) in MeCN (50 mL) was refluxed for 3 h. Then, the crude reaction mixture was filtered and the solvent was evaporated to yield the title compound (4.5 g, 97%), which was used in the next step without further purification.</p><p id="p-0381" num="0449">Step D: 6-Bromo-1-(2-methoxyethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 3-benzhydryl-6-bromo-1-(2-methoxyethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (4.5 g, 10.2 mmol) in TFA (40 mL) was added thioanisole (0.045 g), and the reaction mixture was stirred at 80&#xb0; C. for 1 h. Then, the solvent was evaporated and the crude residue was purified (FCC, SiO<sub>2</sub>, 0-10% MeOH in DCM) to yield the title compound (1.4 g, 51%).</p><heading id="h-0043" level="1">Intermediate 33: 2-(6-Bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-ethylacetamide</heading><p id="p-0382" num="0450"><chemistry id="CHEM-US-00092" num="00092"><img id="EMI-C00092" he="25.15mm" wi="42.67mm" file="US20230000833A1-20230105-C00092.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0383" num="0451">The title compound was prepared in a manner analogous to Intermediate 32, using 2-chloro-N-ethylacetamide in Step C.</p><heading id="h-0044" level="1">Intermediate 34: 2-(6-Bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-cyclopropylacetamide</heading><p id="p-0384" num="0452"><chemistry id="CHEM-US-00093" num="00093"><img id="EMI-C00093" he="25.15mm" wi="44.20mm" file="US20230000833A1-20230105-C00093.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0385" num="0453">The title compound was prepared in a manner analogous to Intermediate 32, using 2-bromo-N-cyclopropylacetamide in Step C.</p><heading id="h-0045" level="1">Intermediate 35: Ethyl 6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate</heading><p id="p-0386" num="0454"><chemistry id="CHEM-US-00094" num="00094"><img id="EMI-C00094" he="45.04mm" wi="40.13mm" file="US20230000833A1-20230105-C00094.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0387" num="0455">To a solution of ethyl 6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate (Intermediate 9, 703 mg, 2.46 mmol) in DCM (25 mL) was added trityl chloride (788 mg, 2.82 mmol) followed by Et<sub>3</sub>N (615 &#x3bc;L, 4.42 mmol). The mixture was stirred at room temperature for 48 h then concentrated and the crude oil was purified by SiO<sub>2 </sub>(0 to 25% EtOAc in hexanes) to yield the title compound as an amorphous solid (1.22 g, 94%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): 8.15 (d, J=2.1 Hz, 1H), 7.90 (d, J=2.2 Hz, 1H), 7.54-7.43 (m, 6H), 7.25-7.14 (m, 9H), 4.47 (q, J=7.1 Hz, 2H), 1.42 (t, J=7.1 Hz, 3H).</p><heading id="h-0046" level="1">Intermediate 36: 6-Bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0388" num="0456"><chemistry id="CHEM-US-00095" num="00095"><img id="EMI-C00095" he="33.87mm" wi="40.13mm" file="US20230000833A1-20230105-C00095.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0389" num="0457">A mixture of ethyl 6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate (Intermediate 35, 3.7 g, 7.0 mmol) and isopropylamine (0.72 mL, 8.4 mmol) in THF (35 mL) was stirred at room temperature for 2 h. Then, the reaction mixture was concentrated under vacuum to yield the title compound as a yellow oil (3.2 g, 7.0 mmol, 100%), which was used without further purification. MS (ESI): mass calcd. for C<sub>25</sub>H<sub>18</sub>BrN<sub>3</sub>O, 455.1; m/z found, 454 [M+H]<sup>+</sup>.</p><heading id="h-0047" level="1">Intermediate 37: Ethyl 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate</heading><p id="p-0390" num="0458"><chemistry id="CHEM-US-00096" num="00096"><img id="EMI-C00096" he="44.37mm" wi="42.67mm" file="US20230000833A1-20230105-C00096.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0391" num="0459">Under a nitrogen atmosphere was added 6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 36, 2 g, 4.4 mmol) to a suspension of NaH (60% dispersion in mineral oil, 245 mg, 6.1 mmol) in DMF (20 mL). After 5 minutes, ethyl bromoacetate (0.68 mL, 6.1 mmol) was added to the reaction mixture. After 16 h, the reaction mixture was quenched with water (100 mL). The precipitates were filtered off, washed with water and dried under vacuum to afford the title product. The crude material was moved forward to the next step as is.</p><heading id="h-0048" level="1">Intermediate 38: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0392" num="0460"><chemistry id="CHEM-US-00097" num="00097"><img id="EMI-C00097" he="51.31mm" wi="40.13mm" file="US20230000833A1-20230105-C00097.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0393" num="0461">Step A: 2-(6-Bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid. To a solution of ethyl 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (Intermediate 37, 2.4 g, 4.4 mmol) in THF (60 mL) at room temperature was added LiOH (2 M, 3.1 mL, 6.1 mmol). After 16 h, the precipitates were collected by filtration, washed with water and dried under vacuum to afford the title compound (546 mg, 1.1 mmol, 24.3%). A saturated aqueous solution of NH<sub>4</sub>Cl was added to the filtrate. The mixture was extracted with EtOAc (3&#xd7;) to remove organic impurities. The solids in the aqueous layer were collected by filtration, rinsed with water and dried under vacuum to afford the title compound (1.51 g, 67%). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 7.70 (d, J=2.1 Hz, 1H), 7.44-7.38 (m, 6H), 7.36 (d, J=2.1 Hz, 1H), 7.25-7.11 (m, 10H), 3.93 (s, 2H).</p><p id="p-0394" num="0462">Step B: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. HATU (582 mg, 1.5 mmol) was added to a mixture of 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (656 mg, 1.3 mmol), azetidine (0.103 mL, 1.5 mmol) and DIPEA (0.44 mL, 2.6 mmol) in DMF (15 mL) at room temperature. After completion, a saturated aqueous solution of NaHCO<sub>3 </sub>(20 mL) was added, and the mixture was extracted using EtOAc (3&#xd7;30 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0-90% EtOAc in hexanes) to afford the title compound (260 mg, 37%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 7.79 (d, J=2.1 Hz, 1H), 7.70 (d, J=2.1 Hz, 1H), 7.42-7.38 (m, 6H), 7.26-7.12 (m, 9H), 4.47 (s, 2H), 4.09 (t, J=7.6 Hz, 2H), 3.87 (t, J=7.6 Hz, 2H), 2.22 (p, J=7.8 Hz, 2H).</p><heading id="h-0049" level="1">Intermediate 39: 2-(6-Bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide</heading><p id="p-0395" num="0463"><chemistry id="CHEM-US-00098" num="00098"><img id="EMI-C00098" he="48.94mm" wi="40.13mm" file="US20230000833A1-20230105-C00098.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0396" num="0464">2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide solution (T3P&#xae;) (3.25 mL, 5.4 mmol) was added to a mixture of 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 38, product from Step A, 941 mg, 1.8 mmol), dimethylamine hydrochloride (177 mg, 2.2 mmol) and DIPEA (0.94 mL, 5.4 mmol) in DCM (10 mL) at room temperature. After completion, a saturated aqueous solution of NaHCO<sub>3 </sub>(20 mL) was added, and the mixture was extracted using DCM (3&#xd7;30 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in hexanes) to afford the title compound (927 mg, 1.7 mmol, 94%). No NMR only LCMS of reaction. TFA used to deprotect trityl in LCMS sample; trityl group swamps out product signal.</p><heading id="h-0050" level="1">Intermediate 40: 1-(2-(3-Fluoroazetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0397" num="0465"><chemistry id="CHEM-US-00099" num="00099"><img id="EMI-C00099" he="57.49mm" wi="40.13mm" file="US20230000833A1-20230105-C00099.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0398" num="0466">The title compounds was made in an analogous manner to 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 39) using 3-fluoroazetidine hydrochloride in Step B. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 7.85-7.82 (m, 1H), 7.51-7.46 (m, 6H), 7.29-7.27 (m, 1H), 7.25-7.15 (m, 9H), 5.23-5.06 (m, 1H), 4.44-4.31 (m, 2H), 4.31-4.21 (m, 1H), 4.11-4.05 (m, 1H), 4.02-3.93 (m, 1H), 3.93-3.83 (m, 1H).</p><heading id="h-0051" level="1">Intermediate 41: 1-(2-(Pyrrolidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0399" num="0467"><chemistry id="CHEM-US-00100" num="00100"><img id="EMI-C00100" he="52.75mm" wi="40.13mm" file="US20230000833A1-20230105-C00100.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0400" num="0468">The title compounds was made in an analogous manner to 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 39) using pyrrolidine in Step B.</p><heading id="h-0052" level="1">Intermediate 42: 2-(6-Bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetaldehyde</heading><p id="p-0401" num="0469"><chemistry id="CHEM-US-00101" num="00101"><img id="EMI-C00101" he="44.45mm" wi="40.13mm" file="US20230000833A1-20230105-C00101.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0402" num="0470">Step A: 6-Bromo-1-(2-hydroxyethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A solution of ethyl 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (Intermediate 37, 8.1 g, 15 mmol) in THF (406 mL) was cooled to 0&#xb0; C. in an ice and acetone bath. To the reaction was added lithium borohydride (15 mL, 30 mmol) and the reaction was allowed to warm to room temperature for 10 minutes and then heated to 65&#xb0; C. for an additional hour. Then, the reaction mixture was cooled to room temperature, and the crude mixture was quenched with water (250 mL) and extracted with ethyl acetate (500 mL). The organics were dried over MgSO<sub>4</sub>, concentrated in vacuo, and purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in hexanes) to provide the title compound (6.6 g, 88%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 7.80-7.75 (m, 1H), 7.75-7.66 (m, 1H), 7.49-7.39 (m, 6H), 7.28-7.18 (m, 6H), 7.18-7.07 (m, 3H), 4.96-4.85 (m, 1H), 3.87-3.74 (m, 2H), 3.65-3.53 (d, J=5.1 Hz, 2H).</p><p id="p-0403" num="0471">Step B: 2-(6-Bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetaldehyde. A solution of 6-bromo-1-(2-hydroxyethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (5.5 g, 11 mmol) and sodium bicarbonate (2.8 g, 33 mmol) in DCM (48 mL) was cooled to 0&#xb0; C. in an ice and acetone bath, and Dess-Martin Periodinane (5.6 g, 13 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 1 hour. Then, the reaction mixture was concentrated in vacuo and taken up in THF (50 mL). The crude reaction was filtered through a pad of Celite&#xae;, concentrated down in vacuo and purified (FCC, SiO<sub>2</sub>, 25-80% EtOAc in hexanes) to afford the title compound (4.2 g, 90%). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.53 (s, 1H), 7.85-7.80 (d, J=2.1 Hz, 1H), 7.75-7.69 (d, J=2.1 Hz, 1H), 7.52-7.39 (m, 6H), 7.31-7.20 (m, 6H), 7.20-7.12 (m, 3H), 4.82 (s, 2H).</p><heading id="h-0053" level="1">Intermediate 43: 6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0404" num="0472"><chemistry id="CHEM-US-00102" num="00102"><img id="EMI-C00102" he="47.75mm" wi="47.92mm" file="US20230000833A1-20230105-C00102.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0405" num="0473">Step A: 5-(3-(Trifluoromethyl)phenyl)pyridine-2,3-diamine. A mixture of 2,3-diamino-5-bromopyridine (2 g, 10.6 mmol), 3-(trifluoromethyl)phenylboronic acid (4.04 g, 21.3 mmol), 1,1&#x2032;-bis(diphenylphosphino)ferrocene palladium(II)dichloride dichloromethane complex (608 mg, 0.75 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(6.93 g, 21.3 mmol), dioxane (98 mL) and H<sub>2</sub>O (21 mL) was heated to 90&#xb0; C. using an oil bath. After 16 h, starting material was completely consumed. The reaction mixture was cooled to room temperature and volatiles were removed. A saturated aqueous solution of NaHCO<sub>3 </sub>(30 mL) followed by solid NaCl was added to the reaction mixture, and the mixture was extracted with EtOAc (3&#xd7;60 mL).The combined organic layers were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude material was purified (FCC, 0-100% EtOAc in hexanes), to give the title compound (2.6 g, 97%). MS (ESI): mass calcd. for C<sub>12</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>, 253.1; m/z found, 254.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 7.84-7.79 (m, 1H), 7.77-7.74 (m, 1H), 7.69 (d, J=2.2 Hz, 1H), 7.64-7.56 (m, 2H), 7.06 (d, J=2.3 Hz, 1H), 5.68 (s, 2H), 4.84 (s, 2H)</p><p id="p-0406" num="0474">Step B: 6-(3-(Trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. Under a nitrogen atmosphere, CDI (8.2 g, 50.8 mmol) was added to a mixture of 5-(3-(trifluoromethyl)phenyl)pyridine-2,3-diamine (10.7 g, 42.3 mmol) in DMF (428 mL) at room temperature. After 3 h, conversion was not complete and additional CDI (3.4 g, 21.4 mmol) was added to the reaction mixture. Once complete conversion was observed water was added, and the mixture was allowed to stir for an additional 30 min. The solids were collected by filtration, washed with water and dried under vacuum to afford the title compound (11.3 g, 40.6 mmol, 96%), which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>13</sub>H<sub>8</sub>F<sub>3</sub>N<sub>3</sub>O, 279.1; m/z found, 280.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.47 (s, 1H), 11.02 (s, 1H), 8.25 (d, J=2.0 Hz, 1H), 8.01-7.95 (m, 2H), 7.75-7.66 (m, 2H), 7.55 (d, J=2.0 Hz, 1H).</p><p id="p-0407" num="0475">Step C: Ethyl 2-oxo-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate. Under a nitrogen atmosphere, a mixture of 6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (2.86 g, 10.2 mmol), ethyl pyridin-2-yl carbonate (2.57 g, 15.4 mmol) and K<sub>2</sub>CO<sub>3 </sub>(2.12 g, 15.4 mmol) in DMF (80 mL) was heated to 75&#xb0; C. After 16 h, water was added followed by 10% HCl until the mixture reached pH 1. The precipitates were filtered, washed with water and collected to afford the title compound, which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 351.1; m/z found, 352.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3b4; 12.15 (s, 1H), 8.46 (d, J=2.1 Hz, 1H), 8.15 (d, J=2.1 Hz, 1H), 8.01-7.94 (m, 2H), 7.80-7.70 (m, 2H), 4.44 (q, J=7.1 Hz, 2H), 1.38 (t, J=7.1 Hz, 3H).</p><p id="p-0408" num="0476">Step D: Ethyl 2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate. A mixture of TEA (1.42 mL, 10.2 mmol), ethyl 2-oxo-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate (2.0 g, 5.7 mmol) and trityl chloride (1.9 g, 6.8 mmol) in DMF was stirred at room temperature. After 16 h, the reaction mixture was quenched with a saturated aqueous solution of NH<sub>4</sub>Cl (40 mL). The precipitates were collected by filtration, washed with water and dried under vacuum to afford the title compound, which was contaminated with a small amount of impurities. The crude material was moved forward to the next step as is.</p><p id="p-0409" num="0477">Step E: 6-(3-(Trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A mixture of ethyl 2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate (3.4 g, 5.7 mmol) and isopropylamine (0.59 mL, 6.8 mmol) in THF (30 mL) was stirred at room temperature. After 16 h, the reaction mixture was concentrated under vacuum and the crude material was purified (FCC, SiO<sub>2</sub>, 0-90% EtOAc in hexanes) to give the title compound (2.7 g, 92%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.21 (s, 1H), 8.08 (d, J=2.1 Hz, 1H), 7.96-7.91 (m, 2H), 7.70-7.62 (m, 2H), 7.55-7.47 (m, 7H), 7.26-7.21 (m, 6H), 7.18-7.12 (m, 3H).</p><heading id="h-0054" level="1">Intermediate 44: 2-(2-Oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid</heading><p id="p-0410" num="0478"><chemistry id="CHEM-US-00103" num="00103"><img id="EMI-C00103" he="47.75mm" wi="47.92mm" file="US20230000833A1-20230105-C00103.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0411" num="0479">Step A: Ethyl 2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate. Under a nitrogen atmosphere was added 6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 43, 1 g, 1.9 mmol) to a suspension of NaH (60% dispersion in mineral oil, 107 mg, 2.7 mmol) in DMF (20 mL). After 5 minutes, ethyl bromoacetate (0.30 mL, 2.7 mmol) was added to the reaction mixture. After 16 h, the reaction mixture was quenched with water (100 mL). The precipitates were filtered off, washed with water and dried under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0-90% EtOAc in hexanes) to give the title compound (904 mg, 78%) as a foam. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.19 (d, J=2.0 Hz, 1H), 8.02 (d, J=2.1 Hz, 1H), 8.01-7.93 (m, 2H), 7.72-7.63 (m, 2H), 7.49-7.42 (m, 6H), 7.29-7.11 (m, 9H), 4.76 (s, 2H), 4.10 (q, J=7.1 Hz, 2H), 1.14 (t, J=7.1 Hz, 3H).</p><p id="p-0412" num="0480">Step B: 2-(2-Oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid. To a solution of ethyl 2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (904 mg, 1.5 mmol) in THF at room temperature was added LiOH (2 M, 1.04 mL, 2.1 mmol). After 16 h, complete conversion was observed and a saturated aqueous solution of NH<sub>4</sub>Cl (20 mL) was added. The mixture was extracted using EtOAc (3&#xd7;30 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to afford the title compound. The crude product was used in the next step without further purification.</p><heading id="h-0055" level="1">Intermediate 45: 2-(2-Oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)propanoic acid</heading><p id="p-0413" num="0481"><chemistry id="CHEM-US-00104" num="00104"><img id="EMI-C00104" he="47.75mm" wi="48.43mm" file="US20230000833A1-20230105-C00104.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0414" num="0482">The title compound was prepared in a manner analogous to Intermediate 44, using ethyl 2-bromopropanoate in Step A. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) d 8.10 (d, J=2.1 Hz, 1H), 7.98-7.89 (m, 2H), 7.82-7.60 (m, 3H), 7.51-7.40 (m, 6H), 7.29-7.10 (m, 9H), 5.04-4.88 (m, 1H), 1.53 (d, J=7.2 Hz, 3H).</p><heading id="h-0056" level="1">Intermediate 46: 1-((2-Methoxypyridin-3-yl)methyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0415" num="0483"><chemistry id="CHEM-US-00105" num="00105"><img id="EMI-C00105" he="48.34mm" wi="55.71mm" file="US20230000833A1-20230105-C00105.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0416" num="0484">The title compound was prepared in a manner analogous to Intermediate 37 using 6-(3-(trifluoromethyl)phenyl)-3-trityl-1H-imidazo[4,5-b]pyridin-2(3H)-one (Intermediate 43) and 3-(chloromethyl)-2-methoxypyridine.</p><heading id="h-0057" level="1">Intermediate 47: N<sup>3</sup>-((5-Methylisoxazol-3-yl)methyl)-5-(3-(trifluoromethyl)phenyl)pyridine-2,3-diamine</heading><p id="p-0417" num="0485"><chemistry id="CHEM-US-00106" num="00106"><img id="EMI-C00106" he="33.02mm" wi="44.03mm" file="US20230000833A1-20230105-C00106.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0418" num="0486">Step A: 5-Bromo-N<sup>3</sup>-((5-methylisoxazol-3-yl)methyl)pyridine-2,3-diamine. A 1 L round bottomed flask was charged with 5-bromopyridine-2,3-diamine (16 g), 5-methylisoxazole-3-carbaldehyde (11.3 g), activated 4A molecular sieves (24 g) and THF (500 mL). The solution was heated to reflux at 70&#xb0; C. overnight and then filtered to remove the molecular sieves. All volatiles were removed under vacuum to leave a crude yellow solid which consisted of a mixture of multiple products and excess aldehyde. This material was used directly in the next step without any further purification. The crude was dissolved in EtOH and NaBH<sub>4 </sub>(1.40 g) was added and the solution was heated to reflux at 85&#xb0; C. for 18 h. Then the reaction was quenched with water and the product was extracted with DCM, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated down to a red residue. The product was purified (FCC, SiO<sub>2</sub>, 0-10% MeOH in DCM) to afford the title compound as solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.70 (d, 1H), 6.98 (d, 1H), 5.98 (s, 1H), 4.43 (d, 2H), 4.20 (br s, 2H), 3.81 (br s, 1H), 2.45 (s, 3H).</p><p id="p-0419" num="0487">Step B: N<sup>3</sup>-((5-Methylisoxazol-3-yl)methyl)-5-(3-(trifluoromethyl)phenyl)pyridine-2,3-diamine. To a solution of 5-bromo-N<sup>3</sup>-((5-methylisoxazol-3-yl)methyl)pyridine-2,3-diamine (2.8 g, 9.8 mmol) in 1,4-dioxane (50 mL) was added 3-(trifluoromethyl)phenylboronic acid (2.8 g, 14.8 mmol). Then, Na<sub>2</sub>CO<sub>3 </sub>(2.1 g, 19.7 mmol), deionized water (7 mL), and Pd(PPh<sub>3</sub>)<sub>4 </sub>(569.4 mg, 0.49 mmol) was added, and the reaction was heated to 100&#xb0; C. overnight. The reaction was cooled to room temperature, diluted with ethyl acetate (100 mL) and washed with water (50 mL). The organic layer was collected, dried, filtered and concentrated in vacuo. The crude reaction was purified (FCC, SiO<sub>2</sub>, 0-20% MeOH in DCM) to provide the title compound (1.0 g, 31%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 348.3; m/z found, 349.2 [M+H]<sup>+</sup>.</p><heading id="h-0058" level="1">Intermediate 48: 2-Bromo-5-methylthiophene</heading><p id="p-0420" num="0488"><chemistry id="CHEM-US-00107" num="00107"><img id="EMI-C00107" he="11.18mm" wi="21.00mm" file="US20230000833A1-20230105-C00107.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0421" num="0489">NBS (1.1 eq, 4.0g, 22.7 mmol) was added to a solution of 2-methylthiophene (1.0 eq., 2 mL, 20.7 mmol) in a mixture of chloroform/AcOH (10:1, 20 mL) at 0&#xb0; C. in the absence of light. The mixture reaction was stirred at 0&#xb0; C. for 1 h. Then the mixture was warmed to rt for 12 hours. The reaction was quenched with aqueous sat. NaHCO<sub>3 </sub>solution. The organic layer was dried (MgSO<sub>4</sub>), filtered and the solvents were evaporated in vacuo. The crude product was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in heptane) to provide the title compound (2.5 g, 69%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 6.83 (d, J=3.6 Hz, 1H), 6.52 (d, J=2.5 Hz, 1H), 2.43 (s, 3H).</p><heading id="h-0059" level="1">Intermediate 49: 2-Bromo-5-(difluoromethyl)thiophene</heading><p id="p-0422" num="0490"><chemistry id="CHEM-US-00108" num="00108"><img id="EMI-C00108" he="16.85mm" wi="26.59mm" file="US20230000833A1-20230105-C00108.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0423" num="0491">Step A: 5-bromothiophene-2-carbaldehyde. NBS (1.5 eq, 5.8 g, 33 mmol) was added to a solution of thiophene-2-carbaldehyde (1.0 eq., 2 mL, 22 mmol) in a mixture of chloroform/AcOH (10:1, 22 mL) at 0&#xb0; C. in the absence of light. The reaction mixture was stirred at 0&#xb0; C. for 1 h. Then the mixture was allowed to warm to rt for 12 hours. The reaction was quenched with an aqueous sat. NaHCO<sub>3 </sub>solution. The organic layer was washed with brine, dried (MgSO<sub>4</sub>), filtered, and the solvents were evaporated in vacuo. The crude product was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in heptane) to provide the title compound (1.4 g, 35%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.76 (s, 1H), 7.51 (d, J=4.0 Hz, 1H), 7.18 (d, J=4.0 Hz, 1H).</p><p id="p-0424" num="0492">Step B: 2-Bromo-5-(difluoromethyl)thiophene. DAST (2.9 eq., 2.9 mL, 22 mmol) was added to a solution of 5-bromothiophene-2-carbaldehyde (1.0 eq., 1.44g, 7.5 mmol) in DCM at 0&#xb0; C. under inert atmosphere. The mixture was stirred at rt for 16 hours. The mixture was quenched with ice-cold water and extracted with DCM. The combined organic extracts were washed with water and brine, the organic layer was separated, dried (MgSO<sub>4</sub>), filtered and the solvents were evaporated in vacuo. The crude product was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in heptane) to provide the title compound (511 mg, 32%).<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.03 (d, J=3.9 Hz, 2H), 6.74 (t, J=55.9 Hz, 1H).</p><heading id="h-0060" level="1">Intermediate 50: 6-Bromo-3-methyl-1-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0425" num="0493"><chemistry id="CHEM-US-00109" num="00109"><img id="EMI-C00109" he="26.75mm" wi="43.69mm" file="US20230000833A1-20230105-C00109.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0426" num="0494">The title compound was prepared in a manner analogous to 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 22) using 4-(chloromethyl)-1-methyl-1H-1,2,3-triazole hydrochloride. MS (ESI): mass calcd. for C<sub>11</sub>H<sub>11</sub>BrN<sub>6</sub>O, 322.0; m/z found, 324 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO) &#x3b4; 8.10 (d, J=1.7 Hz, 1H), 8.05 (s, 1H), 7.83 (d, J=1.6 Hz, 1H), 5.13 (s, 2H), 3.99 (s, 3H), 3.32 (s, 3H).</p><heading id="h-0061" level="1">Intermediate 51: 6-Bromo-3-methyl-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0427" num="0495"><chemistry id="CHEM-US-00110" num="00110"><img id="EMI-C00110" he="29.55mm" wi="41.15mm" file="US20230000833A1-20230105-C00110.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0428" num="0496">The title compound was prepared in a manner analogous to 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 22) using 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole. MS (ESI): mass calcd. for C<sub>11</sub>H<sub>10</sub>BrN<sub>5</sub>O<sub>2</sub>, 323.0; m/z found, 325 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.14 (d, J=1.6 Hz, 1H), 7.44 (d, J=1.6 Hz, 1H), 5.25 (s, 2H), 3.50 (s, 3H), 2.52 (s, 3H).</p><heading id="h-0062" level="1">Intermediate 52: 6-Bromo-3-methyl-1-((1-methyl-1H-pyrazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0429" num="0497"><chemistry id="CHEM-US-00111" num="00111"><img id="EMI-C00111" he="29.46mm" wi="41.15mm" file="US20230000833A1-20230105-C00111.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0430" num="0498">The title compound was prepared in a manner analogous to 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 22) using 4-(chloromethyl)-1-methyl-1H-pyrazole. The halide was added as a solution of DMF (5 mL) and DIPEA (1 equivalent). MS (ESI): mass calcd. for C<sub>12</sub>H<sub>12</sub>BrN<sub>5</sub>O, 321.0; m/z found, 322 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) d 8.07 (s, 1H), 7.87 (s, 1H), 7.70 (s, 1H), 7.43 (s, 1H), 4.89 (s, 2H), 3.75 (s, 3H), 3.27 (s, 3H).</p><heading id="h-0063" level="1">Intermediate 53: 14(1,2,3-Thiadiazol-4-yl)methyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0431" num="0499"><chemistry id="CHEM-US-00112" num="00112"><img id="EMI-C00112" he="26.75mm" wi="39.29mm" file="US20230000833A1-20230105-C00112.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0432" num="0500">The title compound was prepared in a manner analogous to 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 22) using 4-(chloromethyl)-1,2,3-thiadiazole (Intermediate 61). MS (ESI): mass calcd. for C<sub>10</sub>H<sub>8</sub>BrN<sub>5</sub>OS, 325.0 m/z found, 326 [M+H]<sup>+</sup>.</p><heading id="h-0064" level="1">Intermediate 54: 6-Bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0433" num="0501"><chemistry id="CHEM-US-00113" num="00113"><img id="EMI-C00113" he="29.55mm" wi="41.15mm" file="US20230000833A1-20230105-C00113.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0434" num="0502">The title compound was prepared in a manner analogous to 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 22) using 3-chloromethyl-5-methylisoxazole. MS (ESI): mass calcd. for C<sub>11</sub>H<sub>11</sub>BrN<sub>6</sub>O, 322.0; m/z found, 324 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.10 (d, J=1.7 Hz, 1H), 8.05 (s, 1H), 7.83 (d, J=1.6 Hz, 1H), 5.13 (s, 2H), 3.99 (s, 3H), 3.32 (s, 3H).</p><heading id="h-0065" level="1">Intermediate 55: 6-Bromo-3-methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0435" num="0503"><chemistry id="CHEM-US-00114" num="00114"><img id="EMI-C00114" he="26.67mm" wi="43.69mm" file="US20230000833A1-20230105-C00114.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0436" num="0504">The title compound was prepared in a manner analogous to 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 22) using 5-(chloromethyl)-3-methyl-1,2,4-oxadiazole. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.17 (d, J=1.7 Hz, 1H), 7.96 (d, J=1.7 Hz, 1H), 5.48 (s, 2H), 3.36 (s, 3H), 2.29 (s, 3H).</p><heading id="h-0066" level="1">Intermediate 56: 6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0437" num="0505"><chemistry id="CHEM-US-00115" num="00115"><img id="EMI-C00115" he="33.02mm" wi="45.21mm" file="US20230000833A1-20230105-C00115.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0438" num="0506">The title compound was prepared in a manner analogous to 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 27) using PdCl<sub>2</sub>(dppf)<sub>2 </sub>and (3-(difluoromethyl)-4-fluorophenyl)boronic acid (Intermediate 62). MS (ESI): mass calcd. for C<sub>14</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O, 293.1; m/z found, 294 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.28 (s, 1H), 8.25 (s, 1H), 7.89 (d, J=6.1 Hz, 2H), 7.54 (s, 1H), 7.47 (t, J=9.7 Hz, 1H), 7.23 (t, J=54.2 Hz, 1H), 3.33-3.31 (m, 3H).</p><heading id="h-0067" level="1">Intermediate 57: 6-(4-Chloro-3-(difluoromethoxy)phenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0439" num="0507"><chemistry id="CHEM-US-00116" num="00116"><img id="EMI-C00116" he="38.61mm" wi="46.57mm" file="US20230000833A1-20230105-C00116.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0440" num="0508">The title compound was prepared in a manner analogous to 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 27) using PdCl<sub>2</sub>(dppf)<sub>2 </sub>and 2-(4-chloro-3-(difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate 63). MS (ESI): mass calcd. for C<sub>14</sub>H<sub>10</sub>CIF<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 325.0 m/z found, 326 [M+H]<sup>+</sup>.</p><heading id="h-0068" level="1">Intermediate 58: 6-(3-(Difluoromethoxy)-4-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0441" num="0509"><chemistry id="CHEM-US-00117" num="00117"><img id="EMI-C00117" he="38.61mm" wi="45.21mm" file="US20230000833A1-20230105-C00117.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0442" num="0510">The title compound was prepared in a manner analogous to 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 27) , using PdCl<sub>2</sub>(dppf)<sub>2 </sub>and (3-(difluoromethoxy)-4-fluorophenyl)boronic acid. MS (ESI): mass calcd. for C<sub>14</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 309.1; m/z found, 310 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.28 (s, 1H), 8.26 (s, 1H), 7.69-7.10 (m, 5H), 3.34 (s, 3H).</p><heading id="h-0069" level="1">Intermediate 59: 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid</heading><p id="p-0443" num="0511"><chemistry id="CHEM-US-00118" num="00118"><img id="EMI-C00118" he="32.94mm" wi="45.21mm" file="US20230000833A1-20230105-C00118.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0444" num="0512">The title compound was prepared in a manner analogous to 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 13) using 6-(3-(difluoromethyl)-4-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 56) in Step A and 3M sodium hydroxide in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 351.1; m/z found, 352 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (s, 1H), 8.00 (s, 1H), 7.92 (d, J=6.0 Hz, 2H), 7.50 (t, J=9.7 Hz, 1H), 7.26 (t, J=54.2 Hz, 1H), 4.70 (s, 2H), 3.39 (s, 3H).</p><heading id="h-0070" level="1">Intermediate 60: 2-(6-(3-(Difluoromethoxy)-4-fluorophenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid</heading><p id="p-0445" num="0513"><chemistry id="CHEM-US-00119" num="00119"><img id="EMI-C00119" he="38.61mm" wi="45.21mm" file="US20230000833A1-20230105-C00119.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0446" num="0514">The title compound was prepared in a manner analogous to 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 13) using 6-(3-(difluoromethoxy)-4-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 58) in Step A and 3M sodium hydroxide in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>, 367.1; m/z found, 368 [M+H]<sup>+</sup>.</p><heading id="h-0071" level="1">Intermediate 61: 4-(Chloromethyl)-1,2,3-thiadiazole</heading><p id="p-0447" num="0515"><chemistry id="CHEM-US-00120" num="00120"><img id="EMI-C00120" he="11.35mm" wi="19.98mm" file="US20230000833A1-20230105-C00120.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0448" num="0516">Step A: Methyl 1,2,3-thiadiazole-4-carboxylate. 1,2,3-Thiadiazole-4-carboxylic acid (1.0, 1 g, 7.7 mmol) was added to HCl (1.25 M in MeOH, 10 mL) and the reaction mixture was stirred at 65&#xb0; C. for 16 h. The solvent was removed under reduced pressure and the resulting crude mixture was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in DCM) to provide the title compound (1.1 g, 99.9%). MS (ESI): mass calcd. for C<sub>4</sub>H<sub>4</sub>N<sub>2</sub>O<sub>2</sub>S, 144.0; m/z found, 145 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.27 (s, 1H), 4.07 (s, 3H).</p><p id="p-0449" num="0517">Step B: (1,2,3-Thiadiazol-4-yl)methanol. CaCl<sub>2 </sub>(5 mg, 0.05 mmol) and NaBH<sub>4 </sub>(945 mg, 25 mmol) were added to a mixture of methyl 1,2,3-thiadiazole-4-carboxylate (1.1 g, 7.8 mmol) in THF (9 mL) and EtOH (18 mL). The mixture was stirred at rt for 2 h. The mixture was diluted with water and extracted with DCM/MeOH (9:1). The organic layer was separated, dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification (FCC, SiO<sub>2</sub>, 0-10% MeOH in DCM) provided the title compound (389 mg, 43%). MS (ESI): mass calcd. for C<sub>3</sub>H<sub>4</sub>N<sub>2</sub>OS, 116.0; m/z found, 117 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.51 (s, 1H), 6.45 (s, 1H), 5.22 (s, 2H).</p><p id="p-0450" num="0518">Step C: 4-(Chloromethyl)-1,2,3-thiadiazole. A flask containing (1,2,3-thiadiazol-4-yl)methanol (380 mg, 3.3 mmol) and DCM (20 mL) was placed under N<sub>2 </sub>atmosphere at 0&#xb0; C. To this solution was added SOCl<sub>2 </sub>(1.5 eq., 357 &#x3bc;L, 4.9 mmol) portionwise and the reaction mixture was stirred at rt for 30 minutes. The solvent was removed under reduced pressure. Purification (FCC, SiO<sub>2</sub>, 0-100% EtOAc in heptane) afforded the title compound (175 mg, 40%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.58 (s, 1H), 5.09 (s, 2H).</p><heading id="h-0072" level="1">Intermediate 62: (3-(Difluoromethyl)-4-fluorophenyl)boronic Acid</heading><p id="p-0451" num="0519"><chemistry id="CHEM-US-00121" num="00121"><img id="EMI-C00121" he="21.51mm" wi="27.26mm" file="US20230000833A1-20230105-C00121.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0452" num="0520">To a cooled, &#x2212;78&#xb0; C., solution of bromo-2-difluoromethyl-1-fluorobenzene (1.5 mL, 11.1 mmol) and triisopropyl borate (3.8 mL, 16.7 mmol) in THF (25 mL), under a nitrogen atmosphere, was added nBuLi (2.5 M in hexanes, 8.9 mL, 22.2 mmol). The reaction mixture was stirred at rt for 30 minutes. The reaction mixture was quenched using 2 N aq. HCl. The resulting mixture was extracted with EtOAc. The organic layers were separated and the aqueous was extracted with DCM. The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure to afford title compound (2.4 g, 99%, 87% pure), which was used crude without further purification.</p><heading id="h-0073" level="1">Intermediate 63: 2-(4-Chloro-3-(difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane</heading><p id="p-0453" num="0521"><chemistry id="CHEM-US-00122" num="00122"><img id="EMI-C00122" he="39.12mm" wi="35.90mm" file="US20230000833A1-20230105-C00122.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0454" num="0522">Step A: 4-Bromo-1-chloro-2-(difluoromethoxy)benzene. To a mixture of 5-bromo-2-chlorophenol (7g, 34 mmol) and K<sub>2</sub>CO<sub>3 </sub>(16 g, 118 mmol) in DMF (200 mL) was added ethyl chlorodifluoroacetate (15 mL, 118 mmol). The reaction mixture was heated to 80&#xb0; C. overnight. The residue was diluted with ice-water and was extracted with EtOAc. The combined organic layers were dried (MgSO<sub>4</sub>), filtered and concentrated under vacuo.</p><p id="p-0455" num="0523">Purification (FCC, SiO<sub>2</sub>, 0-100% EtOAc in heptane) afforded the title compound (5.8 g, 67%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.41 (s, 1H), 7.32 (s, 2H), 6.53 (t, J=72.9 Hz, 1H).</p><p id="p-0456" num="0524">Step B: 2-(4-Chloro-3-(difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. The title compound was prepared in a manner analogous to Intermediate 8, using 4-bromo-1-chloro-2-(difluoromethoxy)benzene.</p><heading id="h-0074" level="1">Intermediate 64: 3-(Chloromethyl)-5-fluoropyridine</heading><p id="p-0457" num="0525"><chemistry id="CHEM-US-00123" num="00123"><img id="EMI-C00123" he="13.04mm" wi="26.59mm" file="US20230000833A1-20230105-C00123.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0458" num="0526">Step A: (5-Fluoropyridin-3-yl)methanol. To a cooled, 0&#xb0; C., solution of 5-fluoropyridine-3-carboxylic acid (1.0g, 7.1 mmol) in THF (30 mL) under a nitrogen atmosphere was added LAH (430 mg, 11 mmol). After 1 h, the reaction mixture was quenched with water and extracted with DCM/MeOH (9:1). The organic layer was dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure to provide title compound (480 mg, 53%) which was used crude without further purification. MS (ESI): mass calcd. for C<sub>6</sub>H<sub>6</sub>FNO, 127.0; m/z found, 128 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) 6 8.40 (s, 2H), 7.48 (d, J=9.2 Hz, 1H), 4.78 (s, 2H).</p><p id="p-0459" num="0527">Step B: 3-(Chloromethyl)-5-fluoropyridine. The title compound was prepared in a manner analogous to Intermediate 61, Step C, using (5-fluoropyridin-3-yl)methanol. MS (ESI): mass calcd. for C<sub>6</sub>H<sub>5</sub>ClFN, 145.0; m/z found, 146 [M+H]<sup>+</sup>.</p><heading id="h-0075" level="1">Intermediate 65: 2-(6-(4-Chloro-3-(difluoromethoxy)phenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic Acid</heading><p id="p-0460" num="0528"><chemistry id="CHEM-US-00124" num="00124"><img id="EMI-C00124" he="39.20mm" wi="46.57mm" file="US20230000833A1-20230105-C00124.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0461" num="0529">The title compound was prepared in a manner analogous to 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 13) using 6-(4-chloro-3-(difluoromethoxy)phenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 57). (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>4</sub>, 383.1; m/z found, 384 [M+H]<sup>+</sup>.</p><heading id="h-0076" level="1">Intermediate 66: 2-(6-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-(2-fluoroethyl)-N-methylacetamide</heading><p id="p-0462" num="0530"><chemistry id="CHEM-US-00125" num="00125"><img id="EMI-C00125" he="31.16mm" wi="46.23mm" file="US20230000833A1-20230105-C00125.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0463" num="0531">The title compound was prepared in a manner analogous to Intermediate 39, using 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid Lithium salt (Intermediate 13) and 2-fluoro-N-methylethan-1-amine HCl salt. MS (ESI): mass calcd. for C<sub>12</sub>H<sub>14</sub>BrFN402, 344.0 m/z found, 345.1 [M+H]<sup>+</sup>.</p><heading id="h-0077" level="1">Intermediate 67: 2-(3-Methyl-2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic Acid</heading><p id="p-0464" num="0532"><chemistry id="CHEM-US-00126" num="00126"><img id="EMI-C00126" he="34.88mm" wi="46.57mm" file="US20230000833A1-20230105-C00126.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0465" num="0533">The title compound was prepared in a manner analogous to Intermediate 26, Step A, using 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 13) and (5-(trifluoromethyl)thiophen-2-yl)boronic acid. MS (ESI): mass calcd. for C<sub>14</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S, 357.3; m/z found, 358.1 [M+H]<sup>+</sup>.</p><p id="p-0466" num="0534">Intermediate 68: 6-Bromo-1-(2-(3-(2-fluoroethypazetidin-1-yl)-2-oxoethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one</p><p id="p-0467" num="0000"><chemistry id="CHEM-US-00127" num="00127"><img id="EMI-C00127" he="60.62mm" wi="45.30mm" file="US20230000833A1-20230105-C00127.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0468" num="0535">Step A: 6-Bromo-1-(2-(3-(2-hydroxyethyl)azetidin-1-yl)-2-oxoethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Intermediate 39 using 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 38, product from Step A) and 2-(azetidin-3-yl)ethan-1-ol. MS (ESI): mass calcd. for C<sub>32</sub>H<sub>29</sub>BrFN<sub>4</sub>O<sub>3</sub>, 596.1 m/z found, 619.1 [M+Na]<sup>+</sup>.</p><p id="p-0469" num="0536">Step B: 2-(1-(2-(6-Bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetyl)azetidin-3-yl)ethyl 4-methanesulfonate. To a solution of 6-bromo-1-(2-(3-(2-hydroxyethyl)azetidin-1-yl)-2-oxoethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (95 mg, 0.16 mmol) and 4-methylbenzenesulfonyl chloride (91 mg, 0.48 mmol) in DCM (0.5 mL), was added TEA (0.11 mL, 0.80 mmol). The reaction mixture was stirred at rt overnight. Purification (50 mg) (FCC, SiO<sub>2</sub>, Ethyl Acetate in hexanes (20-90%)) afforded the title compound. MS (ESI): mass calcd. for C<sub>39</sub>H<sub>35</sub>BrFN<sub>4</sub>O<sub>5</sub>S 750.2 m/z found, 783.2 [M+Na]<sup>+</sup>.</p><p id="p-0470" num="0537">Step C: 6-Bromo-1-(2-(3-(2-fluoroethypazetidin-1-yl)-2-oxoethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. 2-(1-(2-(6-Bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetyl)azetidin-3-yl)ethyl 4-methanesulfonate (50 mg) was dissolved in THF (0.5 mL), and TBAF (1.0 M in THF, 200 &#x3bc;L, 0.2 mmol) was added. The reaction mixture was heated at 60&#xb0; C. for an hour. The solvent was removed under vacuum. Purification (FCC, SiO<sub>2</sub>, Ethyl Acetate in hexanes (10% to 80%)) provided the title compound as a colorless oil (26 mg, 26% over Steps B-C). MS (ESI): mass calcd. for C<sub>32</sub>H<sub>28</sub>BrFN<sub>4</sub>O<sub>2</sub>, 598.1 m/z found, 626.1 [M+Na]<sup>+</sup>.</p><heading id="h-0078" level="1">Example 1: 6-(4-Methoxyphenyl)-1-(2-morpholino-2-oxo-ethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0471" num="0538"><chemistry id="CHEM-US-00128" num="00128"><img id="EMI-C00128" he="38.61mm" wi="48.77mm" file="US20230000833A1-20230105-C00128.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0472" num="0539">Step A: N-Benzhydryl-5-(4-methoxyphenyl)-3-nitropyridin-2-amine. To a solution a N-benzhydryl-5-bromo-3-nitropyridin-2-amine (Intermediate 31, 7.58 g, 19.7 mmol) and 4-methoxyphenylboronic acid (3 g, 19.7 mmol) in EtOH (30 mL) and toluene (40 mL) was added an aqueous solution of 2 M Na<sub>2</sub>CO<sub>3 </sub>(20 mL) and Pd(Ph<sub>3</sub>)<sub>4 </sub>(2.27 g, 1.97 mmol). The reaction mixture was stirred at 80&#xb0; C. overnight. Then, the crude reaction mixture cooled, filtered, and the filtrate was evaporated. The crude residue was purified (FCC, SiO<sub>2</sub>, 20:1 petroleum ether/EtOAc) to yield the title compound (2.8 g, 35%).</p><p id="p-0473" num="0540">Step B: N<sup>2</sup>-Benzhydryl-5-(4-methoxyphenyl)pyridine-2,3-diamine. To a solution of N-benzhydryl-5-(4-methoxyphenyl)-3-nitropyridin-2-amine (2.7 g, 6.6 mmol) in EtOH (80 mL) was added Pd/C (0.27 g), and the reaction mixture was stirred at room temperature for 5 h under an atmosphere of H<sub>2</sub>. After uptake of H<sub>2 </sub>(1 equivalent), the catalyst was filtered off and the filtrate as evaporated to yield the title compound (2.3 g, 92%), which was used in the next step without further purification.</p><p id="p-0474" num="0541">Step C: 3-Benzhydryl-6-(4-methoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A solution of N<sup>2</sup>-benzhydryl-5-(4-methoxyphenyl)pyridine-2,3-diamine (2.2 g, 5.8 mmol) and CDI (1.9 g, 11.5 mmol) in 1,4-dioxane (100 mL) was refluxed for 5 h. Then, the solvent was evaporated and the resultant solid was washed with water and dried to yield the title compound (2.3 g, 100%), which was used in the next step without further purification.</p><p id="p-0475" num="0542">Step D: tert-Butyl 2-(3-benzhydryl-6-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate. A solution of 3-benzhydryl-6-(4-methoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (2.2 g, 5.4 mmol), tert-butyl bromoacetate (1.3 g, 6.5 mmol) and K<sub>2</sub>CO<sub>3 </sub>(1.5 g, 10.8 mmol) in MeCN (80 mL) was heated to reflux for 5 h. Then, the reaction mixture was cooled, filtered, and the filtrate was evaporated to yield the title compound (2.8 g, 100%), which was used in the next step without further purification.</p><p id="p-0476" num="0543">Step E: 2-(6-(4-Methoxyphenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid. To a solution of tert-butyl 2-(3-benzhydryl-6-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (2.8 g, 5.4 mmol) in TFA (50 mL) was added thioanisole (0.28 g), and the reaction mixture was stirred at 80&#xb0; C. for 1 h. Then, the solvent was evaporated to yield the title compound as the TFA salt (2.2 g, 100%).</p><p id="p-0477" num="0544">Step F: 6-(4-Methoxyphenyl)-1-(2-morpholino-2-oxo-ethyl)-3H-imidazo[4,5-b]pyridin-2-one. A solution of 2-(6-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid TFA salt (0.4 g, 0.97 mmol), morpholine (0.25 g, 2.9 mmol), HBTU (0.38 g, 0.97 mmol), HOBT (0.13 g, 0.97 mmol), and NEt<sub>3 </sub>(0.29 g, 2.9 mmol) in DMF (10 mL) was stirred at room temperature for 12 h. Then, water (20 mL) was added to the reaction mixture and the reaction was extracted with EtOAc (3&#xd7;30 mL). The combined organic layers were washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure to afford the free base of the title compound. The residue was purified by preparative HPLC (gradient elution: 0.1% TFA in CH<sub>3</sub>CN/0.1% TFA in H<sub>2</sub>O) and the desired fractions were collected and washed with a saturated aqueous solution of NaHCO<sub>3</sub>. The biphasic mixture was extracted with EtOAc (3&#xd7;30 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to yield the title compound as a white solid (0.11 g, 30%). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>, 368.1; m/z found, 369.0 [M+H]<sup>+</sup>. MP=239.1-244.1&#xb0; C.</p><heading id="h-0079" level="1">Example 2: 6-(4-Fluoro-2-methyl-phenyl)-1-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0478" num="0545"><chemistry id="CHEM-US-00129" num="00129"><img id="EMI-C00129" he="27.69mm" wi="45.21mm" file="US20230000833A1-20230105-C00129.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0479" num="0546">A solution of 6-bromo-1-(2-methoxyethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 32, 0.3 g, 1.1 mmol), (4-fluoro-2-methylphenyl)boronic acid (0.25 g, 1.7 mmol), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2 </sub>(0.03 g, 0.04 mmol), and 2 M Na<sub>2</sub>CO<sub>3 </sub>(2mL) in 1,2-dimethoxyethane (6 mL) was heated to 140&#xb0; C. via microwave irradiation for 10 min. Then, water (30 mL) was added to the crude reaction mixture and the mixture was extracted with EtOAc (3&#xd7;30 mL). The combined organic layers were washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude residue was purified by preparative HPLC (gradient elution: 0.1% TFA in CH<sub>3</sub>CN/0.1% TFA in H<sub>2</sub>O) and the desired fractions were collected and washed with a saturated aqueous solution of NaHCO<sub>3</sub>. The biphasic mixture was extracted with EtOAc (3&#xd7;30 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to yield the title compound as a white solid (0.23 g, 69%). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>2</sub>, 301.1; m/z found, 302.1 [M+H]<sup>+</sup>.</p><heading id="h-0080" level="1">Example 3: N-Ethyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0480" num="0547"><chemistry id="CHEM-US-00130" num="00130"><img id="EMI-C00130" he="36.32mm" wi="45.21mm" file="US20230000833A1-20230105-C00130.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0481" num="0548">A solution of 2-(6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-ethylacetamide (Intermediate 33, 0.3 g, 1 mmol), (4-fluoro-2-methylphenyl)boronic acid (0.23 g, 1.5 mmol), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2 </sub>(0.03 g, 0.04 mmol), and 2 M Na<sub>2</sub>CO<sub>3 </sub>(2 mL) in EtOH (6 mL) was heated to 180&#xb0; C. via microwave irradiation for 1 h. Then, water (30 mL) was added to the crude reaction mixture and the mixture was extracted with EtOAc (3&#xd7;30 mL). The combined organic layers were washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude residue was purified by preparative HPLC (gradient elution: 0.1% TFA in CH<sub>3</sub>CN/0.1% TFA in H<sub>2</sub>O) and the desired fractions were collected and washed with a saturated aqueous solution of NaHCO<sub>3</sub>. The biphasic mixture was extracted with EtOAc (3&#xd7;30 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to yield the title compound as a white solid (0.061 g, 18%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>2</sub>, 328.1; m/z found, 329.0 [M+H]<sup>+</sup>. MP=225.1-232.3&#xb0; C.</p><heading id="h-0081" level="1">Example 4: (S*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0482" num="0549"><chemistry id="CHEM-US-00131" num="00131"><img id="EMI-C00131" he="30.90mm" wi="48.77mm" file="US20230000833A1-20230105-C00131.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0483" num="0550">Step A: 3-Benzhydryl-6-bromo-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. 1-Bromobutan-2-one (1.6 g, 11 mmol) was added to a solution of 3-benzhydryl-6-bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 32, Product from Step B, 2 g, 5.3 mmol), and Na<sub>2</sub>CO<sub>3 </sub>(1.1 g, 11 mmol) in MeCN (30 mL), and the reaction mixture was refluxed for 2 h. Then, the crude reaction mixture was filtered and washed with MeOH. The solvent was evaporated to yield the title compound (2.3 g, 96%), which was used in the next step without further purification.</p><p id="p-0484" num="0551">Step B: 3-Benzhydryl-6-bromo-1-(2-hydroxybutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 3-benzhydryl-6-bromo-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (2.3 g, 5.1 mmol) in EtOH (50 mL) at 0&#xb0; C. was added NaBH<sub>4 </sub>(0.8 g, 21 mmol), and the mixture was warmed to room temperature and stirred for 2 h. Then water was added and the reaction mixture was filtered. The solids were collected and dried to yield the title compound (2 g, 87%), which was used in the next step without further purification.</p><p id="p-0485" num="0552">Step C: 6-Bromo-1-(2-hydroxybutyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one. A solution of 3-benzhydryl-6-bromo-1-(2-hydroxybutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (2 g, 4.4 mmol) in TFA (20 mL) and thioanisole (0.05 mL) was heated to reflux for 4 h. The reaction mixture was cooled, and concentrated under reduced pressure. Ammonia/water was added to adjust the pH to 8. The reaction mixture was concentrated under reduced pressure and purified (FCC, SiO<sub>2</sub>, DCM/MeOH 1:0 to 0:1) to afford the title compound the desired (1.2 g, 96%).</p><p id="p-0486" num="0553">Step D: (S*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 2, using (4-methoxyphenyl)boronic acid in and 6-bromo-1-(2-hydroxybutyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one. Purification (SFC separation, Chiralcel AD-H, 20 &#x3bc;m; Supercritical CO<sub>2</sub>: MeOH, v/v, 200 mL/min) afforded the title compound and (R*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one (Example 5). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>, 313.1; m/z found, 314.0 [M+H]<sup>+</sup>.</p><heading id="h-0082" level="1">Example 5: (R*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0487" num="0554"><chemistry id="CHEM-US-00132" num="00132"><img id="EMI-C00132" he="30.90mm" wi="48.77mm" file="US20230000833A1-20230105-C00132.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0488" num="0555">The title compound was separated as a product from Example 4. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>, 313.1; m/z found, 314.1 [M+H]<sup>+</sup>.</p><heading id="h-0083" level="1">Example 6: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(2-pyridylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-0489" num="0556"><chemistry id="CHEM-US-00133" num="00133"><img id="EMI-C00133" he="29.29mm" wi="53.34mm" file="US20230000833A1-20230105-C00133.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0490" num="0557">To a solution a 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 27, 75 mg, 0.29 mmol) and 2-(chloromethyl)pyridine hydrochloride (74 mg, 0.45 mmol) in DMF (7.5 mL) at 0&#xb0; C. was added portion-wise NaH (60% dispersion in mineral oil, 27 mg, 0.67 mmol), and the reaction mixture was stirred at 0&#xb0; C. for 20 min. Then, the mixture was heated to 75&#xb0; C. and stirred for 2 h. Upon completion, water was added followed by EtOAc. The resulting biphasic mixture was separated and the aqueous layer further extracted with DCM. The combined organic layers were dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The residue was purified (FCC, SiO<sub>2</sub>, 0-10% 7 M solution of NH<sub>3</sub>/MeOH in EtOAc) to yield the title compound as a pink solid (25 g, 25%). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O, 348.1; m/z found, 349.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.22 (d, J=1.62 Hz, 3H), 3.34 (s, 3H), 5.19 (s, 2H), 7.15 (t, J=9.13 Hz, 1H), 7.21 (dd, J=7.40, 4.85 Hz, 1H), 7.25 (d, J=7.86 Hz, 1H), 7.36-7.44 (m, 1H), 7.50 (dd, J=7.40, 1.85 Hz, 1H), 7.65-7.74 (m, 2H), 8.21 (d, J=1.85 Hz, 1H), 8.41 (d, J=3.93 Hz, 1H).</p><heading id="h-0084" level="1">Example 7: 6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0491" num="0558"><chemistry id="CHEM-US-00134" num="00134"><img id="EMI-C00134" he="30.14mm" wi="48.77mm" file="US20230000833A1-20230105-C00134.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0492" num="0559">To a solution of 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 28, 60 mg, 0.25 mmol), pyrimidin-4-ylmethanol (27 mg, 0.25 mmol) and triphenylphosphine (129 mg, 0.493 mmol) in CH<sub>3</sub>CN (7.5 mL) at 0&#xb0; C. was added di-tert-butyl azodicarboxylate (85 mg, 0.37 mmol), and the reaction mixture was stirred at 110&#xb0; C. for 15 min under microwave irradiation. Then, the mixture was concentrated to dryness and the crude product was purified by HPLC purification (Stationary phase: C<sub>18 </sub>XBridge 30&#xd7;100 mm 5 um), Mobile phase: Gradient from 74% 10 mM NH<sub>4</sub>CO<sub>3</sub>H pH 9 solution in Water, 26% CH<sub>3</sub>CN to 58% 10mM NH<sub>4</sub>CO<sub>3</sub>H pH 9 solution in Water, 42% CH<sub>3</sub>CN) to yield the title compound as a white solid (36 mg, 44%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O, 335.1; m/z found, 336.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 3.42 (s, 3H), 5.31 (s, 2H), 7.09-7.30 (m, 1H), 7.41-7.58 (m, 4H), 7.91 (d, J=2.08 Hz, 1H), 8.41 (d, J=2.08 Hz, 1H), 8.75 (d, J=5.32 Hz, 1H), 9.08 (d, J=1.39 Hz, 1H).</p><heading id="h-0085" level="1">Example 8: 6-(3,4-Difluorophenyl)-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0493" num="0560"><chemistry id="CHEM-US-00135" num="00135"><img id="EMI-C00135" he="30.65mm" wi="54.44mm" file="US20230000833A1-20230105-C00135.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0494" num="0561">Step A: 3-Methyl-1-((5-methylisoxazol-3-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution a of 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 22, 150 mg, 0.46) in 1,4-dioxane (3 mL) was added bis(pinacolato)diboron (140 mg, 0.551 mmol), KOAc (135 mg, 1.38 mmol) and PdCl<sub>2</sub>(dppf) (11 mg, 0.014 mmol). The reaction mixture was stirred at 130&#xb0; C. for 2 h. Then, the crude reaction mixture was cooled and filtered through Celite&#xae;. The filtrate was diluted with water and extracted with EtOAc. The combined organic layers were dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The residue was purified (FCC, SiO<sub>2</sub>, 0-40% EtOAc in heptanes) to yield the title compound (130 mg, 76%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>23</sub>BN<sub>4</sub>O<sub>4</sub>, 370.2; m/z found, 371 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.44 (s, 1H), 7.60 (s, 1H), 5.99 (s, 1H), 5.08 (s, 2H), 3.53 (s, 3H), 2.37 (s, 3H), 1.34 (s, 12H).</p><p id="p-0495" num="0562">Step B: 6-(3,4-Difluorophenyl)-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-2-one. To a solution of 3-methyl-1-((5-methylisoxazol-3-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (210 mg, 0.567 mmol),1-bromo-3,4-difluorobenzene (84 &#x3bc;L, 0.732 mmol) and NaHCO<sub>3 </sub>(164 mg, 1.95 mmol) in 1,4-dioxane (4 mL) and water (0.9 mL) was added [1,1&#x2032;-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (32 mg, 0.049 mmol). The reaction mixture was stirred at 70&#xb0; C. for 3 h. Then, the crude reaction mixture was cooled, diluted with water and extracted with EtOAc. The organic layer was separated, dried Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified (FCC, SiO<sub>2</sub>, 0-80% EtOAc in heptanes) and the fractions containing desired product were concentrated. The product was then triturated with DIPE to yield the title compound (204 mg, 36%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 356.1; m/z found, 357 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.19 (s, 1H), 7.40 (s, 1H), 7.36-7.26 (m, 2H), 7.25-7.21 (m, 1H), 6.03 (s, 1H), 5.13 (s, 2H), 3.54 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0086" level="1">Example 9: 2-[6-(5-Chloro-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-0496" num="0563"><chemistry id="CHEM-US-00136" num="00136"><img id="EMI-C00136" he="34.21mm" wi="46.48mm" file="US20230000833A1-20230105-C00136.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0497" num="0564">A mixture of 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15, 180 mg, 0.58 mmol), 5-chlorothiophene-2-boronic acid (140 mg, 0.86 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(375 mg, 1.15 mmol), and Pd(dppf)Cl<sub>2</sub>. DCM (29.4 mg, 0.04 mmol) in dioxane (5 mL) and water (1 mL) was sealed in a microwave vial and heated to 90&#xb0; C. The reaction mixture was stirred at 90&#xb0; C. for 3 hours then cooled down to room temperature and quenched with a saturated aqueous solution of NaHCO<sub>3</sub>. The resulting reaction mixture was extracted with EtOAc (3&#xd7;60 mL) and the combined organic layers were dried using MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude material was purified via basic HPLC (Agilent prep system, Waters XBridge C<sub>18 5 </sub>pm 50&#xd7;100 mm column, 5-95% MeCN/20 nM NH<sub>4</sub>OH over 22 min at 80 mL/min) to provide the title compound (42 mg, 21%). MS (ESI): mass calcd. for C<sub>15</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub>S, 350.1; m/z found, 351.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.23-8.17 (d, J=1.9 Hz, 1H), 7.26-7.25 (m, 1H), 7.02-6.97 (d, J=3.9 Hz, 1H), 6.92-6.86 (d, J=3.8 Hz, 1H), 4.73-4.69 (s, 2H), 3.54-3.49 (s, 3H), 3.19-3.14 (s, 3H), 3.02-2.97 (s, 3H).</p><heading id="h-0087" level="1">Example 10: 6-[5-(Difluoromethyl)-2-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0498" num="0565"><chemistry id="CHEM-US-00137" num="00137"><img id="EMI-C00137" he="41.91mm" wi="48.94mm" file="US20230000833A1-20230105-C00137.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0499" num="0566">To a solution of 2-bromo-5-(difluoromethyl)thiophene (100 mg, 0.47 mmol) in dioxane (3 mL) was added bis(pinacolato)diboron (143 mg, 0.56 mmol), KOAc (138 mg, 1.4 mmol), and PdCl<sub>2</sub>(dppf).DCM (34 mg, 0.5 mmol). The resulting reaction mixture was stirred at 90&#xb0; C. for 2 hours under a nitrogen atmosphere. The reaction mixture was then cooled down to room temperature and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18) (32 mg, 0.09 mmol) was subsequently added to the reaction mixture along with Cs<sub>2</sub>CO<sub>3 </sub>(114 mg, 0.35 mmol), dioxane (2 mL) and an additional amount of PdCl<sub>2</sub>(dppf).DCM (34 mg, 0.5 mmol). The resulting reaction mixture was stirred at 90&#xb0; C. for an additional 2 hours under a nitrogen atmosphere. The reaction was cooled to room temperature and washed with water. The organic layer was dried with MgSO<sub>4 </sub>and concentrated into a brown residue which was purified (FCC, SiO<sub>2</sub>, 0-7% 2M NH<sub>3</sub>/MeOH in DCM). Further purification via basic HPLC (Agilent prep system, Waters XBridge C<sub>18 5 </sub>&#x3bc;m 50&#xd7;100 mm column, 5-95% MeCN/20 nM NH<sub>4</sub>OH over 22 min at 80 mL/min) to provide the title compound (6 mg, 16%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 396.1; m/z found, 396.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.34-8.30 (d, J=1.9 Hz, 1H), 7.45-7.42 (d, J=1.9 Hz, 1H), 7.28-7.26 (m, 1H), 7.20-7.17 (m, 1H), 6.98-6.68 (m, 1H), 5.48-5.25 (m, 1H), 4.68-4.11 (m, 6H), 3.56-3.50 (s, 3H).</p><heading id="h-0088" level="1">Example 11: 1-[(5-Methylisoxazol-3-yl)methyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0500" num="0567"><chemistry id="CHEM-US-00138" num="00138"><img id="EMI-C00138" he="27.43mm" wi="49.02mm" file="US20230000833A1-20230105-C00138.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0501" num="0568">Step A: 6-Bromo-1-((5-methylisoxazol-3-yl)methyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 36, 303 mg, 0.66 mmol) in DMF (3 mL) was added NaH (60% dispersion in mineral oil, 35 mg, 0.87 mmol) in one portion at room temperature. The reaction was stirred until gas evolution had ceased, then 3-(chloromethyl)-5-methylisoxazole (87 &#x3bc;L, 0.79 mmol) was added. The mixture was stirred at room temperature overnight then diluted with water. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with water (2&#xd7;), then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude solid was purified (FCC, SiO<sub>2</sub>, 0 to 25% EtOAc in hexanes) to yield the title compound as a solid (356 mg, 97%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 7.79 (d, J=2.0 Hz, 1H), 7.53-7.45 (m, 6H), 7.29 (d, J=2.0 Hz, 1H), 7.25-7.16 (m, 9H), 5.67 (d, J=0.9 Hz, 1H), 4.94 (s, 2H), 2.34 (d, J=0.9 Hz, 3H).</p><p id="p-0502" num="0569">Step B: 1-((5-Methylisoxazol-3-yl)methyl)-6-phenyl-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a microwave tube was added solid 6-bromo-1-((5-methylisoxazol-3-yl)methyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (184 mg, 0.33 mmol) followed by phenylboronic acid (60 mg, 0.49 mmol) and Pd(PPh<sub>3</sub>)<sub>4 </sub>(25 mg, 0.02 mmol). To these solids were added dioxane (1.6 mL) followed by 2M Na<sub>2</sub>CO<sub>3 </sub>(332 &#x3bc;L, 0.67 mmol). The vial was capped and heated at 100&#xb0; C. for 5 h. Then dioxane was removed via pipette and the remaining solids were triturated with EtOAc (3&#xd7;). The combined organic layers were concentrated to yield the title compound (287 mg, 81%) as a solid, which was used in the next step without further purification.</p><p id="p-0503" num="0570">Step C: 1-[(5-Methylisoxazol-3-yl)methyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one. To a solution of 1-((5-methylisoxazol-3-yl)methyl)-6-phenyl-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (183 mg, 0.33 mmol) in DCM (3 mL) was added TFA (666 &#x3bc;L). The mixture was stirred at room temperature overnight and then concentrated. The residue was dissolved in DCM and washed with a saturated aqueous solution of NaHCO<sub>3</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude oil was purified (FCC, SiO<sub>2</sub>, 0 to 50% EtOAc in hexanes) to yield the title compound as a solid (62 mg, 60%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>, 306.1; m/z found, 307.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 10.44 (s, 1H), 8.31 (d, J=1.9 Hz, 1H), 7.57-7.52 (m, 2H), 7.51 (d, J=1.9 Hz, 1H), 7.50-7.43 (m, 2H), 7.41-7.36 (m, 1H), 6.05 (d, J=1.0 Hz, 1H), 5.14 (s, 2H), 2.38 (d, J=0.9 Hz, 3H).</p><heading id="h-0089" level="1">Example 12: 6-(4-Fluorophenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0504" num="0571"><chemistry id="CHEM-US-00139" num="00139"><img id="EMI-C00139" he="27.43mm" wi="54.44mm" file="US20230000833A1-20230105-C00139.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0505" num="0572">Step A: 6-(4-Fluorophenyl)-3-(4-methoxybenzyl)-1,3-dihydro-2H-imidazol[4,5-b]pyridin-2-one. To a microwave tube was added 6-bromo-3-(4-methoxybenzyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 10, 287 mg, 0.86 mmol) followed by 4-fluorophenylboronic acid (159 mg, 1.14 mmol) and Pd(PPh<sub>3</sub>)<sub>4 </sub>(51 mg, 0.04 mmol). To these solids were added dioxane (4 mL) followed by 2 M Na<sub>2</sub>CO<sub>3 </sub>(859 &#x3bc;L, 1.72 mmol). The vial was capped and heated in the microwave at 150&#xb0; C. for 1 h. Then dioxane was removed via pipette and the remaining solids were triturated with EtOAc (3&#xd7;). The combined organic layers were concentrated and the crude solid was purified (FCC, SiO<sub>2, </sub>0 to 55% 1% IPA in EtOAc in hexanes) to yield the title compound (52 mg, 17%) as a solid. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>2</sub>, 349.1; m/z found, 350.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 9.34 (s, 1H), 8.24 (d, J=2.0 Hz, 1H), 7.52-7.45 (m, 4H), 7.43 (d, J=1.9 Hz, 1H), 7.19-7.11 (m, 2H), 6.88-6.81 (m, 2H), 5.14 (s, 2H), 3.76 (s, 3H).</p><p id="p-0506" num="0573">Step B: 6-(4-Fluorophenyl)-3-(4-methoxybenzyl)-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 6-(4-fluorophenyl)-3-(4-methoxybenzyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (43 mg, 0.12 mmol) in DMF (2 mL) was added NaH (60% dispersion in mineral oil, 6 mg, 0.16 mmol) in one portion at room temperature. The reaction was stirred until gas evolution ceased, and then 3-(chloromethyl)-5-methylisoxazole (16 &#x3bc;L, 0.15 mmol) was added. The mixture was stirred at room temperature overnight but was incomplete. To the reaction mixture was added additional NaH (60% dispersion in mineral oil, 6 mg, 0.16 mmol) in one portion at room temperature. The reaction was stirred until gas evolution ceased, and then additional 3-(chloromethyl)-5-methylisoxazole (16 &#x3bc;L, 0.15 mmol) was added. The mixture was again stirred at room temperature overnight. Then, the reaction was diluted with water and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to yield the title compound (66 mg) as a solid, which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>25</sub>H<sub>21</sub>FN<sub>4</sub>O<sub>3</sub>, 444.2; m/z found, 445.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.21 (d, J=1.9 Hz, 1H), 7.51-7.42 (m, 4H), 7.40 (d, J=1.9 Hz, 1H), 7.17-7.10 (m, 2H), 6.88-6.82 (m, 2H), 6.03-5.96 (m, 1H), 5.18-5.07 (m, 4H), 3.77 (s, 3H), 2.37 (d, J=0.9 Hz, 3H).</p><p id="p-0507" num="0574">Step C: 6-(4-Fluorophenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one. A solution of 48% aqueous HBr (3 mL) was added to 6-(4-fluorophenyl)-3-(4-methoxybenzyl)-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (55 mg, 0.12 mmol) and the mixture was heated at 115&#xb0; C. for 7 h. The mixture was concentrated and the residue was partitioned between DCM and a saturated aqueous solution of NaHCO<sub>3</sub>. The layers were separated and the aqueous layer was extracted with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude material was purified (FCC, SiO<sub>2</sub>, 0 to 50% 1.5% IPA in EtOAc in hexanes) to yield the title compound (33 mg, 82%) as a solid. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>2</sub>, 324.1; m/z found, 325.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 10.08 (s, 1H), 8.24 (d, J=1.9 Hz, 1H), 7.52-7.45 (m, 3H), 7.18-7.11 (m, 2H), 6.06 (d, J=1.0 Hz, 1H), 5.13 (s, 2H), 2.38 (d, J=1.0 Hz, 3H).</p><heading id="h-0090" level="1">Example 13: 6-(4-Fluorophenyl)-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0508" num="0575"><chemistry id="CHEM-US-00140" num="00140"><img id="EMI-C00140" he="27.43mm" wi="54.44mm" file="US20230000833A1-20230105-C00140.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0509" num="0576">Step A: 6-(4-Fluorophenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a round bottom flask was added 6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 36, 706 mg, 1.55 mmol) followed by 4-fluorophenylboronic acid (294 mg, 2.10 mmol) and Pd(PPh<sub>3</sub>)<sub>4 </sub>(357 mg, 0.31 mmol). To these solids were added dioxane (8 mL) followed by 2M Na<sub>2</sub>CO<sub>3 </sub>(2.3 mL, 4.64 mmol). The mixture was heated at 90&#xb0; C. for 15 h. Then, the crude reaction mixture was concentrated to remove dioxane, and the resultant residue was partitioned between EtOAc and water. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude material was purified (FCC, SiO<sub>2</sub>, 0 to 50% 1.5% IPA in EtOAc in hexanes) to yield the title compound (400 mg, 55%) as a solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.26-8.18 (m, 1H), 7.95 (d, J=2.0 Hz, 1H), 7.78-7.72 (m, 1H), 7.59-7.52 (m, 6H), 7.44-7.38 (m, 2H), 7.31-7.08 (m, 10H).</p><p id="p-0510" num="0577">Step B: 6-(4-Fluorophenyl)-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 6-(4-fluorophenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (205 mg, 0.44 mmol) in DMF (4 mL) was added NaH (60% dispersion in mineral oil, 23 mg, 0.57 mmol) in one portion at room temperature. The reaction was stirred until gas evolution had ceased, then 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole (58 &#x3bc;L, 0.57 mmol) was added. The mixture was stirred at room temperature overnight. Then the reaction mixture was diluted with water and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water (2&#xd7;), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude solid was purified (FCC, SiO<sub>2</sub>, 0 to 60% EtOAc in hexanes) to yield the title compound (129 mg, 52%) as a foam. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 7.97 (d, J=2.0 Hz, 1H), 7.57-7.50 (m, 6H), 7.44-7.36 (m, 2H), 7.34 (d, J=2.0 Hz, 1H), 7.28-7.26 (m, 1H), 7.26-7.17 (m, 7H), 7.12-7.05 (m, 2H), 5.21 (s, 2H), 2.49 (s, 3H).</p><p id="p-0511" num="0578">Step C: 6-(4-Fluorophenyl)-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one. To a solution of 6-(4-fluorophenyl)-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (129 mg, 0.23 mmol) in DCM (2 mL) was added TFA (455 &#x3bc;L). The mixture was stirred at room temperature overnight and then concentrated. The crude residue was purified (FCC, SiO<sub>2</sub>, 0 to 10% IPA in EtOAc) to yield the title compound (61 mg, 83%) as a solid. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>FN<sub>5</sub>O<sub>2</sub>, 325.1; m/z found, 326.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.86 (br s, 1H), 8.30 (d, J=2.0 Hz, 1H), 7.91 (d, J=2.0 Hz, 1H), 7.79-7.70 (m, 2H), 7.38-7.29 (m, 2H), 5.50 (s, 2H), 2.50 (s, 3H).</p><heading id="h-0091" level="1">Example 14: 3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(4-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0512" num="0579"><chemistry id="CHEM-US-00141" num="00141"><img id="EMI-C00141" he="29.97mm" wi="48.18mm" file="US20230000833A1-20230105-C00141.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0513" num="0580">Step A: 1-((5-Methylisoxazol-3-yl)methyl)-6-(4-methylthiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 11 using (4-methylthiophen-2-yl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>S, 326.1; m/z found, 327.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.79 (s, 1H), 8.25 (d, J=2.0 Hz, 1H), 7.77 (d, J=1.9 Hz, 1H), 7.36-7.31 (m, 1H), 7.16-7.11 (m, 1H), 6.25 (t, J=0.9 Hz, 1H), 5.24 (s, 2H), 2.40 (d, J=0.9 Hz, 3H), 2.26 (d, J=1.0 Hz, 3H).</p><p id="p-0514" num="0581">Step B: 3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(4-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one. To a solution of 14(5-methylisoxazol-3-yl)methyl)-6-(4-methylthiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (43 mg, 0.13 mmol) in DMF (2 mL) was added NaH (60% dispersion in mineral oil, 13 mg, 0.87 mmol) in one portion at room temperature. The reaction was stirred until gas evolution had ceased, then iodomethane (11 &#x3bc;L, 0.17 mmol) was added. The mixture was stirred at room temperature overnight then diluted with water. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude solid was purified (FCC, SiO<sub>2</sub>, 0 to 50% 1% IPA in EtOAc in DCM) to yield the title compound as a solid (37 mg, 82%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S, 340.1; m/z found, 341.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.28 (d, J=1.9 Hz, 1H), 7.42 (d, J=1.9 Hz, 1H), 7.06 (d, J=1.4 Hz, 1H), 6.87 (p, J=1.2 Hz, 1H), 6.01 (d, J=1.0 Hz, 1H), 5.11 (s, 2H), 3.53 (s, 3H), 2.38 (d, J=0.8 Hz, 3H), 2.29 (d, J=1.0 Hz, 3H).</p><heading id="h-0092" level="1">Example 15: 6-(4-Fluorophenyl)-1-[(1-methylpyrazol-4-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0515" num="0582"><chemistry id="CHEM-US-00142" num="00142"><img id="EMI-C00142" he="27.52mm" wi="54.44mm" file="US20230000833A1-20230105-C00142.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0516" num="0583">Step A: 5-(4-Fluorophenyl)-3-nitropyridin-2-amine. A solution of 2-amino-5-bromo-3-nitropyridine (623 mg, 2.86 mmol), 4-fluorophenylboronic acid (525 mg, 3.75 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(1.87 g, 5.74 mmol), and PdCl<sub>2</sub>(dppf) (209 mg, 0.29 mmol) in 1,4-dioxane (14 mL) and water (3 mL) was heated to 80&#xb0; C. for 4 h and then concentrated. The residue was partitioned between DCM and water, upon which time the product crashed out. The heterogeneous mixture was redissolved with a solution of EtOAc containing 1.5% IPA. The aqueous layer was further extracted with EtOAc containing 1.5% IPA. The combined organic layers were dried, filtered and concentrated to yield the title compound (400 mg, 60%) as a solid, which was used in the next step without further purification.</p><p id="p-0517" num="0584">Step B: Bis-tert-Butyl (5-(4-fluorophenyl)-3-nitropyridin-2-yl)carbamate. To a heterogeneous mixture of 5-(4-fluorophenyl)-3-nitropyridin-2-amine (400 mg, 1.72 mmol) in THF (9 mL) was added boc-anhydride (1.14 g, 5.2 mmol) followed by DMAP (316 mg, 2.59 mmol). The mixture became homogeneous and was complete after 30 min. The reaction was concentrated and the crude residue was purified (0 to 25% EtOAc in hexanes) to yield the title compound (663 mg, 89%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.92 (d, J=2.3 Hz, 1H), 8.57 (d, J=2.3 Hz, 1H), 7.68-7.59 (m, 2H), 7.29-7.19 (m, 3H), 1.45 (s, 18H).</p><p id="p-0518" num="0585">Step C: Bis-tert-Butyl (3-amino-5-(4-fluorophenyl)pyridin-2-yl)carbamate. To a round bottom flask containing bis-tert-butyl (5-(4-fluorophenyl)-3-nitropyridin-2-yl)carbamate (649 mg, 1.50 mmol) dissolved in EtOH (15) was added 10% Pd/C (301 mg), and the reaction mixture was stirred under an atmosphere of H<sub>2 </sub>(balloon). After 3 h the reaction was complete and the Pd/C was removed by filtration and washed with EtOH. The filtrate was concentrated and the crude residue was purified (FCC, SiO<sub>2</sub>, 0 to 50% EtOAc in hexanes) to yield the title compound (459 mg, 76%) as a solid. MS (ESI): mass calcd. for C<sub>21</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>4</sub>, 403.2; m/z found, 404.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.11 (d, J=2.2 Hz, 1H), 7.56-7.50 (m, 2H), 7.20 (d, J=2.1 Hz, 1H), 7.18-7.11 (m, 2H), 3.84 (s, 2H), 1.45 (s, 19H).</p><p id="p-0519" num="0586">Step D: Bis-tert-Butyl(5-(4-fluorophenyl)-3-(((1-methyl-1H-pyrazol-4-yl)methyl)amino)pyridin-2-yl)carbamate. To a heterogeneous mixture of bis-tert-butyl (3-amino-5-(4-fluorophenyl)pyridin-2-yl)carbamate (101 mg, 0.25 mmol) in DCE (3.5 mL) was added HOAc (14 &#x3bc;L, 0.25 mmol) followed by 1-methyl-1h-pyrazole-4-carbaldehyde (43 mg, 0.39 mmol). After 10 min NaBH(OAc)<sub>3 </sub>(162 mg, 0.76 mmol) was added and the mixture stirred at room temperature overnight. LCMS analysis showed that the reaction was not complete, and additional 1-methyl-1h-pyrazole-4-carbaldehyde (43 mg, 0.39 mmol) was added. After 5 h the reaction had progressed further and no sign of over alkylated product was seen. Additional 1-methyl-1h-pyrazole-4-carbaldehyde (43 mg, 0.39 mmol) was added and the mixture was stirred overnight during which time it went to completion. The reaction was quenched by the addition of a saturated aqueous solution of NaHCO<sub>3 </sub>and the layers separated. The aqueous layer was extracted with DCM and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude residue was purified by (FCC, SiO<sub>2</sub>, 0 to 55% EtOAc in hexanes) to yield the title compound (107 mg, 85%) as a foam. MS (ESI): mass calcd. for C<sub>26</sub>H<sub>32</sub>FN<sub>5</sub>O4, 497.2; m/z found, 498.3 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.04 (d, J=2.1 Hz, 1H), 7.56-7.49 (m, 2H), 7.43 (s, 1H), 7.30 (s, 1H), 7.18-7.10 (m, 3H), 4.29 (d, J=5.4 Hz, 2H), 4.18-4.10 (m, 1H), 3.87 (s, 3H), 1.43 (s, 18H).</p><p id="p-0520" num="0587">Step E: 5-(4-Fluorophenyl)-N3-((1-methyl-1H-pyrazol-4-yl)methyl)pyridine-2,3-diamine. To a solution of bis-tert-butyl (5-(4-fluorophenyl)-3-(((1-methyl-1H-pyrazol-4-yl)methyl)amino)pyridin-2-yl)carbamate. (107 mg, 0.22 mmol) in DCM (2 mL) was added TFA (430 &#x3bc;L). After 3 h at room temperature the reaction was concentrated and the crude residue was purified (FCC, SiO<sub>2</sub>, 0 to 9% 2M NH<sub>3 </sub>in MeOH in DCM) to yield the title compound (59 mg, 93%) as an oil. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>FN<sub>5</sub>, 297.2; m/z found, 298.2 [M+H]<sup>+</sup>.</p><p id="p-0521" num="0588">Step F: 6-(4-Fluorophenyl)-1-[(1-methylpyrazol-4-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one. To a solution of 5-(4-fluorophenyl)-N3-((1-methyl-1H-pyrazol-4-yl)methyl)pyridine-2,3-diamine (28 mg, 0.09 mmol) in THF (2 mL) was added CDI (22 mg, 0.14 mmol), and the reaction was stirred at room temperature overnight. The reaction did not go to completion and additional CDI (34 mg, 0.21 mmol) was added, and the reaction was stirred at room temperature for 5 h. Analysis showed that the reaction was still not complete and additional CDI (22 mg, 0.14 mmol) was added and the mixture stirred at room temperature overnight and then concentrated. The residue was purified (FCC, SiO<sub>2</sub>, 0 to 100% 2% IPA in EtOAc in hexanes), but the material was contaminated with imidazole. The compound was dissolved in DCM and washed with a 2 M citric acid solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to yield the title compound (29 mg, 94%) as a foam. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>FN<sub>5</sub>O, 323.1; m/z found, 324.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.62 (s, 1H), 8.22 (d, J=2.0 Hz, 1H), 7.91 (d, J=2.0 Hz, 1H), 7.83 (s, 1H), 7.81-7.74 (m, 2H), 7.56 (s, 1H), 7.38-7.28 (m, 2H), 5.03 (s, 2H), 3.83 (s, 3H).</p><heading id="h-0093" level="1">Example 16: 1-[(1,5-Dimethylpyrazol-3-yl)methyl]-6-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0522" num="0589"><chemistry id="CHEM-US-00143" num="00143"><img id="EMI-C00143" he="27.43mm" wi="56.98mm" file="US20230000833A1-20230105-C00143.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0523" num="0590">Step A: Bis-tert-Butyl (5-bromo-3-nitropyridin-2-yl)carbamate. To a heterogeneous mixture of 2-amino-5-bromo-3-nitropyridine (2.28 g, 10.45 mmol) in THF (52 mL) was added boc-anhydride (6.84 g, 31.34 mmol) followed by DMAP (1.91 g, 15.67 mmol).</p><p id="p-0524" num="0591">The mixture was stirred at room temperature overnight during which time it became homogeneous. The mixture was concentrated and purified (FCC, SiO<sub>2</sub>, 0 to 30% EtOAc in hexanes) to yield the title compound (3.09 g, 71%) as a foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.80 (d, J=2.3 Hz, 1H), 8.56 (d, J=2.3 Hz, 1H), 1.43 (s, 18H).</p><p id="p-0525" num="0592">Step B: tert-Butyl (5-bromo-3-nitropyridin-2-yl)carbamate. To a solution of bis-tert-butyl (5-bromo-3-nitropyridin-2-yl)carbamate (269 mg, 0.64 mmol) dissolved in EtOAc (3 mL) was added N,N-dimethylethylenediamine (351 &#x3bc;L, 3.22 mmol). The mixture was stirred at room temperature overnight and then concentrated. The residue was purified (FCC, SiO<sub>2</sub>, 0 to 30% EtOAc in hexanes) to afford the title compound (200 mg, 98%) as a yellow solid. MS (ESI): mass calcd. for C<sub>10</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>4</sub>, 317.0; m/z found, 262.0 [M+H&#x2212;tBu]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 9.45 (s, 1H), 8.74 (d, J=2.3 Hz, 1H), 8.62 (d, J=2.3 Hz, 1H), 1.54 (s, 9H).</p><p id="p-0526" num="0593">Step C: tert-Butyl (5-(4-fluorophenyl)-3-nitropyridin-2-yl)carbamate. To a microwave vial was added tert-butyl (5-bromo-3-nitropyridin-2-yl)carbamate (198 mg, 0.62 mmol), 4-fluorophenylboronic acid (124 mg, 0.88 mmol) and Pd(PPh<sub>3</sub>)<sub>4 </sub>(41 mg, 0.035 mmol). Then, dioxane (4 mL) followed by 2M Na<sub>2</sub>CO<sub>3 </sub>(653 &#x3bc;L, 1.31 mmol) was added and the reaction was heated conventionally at 90&#xb0; C. for 2 h. Then, the reaction mixture was cooled to room temperature, concentrated and the solids were washed with EtOAc (3&#xd7;). The combined organic layers were concentrated and purified (FCC, SiO<sub>2</sub>, 0 to 20% 1.5% IPA in EtOAc in hexanes) to afford the title compound (197 mg, 95%) as a solid. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>4</sub>, 333.1; m/z found, 278.1 [M+H&#x2212;tBu]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 9.57 (s, 1H), 8.94-8.89 (m, 1H), 8.67-8.61 (m, 1H), 7.59-7.52 (m, 2H), 7.25-7.18 (m, 2H), 1.58 (s, 9H).</p><p id="p-0527" num="0594">Step D: tert-Butyl (3-amino-5-(4-fluorophenyl)pyridin-2-yl)carbamate. To a heterogeneous mixture of tert-butyl (5-(4-fluorophenyl)-3-nitropyridin-2-yl)carbamate (191 mg, 0.57 mmol) in EtOH (8 mL) was added 10% Pd/C (154 mg) followed by a H<sub>2 </sub>balloon. The mixture slowly turned homogeneous and after 1 h the reaction was filtered. The filter cake and Pd/C was washed with EtOH. The filtrate was concentrated to afford the title compound (152 mg, 87%) as an oil, which was used in the next step without further purification.</p><p id="p-0528" num="0595">Step E: tert-Butyl(3-(((1,5-dimethyl-1H-pyrazol-3-yl)methyl)amino)-5-(4-fluorophenyl)pyridin-2-yl)carbamate. To a heterogeneous mixture of tert-butyl (3-amino-5-(4-fluorophenyl)pyridin-2-yl)carbamate (152 mg, 0.50 mmol) dissolved in DCE (9 mL) was added HOAc (28 &#x3bc;L, 0.50 mmol) followed by 1,5-dimethyl-1h-pyrazole-3-carbaldehyde (158 mg, 1.28 mmol). After 10 min NaBH(OAc)<sub>3 </sub>(321 mg, 1.51 mmol) was added and the mixture stirred at room temperature overnight. The reaction was quenched by the addition of a saturated aqueous solution of NaHCO<sub>3 </sub>and the layers separated. The aqueous layer was extracted with DCM and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude material was taken on to the next step without further purification. MS (ESI): mass calcd. for C<sub>22</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>2</sub>, 411.2; m/z found, 412.2 [M+H]<sup>+</sup>.</p><p id="p-0529" num="0596">Step F: 1-[(1,5-Dimethylpyrazol-3-yl)methyl]-6-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one. To a solution of tert-butyl(3-(((1,5-dimethyl-1H-pyrazol-3-yl)methyl)amino)-5-(4-fluorophenyl)pyridin-2-yl)carbamate (206 mg, 0.50 mmol) in DCM (9 mL) was added TFA (2 mL). The mixture was stirred at room temperature for 3 h, concentrated and purified (FCC, SiO<sub>2</sub>, 0 to 9% 2M NH<sub>3 </sub>in MeOH in DCM) to afford impure material. This material was then stirred in Et<sub>2</sub>O overnight and then filtered to afford the title compound (46 mg, 27%) as a foam. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>FN<sub>5</sub>O, 337.1; m/z found, 338.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.64 (s, 1H), 8.22 (d, J=2.1 Hz, 1H), 7.78-7.68 (m, 3H), 7.38-7.27 (m, 2H), 5.99 (s, 1H), 5.03 (s, 2H), 3.69 (s, 3H), 2.20 (s, 3H).</p><heading id="h-0094" level="1">Example 17: 1-[2-(Azetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0530" num="0597"><chemistry id="CHEM-US-00144" num="00144"><img id="EMI-C00144" he="32.17mm" wi="43.35mm" file="US20230000833A1-20230105-C00144.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0531" num="0598">Step A: 1-(2-(Azetidin-1-yl)ethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetaldehyde (Intermediate 42, 400 mg, 0.80 mmol) in DCM (1 mL) was added azetidine (0.11 mL, 1.61 mmol) followed by sodium triacetoxyborohydride (336 mg, 1.6 mmol). The reaction was stirred at room temperature overnight and then diluted with a saturated aqueous solution of NaHCO<sub>3 </sub>(25 mL) and stirred for 30 minutes. The organics were then extracted with DCM, combined, dried, and purified (FCC, SiO<sub>2</sub>, 0-20% MeOH in DCM) to provide the title compound (195 mg, 45%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 7.84-7.70 (m, 2H), 7.55-7.38 (m, 6H), 7.32-7.19 (m, 6H), 7.19-7.10 (m, 3H), 3.81-3.55 (m, 2H), 3.02-2.77 (m, 4H), 1.88-1.79 (m, 2H).</p><p id="p-0532" num="0599">Step B: 1-(2-(Azetidin-1-yl)ethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1H-imidazo[4,5-b]pyridin-2(3H)-one. To a solution of 1-(2-(azetidin-1-yl)ethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (22.7 mg, 0.042 mmol) and 3-trifluorometheyl phenyl boronic acid (12 mg, 0.063 mmol) in 1,4-dioxane (0.5 mL) was added sodium bicarbonate (8.9 mg, 0.084 mmol), distilled water (0.03 mL, 1.7 mmol), and tetrakis(triphenylphosphine)palladium (2.4 mg, 0.002 mmol). The reaction was heated to 100&#xb0; C. overnight. The reaction was then cooled to room temperature and diluted with ethyl acetate (10 mL) and water (10 mL). The organic layer was extracted, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The title compound was used crude in the next step without further purification.</p><p id="p-0533" num="0600">Step C: 1-[2-(Azetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt. Crude 1-(2-(azetidin-1-yl)ethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1H-imidazo[4,5-b]pyridin-2(3H)-one was taken up in DCM (2 mL) and TFA (2 mL) and stirred at room temperature for 30 minutes. The reaction was concentrated down, taken up in 2 mL of methanol and loaded onto the acidic HPLC (Method C) to provide the title compound. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O, 362.1; m/z found, 363.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.85 (s, 1H), 9.77-9.64 (s, 1H), 8.43-8.31 (m, 1H), 8.10-8.01 (m, 2H), 8.00-7.93 (d, J=2.0 Hz, 1H), 7.79-7.66 (m, 2H), 4.17-4.04 (d, J=11.4 Hz, 6H), 3.63-3.56 (d, J=5.3 Hz, 2H), 2.46-2.35 (m, 1H), 2.26 (s, 1H).</p><heading id="h-0095" level="1">Example 18: 1-[2-(Azetidin-1-yl)ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0534" num="0601"><chemistry id="CHEM-US-00145" num="00145"><img id="EMI-C00145" he="34.80mm" wi="43.35mm" file="US20230000833A1-20230105-C00145.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0535" num="0602">To a solution of 1-[2-(azetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 17, 49.6 mg, 0.10 mmol) in DMF (2 mL) was added sodium hydride (60% dispersion in oil, 8.3 mg, 0.21 mmol), and the reaction mixture was stirred at room temperature for 10 minutes. Then, iodomethane (0.0078 mL, 0.13 mmol) was added, and the reaction mixture was stirred at room temperature for an additional 3 hours. The crude reaction mixture was quenched with distilled water (1 mL) and concentrated in vacuo. The reaction was taken up in MeOH, filtered, and loaded onto the basic HPLC for purification (Method A) to provide the title compound (11.8 mg, 30%). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O, 376.2; m/z found, 377.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.43-8.29 (d, J=1.9 Hz, 1H), 8.10-8.01 (d, J=2.8 Hz, 2H), 8.01-7.91 (m, 1H), 7.78-7.59 (m, 2H), 3.91-3.79 (t, J=6.1 Hz, 2H), 3.38 (s, 3H), 3.15-3.06 (t, J=7.0 Hz, 4H), 2.71-2.64 (m, 2H), 1.97-1.83 (m, 2H).</p><heading id="h-0096" level="1">Example 19: 1-[(5-Methylisoxazol-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0536" num="0603"><chemistry id="CHEM-US-00146" num="00146"><img id="EMI-C00146" he="28.79mm" wi="49.02mm" file="US20230000833A1-20230105-C00146.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0537" num="0604">To a solution of N<sup>3</sup>-((5-methylisoxazol-3-yl)methyl)-5-(3-(trifluoromethyl)phenyl)pyridine-2,3-diamine (Intermediate 47, 1.0 g, 3.0 mmol) in DMF (19.5 mL) was added 1,1&#x2032;-carbonyldiimidazole (1.5 g, 9.0 mmol). The reaction was heated to 85&#xb0; C. for one hour. The crude mixture was cooled to room temperature and a saturated aqueous solution of NH<sub>4</sub>Cl (10 mL) was added. The resulting solid was collected via filtration, triturated with Et<sub>2</sub>O and filtered to provide the title compound (761 mg, 68%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 374.1; m/z found, 375.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.97-11.79 (s, 1H), 8.42-8.25 (d, J=2.0 Hz, 1H), 8.06-7.96 (m, 2H), 7.93-7.87 (d, J=2.0 Hz, 1H), 7.78-7.64 (m, 2H), 6.25-6.13 (s, 1H), 5.24-4.92 (s, 2H), 2.39-2.26 (s, 3H).</p><heading id="h-0097" level="1">Example 20: N-Cyclopropyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0538" num="0605"><chemistry id="CHEM-US-00147" num="00147"><img id="EMI-C00147" he="37.25mm" wi="39.79mm" file="US20230000833A1-20230105-C00147.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0539" num="0606">Step A: N-cyclopropyl-2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetamide. HATU (59 mg, 0.16 mmol) was added to a mixture of 2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 44, 75 mg, 0.13 mmol), cyclopropylamine (0.011 mL, 0.16 mmol) and DIPEA (0.045 mL, 0.26 mmol) in DMF at room temperature. After completion, a saturated aqueous solution of NaHCO<sub>3 </sub>(10 mL) was added and the mixture was extracted using EtOAc (3&#xd7;15 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0-90% EtOAc in hexanes) to afford the title compound (61 mg, 76%). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.28 (d, J=4.2 Hz, 1H), 8.19-8.13 (m, 1H), 8.00-7.94 (m, 2H), 7.87 (d, J=2.1 Hz, 1H), 7.72-7.63 (m, 2H), 7.51-7.44 (m, 6H), 7.29-7.13 (m, 9H), 4.44 (s, 2H), 2.71-2.61 (m, 1H), 0.64 (td, J=7.0, 4.8 Hz, 2H), 0.47-0.41 (m, 2H).</p><p id="p-0540" num="0607">Step B: N-cyclopropyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide and its trifluoroacetic acid salt. To a solution of N-cyclopropyl-2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetamide (90 mg, 0.15 mmol) in DCM at room temperature was added TFA (0.34 mL, 4.4 mmol). After completion the reaction mixture was concentrated under vacuum. MeOH was added and a precipitate appeared. The solids were filtered off and rinsed with MeOH to afford the title compound (11 mg, 15%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 376.1; m/z found, 377.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.73 (s, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.29 (d, J=4.2 Hz, 1H), 8.04-7.97 (m, 2H), 7.84 (d, J=1.9 Hz, 1H), 7.76-7.68 (m, 2H), 4.48 (s, 2H), 2.65 (tq, J=7.7, 4.0 Hz, 1H), 0.62 (td, J=7.0, 4.8 Hz, 2H), 0.43 (dt, J=7.1, 4.6 Hz, 2H).</p><heading id="h-0098" level="1">Example 21: 1-[(3-Chlorophenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0541" num="0608"><chemistry id="CHEM-US-00148" num="00148"><img id="EMI-C00148" he="32.09mm" wi="47.92mm" file="US20230000833A1-20230105-C00148.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0542" num="0609">Step A: 1-(3-Chlorobenzyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. Under a nitrogen atmosphere was added 6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 43, 100 mg, 0.19 mmol) to a suspension of NaH (60% dispersion in mineral oil, 10.7 mg, 0.3 mmol) in THF (2.1 mL). After 10 minutes 1-(bromomethyl)-3-chlorobenzene (0.035 mL, 0.3 mmol) was added to the reaction mixture, and the reaction mixture was heated to 75&#xb0; C. After 6 h, complete conversion was observed. The reaction mixture was cooled down to room temperature and quenched with water (10 mL). The mixture was extracted using EtOAc (3&#xd7;20 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to give the title compound. The crude material was moved forward to the next step as is.</p><p id="p-0543" num="0610">Step B: 1-[(3-chlorophenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt. To a solution of 1-(3-chlorobenzyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (153 mg, 0.24 mmol) in DCM at room temperature was added TFA (0.55 mL, 7.1 mmol). After completion, the reaction mixture was concentrated under vacuum. The crude material was purified using reversed phase HPLC (Method C) to afford the title compound (29 mg, 23%). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>13</sub>ClF<sub>3</sub>N<sub>3</sub>O, 403.1; m/z found, 404.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.01-7.96 (m, 2H), 7.94 (d, J=2.0 Hz, 1H), 7.75-7.68 (m, 2H), 7.49-7.45 (m, 1H), 7.40-7.29 (m, 3H), 5.13 (s, 2H).</p><heading id="h-0099" level="1">Example 22: 1-[(2-Methoxy-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0544" num="0611"><chemistry id="CHEM-US-00149" num="00149"><img id="EMI-C00149" he="29.21mm" wi="47.92mm" file="US20230000833A1-20230105-C00149.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0545" num="0612">The title compound was prepared in a manner analogous to Example 21 using 3-(chloromethyl)-2-methoxypyridine. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 400.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO) &#x3b4; 11.84 (s, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.09 (dd, J=5.0, 1.8 Hz, 1H), 8.01-7.96 (m, 2H), 7.85 (d, J=2.0 Hz, 1H), 7.74-7.66 (m, 2H), 7.33 (dd, J=7.3, 1.8 Hz, 1H), 6.93 (dd, J=7.3, 5.0 Hz, 1H), 5.04 (s, 2H), 3.93 (s, 3H).</p><heading id="h-0100" level="1">Example 23: 1-(Pyrimidin-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0546" num="0613"><chemistry id="CHEM-US-00150" num="00150"><img id="EMI-C00150" he="28.62mm" wi="48.77mm" file="US20230000833A1-20230105-C00150.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0547" num="0614">Step A: Pyrimidin-4-ylmethyl methanesulfonate. To a mixture of pyrimidin-4-ylmethanol (100 mg, 0.9 mmol) and triethylamine (0.2 mL, 1.4 mmol) in DCM (3.5 mL) at 0&#xb0; C. was added methanesulfonyl chloride (0.9 mL, 1.2 mmol). After 30 minutes, water (10 mL) and a saturated aqueous solution of NaHCO<sub>3 </sub>(10 mL) were added to the reaction mixture, respectively. The mixture was extracted with DCM (2&#xd7;30 mL). The combined organics were dried (MgSO<sub>4</sub>), filtered and concentrated under vacuum to give the title compound (170 mg, 99%). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) 67  9.20 (d, J=1.4 Hz, 1H), 8.89 (d, J=5.1 Hz, 1H), 7.63-7.60 (m, 1H), 5.35 (s, 2H), 3.34 (s, 3H).</p><p id="p-0548" num="0615">Step B: 1-(Pyrimidin-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt. The title compound was prepared in a manner analogous to Example 21 using pyrimidin-4-ylmethyl methanesulfonate and 6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 43) in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>O, 371.1; m/z found, 372.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 9.09 (d, J=1.4 Hz, 1H), 8.75 (d, J=5.2 Hz, 1H), 8.36 (d, J=2.0 Hz, 1H), 8.01-7.96 (m, 2H), 7.91 (d, J=2.0 Hz, 1H), 7.73-7.65 (m, 2H), 7.44 (dd, J=5.2, 1.4 Hz, 1H), 5.27 (s, 2H).</p><heading id="h-0101" level="1">Example 24: (R/S)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0549" num="0616"><chemistry id="CHEM-US-00151" num="00151"><img id="EMI-C00151" he="28.53mm" wi="46.40mm" file="US20230000833A1-20230105-C00151.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0550" num="0617">Step A: 6-Bromo-1-((tetrahydrofuran-2-yl)methyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 36, 500 mg, 1.10 mmol) and NaH (60% dispersion in mineral oil, 61 mg, 1.5 mmol) in DMF (11 mL), was added tetrandyrofurfuryl bromide (0.18 mL, 1.5 mmol). After 16 h, low conversion to the desired product was observed and additional NaH (60% dispersion in mineral oil, 131 mg, 3.29 mmol) and tetrandyrofurfuryl bromide (0.37 mL, 3.29 mmol) was added and the reaction mixture was heated to 80&#xb0; C. After completion, the reaction mixture was quenched with a saturated aqueous solution of NH<sub>4</sub>Cl (50 mL). The precipitates were filtered off, washed with water and dried under vacuum to afford the title product, contaminated with some impurities. The crude material was moved forward to the next step as is.</p><p id="p-0551" num="0618">Step B: 1-((tetrahydrofuran-2-yl)methyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A mixture of 6-bromo-1-((tetrahydrofuran-2-yl)methyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (150 mg, 0.3 mmol), 3-(trifluoromethyl)phenylboronic acid (105 mg, 0.6 mmol), 1,1&#x2032;-bis(diphenylphosphino)ferrocene palladium(II)dichloride dichloromethane complex (Pd(dppf)Cl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub>) (16 mg, 0.02 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(181 mg, 0.6 mmol), dioxane (2.6 mL) and H<sub>2</sub>O (0.5 mL) was heated to 90&#xb0; C. using an oil bath. After 16 h, the reaction mixture was concentrated under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in hexanes), to give the title compound (51 mg, 30%).</p><p id="p-0552" num="0619">Step C: (R/S)-1-(tetrahydrofuran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt. To a solution of 1-((tetrahydrofuran-2-yl)methyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (51 mg, 0.08 mmol) in DCM at room temperature was added TFA (0.59 mL, 9.2 mmol). After completion, the reaction mixture was concentrated under vacuum. The crude material was purified using reversed phase HPLC (Method C) to give the title compound (32 mg, 23%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, 364.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.71 (s, 1H), 8.30 (d, J=2.0 Hz, 1H), 8.04-7.98 (m, 2H), 7.89 (d, J=2.0 Hz, 1H), 7.76-7.69 (m, 2H), 4.27-4.18 (m, 1H), 3.99-3.87 (m, 2H), 3.77-3.69 (m, 1H), 3.65-3.56 (m, 1H), 2.00-1.73 (m, 3H), 1.70-1.60 (m, 1H).</p><heading id="h-0102" level="1">Example 25: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0553" num="0620"><chemistry id="CHEM-US-00152" num="00152"><img id="EMI-C00152" he="34.12mm" wi="39.79mm" file="US20230000833A1-20230105-C00152.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0554" num="0621">Step A: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A mixture of 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 38, 260 mg, 0.47 mmol), 1,1&#x2032;-bis(diphenylphosphino) ferrocene palladium(II)dichloride dichloromethane complex (24 mg, 0.033 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(306 mg, 0.94 mmol), (3-(trifluoromethyl)phenyl)boronic acid (178 mg, 0.94 mmol), dioxane (5 mL) and H<sub>2</sub>O (0.9 mL) was heated to 90&#xb0; C. using an oil bath. After 16 h, the reaction mixture was cooled to room temperature and volatiles were removed. The crude material was purified (FCC SiO<sub>2</sub>, 0-100% EtOAc in hexanes), to give the title compound (90 mg, 31%).</p><p id="p-0555" num="0622">Step B: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt. To a solution of 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (80 mg, 0.13 mmol) in DCM at room temperature was added TFA (0.30 mL, 3.9 mmol). After completion the reaction mixture was concentrated under vacuum. The was crude material was purified (Method C) to afford the title compound (13 mg, 21%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 376.1; m/z found, 377.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.76 (s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.03-7.97 (m, 2H), 7.82 (d, J=2.0 Hz, 1H), 7.76-7.70 (m, 2H), 4.86 (s, 2H), 4.28 (t, J=7.6 Hz, 2H), 3.91 (t, J=7.7 Hz, 2H), 2.33-2.23 (m, 2H).</p><heading id="h-0103" level="1">Example 26: N,N-Dimethyl-2-[2-oxo-6-(5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-1-yl)acetamide</heading><p id="p-0556" num="0623"><chemistry id="CHEM-US-00153" num="00153"><img id="EMI-C00153" he="30.82mm" wi="47.58mm" file="US20230000833A1-20230105-C00153.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0557" num="0624">Method A:</p><p id="p-0558" num="0625">Step A: Ethyl 2-(2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate. A mixture of ethyl 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (Intermediate 37, 230 mg, 0.4 mmol), 4,4,5,5-tetramethyl-2-(5-(trifluoromethyl)thiophen-2-yl)-1,3,2-dioxaborolane (153 mg, 0.6 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(240 mg, 0.7 mmol) and PdCl<sub>2</sub>(dppf).DCM (21 mg, 0.06 mmol) in dioxane (3.5 mL) was combined in a microwave vial and heated to 75&#xb0; C. The reaction mixture was stirred at 75&#xb0; C. for 16 hours then cooled down to room temperature and quenched with a saturated aqueous solution of NaHCO<sub>3</sub>. The resulting reaction mixture was extracted with EtOAc (3&#xd7;60 mL) and the combined organic layers were dried using MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0-40% EtOAc in hexanes) to afford the title compound (215 mg, 0.4 mmol, 82%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 7.97-7.95 (d, J=2.1 Hz, 1H), 7.45-7.40 (m, 6H), 7.30-7.27 (m, 1H), 7.19-7.14 (m, 6H), 7.14-7.09 (m, 3H), 7.04-7.03 (d, J=2.0 Hz, 1H), 7.03-7.00 (m, 1H), 4.49-4.45 (s, 2H), 4.17-4.10 (m, 2H), 1.19-1.15 (m, 3H).</p><p id="p-0559" num="0626">Step B: 2-(2-Oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid. To a solution ethyl 2-(2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (210 mg, 0.34 mmol) in THF (4.5 mL) at room temperature was added LiOH (2 M, 0.24 mL, 0.47 mmol). After stirring over the weekend, 2 M HCl was added (&#x2dc;0.1 mL). The mixture was rotovaped, then placed on high vac overnight. The solids were used as is in the next step (450 mg, contains water).</p><p id="p-0560" num="0627">Step C: N,N-Dimethyl-2-(2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetamide. T3P (w/w 50% in DCM)) (0.365 mL, 0.61 mmol) was added to a mixture of 2-(2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (246 mg, 0.20 mmol), dimethylamine hydrochloride (20 mg, 0.24 mmol) and DIPEA (0.11 mL, 0.61 mmol) in DCM (1 mL) at room temperature for 16 hours. After completion, the reaction mixture was concentrated under reduced pressure and the crude material was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in hexanes). To the EA/hexanes solution containing the product was added 1 mL TFA. The resulting reaction mixture was allowed to stir at room temperature for 16 hours. The excess TFA was evaporated under reduced pressure and the crude material was purified (FCC, SiO<sub>2</sub>, 0-15% 2M NH<sub>3</sub>/MeOH in DCM) to afford the title compound (25 mg, 33%). MS (ESI): mass calcd. for C<sub>15</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 370.1; m/z found, 371.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.8-11.7 (s, 1H), 8.34-8.32 (d, J=2.0 Hz, 1H), 7.79-7.76 (s, 1H), 7.76-7.74 (d, J=3.7 Hz, 1H), 7.57-7.55 (s, 1H), 4.80-4.75 (s, 2H), 3.12-3.07 (s, 3H), 2.87-2.83 (s, 3H).</p><p id="p-0561" num="0628">Method B:</p><p id="p-0562" num="0629">The title compound was prepared in a manner analogous to Example 25, Steps A-B, using 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 39) and (5-(trifluoromethyl)thiophen-2-yl)boronic acid in step A.</p><heading id="h-0104" level="1">Example 27: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0563" num="0630"><chemistry id="CHEM-US-00154" num="00154"><img id="EMI-C00154" he="37.42mm" wi="47.58mm" file="US20230000833A1-20230105-C00154.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0564" num="0631">Method A:</p><p id="p-0565" num="0632">The title compound was prepared in a manner analgous to Example 15, Step B, using 1-[2-(azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 323).</p><p id="p-0566" num="0633">Method B:</p><p id="p-0567" num="0634">Step A: Ethyl 2-(3-methyl-2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)acetate. Into a 10 L four-necked flask was charged with ethyl 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (Intermediate 12, 410.0 g, 1.31 mol), K<sub>2</sub>CO<sub>3 </sub>(360.8 g, 2.62 mol), PdC<sub>12</sub>(dppf) CH<sub>2</sub>Cl<sub>2 </sub>(32.0 g, 0.04 mol), a solution of 4,4,5,5-tetramethyl-2-(5-(trifluoromethyl)thiophen-2-yl)-1,3,2-dioxaborolane in toluene (5100 g, 10% w/w, assay by Q-NMR, 1.83 mol), toluene (291 mL) and H<sub>2</sub>O (559 mL) successively under N<sub>2 </sub>atmosphere. The resulting mixture was stirred at 80 to 85&#xb0; C. for 2.5 h and then cooled to 60 to 65&#xb0; C. followed by filtration through a pad of Celite&#xae;. The cake was washed with toluene (500 mL) and the filtrate was concentrated at 40 to 45&#xb0; C. under vacuum until the total volume was less than 2 V. n-heptane (1500 mL) was added into the residue and the resulting mixture was stirred at 25 to 30&#xb0; C. for 3 min followed by filtration. The cake was washed with n-heptane (500 mL) and dried in vacuum oven at 50&#xb0; C. for 8 h to give the title compound (530 g). The title compound (530 g) and THF (11 L, 20 V) was charged into a 50 L reactor followed by stirring at 25 to 30&#xb0; C. for 5 min. Then Darco&#xae;-G60 (60 g, 11% w/w) was charged into the THF solution and the resulting mixture was stirred at 25 to 30&#xb0; C. for 2 h followed by filtration through a pad of Celite&#xae;. After washing the cake with THF (500 mL), the combined filtrate and Darco&#xae;-G60 (60 g, 11% w/w) was charged into the reactor again. The mixture was stirred at 25 to 30&#xb0; C. for another 2 h followed by filtration through a pad of Celite&#xae;. The cake was washed with THF (500 mL) then the combined filtrate and SiliaMetS (50 g, 10% w/w) was charged into the reactor. After stirring at 25 to 30&#xb0; C. overnight, the mixture was filtered through a pad of Celite&#xae; and the cake was washed with THF (500 mL). The filtrate was concentrated at 40 to 45&#xb0; C. under vacuum until 3-4 volume of THF was left. n-Heptane (3500 mL) was added into the residue and the resulting mixture was stirred at 25 to 30&#xb0; C. for 5 min followed by filtration. The cake was washed with n-heptane (500 mL) and dried at 50&#xb0; C. vacuum oven to give the title compound (402 g, 80%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.33 (d, J=1.9 Hz, 1H), 7.42 (dq, J=4.0, 1.3 Hz, 1H), 7.23 (d, J=3.0 Hz, 1H), 7.18 (dq, J=4.0, 1.3 Hz, 1H), 4.68 (s, 2H), 4.27 (q, J=7.1 Hz, 2H), 3.55 (s, 3H), 1.32 (t, J=7.1 Hz, 3H).</p><p id="p-0568" num="0635">Step B: 2-(3-Methyl-2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)acetic acid. The title compound was prepared in a manner analogous to</p><p id="p-0569" num="0636">Intermediate 38, Step A, using ethyl 2-(3-methyl-2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)acetate. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.42 (d, J=1.9 Hz, 1H), 8.03 (d, J=2.0 Hz, 1H), 7.76 (dq, J=3.9, 1.3 Hz, 1H), 7.60 (dq, J=3.9, 1.3 Hz, 1H), 4.69 (s, 2H).</p><p id="p-0570" num="0637">Step C: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one. Into a suspension of 2-(3-methyl-2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydroimidazo[4,5-b]pyridin-1-Aacetic acid (357.4 g, 1.0 mol, 1.0 eq.) and ACN (7.2 L) was added DIEA (530.02 g, 4.1 mol, 4.1 eq.). Then T<sub>3</sub>P (w/w 50% in EA, 1368.52 g, 2.15 mol, 2.15 eq.) was added dropwise into the mixture at 10 to 20&#xb0; C. followed by the addition of azetidine (74.24 g, 1.3 mol, 1.3 eq.) at the same temperature. After stirring at 10 to 15&#xb0; C. for 2 h, the mixture was poured into water (14.4 L) and stirred for 10 min followed by filtration. The cake was washed with water (500 mL) and dried at 50&#xb0; C. vacuum oven for 24 h to give 340 g of crude solid as a light purple solid of the title compound. Purification (FCC, SiO<sub>2</sub>, eluent: EA/n-heptane=50/1 to 100/1 then DCM/MeOH=10/1) afforded the title compound (260 g). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.32 (d, J=1.9 Hz, 1H), 7.46 (d, J=1.9 Hz, 1H), 7.43 (dq, J=3.7, 1.1 Hz, 1H), 7.21 (dq, J=3.7, 1.1 Hz, 1H), 4.51 (s, 2H), 4.36 (t, J=7.8 Hz, 2H), 4.11 (t, J=7.8 Hz, 2H), 3.55 (s, 3H), 2.43-2.35 (m, 2H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) 6 &#x2212;55.34. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x3b4; 165.56, 153.75, 145.16, 143.99, 138.72, 129.46, 129.42, 124.42, 123.64, 123.19, 112.78, 77.35, 77.23, 77.03, 76.71, 50.47, 48.62, 40.70, 26.39, 15.73. LC/MS (ES<sup>+</sup>) m/z 397.1 (M+H).</p><heading id="h-0105" level="1">Example 28: N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0571" num="0638"><chemistry id="CHEM-US-00155" num="00155"><img id="EMI-C00155" he="33.61mm" wi="47.58mm" file="US20230000833A1-20230105-C00155.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0572" num="0639">The title compound was prepared in a manner analogous to Example 14, Step B, using N,N-dimethyl-2-(2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetamide (Example 26). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 384.1; m/z found, 385.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.31-8.29 (d, J=1.9 Hz, 1H), 7.42-7.39 (m, 1H), 7.34-7.32 (d, J=1.9 Hz, 1H), 7.19-7.16 (m, 1H),4.75-4.70 (s, 2H), 3.56-3.50 (s, 3H), 3.20-3.17 (s, 3H), 3.02-2.97 (s, 3H).</p><heading id="h-0106" level="1">Example 29: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0573" num="0640"><chemistry id="CHEM-US-00156" num="00156"><img id="EMI-C00156" he="34.12mm" wi="47.75mm" file="US20230000833A1-20230105-C00156.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0574" num="0641">Step A: 2-(6-(2-Methyl-5-(trifluoromethyl)phenyl)-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid. A solution of 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 38, product from Step A, 200 mg, 0.39 mmol), 1,1&#x2032;-bis(diphenylphosphino) ferrocene palladium(II)dichloride dichloromethane complex (22 mg, 0.027 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(253 mg, 0.78 mmol), (2-methyl-5-(trifluoromethyl)phenyl)boronic acid (135 mg, 0.66 mmol), dioxane (3.6 mL) and H<sub>2</sub>O (0.8 mL) was heated to 90&#xb0; C. using an oil bath. After 16 h, the reaction mixture was cooled to room temperature and quenched with a saturated aqueous solution of NH<sub>4</sub>Cl (15 mL). The mixture was extracted with EtOAc (3&#xd7;20 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to afford the title compound, contaminated with some impurities. The crude material was moved forward to the next step as is.</p><p id="p-0575" num="0642">Step B: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(2-methyl-5-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. HATU (177 mg, 0.5 mmol) was added to a mixture of 2-(6-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxo-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (230 mg, 0.4 mmol), azetidine (0.031 mL, 0.47 mmol) and DIPEA (0.13 mL, 0.78 mmol) in DMF (3 mL) at room temperature. After completion, a saturated aqueous solution of NaHCO<sub>3 </sub>(10 mL) was added, and the mixture was extracted using EtOAc (3&#xd7;15 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to afford the title compound. The crude material was moved forward to the next step as is.</p><p id="p-0576" num="0643">Step C: 1-[2-(azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one. TFA (0.89 mL, 12 mmol) was added to a mixture of 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-(2-methyl-5-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (245 mg, 0.39 mmol) in DCM at room temperature. After 1 h, complete conversion was observed and the mixture was purified using reversed phase HPLC (Method C) to afford the title compound contaminated with impurities. The material was triturated between EtOAc (10 mL) and a saturated aqueous solution of NaHCO<sub>3 </sub>(10 mL). The organic layer was collected and the aqueous layer was washed with EtOAc (3&#xd7;15 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum. The material was further purified (FCC, SiO<sub>2</sub>, 0-90% EtOAc in hexanes) to afford the title compound (17 mg, 11% over 3 steps). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.73 (br s, 1H), 7.92 (d, J=1.9 Hz, 1H), 7.68-7.64 (m, 1H), 7.60-7.55 (m, 1H), 7.54-7.50 (m, 1H), 7.46 (d, J=1.9 Hz, 1H), 4.51 (s, 2H), 4.24 (t, J=7.6 Hz, 2H), 3.88 (t, J=7.7 Hz, 2H), 2.33 (s, 3H), 2.34-2.20 (m, 2H).</p><heading id="h-0107" level="1">Example 30: 6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0577" num="0644"><chemistry id="CHEM-US-00157" num="00157"><img id="EMI-C00157" he="27.09mm" wi="49.28mm" file="US20230000833A1-20230105-C00157.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0578" num="0645">Step A: 6-Bromo-3-(4-methoxybenzyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. Under a nitrogen atmosphere was added 6-bromo-3-(4-methoxybenzyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 10, 2 g, 6.0 mmol) to a suspension of NaH (527 mg, 13 mmol) in DMF (30 mL). After 10 minutes, 1-bromo-2-butanone (1.3 mL, 13.2 mmol) was added to the reaction mixture, and the reaction was heated to 65&#xb0; C. After 3 h, the reaction mixture was cooled to room temperature and quenched with water (150 mL) and a solid precipitate appeared. The precipitates were collected by filtration, washed with water and dried under vacuum to give the title compound (1.7 g, 68%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>3</sub>, 403.1; m/z found, 404.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.10 (d, J=2.0 Hz, 1H), 7.80 (d, J=2.0 Hz, 1H), 7.28-7.24 (m, 2H), 6.91-6.84 (m, 2H), 4.98 (s, 2H), 4.88 (s, 2H), 3.71 (s, 3H), 2.61 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).</p><p id="p-0579" num="0646">Step B: 6-(2,4-difluoro-3-methylphenyl)-3-(4-methoxybenzyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A mixture of 6-bromo-3-(4-methoxybenzyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (200 mg, 0.5 mmol), (2,4-difluoro-3-methylphenyl)boronic acid (128 mg, 0.7 mmol), 1,1&#x2032;-bis(diphenylphosphino)ferrocene palladium(II)dichloride dichloromethane complex (25 mg, 0.03 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(322 mg, 1.0 mmol), dioxane (4.6 mL) and H<sub>2</sub>O (0.4 mL) was heated to 110&#xb0; C. using an oil bath. After 16 h, the reaction mixture was cooled to room temperature and volatiles were removed. The crude material was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in hexanes) to give the title compound (148 mg, 66%). MS (ESI): mass calcd. for C<sub>25</sub>H<sub>23</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>, 451.2; m/z found, 452.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.11 (t, J=1.6 Hz, 1H), 7.65 (t, J=1.6 Hz, 1H), 7.42-7.35 (m, 1H), 7.34-7.28 (m, 2H), 7.21-7.14 (m, 1H), 6.92-6.87 (m, 2H), 5.04 (s, 2H), 4.92 (s, 2H), 3.71 (s, 3H), 2.61 (q, J=7.4 Hz, 2H), 2.22 (t, J=1.9 Hz, 3H), 0.98 (t, J=7.3 Hz, 3H).</p><p id="p-0580" num="0647">Step C: 6-(2,4-difluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one. A mixture of 6-(2,4-difluoro-3-methylphenyl)-3-(4-methoxybenzyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (140 mg, 0.31 mmol) and hydrobromic acid (48% in H<sub>2</sub>O, 6 mL) was heated to 115&#xb0; C. After completion, the reaction was cooled to 0&#xb0; C. and sodium hydroxide pellets were added until basic pH was reached. The mixture was extracted with EtOAc (3&#xd7;). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude material was triturated in MeOH and the solids were filtered off and rinsed with MeOH to afford the title compound (16 mg, 16%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 331.1; m/z found, 332.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.76 (s, 1H), 8.04 (t, J=1.6 Hz, 1H), 7.55 (t, J=1.6 Hz, 1H), 7.42-7.35 (m, 1H), 7.21-7.14 (m, 1H), 4.82 (s, 2H), 2.59 (q, J=7.2 Hz, 2H), 2.22 (t, J=1.8 Hz, 3H), 0.97 (t, J=7.3 Hz, 3H).</p><heading id="h-0108" level="1">Example 31: (R/S)-1-(2-Cyclopropyl-2-hydroxy-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0581" num="0648"><chemistry id="CHEM-US-00158" num="00158"><img id="EMI-C00158" he="32.94mm" wi="39.79mm" file="US20230000833A1-20230105-C00158.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0582" num="0649">Step A: 1-(2-Cyclopropyl-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. Under a nitrogen atmosphere was added 6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 43, 200 mg, 0.38 mmol) to a suspension of NaH (60% dispersion in mineral oil, 30.7 mg, 0.8 mmol) in DMF (4 mL). After 10 minutes 2-bromo-1-cyclopropylethanone (93.8 mg, 0.6 mmol) was added to the reaction mixture, and the reaction mixture was heated to 75&#xb0; C. After completion, the reaction mixture was cooled down to room temperature and quenched with water (20 mL). The mixture was extracted using EtOAc (3&#xd7;20 mL). The precipitates were collected by filtration, washed with water and dried under vacuum to give the title compound which was used crude without further purification.</p><p id="p-0583" num="0650">Step B: 1-(2-Cyclopropyl-2-hydroxyethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. Under a nitrogen atmosphere was added sodium borohydride (18 mg, 0.5 mmol) to a mixture of 1-(2-cyclopropyl-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (140 mg, 0.2 mmol) in MeOH at 0&#xb0; C., and then the reaction mixture was allowed to warm to room temperature. After completion, the reaction mixture was concentrated under vacuum. The crude material was partitioned between EtOAc (20 mL) and water (20 mL). The organic layer was isolated and the aqueous layer was washed with EtOAc (2&#xd7;30 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to afford the title compound, which was used in the next step without further purification.</p><p id="p-0584" num="0651">Step C: (R/S)-1-(2-Cyclopropyl-2-hydroxy-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt. To a solution of 1-(2-cyclopropyl-2-hydroxyethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (140 mg, 0.2 mmol) in DCM at room temperature was added TFA (0.26 mL, 3.5 mmol). After completion the reaction mixture was concentrated under vacuum and the crude material was purified using reversed phase HPLC (Method C) to afford the title compound (30 mg, 27%).MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, 364.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.65 (s, 1H), 8.28 (d, J=2.0 Hz, 1H), 8.03-7.97 (m, 2H), 7.86 (d, J=2.0 Hz, 1H), 7.75-7.69 (m, 2H), 3.31-3.24 (m, 1H), 0.94-0.84 (m, 1H), 0.41-0.23 (m, 3H), 0.15-0.07 (m, 1H).</p><heading id="h-0109" level="1">Example 32: 1-[(2-Oxo-1H-pyridin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0585" num="0652"><chemistry id="CHEM-US-00159" num="00159"><img id="EMI-C00159" he="29.13mm" wi="47.92mm" file="US20230000833A1-20230105-C00159.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0586" num="0653">Under a nitrogen atmosphere was added chlorotrimethylsilane (0.06 mL, 0.5 mmol) to a mixture of 1-[(2-methoxy-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 22, 100 mg, 0.2 mmol) and sodium iodide (73 mg, 0.5 mmol) in MeCN (0.7 mL) at room temperature. After 16 hours, almost complete conversion was observed, and the reaction mixture was concentrated under vacuum to afford the title compound as a free base. The crude material was purified using reversed phase HPLC (Method C) to afford title compound (36 mg, 37%). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 386.1; m/z found, 387.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.82-11.72 (m, 2H), 8.32 (d, J=2.0 Hz, 1H), 8.01-7.96 (m, 2H), 7.93 (d, J=2.0 Hz, 1H), 7.73-7.67 (m, 2H), 7.32 (dd, J=6.5, 2.0 Hz, 1H), 7.15-7.11 (m, 1H), 6.13 (t, J=6.6 Hz, 1H), 4.85 (s, 2H).</p><heading id="h-0110" level="1">Example 33: (R/S)-6-(4-Fluoro-2-methyl-phenyl)-3-methyl-1-(oxetan-2-ylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-0587" num="0654"><chemistry id="CHEM-US-00160" num="00160"><img id="EMI-C00160" he="26.59mm" wi="50.12mm" file="US20230000833A1-20230105-C00160.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0588" num="0655">Step A: 6-Bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Intermediate 22, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 2-(bromomethyl)oxetane.</p><p id="p-0589" num="0656">Step B: (R/S)-6-(4-Fluoro-2-methyl-phenyl)-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one. A mixture of 6-bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 25, 85 mg, 0.3 mmol), (4-fluoro-2-methylphenyl)boronic acid (57 mg, 0.4 mmol), 1,1&#x2032;-bis(diphenylphosphino)ferrocene palladium(II)dichloride dichloromethane complex (15 mg, 0.02 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(186 mg, 0.6 mmol) and dioxane (2.6 mL) was heated to 110&#xb0; C. After completion, the reaction mixture was filtered and was (Method C). The collected fractions were combined and diluted with a saturated aqueous solution of NaHCO<sub>3</sub>. The mixture was extracted using DCM (3&#xd7;). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to give title compound (9.9 mg, 11%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 327.1; m/z found, 328.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 7.93 (d, J=1.8 Hz, 1H), 7.60 (d, J=1.9 Hz, 1H), 7.29-7.24 (m, 1H), 7.22-7.17 (m, 1H), 7.15-7.09 (m, 1H), 5.05-4.95 (m, 1H), 4.48-4.40 (m, 1H), 4.35-4.27 (m, 1H), 4.23-4.03 (m, 2H), 3.40 (s, 3H), 2.71-2.57 (m, 1H), 2.51-2.37 (m, 1H), 2.24 (s, 3H).</p><heading id="h-0111" level="1">Example 34: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0590" num="0657"><chemistry id="CHEM-US-00161" num="00161"><img id="EMI-C00161" he="42.50mm" wi="39.79mm" file="US20230000833A1-20230105-C00161.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0591" num="0658">Step A: 6-Bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A mixture of 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 13, 500 mg, 1.7 mmol), 3-fluoroazetidine hydrochloride (234 mg, 2.1 mmol), DIPEA (0.7 mL, 3.9 mmol), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (T3P&#xae;, 50% solution in DMF, 3.1 mL, 5.2 mmol) in DMF (13 mL) was heated to 50&#xb0; C. After completion, the reaction mixture was cooled to room temperature and a saturated aqueous solution of NaHCO<sub>3 </sub>(20 mL) was added. The mixture was extracted using DCM (3&#xd7;30 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to give the title compound (435 mg, 73%). MS (ESI): mass calcd. for C<sub>12</sub>H<sub>12</sub>BrFN<sub>4</sub>O<sub>2</sub>, 342.0; m/z found, 342.8 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.11 (d, J=2.0 Hz, 1H), 7.79 (d, J=2.0 Hz, 1H), 5.55-5.38 (m, 1H), 4.67-4.57 (m, 3H), 4.45-4.33 (m, 1H), 4.30-4.18 (m, 1H), 4.03-3.91 (m, 1H), 3.34 (s, 3H).</p><p id="p-0592" num="0659">Step B: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt. A mixture of 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (40 mg, 0.1 mmol), 3-(trifluoromethyl)phenylboronic acid (43 mg, 0.2 mmol), 1,1&#x2032;-bis(diphenylphosphino)ferrocene palladium(II)dichloride dichloromethane complex (6 mg, 0.01 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(76 mg, 0.2 mmol) and dioxane (1.1 mL) was heated to 100&#xb0; C. using an oil bath. After 16 h, the reaction mixture cooled to rt to afford the crude title compound as a free base. Purification (Method C), afforded the title compound (19 mg, 31%). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 408.1; m/z found, 409.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.40 (d, J=1.9 Hz, 1H), 8.02-7.97 (m, 2H), 7.89 (d, J=2.0 Hz, 1H), 7.78-7.70 (m, 2H), 5.58-5.37 (m, 1H), 4.76-4.57 (m, 3H), 4.47-4.34 (m, 1H), 4.31-4.18 (m, 1H), 4.04-3.90 (m, 1H), 3.40 (s, 3H).</p><heading id="h-0112" level="1">Example 35: 6-(4-Methoxyphenyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0593" num="0660"><chemistry id="CHEM-US-00162" num="00162"><img id="EMI-C00162" he="36.07mm" wi="48.77mm" file="US20230000833A1-20230105-C00162.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0594" num="0661">The title compound was prepared in a manner analogous to Example 1, using morpholine in Step F. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>2</sub>ON<sub>4</sub>O<sub>3</sub>, 352.2; m/z found, 353.1 [M+H]<sup>+</sup>.</p><heading id="h-0113" level="1">Example 36: N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0595" num="0662"><chemistry id="CHEM-US-00163" num="00163"><img id="EMI-C00163" he="36.66mm" wi="45.21mm" file="US20230000833A1-20230105-C00163.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0596" num="0663">The title compound was prepared in a manner analogous to Example 3, using 2-(6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-cyclopropylacetamide (Intermediate 34). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>2</sub>, 340.1; m/z found, 341.3 [M+H]<sup>+</sup>.</p><heading id="h-0114" level="1">Example 37: 2-[6-(2-Chloro-4-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-acetamide</heading><p id="p-0597" num="0664"><chemistry id="CHEM-US-00164" num="00164"><img id="EMI-C00164" he="36.58mm" wi="48.77mm" file="US20230000833A1-20230105-C00164.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0598" num="0665">The title compound was prepared in a manner analogous to Example 3, using 2-(6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-cyclopropylacetamide (Intermediate 34) and (2-chloro-4-methoxyphenyl)boronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>3</sub>, 372.1; m/z found, 373.1 [M+H]<sup>+</sup>.</p><heading id="h-0115" level="1">Example 38: N-Cyclopropyl-2-[6-(4-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0599" num="0666"><chemistry id="CHEM-US-00165" num="00165"><img id="EMI-C00165" he="36.49mm" wi="48.77mm" file="US20230000833A1-20230105-C00165.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0600" num="0667">The title compound was prepared in a manner analogous to Example 3, using 2-(6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-cyclopropylacetamide (Intermediate 34) and 4-methoxyphenylboronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>, 338.1; m/z found, 339.2 [M+H]<sup>+</sup>.</p><heading id="h-0116" level="1">Example 39: N-Cyclopropyl-2-[6-(3,5-dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0601" num="0668"><chemistry id="CHEM-US-00166" num="00166"><img id="EMI-C00166" he="36.41mm" wi="44.70mm" file="US20230000833A1-20230105-C00166.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0602" num="0669">The title compound was prepared in a manner analogous to Example 3, using 2-(6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-cyclopropylacetamide (Intermediate 34) and (3,5-dimethyl)boronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>, 336.2; m/z found, 337.2 [M+H]<sup>+</sup>.</p><heading id="h-0117" level="1">Example 40: N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide</heading><p id="p-0603" num="0670"><chemistry id="CHEM-US-00167" num="00167"><img id="EMI-C00167" he="36.49mm" wi="45.21mm" file="US20230000833A1-20230105-C00167.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0604" num="0671">The title compound was prepared in a manner analogous to Example 3, using 2-(6-bromo-2-oxo-1H-imidazo[4,5-b]pyridin-3(2H)-yl)-N-cyclopropyl-N-methylacetamide. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>, 354.1; m/z found, 355.0 [M+H]<sup>+</sup>.</p><heading id="h-0118" level="1">Example 41: N-Cyclopropyl-2-[6-(4-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide</heading><p id="p-0605" num="0672"><chemistry id="CHEM-US-00168" num="00168"><img id="EMI-C00168" he="36.41mm" wi="48.77mm" file="US20230000833A1-20230105-C00168.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0606" num="0673">The title compound was prepared in a manner analogous to Example 3, using 2-(6-bromo-2-oxo-1H-imidazo[4,5-b]pyridin-3(2H)-yl)-N-cyclopropyl-N-methylacetamide and 4-methoxyphenylboronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>, 352.2; m/z found, 353.0 [M+H]<sup>+</sup>.</p><heading id="h-0119" level="1">Example 42: N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0607" num="0674"><chemistry id="CHEM-US-00169" num="00169"><img id="EMI-C00169" he="39.12mm" wi="45.30mm" file="US20230000833A1-20230105-C00169.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0608" num="0675">The title compound was prepared in a manner analogous to Example 3, using 2-(6-bromo-1-methyl-2-oxo-1H-imidazo[4,5-b]pyridin-3(2H)-yl)-N-cyclopropylacetamide. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>, 354.1; m/z found, 354.96 [M+H]<sup>+</sup>.</p><heading id="h-0120" level="1">Example 43: (R*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0609" num="0676"><chemistry id="CHEM-US-00170" num="00170"><img id="EMI-C00170" he="30.90mm" wi="45.21mm" file="US20230000833A1-20230105-C00170.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0610" num="0677">The title compound was prepared in a manner analogous to Example 4, using (4-fluoro-2-methylphenyl)boronic acid in Step D. Purification (SFC separation, Chiralcel AD-H, 20 &#x3bc;m; Supercritical CO<sub>2</sub>: MeOH, v/v, 200 mL/min) afforded the title compound and (S*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one (Example 44). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 315.1; m/z found, 316.0 [M+H]<sup>+</sup>.</p><heading id="h-0121" level="1">Example 44: (S*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0611" num="0678"><chemistry id="CHEM-US-00171" num="00171"><img id="EMI-C00171" he="30.90mm" wi="45.21mm" file="US20230000833A1-20230105-C00171.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0612" num="0679">Isolated during purification of Example 43. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 315.1; m/z found, 315.93 [M+H]<sup>+</sup>.</p><heading id="h-0122" level="1">Example 45: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0613" num="0680"><chemistry id="CHEM-US-00172" num="00172"><img id="EMI-C00172" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00172.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0614" num="0681">The title compound was prepared in a manner analogous to Example 6 using 3-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O, 348.1; m/z found, 349.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 2.30 (d, J=1.16 Hz, 3H), 3.39 (s, 3H), 5.19 (s, 2H), 7.24 (t, J=9.13 Hz, 1H), 7.36 (dd, J=7.86, 4.85 Hz, 1H), 7.50 (ddd, J=8.03, 5.03, 2.43 Hz, 1H), 7.60 (dd, J=7.28, 1.73 Hz, 1H), 7.76 (d, J=7.86 Hz, 1H), 7.90 (d, J=1.85 Hz, 1H), 8.28 (d, J=1.85 Hz, 1H), 8.48 (dd, J=4.74, 1.50 Hz, 1H), 8.67 (d, J=1.62 Hz, 1H).</p><heading id="h-0123" level="1">Example 46: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0615" num="0682"><chemistry id="CHEM-US-00173" num="00173"><img id="EMI-C00173" he="29.89mm" wi="54.19mm" file="US20230000833A1-20230105-C00173.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0616" num="0683">The title compound was prepared in a manner analogous to Example 6 using 4-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O, 348.1; m/z found, 349.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.29 (d, J=1.39 Hz, 3H), 3.42 (s, 3H), 5.20 (s, 2H), 7.16-7.27 (m, 1H), 7.30 (d, J=6.01 Hz, 2H), 7.49 (ddd, J=8.15, 5.14, 2.43 Hz, 1H), 7.59 (dd, J=7.28, 1.96 Hz, 1H), 7.81 (d, J=1.85 Hz, 1H), 8.30 (d, J=1.85 Hz, 1H), 8.45-8.59 (m, 2H).</p><heading id="h-0124" level="1">Example 47: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0617" num="0684"><chemistry id="CHEM-US-00174" num="00174"><img id="EMI-C00174" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00174.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0618" num="0685">The title compound was prepared in a manner analogous to Example 6 using Intermediate 27: 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and Intermediate 1: 2-(chloromethyl)pyrazine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>FN<sub>5</sub>O, 349.1; m/z found, 350.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 2.34 (d, J=1.85 Hz, 3H), 3.57 (s, 3H), 5.27 (s, 2H), 7.08 (t, J=8.79 Hz, 1H), 7.20-7.33 (m, 4H), 7.37 (d, J=1.85 Hz, 1H), 8.21 (d, J=1.85 Hz, 1H), 8.29 (s, 1H), 8.47-8.59 (m, 2H), 8.69 (d, J=0.92 Hz, 1H).</p><heading id="h-0125" level="1">Example 48: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-5-ylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-0619" num="0686"><chemistry id="CHEM-US-00175" num="00175"><img id="EMI-C00175" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00175.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0620" num="0687">The title compound was prepared in a manner analogous to Example 6 using Intermediate 27: 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and Intermediate 3: 5-(chloromethyl)pyrimidine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>FN<sub>5</sub>O, 349.1; m/z found, 350.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 2.35 (d, J=1.62 Hz, 3H), 3.58 (s, 3H), 5.14 (s, 2H), 7.09 (t, J=8.79 Hz, 1H), 7.19 (d, J=1.85 Hz, 1H), 7.22-7.33 (m, 2H), 8.23 (d, J=1.85 Hz, 1H), 8.80 (s, 2H), 9.19 (s, 1H).</p><heading id="h-0126" level="1">Example 49: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-2-ylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-0621" num="0688"><chemistry id="CHEM-US-00176" num="00176"><img id="EMI-C00176" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00176.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0622" num="0689">The title compound was prepared in a manner analogous to Example 6 using Intermediate 27: 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 2-(chloromethyl)pyrimidine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>FN<sub>5</sub>O, 349.1; m/z found, 350.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 2.32 (d, J=1.85 Hz, 3H), 3.59 (s, 3H), 5.37 (s, 2H), 7.05 (t, J=8.90 Hz, 1H), 7.17-7.35 (m, 4H), 8.20 (d, J=1.85 Hz, 1H), 8.69 (d, J=5.09 Hz, 2H).</p><heading id="h-0127" level="1">Example 50: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0623" num="0690"><chemistry id="CHEM-US-00177" num="00177"><img id="EMI-C00177" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00177.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0624" num="0691">The title compound was prepared in a manner analogous to Example 6 using Intermediate 27: 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 3-(chloromethyl)pyridazine (Intermediate 2). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>FN<sub>5</sub>O, 349.1; m/z found, 350.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.29 (d, J=1.62 Hz, 3H), 3.41 (s, 3H), 5.47 (s, 2H), 7.11-7.33 (m, 1H), 7.37-7.53 (m, 1H), 7.58 (dd, J=7.40, 2.08 Hz, 1H), 7.62-7.74 (m, 2H), 7.83 (d, J=1.85 Hz, 1H), 8.30 (d, J=2.08 Hz, 1H), 9.15 (dd, J=4.62, 2.08 Hz, 1H).</p><heading id="h-0128" level="1">Example 51: 6-(3-Fluorophenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0625" num="0692"><chemistry id="CHEM-US-00178" num="00178"><img id="EMI-C00178" he="30.73mm" wi="47.92mm" file="US20230000833A1-20230105-C00178.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0626" num="0693">The title compound was prepared in a manner analogous to Example 6 using Intermediate 28: 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 3-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>FN<sub>4</sub>O, 334.1; m/z found, 335.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 3.59 (s, 3H), 5.15 (s, 2H), 7.02-7.12 (m, 1H), 7.17 (dt, J=9.94, 2.08 Hz, 1H), 7.20 (d, J=2.08 Hz, 1H), 7.22-7.26 (m, 1H), 7.30 (dd, J=7.86, 4.86 Hz, 1H), 7.42 (td, J=7.98, 6.01 Hz, 1H), 7.70 (dt, J=7.86, 1.97 Hz, 1H), 8.25 (d, J=1.85 Hz, 1H), 8.58 (dd, J=4.86, 1.62 Hz, 1H), 8.68 (d, J=2.08 Hz, 1H).</p><p id="p-0627" num="0694">Example 52: 6-(3-Fluorophenyl)-3-methyl-1-(4-pyridylmethypimidazo[4,5-1D]pyridin-2-one</p><p id="p-0628" num="0000"><chemistry id="CHEM-US-00179" num="00179"><img id="EMI-C00179" he="30.73mm" wi="48.77mm" file="US20230000833A1-20230105-C00179.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0629" num="0695">The title compound was prepared in a manner analogous to Example 6 using Intermediate 28: 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 4-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>FN<sub>4</sub>O, 334.1; m/z found, 335.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 3.60 (s, 3H), 5.14 (s, 2H), 7.07 (tdd, J=8.41, 2.49, 0.81 Hz, 1H), 7.12 (d, J=1.85 Hz, 1H), 7.16 (dt, J=9.83, 2.14 Hz, 1H), 7.20-7.26 (m, 3H), 7.41 (td, J=7.98, 6.01 Hz, 1H), 8.28 (d, J=1.85 Hz, 1H), 8.36-8.84 (m, 2H).</p><heading id="h-0129" level="1">Example 53: 6-(3-Fluorophenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0630" num="0696"><chemistry id="CHEM-US-00180" num="00180"><img id="EMI-C00180" he="30.73mm" wi="47.92mm" file="US20230000833A1-20230105-C00180.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0631" num="0697">The title compound was prepared in a manner analogous to Example 6 using Intermediate 28: 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 2-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>FN<sub>4</sub>O, 334.1; m/z found, 335.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 3.58 (s, 3H), 5.25 (s, 2H), 7.06 (tdd, J=8.32, 2.54, 0.92 Hz, 1H), 7.16-7.26 (m, 2H), 7.27 (s, 2H), 7.33 (d, J=7.63 Hz, 1H), 7.36-7.48 (m, 2H), 7.67 (td, J=7.74, 1.85 Hz, 1H), 8.25 (d, J=1.85 Hz, 1H), 8.51-8.70 (m, 1H).</p><heading id="h-0130" level="1">Example 54: 6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0632" num="0698"><chemistry id="CHEM-US-00181" num="00181"><img id="EMI-C00181" he="30.73mm" wi="47.92mm" file="US20230000833A1-20230105-C00181.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0633" num="0699">The title compound was prepared in a manner analogous to Example 6 using Intermediate 28: 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 5-(chloromethyl)pyrimidine hydrochloride (Intermediate 3). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O, 335.1; m/z found, 336.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 3.58 (s, 2H), 3.52 (s, 1H), 5.15 (s, 2H), 6.95-7.14 (m, 1H), 7.15-7.32 (m, 4H), 7.43 (td, J=7.98, 6.01 Hz, 1H), 8.28 (d, J=1.85 Hz, 1H), 8.80 (s, 2H), 9.20 (s, 1H).</p><heading id="h-0131" level="1">Example 55: 6-(3-Fluorophenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0634" num="0700"><chemistry id="CHEM-US-00182" num="00182"><img id="EMI-C00182" he="30.73mm" wi="47.84mm" file="US20230000833A1-20230105-C00182.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0635" num="0701">The title compound was prepared in a manner analogous to Example 6 using Intermediate 28: 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and Intermediate 1: 2-(chloromethyl)pyrazine. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O, 335.1; m/z found, 336.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 3.58 (s, 3H), 5.29 (s, 2H), 7.02-7.13 (m, 1H), 7.22 (dt, J=9.94, 2.08 Hz, 1H), 7.30 (dt, J=7.86, 1.16 Hz, 1 H), 7.35-7.50 (m, 2H), 8.27 (d, J=1.85 Hz, 1H), 8.47-8.61 (m, 2H), 8.71 (s, 1H).</p><heading id="h-0132" level="1">Example 56: 6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-2-ylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-0636" num="0702"><chemistry id="CHEM-US-00183" num="00183"><img id="EMI-C00183" he="30.73mm" wi="47.84mm" file="US20230000833A1-20230105-C00183.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0637" num="0703">The title compound was prepared in a manner analogous to Example 6 using Intermediate 28: 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 2-(chloromethyl)pyrimidine hydrochloride. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O, 335.1; m/z found, 336.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 3.37-3.56 (m, 3H), 5.39 (s, 2H), 7.05-7.28 (m, 1H), 7.41 (t, J=4.91 Hz, 1H), 7.45-7.72 (m, 3H), 7.91 (d, J=2.02 Hz, 1H), 8.39 (d, J=2.02 Hz, 1H), 8.75 (d, J=4.91 Hz, 2H).</p><heading id="h-0133" level="1">Example 57: 6-(3-Fluorophenyl)-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-0638" num="0704"><chemistry id="CHEM-US-00184" num="00184"><img id="EMI-C00184" he="30.73mm" wi="47.84mm" file="US20230000833A1-20230105-C00184.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0639" num="0705">The title compound was prepared in a manner analogous to Example 6 using Intermediate 28: 6-(3-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and Intermediate 2: 3-(chloromethyl)pyridazine. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O, 335.1; m/z found, 336.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 3.42 (s, 3H), 5.48 (s, 2H), 7.11-7.28 (m, 1H), 7.40-7.60 (m, 3H), 7.60-7.79 (m, 2H), 7.92 (d, J=2.08 Hz, 1H), 8.40 (d, J=1.85 Hz, 1H), 9.15 (dd, J=4.28, 2.20 Hz, 1H).</p><heading id="h-0134" level="1">Example 58: 6-(3,4-Difluorophenyl)-3-methyl-1-(4-pyridylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-0640" num="0706"><chemistry id="CHEM-US-00185" num="00185"><img id="EMI-C00185" he="30.73mm" wi="54.19mm" file="US20230000833A1-20230105-C00185.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0641" num="0707">The title compound was prepared in a manner analogous to Example 6 using Intermediate 29: 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 4-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 3.60 (s, 3H), 5.14 (s, 2H), 7.06 (d, J=1.85 Hz, 1H), 7.12-7.19 (m, 1H), 7.19-7.23 (m, 2H), 7.23-7.32 (m, 3H), 8.22 (d, J=1.85 Hz, 1H), 8.38-8.86 (m, 2H).</p><heading id="h-0135" level="1">Example 59: 6-(3,4-Difluorophenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0642" num="0708"><chemistry id="CHEM-US-00186" num="00186"><img id="EMI-C00186" he="30.65mm" wi="53.34mm" file="US20230000833A1-20230105-C00186.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0643" num="0709">The title compound was prepared in a manner analogous to Example 6 using Intermediate 29: 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and 3-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 3.39 (s, 9H), 5.18 (s, 2H), 7.36 (dd, J=7.86, 4.86 Hz, 1H), 7.46-7.63 (m, 2H), 7.68-7.90 (m, 2H), 7.97 (d, J=1.85 Hz, 1H), 8.35 (d, J=1.85 Hz, 1H), 8.48 (dd, J=4.74, 1.50 Hz, 1H), 8.67 (d, J=1.85 Hz, 1H).</p><heading id="h-0136" level="1">Example 60: 6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0644" num="0710"><chemistry id="CHEM-US-00187" num="00187"><img id="EMI-C00187" he="30.73mm" wi="53.34mm" file="US20230000833A1-20230105-C00187.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0645" num="0711">The title compound was prepared in a manner analogous to Example 6 using Intermediate 29: 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-1D]pyridin-2-one and 5-(chloromethyl)pyrimidine hydrochloride (Intermediate 3). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O, 353.1; m/z found, 352.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 3.58 (s, 3H), 5.15 (s, 2H), 7.15-7.22 (m, 2H), 7.27 (s, 3H), 8.23 (d, J=1.85 Hz, 1H), 8.80 (s, 2H), 9.20 (s, 1H). MP =184.9&#xb0; C.</p><heading id="h-0137" level="1">Example 61: 6-(3,4-Difluorophenyl)-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-0646" num="0712"><chemistry id="CHEM-US-00188" num="00188"><img id="EMI-C00188" he="30.73mm" wi="53.34mm" file="US20230000833A1-20230105-C00188.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0647" num="0713">The title compound was prepared in a manner analogous to Example 6 using Intermediate 29: 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and Intermediate 2: 3-(chloromethyl)pyridazine. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O, 353.1; m/z found, 354.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 3.41 (s, 3H), 5.47 (s, 2H), 7.42-7.59 (m, 2H), 7.58-7.74 (m, 2H), 7.74-7.85 (m, 1H), 7.91 (d, J=1.85 Hz, 1H), 8.38 (d, J=1.85 Hz, 1H), 9.15 (dd, J=4.39, 2.08 Hz, 1H).</p><heading id="h-0138" level="1">Example 62: 6-(3,4-difluorophenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0648" num="0714"><chemistry id="CHEM-US-00189" num="00189"><img id="EMI-C00189" he="30.73mm" wi="53.34mm" file="US20230000833A1-20230105-C00189.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0649" num="0715">The title compound was prepared in a manner analogous to Example 6 using 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 29) and 2-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 3.58 (s, 3H), 5.24 (s, 2H), 7.19-7.26 (m, 3H), 7.28-7.40 (m, 3H), 7.68 (td, J=7.69, 1.73 Hz, 1H), 8.19 (d, J=1.85 Hz, 1H), 8.47-8.70 (m, 1H).</p><heading id="h-0139" level="1">Example 63: 6-(3,4-Difluorophenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0650" num="0716"><chemistry id="CHEM-US-00190" num="00190"><img id="EMI-C00190" he="30.65mm" wi="53.34mm" file="US20230000833A1-20230105-C00190.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0651" num="0717">The title compound was prepared in a manner analogous to Example 6 using 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 29) and 2-(chloromethyl)pyrazine (Intermediate 1). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O, 353.1; m/z found, 354.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 3.40 (s, 3H), 5.35 (s, 2H), 7.46-7.61 (m, 2H), 7.72-7.84 (m, 1H), 7.90 (d, J=1.85 Hz, 1H), 8.36 (d, J=1.85 Hz, 1H), 8.47-8.64 (m, 2H), 8.74 (s, 1H).</p><heading id="h-0140" level="1">Example 64: 6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0652" num="0718"><chemistry id="CHEM-US-00191" num="00191"><img id="EMI-C00191" he="30.73mm" wi="53.34mm" file="US20230000833A1-20230105-C00191.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0653" num="0719">The title compound was prepared in a manner analogous to Example 6 using 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 29) and 2-(chloromethyl)pyrimidine hydrochloride. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O, 353.1; m/z found, 354.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 3.42 (s, 3H), 5.37 (s, 2H), 7.41 (t, J=4.97 Hz, 1H), 7.45-7.64 (m, 2H), 7.69-7.84 (m, 1H), 7.89 (d, J=1.85 Hz, 1H), 8.37 (d, J=1.85 Hz, 1H), 8.75 (d, J=4.86 Hz, 2H).</p><heading id="h-0141" level="1">Example 65: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0654" num="0720"><chemistry id="CHEM-US-00192" num="00192"><img id="EMI-C00192" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00192.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0655" num="0721">The title compound was prepared in a manner analogous to Example 6 using 6-(2,4-difluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 30) and 2-(chloromethyl)pyrimidine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O, 367.1; m/z found, 368.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.19 (s, 3H), 3.37-3.59 (m, 3H), 5.36 (s, 2H), 7.15 (t, J=8.67 Hz, 1H), 7.28-7.51 (m, 2H), 7.64 (t, J=1.44 Hz, 1H), 8.14 (t, J=1.59 Hz, 1H), 8.75 (d, J=4.91 Hz, 2H).</p><heading id="h-0142" level="1">Example 66: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0656" num="0722"><chemistry id="CHEM-US-00193" num="00193"><img id="EMI-C00193" he="29.89mm" wi="54.19mm" file="US20230000833A1-20230105-C00193.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0657" num="0723">The title compound was prepared in a manner analogous to Example 6 using: 6-(2,4-difluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 30) and 4-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 367.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 2.20-2.28 (m, 3H), 3.59 (s, 3H), 5.12 (s, 2H), 6.92 (td, J=8.55, 1.39 Hz, 1H), 7.08-7.16 (m, 2H), 7.18-7.23 (m, 2H), 8.10-8.20 (m, 1H), 8.54-8.63 (m, 2H).</p><heading id="h-0143" level="1">Example 67: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0658" num="0724"><chemistry id="CHEM-US-00194" num="00194"><img id="EMI-C00194" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00194.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0659" num="0725">The title compound was prepared in a manner analogous to Example 6 using: 6-(2,4-difluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 30) and 3-(chloromethyl)pyridazine (Intermediate 2). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O, 367.1; m/z found, 368.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.16 (dd, J=4.5, 2.1 Hz, 1H), 8.15 (t, J=1.6 Hz, 1H), 7.72-7.63 (m, 3H), 7.38 (td, J=8.7, 6.4 Hz, 1H), 7.17 (td, J=8.7, 1.3 Hz, 1H), 5.45 (s, 2H), 3.42 (s, 3H), 2.20 (t, J=1.8 Hz, 3H).</p><heading id="h-0144" level="1">Example 68: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0660" num="0726"><chemistry id="CHEM-US-00195" num="00195"><img id="EMI-C00195" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00195.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0661" num="0727">The title compound was prepared in a manner analogous to Example 6 using 6-(2,4-difluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 30) and 2-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 367.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.20 (s, 3H), 3.42 (s, 3H), 5.23 (s, 2H), 7.16 (t, J=8.44 Hz, 1H), 7.28 (dd, J=7.40, 4.86 Hz, 1H), 7.31-7.48 (m, 2H), 7.57 (t, J=1.50 Hz, 1H), 7.77 (td, J=7.69, 1.73 Hz, 1H), 8.13 (t, J=1.62 Hz, 1H), 8.47 (d, J=3.93 Hz, 1H).</p><heading id="h-0145" level="1">Example 69: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-5-yl)methyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0662" num="0728"><chemistry id="CHEM-US-00196" num="00196"><img id="EMI-C00196" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00196.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0663" num="0729">The title compound was prepared in a manner analogous to Example 6 using: 6-(2,4-difluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 30) and 5-(chloromethyl)pyrimidine hydrochloride (Intermediate 3). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>2</sub>N<sub>5</sub>O, 367.1; m/z found, 368.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 2.27 (t, J=1.73 Hz, 3H), 3.58 (s, 3H), 5.13 (s, 2H), 6.95 (td, J=8.60, 1.30 Hz, 1H), 7.16 (td, J=8.53, 6.36 Hz, 1H), 7.24 (t, J=1.88 Hz, 1H), 8.06-8.28 (m, 1H), 8.80 (s, 2H), 9.19 (s, 1H).</p><heading id="h-0146" level="1">Example 70: 6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0664" num="0730"><chemistry id="CHEM-US-00197" num="00197"><img id="EMI-C00197" he="30.23mm" wi="54.19mm" file="US20230000833A1-20230105-C00197.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0665" num="0731">The title compound was prepared in a manner analogous to Example 7 using: 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 29). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O, 353.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 3.42 (s, 3H), 5.30 (s, 2H), 7.47 (dd, J=5.36, 0.95 Hz, 1H), 7.49-7.58 (m, 2H), 7.75-7.83 (m, 1H), 7.90 (d, J=2.21 Hz, 1H), 8.39 (d, J=1.89 Hz, 1H), 8.75 (d, J=5.36 Hz, 1H), 9.09 (d, J=1.26 Hz, 1H).</p><heading id="h-0147" level="1">Example 71: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0666" num="0732"><chemistry id="CHEM-US-00198" num="00198"><img id="EMI-C00198" he="29.38mm" wi="54.19mm" file="US20230000833A1-20230105-C00198.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0667" num="0733">The title compound was prepared in a manner analogous to Example 7 using: 6-(4-fluoro-3-methylphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 27). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>FN<sub>5</sub>O, 349.1; m/z found, 349.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.29 (d, J=1.26 Hz, 3H), 3.42 (s, 3H), 5.30 (s, 2H), 7.13-7.29 (m, 1H), 7.41-7.53 (m, 2H), 7.59 (dd, J=7.41, 2.05 Hz, 1H), 7.83 (d, J=1.89 Hz, 1H), 8.31 (d, J=1.89 Hz, 1H), 8.75 (d, J=5.36 Hz, 1H), 9.09 (d, J=1.58 Hz, 1H).</p><heading id="h-0148" level="1">Example 72: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0668" num="0734"><chemistry id="CHEM-US-00199" num="00199"><img id="EMI-C00199" he="29.38mm" wi="54.19mm" file="US20230000833A1-20230105-C00199.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0669" num="0735">The title compound was prepared in a manner analogous to Intermediate 27 using 6-bromo-3-methyl-1-(pyrimidin-4-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 20) and 2-(2,4-difluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate 8). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O, 367.1; m/z found, 368.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 2.20 (s, 3H), 3.37-3.61 (m, 3H), 5.28 (s, 2H), 7.16 (t, J=8.79 Hz, 1H), 7.38 (td, J=8.67, 6.70 Hz, 1H), 7.47 (dd, J=5.32, 1.39 Hz, 1H), 7.65 (t, J=1.62 Hz, 1H), 8.15 (t, J=1.62 Hz, 1H), 8.75 (d, J=5.32 Hz, 1H), 9.08 (d, J=1.39 Hz, 1H).</p><heading id="h-0149" level="1">Example 73: 6-(3,4-Difluorophenyl)-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0670" num="0736"><chemistry id="CHEM-US-00200" num="00200"><img id="EMI-C00200" he="32.68mm" wi="53.42mm" file="US20230000833A1-20230105-C00200.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0671" num="0737">The title compound was prepared in a manner analogous to Example 8 using 6-bromo-3-methyl-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 23) in Step A and 4-bromo-1,2-difluorobenzene in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>, 357.1; m/z found, 358 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.23 (d, J=0.9 Hz, 1H), 7.43 (s, 1H), 7.37-7.29 (m, 1H), 7.25-7.20 (m, 2H), 5.33 (s, 2H), 3.56 (s, 3H), 2.52 (s, 3H).</p><heading id="h-0150" level="1">Example 74: 3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0672" num="0738"><chemistry id="CHEM-US-00201" num="00201"><img id="EMI-C00201" he="31.33mm" wi="49.02mm" file="US20230000833A1-20230105-C00201.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0673" num="0739">The title compound was prepared in a manner analogous to Example 8, Step B using 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 22) and (3-(trifluoromethyl)phenyl)boronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 388.1; m/z found, 389 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.26 (d, J=1.5 Hz, 1H), 7.74 (s, 1H), 7.72-7.52 (m, 3H), 7.46 (d, J=1.6 Hz, 1H), 6.04 (s, 1H), 5.15 (s, 2H), 3.56 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0151" level="1">Example 75: 3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0674" num="0740"><chemistry id="CHEM-US-00202" num="00202"><img id="EMI-C00202" he="31.33mm" wi="49.02mm" file="US20230000833A1-20230105-C00202.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0675" num="0741">The title compound was prepared in a manner analogous to Example 8, Step B, using 6-bromo-3-methyl-14(5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 23) and (3-(trifluoromethyl)phenyl)boronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 389.1; m/z found, 390 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.29 (d, J=1.3 Hz, 1H), 7.75 (s, 1H), 7.73-7.54 (m, 3H), 7.49 (d, J=1.3 Hz, 1H), 5.35 (s, 2H), 3.57 (s, 3H), 2.52 (s, 3H).</p><heading id="h-0152" level="1">Example 76: 3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0676" num="0742"><chemistry id="CHEM-US-00203" num="00203"><img id="EMI-C00203" he="31.33mm" wi="51.48mm" file="US20230000833A1-20230105-C00203.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0677" num="0743">The title compound was prepared in a manner analogous to Example 8, Step B using: 6-bromo-3-methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 24) and (3-(trifluoromethyl)phenyl)boronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 389.1; m/z found, 390 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.31 (d, J=1.3 Hz, 1H), 7.75 (s, 1H), 7.71 (d, J=7.5 Hz, 1H), 7.68-7.55 (m, 2H), 7.37 (d, J=1.3 Hz, 1H), 5.35 (s, 2H), 3.58 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0153" level="1">Example 77: 6-(3,4-Difluorophenyl)-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0678" num="0744"><chemistry id="CHEM-US-00204" num="00204"><img id="EMI-C00204" he="30.65mm" wi="56.98mm" file="US20230000833A1-20230105-C00204.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0679" num="0745">The title compound was prepared in a manner analogous to Example 8, using Intermediate 24: 6-bromo-3-methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one in Step A, and 4-bromo-1,2-difluorobenzene in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>, 357.1; m/z found, 358.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.28 (d, J=1.4 Hz, 1H), 7.40-7.34 (m, 1H), 7.33 (d, J=1.2 Hz, 1H), 7.29 (s, 1H), 7.28 (d, J=1.9 Hz, 1H), 5.37 (s, 2H), 3.60 (s, 3H), 2.41 (s, 3H).</p><heading id="h-0154" level="1">Example 78: N,N-Dimethyl-2-[3-methyl-6-(5-methyl-2-thienyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0680" num="0746"><chemistry id="CHEM-US-00205" num="00205"><img id="EMI-C00205" he="34.21mm" wi="44.53mm" file="US20230000833A1-20230105-C00205.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0681" num="0747">The title compound was prepared in a manner analogous to Example 9, using 5-methylthiophene-2-boronic acid. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S, 330.1; m/z found, 331.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.31-8.25 (d, J=1.9 Hz, 1H), 7.34-7.32 (d, J=1.8 Hz, 1H), 7.09-7.04 (d, J=1.5 Hz, 1H), 6.88-6.84 (m, 1H), 4.75-4.66 (s, 2H), 3.55-3.49 (s, 3H), 3.20-3.13 (s, 3H), 3.03-2.96 (s, 3H), 2.32-2.24 (d, J=1.1 Hz, 3H).</p><heading id="h-0155" level="1">Example 79: 2-[6-(5-Ethyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-0682" num="0748"><chemistry id="CHEM-US-00206" num="00206"><img id="EMI-C00206" he="34.21mm" wi="47.92mm" file="US20230000833A1-20230105-C00206.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0683" num="0749">The title compound was prepared in a manner analogous to Example 9, using 5-ethylthiophene-2-boronic acid. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S, 344.1; m/z found, 345.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.27-8.24 (d, J=1.8 Hz, 1H), 7.32-7.29 (d, J=1.9 Hz, 1H), 7.07-7.03 (d, J=3.5 Hz, 1H), 6.77-6.73 (m, 1H), 4.71-4.68 (s, 2H), 3.55-3.48 (s, 3H), 3.19-3.13 (s, 3H), 3.01-2.96 (s, 3H), 2.90-2.81 (m, 2H), 1.37-1.30 (m, 3H).</p><heading id="h-0156" level="1">Example 80: N,N-Dimethyl-2-[3-methyl-6-(4-methyl-2-thienyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0684" num="0750"><chemistry id="CHEM-US-00207" num="00207"><img id="EMI-C00207" he="34.21mm" wi="39.03mm" file="US20230000833A1-20230105-C00207.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0685" num="0751">The title compound was prepared in a manner analogous to Example 9, using 4,4,5,5-tetramethyl-2-(4-methylthiophen-2-yl)-1,3,2-dioxaborolane and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S, 330.1; m/z found, 331.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 67  8.30-8.27 (d, J=1.9 Hz, 1H), 7.35-7.31 (d, J=1.9 Hz, 1H), 7.08-7.04 (d, J=1.4 Hz, 1H), 6.88-6.84 (m, 1H), 4.76-4.66 (s, 2H), 3.55-3.49 (s, 3H), 3.20-3.14 (s, 3H), 3.04-2.96 (s, 3H), 2.33-2.25 (d, J=1.1 Hz, 3H).</p><heading id="h-0157" level="1">Example 81: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-fluoro-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0686" num="0752"><chemistry id="CHEM-US-00208" num="00208"><img id="EMI-C00208" he="36.32mm" wi="45.13mm" file="US20230000833A1-20230105-C00208.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0687" num="0753">The title compound was prepared in a manner analogous to Example 9, using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16) and 2-(5-fluoro-2-thienyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>2</sub>S, 346.1; m/z found, 346.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.19-8.17 (d, J=1.9 Hz, 1H), 7.36-7.33 (d, J=1.9 Hz, 1H), 6.85-6.82 (m, 1H), 6.48-6.45 (m, 1H), 4.50-4.45 (s, 2H), 4.35-4.28 (m, 2H), 4.12-4.06 (m, 2H), 3.53-3.50 (s, 3H), 2.41-2.31 (m, 2H).</p><heading id="h-0158" level="1">Example 82: 2-[6-(5-Fluoro-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-0688" num="0754"><chemistry id="CHEM-US-00209" num="00209"><img id="EMI-C00209" he="34.21mm" wi="45.13mm" file="US20230000833A1-20230105-C00209.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0689" num="0755">The title compound was prepared in a manner analogous to Example 9, using 2-(5-fluoro-2-thienyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>15</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>2</sub>S, 334.1; m/z found, 334.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.19-8.17 (d, J=1.9 Hz, 1H), 7.25-7.24 (d, J=1.9 Hz, 1H), 6.84-6.81 (m, 1H), 6.47-6.44 (dd, J=4.1, 1.9 Hz, 1H), 4.72-4.69 (s, 2H), 3.53-3.50 (s, 3H), 3.19-3.15 (s, 3H), 3.02-2.97 (s, 3H).</p><heading id="h-0159" level="1">Example 83: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(5-fluoro-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0690" num="0756"><chemistry id="CHEM-US-00210" num="00210"><img id="EMI-C00210" he="41.91mm" wi="45.64mm" file="US20230000833A1-20230105-C00210.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0691" num="0757">The title compound was prepared in a manner analogous to Example 9, using 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18) and 2-(5-fluoro-2-thienyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, 364.1; m/z found, 364.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.21-8.19 (d, J=1.9 Hz, 1H), 7.35-7.32 (d, J=1.9 Hz, 1H), 6.86-6.83 (m, 1H), 6.48-6.45 (m, 1H), 5.45-5.27 (m, 1H), 4.66-4.11 (m, 6H), 3.52-3.51 (s, 3H).</p><heading id="h-0160" level="1">Example 84: 3-Methyl-1-(pyridazin-3-ylmethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0692" num="0758"><chemistry id="CHEM-US-00211" num="00211"><img id="EMI-C00211" he="27.86mm" wi="56.22mm" file="US20230000833A1-20230105-C00211.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0693" num="0759">The title compound was prepared in a manner analogous to Example 9, using 6-bromo-3-methyl-1-(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 19) and (5-(trifluoromethyl)thiophen-2-yl)boronic acid. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>OS, 391.1; m/z found, 391.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 9.20-9.12 (d, J=4.6 Hz, 1H), 8.32-8.27 (d, J=1.4 Hz, 1H), 7.67-7.62 (d, J=8.3 Hz, 1H), 7.57-7.53 (d, J=1.9 Hz, 1H), 7.53-7.46 (m, 1H), 7.43-7.39 (s, 1H), 7.21-7.13 (s, 1H), 5.46-5.41 (s, 2H), 3.58-3.51 (s, 3H).</p><heading id="h-0161" level="1">Example 85: 6-(5-Fluoro-2-thienyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0694" num="0760"><chemistry id="CHEM-US-00212" num="00212"><img id="EMI-C00212" he="28.62mm" wi="53.00mm" file="US20230000833A1-20230105-C00212.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0695" num="0761">The title compound was prepared in a manner analogous to Example 9, using 6-bromo-3-methyl-1-(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 19) and 2-(5-fluoro-2-thienyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>FN<sub>5</sub>OS, 341.1; m/z found, 341.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 9.18-9.12 (m, 1H), 8.19-8.12 (d, J=1.9 Hz, 1H), 7.66-7.58 (dd, J=8.5, 1.7 Hz, 1H), 7.51-7.46 (dd, J=8.5, 4.9 Hz, 1H), 7.46-7.42 (d, J=1.9 Hz, 1H), 6.83-6.79 (m, 1H), 6.48-6.42 (m, 1H), 5.47-5.39 (s, 2H), 3.56-3.51 (s, 3H).</p><heading id="h-0162" level="1">Example 86: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(4-methylthiazol-2-yl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0696" num="0762"><chemistry id="CHEM-US-00213" num="00213"><img id="EMI-C00213" he="41.99mm" wi="39.54mm" file="US20230000833A1-20230105-C00213.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0697" num="0763">The title compound was prepared in a manner analogous to Example 9, using 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18) and 4-methylthiazol-2yl boronic acid pinacol ester. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>FN<sub>5</sub>O<sub>2</sub>S, 361.1; m/z found, 361.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.59-8.56 (d, J=1.8 Hz, 1H), 7.86-7.80 (d, J=1.8 Hz, 1H), 6.91-6.84 (m, 1H), 5.46-5.26 (m, 1H), 4.65-4.11 (m, 6H), 3.56-3.51 (s, 3H), 2.54-2.46 (d, J=1.0 Hz, 3H).</p><heading id="h-0163" level="1">Example 87: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-ethyl-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0698" num="0764"><chemistry id="CHEM-US-00214" num="00214"><img id="EMI-C00214" he="36.41mm" wi="48.43mm" file="US20230000833A1-20230105-C00214.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0699" num="0765">The title compound was prepared in a manner analogous to Example 9, using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16) and 5-ethylthiophene-2-boronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S, 356.1; m/z found, 356.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.28-8.25 (d, J=1.9 Hz, 1H), 7.42-7.38 (d, J=1.9 Hz, 1H), 7.09-7.05 (d, J=3.5 Hz, 1H), 6.78-6.74 (m, 1H), 4.51-4.44 (s, 2H), 4.32-4.25 (m, 2H), 4.13-4.04 (m, 2H), 3.53-3.49 (s, 3H), 2.90-2.82 (m, 2H), 2.39-2.29 (m, 2H), 1.36-1.30 (m, 3H).</p><heading id="h-0164" level="1">Example 88: 6-(5-Ethyl-2-thienyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0700" num="0766"><chemistry id="CHEM-US-00215" num="00215"><img id="EMI-C00215" he="41.99mm" wi="48.94mm" file="US20230000833A1-20230105-C00215.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0701" num="0767">The title compound was prepared in a manner analogous to Example 9, using 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18) and 5-ethylthiophene-2-boronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>S, 374.1; m/z found, 374.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.31-8.26 (d, J=1.9 Hz, 1H), 7.41-7.36 (d, J=1.9 Hz, 1H), 7.10-7.05 (d, J=3.5 Hz, 1H), 6.79-6.72 (m, 1H), 5.43-5.22 (m, 1H), 4.64-4.09 (m, 6H), 3.52-3.50 (s, 3H), 2.90-2.81 (m, 2H), 1.36-1.29 (t, J=7.5 Hz, 3H).</p><heading id="h-0165" level="1">Example 89: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(hydroxymethyl)-2-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0702" num="0768"><chemistry id="CHEM-US-00216" num="00216"><img id="EMI-C00216" he="36.41mm" wi="51.05mm" file="US20230000833A1-20230105-C00216.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0703" num="0769">The title compound was prepared in a manner analogous to Example 9, using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16) and (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-2-yl)methanol. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>S, 358.1; m/z found, 358.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.28-8.25 (d, J=1.9 Hz, 1H), 7.74-7.71 (d, J=2.0 Hz, 1H), 7.33-7.30 (d, J=3.6 Hz, 1H), 6.99-6.96 (m, 1H), 5.55-5.49 (m, 1H), 4.66-4.62 (m, 2H), 4.62-4.56 (s, 2H), 4.33-4.26 (m, 2H), 3.95-3.88 (m, 2H), 3.38-3.35 (s, 3H), 2.36-2.23 (m, 2H).</p><heading id="h-0166" level="1">Example 90: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-(hydroxymethyl)-2-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0704" num="0770"><chemistry id="CHEM-US-00217" num="00217"><img id="EMI-C00217" he="41.99mm" wi="51.48mm" file="US20230000833A1-20230105-C00217.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0705" num="0771">The title compound was prepared in a manner analogous to Example 9, using 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18) and (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-2-yl)methanol. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>3</sub>S, 376.1; m/z found, 376.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.28-8.26 (d, J=1.9 Hz, 1H), 7.73-7.70 (d, J=2.0 Hz, 1H), 7.33-7.29 (d, J=3.6 Hz, 1H), 6.98-6.96 (m, 1H), 5.58-5.37 (m, 2H), 4.70-4.58 (m, 5H), 4.48-4.34 (m, 1H), 4.32-4.20 (m, 1H), 4.04-3.90 (m, 1H), 3.39-3.35 (s, 3H).</p><heading id="h-0167" level="1">Example 91: 2-[6-[5-(Hydroxymethyl)-2-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-0706" num="0772"><chemistry id="CHEM-US-00218" num="00218"><img id="EMI-C00218" he="34.29mm" wi="51.05mm" file="US20230000833A1-20230105-C00218.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0707" num="0773">The title compound was prepared in a manner analogous to Example 9, using (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-2-yl)methanol and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>S, 346.1; m/z found, 347.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.28-8.24 (d, J=1.9 Hz, 1H), 7.75-7.71 (d, J=2.0 Hz, 1H), 7.32-7.27 (d, J=3.6 Hz, 1H), 6.99-6.94 (d, J=3.6 Hz, 1H), 5.54-5.48 (t, J=5.7 Hz, 1H), 4.87-4.80 (s, 2H), 4.68-4.59 (m, 2H), 3.40-3.34 (s, 3H), 3.15-3.06 (s, 3H), 2.89-2.81 (s, 3H).</p><heading id="h-0168" level="1">Example 92: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0708" num="0774"><chemistry id="CHEM-US-00219" num="00219"><img id="EMI-C00219" he="41.99mm" wi="39.54mm" file="US20230000833A1-20230105-C00219.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0709" num="0775">The title compound was prepared in a manner analogous to Example 10, using 3-bromo-2-(trifluoromethyl)thiophene and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 414.1; m/z found, 414.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.17-8.11 (d, J=1.9 Hz, 1H), 7.53-7.50 (d, J=5.1 Hz, 1H), 7.36-7.32 (d, J=1.9 Hz, 1H), 7.12-7.08 (dd, J=4.5, 1.7 Hz, 1H), 5.44-5.26 (m, 1H), 4.64-4.11 (m, 6H), 3.58-3.51 (s, 3H).</p><heading id="h-0169" level="1">Example 93: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(difluoromethyl)-2-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0710" num="0776"><chemistry id="CHEM-US-00220" num="00220"><img id="EMI-C00220" he="36.41mm" wi="48.43mm" file="US20230000833A1-20230105-C00220.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0711" num="0777">The title compound was prepared in a manner analogous to Example 10 using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, 378.1; m/z found, 378.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.33-8.27 (d, J=2.0 Hz, 1H), 7.47-7.40 (d, J=2.1 Hz, 1H), 7.26-7.24 (m, 1H), 7.21-7.15 (m, 1H), 6.96-6.68 (t, J=56.1 Hz, 1H), 4.53-4.43 (s, 2H), 4.38-4.25 (m, 2H), 4.12-4.05 (m, 2H), 3.55-3.50 (s, 3H), 2.43-2.26 (m, 2H).</p><heading id="h-0170" level="1">Example 94: 2-[6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-0712" num="0778"><chemistry id="CHEM-US-00221" num="00221"><img id="EMI-C00221" he="34.80mm" wi="48.94mm" file="US20230000833A1-20230105-C00221.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0713" num="0779">The title compound was prepared in a manner analogous to Example 10 using 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, 366.1; m/z found, 366.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.33-8.28 (d, J=1.9 Hz, 1H), 7.35-7.31 (d, J=1.9 Hz, 1H), 7.26-7.24 (m, 1H), 7.18-7.15 (m, 1H), 6.95-6.70 (m, 1H), 4.75-4.68 (s, 2H), 3.56-3.50 (s, 3H), 3.20-3.14 (s, 3H), 3.02-2.96 (s, 3H).</p><heading id="h-0171" level="1">Example 95: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0714" num="0780"><chemistry id="CHEM-US-00222" num="00222"><img id="EMI-C00222" he="36.91mm" wi="39.03mm" file="US20230000833A1-20230105-C00222.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0715" num="0781">The title compound was prepared in a manner analogous to Example 10 using 3-bromo-2-(trifluoromethyl)thiophene and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 396.1; m/z found, 396.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.15-8.10(d, J=1.8 Hz, 1H), 7.52-7.49 (d, J=5.1 Hz, 1H), 7.36-7.32 (d, J=1.8 Hz, 1H), 7.12-7.08 (m, 1H), 4.50-4.43 (s, 2H), 4.33-4.27 (m, 2H), 4.11-4.04 (m, 2H), 3.56-3.51 (s, 3H), 2.39-2.29 (m, 2H).</p><heading id="h-0172" level="1">Example 96: N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0716" num="0782"><chemistry id="CHEM-US-00223" num="00223"><img id="EMI-C00223" he="34.80mm" wi="39.03mm" file="US20230000833A1-20230105-C00223.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0717" num="0783">The title compound was prepared in a manner andalogous to Example 10, using 3-Bromo-2-(trifluoromethyl)thiophene and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 384.1; m/z found, 384.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.14-8.09 (d, J=1.8 Hz, 1H), 7.52-7.48 (d, J=5.1 Hz, 1H), 7.26-7.25 (d, J=2.2 Hz, 1H), 7.12-7.07 (m, 1H), 4.73-4.68 (s, 2H), 3.57-3.51 (s, 3H), 3.18-3.13 (s, 3H), 3.00-2.94 (s, 3H).</p><heading id="h-0173" level="1">Example 97: 2-[6-[5-(Difluoromethyl)-3-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-0718" num="0784"><chemistry id="CHEM-US-00224" num="00224"><img id="EMI-C00224" he="34.88mm" wi="44.62mm" file="US20230000833A1-20230105-C00224.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0719" num="0785">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(difluoromethyl)-thiophene and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, 366.1; m/z found, 366.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.27-8.26 (d, J=1.8 Hz, 1H), 7.52-7.50 (m, 2H), 7.35-7.34 (d, J=1.9 Hz, 1H), 6.99-6.75 (t, J=56.1 Hz, 1H), 4.74-4.71 (s, 2H), 3.55-3.52 (s, 3H), 3.19-3.16 (s, 3H), 3.01-2.98 (s, 3H).</p><heading id="h-0174" level="1">Example 98: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(difluoromethyl)-3-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0720" num="0786"><chemistry id="CHEM-US-00225" num="00225"><img id="EMI-C00225" he="37.00mm" wi="44.62mm" file="US20230000833A1-20230105-C00225.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0721" num="0787">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(difluoromethyl)-thiophene and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, 378.1; m/z found, 378.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.28-8.27 (d, J=1.8 Hz, 1H), 7.55-7.51 (m, 2H), 7.45-7.43 (d, J=1.8 Hz, 1H), 7.02-6.72 (m, 1H), 4.52-4.47 (s, 2H), 4.36-4.29 (m, 2H), 4.12-4.05 (m, 2H), 3.54-3.51 (s, 3H), 2.41-2.30 (m, 2H).</p><heading id="h-0175" level="1">Example 99: 6-[5-(Difluoromethyl)-3-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0722" num="0788"><chemistry id="CHEM-US-00226" num="00226"><img id="EMI-C00226" he="42.59mm" wi="44.62mm" file="US20230000833A1-20230105-C00226.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0723" num="0789">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(difluoromethyl)-thiophene and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 396.1; m/z found, 369.9 [M+H<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.30-8.28 (d, J=1.7 Hz, 1H), 7.54-7.51 (m, 2H), 7.44-7.42 (d, J=1.8 Hz, 1H), 7.03-6.71 (m, 1H), 5.46-5.25 (d, J=56.3 Hz, 1H), 4.70-4.10 (m, 6H), 3.56-3.51 (s, 3H).</p><heading id="h-0176" level="1">Example 100: 6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0724" num="0790"><chemistry id="CHEM-US-00227" num="00227"><img id="EMI-C00227" he="28.62mm" wi="56.56mm" file="US20230000833A1-20230105-C00227.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0725" num="0791">The title compound was prepared in a manner analogous to Example 10, using 6-bromo-3-methyl-1-(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 19). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>OS, 373.1; m/z found, 373.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 9.18-9.13 (m, 1H), 8.31-8.28 (d, J=1.9 Hz, 1H), 7.66-7.62 (m, 1H), 7.55-7.53 (d, J=1.9 Hz, 1H), 7.51-7.47 (m, 1H), 7.26-7.23 (m, 1H), 7.18-7.15 (m, 1H), 6.98-6.67 (m, 1H), 5.45-5.42 (s, 2H), 3.56-3.53 (s, 3H).</p><heading id="h-0177" level="1">Example 101: N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0726" num="0792"><chemistry id="CHEM-US-00228" num="00228"><img id="EMI-C00228" he="34.88mm" wi="41.49mm" file="US20230000833A1-20230105-C00228.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0727" num="0793">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(trifluoromethyl)thiophene and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 384.1; m/z found, 384.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.27-8.25 (d, J=1.8 Hz, 1H), 7.67-7.64 (m, 1H), 7.56-7.53 (d, J=1.6 Hz, 1H), 7.35-7.32 (d, J=1.9 Hz, 1H), 4.75-4.72 (s, 2H), 3.55-3.53 (s, 3H), 3.19-3.17 (s, 3H), 3.01-2.98 (s, 3H).</p><heading id="h-0178" level="1">Example 102: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0728" num="0794"><chemistry id="CHEM-US-00229" num="00229"><img id="EMI-C00229" he="42.50mm" wi="41.99mm" file="US20230000833A1-20230105-C00229.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0729" num="0795">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(trifluoromethyl)thiophene and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 414.1; m/z found, 441.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.29-8.27 (d, J=1.8 Hz, 1H), 7.68-7.66 (m, 1H), 7.57-7.55 (d, J=1.6 Hz, 1H), 7.44-7.41 (d, J=1.9 Hz, 1H), 5.45-5.26 (m, 1H), 4.68-4.10 (m, 6H), 3.54-3.53 (s, 3H).</p><heading id="h-0179" level="1">Example 103: 3-Methyl-1-(pyridazin-3-ylmethyl)-6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0730" num="0796"><chemistry id="CHEM-US-00230" num="00230"><img id="EMI-C00230" he="28.87mm" wi="50.04mm" file="US20230000833A1-20230105-C00230.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0731" num="0797">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(trifluoromethyl)thiophene and 6-bromo-3-methyl-1-(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 19). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>OS, 391.1; m/z found, 391.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 9.17-9.13 (m, 1H), 8.28-8.23 (d, J=1.9 Hz, 1H), 7.68-7.65 (m, 1H), 7.65-7.63 (m, 1H), 7.55-7.53 (m, 2H), 7.51-7.48 (m, 1H), 5.48-5.41 (s, 2H), 3.61-3.53 (s, 3H).</p><heading id="h-0180" level="1">Example 104: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0732" num="0798"><chemistry id="CHEM-US-00231" num="00231"><img id="EMI-C00231" he="36.91mm" wi="41.99mm" file="US20230000833A1-20230105-C00231.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0733" num="0799">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(trifluoromethyl)thiophene and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 396.1; m/z found, 397.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.31-8.20 (s, 1H), 7.71-7.63 (s, 1H), 7.59-7.52 (s, 1H), 7.49-7.41 (s, 1H), 4.58-4.42 (s, 2H), 4.40-4.26 (m, 2H), 4.18-4.01 (m, 2H), 3.73-3.38 (s, 3H), 2.45-2.27 (m, 2H).</p><heading id="h-0181" level="1">Example 105: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-cyclopropyl-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0734" num="0800"><chemistry id="CHEM-US-00232" num="00232"><img id="EMI-C00232" he="37.00mm" wi="49.78mm" file="US20230000833A1-20230105-C00232.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0735" num="0801">The title compound was prepared in a manner analogous to Example 10, using 2-bromo-5-(cyclopropyl)thiophene and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S, 368.1; m/z found, 369.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.26-8.23 (d, J=1.8 Hz, 1H), 7.39-7.37 (d, J=1.9 Hz, 1H), 7.05-7.01 (d, J=3.6 Hz, 1H), 6.75-6.71 (m, 1H), 4.50-4.44 (s, 2H), 4.32-4.24 (m, 2H), 4.12-4.05 (m, 2H), 3.52-3.49 (s, 3H), 2.38-2.28 (m, 2H), 2.12-2.04 (m, 1H), 1.05-0.97 (m, 2H), 0.80-0.72 (m, 2H).</p><heading id="h-0182" level="1">Example 106: 6-(5-Cyclopropyl-2-thienyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0736" num="0802"><chemistry id="CHEM-US-00233" num="00233"><img id="EMI-C00233" he="42.59mm" wi="49.78mm" file="US20230000833A1-20230105-C00233.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0737" num="0803">The title compound was prepared in a manner analogous to Example 10, using 2-bromo-5-(cyclopropyl)thiophene and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>S, 386.1; m/z found, 387.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.28-8.24 (d, J=1.9 Hz, 1H), 7.39-7.34 (d, J=1.9 Hz, 1H), 7.06-7.00 (d, J=3.6 Hz, 1H), 6.76-6.71 (m, 1H), 5.43-5.26 (m, 1H), 4.62-4.11 (m, 6H), 3.55-3.47 (s, 3H), 2.14-2.03 (m, 1H), 1.04-0.98 (m, 2H), 0.79-0.74 (m, 2H).</p><heading id="h-0183" level="1">Example 107: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0738" num="0804"><chemistry id="CHEM-US-00234" num="00234"><img id="EMI-C00234" he="36.91mm" wi="41.99mm" file="US20230000833A1-20230105-C00234.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0739" num="0805">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(trifluoromethyl)-1,3-thiazole and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S, 397.1; m/z found, 397.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.58-8.55 (d, J=1.8 Hz, 1H), 7.83-7.79 (d, J=1.9 Hz, 1H), 7.71-7.67 (s, 1H), 4.54-4.49 (s, 2H), 4.38-4.29 (m, 2H), 4.11-4.05 (m, 2H), 3.55-3.52 (s, 3H), 2.43-2.31 (m, 2H).</p><heading id="h-0184" level="1">Example 108: N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0740" num="0806"><chemistry id="CHEM-US-00235" num="00235"><img id="EMI-C00235" he="34.80mm" wi="41.99mm" file="US20230000833A1-20230105-C00235.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0741" num="0807">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(trifluoromethyl)-1,3-thiazole and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>15</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S, 385.1; m/z found, 385.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.56-8.51 (d, J=1.8 Hz, 1H), 7.76-7.70 (d, J=1.8 Hz, 1H), 7.70-7.66 (s, 1H), 4.78-4.72 (s, 2H), 3.56-3.51 (s, 3H), 3.19-3.15 (s, 3H), 3.01-2.96 (s, 3H).</p><heading id="h-0185" level="1">Example 109: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0742" num="0808"><chemistry id="CHEM-US-00236" num="00236"><img id="EMI-C00236" he="42.50mm" wi="41.99mm" file="US20230000833A1-20230105-C00236.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0743" num="0809">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(trifluoromethyl)-1,3-thiazole and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>4</sub>N<sub>5</sub>O<sub>2</sub>S, 415.1; m/z found, 415.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.59-8.55 (d, J=1.8 Hz, 1H), 7.84-7.79 (d, J=1.8 Hz, 1H), 7.73-7.68 (s, 1H), 5.46-5.29 (m, 1H), 4.67-4.11 (m, 6H), 3.56-3.51 (s, 3H).</p><heading id="h-0186" level="1">Example 110: 2-[6-(5-Cyclopropyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-0744" num="0810"><chemistry id="CHEM-US-00237" num="00237"><img id="EMI-C00237" he="34.80mm" wi="49.95mm" file="US20230000833A1-20230105-C00237.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0745" num="0811">The title compound was prepared in a manner analogous to Example 10, using 2-bromo-5-(cyclopropyl)thiophene and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S, 356.1; m/z found, 356.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.26-8.22 (d, J=1.8 Hz, 1H), 7.31-7.28 (d, J=1.9 Hz, 1H), 7.03-6.99 (d, J=3.6 Hz, 1H), 6.75-6.70 (m, 1H), 4.72-4.67 (s, 2H), 3.53-3.50 (s, 3H), 3.18-3.14 (s, 3H), 3.00-2.96 (s, 3H), 2.12-2.03 (m, 1H), 1.03-0.97 (m, 2H), 0.78-0.73 (m, 2H).</p><heading id="h-0187" level="1">Example 111: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(1,1,2,2,2-pentafluoroethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0746" num="0812"><chemistry id="CHEM-US-00238" num="00238"><img id="EMI-C00238" he="36.91mm" wi="51.48mm" file="US20230000833A1-20230105-C00238.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0747" num="0813">The title compound was prepared in a manner analogous to Example 10, using 2-bromo-5-pentafluoroethyl-thiophene and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>S, 446.1; m/z found,446.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.32-8.29 (d, J=1.9 Hz, 1H), 7.46-7.43 (d, J=1.9 Hz, 1H), 7.42-7.39 (m, 1H), 7.26-7.22 (m, 1H), 4.52-4.46 (s, 2H), 4.37-4.31 (m, 2H), 4.12-4.06 (m, 2H), 3.56-3.50 (s, 3H), 2.43-2.31 (m, 2H).</p><heading id="h-0188" level="1">Example 112: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(2-methylthiazol-5-yl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0748" num="0814"><chemistry id="CHEM-US-00239" num="00239"><img id="EMI-C00239" he="36.91mm" wi="44.37mm" file="US20230000833A1-20230105-C00239.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0749" num="0815">The title compound was prepared in a manner analogous to Example 10, using 5-bromo-2-methylthiazole and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>S, 343.1; m/z found, 343.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.23-8.17 (d, J=2.0 Hz, 1H), 7.77-7.71 (s, 1H), 7.41-7.35 (d, J=2.0 Hz, 1H), 4.52-4.41 (s, 2H), 4.39-4.28 (m, 2H), 4.15-4.03 (m, 2H), 3.58-3.47 (s, 3H), 2.81-2.64 (s, 3H), 2.44-2.30 (m, 2H).</p><heading id="h-0189" level="1">Example 113: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(2-methylthiazol-5-yl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0750" num="0816"><chemistry id="CHEM-US-00240" num="00240"><img id="EMI-C00240" he="42.50mm" wi="44.37mm" file="US20230000833A1-20230105-C00240.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0751" num="0817">The title compound was prepared in a manner analogous to Example 10, using 5-bromo-2-methylthiazole and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>FN<sub>5</sub>O<sub>2</sub>S, 361.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.24-8.17 (d, J=1.9 Hz, 1H), 7.76-7.72 (s, 1H), 7.39-7.36 (d, J=1.9 Hz, 1H), 5.48-5.23 (m, 1H), 4.68-4.08 (m, 6H), 3.56-3.48 (s, 3H), 2.80-2.71 (s, 3H).</p><heading id="h-0190" level="1">Example 114: N,N-Dimethyl-2-[3-methyl-6-(2-methylthiazol-5-yl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0752" num="0818"><chemistry id="CHEM-US-00241" num="00241"><img id="EMI-C00241" he="34.80mm" wi="44.37mm" file="US20230000833A1-20230105-C00241.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0753" num="0819">The title compound was prepared in a manner analogous to Example 10, using 5-bromo-2-methylthiazole and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>15</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>S, 331.1; m/z found, 332.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.23-8.18 (d, J=1.9 Hz, 1H), 7.75-7.69 (s, 1H), 7.30-7.27 (d, J=1.9 Hz, 1H), 4.76-4.67 (s, 2H), 3.56-3.47 (s, 3H), 3.20-3.12 (s, 3H), 3.04-2.96 (s, 3H), 2.78-2.69 (s, 3H).</p><heading id="h-0191" level="1">Example 115: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethypthiazol-5-yl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0754" num="0820"><chemistry id="CHEM-US-00242" num="00242"><img id="EMI-C00242" he="36.91mm" wi="47.41mm" file="US20230000833A1-20230105-C00242.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0755" num="0821">The title compound was prepared in a manner analogous to Example 10, using 5-bromo-2-(trifluoromethyl)thiazole and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S, 397.1; m/z found, 397.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.29-8.25 (d, J=1.9 Hz, 1H), 8.04-8.01 (m, 1H), 7.46-7.43 (d, J=2.0 Hz, 1H), 4.52-4.45 (s, 2H), 4.40-4.31 (m, 2H), 4.14-4.04 (m, 2H), 3.58-3.46 (s, 3H), 2.45-2.30 (m, 2H).</p><heading id="h-0192" level="1">Example 116: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-5-yl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0756" num="0822"><chemistry id="CHEM-US-00243" num="00243"><img id="EMI-C00243" he="42.50mm" wi="47.41mm" file="US20230000833A1-20230105-C00243.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0757" num="0823">The title compound was prepared in a manner analogous to Example 10, using 5-bromo-2-(trifluoromethyl)thiazole and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>4</sub>N<sub>5</sub>O<sub>2</sub>S, 415.1; m/z found, 415.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.31-8.28 (d, J=1.9 Hz, 1H), 8.05-8.01 (m, 1H), 7.46-7.41 (d, J=1.9 Hz, 1H), 5.48-5.26 (m, 1H), 4.71-4.08 (m, 6H), 3.57-3.50 (s, 3H).</p><heading id="h-0193" level="1">Example 117: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-(difluoromethyl)-2-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0758" num="0824"><chemistry id="CHEM-US-00244" num="00244"><img id="EMI-C00244" he="37.00mm" wi="44.62mm" file="US20230000833A1-20230105-C00244.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0759" num="0825">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(difluoromethyl)-thiophene and 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 16). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, 378.1; m/z found, 378.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.30-8.28 (d, J=1.9 Hz, 1H), 7.51-7.47 (m, 1H), 7.45-7.41 (d, J=1.9 Hz, 1H), 7.35-7.32 (d, J=1.3 Hz, 1H), 6.81-6.54 (m, 1H), 4.51-4.45 (s, 2H), 4.37-4.29 (m, 2H), 4.13-4.06 (m, 2H), 3.55-3.48 (s, 3H), 2.41-2.30 (m, 2H).</p><heading id="h-0194" level="1">Example 118: 6-[4-(Difluoromethyl)-2-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0760" num="0826"><chemistry id="CHEM-US-00245" num="00245"><img id="EMI-C00245" he="42.50mm" wi="44.62mm" file="US20230000833A1-20230105-C00245.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0761" num="0827">The title compound was prepared in a manner analogous to Example 10, using 4-bromo-2-(difluoromethyl)-thiophene and 6-bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 18). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 396.1; m/z found, 396.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.33-8.29 (d, J=1.9 Hz, 1H), 7.52-7.48 (m, 1H), 7.45-7.41 (d, J=1.9 Hz, 1H), 7.36-7.32 (s, 1H), 6.81-6.54 (m, 1H), 5.46-5.26 (m, 1H), 4.68-4.13 (m, 6H), 3.55-3.48 (s, 3H).</p><heading id="h-0195" level="1">Example 119: N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)thiazol-5-yl]imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0762" num="0828"><chemistry id="CHEM-US-00246" num="00246"><img id="EMI-C00246" he="33.61mm" wi="47.41mm" file="US20230000833A1-20230105-C00246.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0763" num="0829">The title compound was prepared in a manner analogous to Example 10, using 5-bromo-2-(trifluoromethyl)thiazole and 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N,N-dimethylacetamide (Intermediate 15). MS (ESI): mass calcd. for C<sub>15</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S, 385.1; m/z found, 385.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.29-8.26 (d, J=1.9 Hz, 1H), 8.03-8.00 (m, 1H), 7.33-7.31 (d, J=1.9 Hz, 1H), 4.76-4.71 (s, 2H), 3.56-3.51 (s, 3H), 3.20-3.16 (s, 3H), 3.02-2.97 (s, 3H).</p><heading id="h-0196" level="1">Example 120: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one-7-D and its Trifluoroacetic Acid Salt</heading><p id="p-0764" num="0830"><chemistry id="CHEM-US-00247" num="00247"><img id="EMI-C00247" he="34.88mm" wi="45.55mm" file="US20230000833A1-20230105-C00247.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0765" num="0831">Step A: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-7-chloro-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Intermediate 26, Step A, using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-7-chloro-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 17) and (5-(trifluoromethyl)thiophen-2-yl)boronic acid, no H<sub>2</sub>O.</p><p id="p-0766" num="0832">Step B: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one-7-D and its trifluoroacetic acid salt. To a solution of 1-(2-(azetidin-1-yl)-2-oxoethyl)-7-chloro-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (7 mg, 0.02 mmol) in a mixture of CD<sub>3</sub>OD (1 mL) and EtOAc (1 mL) was added Pd/C (10% on carbon, dry, 1 mg, 0.0008 mmol) and the reaction mixture was stirred at room temperature under an atmosphere of D2 (99.8 atom % D, 1 atm, balloon). After 1 day, the reaction mixture was filtered through Celite&#xae; and rinsed with EtOAc followed by MeOH. The volatiles were removed to afford the title compound as the free base. The crude material was purified (Method C, using a Sunfire C<sub>18 </sub>OBD column), to give the title compound (4.8 mg, 0.009 mmol, 57%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 397.1; m/z found, 397.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.42 (s, 1H), 7.79-7.76 (m, 1H), 7.61-7.58 (m, 1H), 4.60 (s, 2H), 4.30 (t, J=7.6 Hz, 2H), 3.91 (t, J=7.7 Hz, 2H), 3.38 (s, 3H), 2.34-2.25 (m, 2H).</p><heading id="h-0197" level="1">Example 121: N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-0767" num="0833"><chemistry id="CHEM-US-00248" num="00248"><img id="EMI-C00248" he="34.88mm" wi="53.59mm" file="US20230000833A1-20230105-C00248.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0768" num="0834">Under a nitrogen atmosphere was added 2-[6-[5-(hydroxymethyl)-2-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide (Example 91, 38 mg, 0.11 mmol) to a suspension of NaH (6.5 mg, 0.17 mmol) in DMF (1 mL). After 10 minutes, iodomethane-D<sub>3 </sub>(21 mg, 0.14 mmol) was added to the reaction mixture at room temperature and the reaction was stirred at room temperature for 16 hours. Then, the reaction mixture was quenched with water and extracted with EtOAc (3&#xd7;20 mL). The combined organic layers were dried using MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude material was purified via basic HPLC (Method A) to provide the title compound (19 mg, 47%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>D<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S, 363.1; m/z found, 364.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.32-8.25 (d, J=2.0 Hz, 1H), 7.35-7.30 (d, J=2.0 Hz, 1H), 7.13-7.06 (d, J=3.6 Hz, 1H), 6.98-6.93 (d, J=3.6 Hz, 1H), 4.75-4.65 (s, 2H), 4.63-4.58 (s, 2H), 3.57-3.49 (s, 3H), 3.20-3.14 (s, 3H), 3.02-2.97 (s, 3H).</p><heading id="h-0198" level="1">Example 122: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0769" num="0835"><chemistry id="CHEM-US-00249" num="00249"><img id="EMI-C00249" he="36.91mm" wi="53.59mm" file="US20230000833A1-20230105-C00249.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0770" num="0836">The title compound was prepared in a manner analogous to Example 121 using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-(5-(hydroxymethyl)thiophen-2-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Example 89). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>D<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S, 375.1; m/z found, 376.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.32-8.28 (d, J=1.9 Hz, 1H), 7.44-7.39 (d, J=1.9 Hz, 1H), 7.14-7.09 (d, J=3.6 Hz, 1H), 7.00-6.94 (m, 1H), 4.64-4.57 (d, J=0.8 Hz, 2H), 4.50-4.46 (s, 2H), 4.36-4.26 (m, 2H), 4.14-4.04 (m, 2H), 3.56-3.47 (s, 3H), 2.43-2.27 (m, 2H).</p><heading id="h-0199" level="1">Example 123: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0771" num="0837"><chemistry id="CHEM-US-00250" num="00250"><img id="EMI-C00250" he="42.50mm" wi="53.59mm" file="US20230000833A1-20230105-C00250.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0772" num="0838">The title compound was prepared in a manner analogous to Example 121 using 1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-6-(5-(hydroxymethyl)thiophen-2-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Example 90). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>D<sub>3</sub>FN<sub>4</sub>O<sub>3</sub>S, 393.1; m/z found, 393.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.32-8.29 (d, J=1.9 Hz, 1H), 7.44-7.39 (d, J=1.9 Hz, 1H), 7.15-7.09 (d, J=3.6 Hz, 1H), 7.01-6.95 (m, 1H), 5.44-5.24 (m, 1H), 4.65-4.13 (m, 8H), 3.56-3.48 (s, 3H).</p><heading id="h-0200" level="1">Example 124: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one-7-T and its Trifluoroacetic Acid Salt</heading><p id="p-0773" num="0839"><chemistry id="CHEM-US-00251" num="00251"><img id="EMI-C00251" he="34.88mm" wi="45.55mm" file="US20230000833A1-20230105-C00251.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0774" num="0840">A solution of 1-(2-(azetidin-1-yl)-2-oxoethyl)-7-chloro-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Example 120, product from Step A, 4.3 mg), in DMF (0.3 mL), was added 10% Pd/C (3 mg), DIPEA (0.02 mL). The mixture was stirred under 760 mmHg tritium gas for 90 min. The crude product was dissolved in ethanol and filtered. The labile tritium was removed by under reduced pressure. The process was repeated 2&#xd7; to afford the free base of the title compound. Purification (HPLC-C18 column, mobile phase: Gradient A: 0.1% TFA, B: 100% ACN: A to 100% B in 60 min, flow 6 mL/min, U.V.=241 nm) afforded the title compound.</p><heading id="h-0201" level="1">Example 125: 1-[(5-Methylisoxazol-3-yl)methyl]-6-(4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0775" num="0841"><chemistry id="CHEM-US-00252" num="00252"><img id="EMI-C00252" he="27.86mm" wi="47.75mm" file="US20230000833A1-20230105-C00252.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0776" num="0842">The title compound was made analogous to Example 11, using 4,4,5,5-tetramethyl-2-(4-methylthiophen-2-yl)-1,3,2-dioxaborolane in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>S, 326.1; m/z found, 327.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.79 (s, 1H), 8.25 (d, J=1.9 Hz, 1H), 7.78 (d, J=1.9 Hz, 1H), 7.34 (d, J=1.4 Hz, 1H), 7.14 (p, J=1.1 Hz, 1H), 6.25 (d, J=1.0 Hz, 1H), 5.24 (s, 2H), 2.40 (d, J=1.0 Hz, 3H), 2.26 (d, J=1.1 Hz, 3H).</p><heading id="h-0202" level="1">Example 126: 1-[(5-Methylisoxazol-3-yl)methyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0777" num="0843"><chemistry id="CHEM-US-00253" num="00253"><img id="EMI-C00253" he="27.86mm" wi="48.60mm" file="US20230000833A1-20230105-C00253.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0778" num="0844">The title compound was prepared in a manner analogous to Example 11, using o-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>, 320.1; m/z found, 321.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 9.97 (s, 1H), 8.03 (d, J=1.8 Hz, 1H), 7.32-7.26 (m, 3H), 7.26-7.17 (m, 2H), 6.04 (t, J=0.9 Hz, 1H), 5.10 (s, 2H), 2.38 (d, J=0.9 Hz, 3H), 2.24 (s, 3H).</p><heading id="h-0203" level="1">Example 127: 1-[(3-Methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0779" num="0845"><chemistry id="CHEM-US-00254" num="00254"><img id="EMI-C00254" he="24.98mm" wi="50.12mm" file="US20230000833A1-20230105-C00254.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0780" num="0846">The title compound was prepared in a manner analogous to Example 11, using 5-(chloromethyl)-3-methyl-1,2,4-oxadiazole in Step A and (4-methylthiophen-2-yl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>15</sub>H<sub>13</sub>N<sub>5</sub>O<sub>2</sub>S, 327.1; m/z found, 328.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 9.47 (s, 1H), 8.44-8.24 (m, 1H), 7.43-7.29 (m, 1H), 7.14-7.04 (m, 1H), 6.96-6.84 (m, 1H), 5.31 (s, 2H), 2.39 (s, 3H), 2.30 (s, 3H).</p><heading id="h-0204" level="1">Example 128: 6-(4-Fluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0781" num="0847"><chemistry id="CHEM-US-00255" num="00255"><img id="EMI-C00255" he="24.21mm" wi="56.39mm" file="US20230000833A1-20230105-C00255.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0782" num="0848">The title compound was prepared in a manner analogous to Example 11, using 3-(chloromethyl)-1-methyl-1H-pyrazole in Step A and 4-fluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>FN<sub>5</sub>O, 323.1; m/z found, 324.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.04 (d, J=1.8 Hz, 1H), 7.70 (d, J=1.8 Hz, 1H), 7.52-7.42 (m, 2H), 7.31 (d, J=2.3 Hz, 1H), 7.22-7.14 (m, 2H), 6.27 (d, J=2.3 Hz, 1H), 5.12 (s, 2H), 3.87 (s, 3H).</p><heading id="h-0205" level="1">Example 129: 6-(4-Fluoro-3-methyl-phenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0783" num="0849"><chemistry id="CHEM-US-00256" num="00256"><img id="EMI-C00256" he="27.09mm" wi="56.39mm" file="US20230000833A1-20230105-C00256.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0784" num="0850">The title compound was prepared in a manner analogous to Example 11, using 3-(chloromethyl)-1-methyl-1H-pyrazole in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>FN<sub>5</sub>O, 337.1; m/z found, 338.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.62 (s, 1H), 8.21 (d, J=2.0 Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.67-7.59 (m, 2H), 7.57-7.49 (m, 1H), 7.29-7.19 (m, 1H), 6.23 (d, J=2.2 Hz, 1H), 5.11 (s, 2H), 3.83 (s, 3H), 3.48 (s, 3H).</p><heading id="h-0206" level="1">Example 130: 6-(3-Chloro-4-fluoro-phenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0785" num="0851"><chemistry id="CHEM-US-00257" num="00257"><img id="EMI-C00257" he="28.02mm" wi="56.39mm" file="US20230000833A1-20230105-C00257.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0786" num="0852">The title compound was prepared in a manner analogous to Example 11, using 3-(chloromethyl)-1-methyl-1H-pyrazole in Step A and (3-chloro-4-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>C<sub>1</sub>FN<sub>5</sub>O, 357.1; m/z found, 358.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.70 (s, 1H), 8.28 (d, J=2.0 Hz, 1H), 7.92 (dd, J=7.1, 2.3 Hz, 1H), 7.83 (d, J=2.0 Hz, 1H), 7.77-7.69 (m, 1H), 7.63 (d, J=2.2 Hz, 1H), 7.53 (t, J=9.0 Hz, 1H), 6.24 (d, J=2.2 Hz, 1H), 5.12 (s, 2H), 3.83 (s, 3H).</p><heading id="h-0207" level="1">Example 131: 6-(3,4-Difluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0787" num="0853"><chemistry id="CHEM-US-00258" num="00258"><img id="EMI-C00258" he="27.94mm" wi="56.39mm" file="US20230000833A1-20230105-C00258.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0788" num="0854">The title compound was prepared in a manner analogous to Example 11, using 3-(chloromethyl)-1-methyl-1H-pyrazole in Step A and 3,4-difluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O, 341.1; m/z found, 342.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.69 (s, 1H), 8.28 (d, J=2.0 Hz, 1H), 7.84-7.75 (m, 2H), 7.63 (d, J=2.2 Hz, 1H), 7.60-7.50 (m, 2H), 6.24 (d, J=2.2 Hz, 1H), 5.11 (s, 2H), 3.83 (s, 3H).</p><heading id="h-0208" level="1">Example 132: 6-(2,4-Difluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0789" num="0855"><chemistry id="CHEM-US-00259" num="00259"><img id="EMI-C00259" he="24.21mm" wi="56.39mm" file="US20230000833A1-20230105-C00259.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0790" num="0856">The title compound was prepared in a manner analogous to Example 11, using 3-(chloromethyl)-1-methyl-1H-pyrazole in Step A and 2,4-difluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O, 341.1; m/z found, 342.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.73 (s, 1H), 8.14-8.06 (m, 1H), 7.70-7.59 (m, 3H), 7.42-7.31 (m, 1H), 7.28-7.19 (m, 1H), 6.23 (d, J=2.2 Hz, 1H), 5.09 (s, 2H), 3.83 (s, 3H).</p><heading id="h-0209" level="1">Example 133: (R/S)-3-methyl-1-(oxetan-2-yl methyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0791" num="0857"><chemistry id="CHEM-US-00260" num="00260"><img id="EMI-C00260" he="31.33mm" wi="44.70mm" file="US20230000833A1-20230105-C00260.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0792" num="0858">The title compound was prepared in a manner analogous to Example 11, Step A using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and 2-(bromomethyl)oxetane. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, 364.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.40-8.38(m, 1H), 8.04-7.99 (m, 3H), 7.77-7.70 (m, 2H), 5.10-5.03 (m, 1H), 4.49-4.42 (m, 1H), 4.37-4.31 (m, 1H), 4.27-4.12 (m, 2H), 3.42-3.40 (m, 3H), 2.72-2.61 (m, 1H), 2.51-2.42 (m, 1H overlaps with DMSO).</p><heading id="h-0210" level="1">Example 134: Ethyl 2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetate and its Trifluoroacetic Acid Salt</heading><p id="p-0793" num="0859"><chemistry id="CHEM-US-00261" num="00261"><img id="EMI-C00261" he="32.77mm" wi="39.79mm" file="US20230000833A1-20230105-C00261.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0794" num="0860">The title compound was prepared in a manner analogous to Example 11, Step C using ethyl 2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetate (Intermediate 44, product from Step A). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 365.1; m/z found, 366.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.84 (s, 1H), 8.36 (d, J=2.0 Hz, 1H), 8.04-7.99 (m, 3H), 7.75-7.69 (m, 2H), 4.77 (s, 2H), 4.17 (q, J=7.1 Hz, 2H), 1.22 (t, J=7.1 Hz, 3H).</p><heading id="h-0211" level="1">Example 135: 2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-1D]pyridin-1-yl]acetic Acid and its Trifluoroacetic Acid Salt</heading><p id="p-0795" num="0861"><chemistry id="CHEM-US-00262" num="00262"><img id="EMI-C00262" he="28.62mm" wi="39.79mm" file="US20230000833A1-20230105-C00262.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0796" num="0862">The title compound was prepared in a manner analogous to Example 11, Step C using 2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 44). MS (ESI): mass calcd. for C<sub>15</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 337.1; m/z found, 338.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 13.14 (s, 1H), 11.80 (s, 1H), 8.36 (d, J=2.0 Hz, 1H), 8.05-7.99 (m, 3H), 7.76-7.68 (m, 2H), 4.67 (s, 2H).</p><heading id="h-0212" level="1">Example 136: Ethyl 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetate</heading><p id="p-0797" num="0863"><chemistry id="CHEM-US-00263" num="00263"><img id="EMI-C00263" he="36.83mm" wi="39.79mm" file="US20230000833A1-20230105-C00263.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0798" num="0864">The title compound was prepared in a manner analogous to Example 11, Step A using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and ethyl 2-bromoacetate. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 379.1; m/z found, 380.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.45 (d, J=1.9 Hz, 1H), 8.08 (d, J=2.0 Hz, 1H), 8.06-8.00 (m, 2H), 7.78-7.69 (m, 2H), 4.84 (s, 2H), 4.17 (q, J=7.1 Hz, 2H), 3.41 (s, 3H), 1.22 (t, J=7.1 Hz, 3H).</p><heading id="h-0213" level="1">Example 137: 2-[3-Methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]Acetic Acid and its Trifluoroacetic Acid Salt</heading><p id="p-0799" num="0865"><chemistry id="CHEM-US-00264" num="00264"><img id="EMI-C00264" he="31.33mm" wi="43.52mm" file="US20230000833A1-20230105-C00264.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0800" num="0866">The title compound was prepared in a manner analogous to Intermediate 38, Step A, using ethyl 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetate (Example 136). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 351.1; m/z found, 352.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 13.19 (s, 1H), 8.44 (d, J=1.8 Hz, 1H), 8.09 (d, J=2.0 Hz, 1H), 8.06-8.01 (m, 2H), 7.76-7.69 (m, 2H), 4.73 (s, 2H), 3.42-3.40 (m, 3H).</p><heading id="h-0214" level="1">Example 138: 1-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-0801" num="0867"><chemistry id="CHEM-US-00265" num="00265"><img id="EMI-C00265" he="42.50mm" wi="41.66mm" file="US20230000833A1-20230105-C00265.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0802" num="0868">The title compound was prepared in a manner analogous to Intermediate 38, Step B, using 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetic acid (Example 137). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 426.1; m/z found, 427.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) 6 8.40 (d, J=1.9 Hz, 1H), 8.03-7.95 (m, 2H), 7.88 (d, J=2.0 Hz, 1H), 7.79-7.70 (m, 2H), 4.90-4.73 (m, 4H), 4.38 (t, J=12.5 Hz, 2H), 3.41 (s, 3H).</p><heading id="h-0215" level="1">Example 139: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-0803" num="0869"><chemistry id="CHEM-US-00266" num="00266"><img id="EMI-C00266" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00266.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0804" num="0870">The title compound was prepared in a manner analogous to Example 12, Step A, using 6-bromo-3-methyl-1-(pyrazin-2-ylmethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one (Intermediate 21) and 2-(2,4-difluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O, 367.1; m/z found, 368.0 [M+H]<sup>+</sup>.</p><heading id="h-0216" level="1">Example 140: 6-(4-Fluorophenyl)-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one.</heading><p id="p-0805" num="0871"><chemistry id="CHEM-US-00267" num="00267"><img id="EMI-C00267" he="24.98mm" wi="56.39mm" file="US20230000833A1-20230105-C00267.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0806" num="0872">The title compound was prepared in a manner analogous to Example 13, using 5-(chloromethyl)-3-methyl-1,2,4-oxadiazole in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>FN<sub>5</sub>O<sub>2</sub>, 325.1; m/z found, 326.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.91 (br s, 1H), 8.32 (d, J=1.9 Hz, 1H), 8.01 (d, J=2.0 Hz, 1H), 7.83-7.72 (m, 2H), 7.38-7.28 (m, 2H), 5.60 (s, 2H), 2.31 (s, 3H).</p><heading id="h-0217" level="1">Example 141: 6-(4-Fluorophenyl)-1-[(1-methyl-1,2,4-triazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0807" num="0873"><chemistry id="CHEM-US-00268" num="00268"><img id="EMI-C00268" he="24.98mm" wi="56.39mm" file="US20230000833A1-20230105-C00268.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0808" num="0874">The title compound was prepared in a manner analogous to Example 13, using 3-(chloromethyl)-1-methyl-1H-1,2,4-triazole in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>FN<sub>6</sub>O, 324.1; m/z found, 325.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.68 (s, 1H), 8.42 (s, 1H), 8.24 (d, J=2.0 Hz, 1H), 7.79 (d, J=2.0 Hz, 1H), 7.77-7.70 (m, 2H), 7.39-7.27 (m, 2H), 5.22 (s, 2H), 3.88 (s, 3H).</p><heading id="h-0218" level="1">Example 142: 6-(4-Fluorophenyl)-1-[(1-methyltriazol-4-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0809" num="0875"><chemistry id="CHEM-US-00269" num="00269"><img id="EMI-C00269" he="24.98mm" wi="56.39mm" file="US20230000833A1-20230105-C00269.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0810" num="0876">The title compound was prepared in a manner analogous to Example 13, using 4-(chloromethyl)-1-methyl-1H-1,2,3-triazole in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>FN<sub>6</sub>O, 324.1; m/z found, 325.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.67 (s, 1H), 8.24 (d, J=2.0 Hz, 1H), 8.14 (s, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.79-7.71 (m, 2H), 7.37-7.29 (m, 2H), 5.25 (s, 2H), 4.08 (s, 3H).</p><heading id="h-0219" level="1">Example 143: 6-(3,4-Difluorophenyl)-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0811" num="0877"><chemistry id="CHEM-US-00270" num="00270"><img id="EMI-C00270" he="27.94mm" wi="56.39mm" file="US20230000833A1-20230105-C00270.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0812" num="0878">The title compound was prepared in a manner analogous to Example 13, using 3,4-difluorophenylboronic acid in Step A and 5-(chloromethyl)-3-methyl-1,2,4-oxadiazole in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>11</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>, 343.1; m/z found, 344.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.96 (s, 1H), 8.42-8.36 (m, 1H), 8.08-8.05 (m, 1H), 7.86-7.77 (m, 1H), 7.64-7.50 (m, 2H), 5.59 (s, 2H), 2.31 (s, 3H).</p><heading id="h-0220" level="1">Example 144: 6-(3,4-Difluorophenyl)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0813" num="0879"><chemistry id="CHEM-US-00271" num="00271"><img id="EMI-C00271" he="27.94mm" wi="54.02mm" file="US20230000833A1-20230105-C00271.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0814" num="0880">The title compound was prepared in a manner analogous to Example 13, using 3,4-difluorophenylboronic acid in Step A and 3-(chloromethyl)-5-methyl-1,2,4-oxadiazole in Step B.MS (ESI): mass calcd. for C<sub>16</sub>H<sub>11</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>, 343.1; m/z found, 344.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF-d<sub>7</sub>) &#x3b4; 11.86 (s, 1H), 8.35 (d, J=2.0 Hz, 1H), 7.96 (d, J=2.0 Hz, 1H), 7.84-7.77 (m, 1H), 7.63-7.51 (m, 2H), 5.36 (s, 2H), 2.59 (s, 3H).</p><heading id="h-0221" level="1">Example 145: 6-(3,4-Difluorophenyl)-1-[[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0815" num="0881"><chemistry id="CHEM-US-00272" num="00272"><img id="EMI-C00272" he="27.94mm" wi="65.02mm" file="US20230000833A1-20230105-C00272.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0816" num="0882">The title compound was prepared in a manner analogous to Example 13, using 3,4-difluorophenylboronic acid in Step A and 5-(chloromethyl)-3-(methoxymethyl)-1,2,4-oxadiazole in Step B.MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub>, 373.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMF): 11.97 (s, 1H), 8.39 (d, J=2.0 Hz, 1H), 8.07 (d, J=2.0 Hz, 1H), 7.85-7.76 (m, 1H), 7.64-7.51 (m, 2H), 5.65 (s, 2H), 4.53 (s, 2H), 3.35 (s, 3H).</p><heading id="h-0222" level="1">Example 146: 1-(2-Pyrrolidin-1-ylethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0817" num="0883"><chemistry id="CHEM-US-00273" num="00273"><img id="EMI-C00273" he="33.61mm" wi="44.70mm" file="US20230000833A1-20230105-C00273.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0818" num="0884">The title compound was prepared in a manner analogous to Example 17, using pyrrolidine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O, 376.2; m/z found 377.2, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 9.42 (s, 1H), 8.42-8.31 (d, J=1.9 Hz, 1H), 8.10-8.02 (m, 2H), 8.02-7.96 (d, J=2.0 Hz, 1H), 7.78-7.71 (m, 2H), 4.31-4.18 (m, 2H), 3.66 (s, 2H), 3.20-3.01 (m, 2H), 2.01 (s, 2H), 1.91-1.78 (d, J=4.6 Hz, 2H).</p><heading id="h-0223" level="1">Example 147: 1-[2-(3-Hydroxyazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0819" num="0885"><chemistry id="CHEM-US-00274" num="00274"><img id="EMI-C00274" he="38.35mm" wi="44.53mm" file="US20230000833A1-20230105-C00274.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0820" num="0886">The title compound was prepared in a manner analogous to Example 17, using 3-hydroxyazetidine. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 378.1; m/z found 379.2, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.33-8.29 (d, J=1.9 Hz, 1H), 7.98-7.91 (m, 2H), 7.89-7.86 (d, J=2.0 Hz, 1H), 7.73-7.66 (m, 2H), 4.65 (s, 1H), 4.54 (s, 1H), 4.37 (s, 1H), 4.31-4.22 (m, 2H), 4.14 (s, 1H), 4.00 (s, 1H), 3.76-3.60 (d, J=18.1 Hz, 2H).</p><heading id="h-0224" level="1">Example 148: 1-[2-(Cyclopropylamino)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0821" num="0887"><chemistry id="CHEM-US-00275" num="00275"><img id="EMI-C00275" he="33.87mm" wi="41.15mm" file="US20230000833A1-20230105-C00275.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0822" num="0888">The title compound was prepared in a manner analogous to Example 17, using cyclopropylamine. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O, 362.1; m/z found 363.2, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.85 (s, 1H), 8.80 (s, 2H), 8.40-8.28 (m, 1H), 8.13-8.02 (m, 2H), 7.96-7.91 (d, J=2.0 Hz, 1H), 7.80-7.72 (m, 2H), 4.24-4.12 (m, 2H), 3.45 (s, 2H), 2.81(s, 1H), 0.88-0.71 (m, 4H).</p><heading id="h-0225" level="1">Example 149: 1-[2-(3-Methoxyazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0823" num="0889"><chemistry id="CHEM-US-00276" num="00276"><img id="EMI-C00276" he="38.35mm" wi="46.06mm" file="US20230000833A1-20230105-C00276.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0824" num="0890">The title compound was prepared in a manner analogous to Example 17, using 3-hydroxymethylazetidine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 392.1; m/z found 393.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.85 (s, 1H), 10.22 (s, 0.5H), 9.61 (s, 0.5H), 8.43-8.25 (m, 1H), 8.12-8.02 (m, 2H), 8.00-7.92 (m, 1H), 7.78-7.69 (m, 2H), 4.45-4.29 (m, 2H), 4.27-4.10 (m, 6H), 3.62 (s, 1H), 3.31-3.22 (d, J=5.6 Hz, 3H).</p><heading id="h-0226" level="1">Example 150: 1-[2-(Cyclobutylamino)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0825" num="0891"><chemistry id="CHEM-US-00277" num="00277"><img id="EMI-C00277" he="35.48mm" wi="41.15mm" file="US20230000833A1-20230105-C00277.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0826" num="0892">The title compound was prepared in a manner analogous to Example 17, using cyclobutylamine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O, 376.2; m/z found 377.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.84 (s, 1H), 8.73 (s, 2H), 8.47-8.27 (d, J=2.0 Hz, 1H), 8.15-8.02 (m, 2H), 7.96-7.85 (d, J=1.9 Hz, 1H), 7.80-7.68 (m, 2H), 4.23-4.12 (m, 2H), 3.81-3.68 (m, 1H), 3.20 (s, 2H), 2.22-2.02 (m, 4H), 1.85-1.68 (m, 2H).</p><heading id="h-0227" level="1">Example 151: 1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0827" num="0893"><chemistry id="CHEM-US-00278" num="00278"><img id="EMI-C00278" he="32.26mm" wi="48.77mm" file="US20230000833A1-20230105-C00278.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0828" num="0894">The title compound was prepared in a manner analogous to Example 17, using 4-fluoro-2-methylphenylboronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>FN<sub>4</sub>O, 326.2; m/z found 327.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.69 (s, 1H), 9.58 (s, 1H), 7.97-7.76 (m, 1H), 7.60-7.49 (d, J=1.9 Hz, 1H), 7.31-7.25 (m, 1H), 7.25-7.17 (m, 1H), 7.15-7.07 (m, 1H), 4.16-4.03 (m, 6H), 3.76-3.34 (m, 2H), 2.45-2.33 (m, 1H), 2.26 (s, 3H).</p><heading id="h-0228" level="1">Example 152: 1-[2-(Azetidin-1-yl)ethyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0829" num="0895"><chemistry id="CHEM-US-00279" num="00279"><img id="EMI-C00279" he="32.09mm" wi="43.35mm" file="US20230000833A1-20230105-C00279.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0830" num="0896">The title compound was prepared in a manner analogous to Example 17, using 2-methylphenylboronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O, 308.2; m/z found 309.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 9.59 (s, 1H), 7.98-7.80 (m, 1H), 7.65-7.54 (d, J=1.9 Hz, 1H), 7.41-7.20 (m, 4H), 4.23-3.97 (m, 6H), 2.47-2.35 (d, J=10.1 Hz, 2H), 2.46-2.21 (m, 5H).</p><heading id="h-0229" level="1">Example 153: 1-[2-(Azetidin-1-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one and its Ttrifluoroacetic Acid Salt</heading><p id="p-0831" num="0897"><chemistry id="CHEM-US-00280" num="00280"><img id="EMI-C00280" he="32.09mm" wi="43.35mm" file="US20230000833A1-20230105-C00280.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0832" num="0898">The title compound was prepared in a manner analogous to Example 17, using phenylboronic acid. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O, 294.1; m/z found 395.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.71 (s, 1H), 9.58 (s, 1H), 8.35-8.14 (m, 1H), 7.92-7.82 (d, J=1.8 Hz, 1H), 7.78-7.62 (m, 2H), 7.58-7.44 (m, 2H), 7.42-7.32 (m, 1H), 4.22-3.97 (m, 6H), 3.61-3.52 (m, 2H), 2.44-2.33 (m, 1H), 2.26 (s, 1H).</p><heading id="h-0230" level="1">Example 154: 1-[2-(Azetidin-1-yl)ethyl]-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0833" num="0899"><chemistry id="CHEM-US-00281" num="00281"><img id="EMI-C00281" he="32.09mm" wi="43.35mm" file="US20230000833A1-20230105-C00281.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0834" num="0900">The title compound was prepared in a manner analogous to Example 17, using 3-methylphenylboronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O, 308.2; m/z found, 309.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 9.68-9.44 (d, J=11.1 Hz, 1H), 8.33-8.17 (m, 1H), 7.90-7.77 (m, 1H), 7.58-7.44 (m, 2H), 7.41-7.32 (m, 1H), 7.25-7.11 (d, J=7.4 Hz, 1H), 4.15-4.01 (m, 6H), 3.62-3.50 (d, J=6.9 Hz, 2H), 2.38 (s, 4H), 2.26 (s, 1H).</p><heading id="h-0231" level="1">Example 155: 1-[2-(Azetidin-1-yl)ethyl]-6-[2-(trifluoromethyl)-4-pyridyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0835" num="0901"><chemistry id="CHEM-US-00282" num="00282"><img id="EMI-C00282" he="32.09mm" wi="44.11mm" file="US20230000833A1-20230105-C00282.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0836" num="0902">The title compound was prepared in a manner analogous to Example 17, using (2-(trifluoromethyl)pyridin-4-yl)boronic acid. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>O, 363.1; m/z found, 364.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.96 (s, 1H), 9.67 (s, 1H), 8.92-8.76 (m, 1H), 8.64-8.53 (d, J=2.7 Hz, 1H), 8.29 (s, 1H), 8.20-8.06 (d, J=2.1 Hz, 2H), 4.30-3.95 (m, 6H), 3.55 (s, 2H), 2.51-2.34 (m, 1H), 2.28 (s, 1H).</p><heading id="h-0232" level="1">Example 156: 1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0837" num="0903"><chemistry id="CHEM-US-00283" num="00283"><img id="EMI-C00283" he="32.09mm" wi="48.77mm" file="US20230000833A1-20230105-C00283.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0838" num="0904">The title compound was prepared in a manner analogous to Example 17, using 3-methyl-4-fluoroboronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>FN<sub>4</sub>O, 326.2; m/z found 327.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.73 (s, 1H), 9.61 (s, 1H), 8.33-8.10 (m, 1H), 7.87-7.78 (d, J=2.1 Hz, 1H), 7.68-7.59 (m, 1H), 7.60-7.49 (m, 1H), 7.34-7.14 (m, 1H), 4.28-3.93 (m, 6H), 3.57 (s, 2H), 2.54-2.46 (m, 1H), 2.45-2.33 (m, 3H), 2.25 (s, 1H).</p><heading id="h-0233" level="1">Example 157: 1-[2-(Azetidin-1-yl)ethyl]-6-(2,6-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0839" num="0905"><chemistry id="CHEM-US-00284" num="00284"><img id="EMI-C00284" he="32.09mm" wi="43.35mm" file="US20230000833A1-20230105-C00284.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0840" num="0906">The title compound was prepared in a manner analogous to Example 17, using 2,6-dimethylphenylboronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O, 322.2; m/z found 323.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.77 (s, 1H), 9.54 (s, 1H), 7.83-7.59 (m, 1H), 7.51-7.39 (d, J=2.3 Hz, 1H), 7.30-7.07 (m, 3H), 4.27-3.95 (m, 6H), 3.75-3.05 (m, 2H), 2.44-2.34 (m, 1H), 2.28 (s, 1H), 2.16-1.79 (m, 6H).</p><heading id="h-0234" level="1">Example 158: 1-[2-(Azetidin-1-yl)ethyl]-6-(3-chlorophenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0841" num="0907"><chemistry id="CHEM-US-00285" num="00285"><img id="EMI-C00285" he="32.09mm" wi="43.35mm" file="US20230000833A1-20230105-C00285.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0842" num="0908">The title compound was prepared in a manner analogous to Example 17, using 3-chlorophenylboronic acid. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>C<sub>1</sub>N<sub>4</sub>O, 328.1; m/z found 329.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.78 (s, 1H), 9.62 (s, 1H), 8.50-8.11 (m, 1H), 8.00-7.89 (m, 1H), 7.88-7.77 (m, 1H), 7.77-7.67 (m, 1H), 7.60-7.48 (m, 1H), 7.48-7.39 (m, 1H), 4.24-4.01 (d, J=5.9 Hz, 6H), 3.59 (s, 2H), 2.46-2.35 (d, J=9.6 Hz, 1H), 2.26 (s, 1H).</p><heading id="h-0235" level="1">Example 159: 1-[2-(Azetidin-1-yl)ethyl]-6-(3,5-difluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0843" num="0909"><chemistry id="CHEM-US-00286" num="00286"><img id="EMI-C00286" he="32.09mm" wi="48.77mm" file="US20230000833A1-20230105-C00286.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0844" num="0910">The free base of the title compound was prepared in a manner analogous to Example 17, using 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 330.1; m/z found 331.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.88 (s, 1H), 9.64 (s, 1H), 8.58-8.34 (d, J=2.1 Hz, 1H), 8.08-7.85 (m, 1H), 7.68-7.41 (d, J=9.2 Hz, 2H), 7.26 (s, 1H), 4.66 (s, 6H), 3.59 (s, 2H), 2.41 (s, 1H), 2.27 (s, 1H).</p><heading id="h-0236" level="1">Example 160: 1-[2-(Azetidin-1-yl)ethyl]-6-[3-(trifluoromethoxy)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0845" num="0911"><chemistry id="CHEM-US-00287" num="00287"><img id="EMI-C00287" he="32.09mm" wi="43.35mm" file="US20230000833A1-20230105-C00287.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0846" num="0912">The title compound was prepared in a manner analogous to Example 17, using 3-(trifluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 378.1; m/z found 379.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.83 (s, 1H), 9.61 (s, 1H), 8.49-8.26 (m, 1H), 8.01-7.89 (d, J=1.8 Hz, 1H), 7.84-7.76 (d, J=8.2 Hz, 1H), 7.72 (s, 1H), 7.69-7.59 (m, 1H), 7.46-7.31 (m, 1H), 4.09 (s, 6H), 3.60 (s, 2H), 2.47-2.35 (d, J=8.9 Hz, 1H), 2.27(s, 1H).</p><heading id="h-0237" level="1">Example 161: 1-[2-(1-Piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0847" num="0913"><chemistry id="CHEM-US-00288" num="00288"><img id="EMI-C00288" he="35.31mm" wi="45.38mm" file="US20230000833A1-20230105-C00288.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0848" num="0914">The title compound was prepared in a manner analogous to Example 17, using piperidine. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O, 390.2; m/z found 391.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 8.90 (s, 1H), 8.43-8.32 (d, J=1.9 Hz, 1H), 8.05 (s, 2H), 8.00-7.90 (d, J=2.1 Hz, 1H), 7.80-7.69 (d, J=7.2 Hz, 2H), 4.37-4.22 (m, 2H), 3.74-3.64 (d, J=11.6 Hz, 2H), 3.41 (s, 2H), 3.08-2.89 (m, 2H), 1.91-1.81 (d, J=14.3 Hz, 2H), 1.77-1.68 (d, J=12.3 Hz, 1H), 1.65-1.53 (d, J=13.4 Hz, 2H), 1.44-1.32 (d, J=13.0 Hz, 1H).</p><heading id="h-0238" level="1">Example 162: 1-[2-(4-Fluoro-1-piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0849" num="0915"><chemistry id="CHEM-US-00289" num="00289"><img id="EMI-C00289" he="41.49mm" wi="45.38mm" file="US20230000833A1-20230105-C00289.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0850" num="0916">The title compound was prepared in a manner analogous to Example 17, using 4-fluoropiperidine. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>20</sub>F<sub>4</sub>N<sub>4</sub>O, 408.2; m/z found 409.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 8.90 (s, 1H), 8.43-8.32 (d, J=1.9 Hz, 1H), 8.05 (s, 2H), 8.00-7.90 (d, J=2.1 Hz, 1H), 7.80-7.69 (d, J=7.2 Hz, 2H), 4.37-4.22 (m, 2H), 3.74-3.64 (d, J=11.6 Hz, 2H), 3.41 (s, 2H), 3.08-2.89 (m, 2H), 1.91-1.81 (d, J=14.3 Hz, 2H), 1.77-1.68 (d, J=12.3 Hz, 1H), 1.65-1.53 (d, J=13.4 Hz, 2H).</p><heading id="h-0239" level="1">Example 163: 1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0851" num="0917"><chemistry id="CHEM-US-00290" num="00290"><img id="EMI-C00290" he="38.27mm" wi="43.35mm" file="US20230000833A1-20230105-C00290.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0852" num="0918">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O, 380.1; m/z found 381.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.82 (s, 1H), 8.52-8.23 (d, J=1.9 Hz, 1H), 8.09-8.02 (m, 2H), 7.99 (s, 1H), 7.79-7.63 (m, 2H), 5.44 (s, 1H), 5.30 (s, 1H), 4.51 (s, 3H), 4.19 (s, 2H), 3.65 (s, 2H).</p><heading id="h-0240" level="1">Example 164: 1-[2-(3-Methylpyrrolidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0853" num="0919"><chemistry id="CHEM-US-00291" num="00291"><img id="EMI-C00291" he="33.95mm" wi="49.61mm" file="US20230000833A1-20230105-C00291.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0854" num="0920">The title compound was prepared in a manner analogous to Example 17, using 3-methylpyrrolidine. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O, 390.2; m/z found 391.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.51 (s, 1H), 8.39 (s, 1H), 8.12-8.02 (d, J=6.3 Hz, 2H), 8.95 (s, 1H), 7.85-7.65 (m, 2H), 4.54-4.22 (d, J=4.5 Hz, 2H), 3.77 (s, 1H), 3.62 (s, 1H), 3.22 (s, 2H), 2.81-2.66 (d, J=10.2 Hz, 1H), 2.26 (s, 1H), 2.08 (s, 1H), 1.67 (s, 1H), 1.41 (s, 1H), 1.18-0.90 (m, 3H).</p><heading id="h-0241" level="1">Example 165: 1-[2-(4-Hydroxy-1-piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0855" num="0921"><chemistry id="CHEM-US-00292" num="00292"><img id="EMI-C00292" he="41.49mm" wi="45.38mm" file="US20230000833A1-20230105-C00292.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0856" num="0922">The title compound was prepared in a manner analogous to Example 17, using 4-hydroxypiperidine. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 406.2; m/z found 407.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD) 67  6.89-6.70 (d, J=1.8 Hz, 1H), 6.46 (s, 1H), 6.45-6.42 (d, J=7.2 Hz, 1H), 6.38 (s, 1H), 6.21-6.17 (m, 2H), 2.88 (s, 2H), 2.35 (s, 2H), 2.26 (s, 1H), 2.07 (s, 2H), 1.88 (s, 2H), 1.69-1.57 (m, 1H), 0.66 (s, 1H), 0.45 (s, 2H), 0.21(s, 1H).</p><heading id="h-0242" level="1">Example 166: 1-[2-[3-(Trifluoromethyl)azetidin-1-yl]ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0857" num="0923"><chemistry id="CHEM-US-00293" num="00293"><img id="EMI-C00293" he="38.86mm" wi="45.04mm" file="US20230000833A1-20230105-C00293.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0858" num="0924">The title compound was prepared in a manner analogous to Example 17, using 3-(trifluoromethyl)azetidine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>6</sub>N<sub>4</sub>O, 430.1; m/z found 431.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.74 (s, 1H), 8.50-8.17 (m, 1H), 8.17-7.85 (m, 3H), 7.85-7.53 (m, 2H), 4.35 (s, 6H), 3.91-3.21 (m, 3H).</p><heading id="h-0243" level="1">Example 167: 1-[2-(3,3-Difluoroazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0859" num="0925"><chemistry id="CHEM-US-00294" num="00294"><img id="EMI-C00294" he="38.27mm" wi="46.74mm" file="US20230000833A1-20230105-C00294.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0860" num="0926">The title compound was prepared in a manner analogous to Example 17, using 3,3-difluoroazetidine. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>5</sub>N<sub>4</sub>O, 398.1; m/z found 399.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.79 (s, 1H), 8.49-8.21 (m, 1H), 8.09-7.92 (m, 4H), 7.80-7.61 (m, 3H), 4.39 (s, 4H), 4.06 (s, 2H).</p><heading id="h-0244" level="1">Example 168: 1-[2-(Azetidin-1-yl)ethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0861" num="0927"><chemistry id="CHEM-US-00295" num="00295"><img id="EMI-C00295" he="32.09mm" wi="43.35mm" file="US20230000833A1-20230105-C00295.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0862" num="0928">The title compound was prepared in a manner analogous to Example 17, using 2-methyl-3-(trifluoromethyl)phenylboronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O, 376.2; m/z found 377.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.78 (s, 1H), 9.65 (s, 1H), 7.94-7.91 (d, J=1.8 Hz, 1H), 7.79-7.73 (m, 1H), 7.64-7.60 (d, J=1.9 Hz, 1H), 7.59-7.45 (m, 2H), 4.17-3.98 (m, 6H), 3.54 (s, 2H), 2.45-2.38 (m, 1H), 2.37-2.32 (d, J=1.9 Hz, 3H), 2.25 (s, 1H).</p><heading id="h-0245" level="1">Example 169: 1-[2-(Azetidin-1-yl)ethyl]-6-(2,3-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0863" num="0929"><chemistry id="CHEM-US-00296" num="00296"><img id="EMI-C00296" he="32.09mm" wi="43.35mm" file="US20230000833A1-20230105-C00296.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0864" num="0930">The title compound was prepared in a manner analogous to Example 17, using 2,3-dimethylphenylboronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O, 322.2; m/z found 323.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 9.64 (s, 1H), 7.97-7.78 (m, 1H), 7.59-7.48 (d, J=1.8 Hz, 1H), 7.25-7.12 (m, 2H), 7.13-7.03 (m, 1H), 4.20-3.92 (m, 6H), 3.45 (s, 2H), 2.44-2.35 (m, 1H), 2.32 (s, 3H), 2.28-2.18 (m, 1H), 2.14 (s, 3H).</p><heading id="h-0246" level="1">Example 170: 1-[2-(Azetidin-1-yl)ethyl]-6-(3,5-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0865" num="0931"><chemistry id="CHEM-US-00297" num="00297"><img id="EMI-C00297" he="32.09mm" wi="48.26mm" file="US20230000833A1-20230105-C00297.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0866" num="0932">The title compound was prepared in a manner analogous to Example 17, using 3,5-dimethylphenylboronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O, 322.2; m/z found 323.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.76 (s, 1H), 9.64 (s, 1H), 8.40-8.19 (d, J=1.9 Hz, 1H), 7.92-7.78 (d, J=2.0 Hz, 1H), 7.39-7.24 (m, 2H), 7.00 (s, 1H), 4.20-3.95 (m, 6H), 3.66-3.51 (d, J=5.4 Hz, 2H), 2.45-2.20 (m, 8H).</p><heading id="h-0247" level="1">Example 171: 1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-2,3-dimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0867" num="0933"><chemistry id="CHEM-US-00298" num="00298"><img id="EMI-C00298" he="32.09mm" wi="48.77mm" file="US20230000833A1-20230105-C00298.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0868" num="0934">The title compound was prepared in a manner analogous to Example 17, using 4-fluoro-2,3-dimethylphenylboronic. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>21</sub>FN<sub>4</sub>O, 340.2; m/z found, 341.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.73 (s, 1H), 9.69 (s, 1H), 7.95-7.66 (d, J=1.8 Hz, 1H), 7.60-7.47 (d, J=1.9 Hz, 1H), 7.21-7.03 (m, 2H), 4.20-3.93 (m, 6H), 3.51 (s, 2H), 2.45-2.32 (m, 2H), 2.25-2.21 (d, J=2.1 Hz, 3H), 2.18 (s, 3H).</p><heading id="h-0248" level="1">Example 172: 1-[2-(Azetidin-1-yl)ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0869" num="0935"><chemistry id="CHEM-US-00299" num="00299"><img id="EMI-C00299" he="32.09mm" wi="51.22mm" file="US20230000833A1-20230105-C00299.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0870" num="0936">The title compound was prepared in a manner analogous to Example 17, using (2-methyl-5-(trifluoromethyl)phenyl)boronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O, 376.2; m/z found, 377.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.92 (s, 1H), 9.68 (s, 1H), 8.01-7.96 (d, J=1.8 Hz, 1H), 7.71-7.63 (m, 2H), 7.62-7.54 (m, 2H), 4.20-3.97 (m, 6H), 3.68-3.36 (m, 2H), 2.46-2.38 (d, J=9.2 Hz, 1H), 2.36 (s, 3H), 2.32-2.21 (d, J=2.3 Hz, 1H).</p><heading id="h-0249" level="1">Example 173: 6-(3,5-Difluorophenyl)-1-[2-(2-hydroxyethylamino)ethyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0871" num="0937"><chemistry id="CHEM-US-00300" num="00300"><img id="EMI-C00300" he="33.53mm" wi="58.84mm" file="US20230000833A1-20230105-C00300.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0872" num="0938">The title compound was prepared in a manner analogous to Example 17, using ethanolamine in Step A and 3,5-difluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 334.1; m/z found, 335.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) &#x3b4; 8.31 (d, J=2.0 Hz, 1H), 7.84 (d, J=2.0 Hz, 1H), 7.37-7.27 (m, 2H), 6.98 (tt, J=9.1, 2.3 Hz, 1H), 4.33 (t, J=5.8 Hz, 2H), 3.86-3.77 (m, 2H), 3.51 (t, J=5.8 Hz, 2H), 3.28-3.21 (m, 2H).</p><heading id="h-0250" level="1">Example 174: 6-(3,5-Difluorophenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0873" num="0939"><chemistry id="CHEM-US-00301" num="00301"><img id="EMI-C00301" he="33.44mm" wi="50.12mm" file="US20230000833A1-20230105-C00301.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0874" num="0940">The title compound was prepared in a manner analogous to Example 17, using pyrrolidine in Step A and 3,5-difluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O, 344.1; m/z found, 345.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.91 (s, 1H), 9.54 (s, 1H), 8.41 (d, J=1.9 Hz, 1H), 7.98 (d, J=2.0 Hz, 1H), 7.69-7.51 (m, 2H), 7.26 (tt, J=9.2, 2.3 Hz, 1H), 4.24 (t, J=5.7 Hz, 2H), 3.61 (d, J=6.0 Hz, 2H), 3.17 (s, 2H), 3.13 (dd, J=11.3, 7.3 Hz, 2H), 2.04 (dd, J=9.0, 5.3 Hz, 2H), 1.94-1.62 (m, 2H).</p><heading id="h-0251" level="1">Example 175: 6-(3,5-Difluorophenyl)-1-[2-(3-hydroxypyrrolidin-1-yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0875" num="0941"><chemistry id="CHEM-US-00302" num="00302"><img id="EMI-C00302" he="34.63mm" wi="57.66mm" file="US20230000833A1-20230105-C00302.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0876" num="0942">The title compound was prepared in a manner analogous to Example 17, using 3-hydroxypyrrolidine in Step A and 3,5-difluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 360.1; m/z found, 361.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.64 (s, 1H), 8.25 (d, J=2.0 Hz, 1H), 7.82 (d, J=2.0 Hz, 1H), 7.55-7.39 (m, 2H), 7.15 (tt, J=9.2, 2.3 Hz, 1H), 4.60 (d, J=4.4 Hz, 1H), 4.07 (t, J=8.8 Hz, 1H), 3.88 (t, J=6.5 Hz, 2H), 2.76-2.50 (m, 4H), 2.34-2.24 (m, 1H), 1.84 (dd, J=13.0, 7.1 Hz, 1H), 1.51-1.35 (m, 1H).</p><heading id="h-0252" level="1">Example 176: 6-(3,5-Difluorophenyl)-1-[2-(3-methoxypyrrolidin-1-yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0877" num="0943"><chemistry id="CHEM-US-00303" num="00303"><img id="EMI-C00303" he="34.63mm" wi="59.10mm" file="US20230000833A1-20230105-C00303.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0878" num="0944">The title compound was prepared in a manner analogous to Example 17, using 3-methoxypyrrolidine in Step A and 3,5-difluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 374.2; m/z found, 375.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.73 (s, 1H), 8.33 (d, J=2.0 Hz, 1H), 7.89 (d, J=2.0 Hz, 1H), 7.55 (dt, J=7.8, 2.1 Hz, 2H), 7.24 (tt, J=9.4, 2.3 Hz, 1H), 3.97 (t, J=6.4 Hz, 2H), 3.84 (ddt, J=8.9, 6.3, 3.2 Hz, 1H), 3.14 (s, 3H), 2.84-2.61 (m, 5H), 2.44 (q, J=7.7 Hz, 1H), 2.00-1.86 (m, 1H), 1.67-1.54 (m, 1H).</p><heading id="h-0253" level="1">Example 177: 6-(4-Fluoro-2-methyl-phenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0879" num="0945"><chemistry id="CHEM-US-00304" num="00304"><img id="EMI-C00304" he="33.61mm" wi="50.12mm" file="US20230000833A1-20230105-C00304.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0880" num="0946">The title compound was prepared in a manner analogous to Example 17, using pyrrolidine in Step A and 2-methyl-4-fluorophenylboronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>21</sub>FN<sub>4</sub>O, 340.2; m/z found, 341.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 9.54 (s, 1H), 8.04-7.76 (d, J=1.8 Hz, 1H), 7.75-7.46 (d, J=1.8 Hz, 1H), 7.34-7.27 (m, 1H), 7.25-7.19 (m, 1H), 7.17-7.09 (m, 1H), 4.25-4.14 (m, 2H), 3.71-3.58 (m, 2H), 3.58-3.48 (m, 2H), 3.20-3.02 (m, 2H), 2.28 (s, 3H), 2.05-1.97 (m, 2H), 1.89-1.76 (m, 2H).</p><heading id="h-0254" level="1">Example 178: 6-(2,6-Dimethylphenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0881" num="0947"><chemistry id="CHEM-US-00305" num="00305"><img id="EMI-C00305" he="33.44mm" wi="44.70mm" file="US20230000833A1-20230105-C00305.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0882" num="0948">The title compound was prepared in a manner analogous to Example 17, using pyrrolidine in Step A and 2,6-dimethylphenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>24</sub>N<sub>4</sub>O, 336.2; m/z found, 377.2 [M+H]<sup>+</sup>. 1H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.78 (s, 1H), 9.46 (s, 1H), 7.77-7.68 (d, J=1.7 Hz, 1H), 7.53-7.44 (d, J=1.8 Hz, 1H), 7.25-7.11 (m, 3H), 4.22-4.13 (t, J=5.9 Hz, 2H), 3.79 (s, 2H), 3.55-3.45 (d, J=5.9 Hz, 2H), 3.17-3.01 (m, 2H), 2.01 (s, 8H), 1.88-1.77 (m, 2H).</p><heading id="h-0255" level="1">Example 179: 6-(o-Tolyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0883" num="0949"><chemistry id="CHEM-US-00306" num="00306"><img id="EMI-C00306" he="33.44mm" wi="44.70mm" file="US20230000833A1-20230105-C00306.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0884" num="0950">The title compound was prepared in a manner analogous to Example 17, using pyrrolidine in Step A and 2-methylphenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O, 322.2; m/z found, 323.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.77 (s, 1H), 9.45 (s, 1H), 8.01-7.90 (d, J=1.8 Hz, 1H), 7.68-7.54 (d, J=1.8 Hz, 1H), 7.40-7.19 (m, 4H), 4.28-4.10 (m, 2H), 3.74 (s, 2H), 3.58-3.48 (d, J=5.9 Hz, 2H), 3.20-2.99 (m, 2H), 2.29 (s, 3H), 2.06-1.91 (d, J=7.4 Hz, 2H), 1.90-1.77 (m, 2H).</p><heading id="h-0256" level="1">Example 180: 6-Phenyl-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0885" num="0951"><chemistry id="CHEM-US-00307" num="00307"><img id="EMI-C00307" he="33.44mm" wi="44.70mm" file="US20230000833A1-20230105-C00307.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0886" num="0952">The title compound was prepared in a manner analogous to Example 17, using pyrrolidine in Step A and phenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O, 308.2; m/z found, 309.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 9.48 (s, 1H), 8.35-8.23 (d, J=1.9 Hz, 1H), 7.95-7.85 (d, J=1.9 Hz, 1H), 7.77-7.70 (m, 2H), 7.54-7.45 (m, 2H), 7.43-7.35 (m, 1H), 4.31-4.21 (m, 2H), 3.73-3.50 (m, 4H), 3.20-2.95 (m, 2H), 2.12-1.97 (d, J=7.2 Hz, 2H), 1.92-1.75 (m, 1H).</p><heading id="h-0257" level="1">Example 181: 1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0887" num="0953"><chemistry id="CHEM-US-00308" num="00308"><img id="EMI-C00308" he="38.27mm" wi="43.35mm" file="US20230000833A1-20230105-C00308.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0888" num="0954">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine in Step A and 2-methyl-3(trifluoromethyl)phenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>4</sub>N<sub>4</sub>O, 394.1; m/z found, 295.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3b4; 11.90-11.73 (s, 1H), 10.66-10.27 (s, 1H), 7.98-7.88 (d, J=1.8 Hz, 1H), 7.85-7.69 (m, 1H), 7.70-7.59 (d, J=1.9 Hz, 1H), 7.60-7.34 (m, 2H), 5.56-5.39 (s, 0.5H), 5.39-5.21 (s, 0.5H), 4.68-3.96 (m, 8H), 2.40-2.27 (m, 3H).</p><heading id="h-0258" level="1">Example 182: 6-(2,3-Dimethylphenyl)-1-[2-(3-fluoroazetidin-1-yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0889" num="0955"><chemistry id="CHEM-US-00309" num="00309"><img id="EMI-C00309" he="38.27mm" wi="43.35mm" file="US20230000833A1-20230105-C00309.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0890" num="0956">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine in Step A and 2,3-dimethylphenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>21</sub>FN<sub>4</sub>O, 340.2; m/z found, 341.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.72 (s, 1H), 10.52 (s, 0.6H), 9.52 (s, 0.4H), 7.96-7.71 (d, J=1.8 Hz, 1H), 7.64-7.45(d, J=1.8 Hz, 1H), 7.29-7.13 (m, 2H), 7.13-7.00 (m, 1H), 5.46 (s, 0.5H), 5.28 (s, 0.5H), 4.64-3.99 (m, 6H), 3.6-3.2 (m, 2H), 2.32 (s, 3H), 2.11 (s, 3H).</p><heading id="h-0259" level="1">Example 183: 6-(3,5-Dimethylphenyl)-1-[2-(3-fluoroazetidin-1-yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0891" num="0957"><chemistry id="CHEM-US-00310" num="00310"><img id="EMI-C00310" he="38.27mm" wi="48.26mm" file="US20230000833A1-20230105-C00310.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0892" num="0958">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine in Step A and 3,5-dimethylphenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>21</sub>FN<sub>4</sub>O, 340.2; m/z found, 341.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.78 (s, 1H), 10.4 (s, 0.6H), 9.7 (s, 0.4H), 8.37-8.17 (d, J=1.9 Hz, 1H), 7.87-7.76 (d, J=2.0 Hz, 1H), 7.37-7.20 (d, J=1.7 Hz, 2H), 7.01 (s, 1H), 5.44 (s, 0.5H), 5.30 (s, 0.5H), 4.64-4.03 (m, 6H), 3.45 (s, 2H), 2.33 (s, 6H).</p><heading id="h-0260" level="1">Example 184: 1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(4-fluoro-2,3-dimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0893" num="0959"><chemistry id="CHEM-US-00311" num="00311"><img id="EMI-C00311" he="38.27mm" wi="48.77mm" file="US20230000833A1-20230105-C00311.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0894" num="0960">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine in Step A and 2,3-dimethyl-4-fluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>F<sub>2</sub>N<sub>4</sub>O, 358.2; m/z found, 359.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.84 (s, 1H), 10.7 (s, 0.6H), 9.6 (s, 0.4H), 8.01-7.75 (d, J=1.8 Hz, 1H), 7.62-7.43 (d, J=1.8 Hz, 1H), 7.23-6.95 (m, 2H), 5.51-5.39 (m, 0.5H), 5.39-5.23 (m, 0.5H), 4.67-3.92 (m, 6H), 3.48 (s, 2H), 2.25-2.19 (d, J=2.1 Hz, 3H), 2.17 (s, 3H).</p><heading id="h-0261" level="1">Example 185: 1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0895" num="0961"><chemistry id="CHEM-US-00312" num="00312"><img id="EMI-C00312" he="38.27mm" wi="51.22mm" file="US20230000833A1-20230105-C00312.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0896" num="0962">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine in Step A and 2-methyl-5-(trifluoromethyl)phenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>4</sub>N<sub>4</sub>O, 394.1; m/z found, 395.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.88 (s, 1H), 10.55 (s, 0.6H), 9.7 (s, 0.4H), 8.06-7.92 (d, J=1.8</p><p id="p-0897" num="0963">Hz, 1H), 7.77-7.42 (m, 4H), 5.46 (s, 0.5H), 5.39-5.20 (d, J=6.0 Hz, 0.5H), 4.63-4.43 (m, 2H), 4.31 (s, 2H), 4.20-4.02 (m, 2H), 3.44 (s, 2H), 2.34 (s, 3H).</p><heading id="h-0262" level="1">Example 186: 1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0898" num="0964"><chemistry id="CHEM-US-00313" num="00313"><img id="EMI-C00313" he="38.27mm" wi="43.35mm" file="US20230000833A1-20230105-C00313.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0899" num="0965">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine in Step A and 2-methylphenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>FN<sub>4</sub>O, 326.2; m/z found, 327.2 [M+H]<sup>+</sup>.</p><heading id="h-0263" level="1">Example 187: 1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0900" num="0966"><chemistry id="CHEM-US-00314" num="00314"><img id="EMI-C00314" he="38.27mm" wi="48.77mm" file="US20230000833A1-20230105-C00314.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0901" num="0967">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine in Step A and 2-methyl-4-fluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O, 344.1; m/z found, 345.2 [M+H]<sup>+</sup>.</p><heading id="h-0264" level="1">Example 188: 1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0902" num="0968"><chemistry id="CHEM-US-00315" num="00315"><img id="EMI-C00315" he="38.27mm" wi="43.35mm" file="US20230000833A1-20230105-C00315.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0903" num="0969">The title compound was prepared in a manner analogous to Example 17, using 3-fluoroazetidine in Step A and phenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>FN<sub>4</sub>O, 312.1; m/z found, 313.1 [M+H]<sup>+</sup>.</p><heading id="h-0265" level="1">Example 189: 6-(3,5-Difluorophenyl)-1-[2-(propylamino)ethyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0904" num="0970"><chemistry id="CHEM-US-00316" num="00316"><img id="EMI-C00316" he="32.77mm" wi="56.22mm" file="US20230000833A1-20230105-C00316.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0905" num="0971">The title compound was prepared in a manner analogous to Example 17, using propylamine in Step A and 3,5-difluorophenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O, 332.1; m/z found, 333.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 8.48 (s, 2H), 8.39 (d, J=2.0 Hz, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.67-7.36 (m, 2H), 7.26 (tt, J=9.3, 2.3 Hz, 1H), 4.18 (t, J=5.7 Hz, 2H), 3.35 (t, J=6.1 Hz, 2H), 2.95 (d, J=6.9 Hz, 2H), 1.58 (dt, J=15.1, 7.5 Hz, 2H), 0.90 (t, J=7.4 Hz, 3H).</p><heading id="h-0266" level="1">Example 190: N-Cyclobutyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0906" num="0972"><chemistry id="CHEM-US-00317" num="00317"><img id="EMI-C00317" he="39.03mm" wi="39.79mm" file="US20230000833A1-20230105-C00317.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0907" num="0973">The title compound was prepared in a manner analogous to Example 20, using cyclobutylamine in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.3 [M+H]<sup>+</sup>.</p><heading id="h-0267" level="1">Example 191: 1-[2-(3-Methoxyazetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0908" num="0974"><chemistry id="CHEM-US-00318" num="00318"><img id="EMI-C00318" he="39.79mm" wi="42.42mm" file="US20230000833A1-20230105-C00318.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0909" num="0975">The title compound was prepared in a manner analogous to Example 20 using 3-methoxyazetidine hydrochloride in Step A. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.01-7.96 (m, 2H), 7.82 (d, J=2.0 Hz, 1H), 7.75-7.69 (m, 2H), 4.60 (s, 2H), 4.49-4.42 (m, 1H), 4.3-4.25 (m, 1H), 4.15-4.05 (m, 2H), 3.74-3.68 (m, 1H), 3.24 (s, 3H).</p><heading id="h-0268" level="1">Example 192: N-(Oxetan-3-yl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0910" num="0976"><chemistry id="CHEM-US-00319" num="00319"><img id="EMI-C00319" he="39.79mm" wi="39.79mm" file="US20230000833A1-20230105-C00319.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0911" num="0977">The title compound was prepared in a manner analogous to Example 20, using oxetan-3-amine in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 392.1; m/z found, 393.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 8.98 (d, J=6.9 Hz, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.05-7.96 (m, 2H), 7.88 (d, J=2.0 Hz, 1H), 7.79-7.66 (m, 2H), 4.83 (h, J=6.9 Hz, 1H), 4.70 (t, J=6.8 Hz, 2H), 4.56 (s, 2H), 4.44 (t, J=6.3 Hz, 2H).</p><heading id="h-0269" level="1">Example 193: 1-[2-(4-Methylpiperazin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0912" num="0978"><chemistry id="CHEM-US-00320" num="00320"><img id="EMI-C00320" he="37.85mm" wi="41.32mm" file="US20230000833A1-20230105-C00320.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0913" num="0979">The title compound was prepared in a manner analogous to Example 20, using 1-methylpiperazine in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 419.2; m/z found, 420.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3b4; 11.78 (s, 1H), 9.96 (s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.00-7.93 (m, 2H), 7.78-7.68 (m, 3H), 5.10-4.73 (m, 2H), 4.45-4.10 (m, 2H), 3.24-2.91 (m, 4H), 2.85 (s, 3H).</p><heading id="h-0270" level="1">Example 194: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0914" num="0980"><chemistry id="CHEM-US-00321" num="00321"><img id="EMI-C00321" he="39.88mm" wi="41.66mm" file="US20230000833A1-20230105-C00321.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0915" num="0981">The title compound was prepared in a manner analogous to Example 20, using 3,3-difluoroazetidine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 412.1; m/z found, 413.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO DMSO-d<sub>6</sub>) &#x3b4; 11.79 (s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.01-7.95 (m, 2H), 7.81 (d, J=2.0 Hz, 1H), 7.78-7.69 (m, 2H), 4.81 (t, J=12.3 Hz, 2H), 4.71 (s, 2H), 4.38 (t, J=12.3 Hz, 2H).</p><heading id="h-0271" level="1">Example 195: N-(3,3-Difluorocyclobutyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0916" num="0982"><chemistry id="CHEM-US-00322" num="00322"><img id="EMI-C00322" he="42.76mm" wi="39.79mm" file="US20230000833A1-20230105-C00322.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0917" num="0983">The title compound was prepared in a manner analogous to Example 20, using 3,3-difluorocyclobutan-1-amine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 426.1; m/z found, 427.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.76 (s, 1H), 8.67 (d, J=6.8 Hz, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.05-7.96 (m, 2H), 7.87 (d, J=2.0 Hz, 1H), 7.77-7.67 (m, 2H), 4.54 (s, 2H), 4.15-4.02 (m, 1H), 2.99-2.84 (m, 2H).</p><heading id="h-0272" level="1">Example 196: 1-[2-(3,3-Difluoropyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0918" num="0984"><chemistry id="CHEM-US-00323" num="00323"><img id="EMI-C00323" he="39.62mm" wi="43.86mm" file="US20230000833A1-20230105-C00323.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0919" num="0985">The title compound was prepared in a manner analogous to Example 20, using 3,3-difluoropyrrolidine hydrochloride and 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetic acid (Example 137). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 440.1; m/z found, 441.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.40 (d, J=1.9 Hz, 1H), 8.03-7.95 (m, 2H), 7.89 (dd, J=10.3, 2.0 Hz, 1H), 7.79-7.71 (m, 2H), 4.91-4.81 (m, 2H), 4.17 (t, J=13.1 Hz, 1H), 3.92 (t, J=7.4 Hz, 1H), 3.74 (t, J=13.1 Hz, 1H), 3.56 (t, J=7.5 Hz, 1H), 3.41 (s, 3H), 2.64-2.53 (m, 1H), 2.49-2.37 (m, 1H).</p><heading id="h-0273" level="1">Example 197: 3-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0920" num="0986"><chemistry id="CHEM-US-00324" num="00324"><img id="EMI-C00324" he="38.95mm" wi="39.79mm" file="US20230000833A1-20230105-C00324.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0921" num="0987">The title compound was prepared in a manner analogous to Example 20, using pyrrolidine and 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetic acid (Example 137). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 404.1; m/z found, 405.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.40 (d, J=1.9 Hz, 1H), 8.04-7.96 (m, 2H), 7.90 (d, J=2.0 Hz, 1H), 7.77-7.70 (m, 2H), 4.78 (s, 2H), 3.59 (t, J=6.8 Hz, 2H), 3.30 (t, J=6.9 Hz, 2H), 2.00-1.90 (m, 2H), 1.85-1.75 (m, 2H).</p><heading id="h-0274" level="1">Example 198: N-(3,3-Difluoro-1-methyl-cyclobutyl)-2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0922" num="0988"><chemistry id="CHEM-US-00325" num="00325"><img id="EMI-C00325" he="45.55mm" wi="39.79mm" file="US20230000833A1-20230105-C00325.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0923" num="0989">The title compound was prepared in a manner analogous to Example 20, using 3,3-difluoro-1-methylcyclobutan-1-amine hydrochloride and 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetic acid (Example 137). MS (ESI): mass calcd. for C<sub>21</sub>H<sub>19</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 454.1; m/z found, 455.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.65 (s, 1H), 8.41 (d, J=2.0 Hz, 1H), 8.04-7.97 (m, 2H), 7.93 (d, J=2.0 Hz, 1H), 7.78-7.69 (m, 2H), 4.58 (s, 2H), 3.40 (s, 3H), 2.95-2.81 (m, 2H), 2.66-2.53 (m, 2H), 1.46-1.39 (s, 3H).</p><heading id="h-0275" level="1">Example 199: N-(3-Methyloxetan-3-yl)-2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0924" num="0990"><chemistry id="CHEM-US-00326" num="00326"><img id="EMI-C00326" he="40.13mm" wi="39.79mm" file="US20230000833A1-20230105-C00326.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0925" num="0991">The title compound was prepared in a manner analogous to Example 20, using 3-methyloxetan-3-amine and 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetic acid (Example 137). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 420.1; m/z found, 421.20 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.71 (s, 1H), 8.41 (d, J=2.0 Hz, 1H), 8.08-7.98 (m, 2H), 7.96 (d, J=2.0 Hz, 1H), 7.78-7.69 (m, 2H), 4.63-4.55 (m, 4H), 4.28 (d, J=6.1 Hz, 2H), 1.50 (s, 3H).</p><heading id="h-0276" level="1">Example 200: N-(3,3-Difluorocyclobutyl)-2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0926" num="0992"><chemistry id="CHEM-US-00327" num="00327"><img id="EMI-C00327" he="45.55mm" wi="39.79mm" file="US20230000833A1-20230105-C00327.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0927" num="0993">The title compound was prepared in a manner analogous to Example 20, using 3,3-difluorocyclobutan-1-amine hydrochloride and 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetic acid (Example 137). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>F<sub>5</sub>N<sub>4</sub>O2, 440.1; m/z found, 441.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.68 (d, J=6.7 Hz, 1H), 8.42 (d, J=1.9 Hz, 1H), 8.05-7.99 (m, 2H), 7.96 (d, J=2.0 Hz, 1H), 7.77-7.68 (m, 2H), 4.60 (s, 2H), 4.14-4.01 (m, 1H), 3.40 (s, 3H), 2.98-2.83 (m, 2H), 2.67-2.47 (m, 2H).</p><heading id="h-0277" level="1">Example 201: 1-(2-Oxo-2-pyrrolidin-1-yl-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0928" num="0994"><chemistry id="CHEM-US-00328" num="00328"><img id="EMI-C00328" he="36.24mm" wi="39.79mm" file="US20230000833A1-20230105-C00328.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0929" num="0995">The title compound was prepared in a manner analogous to Example 20, using pyrrolidine in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.74 (s, 1H), 8.38-8.29 (m, 1H), 8.06-7.95 (m, 2H), 7.88-7.81 (m, 1H), 7.80-7.68 (m, 2H), 4.72 (s, 2H), 3.58 (t, J=6.7 Hz, 2H), 2.08-1.92 (m, 2H), 1.91-1.76 (m, 2H).</p><heading id="h-0278" level="1">Example 202: (R/S)-N-Cyclopropyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]propanamide and its Trifluoroacetic Acid Salt</heading><p id="p-0930" num="0996"><chemistry id="CHEM-US-00329" num="00329"><img id="EMI-C00329" he="37.85mm" wi="39.79mm" file="US20230000833A1-20230105-C00329.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0931" num="0997">The title compound was prepared in a manner analogous to Example 20 using 2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1 -yl)propanoic acid (Intermediate 44) and cyclopropanamine in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.73 (s, 1H), 8.30 (d, J=1.9 Hz, 1H), 8.18 (d, J=4.1 Hz, 1H), 8.00-7.94 (m, 2H), 7.76-7.69 (m, 3H), 5.01 (q, J=7.2 Hz, 1H), 2.69-2.60 (m, 1H), 1.57 (d, J=7.2 Hz, 3H), 0.63-0.54 (m, 2H), 0.44-0.34 (m, 2H).</p><heading id="h-0279" level="1">Example 203: (R/S)-1-[2-(Azetidin-1-yl)-1-methyl-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-1D]pyridin-2-one and its trifluoroacetic acid salt</heading><p id="p-0932" num="0998"><chemistry id="CHEM-US-00330" num="00330"><img id="EMI-C00330" he="34.21mm" wi="39.79mm" file="US20230000833A1-20230105-C00330.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0933" num="0999">The title compound was prepared in a manner analogous to Example 20 using 2-(2-oxo-6-(3-(trifluoromethyl)phenyl)-3-trityl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)propanoic acid (Intermediate 44) and azetidine in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.84 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 7.98-7.93 (m, 2H), 7.77-7.70 (m, 3H), 5.16 (q, J=7.1 Hz, 1H), 4.26 4.18 (m, 1H), 3.93-3.79 (m, 3H), 2.22-2.09 (m, 2H), 1.52 (d, J=7.1 Hz, 3H).</p><heading id="h-0280" level="1">Example 204: 1-(2-Morpholino-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0934" num="1000"><chemistry id="CHEM-US-00331" num="00331"><img id="EMI-C00331" he="37.76mm" wi="39.96mm" file="US20230000833A1-20230105-C00331.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0935" num="1001">The title compound was prepared in a manner analogous to Example 20, using morpholine in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 406.1; m/z found, 407.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.01-7.95 (m, 2H), 7.81 (d, J=2.0 Hz, 1H), 7.76-7.68 (m, 2H), 4.85 (s, 2H), 3.69 (t, J=4.5</p><p id="p-0936" num="1002">Hz, 2H), 3.59 (t, J=4.9 Hz, 4H).</p><p id="p-0937" num="1003">Example 205: N-Cyclopentyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</p><p id="p-0938" num="0000"><chemistry id="CHEM-US-00332" num="00332"><img id="EMI-C00332" he="41.06mm" wi="39.79mm" file="US20230000833A1-20230105-C00332.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0939" num="1004">The title compound was prepared in a manner analogous to Example 20, using cyclopentanamine in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 404.1; m/z found, 405.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.71 (s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.19 (d, J=7.2 Hz, 1H), 8.03-7.95 (m, 2H), 7.81 (d, J=2.0 Hz, 1H), 7.75-7.68 (m, 2H), 4.49 (s, 2H), 4.05-3.96 (m, 1H), 1.85-1.75 (m, 2H), 1.64 (dd, J=9.8, 5.7 Hz, 2H), 1.56-1.45 (m, 2H), 1.45-1.35 (m, 2H).</p><heading id="h-0281" level="1">Example 206: 1-[2-Oxo-2-(1-piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0940" num="1005"><chemistry id="CHEM-US-00333" num="00333"><img id="EMI-C00333" he="37.00mm" wi="39.96mm" file="US20230000833A1-20230105-C00333.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0941" num="1006">The title compound was prepared in a manner analogous to Example 20, using piperidine in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 404.1; m/z found, 405.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.72 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.01-7.94 (m, 2H), 7.80 (d, J=2.0 Hz, 1H), 7.76-7.68 (m, 2H), 4.81 (s, 2H), 3.54-3.48 (m, 2H), 3.41 (t, J=5.5 Hz, 2H), 1.65-1.57 (m, 4H), 1.49-1.40 (m, 2H).</p><heading id="h-0282" level="1">Example 207: 1-[2-(2,6-Diazaspiro[3.3]heptan-6-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0942" num="1007"><chemistry id="CHEM-US-00334" num="00334"><img id="EMI-C00334" he="41.83mm" wi="42.16mm" file="US20230000833A1-20230105-C00334.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0943" num="1008">The title compound was prepared in a manner analogous to Example 20, using tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 417.1; m/z found, 418.2 [M+H]<sup>+</sup>.</p><heading id="h-0283" level="1">Example 208: 2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-pyridyl)acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0944" num="1009"><chemistry id="CHEM-US-00335" num="00335"><img id="EMI-C00335" he="41.91mm" wi="39.79mm" file="US20230000833A1-20230105-C00335.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0945" num="1010">The title compound was prepared in a manner analogous to Example 20, using pyridin-2-amine in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 413.1; m/z found, 414.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 10.92 (s, 1H), 8.39-8.32 (m, 2H), 8.06-7.92 (m, 4H), 7.81-7.66 (m, 3H), 7.12 (ddd, J=7.4, 4.9, 1.1 Hz, 1H), 4.86 (s, 2H).</p><heading id="h-0284" level="1">Example 209: N-(3,3-Difluoro-1-methyl-cyclobutyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-0946" num="1011"><chemistry id="CHEM-US-00336" num="00336"><img id="EMI-C00336" he="42.76mm" wi="39.79mm" file="US20230000833A1-20230105-C00336.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0947" num="1012">The title compound was prepared in a manner analogous to Example 20, using 3,3-difluoro-1-methylcyclobutan-1-amine in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 440.1; m/z found, 441.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.73 (s, 1H), 8.63 (s, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.02-7.96 (m, 2H), 7.82 (d, J=2.1 Hz, 1H), 7.75-7.68 (m, 2H), 4.51 (s, 2H), 2.95-2.82 (m, 2H), 1.43 (s, 3H).</p><heading id="h-0285" level="1">Example 210: 1-[(6-Methoxy-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0948" num="1013"><chemistry id="CHEM-US-00337" num="00337"><img id="EMI-C00337" he="28.53mm" wi="57.40mm" file="US20230000833A1-20230105-C00337.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0949" num="1014">The title compound was prepared in a manner analogous to Example 21, using 5-(chloromethyl)-2-methoxypyridine. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 400.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3b4; 11.82 (s, 1H), 8.31 (dd, J=7.3, 2.2 Hz, 2H), 8.03-7.96 (m, 3H), 7.77-7.68 (m, 3H), 6.79 (d, J=8.6 Hz, 1H), 5.06 (s, 2H), 3.80 (s, 3H).</p><heading id="h-0286" level="1">Example 211: 1-(Cyclopropylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0950" num="1015"><chemistry id="CHEM-US-00338" num="00338"><img id="EMI-C00338" he="28.70mm" wi="42.50mm" file="US20230000833A1-20230105-C00338.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0951" num="1016">The title compound was prepared in a manner analogous to Example 21, using (bromomethyl)cyclopropane in Step A (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O, 333.1; m/z found, 334.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.70 (s, 1H), 8.30 (d, J=2.0 Hz, 1H), 8.07-8.00 (m, 2H), 7.97 (d, J=2.0 Hz, 1H), 7.75-7.67 (m, 2H), 3.77 (d, J=7.1 Hz, 2H), 1.36-1.21 (m, 1H), 0.50-0.43 (m, 2H), 0.43-0.34 (m, 2H).</p><heading id="h-0287" level="1">Example 212: 3-[[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile and its Trifluoroacetic Acid Salt</heading><p id="p-0952" num="1017"><chemistry id="CHEM-US-00339" num="00339"><img id="EMI-C00339" he="32.26mm" wi="47.92mm" file="US20230000833A1-20230105-C00339.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0953" num="1018">The title compound was prepared in a manner analogous to Example 21, using 3-(bromomethyl)benzonitrile in Step A. MS (ESI): mass calcd. for C<sub>21</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 394.1; m/z found, 395.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.02-7.97 (m, 2H), 7.94 (d, J=1.9 Hz, 1H), 7.89-7.86 (m, 1H), 7.79-7.66 (m, 4H), 7.59-7.53 (m, 1H), 5.17 (s, 2H).</p><heading id="h-0288" level="1">Example 213: 2-[[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile and its Trifluoroacetic Acid Salt</heading><p id="p-0954" num="1019"><chemistry id="CHEM-US-00340" num="00340"><img id="EMI-C00340" he="29.13mm" wi="47.92mm" file="US20230000833A1-20230105-C00340.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0955" num="1020">The title compound was prepared in a manner analogous to Example 21, using 2-(bromomethyl)benzonitrile in Step A. MS (ESI): mass calcd. for C<sub>21</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 394.1; m/z found, 395.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.92 (s, 1H), 8.37 (d, J=1.9 Hz, 1H), 8.00-7.96 (m, 2H), 7.93-7.89 (m, 2H), 7.74-7.63 (m, 3H), 7.52-7.48 (m, 1H), 7.26 (d, J=7.9 Hz, 1H), 5.33 (s, 2H).</p><heading id="h-0289" level="1">Example 214: 1-[2-Oxo-2-(2-thienyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0956" num="1021"><chemistry id="CHEM-US-00341" num="00341"><img id="EMI-C00341" he="36.24mm" wi="39.79mm" file="US20230000833A1-20230105-C00341.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0957" num="1022">The title compound was prepared in a manner analogous to Example 21, using 2-bromo-1-(thiophen-2-yl)ethanone in Step A MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S, 403.1; m/z found, 404.1 [M+H]<sup>+</sup>.</p><heading id="h-0290" level="1">Example 215: 1-(2-Oxo-2-thiazol-2-yl-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0958" num="1023"><chemistry id="CHEM-US-00342" num="00342"><img id="EMI-C00342" he="36.24mm" wi="39.79mm" file="US20230000833A1-20230105-C00342.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0959" num="1024">The title compound was prepared in a manner analogous to Example 21, using 2-bromo-1-(thiazol-2-yl)ethan-1-one in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>11</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 404.1; m/z found, 405.1 [M+H]<sup>+</sup>.<sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.90 (s, 1H), 8.41-8.35 (m, 2H), 8.32-8.28 (m, 1H), 8.09-7.96 (m, 3H), 7.77-7.66 (m, 2H), 5.60 (s, 2H).</p><heading id="h-0291" level="1">Example 216: (R/S)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0960" num="1025"><chemistry id="CHEM-US-00343" num="00343"><img id="EMI-C00343" he="28.53mm" wi="44.70mm" file="US20230000833A1-20230105-C00343.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0961" num="1026">The title compound was prepared in a manner analogous to Example 21, using 2-(bromomethyl)oxetane in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 349.1; m/z found, 350.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.77 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.05-7.97 (m, 2H), 7.93 (d, J=2.0 Hz, 1H), 7.76-7.68 (m, 2H), 5.10-5.02 (m, 1H), 4.49-4.42 (m, 1H), 4.33 (dt, J=9.0, 6.0 Hz, 1H), 4.22-4.05 (m, 2H), 2.72-2.60 (m, 1H).</p><heading id="h-0292" level="1">Example 217: (R/S)-1-(Morpholin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0962" num="1027"><chemistry id="CHEM-US-00344" num="00344"><img id="EMI-C00344" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00344.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0963" num="1028">The title compound was prepared in a manner analogous to Example 21, using tert-butyl 2-(bromomethyl)morpholine-4-carboxylate in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 378.1; m/z found, 379.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.81 (s, 1H), 8.94-8.85 (m, 1H), 8.84-8.72 (m, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.03-7.99 (m, 2H), 7.87 (d, J=1.9 Hz, 1H), 7.77-7.70 (m, 2H), 4.11-3.99 (m, 3H), 3.98-3.92 (m, 1H), 3.65 (td, J=12.5, 2.4 Hz, 1H), 3.37-3.30 (m, 1H), 3.18-3.11 (m, 1H), 3.04-2.86 (m, 2H).</p><heading id="h-0293" level="1">Example 218: (R/S)-1-(Tetrahydropyran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0964" num="1029"><chemistry id="CHEM-US-00345" num="00345"><img id="EMI-C00345" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00345.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0965" num="1030">The title compound was prepared in a manner analogous to Example 21, using 2-(bromomethyl)tetrahydro-2H-pyran in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 377.1; m/z found, 378.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.69 (s, 1H), 8.29 (d, J=2.0 Hz, 1H), 8.03-7.98 (m, 2H), 7.85 (d, J=2.0 Hz, 1H), 7.76-7.69 (m, 2H), 3.97-3.90 (m, 1H), 3.87-3.78 (m, 2H), 3.70-3.63 (m, 1H), 1.81-1.73 (m, 1H), 1.64-1.56 (m, 1H), 1.51-1.38 (m, 3H), 1.33-1.22 (m, 1H).</p><heading id="h-0294" level="1">Example 219: 6-[3-(Trifluoromethyl)phenyl]-1-[[4-(trifluoromethyl)phenyl]methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0966" num="1031"><chemistry id="CHEM-US-00346" num="00346"><img id="EMI-C00346" he="28.62mm" wi="56.39mm" file="US20230000833A1-20230105-C00346.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0967" num="1032">The title compound was prepared in a manner analogous to Example 21, using 1-(bromomethyl)-4-(trifluoromethyl)benzene in Step A. MS (ESI): mass calcd. for C<sub>21</sub>H<sub>13</sub>F<sub>6</sub>N<sub>3</sub>O, 437.1; m/z found, 438.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.89 (s, 1H), 8.34 (d, J=1.9 Hz, 1H), 8.01-7.96 (m, 2H), 7.93 (d, J=2.0 Hz, 1H), 7.75-7.67 (m, 4H), 7.57 (d, J=8.0 Hz, 2H), 5.23 (s, 2H).</p><heading id="h-0295" level="1">Example 220: 1-[(3-Fluoro-4-methoxy-phenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0968" num="1033"><chemistry id="CHEM-US-00347" num="00347"><img id="EMI-C00347" he="32.00mm" wi="57.40mm" file="US20230000833A1-20230105-C00347.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0969" num="1034">The title compound was prepared in a manner analogous to Example 21, using 4-(bromomethyl)-2-fluoro-1-methoxybenzene in Step A. MS (ESI): mass calcd. for C<sub>21</sub>H<sub>15</sub>F<sub>4</sub>N<sub>3</sub>O<sub>2</sub>, 417.1; m/z found, 418.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.83 (s, 1H), 8.32(d, J=2.0 Hz, 1H), 8.02-7.96 (m, 2H), 7.91 (d, J=2.1 Hz, 1H), 7.76-7.68 (m, 2H), 7.32-7.25 (m, 1H), 7.21-7.09 (m, 2H), 5.04(s, 2H), 3.78 (s, 3H).</p><heading id="h-0296" level="1">Example 221: 1-[(4-Fluoro-3-methyl-phenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0970" num="1035"><chemistry id="CHEM-US-00348" num="00348"><img id="EMI-C00348" he="31.41mm" wi="54.02mm" file="US20230000833A1-20230105-C00348.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0971" num="1036">The title compound was prepared in a manner analogous to Example 21, using 4-(bromomethyl)-1-fluoro-2-methylbenzene in Step A. MS (ESI): mass calcd. for C<sub>21</sub>H<sub>15</sub>F<sub>4</sub>N<sub>3</sub>O, 401.1; m/z found, 402.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.82 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.00-7.95 (m, 2H), 7.88 (d, J=2.0 Hz, 1H), 7.75-7.68 (m, 2H), 7.34-7.29 (m, 1H), 7.25-7.20 (m, 1H), 7.12-7.06 (m, 1H), 5.05 (s, 2H), 2.19 (d, J=1.9 Hz, 3H).</p><heading id="h-0297" level="1">Example 222: 1-[(3-Fluorophenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0972" num="1037"><chemistry id="CHEM-US-00349" num="00349"><img id="EMI-C00349" he="32.00mm" wi="47.92mm" file="US20230000833A1-20230105-C00349.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0973" num="1038">The title compound was prepared in a manner analogous to Example 21, using 1-(bromomethyl)-3-fluorobenzene in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>13</sub>F<sub>4</sub>N<sub>3</sub>O, 387.1; m/z found, 388.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 8.33 (t, J=1.7 Hz, 1H), 8.01-7.96 (m, 2H), 7.92 (t, J=1.7 Hz, 1H), 7.75-7.68 (m, 2H), 7.42-7.36 (m, 1H), 7.25-7.17 (m, 2H), 7.14-7.08 (m, 1H), 5.14 (s, 2H).</p><heading id="h-0298" level="1">Example 223: (R*)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0974" num="1039"><chemistry id="CHEM-US-00350" num="00350"><img id="EMI-C00350" he="28.53mm" wi="44.70mm" file="US20230000833A1-20230105-C00350.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0975" num="1040">The title compound was prepared in a manner analogous to Example 21, using 2-(bromomethyl)oxetane in Step A. Purification (SFC separation, Chiralpak IA, 5 mm; Supercritical CO<sub>2</sub>: MeOH, 75/25, 200 mL/min) afforded the title compound and (S*)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 224). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 349.1; m/z found, 350.2 [M+H]<sup>+</sup>.<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.77 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.05-7.97 (m, 2H), 7.93 (d, J=2.0 Hz, 1H), 7.76-7.68 (m, 2H), 5.10-5.02 (m, 1H), 4.49-4.42 (m, 1H), 4.33 (dt, J=9.0, 6.0 Hz, 1H), 4.22-4.05 (m, 2H), 2.72-2.60 (m, 1H).</p><heading id="h-0299" level="1">Example 224: (S*)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0976" num="1041"><chemistry id="CHEM-US-00351" num="00351"><img id="EMI-C00351" he="28.53mm" wi="44.70mm" file="US20230000833A1-20230105-C00351.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0977" num="1042">Isolated from SFC Chiral Separation, Example 223. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 349.1; m/z found, 350.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.77 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.05-7.97 (m, 2H), 7.93 (d, J=2.0 Hz, 1H), 7.76-7.68 (m, 2H), 5.10-5.02 (m, 1H), 4.49-4.42 (m, 1H), 4.33 (dt, J=9.0, 6.0 Hz, 1H), 4.22-4.05 (m, 2H), 2.72-2.60 (m, 1H).</p><heading id="h-0300" level="1">Example 225: (R/S)-1-[(2,2-Difluorocyclopropyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0978" num="1043"><chemistry id="CHEM-US-00352" num="00352"><img id="EMI-C00352" he="29.13mm" wi="45.55mm" file="US20230000833A1-20230105-C00352.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0979" num="1044">The title compound was prepared in a manner analogous to Example 21, using 2-(bromomethyl)-1,1-difluorocyclopropane in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>5</sub>N<sub>3</sub>O, 369.1; m/z found, 370.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.78 (s, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.07-8.01 (m, 2H), 7.98 (d, J=2.0 Hz, 1H), 7.76-7.69 (m, 2H), 4.14-4.07 (m, 1H), 4.02-3.94 (m, 1H), 2.41-2.29 (m, 1H), 1.70-1.60 (m, 1H), 1.52-1.42 (m, 1H).</p><heading id="h-0301" level="1">Example 226: 1-[(3-Fluorooxetan-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0980" num="1045"><chemistry id="CHEM-US-00353" num="00353"><img id="EMI-C00353" he="28.62mm" wi="45.55mm" file="US20230000833A1-20230105-C00353.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0981" num="1046">The title compound was prepared in a manner analogous to Example 21, using 3-(bromomethyl)-3-fluorooxetane in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>4</sub>N<sub>3</sub>O<sub>2</sub>, 367.1; m/z found, 368.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.89 (s, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.03-7.96 (m, 2H), 7.89 (t, J=1.7 Hz, 1H), 7.77-7.69 (m, 2H), 4.85-4.62 (m, 4H), 4.55-4.45 (m, 2H).</p><heading id="h-0302" level="1">Example 227: 1-(Pyrimidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0982" num="1047"><chemistry id="CHEM-US-00354" num="00354"><img id="EMI-C00354" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00354.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0983" num="1048">The title compound was prepared in a manner analogous to Example 21, using 2-(chloromethyl)pyrimidine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>O, 371.1; m/z found, 372.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.79 (s, 1H), 8.75 (d, J=4.9 Hz, 2H), 8.34 (d, J=2.0 Hz, 1H), 8.01-7.96 (m, 2H), 7.90 (d, J=2.0 Hz, 1H), 7.72-7.65 (m, 2H), 7.41 (t, J=4.9 Hz, 1H), 5.35 (s, 2H).</p><heading id="h-0303" level="1">Example 228: 1-(2-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0984" num="1049"><chemistry id="CHEM-US-00355" num="00355"><img id="EMI-C00355" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00355.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0985" num="1050">The title compound was prepared in a manner analogous to Example 21, using 2-(chloromethyl)pyridine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.82 (s, 1H), 8.53-8.47 (m, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.00-7.93 (m, 2H), 7.84 (d, J=2.0 Hz, 1H), 7.80 (td, J=7.7, 1.8 Hz, 1H), 7.73-7.66 (m, 2H), 7.36-7.27 (m, 2H), 5.24 (s, 2H).</p><heading id="h-0304" level="1">Example 229: 1-(4-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0986" num="1051"><chemistry id="CHEM-US-00356" num="00356"><img id="EMI-C00356" he="28.62mm" wi="48.77mm" file="US20230000833A1-20230105-C00356.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0987" num="1052">The title compound was prepared in a manner analogous to Example 21, using 4-(chloromethyl)pyridine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.95 (s, 1H), 8.71-8.67 (m, 2H), 8.37 (d, J=2.0 Hz, 1H), 8.00-7.96 (m, 2H), 7.92 (d, J=2.0 Hz, 1H), 7.74-7.67 (m, 2H), 7.63-7.60 (m, 2H), 5.31 (s, 2H).</p><heading id="h-0305" level="1">Example 230: 1-(3-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0988" num="1053"><chemistry id="CHEM-US-00357" num="00357"><img id="EMI-C00357" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00357.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0989" num="1054">The title compound was prepared in a manner analogous to Example 21, using 3-(chloromethyl)pyridine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.89 (s, 1H), 8.78 (d, J=2.2 Hz, 1H), 8.62 (dd, J=5.1, 1.6 Hz, 1H), 8.35 (d, J=2.0 Hz, 1H), 8.07-7.96 (m, 4H), 7.76-7.67 (m, 2H), 7.60 (dd, J=7.9, 5.1 Hz, 1H), 5.22 (s, 2H).</p><heading id="h-0306" level="1">Example 231: 1-[(2-Methylpyrimidin-5-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-0990" num="1055"><chemistry id="CHEM-US-00358" num="00358"><img id="EMI-C00358" he="28.62mm" wi="53.26mm" file="US20230000833A1-20230105-C00358.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0991" num="1056">The title compound was prepared in a manner analogous to Example 21, using 5-(chloromethyl)-2-methylpyrimidine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, 386.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.75 (s, 2H), 8.33 (d, J=2.0 Hz, 1H), 8.05-7.98 (m, 3H), 7.78-7.67 (m, 2H), 5.12 (s, 2H), 2.58 (s, 3H).</p><heading id="h-0307" level="1">Example 232: 1-(Pyridazin-3-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0992" num="1057"><chemistry id="CHEM-US-00359" num="00359"><img id="EMI-C00359" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00359.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0993" num="1058">The title compound was prepared in a manner analogous to Example 21, using 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>O, 371.1; m/z found,372.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 9.15 (dd, J=4.8, 1.8 Hz, 1H), 8.36 (d, J=2.0 Hz, 1H), 8.01-7.95 (m, 2H), 7.92 (d, J=2.0 Hz, 1H), 7.74-7.61 (m, 4H), 5.44 (s, 2H).</p><heading id="h-0308" level="1">Example 233: 1-[(3-Methoxy-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0994" num="1059"><chemistry id="CHEM-US-00360" num="00360"><img id="EMI-C00360" he="29.21mm" wi="47.92mm" file="US20230000833A1-20230105-C00360.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0995" num="1060">The title compound was prepared in a manner analogous to Example 21, using 2-(chloromethyl)-3-methoxypyridine in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 400.1; m/z found, 401.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.72 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 7.98-7.91 (m, 3H), 7.77 (d, J=2.1 Hz, 1H), 7.72-7.64 (m, 2H), 7.46 (dd, J=8.3, 1.3 Hz, 1H), 7.27 (dd, J=8.3, 4.7 Hz, 1H), 5.21 (s, 2H), 3.91 (s, 3H).</p><heading id="h-0309" level="1">Example 234: 1-[(3-Fluoro-5-methyl-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0996" num="1061"><chemistry id="CHEM-US-00361" num="00361"><img id="EMI-C00361" he="29.21mm" wi="53.26mm" file="US20230000833A1-20230105-C00361.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0997" num="1062">The title compound was prepared in a manner analogous to Example 21, using 2-(chloromethyl)-3-fluoro-5-methylpyridine in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O, 402.1; m/z found, 403.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.77 (s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.13-8.10 (m, 1H), 7.99-7.92 (m, 2H), 7.83 (d, J=2.0 Hz, 1H), 7.73-7.66 (m, 2H), 7.62-7.57 (m, 1H), 5.28 (s, 2H), 2.27 (s, 3H).</p><heading id="h-0310" level="1">Example 235: 1-[(6-Methyl-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-0998" num="1063"><chemistry id="CHEM-US-00362" num="00362"><img id="EMI-C00362" he="28.62mm" wi="53.26mm" file="US20230000833A1-20230105-C00362.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0999" num="1064">The title compound was prepared in a manner analogous to Example 21, using 5-(chloromethyl)-2-methylpyridine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 384.1; m/z found, 385.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.71-8.67 (m, 1H), 8.34 (d, J=1.9 Hz, 1H), 8.04-7.96 (m, 4H), 7.76-7.68 (m, 2H), 7.55-7.48 (m, 1H), 5.18 (s, 2H), 2.54 (s, 3H).</p><heading id="h-0311" level="1">Example 236: 1-(2H-Tetrazol-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1000" num="1065"><chemistry id="CHEM-US-00363" num="00363"><img id="EMI-C00363" he="28.62mm" wi="48.77mm" file="US20230000833A1-20230105-C00363.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1001" num="1066">The title compound was prepared in a manner analogous to Example 21, using 5-(chloromethyl)-2H-tetrazole in Step A. MS (ESI): mass calcd. for C<sub>15</sub>H<sub>10</sub>F<sub>3</sub>N<sub>7</sub>O, 361.1; m/z found, 362.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.91 (s, 1H), 8.38 (d, J=2.0 Hz, 1H), 8.01-7.98 (m, 2H), 7.95 (d, J=2.0 Hz, 1H), 7.75-7.69 (m, 2H), 5.50-5.46 (s, 2H).</p><heading id="h-0312" level="1">Example 237: 1-[Difluoro(3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1002" num="1067"><chemistry id="CHEM-US-00364" num="00364"><img id="EMI-C00364" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00364.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1003" num="1068">The title compound was prepared in a manner analogous to Example 21, using 3-(chlorodifluoromethyl)pyridine in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>11</sub>F<sub>5</sub>N<sub>4</sub>O, 406.1; m/z found, 407.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 12.25 (s, 1H), 9.02-8.95 (m, 1H), 8.81 (d, J=4.3 Hz, 1H), 8.48 (d, J=1.9 Hz, 1H), 8.23-8.17 (m, 1H), 8.06-8.00 (m, 2H), 7.95-7.92 (m, 1H), 7.80-7.70 (m, 2H), 7.62 (dd, J=8.0, 4.9 Hz, 1H).</p><heading id="h-0313" level="1">Example 238: 1-[(6-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-1D]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1004" num="1069"><chemistry id="CHEM-US-00365" num="00365"><img id="EMI-C00365" he="28.70mm" wi="54.02mm" file="US20230000833A1-20230105-C00365.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1005" num="1070">The title compound was prepared in a manner analogous to Example 21, using 5-(chloromethyl)-2-fluoropyridine in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>F<sub>4</sub>N<sub>4</sub>O, 388.1; m/z found, 389.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.38-8.34 (m, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.04-7.95 (m, 4H), 7.76-7.68 (m, 2H), 7.16 (dd, J=8.5, 2.7 Hz, 1H), 5.15 (s, 2H).</p><heading id="h-0314" level="1">Example 239: 1-(2-Cyclopropyl-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1006" num="1071"><chemistry id="CHEM-US-00366" num="00366"><img id="EMI-C00366" he="32.94mm" wi="39.79mm" file="US20230000833A1-20230105-C00366.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1007" num="1072">The title compound was prepared in a manner analogous to Example 21, using 2-bromo-1-cyclopropylethan-1-one in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 361.1; m/z found, 362.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.78 (s, 1H), 8.32 (d, J=1.9 Hz, 1H), 8.01-7.96 (m, 2H), 7.85 (d, J=2.0 Hz, 1H), 7.76-7.67 (m, 2H), 5.03 (s, 2H), 2.26-2.16 (m, 1H), 1.05-0.90 (m, 4H).</p><heading id="h-0315" level="1">Example 240: 1-(2-Oxobutyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1008" num="1073"><chemistry id="CHEM-US-00367" num="00367"><img id="EMI-C00367" he="32.09mm" wi="39.79mm" file="US20230000833A1-20230105-C00367.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1009" num="1074">The title compound was prepared in a manner analogous to Example 21, using 1-bromobutan-2-one in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 349.1; m/z found, 350.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.79 (s, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.01-7.94 (m, 2H), 7.81 (d, J=2.1 Hz, 1H), 7.75-7.67 (m, 2H), 4.86 (s, 2H), 2.62 (q, J=7.2 Hz, 2H), 0.99 (t, J=7.2 Hz, 3H).</p><heading id="h-0316" level="1">Example 241: 1-(3-Methyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1010" num="1075"><chemistry id="CHEM-US-00368" num="00368"><img id="EMI-C00368" he="32.09mm" wi="39.79mm" file="US20230000833A1-20230105-C00368.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1011" num="1076">The title compound was prepared in a manner analogous to Example 21, using 1-bromo-3-methylbutan-2-one in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, 364.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.79 (s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.00-7.94 (m, 2H), 7.77 (d, J=2.0 Hz, 1H), 7.75-7.69 (m, 2H), 4.95 (s, 2H), 2.90-2.80 (m, 1H), 1.12 (d, J=6.9 Hz, 6H).</p><heading id="h-0317" level="1">Example 242: 1-[(5-Methyl-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1012" num="1077"><chemistry id="CHEM-US-00369" num="00369"><img id="EMI-C00369" he="31.24mm" wi="47.92mm" file="US20230000833A1-20230105-C00369.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1013" num="1078">The title compound was prepared in a manner analogous to Example 21, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 384.1; m/z found, 385.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.88 (s, 1H), 8.61-8.58 (m, 1H), 8.49-8.46 (m, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.03-7.95 (m, 3H), 7.90-7.85 (m, 1H), 7.76-7.67 (m, 2H), 5.18 (s, 2H), 2.33 (s, 3H).</p><heading id="h-0318" level="1">Example 243: 1-(Thiadiazol-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1014" num="1079"><chemistry id="CHEM-US-00370" num="00370"><img id="EMI-C00370" he="28.53mm" wi="46.74mm" file="US20230000833A1-20230105-C00370.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1015" num="1080">The title compound was prepared in a manner analogous to Example 21, using 4-(chloromethyl)-1,2,3-thiadiazole in Step A. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>10</sub>F<sub>3</sub>N<sub>5</sub>OS, 377.1; m/z found, 378.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 9.17 (s, 1H), 8.35 (d, J=2.0 Hz, 1H), 8.02-7.98 (m, 3H), 7.76-7.67 (m, 2H), 5.62 (s, 2H).</p><heading id="h-0319" level="1">Example 244: 1-[(6-Oxo-1H-pyridin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1016" num="1081"><chemistry id="CHEM-US-00371" num="00371"><img id="EMI-C00371" he="28.53mm" wi="54.19mm" file="US20230000833A1-20230105-C00371.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1017" num="1082">The title compound was prepared in a manner analogous to Example 21, using 5-(chloromethyl)pyridin-2(1H)-one in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 386.1; m/z found, 387.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 11.51 (br s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.04-7.98 (m, 3H), 7.76-7.69 (m, 2H), 7.58 (d, J=2.6 Hz, 1H), 7.48 (dd, J=9.5, 2.6 Hz, 1H), 6.30 (d, J=9.5 Hz, 1H), 4.83 (s, 2H).</p><heading id="h-0320" level="1">Example 245: (R/S)-1-(Azetidin-2-ylmethyl)-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1018" num="1083"><chemistry id="CHEM-US-00372" num="00372"><img id="EMI-C00372" he="31.33mm" wi="44.70mm" file="US20230000833A1-20230105-C00372.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1019" num="1084">The title compound was prepared in a manner analogous to Example 21, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and tert-butyl 2-(bromomethyl)azetidine-1-carboxylate in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O, 362.1; m/z found, 363.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 10.21-9.98 (m, 1H), 8.88-8.67 (m, 1H), 8.40 (d, J=1.7 Hz, 1H), 7.79-7.76 (m, 1H), 7.76-7.72 (m, 1H), 7.70-7.65 (m, 1H), 7.64-7.58 (m, 1H), 7.52 (d, J=1.8 Hz, 1H), 5.26-5.11 (m, 1H), 4.55-4.21 (m, 3H), 4.11-3.99 (m, 1H), 3.58 (s, 3H), 2.86-2.71 (m, 1H), 2.57-2.42 (m, 1H).</p><heading id="h-0321" level="1">Example 246: 3-Methyl-1-(pyrimidin-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1020" num="1085"><chemistry id="CHEM-US-00373" num="00373"><img id="EMI-C00373" he="31.33mm" wi="48.77mm" file="US20230000833A1-20230105-C00373.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1021" num="1086">The title compound was prepared in a manner analogous to Example 21, Step A, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and pyrimidin-4-ylmethyl methanesulfonate (prepared in a manner analogous to Example 23, Step A) MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, 386.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.09 (d, J=1.4 Hz, 1H), 8.75 (d, J=5.2 Hz, 1H), 8.44 (d, J=1.9 Hz, 1H), 8.02-7.96 (m, 3H), 7.75-7.66 (m, 2H), 7.47 (dd, J=5.2, 1.4 Hz, 1H), 5.33 (s, 2H), 3.43 (s, 3H).</p><heading id="h-0322" level="1">Example 247: 3-Methyl-1-(pyrimidin-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1022" num="1087"><chemistry id="CHEM-US-00374" num="00374"><img id="EMI-C00374" he="31.33mm" wi="47.92mm" file="US20230000833A1-20230105-C00374.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1023" num="1088">The title compound was prepared in a manner analogous to Example 21, Step A using pyrimidin-5-ylmethyl methanesulfonate (prepared in a manner analogous to Example 23, Step A) and 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.12 (s, 1H), 8.87 (s, 2H), 8.42 (d, J=1.9 Hz, 1H), 8.11 (d, J=1.9 Hz, 1H), 8.04-7.99 (m, 2H), 7.76-7.69 (m, 2H), 5.24 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0323" level="1">Example 248: 3-Methyl-1-[(2-methylpyrimidin-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1024" num="1089"><chemistry id="CHEM-US-00375" num="00375"><img id="EMI-C00375" he="31.33mm" wi="50.38mm" file="US20230000833A1-20230105-C00375.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1025" num="1090">The title compound was prepared in a manner analogous to Example 21, Step A, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and (2-methylpyrimidin-4-yl)methyl methanesulfonate (prepared analogous to Example 23, Step A). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>O, 399.1; m/z found, 400.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.61 (d, J=5.2 Hz, 1H), 8.45 (d, J=1.9 Hz, 1H), 8.04-7.97 (m, 3H), 7.75-7.65 (m, 2H), 7.12 (d, J=5.2 Hz, 1H), 5.25 (s, 2H), 3.18 (s, 3H), 2.57 (s, 3H).</p><heading id="h-0324" level="1">Example 249: 3-Methyl-1-(pyrazin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1026" num="1091"><chemistry id="CHEM-US-00376" num="00376"><img id="EMI-C00376" he="31.33mm" wi="47.92mm" file="US20230000833A1-20230105-C00376.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1027" num="1092">The title compound was prepared in a manner analogous to Example 21, Step A, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and pyrazin-2-ylmethyl methanesulfonate (prepared analogous to Example 23, Step A). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, 386.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.74 (d, J=1.4 Hz, 1H), 8.57-8.53 (m, 2H), 8.42 (d, J=1.9 Hz, 1H), 8.02-7.96 (m, 3H), 7.76-7.67 (m, 2H), 5.39 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0325" level="1">Example 250: 3-Methyl-1-(4-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1028" num="1093"><chemistry id="CHEM-US-00377" num="00377"><img id="EMI-C00377" he="31.33mm" wi="48.77mm" file="US20230000833A1-20230105-C00377.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1029" num="1094">The title compound was prepared in a manner analogous to Example 21, Step A, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and 4-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 384.1; m/z found, 385.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.77 8.73 (m, 2H), 8.46 (d, J=1.9 Hz, 1H), 8.02-7.97 (m, 3H), 7.78-7.67 (m, 4H), 5.42 (s, 2H), 3.44 (s, 3H).</p><heading id="h-0326" level="1">Example 251: 3-Methyl-1-(2-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1030" num="1095"><chemistry id="CHEM-US-00378" num="00378"><img id="EMI-C00378" he="31.33mm" wi="47.92mm" file="US20230000833A1-20230105-C00378.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1031" num="1096">The title compound was prepared in a manner analogous to Example 21, Step A, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and 2-(chloromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 384.1; m/z found, 385.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.48 (ddd, J=4.8, 1.9, 1.0 Hz, 1H), 8.41 (d, J=1.9 Hz, 1H), 8.01-7.96 (m, 2H), 7.92 (d, J=2.0 Hz, 1H), 7.77 (td, J=7.7, 1.8 Hz, 1H), 7.74-7.67 (m, 2H), 7.35-7.31 (m, 1H), 7.28 (ddd, J=7.6, 4.8, 1.1 Hz, 1H), 5.29 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0327" level="1">Example 252: 1-[(6-Methoxypyridazin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1032" num="1097"><chemistry id="CHEM-US-00379" num="00379"><img id="EMI-C00379" he="28.53mm" wi="57.40mm" file="US20230000833A1-20230105-C00379.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1033" num="1098">The title compound was prepared in a manner analogous to Example 23, using (6-methoxypyridazin-3-yl)methanol in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 401.1; m/z found, 402.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.84 (s, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.00-7.96 (m, 2H), 7.88 (d, J=2.0 Hz, 1H), 7.74-7.67 (m, 2H), 7.61 (d, J=9.2 Hz, 1H), 7.21 (d, J=9.1 Hz, 1H), 5.34 (s, 2H), 3.96 (s, 3H).</p><heading id="h-0328" level="1">Example 253: 1-(Pyrazin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1034" num="1099"><chemistry id="CHEM-US-00380" num="00380"><img id="EMI-C00380" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00380.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1035" num="1100">The title compound was prepared in a manner analogous to Example 23, using pyrazin-2-ylmethanol in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>O, 371.1; m/z found, 372.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.83 (s, 1H), 8.72 (d, J=1.3 Hz, 1H), 8.57-8.53 (m, 2H), 8.34 (d, J=2.0 Hz, 1H), 8.00-7.95 (m, 2H), 7.93-7.90 (d, J=2.0 Hz, 1H), 7.74-7.66 (m, 2H), 5.33 (s, 2H).</p><heading id="h-0329" level="1">Example 254: 1-[(2-Methylpyrimidin-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1036" num="1101"><chemistry id="CHEM-US-00381" num="00381"><img id="EMI-C00381" he="28.62mm" wi="50.38mm" file="US20230000833A1-20230105-C00381.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1037" num="1102">The title compound was prepared in a manner analogous to Example 23, using (2-methylpyrimidin-4-yl)methanol in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, 386.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.89 (s, 1H), 8.62 (d, J=5.2 Hz, 1H), 8.37 (d, J=2.0 Hz, 1H), 8.03-7.96 (m, 2H), 7.92 (d, J=2.0 Hz, 1H), 7.74-7.65 (m, 2H), 7.10 (d, J=5.2 Hz, 1H), 5.20 (s, 2H), 2.57 (s, 3H).</p><heading id="h-0330" level="1">Example 255: 1-(Pyrimidin-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1038" num="1103"><chemistry id="CHEM-US-00382" num="00382"><img id="EMI-C00382" he="28.62mm" wi="47.92mm" file="US20230000833A1-20230105-C00382.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1039" num="1104">The title compound was prepared in a manner analogous to Example 23, using pyrimidin-5-ylmethanol in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>O, 371.1; m/z found, 372.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.88 (s, 1H), 9.12 (s, 1H), 8.86 (s, 2H), 8.34 (d, J=1.9 Hz, 1H), 8.05 (d, J=2.0 Hz, 1H), 8.04-7.97 (m, 2H), 7.77-7.68 (m, 2H), 5.18 (s, 2H).</p><heading id="h-0331" level="1">Example 256: 1-[(5-Fluoropyrimidin-2-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1040" num="1105"><chemistry id="CHEM-US-00383" num="00383"><img id="EMI-C00383" he="28.62mm" wi="54.02mm" file="US20230000833A1-20230105-C00383.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1041" num="1106">The title compound was prepared in a manner analogous to Example 23, using (5-fluoropyrimidin-2-yl)methanol in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>11</sub>F<sub>4</sub>N<sub>5</sub>O, 389.1; m/z found, 390.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.82 (s, 1H), 8.86-8.85 (m, 2H), 8.34 (d, J=2.0 Hz, 1H), 8.00-7.96 (m, 2H), 7.90 (d, J=2.0 Hz, 1H), 7.73-7.66 (m, 2H), 5.37 (s, 2H).</p><heading id="h-0332" level="1">Example 257: 6-[3-(Trifluoromethyl)phenyl]-1-[[6-(trifluoromethyl)-3-pyridyl]methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1042" num="1107"><chemistry id="CHEM-US-00384" num="00384"><img id="EMI-C00384" he="28.62mm" wi="56.39mm" file="US20230000833A1-20230105-C00384.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1043" num="1108">The title compound was prepared in a manner analogous to Example 23, using (6-(trifluoromethyl)pyridin-3-yl)methanol in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>12</sub>F<sub>6</sub>N<sub>4</sub>O, 438.1; m/z found, 439.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.90 (s, 1H), 8.85 (d, J=2.3 Hz, 1H), 8.35 (d, J=1.9 Hz, 1H), 8.05-7.96 (m, 4H), 7.90-7.86 (m, 1H), 7.76-7.68 (m, 2H), 5.28 (s, 2H).</p><heading id="h-0333" level="1">Example 258: 1-[(5-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1044" num="1109"><chemistry id="CHEM-US-00385" num="00385"><img id="EMI-C00385" he="32.09mm" wi="47.92mm" file="US20230000833A1-20230105-C00385.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1045" num="1110">The title compound was prepared in a manner analogous to Example 23, using (5-fluoropyridin-3-yl)methanol in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>F<sub>4</sub>N<sub>4</sub>O, 388.1; m/z found, 389.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.88 (s, 1H), 8.54-8.50 (m, 2H), 8.35-8.33 (d, J=2.0 Hz, 1H), 8.02-7.98 (m, 3H), 7.76-7.67 (m, 3H), 5.20 (s, 2H).</p><heading id="h-0334" level="1">Example 259: 6-[3-(Trifluoromethyl)phenyl]-1-[[5-(trifluoromethyl)-3-pyridyl]methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1046" num="1111"><chemistry id="CHEM-US-00386" num="00386"><img id="EMI-C00386" he="32.68mm" wi="48.43mm" file="US20230000833A1-20230105-C00386.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1047" num="1112">The title compound was prepared in a manner analogous to Example 23, using (5-(trifluoromethyl)pyridin-3-yl)methanol in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>12</sub>F<sub>6</sub>N<sub>4</sub>O, 438.1; m/z found, 439.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.89 (s, 1H), 8.96-8.89 (m, 2H), 8.35 (d, J=2.0 Hz, 1H), 8.28-8.25 (m, 1H), 8.05 (d, J=2.0 Hz, 1H), 8.03-7.95 (m, 2H), 7.77-7.67 (m, 2H), 5.27 (s, 2H).</p><heading id="h-0335" level="1">Example 260: 6-[3-(Trifluoromethyl)phenyl]-1-[[4-(trifluoromethyl)-3-pyridyl]methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1048" num="1113"><chemistry id="CHEM-US-00387" num="00387"><img id="EMI-C00387" he="29.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00387.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1049" num="1114">The title compound was prepared in a manner analogous to Example 23, using (4-(trifluoromethyl)pyridin-3-yl)methanol in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>12</sub>F<sub>6</sub>N<sub>4</sub>O, 438.1; m/z found, 439.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.96 (s, 1H), 8.80 (d, J=5.1 Hz, 1H), 8.43 (s, 1H), 8.39 (d, J=2.0 Hz, 1H), 8.01-7.96 (m, 2H), 7.91 (d, J=2.0 Hz, 1H), 7.82 (d, J=5.1 Hz, 1H), 7.74-7.67 (m, 2H), 5.36 (s, 2H).</p><heading id="h-0336" level="1">Example 261: 3-Methyl-1-(pyrimidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1050" num="1115"><chemistry id="CHEM-US-00388" num="00388"><img id="EMI-C00388" he="31.33mm" wi="47.92mm" file="US20230000833A1-20230105-C00388.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1051" num="1116">The title compound was prepared in a manner analogous to Example 23, using pyrimidin-2-ylmethanol in Step A and 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, 386.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.75 (d, J=4.9 Hz, 2H), 8.43 (d, J=1.9 Hz, 1H), 8.03-7.96 (m, 3H), 7.74-7.65 (m, 2H), 7.42 (t, J=4.9 Hz, 1H), 5.41 (s, 2H), 3.43 (s, 3H).</p><heading id="h-0337" level="1">Example 262: 1-(2-cyclobutyl-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1052" num="1117"><chemistry id="CHEM-US-00389" num="00389"><img id="EMI-C00389" he="34.29mm" wi="39.79mm" file="US20230000833A1-20230105-C00389.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1053" num="1118">The title compound was prepared in a manner analogous to Example 24, using 2-bromo-1-cyclobutylethan-1-one in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 375.1; m/z found, 376.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 8.33 (d, J=2.0 Hz, 1H), 8.06-7.94 (m, 2H), 7.82 (d, J=2.0 Hz, 1H), 7.79-7.65 (m, 2H), 4.81 (s, 2H), 2.29-2.09 (m, 4H), 2.05-1.88 (m, 1H), 1.85-1.69 (m, 1H).</p><heading id="h-0338" level="1">Example 263: (R/S)-1-(Azetidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1054" num="1119"><chemistry id="CHEM-US-00390" num="00390"><img id="EMI-C00390" he="28.70mm" wi="44.70mm" file="US20230000833A1-20230105-C00390.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1055" num="1120">The title compound was prepared in a manner analogous to Example 24, using tert-butyl 2-(bromomethyl)azetidine-1-carboxylate in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 348.1; m/z found, 349.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.92 (s, 1H), 8.72-8.57 (m, 2H), 8.40-8.35 (m, 1H), 8.06-7.98 (m, 3H), 7.78-7.71 (m, 2H), 4.82-4.70 (m, 1H), 4.43-4.25 (m, 2H).</p><heading id="h-0339" level="1">Example 264: (R/S)-1-(Azetidin-2-ylmethyl)-6-[2-fluoro-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1056" num="1121"><chemistry id="CHEM-US-00391" num="00391"><img id="EMI-C00391" he="28.53mm" wi="44.70mm" file="US20230000833A1-20230105-C00391.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1057" num="1122">The title compound was prepared in a manner analogous to Example 24, using tert-butyl 2-(bromomethyl)azetidine-1-carboxylate in Step A and (2-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O, 366.1; m/z found, 367.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.98 (s, 1H), 8.67-8.55 (m, 2H), 8.18-8.14 (m, 1H), 7.94-7.89 (m, 1H), 7.88-7.82 (m, 2H), 7.56 (t, J=7.8 Hz, 1H), 4.74-4.67 (m, 1H) 4.39-4.19 (m, 2H), 3.97-3.86 (m, 1H), 3.81-3.72 (m, 1H), 2.45-2.33 (m, 2H).</p><heading id="h-0340" level="1">Example 265: (R/S)-1-(Azetidin-2-ylmethyl)-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1058" num="1123"><chemistry id="CHEM-US-00392" num="00392"><img id="EMI-C00392" he="23.88mm" wi="44.70mm" file="US20230000833A1-20230105-C00392.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1059" num="1124">The title compound was prepared in a manner analogous to Example 24, using tert-butyl 2-(bromomethyl)azetidine-1-carboxylate in Step A and phenylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>O, 280.1; m/z found, 281.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.83 (s, 1H), 8.73-8.56 (m, 2H), 8.27 (d, J=1.9 Hz, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.74-7.67 (m, 2H), 7.53-7.47 (m, 2H), 7.43-7.36 (m, 1H), 4.81-4.68 (m, 1H), 4.40-4.23 (m, 2H).</p><heading id="h-0341" level="1">Example 266: (R/S)-1-(Azetidin-2-ylmethyl)-6-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1060" num="1125"><chemistry id="CHEM-US-00393" num="00393"><img id="EMI-C00393" he="23.88mm" wi="50.12mm" file="US20230000833A1-20230105-C00393.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1061" num="1126">The title compound was prepared in a manner analogous to Example 24, using tert-butyl 2-(bromomethyl)azetidine-1-carboxylate in Step A and (4-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>FN<sub>4</sub>O, 298.1; m/z found, 299.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.84 (s, 1H), 8.82-8.62 (m, 2H), 8.29-8.23 (m, 1H), 7.92 (d, J=2.0 Hz, 1H), 7.77-7.72 (m, 2H), 7.37-7.31 (m, 2H), 4.80-4.68 (m, 1H), 4.41-4.22 (m, 2H), 3.99-3.86 (m, 1H), 3.84-3.73 (m, 1H), 2.48-2.34 (m, 2H).</p><heading id="h-0342" level="1">Example 267: (R/S)-1-(Azetidin-2-ylmethyl)-6-[4-fluoro-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1062" num="1127"><chemistry id="CHEM-US-00394" num="00394"><img id="EMI-C00394" he="28.53mm" wi="50.12mm" file="US20230000833A1-20230105-C00394.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1063" num="1128">The title compound was prepared in a manner analogous to Example 24, using tert-butyl 2-(bromomethyl)azetidine-1-carboxylate in Step A and (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O, 366.1; m/z found, 367.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.91 (s, 1H), 8.74-8.57 (m, 2H), 8.34 (d, J=1.9 Hz, 1H), 8.10-8.05 (m, 1H), 8.03 (dd, J=6.8, 2.4 Hz, 1H), 7.98 (d, J=2.0 Hz, 1H), 4.80-4.70 (m, 1H), 4.40-4.23 (m, 2H), 2.47-2.38 (m, 2H).</p><heading id="h-0343" level="1">Example 268: (R/S)-1-(Azetidin-2-ylmethyl)-6-(2,3-dichlorophenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1064" num="1129"><chemistry id="CHEM-US-00395" num="00395"><img id="EMI-C00395" he="28.19mm" wi="44.70mm" file="US20230000833A1-20230105-C00395.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1065" num="1130">The title compound was prepared in a manner analogous to Example 24, using tert-butyl 2-(bromomethyl)azetidine-1-carboxylate in Step A and (2,3-dichlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>C<sub>12</sub>N<sub>4</sub>O, 348.1; m/z found, 349.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.94 (s, 1H), 8.71-8.55 (m, 2H), 8.02 (d, J=1.8 Hz, 1H), 7.77 (d, J=1.9 Hz, 1H), 7.72 (dd, J=7.9, 1.7 Hz, 1H), 7.51-7.47 (m, 1H), 7.46-7.43 (m, 1H), 4.72-4.62 (m, 1H), 4.35-4.19 (m, 2H), 3.96-3.85 (m, 1H), 3.81-3.71 (m, 1H), 2.45-2.34 (m, 2H).</p><heading id="h-0344" level="1">Example 269: 6-(4-Fluoro-3-methyl-phenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1066" num="1131"><chemistry id="CHEM-US-00396" num="00396"><img id="EMI-C00396" he="31.24mm" wi="53.34mm" file="US20230000833A1-20230105-C00396.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1067" num="1132">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O, 348.1; m/z found, 349.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.84-11.79 (m, 1H), 8.70-8.68 (m, 1H), 8.60-8.58 (m, 1H), 8.23 (d, J=1.9 Hz, 1H), 8.10-8.06 (m, 1H), 7.83 (d, J=2.0 Hz, 1H), 7.61-7.57 (m, 1H), 7.52-7.47 (m, 1H), 7.26-7.20 (m, 1H), 5.20 (s, 2H), 2.39 (s, 3H), 2.30 (d, J=1.9 Hz, 3H).</p><heading id="h-0345" level="1">Example 270: 6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1068" num="1133"><chemistry id="CHEM-US-00397" num="00397"><img id="EMI-C00397" he="31.24mm" wi="53.34mm" file="US20230000833A1-20230105-C00397.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1069" num="1134">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 367.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.60-8.57 (m, 1H), 8.51-8.48 (m, 1H), 8.05 (t, J=1.6 Hz, 1H), 7.91-7.88 (m, 1H), 7.68 (t, J=1.6 Hz, 1H), 7.42-7.36 (m, 1H), 7.20-7.15 (m, 1H), 5.14 (s, 2H), 2.34 (s, 3H), 2.21 (t, J=1.8 Hz, 3H).</p><heading id="h-0346" level="1">Example 271: (R/S)-6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1070" num="1135"><chemistry id="CHEM-US-00398" num="00398"><img id="EMI-C00398" he="28.62mm" wi="50.12mm" file="US20230000833A1-20230105-C00398.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1071" num="1136">The title compound was prepared in a manner analogous to Example 24, using 2-(bromomethyl)oxetane in Step A and (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>4</sub>N<sub>3</sub>O<sub>2</sub>, 367.1; m/z found, 368.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.77 (s, 1H), 8.29 (d, J=2.0 Hz, 1H), 8.09-7.98 (m, 2H), 7.91 (d, J=2.0 Hz, 1H), 7.67-7.60 (m, 1H), 5.10-5.01 (m, 1H), 4.49-4.42 (m, 1H), 4.37-4.30 (m, 1H), 4.21-4.05 (m, 2H), 2.71-2.62 (m, 1H).</p><heading id="h-0347" level="1">Example 272: 6-(3,4-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1072" num="1137"><chemistry id="CHEM-US-00399" num="00399"><img id="EMI-C00399" he="31.24mm" wi="53.34mm" file="US20230000833A1-20230105-C00399.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1073" num="1138">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.65 (d, J=2.0 Hz, 1H), 8.53 (d, J=2.1 Hz, 1H), 8.29 (d, J=2.0 Hz, 1H), 7.99-7.95 (m, 1H), 7.89 (d, J=2.0 Hz, 1H), 7.83-7.77 (m, 1H), 7.57-7.50 (m, 2H), 5.17 (s, 2H), 2.38-2.33 (m, 3H).</p><heading id="h-0348" level="1">Example 273: 6-(3-Chlorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1074" num="1139"><chemistry id="CHEM-US-00400" num="00400"><img id="EMI-C00400" he="31.24mm" wi="47.92mm" file="US20230000833A1-20230105-C00400.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1075" num="1140">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (3-chlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>C<sub>1</sub>N<sub>4</sub>O, 350.1; m/z found, 351.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.64-8.61 (m, 1H), 8.53-8.50 (m, 1H), 8.30 (d, J=1.9 Hz, 1H), 7.96-7.90 (m, 2H), 7.76 (t, J=1.9 Hz, 1H), 7.66 (ddd, J=7.8, 1.8, 1.1 Hz, 1H), 7.50 (t, J=7.9 Hz, 1H), 7.44-7.41 (m, 1H), 5.18 (s, 2H), 2.35 (s, 3H).</p><heading id="h-0349" level="1">Example 274: 6-(3-Fluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1076" num="1141"><chemistry id="CHEM-US-00401" num="00401"><img id="EMI-C00401" he="31.24mm" wi="47.92mm" file="US20230000833A1-20230105-C00401.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1077" num="1142">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (3-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>FN<sub>4</sub>O, 334.1; m/z found, 335.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.65-8.63 (m, 1H), 8.53-8.51 (m, 1H), 8.31 (d, J=2.0 Hz, 1H), 7.96-7.94 (m, 1H), 7.91 (d, J=2.0 Hz, 1H), 7.57-7.48 (m, 3H), 7.23-7.17 (m, 1H), 5.18 (s, 2H), 2.35 (s, 3H).</p><heading id="h-0350" level="1">Example 275: 6-(3,4-Difluorophenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1078" num="1143"><chemistry id="CHEM-US-00402" num="00402"><img id="EMI-C00402" he="28.36mm" wi="53.34mm" file="US20230000833A1-20230105-C00402.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1079" num="1144">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-4-methylpyridine hydrochloride in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.90 (s, 1H), 8.57 (d, J=5.4 Hz, 1H), 8.43 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 7.80-7.73 (m, 2H), 7.66 (d, J=5.4 Hz, 1H), 7.58-7.48 (m, 2H), 5.21 (s, 2H), 2.55 (s, 3H).</p><heading id="h-0351" level="1">Example 276: 6-(3-Fluorophenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1080" num="1145"><chemistry id="CHEM-US-00403" num="00403"><img id="EMI-C00403" he="28.36mm" wi="47.92mm" file="US20230000833A1-20230105-C00403.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1081" num="1146">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-4-methylpyridine hydrochloride in Step A and (3-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>FN<sub>4</sub>O, 334.1; m/z found, 335.1 [M+H]<sup>+</sup>. 11.90 (s, 1H), 8.62-8.53 (m, 1H), 8.48-8.40 (m, 1H), 8.33 (d, J=1.9 Hz, 1H), 7.79 (d, J=2.0 Hz, 1H), 7.70-7.63 (m, 1H), 7.55-7.43 (m, 3H), 7.23-7.14 (m, 1H), 5.23 (s, 2H), 2.55 (s, 3H).</p><heading id="h-0352" level="1">Example 277: 6-(4-Fluoro-3-methyl-phenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1082" num="1147"><chemistry id="CHEM-US-00404" num="00404"><img id="EMI-C00404" he="28.36mm" wi="53.34mm" file="US20230000833A1-20230105-C00404.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1083" num="1148">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-4-methylpyridine hydrochloride in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O, 348.1; m/z found, 349.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.83 (s, 1H), 8.56 (d, J=5.4 Hz, 1H), 8.41 (s, 1H), 8.24 (d, J=1.9 Hz, 1H), 7.71 (d, J=2.0 Hz, 1H), 7.64 (d, J=5.4 Hz, 1H), 7.58-7.53 (m, 1H), 7.49-7.44 (m, 1H), 7.22 (dd, J=9.7, 8.5 Hz, 1H), 5.22 (s, 2H), 2.54 (s, 3H), 2.29 (d, J=1.9 Hz, 3H).</p><heading id="h-0353" level="1">Example 278: 6-(2,4-Difluoro-3-methyl-phenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1084" num="1149"><chemistry id="CHEM-US-00405" num="00405"><img id="EMI-C00405" he="28.36mm" wi="53.34mm" file="US20230000833A1-20230105-C00405.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1085" num="1150">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-4-methylpyridine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 367.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.92 (s, 1H), 8.63 (d, J=5.6 Hz, 1H), 8.49 (s, 1H), 8.09 (t, J=1.7 Hz, 1H), 7.76 (d, J=5.5 Hz, 1H), 7.61 (t, J=1.6 Hz, 1H), 7.42-7.32 (m, 1H), 7.21-7.12 (m, 1H), 5.23 (s, 2H), 2.58 (s, 3H), 2.20 (t, J=1.9 Hz, 3H).</p><heading id="h-0354" level="1">Example 279: 6-(3,4-Difluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1086" num="1151"><chemistry id="CHEM-US-00406" num="00406"><img id="EMI-C00406" he="27.94mm" wi="53.34mm" file="US20230000833A1-20230105-C00406.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1087" num="1152">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>F<sub>2</sub>N<sub>4</sub>O, 338.1; m/z found, 339.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 8.51 (ddd, J=4.8, 1.8, 1.1 Hz, 1H), 8.28 (d, J=2.0 Hz, 1H), 7.86-7.72 (m, 3H), 7.56-7.46 (m, 2H), 7.37-7.30 (m, 2H), 5.22 (s, 2H).</p><heading id="h-0355" level="1">Example 280: 6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1088" num="1153"><chemistry id="CHEM-US-00407" num="00407"><img id="EMI-C00407" he="27.18mm" wi="53.34mm" file="US20230000833A1-20230105-C00407.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1089" num="1154">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.81 (s, 1H), 8.51 (ddd, J=4.9, 1.6, 0.9 Hz, 1H), 8.05 (t, J=1.7 Hz, 1H), 7.82 (td, J=7.7, 1.8 Hz, 1H), 7.51 (t, J=1.7 Hz, 1H), 7.41-7.30 (m, 3H), 7.18-7.11 (m, 1H), 5.19 (s, 2H), 2.20 (t, J=1.9 Hz, 3H).</p><p id="p-1090" num="1155">Example 281: 6-(3-Fluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt.</p><p id="p-1091" num="0000"><chemistry id="CHEM-US-00408" num="00408"><img id="EMI-C00408" he="27.94mm" wi="47.92mm" file="US20230000833A1-20230105-C00408.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1092" num="1156">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and (3-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O, 320.1; m/z found, 321.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 8.51 (ddd, J=4.9, 1.9, 1.1 Hz, 1H), 8.30 (d, J=2.0 Hz, 1H), 7.82 (td, J=7.7, 1.8 Hz, 1H), 7.77 (d, J=2.0 Hz, 1H), 7.54-7.44 (m, 3H), 7.37-7.30 (m, 2H), 7.22-7.14 (m, 1H), 5.23 (s, 2H).</p><heading id="h-0356" level="1">Example 282: 6-(3-Chlorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1093" num="1157"><chemistry id="CHEM-US-00409" num="00409"><img id="EMI-C00409" he="28.02mm" wi="47.92mm" file="US20230000833A1-20230105-C00409.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1094" num="1158">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and (3-chlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>C<sub>1</sub>N<sub>4</sub>O, 336.1; m/z found, 337.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 8.54-8.48 (m, 1H), 8.29 (d, J=2.0 Hz, 1H), 7.83 (td, J=7.7, 1.8 Hz, 1H), 7.79 (d, J=2.0 Hz, 1H), 7.72 (t, J=1.9 Hz, 1H), 7.62 (dt, J=7.7, 1.4 Hz, 1H), 7.47 (t, J=7.8 Hz, 1H), 7.43-7.38 (m, 1H), 7.37-7.31 (m, 2H), 5.24 (s, 2H).</p><heading id="h-0357" level="1">Example 283: 6-(4-Fluoro-3-methyl-phenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1095" num="1159"><chemistry id="CHEM-US-00410" num="00410"><img id="EMI-C00410" he="27.09mm" wi="53.34mm" file="US20230000833A1-20230105-C00410.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1096" num="1160">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>FN<sub>4</sub>O, 334.1; m/z found, 335.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.74 (s, 1H), 8.53-8.51 (m, 1H), 8.21 (d, J=1.9 Hz, 1H), 7.84 (td, J=7.7, 1.8 Hz, 1H), 7.67 (d, J=2.0 Hz, 1H), 7.58-7.54 (m, 1H), 7.48-7.44 (m, 1H), 7.37-7.32 (m, 2H), 7.23-7.17 (m, 1H), 5.22 (s, 2H), 2.28 (d, J=1.8 Hz, 3H).</p><heading id="h-0358" level="1">Example 284: 6-(3,4-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt.</heading><p id="p-1097" num="1161"><chemistry id="CHEM-US-00411" num="00411"><img id="EMI-C00411" he="28.28mm" wi="53.34mm" file="US20230000833A1-20230105-C00411.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1098" num="1162">The title compound was prepared in a manner analogous to Example 24, using (3-methylpyridin-2-yl)methyl methanesulfonate (prepared analogous to Example 23, Step A) in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 323.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.72 (s, 1H), 8.25 (d, J=2.0 Hz, 1H), 8.22-8.19 (m, 1H), 7.72 (ddd, J=12.0, 7.7, 2.1 Hz, 1H), 7.69-7.62 (m, 2H), 7.54-7.44 (m, 2H), 7.24-7.18 (m, 1H), 5.21 (s, 2H), 2.43 (s, 3H).</p><heading id="h-0359" level="1">Example 285: 6-(3-Fluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1099" num="1163"><chemistry id="CHEM-US-00412" num="00412"><img id="EMI-C00412" he="28.28mm" wi="47.92mm" file="US20230000833A1-20230105-C00412.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1100" num="1164">The title compound was prepared in a manner analogous to Example 24, using (3-methylpyridin-2-yl)methyl methanesulfonate (prepared analogous to Example 23, Step A) in Step A and (3-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>FN<sub>4</sub>O, 334.1; m/z found, 335.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 8.30-8.23 (m, 2H), 7.78-7.69 (m, 2H), 7.52-7.44 (m, 3H), 7.34-7.27 (m, 1H), 7.21-7.12 (m, 1H), 5.25 (s, 2H), 2.45 (s, 3H).</p><heading id="h-0360" level="1">Example 286: 6-(4-Fluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1101" num="1165"><chemistry id="CHEM-US-00413" num="00413"><img id="EMI-C00413" he="25.82mm" wi="53.34mm" file="US20230000833A1-20230105-C00413.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1102" num="1166">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and (4-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O, 320.1; m/z found, 321.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 8.51 (ddd, J=5.0, 1.8, 1.0 Hz, 1H), 8.22 (d, J=2.0 Hz, 1H), 7.82 (td, J=7.7, 1.8 Hz, 1H), 7.70-7.63 (m, 3H), 7.36-7.24 (m, 4H), 5.22 (s, 2H).</p><heading id="h-0361" level="1">Example 287: 6-[3-(Difluoromethyl)phenyl]-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1103" num="1167"><chemistry id="CHEM-US-00414" num="00414"><img id="EMI-C00414" he="30.73mm" wi="48.43mm" file="US20230000833A1-20230105-C00414.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1104" num="1168">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and (3-(difluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 8.52-8.49 (m, 1H), 8.28 (d, J=1.9 Hz, 1H), 7.84-7.78 (m, 3H), 7.77 (d, J=2.0 Hz, 1H), 7.64-7.52 (m, 2H), 7.35-7.28 (m, 2H), 7.07 (t, J=55.9 Hz, 1H), 5.24 (s, 2H).</p><heading id="h-0362" level="1">Example 288: 6-(3-Methoxyphenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1105" num="1169"><chemistry id="CHEM-US-00415" num="00415"><img id="EMI-C00415" he="27.94mm" wi="47.92mm" file="US20230000833A1-20230105-C00415.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1106" num="1170">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and (3-methoxyphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H16N402, 332.1; m/z found, 333.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.75 (s, 1H), 8.51 (ddd, J=4.9, 1.9, 1.0 Hz, 1H), 8.25 (d, J=1.9 Hz, 1H), 7.83 (td, J=7.7, 1.8 Hz, 1H), 7.68 (d, J=2.0 Hz, 1H), 7.42-7.29 (m, 3H), 7.21-7.13 (m, 2H), 6.92 (ddd, J=8.2, 2.6, 0.9 Hz, 1H), 5.23 (s, 2H), 3.81 (s, 3H).</p><heading id="h-0363" level="1">Example 289: 6-(p-Tolyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1107" num="1171"><chemistry id="CHEM-US-00416" num="00416"><img id="EMI-C00416" he="25.99mm" wi="52.75mm" file="US20230000833A1-20230105-C00416.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1108" num="1172">The title compound was prepared in a manner analogous to Example 24, using 2-(chloromethyl)pyridine hydrochloride in Step A and p-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub>O, 316.1; m/z found, 317.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.73 (s, 1H), 8.55-8.52 (m, 1H), 8.21 (d, J=1.9 Hz, 1H), 7.87 (td, J=7.7, 1.7 Hz, 1H), 7.66 (d, J=2.0 Hz, 1H), 7.54-7.48 (m, 2H), 7.42-7.34 (m, 2H), 7.28-7.23 (m, 2H), 5.24 (s, 2H), 2.33 (s, 3H).</p><heading id="h-0364" level="1">Example 290: 6-(3-fluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1109" num="1173"><chemistry id="CHEM-US-00417" num="00417"><img id="EMI-C00417" he="27.94mm" wi="47.92mm" file="US20230000833A1-20230105-C00417.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1110" num="1174">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and (3-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O, 320.1; m/z found, 321.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.82-8.73 (m, 1H), 8.65-8.57 (m, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.04-7.99 (m, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.61-7.47 (m, 4H), 7.22-7.16 (m, 1H), 5.20 (s, 2H).</p><heading id="h-0365" level="1">Example 291: 6-[3-(Difluoromethyl)phenyl]-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1111" num="1175"><chemistry id="CHEM-US-00418" num="00418"><img id="EMI-C00418" he="30.73mm" wi="48.43mm" file="US20230000833A1-20230105-C00418.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1112" num="1176">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and (3-(difluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.77-8.73 (m, 1H), 8.61-8.58 (m, 1H), 8.29 (d, J=1.9 Hz, 1H), 8.01-7.96 (m, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.87-7.82 (m, 2H), 7.65-7.53 (m, 3H), 7.08 (t, J=55.8 Hz, 1H), 5.21 (s, 2H).</p><heading id="h-0366" level="1">Example 292: 6-(3,4-Difluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1113" num="1177"><chemistry id="CHEM-US-00419" num="00419"><img id="EMI-C00419" he="27.94mm" wi="53.34mm" file="US20230000833A1-20230105-C00419.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1114" num="1178">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>F<sub>2</sub>N<sub>4</sub>O, 338.1; m/z found, 339.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.78 (d, J=2.2 Hz, 1H), 8.62 (dd, J=5.2, 1.5 Hz, 1H), 8.29 (d, J=2.0 Hz, 1H), 8.06-8.00 (m, 1H), 7.92 (d, J=2.0 Hz, 1H), 7.84-7.76 (m, 1H), 7.60 (dd, J=8.0, 5.1 Hz, 1H), 7.57-7.49 (m, 2H), 5.19 (s, 2H).</p><heading id="h-0367" level="1">Example 293: 6-(2,4-Difluoro-3-methyl-phenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt.</heading><p id="p-1115" num="1179"><chemistry id="CHEM-US-00420" num="00420"><img id="EMI-C00420" he="27.09mm" wi="53.34mm" file="US20230000833A1-20230105-C00420.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1116" num="1180">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.88 (s, 1H), 8.75 (d, J=2.2 Hz, 1H), 8.61 (dd, J=5.2, 1.5 Hz, 1H), 8.06 (t, J=1.6 Hz, 1H), 8.03-7.98 (m, 1H), 7.70 (t, J=1.6 Hz, 1H), 7.59 (dd, J=7.9, 5.1 Hz, 1H), 7.42-7.35 (m, 1H), 7.21-7.14 (m, 1H), 5.18 (s, 2H), 2.21 (t, J=1.8 Hz, 3H).</p><heading id="h-0368" level="1">Example 294: 6-(4-Fluoro-3-methyl-phenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1117" num="1181"><chemistry id="CHEM-US-00421" num="00421"><img id="EMI-C00421" he="27.09mm" wi="53.34mm" file="US20230000833A1-20230105-C00421.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1118" num="1182">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>FN40, 334.1; m/z found, 335.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.80 (s, 1H), 8.75 (d, J=2.2 Hz, 1H), 8.59 (dd, J=4.8, 1.6 Hz, 1H), 8.22 (d, J=1.9 Hz, 1H), 7.99-7.93 (m, 1H), 7.84 (d, J=2.0 Hz, 1H), 7.61 7.57 (m, 1H), 7.57-7.53 (m, 1H), 7.52-7.47 (m, 1H), 7.26-7.20 (m, 1H), 5.18 (s, 2H), 2.30 (d, J=1.9 Hz, 3H).</p><p id="p-1119" num="1183">Example 295: 6-(4-Fluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt.</p><p id="p-1120" num="0000"><chemistry id="CHEM-US-00422" num="00422"><img id="EMI-C00422" he="25.82mm" wi="53.34mm" file="US20230000833A1-20230105-C00422.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1121" num="1184">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and (4-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O, 320.1; m/z found, 321.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.82 (s, 1H), 8.78 (d, J=2.2 Hz, 1H), 8.62 (dd, J=5.3, 1.6 Hz, 1H), 8.23 (d, J=2.0 Hz, 1H), 8.06-8.00 (m, 1H), 7.86 (d, J=2.0 Hz, 1H), 7.73-7.67 (m, 2H), 7.60 (dd, J=8.0, 5.1 Hz, 1H), 7.34-7.28 (m, 2H), 5.20 (s, 2H).</p><heading id="h-0369" level="1">Example 296: 6-(3-Chlorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1122" num="1185"><chemistry id="CHEM-US-00423" num="00423"><img id="EMI-C00423" he="27.94mm" wi="47.92mm" file="US20230000833A1-20230105-C00423.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1123" num="1186">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and (3-chlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>C<sub>1</sub>N<sub>4</sub>O, 336.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 8.77 (d, J=2.2 Hz, 1H), 8.61 (dd, J=5.0, 1.5 Hz, 1H), 8.30 (d, J=2.0 Hz, 1H), 8.04-7.99 (m, 1H), 7.94 (d, J=2.0 Hz, 1H), 7.76 (t, J=2.0 Hz, 1H), 7.68-7.64 (m, 1H), 7.59 (dd, J=8.0, 5.0 Hz, 1H), 7.49 (t, J=7.9 Hz, 1H), 7.45-7.41 (m, 1H), 5.20 (s, 2H).</p><heading id="h-0370" level="1">Example 297: 6-(m-Tolyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1124" num="1187"><chemistry id="CHEM-US-00424" num="00424"><img id="EMI-C00424" he="27.09mm" wi="47.92mm" file="US20230000833A1-20230105-C00424.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1125" num="1188">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and m-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub>O, 316.1; m/z found, 317.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) 6 11.79 (s, 1H), 8.77-8.75 (m, 1H), 8.60 (dd, J=5.1, 1.5 Hz, 1H), 8.23 (d, J=1.9 Hz, 1H), 8.03-7.98 (m, 1H), 7.84 (d, J=1.9 Hz, 1H), 7.58 (dd, J=8.0, 5.1 Hz, 1H), 7.50-7.47 (m, 1H), 7.46-7.42 (m, 1H), 7.35 (t, J=7.6 Hz, 1H), 7.20-7.16 (m, 1H), 5.20 (s, 2H), 2.37 (s, 3H).</p><heading id="h-0371" level="1">Example 298: 6-(3,4-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1126" num="1189"><chemistry id="CHEM-US-00425" num="00425"><img id="EMI-C00425" he="32.00mm" wi="53.34mm" file="US20230000833A1-20230105-C00425.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1127" num="1190">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>11</sub>F<sub>3</sub>N<sub>4</sub>O, 356.1; m/z found, 357.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.85 (s, 1H), 8.54 (t, J=1.7 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.29 (d, J=2.0 Hz, 1H), 7.92 (d, J=2.0 Hz, 1H), 7.84-7.78 (m, 1H), 7.76-7.71 (m, 1H), 7.58-7.50 (m, 2H), 5.16 (s, 2H).</p><heading id="h-0372" level="1">Example 299: 6-(4-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1128" num="1191"><chemistry id="CHEM-US-00426" num="00426"><img id="EMI-C00426" he="32.00mm" wi="53.34mm" file="US20230000833A1-20230105-C00426.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1129" num="1192">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.79 (s, 1H), 8.53 (t, J=1.7 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.22 (d, J=1.9 Hz, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.72 (ddd, J=9.7, 2.8, 1.7 Hz, 1H), 7.61-7.58 (m, 1H), 7.52-7.48 (m, 1H), 7.23 (dd, J=9.7, 8.5 Hz, 1H), 5.17 (s, 2H), 2.30 (d, J=1.9 Hz, 3H).</p><heading id="h-0373" level="1">Example 300: 6-[3-(Difluoromethoxy)phenyl]-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1130" num="1193"><chemistry id="CHEM-US-00427" num="00427"><img id="EMI-C00427" he="36.41mm" wi="47.92mm" file="US20230000833A1-20230105-C00427.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1131" num="1194">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)pyridine hydrochloride in Step A and (3-(difluoromethoxy)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N402, 368.1; m/z found, 369.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.76 (d, J=2.3 Hz, 1H), 8.60 (dd, J=5.1, 1.6 Hz, 1H), 8.30 (d, J=1.9 Hz, 1H), 8.02-7.98 (m, 1H), 7.91 (d, J=2.0 Hz, 1H), 7.60-7.15 (m, 6H), 5.20 (s, 2H).</p><heading id="h-0374" level="1">Example 301: 6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1132" num="1195"><chemistry id="CHEM-US-00428" num="00428"><img id="EMI-C00428" he="32.00mm" wi="53.34mm" file="US20230000833A1-20230105-C00428.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1133" num="1196">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.53-8.50 (m, 2H), 8.05 (t, J=1.6 Hz, 1H), 7.74-7.70 (m, 2H), 7.42-7.36 (m, 1H), 7.20-7.15 (m, 1H), 5.15 (s, 2H), 2.21 (t, J=1.9 Hz, 3H).</p><heading id="h-0375" level="1">Example 302: 6-[3-(Difluoromethyl)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1134" num="1197"><chemistry id="CHEM-US-00429" num="00429"><img id="EMI-C00429" he="32.00mm" wi="48.43mm" file="US20230000833A1-20230105-C00429.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1135" num="1198">The title compound was prepared in a manner analogous to Example 24 using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3-(difluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.85 (s, 1H), 8.53 (t, J=1.7 Hz, 1H), 8.51 (d, J=2.7 Hz, 1H), 8.29 (d, J=1.9 Hz, 1H), 7.94 (d, J=2.0 Hz, 1H), 7.87-7.83 (m, 2H), 7.73 (ddd, J=9.7, 2.8, 1.7 Hz, 1H), 7.65-7.55 (m, 2H), 7.08 (t, J=55.8 Hz, 1H), 5.20 (s, 2H).</p><heading id="h-0376" level="1">Example 303: 6-(2,3-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1136" num="1199"><chemistry id="CHEM-US-00430" num="00430"><img id="EMI-C00430" he="32.00mm" wi="47.92mm" file="US20230000833A1-20230105-C00430.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1137" num="1200">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (2,3-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>11</sub>F<sub>3</sub>N<sub>4</sub>O, 356.1; m/z found, 357.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.92 (s, 1H), 8.54-8.49 (m, 2H), 8.13 (t, J=1.6 Hz, 1H), 7.79 (t, J=1.6 Hz, 1H), 7.75-7.71 (m, 1H), 7.49-7.42 (m, 1H), 7.39-7.28 (m, 2H), 5.16 (s, 2H).</p><heading id="h-0377" level="1">Example 304: 6-[3-(Difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1138" num="1201"><chemistry id="CHEM-US-00431" num="00431"><img id="EMI-C00431" he="36.41mm" wi="47.92mm" file="US20230000833A1-20230105-C00431.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1139" num="1202">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3-(difluoromethoxy)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 386.1; m/z found, 387.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.85 (s, 1H), 8.53 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.30 (d, J=1.9 Hz, 1H), 7.92 (d, J=2.0 Hz, 1H), 7.73 (ddd, J=9.7, 2.8, 1.7 Hz, 1H), 7.58-7.15 (m, 5H), 5.18 (s, 2H).</p><heading id="h-0378" level="1">Example 305: 6-(3-Chlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1140" num="1203"><chemistry id="CHEM-US-00432" num="00432"><img id="EMI-C00432" he="32.00mm" wi="47.92mm" file="US20230000833A1-20230105-C00432.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1141" num="1204">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3-chlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>ClFN<sub>4</sub>O, 354.1; m/z found, 355.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.86 (s, 1H), 8.54 (t, J=1.7 Hz, 1H), 8.52 (d, J=2.7 Hz, 1H), 8.30 (d, J=2.0 Hz, 1H), 7.95 (d, J=2.0 Hz, 1H), 7.77-7.71 (m, 2H), 7.68-7.64 (m, 1H), 7.50 (t, J=7.9 Hz, 1H), 7.45-7.41 (m, 1H), 5.18 (s, 2H).</p><heading id="h-0379" level="1">Example 306: 6-(4-Chloro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1142" num="1205"><chemistry id="CHEM-US-00433" num="00433"><img id="EMI-C00433" he="32.00mm" wi="54.69mm" file="US20230000833A1-20230105-C00433.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1143" num="1206">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (4-chloro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>ClFN<sub>4</sub>O, 368.1; m/z found, 369.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b9; 11.82 (s, 1H), 8.53 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.26 (d, J=1.9 Hz, 1H), 7.89 (d, J=2.0 Hz, 1H), 7.73 (ddd, J=9.6, 2.7, 1.7 Hz, 1H), 7.70-7.68 (m, 1H), 7.54-7.48 (m, 2H), 5.18 (s, 2H), 2.40 (s, 3H).</p><heading id="h-0380" level="1">Example 307: 1-[(5-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethoxy)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1144" num="1207"><chemistry id="CHEM-US-00434" num="00434"><img id="EMI-C00434" he="32.00mm" wi="47.92mm" file="US20230000833A1-20230105-C00434.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1145" num="1208">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3-(trifluoromethoxy)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 404.1; m/z found, 405.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.88 (s, 1H), 8.54 (t, J=1.7 Hz, 1H), 8.52 (d, J=2.8 Hz, 1H), 8.32 (d, J=2.0 Hz, 1H), 7.96 (d, J=2.0 Hz, 1H), 7.76-7.72 (m, 2H), 7.70-7.67 (m, 1H), 7.61 (t, J=8.0 Hz, 1H), 7.39-7.35 (m, 1H), 5.19 (s, 2H).</p><heading id="h-0381" level="1">Example 308: 1-[(5-Methyl-3-pyridyl)methyl]-6-(3,4,5-trifluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1146" num="1209"><chemistry id="CHEM-US-00435" num="00435"><img id="EMI-C00435" he="31.24mm" wi="53.34mm" file="US20230000833A1-20230105-C00435.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1147" num="1210">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (3,4,5-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.90 (s, 1H), 8.64-8.62 (m, 1H), 8.53-8.50 (m, 1H), 8.35 (d, J=2.0 Hz, 1H), 7.95-7.91 (m, 2H), 7.77-7.69 (m, 2H), 5.15 (s, 2H), 2.35 (s, 3H).</p><heading id="h-0382" level="1">Example 309: 6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1148" num="1211"><chemistry id="CHEM-US-00436" num="00436"><img id="EMI-C00436" he="31.24mm" wi="53.34mm" file="US20230000833A1-20230105-C00436.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1149" num="1212">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O, 402.1; m/z found, 403.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.88 (s, 1H), 8.61-8.59 (m, 1H), 8.50-8.48 (m, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.08-8.02 (m, 1H), 8.02-7.98 (m, 1H), 7.95 (d, J=2.0 Hz, 1H), 7.90-7.88 (m, 1H), 7.64 (dd, J=10.4, 8.9 Hz, 1H), 5.17 (s, 2H), 2.34 (s, 3H).</p><heading id="h-0383" level="1">Example 310: 6-(2,3-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1150" num="1213"><chemistry id="CHEM-US-00437" num="00437"><img id="EMI-C00437" he="31.24mm" wi="47.92mm" file="US20230000833A1-20230105-C00437.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1151" num="1214">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (2,3-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.94 (s, 1H), 8.71-8.68 (m, 1H), 8.62-8.59 (m, 1H), 8.14 (t, J=1.7 Hz, 1H), 8.13-8.10 (m, 1H), 7.77 (t, J=1.6 Hz, 1H), 7.50-7.42 (m, 1H), 7.39-7.28 (m, 2H), 5.20 (s, 2H), 2.39 (s, 3H).</p><heading id="h-0384" level="1">Example 311: 6-(3,5-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1152" num="1215"><chemistry id="CHEM-US-00438" num="00438"><img id="EMI-C00438" he="31.24mm" wi="53.34mm" file="US20230000833A1-20230105-C00438.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1153" num="1216">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-5-methylpyridine hydrochloride in Step A and (3,5-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.91 (s, 1H), 8.64 (s, 1H), 8.52 (s, 1H), 8.38 (d, J=2.0 Hz, 1H), 7.98-7.91 (m, 2H), 7.54-7.45 (m, 2H), 7.23 (tt, J=9.3, 2.4 Hz, 1H), 5.17 (s, 2H), 2.35 (s, 3H).</p><heading id="h-0385" level="1">Example 312: 1-[(4-Methyl-3-pyridyl)methyl]-6-(3,4,5-trifluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1154" num="1217"><chemistry id="CHEM-US-00439" num="00439"><img id="EMI-C00439" he="28.36mm" wi="53.34mm" file="US20230000833A1-20230105-C00439.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1155" num="1218">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-4-methylpyridine hydrochloride in Step A and (3,4,5-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.95 (s, 1H), 8.59-8.55 (m, 1H), 8.44-8.40 (m, 1H), 8.37 (d, J=2.0 Hz, 1H), 7.82 (d, J=2.1 Hz, 1H), 7.74-7.64 (m, 3H), 5.20 (s, 2H), 2.56 (s, 3H).</p><heading id="h-0386" level="1">Example 313: 1-[(4-Methyl-3-pyridyl)methyl]-6-[3-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1156" num="1219"><chemistry id="CHEM-US-00440" num="00440"><img id="EMI-C00440" he="28.53mm" wi="47.92mm" file="US20230000833A1-20230105-C00440.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1157" num="1220">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-4-methylpyridine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 384.1; m/z found, 385.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.95 (s, 1H), 8.65 (d, J=5.6 Hz, 1H), 8.51 (s, 1H), 8.37 (d, J=2.0 Hz, 1H), 7.99-7.95 (m, 2H), 7.88 (d, J=2.0 Hz, 1H), 7.81 (d, J=5.6 Hz, 1H), 7.76-7.67 (m, 2H), 5.28 (s, 2H), 2.62 (s, 3H).</p><heading id="h-0387" level="1">Example 314: 6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1158" num="1221"><chemistry id="CHEM-US-00441" num="00441"><img id="EMI-C00441" he="28.53mm" wi="53.34mm" file="US20230000833A1-20230105-C00441.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1159" num="1222">The title compound was prepared in a manner analogous to Example 24, using 3-(chloromethyl)-4-methylpyridine hydrochloride in Step A and (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O, 402.1; m/z found, 403.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.93 (s, 1H), 8.56 (d, J=5.3 Hz, 1H), 8.41 (s, 1H), 8.34 (d, J=1.9 Hz, 1H), 8.04-7.99 (m, 1H), 7.99-7.95 (m, 1H), 7.84 (d, J=2.0 Hz, 1H), 7.66-7.59 (m, 2H), 5.23 (s, 2H), 2.55 (s, 3H).</p><heading id="h-0388" level="1">Example 315: 1-[(3-Methyl-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1160" num="1223"><chemistry id="CHEM-US-00442" num="00442"><img id="EMI-C00442" he="28.53mm" wi="47.92mm" file="US20230000833A1-20230105-C00442.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1161" num="1224">The title compound was prepared in a manner analogous to Example 24, using (3-methylpyridin-2-yl)methyl methanesulfonate (prepared analogous to Example 23, Step A) in Step A. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 384.1; m/z found, 385.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.76 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.25-8.21 (m, 1H), 7.96-7.90 (m, 2H), 7.76 (d, J=2.0 Hz, 1H), 7.73-7.65 (m, 3H), 7.27-7.22 (m, 1H), 5.25 (s, 2H), 2.44 (s, 3H).</p><heading id="h-0389" level="1">Example 316: 6-(4-Fluoro-3-methyl-phenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1162" num="1225"><chemistry id="CHEM-US-00443" num="00443"><img id="EMI-C00443" he="28.36mm" wi="53.34mm" file="US20230000833A1-20230105-C00443.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1163" num="1226">The title compound was prepared in a manner analogous to Example 24, using (3-methylpyridin-2-yl)methyl methanesulfonate (prepared analogous to Example 23, Step A) in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O, 348.1; m/z found, 349.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.70 (s, 1H), 8.29-8.26 (m, 1H), 8.19 (d, J=2.0 Hz, 1H), 7.79-7.73 (m, 1H), 7.63 (d, J=2.0 Hz, 1H), 7.56-7.50 (m, 1H), 7.46-7.41 (m, 1H), 7.34-7.29 (m, 1H), 7.23-7.18 (m, 1H), 5.25 (s, 2H), 2.44 (s, 3H), 2.28 (d, J=1.9 Hz, 3H).</p><heading id="h-0390" level="1">Example 317: 6-(2,4-Difluoro-3-methyl-phenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1164" num="1227"><chemistry id="CHEM-US-00444" num="00444"><img id="EMI-C00444" he="28.36mm" wi="53.34mm" file="US20230000833A1-20230105-C00444.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1165" num="1228">The title compound was prepared in a manner analogous to Example 24, using (3-methylpyridin-2-yl)methyl methanesulfonate (prepared analogous to Example 23, Step A) in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 367.1 [M+H]<sup>+</sup>.<sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.74 (s, 1H), 8.28-8.23 (m, 1H), 8.03 (t, J=1.7 Hz, 1H), 7.72-7.67 (m, 1H), 7.48 (t, J=1.7 Hz, 1H), 7.38-7.31 (m, 1H), 7.29-7.24 (m, 1H), 7.17-7.11 (m, 1H), 5.21 (s, 2H), 2.41 (s, 3H), 2.19 (t, J=1.9 Hz, 3H).</p><heading id="h-0391" level="1">Example 318: 6-(3,5-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1166" num="1229"><chemistry id="CHEM-US-00445" num="00445"><img id="EMI-C00445" he="28.36mm" wi="53.34mm" file="US20230000833A1-20230105-C00445.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1167" num="1230">The title compound was prepared in a manner analogous to Example 24, using (3-methylpyridin-2-yl)methyl methanesulfonate (prepared analogous to Example 23, Step A) in Step A and (3,5-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.78 (s, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.23-8.20 (m, 1H), 7.76 (d, J=2.0 Hz, 1H), 7.71-7.66 (m, 1H), 7.45-7.38 (m, 2H), 7.27-7.16 (m, 2H), 5.22 (s, 2H), 2.44 (s, 3H).</p><heading id="h-0392" level="1">Example 319: 6-(2,3-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1168" num="1231"><chemistry id="CHEM-US-00446" num="00446"><img id="EMI-C00446" he="28.36mm" wi="47.92mm" file="US20230000833A1-20230105-C00446.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1169" num="1232">The title compound was prepared in a manner analogous to Example 24, using (3-methylpyridin-2-yl)methyl methanesulfonate (prepared analogous to Example 23, Step A) in Step A and (2,3-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.84 (s, 1H), 8.30-8.28 (m, 1H), 8.12 (t, J=1.7 Hz, 1H), 7.79-7.74 (m, 1H), 7.58 (t, J=1.6 Hz, 1H), 7.47-7.39 (m, 1H), 7.36-7.25 (m, 3H), 5.24 (s, 2H), 2.43 (s, 3H).</p><heading id="h-0393" level="1">Example 320: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1170" num="1233"><chemistry id="CHEM-US-00447" num="00447"><img id="EMI-C00447" he="34.21mm" wi="45.21mm" file="US20230000833A1-20230105-C00447.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1171" num="1234">The title compound was prepared in a manner analogous to Example 25, using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 38) and (4-fluoro-2-methylphenyl)boronic acid in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>2</sub>, 340.1; m/z found, 341.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.68 (s, 1H), 7.85 (d, J=1.9 Hz, 1H), 7.40 (d, J=1.9 Hz, 1H), 7.26-7.16 (m, 2H), 7.14-7.07(m, 1H), 4.50 (s, 2H), 4.25 (t, J=7.6 Hz, 2H), 3.88 (t, J=7.7 Hz, 2H), 2.31-2.19 (m, 5H).</p><heading id="h-0394" level="1">Example 321: 2-[6-(5-Chloro-4-methyl-2-thienyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-1172" num="1235"><chemistry id="CHEM-US-00448" num="00448"><img id="EMI-C00448" he="30.90mm" wi="46.40mm" file="US20230000833A1-20230105-C00448.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1173" num="1236">The title compound was made in a manner analogous to Example 26, using 2-(5-chloro-4-methylthiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in Step A. MS (ESI): mass calcd. for C<sub>15</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub>S, 350.1; m/z found, 351.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO) &#x3b4; 11.74-11.71 (s, 1H), 8.15-8.13 (d, J=2.0 Hz, 1H), 7.65-7.63 (d, J=2.0 Hz, 1H), 7.29-7.28 (s, 1H), 4.77-4.74 (s, 2H), 3.11-3.08 (s, 3H), 2.87-2.83 (s, 3H), 2.19-2.16 (s, 3H).</p><heading id="h-0395" level="1">Example 322: 2-[6-(5-Chloro-4-methyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-1174" num="1237"><chemistry id="CHEM-US-00449" num="00449"><img id="EMI-C00449" he="33.61mm" wi="46.40mm" file="US20230000833A1-20230105-C00449.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1175" num="1238">The title compound was prepared in a manner analogous to Example 14, Step B, using 2-[6-(5-chloro-4-methyl-2-thienyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide (Example 321). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub>S, 364.1; m/z found, 365.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.13-8.12 (d, J=1.9 Hz, 1H), 7.19-7.18 (d, J=1.9 Hz, 1H), 6.86-6.85 (s, 1H), 4.64-4.63 (s, 2H), 3.45-3.44 (s, 3H), 3.11-3.09 (s, 3H), 2.93-2.92 (s, 3H), 2.14-2.13 (s, 3H).</p><heading id="h-0396" level="1">Example 323: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1176" num="1239"><chemistry id="CHEM-US-00450" num="00450"><img id="EMI-C00450" he="34.71mm" wi="47.41mm" file="US20230000833A1-20230105-C00450.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1177" num="1240">The title compound was made in a manner analogous to Example 26, using azetidine in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 382.1; m/z found, 383.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO) &#x3b4; 11.88-11.82 (s, 1H), 8.35-8.33 (d, J=2.0 Hz, 1H), 7.79-7.78 (d, J=2.0 Hz, 1H), 7.77-7.75 (m, 1H), 7.59-7.56 (m, 1H), 4.57-4.49 (s, 2H), 4.31-4.24 (t, J=7.7 Hz, 2H), 3.95-3.86 (m, 2H), 2.32-2.25 (m, 2H).</p><heading id="h-0397" level="1">Example 324: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1178" num="1241"><chemistry id="CHEM-US-00451" num="00451"><img id="EMI-C00451" he="34.71mm" wi="46.40mm" file="US20230000833A1-20230105-C00451.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1179" num="1242">The title compound was made in a manner analogous to Example 26, using 2-(5-chloro-4-methylthiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in Step A and azetidine in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub>S, 362.1; m/z found, 363.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3b4; 11.74-11.71 (s, 1H), 8.18-8.12 (m, 1H), 7.65-7.62 (m, 1H), 7.33-7.28 (s, 1H), 4.53-4.49 (s, 2H), 4.32-4.22 (m, 2H), 3.97-3.86 (m, 2H), 2.34-2.25 (m, 2H), 2.22-2.15 (d, J=1.7 Hz, 3H).</p><heading id="h-0398" level="1">Example 325: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1180" num="1243"><chemistry id="CHEM-US-00452" num="00452"><img id="EMI-C00452" he="37.42mm" wi="46.40mm" file="US20230000833A1-20230105-C00452.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1181" num="1244">The title compound was prepared in a manner analogous to Example 14, Step B, using 1-[2-(azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one (Example 324). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub>S, 376.1; m/z found, 377.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO) &#x3b4; 9.70-9.68 (m, 1H), 9.19-9.16 (m, 1H), 8.79-8.76 (s, 1H), 6.05-6.02 (s, 2H), 5.77-5.72 (t, J=7.8 Hz, 2H), 5.39-5.34 (t, J=7.9 Hz, 2H), 4.82-4.81 (s, 3H), 3.79-3.71 (m, 2H), 3.66-3.63 (s, 3H).</p><heading id="h-0399" level="1">Example 326: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1182" num="1245"><chemistry id="CHEM-US-00453" num="00453"><img id="EMI-C00453" he="37.42mm" wi="44.37mm" file="US20230000833A1-20230105-C00453.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1183" num="1246">The title compound was made in a manner analogous to Example 28, using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 38) and 4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-1,3,2-dioxaborolane in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S, 342.1; m/z found, 343.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.27-8.25 (d, J=1.9 Hz, 1H), 7.40-7.38 (d, J=1.9 Hz, 1H), 7.06-7.04 (d, J=3.5 Hz, 1H), 6.75-6.72 (m, 1H), 4.50-4.46 (s, 2H), 4.32-4.27 (m, 2H), 4.12-4.06 (m, 2H), 3.53-3.49 (s, 3H), 2.53-2.49 (d, J=1.1 Hz, 3H), 2.39-2.31 (m, 2H).</p><heading id="h-0400" level="1">Example 327: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1184" num="1247"><chemistry id="CHEM-US-00454" num="00454"><img id="EMI-C00454" he="43.52mm" wi="47.41mm" file="US20230000833A1-20230105-C00454.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1185" num="1248">The title compound was made in a manner analogous to Example 28, using 1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-1D]pyridin-2-one (Intermediate 40) in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 414.1; m/z found, 415.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.33-8.30 (d, J=1.9 Hz, 1H), 7.44-7.43 (d, J=1.9 Hz, 1H), 7.43-7.40 (m, 1H), 7.21-7.18 (m, 1H), 5.45-5.28 (m, 1H), 4.68-4.12 (m, 7H), 3.55-3.50 (s, 3H).</p><heading id="h-0401" level="1">Example 328: 3-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1186" num="1249"><chemistry id="CHEM-US-00455" num="00455"><img id="EMI-C00455" he="38.86mm" wi="47.41mm" file="US20230000833A1-20230105-C00455.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1187" num="1250">The title compound was made in a manner analogous to Example 28, using 1-(2-(pyrrolidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 41) in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 410.1; m/z found, 411.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.31-8.29 (d, J=1.9 Hz, 1H), 7.42-7.39 (m, 1H), 7.39-7.38 (d, J=1.9 Hz, 1H), 7.19-7.17 (m, 1H), 4.67-4.63 (s, 2H), 3.64-3.60 (m, 2H), 3.54-3.53 (s, 3H), 3.53-3.49 (m, 2H), 2.10-2.02 (m, 2H), 1.95-1.87 (m, 2H).</p><heading id="h-0402" level="1">Example 329: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1188" num="1251"><chemistry id="CHEM-US-00456" num="00456"><img id="EMI-C00456" he="34.12mm" wi="39.79mm" file="US20230000833A1-20230105-C00456.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1189" num="1252">The title compound was prepared in a manner analogous to Example 29, using (2-methyl-3-(trifluoromethyl)phenyl)boronic acid in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.72(s, 1H), 7.89-7.86 (m, 1H), 7.78-7.71 (m, 1H), 7.55-7.42 (m, 3H), 4.50 (s, 2H), 4.24 (t, J=7.5 Hz, 2H), 3.88 (t, J=7.6 Hz, 2H), 2.34-2.20 (m, 5H).</p><heading id="h-0403" level="1">Example 330: 6-(3,4-Difluorophenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1190" num="1253"><chemistry id="CHEM-US-00457" num="00457"><img id="EMI-C00457" he="32.09mm" wi="45.21mm" file="US20230000833A1-20230105-C00457.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1191" num="1254">Step A: 6-Bromo-3-(4-methoxybenzyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. Under a nitrogen atmosphere was added 6-bromo-3-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one (Intermediate 10, 2.0 g, 6.0 mmol) to a suspension of NaH (60% dispersion in mineral oil, 527 mg, 13 mmol) in DMF (30 mL) at room temperature. After 10 minutes, 1-bromo-2-butanone (1.3 mL, 13 mmol) was added and the reaction mixture was allowed to heat to 65&#xb0; C. After 3 hours, water (150 mL) was added. The precipitates were filtered off, washed with water and dried under vacuum to yield the title product (1.7 g, 68%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>3</sub>, 403.1; m/z found, 404.0 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.10 (d, J=2.0 Hz, 1H), 7.80 (d, J=2.0 Hz, 1H), 7.28-7.24 (m, 2H), 6.91-6.84 (m, 2H), 4.98 (s, 2H), 4.88 (s, 2H), 3.71 (s, 3H), 2.61 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).</p><p id="p-1192" num="1255">Step B: 6-(3,4-Difluorophenyl)-3-(4-methoxybenzyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. A mixture of 6-bromo-3-(4-methoxybenzyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (200 mg, 0.5 mmol), (3,4-difluorophenyl)boronic acid (117 mg, 0.7 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(322 mg, 1.0 mmol), dichloro(diphenylphosphinoferrocene)palladium (25 mg, 0.03 mmol) in dioxane (4.5 mL) was heated to 110&#xb0; C. After 16 hours, the reaction mixture was concentrated under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0-90% EtOAc in hexanes) to provide the title compound (115 mg, 53%). MS (ESI): mass calcd. for C<sub>24</sub>H<sub>21</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>, 437.2; m/z found, 438.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.34 (d, J=1.9 Hz, 1H), 7.83 (d, J=1.9 Hz, 1H), 7.81-7.74 (m, 1H), 7.60-7.50 (m, 2H), 7.32-7.27 (m, 2H), 6.92-6.86 (m, 2H), 5.03 (s, 2H), 4.92 (s, 2H), 3.71 (s, 3H), 2.63 (q, J=7.3 Hz, 2H), 0.99 (t, J=7.3 Hz, 3H).</p><p id="p-1193" num="1256">Step C. 6-(3,4-Difluorophenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt. A mixture of 6-(3,4-difluorophenyl)-3-(4-methoxybenzyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (115 mg, 0.2 mmol) in HBr (48% in H<sub>2</sub>O, 5.1 mL, 45.0 mmol) was heated to 115&#xb0; C. Upon completion, the reaction mixture was cooled to 0&#xb0; C. and NaOH pellets were added until the reaction mixture reach basic pH. The mixture was extracted with EtOAc (3&#xd7;). The combined organics were dried (MgSO<sub>4</sub>), filtered and concentated under vacuum. The crude material was purified (METHOD B) to yield title product (9.1 mg, 8.0%). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 317.1; m/z found, 318.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) 11.75 (s, 1H), 8.27 (d, J=2.0 Hz, 1H), 7.80-7.73 (m, 2H), 7.58-7.49 (m, 2H), 4.83 (s, 2H), 2.61 (q, J=7.3 Hz, 2H), 0.99 (t, J=7.3 Hz, 3H).</p><heading id="h-0404" level="1">Example 331: 6-(4-Fluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1194" num="1257"><chemistry id="CHEM-US-00458" num="00458"><img id="EMI-C00458" he="32.09mm" wi="45.21mm" file="US20230000833A1-20230105-C00458.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1195" num="1258">The title compound was prepared in a manner analogous to Example 330, using (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>2</sub>, 313.1; m/z found, 314.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.69 (s, 1H), 8.20 (d, J=1.9 Hz, 1H), 7.68 (d, J=2.0 Hz, 1H), 7.59-7.56 (m, 1H), 7.51-7.46 (m, 1H), 7.25-7.20 (m, 1H), 4.83 (s, 2H), 2.61 (q, J=7.4 Hz, 2H), 2.30 (d, J=2.0 Hz, 3H), 0.99 (t, J=7.3 Hz, 3H).</p><heading id="h-0405" level="1">Example 332: 6-(m-Tolyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1196" num="1259"><chemistry id="CHEM-US-00459" num="00459"><img id="EMI-C00459" he="32.09mm" wi="39.79mm" file="US20230000833A1-20230105-C00459.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1197" num="1260">The title compound was prepared in a manner analogous to Example 330, using m-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>, 295.1; m/z found, 296.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.68 (s, 1H), 8.21 (d, J=2.0 Hz, 1H), 7.69 (d, J=2.0 Hz, 1H), 7.48-7.46 (m, 1H), 7.45-7.42 (m, 1H), 7.35 (t, J=7.6 Hz, 1H), 7.21-7.16 (m, 1H), 4.84 (s, 2H), 2.61 (q, J=7.3 Hz, 2H), 2.38 (s, 3H), 0.99 (t, J=7.3 Hz, 3H).</p><heading id="h-0406" level="1">Example 333: (R/S)-6-(3,4-Difluorophenyl)-1-(2-hydroxybutyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1198" num="1261"><chemistry id="CHEM-US-00460" num="00460"><img id="EMI-C00460" he="34.88mm" wi="45.21mm" file="US20230000833A1-20230105-C00460.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1199" num="1262">The title compound was prepared in a manner analogous to Example 31, Step B, using 6-(3,4-difluorophenyl)-3-methyl-1-(2-oxobutypimidazo[4,5-b]pyridin-2-one (Example 390, 65 mg, 0.2 mmol) in THF (4.2 mL) and MeOH (4 mL) at 0&#xb0; C. After completion, the reaction mixture was concentrated under vacuum. The crude material was purified (Method C) to give the title compound (11 mg, 0.03 mmol, 13%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 333.1; m/z found, 334.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.31 (d, J=1.9 Hz, 1H), 7.88-7.78 (m, 2H), 7.60-7.50 (m, 2H), 3.91-3.69 (m, 4H), 3.37 (s, 3H), 1.58-1.30 (m, 2H), 0.93 (t, J=7.4 Hz, 3H).</p><heading id="h-0407" level="1">Example 334: (R/S)-6-(4-Fluoro-3-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1200" num="1263"><chemistry id="CHEM-US-00461" num="00461"><img id="EMI-C00461" he="32.09mm" wi="45.21mm" file="US20230000833A1-20230105-C00461.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1201" num="1264">The title compound was prepared in a manner analogous to Example 31, Step B, using 6-(4-fluoro-3-methylphenyl)-1-(2-oxobutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Example 331). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 315.1; m/z found, 316.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.55 (s, 1H), 8.16 (d, J=2.0 Hz, 1H), 7.71 (d, J=2.0 Hz, 1H), 7.61-7.58 (m, 1H), 7.53-7.48 (m, 1H), 7.27-7.20 (m, 1H), 2.31 (d, J=1.9 Hz, 3H), 1.53-1.43 (m, 1H), 1.42-1.31 (m, 1H), 0.92 (t, J=7.4 Hz, 3H).</p><heading id="h-0408" level="1">Example 335: (R/S)-1-(2-Hydroxybutyl)-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1202" num="1265"><chemistry id="CHEM-US-00462" num="00462"><img id="EMI-C00462" he="32.09mm" wi="39.79mm" file="US20230000833A1-20230105-C00462.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1203" num="1266">The title compound was prepared in a manner analogous to Example 31, Step B, using. 6-(m-tolyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one (Example 332). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>, 297.1; m/z found, 298.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.56 (s, 1H), 8.17 (d, J=1.9 Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.51-7.43 (m, 2H), 7.36 (t, J=7.6 Hz, 1H), 7.21-7.15 (m, 1H), 2.39 (s, 3H), 1.56-1.29 (m, 2H), 0.92 (t, J=7.4 Hz, 3H).</p><heading id="h-0409" level="1">Example 336: (R/S)-6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1204" num="1267"><chemistry id="CHEM-US-00463" num="00463"><img id="EMI-C00463" he="32.09mm" wi="45.21mm" file="US20230000833A1-20230105-C00463.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1205" num="1268">The title compound was prepared in a manner analogous to Example 31, Step B, using 6-(2,4-difluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one (Example 30). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 333.1; m/z found, 334.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.64 (s, 1H), 8.01 (t, J=1.7 Hz, 1H), 7.60 (t, J=1.7 Hz, 1H), 7.45-7.37 (m, 1H), 7.21-7.15 (m, 1H), 2.23 (t, J=1.9 Hz, 3H), 1.53-1.28 (m, 2H), 0.91 (t, J=7.4 Hz, 3H).</p><heading id="h-0410" level="1">Example 337: (R/S)-1-(2-Hydroxybutyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1206" num="1269"><chemistry id="CHEM-US-00464" num="00464"><img id="EMI-C00464" he="32.09mm" wi="39.79mm" file="US20230000833A1-20230105-C00464.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1207" num="1270">The title compound was prepared in a manner analogous to Example 31, using 1-bromobutan-2-one in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 351.1; m/z found, 352.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.66 (s, 1H), 8.28 (d, J=2.0 Hz, 1H), 8.03-7.97 (m, 2H), 7.85 (d, J=2.0 Hz, 1H), 7.76-7.69 (m, 2H), 4.93-4.75 (m, 1H), 3.87-3.68 (m, 3H), 1.55-1.31 (m, 2H), 0.93 (t, J=7.4 Hz, 3H).</p><heading id="h-0411" level="1">Example 338: (R/S)-1-(2-Hydroxy-3-methyl-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1208" num="1271"><chemistry id="CHEM-US-00465" num="00465"><img id="EMI-C00465" he="32.09mm" wi="39.79mm" file="US20230000833A1-20230105-C00465.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1209" num="1272">The title compound was prepared in a manner analogous to Example 31, using 1-bromo-3-methylbutan-2-one in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 365.1; m/z found, 366.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 11.66 (s, 1H), 8.27 (d, J=2.0 Hz, 1H), 8.02-7.96 (m, 2H), 7.81 (d, J=2.0 Hz, 1H), 7.76-7.69 (m, 2H), 3.93-3.87 (m, 1H), 3.78 (dd, J=14.2, 8.5 Hz, 1H), 3.61-3.52 (m, 1H), 1.72-1.61 (m, 1H), 0.95 (t, J=6.7 Hz, 6H).</p><heading id="h-0412" level="1">Example 339: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1210" num="1273"><chemistry id="CHEM-US-00466" num="00466"><img id="EMI-C00466" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00466.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1211" num="1274">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 366.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.65-8.64 (m, 1H), 8.49 (dd, J=4.8, 1.6 Hz, 1H), 8.12 (t, J=1.6 Hz, 1H), 7.78-7.72 (m, 2H), 7.43-7.33 (m, 2H), 7.21-7.15 (m, 1H), 5.17 (s, 2H), 3.40 (s, 3H), 2.22 (t, J=1.9 Hz, 3H).</p><heading id="h-0413" level="1">Example 340: 6-(4-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1212" num="1275"><chemistry id="CHEM-US-00467" num="00467"><img id="EMI-C00467" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00467.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1213" num="1276">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 367.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.54 (t, J=1.9 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.30 (d, J=1.9 Hz, 1H), 7.91 (d, J=1.9 Hz, 1H), 7.73 (ddd, J=9.7, 2.8, 1.7 Hz, 1H), 7.62-7.59 (m, 1H), 7.54-7.49 (m, 1H), 7.24 (dd, J=9.7, 8.5 Hz, 1H), 5.23 (s, 2H), 3.40 (s, 3H), 2.31 (d, J=1.9 Hz, 3H).</p><heading id="h-0414" level="1">Example 341: 6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1214" num="1277"><chemistry id="CHEM-US-00468" num="00468"><img id="EMI-C00468" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00468.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1215" num="1278">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 384.1; m/z found, 385.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.52 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.13 (t, J=1.6 Hz, 1H), 7.77 (t, J=1.6 Hz, 1H), 7.73 (ddd, J=9.7, 2.8, 1.8 Hz, 1H), 7.40 (td, J=8.8, 6.5 Hz, 1H), 7.21-7.16 (m, 1H), 5.21 (s, 2H), 3.40 (s, 3H), 2.22 (t, J=1.8 Hz, 3H).</p><heading id="h-0415" level="1">Example 342: 6-[3-(Difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1216" num="1279"><chemistry id="CHEM-US-00469" num="00469"><img id="EMI-C00469" he="39.20mm" wi="47.92mm" file="US20230000833A1-20230105-C00469.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1217" num="1280">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in A and (3-(difluoromethoxy)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 400.1; m/z found, 401.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.55 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.38 (d, J=1.9 Hz, 1H), 7.98 (d, J=1.9 Hz, 1H), 7.74 (ddd, J=9.8, 2.8, 1.8 Hz, 1H), 7.59-7.17 (m, 5H), 5.24 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0416" level="1">Example 343: 6-(3,4-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1218" num="1281"><chemistry id="CHEM-US-00470" num="00470"><img id="EMI-C00470" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00470.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1219" num="1282">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.55 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.37 (d, J=1.9 Hz, 1H), 7.98 (d, J=2.0 Hz, 1H), 7.86-7.80 (m, 1H), 7.76-7.72 (m, 1H), 7.59-7.50 (m, 2H), 5.22 (s, 2H), 3.40 (s, 3H).</p><p id="p-1220" num="1283">Example 344: 1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one</p><p id="p-1221" num="0000"><chemistry id="CHEM-US-00471" num="00471"><img id="EMI-C00471" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00471.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1222" num="1284">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3,4,5-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>F<sub>4</sub>N<sub>4</sub>O, 388.1; m/z found, 389.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.55 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.43 (d, J=2.0 Hz, 1H), 8.03 (d, J=2.0 Hz, 1H), 7.80-7.72 (m, 3H), 5.21 (s, 2H), 3.39 (s, 3H).</p><heading id="h-0417" level="1">Example 345: 1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-[3-(trifluoromethoxy)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1223" num="1285"><chemistry id="CHEM-US-00472" num="00472"><img id="EMI-C00472" he="34.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00472.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1224" num="1286">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3-(trifluoromethoxy)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 418.1; m/z found, 419.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.55 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.7 Hz, 1H), 8.40 (d, J=1.9 Hz, 1H), 8.01 (d, J=1.9 Hz, 1H), 7.77-7.72 (m, 2H), 7.70-7.68 (m, 1H), 7.62 (t, J=8.0 Hz, 1H), 7.40-7.36 (m, 1H), 5.24 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0418" level="1">Example 346: 6-(2,3-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1225" num="1287"><chemistry id="CHEM-US-00473" num="00473"><img id="EMI-C00473" he="34.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00473.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1226" num="1288">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (2,3-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.53 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.7 Hz, 1H), 8.21 (t, J=1.7 Hz, 1H), 7.84 (t, J=1.6 Hz, 1H), 7.74 (ddd, J=9.7, 2.7, 1.7 Hz, 1H), 7.50-7.44 (m, 1H), 7.39-7.30 (m, 2H), 5.22 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0419" level="1">Example 347: 1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(2,3,4-trifluorophenyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1227" num="1289"><chemistry id="CHEM-US-00474" num="00474"><img id="EMI-C00474" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00474.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1228" num="1290">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (2,3,4-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>F<sub>4</sub>N<sub>4</sub>O, 388.1; m/z found, 389.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.53 (t, J=1.7 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.19 (t, J=1.6 Hz, 1H), 7.82 (t, J=1.6 Hz, 1H), 7.75-7.71 (m, 1H), 7.51-7.38 (m, 2H), 5.21 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0420" level="1">Example 348: 6-(3-Chlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1229" num="1291"><chemistry id="CHEM-US-00475" num="00475"><img id="EMI-C00475" he="34.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00475.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1230" num="1292">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3-chlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>ClFN<sub>4</sub>O, 368.1; m/z found, 369.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.55 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.7 Hz, 1H), 8.38 (d, J=1.9 Hz, 1H), 8.01 (d, J=1.9 Hz, 1H), 7.78 (t, J=1.9 Hz, 1H), 7.74 (ddd, J=9.7, 2.7, 1.7 Hz, 1H), 7.67 (ddd, J=7.8, 1.8, 1.1 Hz, 1H), 7.51 (t, J=7.9 Hz, 1H), 7.45-7.42 (m, 1H), 5.24 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0421" level="1">Example 349: 6-(3-Chloro-2-fluoro-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1231" num="1293"><chemistry id="CHEM-US-00476" num="00476"><img id="EMI-C00476" he="34.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00476.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1232" num="1294">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3-chloro-2-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>ClF<sub>2</sub>N<sub>4</sub>O, 386.1; m/z found, 387.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.53 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.19 (t, J=1.6 Hz, 1H), 7.84 (t, J=1.7 Hz, 1H), 7.73 (ddd, J=9.8, 2.8, 1.8 Hz, 1H), 7.64-7.60 (m, 1H), 7.54-7.50 (m, 1H), 7.34 (td, J=7.9, 1.0 Hz, 1H), 5.22 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0422" level="1">Example 350: 1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(m-tolyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1233" num="1295"><chemistry id="CHEM-US-00477" num="00477"><img id="EMI-C00477" he="34.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00477.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1234" num="1296">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and m-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O, 348.1; m/z found, 349.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.54 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.31 (d, J=1.9 Hz, 1H), 7.91 (d, J=1.9 Hz, 1H), 7.73 (ddd, J=9.7, 2.8, 1.7 Hz, 1H), 7.50-7.48 (m, 1H), 7.47-7.44 (m, 1H), 7.36 (t, J=7.6 Hz, 1H), 7.21-7.17 (m, 1H), 5.24 (s, 2H), 3.40 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0423" level="1">Example 351: 6-(3,4-Dichlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1235" num="1297"><chemistry id="CHEM-US-00478" num="00478"><img id="EMI-C00478" he="34.80mm" wi="54.69mm" file="US20230000833A1-20230105-C00478.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1236" num="1298">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (3,4-dichlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>Cl<sub>2</sub>FN<sub>4</sub>O, 402.0; m/z found, 403.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.55 (t, J=1.8 Hz, 1H), 8.51 (d, J=2.7 Hz, 1H), 8.40 (d, J=1.9 Hz, 1H), 8.03 (d, J=2.0 Hz, 1H), 7.99 (d, J=2.0 Hz, 1H), 7.76-7.69 (m, 3H), 5.23 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0424" level="1">Example 352: 6-(2-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1237" num="1299"><chemistry id="CHEM-US-00479" num="00479"><img id="EMI-C00479" he="34.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00479.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1238" num="1300">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)-5-fluoropyridine hydrochloride in Step A and (2-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 367.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.52 (t, J=1.7 Hz, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.15 (t, J=1.7 Hz, 1H), 7.77 (t, J=1.6 Hz, 1H), 7.75-7.71 (m, 1H), 7.35-7.29 (m, 2H), 7.20 (t, J=7.6 Hz, 1H), 5.22 (s, 2H), 3.41 (s, 3H), 2.30 (d, J=2.1 Hz, 3H).</p><heading id="h-0425" level="1">Example 353: 3-Methyl-1-(3-pyridylmethyl)-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt</heading><p id="p-1239" num="1301"><chemistry id="CHEM-US-00480" num="00480"><img id="EMI-C00480" he="30.65mm" wi="53.34mm" file="US20230000833A1-20230105-C00480.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1240" num="1302">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (3,4,5-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.78-8.75 (m, 1H), 8.61-8.57 (m, 1H), 8.43 (d, J=1.9 Hz, 1H), 8.03 (d, J=2.0 Hz, 1H), 8.00-7.97 (m, 1H), 7.79-7.71 (m, 2H), 7.57-7.52 (m, 1H), 5.22 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0426" level="1">Example 354: 6-(3,5-Difluorophenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1241" num="1303"><chemistry id="CHEM-US-00481" num="00481"><img id="EMI-C00481" he="30.65mm" wi="53.34mm" file="US20230000833A1-20230105-C00481.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1242" num="1304">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (3,5-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O, 352.1; m/z found, 353.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.78 (d, J=2.3 Hz, 1H), 8.63-8.60 (m, 1H), 8.45 (d, J=1.9 Hz, 1H), 8.07-8.01 (m, 2H), 7.59 (dd, J=8.0, 5.0 Hz, 1H), 7.54-7.48 (m, 2H), 7.24 (tt, J=9.3, 2.2 Hz, 1H), 5.25 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0427" level="1">Example 355: 6-(3-Chloro-4-fluoro-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1243" num="1305"><chemistry id="CHEM-US-00482" num="00482"><img id="EMI-C00482" he="30.73mm" wi="53.34mm" file="US20230000833A1-20230105-C00482.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1244" num="1306">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (3-chloro-4-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>ClFN<sub>4</sub>O, 368.1; m/z found, 369.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.78-8.74 (m, 1H), 8.61-8.57 (m, 1H), 8.37 (d, J=1.9 Hz, 1H), 8.02-7.97 (m, 2H), 7.93 (dd, J=7.1, 2.3 Hz, 1H), 7.71 (ddd, J=8.5, 4.6, 2.4 Hz, 1H), 7.58-7.50 (m, 2H), 5.24 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0428" level="1">Example 356: 3-Methyl-6-(m-tolyl)-1-(3-pyridylmethypimidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1245" num="1307"><chemistry id="CHEM-US-00483" num="00483"><img id="EMI-C00483" he="29.89mm" wi="47.92mm" file="US20230000833A1-20230105-C00483.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1246" num="1308">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and m-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>18</sub>N<sub>4</sub>O, 330.1; m/z found, 331.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.79-8.78 (m, 1H), 8.62 (dd, J=5.1, 1.5 Hz, 1H), 8.31 (d, J=1.9 Hz, 1H), 8.08-8.03 (m, 1H), 7.91 (d, J=1.9 Hz, 1H), 7.61 (dd, J=7.9, 5.1 Hz, 1H), 7.50-7.48 (m, 1H), 7.47-7.43 (m, 1H), 7.36 (t, J=7.6 Hz, 1H), 7.21-7.17 (m, 1H), 5.27 (s, 2H), 3.40 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0429" level="1">Example 357: 6-(2-Fluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1247" num="1309"><chemistry id="CHEM-US-00484" num="00484"><img id="EMI-C00484" he="29.89mm" wi="47.92mm" file="US20230000833A1-20230105-C00484.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1248" num="1310">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (2-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O, 348.1; m/z found, 349.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.78-8.76 (m, 1H), 8.64-8.61 (m, 1H), 8.16 (t, J=1.7 Hz, 1H), 8.07-8.03 (m, 1H), 7.78 (t, J=1.6 Hz, 1H), 7.62 (dd, J=7.9, 5.1 Hz, 1H), 7.35-7.29 (m, 2H), 7.20 (t, J=7.6 Hz, 1H), 5.25 (s, 2H), 3.41 (s, 3H), 2.30 (d, J=2.1 Hz, 3H).</p><heading id="h-0430" level="1">Example 358: 6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1249" num="1311"><chemistry id="CHEM-US-00485" num="00485"><img id="EMI-C00485" he="31.33mm" wi="47.92mm" file="US20230000833A1-20230105-C00485.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1250" num="1312">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (2-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F4N<sub>4</sub>O, 402.1; m/z found, 403.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.82 (d, J=1.9 Hz, 1H), 8.68 (dd, J=5.3, 1.5 Hz, 1H), 8.22 (t, J=1.6 Hz, 1H), 8.15 (dt, J=8.0, 1.8 Hz, 1H), 7.91-7.86 (m, 2H), 7.85-7.80 (m, 1H), 7.70 (dd, J=7.9, 5.3 Hz, 1H), 7.54 (t, J=7.8 Hz, 1H), 5.29 (s, 2H), 3.42 (s, 3H).</p><p id="p-1251" num="1313">Example 359: 6-(3-Chloro-2-fluoro-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</p><p id="p-1252" num="0000"><chemistry id="CHEM-US-00486" num="00486"><img id="EMI-C00486" he="30.73mm" wi="47.92mm" file="US20230000833A1-20230105-C00486.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1253" num="1314">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (3-chloro-2-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>ClFN<sub>4</sub>O, 368.1; m/z found, 369.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.78-8.75 (m, 1H), 8.62 (dd, J=5.4, 1.6 Hz, 1H), 8.20 (t, J=1.7 Hz, 1H), 8.05-8.01 (m, 1H), 7.85 (t, J=1.7 Hz, 1H), 7.66-7.57 (m, 2H), 7.55-7.48 (m, 1H), 7.34 (td, J=7.9, 1.0 Hz, 1H), 5.24 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0431" level="1">Example 360: 6-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1254" num="1315"><chemistry id="CHEM-US-00487" num="00487"><img id="EMI-C00487" he="31.33mm" wi="53.34mm" file="US20230000833A1-20230105-C00487.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1255" num="1316">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O, 402.1; m/z found, 403.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.80-8.77 (m, 1H), 8.64-8.61 (m, 1H), 8.40 (d, J=1.9 Hz, 1H), 8.09-7.99 (m, 4H), 7.69-7.57 (m, 2H), 5.27 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0432" level="1">Example 361: 3-Methyl-1-(3-pyridylmethyl)-6-(2,3,4-trifluorophenyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1256" num="1317"><chemistry id="CHEM-US-00488" num="00488"><img id="EMI-C00488" he="30.65mm" wi="53.34mm" file="US20230000833A1-20230105-C00488.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1257" num="1318">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (2,3,4-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O, 370.1; m/z found, 371.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.76-8.74 (m, 1H), 8.63-8.59 (m, 1H), 8.19 (t, J=1.7 Hz, 1H), 8.03-7.97 (m, 1H), 7.82 (t, J=1.6 Hz, 1H), 7.60-7.54 (m, 1H), 7.51-7.37 (m, 2H), 5.23 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0433" level="1">Example 362: 3-Methyl-1-(3-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1258" num="1319"><chemistry id="CHEM-US-00489" num="00489"><img id="EMI-C00489" he="31.33mm" wi="47.92mm" file="US20230000833A1-20230105-C00489.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1259" num="1320">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O, 384.1; m/z found, 385.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.79 (d, J=2.1 Hz, 1H), 8.63 (dd, J=5.2, 1.5 Hz, 1H), 8.43 (d, J=1.9 Hz, 1H), 8.09-8.04 (m, 2H), 8.03-7.99 (m, 2H), 7.77-7.69 (m, 2H), 7.65-7.59 (m, 1H), 5.29 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0434" level="1">Example 363: 6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1260" num="1321"><chemistry id="CHEM-US-00490" num="00490"><img id="EMI-C00490" he="33.53mm" wi="48.43mm" file="US20230000833A1-20230105-C00490.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1261" num="1322">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (3-(difluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O, 366.1; m/z found, 367.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.80-8.77 (m, 1H), 8.64-8.61 (m, 1H), 8.37 (d, J=1.9 Hz, 1H), 8.10-8.04 (m, 1H), 8.01 (d, J=1.9 Hz, 1H), 7.89-7.83 (m, 2H), 7.67-7.55 (m, 3H), 7.09 (t, J=55.8 Hz, 1H), 5.29 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0435" level="1">Example 364: 3-Methyl-1-(3-pyridylmethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1262" num="1323"><chemistry id="CHEM-US-00491" num="00491"><img id="EMI-C00491" he="28.62mm" wi="55.54mm" file="US20230000833A1-20230105-C00491.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1263" num="1324">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (5-(trifluoromethyl)thiophen-2-yl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>OS, 390.1; m/z found, 391.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.77 (d, J=2.2 Hz, 1H), 8.61 (dd, J=5.1, 1.6 Hz, 1H), 8.43 (d, J=1.9 Hz, 1H), 8.03-7.98 (m, 2H), 7.78-7.75 (m, 1H), 7.63-7.54 (m, 2H), 5.24 (s, 2H), 3.39 (s, 3H).</p><heading id="h-0436" level="1">Example 365: 6-(5-Chloro-4-methyl-2-thienyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1264" num="1325"><chemistry id="CHEM-US-00492" num="00492"><img id="EMI-C00492" he="28.62mm" wi="54.36mm" file="US20230000833A1-20230105-C00492.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1265" num="1326">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (5-chloro-4-methylthiophen-2-yl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>ClN<sub>4</sub>OS, 370.1; m/z found, 371.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.75-8.72 (m, 1H), 8.59 (dd, J=4.9, 1.4 Hz, 1H), 8.23 (d, J=1.9 Hz, 1H), 7.98-7.92 (m, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.56-7.51 (m, 1H), 7.33 (s, 1H), 5.21 (s, 2H), 3.37 (s, 3H), 2.18 (s, 3H).</p><heading id="h-0437" level="1">Example 366: 1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1266" num="1327"><chemistry id="CHEM-US-00493" num="00493"><img id="EMI-C00493" he="34.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00493.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1267" num="1328">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>4</sub>O, 418.1; m/z found, 419.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.62 (d, J=1.9 Hz, 1H), 8.56 (d, J=2.3 Hz, 1H), 8.42 (d, J=1.9 Hz, 1H), 8.07 (d, J=1.9 Hz, 1H), 8.03-7.99 (m, 2H), 7.96-7.94 (m, 1H), 7.76-7.69 (m, 2H), 5.23 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0438" level="1">Example 367: 1-[(5-Chloro-3-pyridyl)methyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1268" num="1329"><chemistry id="CHEM-US-00494" num="00494"><img id="EMI-C00494" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00494.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1269" num="1330">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>ClFN<sub>4</sub>O, 382.1; m/z found, 383.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.61 (d, J=1.9 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H), 8.29 (d, J=1.9 Hz, 1H), 7.95-7.94 (m, 1H), 7.92 (d, J=1.9 Hz, 1H), 7.62-7.59 (m, 1H), 7.54-7.49 (m, 1H), 7.24 (dd, J=9.7, 8.5 Hz, 1H), 5.21 (s, 2H), 3.39 (s, 3H), 2.31 (d, J=1.9 Hz, 3H).</p><heading id="h-0439" level="1">Example 368: 1-[(5-Chloro-3-pyridyl)methyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1270" num="1331"><chemistry id="CHEM-US-00495" num="00495"><img id="EMI-C00495" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00495.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1271" num="1332">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>ClF<sub>2</sub>N<sub>4</sub>O, 400.1; m/z found, 401.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.60 (d, J=1.8 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H), 8.13 (t, J=1.6 Hz, 1H), 7.94 (t, J=2.2 Hz, 1H), 7.79 (t, J=1.6 Hz, 1H), 7.43-7.37 (m, 1H), 7.22-7.15 (m, 1H), 5.19 (s, 2H), 3.40 (s, 3H), 2.22 (t, J=1.9 Hz, 3H).</p><heading id="h-0440" level="1">Example 369: 1-[(5-Chloro-3-pyridyl)methyl]-6-(3,4-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1272" num="1333"><chemistry id="CHEM-US-00496" num="00496"><img id="EMI-C00496" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00496.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1273" num="1334">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>ClF<sub>2</sub>N<sub>4</sub>O, 386.1; m/z found, 387.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.62 (d, J=1.9 Hz, 1H), 8.56 (d, J=2.3 Hz, 1H), 8.37 (d, J=1.9 Hz, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.95 (t, J=2.2 Hz, 1H), 7.86-7.78 (m, 1H), 7.60-7.50 (m, 2H), 5.20 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0441" level="1">Example 370: 1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1274" num="1335"><chemistry id="CHEM-US-00497" num="00497"><img id="EMI-C00497" he="34.80mm" wi="53.34mm" file="US20230000833A1-20230105-C00497.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1275" num="1336">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (3,4,5-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>4</sub>O, 404.1; m/z found, 405.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.62 (d, J=1.9 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H), 8.43 (d, J=1.9 Hz, 1H), 8.04 (d, J=2.0 Hz, 1H), 7.95 (t, J=2.1 Hz, 1H), 7.80-7.71 (m, 2H), 5.19 (s, 2H), 3.39 (s, 3H).</p><heading id="h-0442" level="1">Example 371: 1-[(5-Chloro-3-pyridyl)methyl]-6-(2-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1276" num="1337"><chemistry id="CHEM-US-00498" num="00498"><img id="EMI-C00498" he="34.80mm" wi="47.92mm" file="US20230000833A1-20230105-C00498.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1277" num="1338">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (2-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>ClFN<sub>4</sub>O, 382.1; m/z found, 383.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.60 (d, J=1.9 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H), 8.15 (t, J=1.7 Hz, 1H), 7.94 (t, J=2.1 Hz, 1H), 7.80 (t, J=1.7 Hz, 1H), 7.36-7.28 (m, 2H), 7.23-7.16 (m, 1H), 5.19 (s, 2H), 3.40 (s, 3H), 2.30 (d, J=2.2 Hz, 3H).</p><heading id="h-0443" level="1">Example 372: 6-(5-Chloro-4-methyl-2-thienyl)-1-[(5-chloro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1278" num="1339"><chemistry id="CHEM-US-00499" num="00499"><img id="EMI-C00499" he="34.80mm" wi="54.36mm" file="US20230000833A1-20230105-C00499.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1279" num="1340">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (5-chloro-4-methylthiophen-2-yl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>4</sub>OS, 404.0; m/z found, 405.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.61 (d, J=1.9 Hz, 1H), 8.57 (d, J=2.4 Hz, 1H), 8.23 (d, J=1.9 Hz, 1H), 7.93 (t, J=2.1 Hz, 1H), 7.87 (d, J=1.9 Hz, 1H), 7.34 (s, 1H), 5.18 (s, 2H), 3.37 (s, 3H), 2.18 (s, 3H).</p><heading id="h-0444" level="1">Example 373: 1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1280" num="1341"><chemistry id="CHEM-US-00500" num="00500"><img id="EMI-C00500" he="34.88mm" wi="55.54mm" file="US20230000833A1-20230105-C00500.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1281" num="1342">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (5-(trifluoromethyl)thiophen-2-yl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>4</sub>OS, 424.0; m/z found, 425.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.62 (d, J=1.9 Hz, 1H), 8.57 (d, J=2.3 Hz, 1H), 8.42 (d, J=1.9 Hz, 1H), 8.02 (d, J=1.9 Hz, 1H), 7.95 (t, J=2.1 Hz, 1H), 7.78-7.75 (m, 1H), 7.63-7.60 (m, 1H), 5.20 (s, 2H), 3.39 (s, 3H).</p><heading id="h-0445" level="1">Example 374: 1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-(m-tolypimidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1282" num="1343"><chemistry id="CHEM-US-00501" num="00501"><img id="EMI-C00501" he="34.88mm" wi="47.92mm" file="US20230000833A1-20230105-C00501.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1283" num="1344">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and m-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>ClN<sub>4</sub>O, 364.1; m/z found, 365.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.61 (d, J=1.9 Hz, 1H), 8.56 (d, J=2.3 Hz, 1H), 8.31 (d, J=1.9 Hz, 1H), 7.95-7.94 (m, 1H), 7.93 (d, J=1.9 Hz, 1H), 7.50-7.48 (m, 1H),7.47-7.44 (m, 1H), 7.36 (t, J=7.6 Hz, 1H), 7.21-7.17 (m, 1H), 5.22 (s, 2H), 3.40 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0446" level="1">Example 375: 1-[(5-Chloro-3-pyridyl)methyl]-6-(2,3-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1284" num="1345"><chemistry id="CHEM-US-00502" num="00502"><img id="EMI-C00502" he="34.88mm" wi="47.92mm" file="US20230000833A1-20230105-C00502.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1285" num="1346">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-chloro-5-(chloromethyl)pyridine hydrochloride in Step A and (2,3-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>ClF<sub>2</sub>N<sub>4</sub>O, 386.1; m/z found, 387.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.61 (d, J=1.9 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H), 8.21 (t, J=1.6 Hz, 1H), 7.95 (t, J=2.1 Hz, 1H), 7.86 (t, J=1.6 Hz, 1H), 7.50-7.43 (m, 1H), 7.40-7.30 (m, 2H), 5.19 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0447" level="1">Example 376: 6-(3-Chlorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1286" num="1347"><chemistry id="CHEM-US-00503" num="00503"><img id="EMI-C00503" he="30.82mm" wi="47.92mm" file="US20230000833A1-20230105-C00503.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1287" num="1348">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride in Step A and (3-chlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>ClN<sub>5</sub>O, 351.1; m/z found, 352.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.16 (dd, J=4.6, 2.0 Hz, 1H), 8.39 (d, J=1.9 Hz, 1H), 7.94 (d, J=2.0 Hz, 1H), 7.75 (t, J=1.9 Hz, 1H), 7.72-7.63 (m, 3H), 7.49 (t, J=7.9 Hz, 1H), 7.44-7.40 (m, 1H), 5.49 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0448" level="1">Example 377: 6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1288" num="1349"><chemistry id="CHEM-US-00504" num="00504"><img id="EMI-C00504" he="33.53mm" wi="48.43mm" file="US20230000833A1-20230105-C00504.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1289" num="1350">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (3-(difluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O, 367.1; m/z found, 368.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.16 (dd, J=4.5, 2.1 Hz, 1H), 8.38 (d, J=1.9 Hz, 1H), 7.93 (d, J=1.9 Hz, 1H), 7.86-7.82 (m, 2H), 7.72-7.66 (m, 2H), 7.65-7.55 (m, 2H), 7.08 (t, J=55.8 Hz, 1H), 5.50 (s, 2H), 3.43 (s, 3H).</p><heading id="h-0449" level="1">Example 378: 3-Methyl-1-(pyridazin-3-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1290" num="1351"><chemistry id="CHEM-US-00505" num="00505"><img id="EMI-C00505" he="31.33mm" wi="47.92mm" file="US20230000833A1-20230105-C00505.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1291" num="1352">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, 386.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) 67  9.16 (dd, J=4.5, 2.1 Hz, 1H), 8.44 (d, J=1.9 Hz, 1H), 8.01-7.98 (m, 3H), 7.75-7.65 (m, 4H), 5.50 (s, 2H), 3.43 (s, 3H).</p><heading id="h-0450" level="1">Example 379: 3-Methyl-6-(m-tolyl)-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1292" num="1353"><chemistry id="CHEM-US-00506" num="00506"><img id="EMI-C00506" he="29.89mm" wi="47.92mm" file="US20230000833A1-20230105-C00506.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1293" num="1354">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and m-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>O, 331.1; m/z found, 332.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.16 (dd, J=4.6, 2.0 Hz, 1H), 8.32 (d, J=1.9 Hz, 1H), 7.83 (d, J=1.9 Hz, 1H), 7.73-7.64 (m, 2H), 7.48-7.46 (m, 1H), 7.45-7.41 (m, 1H), 7.34 (t, J=7.6 Hz, 1H), 7.20-7.16 (m, 1H), 5.48 (s, 2H), 3.42 (s, 3H), 2.37 (s, 3H).</p><p id="p-1294" num="1355">Example 380: 6-(3-Chloro-4-fluoro-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</p><p id="p-1295" num="0000"><chemistry id="CHEM-US-00507" num="00507"><img id="EMI-C00507" he="30.82mm" wi="53.34mm" file="US20230000833A1-20230105-C00507.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1296" num="1356">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (3-chloro-4-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>13</sub>ClFN<sub>5</sub>O, 369.1; m/z found, 370.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.16 (dd, J=4.6, 1.9 Hz, 1H), 8.38 (d, J=1.9 Hz, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.91 (dd, J=7.1, 2.3 Hz, 1H), 7.72-7.65 (m, 3H), 7.51 (t, J=9.0 Hz, 1H), 5.48 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0451" level="1">Example 381: 6-(3-Fluoro-5-methyl-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1297" num="1357"><chemistry id="CHEM-US-00508" num="00508"><img id="EMI-C00508" he="29.89mm" wi="53.34mm" file="US20230000833A1-20230105-C00508.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1298" num="1358">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (3-fluoro-5-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>FN<sub>5</sub>O, 349.1; m/z found, 350.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.16 (dd, J=4.6, 1.9 Hz, 1H), 8.38 (d, J=1.9 Hz, 1H), 7.90 (d, J=1.9 Hz, 1H), 7.72-7.65 (m, 2H), 7.37-7.34 (m, 1H), 7.34-7.30 (m, 1H), 7.05-7.00 (m, 1H), 5.48 (s, 2H), 3.42 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0452" level="1">Example 382: 6-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1299" num="1359"><chemistry id="CHEM-US-00509" num="00509"><img id="EMI-C00509" he="31.33mm" wi="53.34mm" file="US20230000833A1-20230105-C00509.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1300" num="1360">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>4</sub>N<sub>5</sub>O, 403.1; m/z found, 403.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.15 (dd, J=4.4, 2.1 Hz, 1H), 8.41 (d, J=2.0 Hz, 1H), 8.08-7.96 (m, 3H), 7.72-7.59 (m, 3H), 5.49 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0453" level="1">Example 383: 6-[3-Fluoro-5-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1301" num="1361"><chemistry id="CHEM-US-00510" num="00510"><img id="EMI-C00510" he="31.33mm" wi="53.34mm" file="US20230000833A1-20230105-C00510.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1302" num="1362">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (3-fluoro-5-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>F<sub>4</sub>N<sub>5</sub>O, 403.1; m/z found, 404.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.15 (dd, J=4.6, 1.9 Hz, 1H), 8.51 (d, J=1.9 Hz, 1H), 8.07 (d, J=2.0 Hz, 1H), 7.96-7.92 (m, 1H), 7.91-7.89 (m, 1H), 7.71-7.64 (m, 3H), 5.50 (s, 2H), 3.43 (s, 3H).</p><heading id="h-0454" level="1">Example 384: 6-[4-Chloro-3-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1303" num="1363"><chemistry id="CHEM-US-00511" num="00511"><img id="EMI-C00511" he="31.33mm" wi="54.69mm" file="US20230000833A1-20230105-C00511.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1304" num="1364">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (4-chloro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>13</sub>ClF<sub>3</sub>N<sub>5</sub>O, 419.1; m/z found, 419.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.15 (dd, J=4.5, 2.0 Hz, 1H), 8.44 (d, J=1.9 Hz, 1H), 8.07 (d, J=2.2 Hz, 1H), 8.02-7.97 (m, 2H), 7.84-7.80 (m, 1H), 7.72-7.65 (m, 2H), 5.49 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0455" level="1">Example 385: 6-(5-(Difluoromethyl)-2-fluorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1305" num="1365"><chemistry id="CHEM-US-00512" num="00512"><img id="EMI-C00512" he="28.62mm" wi="58.25mm" file="US20230000833A1-20230105-C00512.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1306" num="1366">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (5-(difluoromethyl)-2-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, 386.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.16 (dd, J=4.2, 2.4 Hz, 1H), 8.23 (t, J=1.8 Hz, 1H), 7.77-7.62 (m, 5H), 7.53-7.46 (m, 1H), 7.08 (t, J=55.7 Hz, 1H), 5.47 (s, 2H), 3.43 (s, 3H).</p><heading id="h-0456" level="1">Example 386: 6-(5-(Difluoromethyl)-2-fluorophenyl)-3-methyl-1-(pyridin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1307" num="1367"><chemistry id="CHEM-US-00513" num="00513"><img id="EMI-C00513" he="28.62mm" wi="58.25mm" file="US20230000833A1-20230105-C00513.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1308" num="1368">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridine hydrochloride in Step A and (5-(difluoromethyl)-2-fluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>3</sub>N40, 384.1; m/z found, 385.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) 6 8.80-8.77 (m, 1H), 8.66-8.63 (m, 1H), 8.22 (t, J=1.8 Hz, 1H), 8.09 (dt, J=8.1, 1.8 Hz, 1H), 7.85 (t, J=1.6 Hz, 1H), 7.78-7.73 (m, 1H), 7.70-7.62 (m, 2H), 7.54-7.47 (m, 1H), 7.09 (t, J=55.7 Hz, 1H), 5.27 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0457" level="1">Example 387: 6-[3,4-Difluoro-5-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1309" num="1369"><chemistry id="CHEM-US-00514" num="00514"><img id="EMI-C00514" he="31.33mm" wi="53.34mm" file="US20230000833A1-20230105-C00514.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1310" num="1370">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 3-(chloromethyl)pyridazine hydrochloride (Intermediate 2) in Step A and (3,4-difluoro-5-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>F<sub>5</sub>N<sub>5</sub>O, 421.1; m/z found, 429.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.16 (dd, J=4.6, 1.9 Hz, 1H), 8.47 (d, J=2.0 Hz, 1H), 8.21 (ddd, J=11.7, 7.3, 2.2 Hz, 1H), 8.04 (d, J=2.0 Hz, 1H), 7.89-7.85 (m, 1H), 7.71-7.64 (m, 2H), 5.48 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0458" level="1">Example 388: 3-Methyl-1-(2-oxobutyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1311" num="1371"><chemistry id="CHEM-US-00515" num="00515"><img id="EMI-C00515" he="34.88mm" wi="39.79mm" file="US20230000833A1-20230105-C00515.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1312" num="1372">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 1-bromobutan-2-one in Step A; and (3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, 364.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.41 (d, J=1.9 Hz, 1H), 8.01-7.96 (m, 2H), 7.89 (d, J=2.0 Hz, 1H), 7.77-7.70 (m, 2H), 4.92 (s, 2H), 3.41 (s, 3H), 2.63 (q, J=7.3 Hz, 2H), 0.99 (t, J=7.3 Hz, 3H).</p><heading id="h-0459" level="1">Example 389: 6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt.</heading><p id="p-1313" num="1373"><chemistry id="CHEM-US-00516" num="00516"><img id="EMI-C00516" he="34.88mm" wi="45.21mm" file="US20230000833A1-20230105-C00516.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1314" num="1374">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 1-bromobutan-2-one in Step A; and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>FN302, 327.1; m/z found, 328.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.28 (d, J=1.9 Hz, 1H), 7.76 (d, J=1.9 Hz, 1H), 7.60-7.56 (m, 1H), 7.52-7.48 (m, 1H), 7.24 (dd, J=9.7, 8.5 Hz, 1H), 4.90 (s, 2H), 3.39 (s, 3H), 2.63 (q, J=7.3 Hz, 2H), 2.31 (d, J=1.9 Hz, 3H), 0.99 (t, J=7.3 Hz, 3H).</p><heading id="h-0460" level="1">Example 390: 6-(3,4-Difluorophenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1315" num="1375"><chemistry id="CHEM-US-00517" num="00517"><img id="EMI-C00517" he="34.88mm" wi="45.21mm" file="US20230000833A1-20230105-C00517.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1316" num="1376">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 1-bromobutan-2-one in Step A; and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 331.1; m/z found, 332.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.36 (d, J=1.9 Hz, 1H), 7.82 (d, J=1.9 Hz, 1H), 7.81-7.75 (m, 1H), 7.59-7.51 (m, 2H), 4.89 (s, 2H), 3.39 (s, 3H), 2.63 (q, J=7.3 Hz, 2H), 0.99 (t, J=7.3 Hz, 3H).</p><heading id="h-0461" level="1">Example 391: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid salt</heading><p id="p-1317" num="1377"><chemistry id="CHEM-US-00518" num="00518"><img id="EMI-C00518" he="34.88mm" wi="45.21mm" file="US20230000833A1-20230105-C00518.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1318" num="1378">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 1-bromobutan-2-one in Step A; and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 345.1; m/z found, 346.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.12 (t, J=1.7 Hz, 1H), 7.63 (t, J=1.6 Hz, 1H), 7.39 (td, J=8.7, 6.5 Hz, 1H), 7.19 (td, J=8.7, 1.3 Hz, 1H), 4.89 (s, 2H), 3.40 (s, 3H), 2.61 (q, J=7.3 Hz, 2H), 2.22 (t, J=1.8 Hz, 3H), 0.97 (t, J=7.3 Hz, 3H).</p><heading id="h-0462" level="1">Example 392: 6-(3-Cyclopropylphenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1319" num="1379"><chemistry id="CHEM-US-00519" num="00519"><img id="EMI-C00519" he="34.88mm" wi="39.79mm" file="US20230000833A1-20230105-C00519.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1320" num="1380">The title compound was prepared in a manner analogous to Example 33, Steps A-B, using 6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 11) and 1-bromobutan-2-one in Step A; and 2-(3-cyclopropylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in Step B. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>, 335.2; m/z found, 336.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.29 (d, J=1.9 Hz, 1H), 7.75 (d, J=1.9 Hz, 1H), 7.42-7.31 (m, 3H), 7.07-7.04 (m, 1H), 4.91 (s, 2H), 3.39 (s, 3H), 2.63 (q, J=7.3 Hz, 2H), 2.03-1.95 (m, 1H), 1.01-0.95 (m, 5H), 0.78-0.74 (m, 2H).</p><heading id="h-0463" level="1">Example 393: (R/S)-6-(4-Fluoro-3-methyl-phenyl)-1-(2-hydroxy-4-methoxy-butyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1321" num="1381"><chemistry id="CHEM-US-00520" num="00520"><img id="EMI-C00520" he="34.88mm" wi="54.86mm" file="US20230000833A1-20230105-C00520.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1322" num="1382">The title compound was prepared in a manner analogous to Example 33, Step B; using 6-bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 25) and (4-fluoro-3-methylphenyl)boronic acid. The title compound was isolated as a degraded product from the oxetane. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>3</sub>, 359.2; m/z found, 360.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.25 (d, J=1.9 Hz, 1H), 7.79 (d, J=2.0 Hz, 1H), 7.63-7.59 (m, 1H), 7.55-7.49 (m, 1H), 7.30-7.22 (m, 1H), 4.93-4.88 (m, 1H), 3.98-3.77 (m, 3H), 3.47-3.42 (m, 2H), 3.40-3.37 (m, 3H), 3.22 (s, 3H), 2.37-2.30 (m, 3H), 1.77-1.67 (m, 1H), 1.63-1.53 (m, 1H).</p><heading id="h-0464" level="1">Example 394: (R/S)-6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(oxetan-2-ylmethyl)imidazo [4,5-b]pyridin-2-one</heading><p id="p-1323" num="1383"><chemistry id="CHEM-US-00521" num="00521"><img id="EMI-C00521" he="33.53mm" wi="45.21mm" file="US20230000833A1-20230105-C00521.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1324" num="1384">The title compound was prepared in a manner analogous to Example 33, Step B; using 6-bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 25) and (3-(difluoromethyl)phenyl)boronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 345.1; m/z found, 346.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (d, J=2.0 Hz, 1H), 7.94 (d, J=2.0 Hz, 1H), 7.90-7.85 (m, 2H), 7.67-7.56 (m, 2H), 7.11 (t, J=55.8 Hz, 1H), 5.10-5.02 (m, 1H), 4.49-4.42 (m, 1H), 4.36-4.30 (m, 1H), 4.19 (ddd, J=48.5, 14.9, 4.9 Hz, 2H), 3.41 (s, 3H), 2.71-2.62 (m, 1H).</p><heading id="h-0465" level="1">Example 395: (R/S)-6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1325" num="1385"><chemistry id="CHEM-US-00522" num="00522"><img id="EMI-C00522" he="29.89mm" wi="50.12mm" file="US20230000833A1-20230105-C00522.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1326" num="1386">The title compound was prepared in a manner analogous to Example 33, Step B; using 6-bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 25) and (4-fluoro-3-methylphenyl)boronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>FN302, 327.1; m/z found, 328.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 7.94 (d, J=1.8 Hz, 1H), 7.60 (d, J=1.9 Hz, 1H), 7.27 (dd, J=8.5, 6.1 Hz, 1H), 7.23-7.18 (m, 1H), 7.15-7.09 (m, 1H), 5.05-4.97 (m, 1H), 4.49-4.41 (m, 1H), 4.35-4.29 (m, 1H), 4.23-4.04 (m, 2H), 3.40 (s, 3H), 2.71-2.60 (m, 1H), 2.25 (s, 3H).</p><heading id="h-0466" level="1">Example 396: (R/S)-6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1327" num="1387"><chemistry id="CHEM-US-00523" num="00523"><img id="EMI-C00523" he="31.33mm" wi="44.70mm" file="US20230000833A1-20230105-C00523.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1328" num="1388">The title compound was prepared in a manner analogous to Example 33, Step B; using 6-bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 25) and (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>4</sub>N<sub>3</sub>O<sub>2</sub>, 381.1; m/z found, 382.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.21 (t, J=1.7 Hz, 1H), 7.91 (td, J=7.7, 1.7 Hz, 1H), 7.86-7.80 (m, 2H), 7.54 (t, J=7.8 Hz, 1H), 5.08-5.00 (m, 1H), 4.49-4.41 (m, 1H), 4.31 (dt, J=9.0, 6.0 Hz, 1H), 4.25-4.06 (m, 2H), 3.41 (s, 3H), 2.71-2.60 (m, 1H), 2.54-2.40 (m, 1H).</p><heading id="h-0467" level="1">Example 397: (R/S)-6-(3-Chlorophenyl)-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1329" num="1389"><chemistry id="CHEM-US-00524" num="00524"><img id="EMI-C00524" he="30.82mm" wi="44.70mm" file="US20230000833A1-20230105-C00524.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1330" num="1390">The title compound was prepared in a manner analogous to Example 33, Step B; using 6-bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 25) and (3-chlorophenyl)boronic acid. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>2</sub>, 329.1; m/z found, 330.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (d, J=2.0 Hz, 1H), 7.95 (d, J=2.0 Hz, 1H), 7.78 (t, J=1.9 Hz, 1H), 7.70-7.64 (m, 1H), 7.51 (t, J=7.8 Hz, 1H), 7.46-7.42 (m, 1H), 5.10-5.01 (m, 1H), 4.50-4.42 (m, 1H), 4.34 (dt, J=9.0, 5.9 Hz, 1H), 4.28-4.08 (m, 2H), 3.40 (s, 3H), 2.73-2.60 (m, 1H).</p><heading id="h-0468" level="1">Example 398: (R/S)-3-Methyl-6-[2-methyl-3-(trifluoromethyl)phenyl]-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1331" num="1391"><chemistry id="CHEM-US-00525" num="00525"><img id="EMI-C00525" he="31.33mm" wi="44.70mm" file="US20230000833A1-20230105-C00525.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1332" num="1392">The title compound was prepared in a manner analogous to Example 33, Step B; using 6-bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 25) and (2-methyl-3-(trifluoromethyl)phenyl)boronic acid. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 377.1; m/z found, 378.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 7.97 (d, J=1.9 Hz, 1H), 7.78-7.73 (m, 1H), 7.64 (d, J=2.0 Hz, 1H), 7.57-7.47 (m, 2H), 5.05-4.97 (m, 1H), 4.49-4.40 (m, 1H), 4.36-4.28 (m, 1H), 4.24-4.03 (m, 2H), 3.41 (s, 3H), 2.71-2.59 (m, 1H), 2.35-2.28 (m, 3H).</p><heading id="h-0469" level="1">Example 399: (R/S)-1-(2,4-Dihydroxybutyl)-3-methyl-6-[2-methyl-3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1333" num="1393"><chemistry id="CHEM-US-00526" num="00526"><img id="EMI-C00526" he="34.88mm" wi="47.92mm" file="US20230000833A1-20230105-C00526.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1334" num="1394">The title compound was prepared in a manner analogous to Example 33, Step B; using 6-bromo-3-methyl-1-(oxetan-2-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 25) and (2-methyl-3-(trifluoromethyl)phenyl)boronic acid, the oxetane decomposed to provide the title compound. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 395.1; m/z found, 396.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) 6 7.94 (d, J=1.9 Hz, 1H), 7.78-7.73 (m, 1H), 7.59-7.47 (m, 3H), 4.83-4.77 (m, 1H), 4.41-4.34 (m, 1H), 3.97-3.89 (m, 1H), 3.88-3.76 (m, 2H), 3.57-3.45 (m, 2H), 2.35-2.30 (m, 3H), 1.64-1.55 (m, 1H), 1.54-1.46 (m, 1H).</p><heading id="h-0470" level="1">Example 400: 6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1335" num="1395"><chemistry id="CHEM-US-00527" num="00527"><img id="EMI-C00527" he="42.50mm" wi="45.21mm" file="US20230000833A1-20230105-C00527.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1336" num="1396">The title compound was prepared in a manner analogous to Example 34, using (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.12 (t, J=1.6 Hz, 1H), 7.64 (t, J=1.7 Hz, 1H), 7.44-7.35 (m, 1H), 7.24-7.15 (m, 1H), 5.57-5.33 (m, 1H), 4.74-4.54 (m, 3H), 4.46-4.33 (m, 1H), 4.30-4.17 (m, 1H), 4.03-3.88 (m, 1H), 3.39 (s, 3H), 2.23 (t, J=1.9 Hz, 3H).</p><heading id="h-0471" level="1">Example 401: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt.</heading><p id="p-1337" num="1397"><chemistry id="CHEM-US-00528" num="00528"><img id="EMI-C00528" he="42.50mm" wi="45.21mm" file="US20230000833A1-20230105-C00528.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1338" num="1398">The title compound was prepared in a manner analogous to Example 34, using (4-fluoro-3-methylphenyl)boronic acid in Step B.</p><p id="p-1339" num="1399">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 372.1; m/z found, 373.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.28 (d, J=1.9 Hz, 1H), 7.76 (d, J=1.9 Hz, 1H), 7.61-7.57 (m, 1H), 7.52-7.48 (m, 1H), 7.28-7.23 (m, 1H), 5.56-5.37 (m, 1H), 4.74-4.58 (m, 3H), 4.46-4.35 (m, 1H), 4.29-4.19 (m, 1H), 4.03-3.90 (m, 1H), 3.38 (s, 3H), 2.32 (d, J=1.9 Hz, 3H).</p><p id="p-1340" num="1400">Example 402: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</p><p id="p-1341" num="0000"><chemistry id="CHEM-US-00529" num="00529"><img id="EMI-C00529" he="42.50mm" wi="45.21mm" file="US20230000833A1-20230105-C00529.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1342" num="1401">The title compound was prepared in a manner analogous to Example 34, using (3,4,5-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 394.1; m/z found, 395.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.41 (d, J=2.0 Hz, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.77-7.67 (m, 2H), 5.60-5.36 (m, 1H), 4.73-4.58 (m, 3H), 4.48-4.34 (m, 1H), 4.32-4.19 (m, 1H), 4.04-3.90 (m, 1H), 3.39 (s, 3H).</p><heading id="h-0472" level="1">Example 403: 6-(3,4-Difluorophenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1343" num="1402"><chemistry id="CHEM-US-00530" num="00530"><img id="EMI-C00530" he="42.50mm" wi="45.21mm" file="US20230000833A1-20230105-C00530.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1344" num="1403">The title compound was prepared in a manner analogous to Example 34, using (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 376.1; m/z found, 377.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (d, J=2.0 Hz, 1H), 7.84-7.75 (m, 2H), 7.61-7.51 (m, 2H), 5.59-5.35 (m, 1H), 4.74-4.57 (m, 3H), 4.47-4.34 (m, 1H), 4.31-4.18 (m, 1H), 4.04-3.91 (m, 1H), 3.39 (s, 3H).</p><heading id="h-0473" level="1">Example 404: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(m-tolypimidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1345" num="1404"><chemistry id="CHEM-US-00531" num="00531"><img id="EMI-C00531" he="42.50mm" wi="39.79mm" file="US20230000833A1-20230105-C00531.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1346" num="1405">The title compound was prepared in a manner analogous to Example 34, using m-tolylboronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>, 354.1; m/z found, 355.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.29 (d, J=1.9 Hz, 1H), 7.77 (d, J=1.9 Hz, 1H), 7.51-7.42 (m, 2H), 7.37 (t, J=7.6 Hz, 1H), 7.22-7.18 (m, 1H), 5.58-5.36 (m, 1H), 4.75-4.57 (m, 3H), 4.48-4.34 (m, 1H), 4.31-4.18 (m, 1H), 4.04-3.89 (m, 1H), 3.39 (s, 3H), 2.39 (s, 3H).</p><heading id="h-0474" level="1">Example 405: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1347" num="1406"><chemistry id="CHEM-US-00532" num="00532"><img id="EMI-C00532" he="42.50mm" wi="39.79mm" file="US20230000833A1-20230105-C00532.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1348" num="1407">The title compound was prepared in a manner analogous to Example 34, using (2-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 372.1; m/z found, 373.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.14 (t, J=1.6 Hz, 1H), 7.65 (t, J=1.7 Hz, 1H), 7.36-7.30 (m, 2H), 7.24-7.17 (m, 1H), 5.57-5.33 (m, 1H), 4.73-4.56 (m, 3H), 4.46-4.33 (m, 1H), 4.30-4.17 (m, 1H), 4.02-3.90 (m, 1H), 3.40 (s, 3H), 2.31 (d, J=2.2 Hz, 3H).</p><heading id="h-0475" level="1">Example 406: 6-(3-Chlorophenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt.</heading><p id="p-1349" num="1408"><chemistry id="CHEM-US-00533" num="00533"><img id="EMI-C00533" he="42.50mm" wi="39.79mm" file="US20230000833A1-20230105-C00533.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1350" num="1409">The title compound was prepared in a manner analogous to Example 34, using (3-chlorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>ClFN<sub>4</sub>O<sub>2</sub>, 374.1; m/z found, 375.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.36 (d, J=1.9 Hz, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.75 (t, J=1.9 Hz, 1H), 7.69-7.64 (m, 1H), 7.52 (t, J=7.8 Hz, 1H), 7.47-7.42 (m, 1H), 5.58-5.36 (m, 1H), 4.76-4.57 (m, 3H), 4.48-4.34 (m, 1H), 4.33-4.17 (m, 1H), 4.06-3.90 (m, 1H), 3.39 (s, 3H).</p><p id="p-1351" num="1410">Example 407: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[4-fluoro-3-(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</p><p id="p-1352" num="0000"><chemistry id="CHEM-US-00534" num="00534"><img id="EMI-C00534" he="42.50mm" wi="45.21mm" file="US20230000833A1-20230105-C00534.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1353" num="1411">The title compound was prepared in a manner analogous to Example 34, using (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 426.1; m/z found, 427.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.38 (d, J=1.9 Hz, 1H), 8.07-8.02 (m, 1H), 8.02-7.98 (m, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.69-7.63 (m, 1H), 5.57-5.38 (m, 1H), 4.75-4.57 (m, 3H), 4.46-4.35 (m, 1H), 4.31-4.18 (m, 1H), 4.03-3.90 (m, 1H), 3.40 (s, 3H).</p><heading id="h-0476" level="1">Example 408: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1354" num="1412"><chemistry id="CHEM-US-00535" num="00535"><img id="EMI-C00535" he="36.91mm" wi="39.79mm" file="US20230000833A1-20230105-C00535.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1355" num="1413">The title compound was prepared in a manner analogous to Example 34, using azetidine in Step A. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.40 (d, J=2.0 Hz, 1H), 8.04-7.97 (m, 2H), 7.90 (d, J=2.0 Hz, 1H), 7.78-7.69 (m, 2H), 4.63 (s, 2H), 4.29 (t, J=7.7 Hz, 2H), 3.91 (t, J=7.7 Hz, 2H), 3.40 (s, 3H), 2.33-2.24 (m, 2H).</p><heading id="h-0477" level="1">Example 409: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1356" num="1414"><chemistry id="CHEM-US-00536" num="00536"><img id="EMI-C00536" he="36.91mm" wi="45.21mm" file="US20230000833A1-20230105-C00536.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1357" num="1415">The title compound was prepared in a manner analogous to Example 34, using azetidine in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>2</sub>N402, 372.1; m/z found, 373.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) 6 8.12 (t, J=1.7 Hz, 1H), 7.63 (t, J=1.7 Hz, 1H), 7.43-7.37 (m, 1H), 7.22-7.17 (m, 1H), 4.59 (s, 2H), 4.27 (t, J=7.6 Hz, 2H), 3.89 (t, J=7.7 Hz, 2H), 3.39 (s, 3H), 2.33-2.21 (m, 5H).</p><heading id="h-0478" level="1">Example 410: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1358" num="1416"><chemistry id="CHEM-US-00537" num="00537"><img id="EMI-C00537" he="36.91mm" wi="45.21mm" file="US20230000833A1-20230105-C00537.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1359" num="1417">The title compound was prepared in a manner analogous to Example 34, using azetidine in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>, 354.1; m/z found, 355.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.27 (d, J=1.9 Hz, 1H), 7.76 (d, J=1.9 Hz, 1H), 7.62-7.58 (m, 1H), 7.53 7.49 (m, 1H), 7.28-7.23 (m, 1H), 4.60 (s, 2H), 4.29 (t, J=7.6 Hz, 2H), 3.90 (t, J=7.7 Hz, 2H), 3.38 (s, 3H), 2.33-2.24 (m, 5H).</p><heading id="h-0479" level="1">Example 411: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1360" num="1418"><chemistry id="CHEM-US-00538" num="00538"><img id="EMI-C00538" he="36.91mm" wi="45.21mm" file="US20230000833A1-20230105-C00538.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1361" num="1419">The title compound was prepared in a manner analogous to Example 34, using azetidine in Step A and (3,4,5-trifluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 376.1; m/z found, 377.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.41 (d, J=2.0 Hz, 1H), 7.88 (d, J=2.1 Hz, 1H), 7.77-7.69 (m, 2H), 4.59 (s, 2H), 4.29 (t, J=7.7 Hz, 2H), 3.91 (t, J=7.7 Hz, 2H), 3.38 (s, 3H), 2.34-2.24 (m, 2H).</p><heading id="h-0480" level="1">Example 412: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(3,5-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1362" num="1420"><chemistry id="CHEM-US-00539" num="00539"><img id="EMI-C00539" he="36.91mm" wi="45.21mm" file="US20230000833A1-20230105-C00539.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1363" num="1421">The title compound was prepared in a manner analogous to Example 34, using azetidine in Step A and (3,5-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>2</sub>N402, 358.1; m/z found, 359.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.43 (d, J=2.0 Hz, 1H), 7.90 (d, J=2.0 Hz, 1H), 7.53-7.46 (m, 2H), 7.29-7.22 (m, 1H), 4.60 (s, 2H), 4.29 (t, J=7.6 Hz, 2H), 3.91 (t, J=7.7 Hz, 2H), 3.39 (s, 3H), 2.34-2.25 (m, 2H).</p><heading id="h-0481" level="1">Example 413: 1-(2-(3,3-Difluoroazetidin-1-yl)-2-oxoethyl)-6-(4-fluoro-3-methylphenyl)-3-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-1364" num="1422"><chemistry id="CHEM-US-00540" num="00540"><img id="EMI-C00540" he="43.52mm" wi="45.21mm" file="US20230000833A1-20230105-C00540.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1365" num="1423">The title compound was prepared in a manner analogous to Example 34, using 3,3-difluoroazetidine hydrochloride in Step A and (4-fluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.28 (d, J=1.9 Hz, 1H), 7.76 (d, J=1.9 Hz, 1H), 7.60-7.56 (m, 1H), 7.52-7.47 (m, 1H), 7.28-7.24 (m, 1H), 4.82 (t, J=12.3 Hz, 2H), 4.75 (s, 2H), 4.38 (t, J=12.5 Hz, 2H), 3.39 (s, 3H), 2.32 (d, J=1.9 Hz, 3H).</p><heading id="h-0482" level="1">Example 414: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1366" num="1424"><chemistry id="CHEM-US-00541" num="00541"><img id="EMI-C00541" he="43.52mm" wi="45.21mm" file="US20230000833A1-20230105-C00541.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1367" num="1425">The title compound was prepared in a manner analogous to Example 34, using 3,3-difluoroazetidine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F4N402, 408.1; m/z found, 409.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) 6 8.12 (t, J=1.6 Hz, 1H), 7.65 (t, J=1.6 Hz, 1H), 7.43 7.36 (m, 1H), 7.23-7.17 (m, 1H), 4.81 (t, J=12.4 Hz, 2H), 4.74 (s, 2H), 4.36 (t, J=12.5 Hz, 2H), 3.40 (s, 3H), 2.23 (t, J=1.9 Hz, 3H).</p><heading id="h-0483" level="1">Example 415: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[2-fluoro-3-(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1368" num="1426"><chemistry id="CHEM-US-00542" num="00542"><img id="EMI-C00542" he="43.52mm" wi="39.79mm" file="US20230000833A1-20230105-C00542.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1369" num="1427">The title compound was prepared in a manner analogous to Example 34, using 3,3-difluoroazetidine hydrochloride in Step A and (2-fluoro-3-(trifluoromethyl)phenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>6</sub>N<sub>4</sub>O<sub>2</sub>, 444.1; m/z found, 445.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.20 (t, J=1.6 Hz, 1H), 7.92-7.81(m, 2H), 7.73 (t, J=1.7 Hz, 1H), 7.55 (t, J=7.8 Hz, 1H), 4.86-4.73 (m, 4H), 4.36 (t, J=12.5 Hz, 2H), 3.41 (s, 3H).</p><heading id="h-0484" level="1">Example 416: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(3,4-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1370" num="1428"><chemistry id="CHEM-US-00543" num="00543"><img id="EMI-C00543" he="43.52mm" wi="45.21mm" file="US20230000833A1-20230105-C00543.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1371" num="1429">The title compound was prepared in a manner analogous to Example 34, using 3,3-difluoroazetidine hydrochloride in Step A and (3,4-difluorophenyl)boronic acidin Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 394.1; m/z found, 395.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (d, J=1.9 Hz, 1H), 7.83 (d, J=2.0 Hz, 1H), 7.81-7.75 (m, 1H), 7.61-7.51 (m, 2H), 4.82 (t, J=12.4 Hz, 2H), 4.75 (s, 2H), 4.38 (t, J=12.5 Hz, 2H), 3.39 (s, 3H).</p><heading id="h-0485" level="1">Example 417: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(3-fluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one and its Trifluoroacetic Acid Salt</heading><p id="p-1372" num="1430"><chemistry id="CHEM-US-00544" num="00544"><img id="EMI-C00544" he="43.52mm" wi="39.79mm" file="US20230000833A1-20230105-C00544.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1373" num="1431">The title compound was prepared in a manner analogous to Example 34, using 3,3-difluoroazetidine hydrochloride in Step A and (3-fluorophenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 376.1; m/z found, 377.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.38 (d, J=1.9 Hz, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.58-7.49 (m, 3H), 7.26-7.18 (m, 1H), 4.82 (t, J=12.4 Hz, 2H), 4.76 (s, 2H), 4.38 (t, J=12.5 Hz, 2H), 3.40 (s, 3H).</p><heading id="h-0486" level="1">Example 418: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1374" num="1432"><chemistry id="CHEM-US-00545" num="00545"><img id="EMI-C00545" he="43.60mm" wi="39.79mm" file="US20230000833A1-20230105-C00545.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1375" num="1433">The title compound was prepared in a manner analogous to Example 34, using 3,3-difluoroazetidine hydrochloride in Step A and (2-fluoro-3-methylphenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.15 (t, J=1.6 Hz, 1H), 7.67 (t, J=1.8 Hz, 1H), 7.36-7.29(m, 2H), 7.25-7.18 (m, 1H), 4.87-4.69 (m, 4H), 4.36 (t, J=12.5 Hz, 2H), 3.40 (s, 3H), 2.31 (d, J=2.2 Hz, 3H).</p><heading id="h-0487" level="1">Example 419: N,N-Dimethyl-2-3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl)acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1376" num="1434"><chemistry id="CHEM-US-00546" num="00546"><img id="EMI-C00546" he="33.61mm" wi="39.79mm" file="US20230000833A1-20230105-C00546.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1377" num="1435">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 378.1; m/z found, 379.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.40 (d, J=2.0 Hz, 1H), 8.03-7.96 (m, 2H), 7.90 (d, J=2.0 Hz, 1H), 7.77-7.69 (m, 2H), 4.87 (s, 2H), 3.40 (s, 3H), 3.11 (s, 3H), 2.85 (s, 3H).</p><heading id="h-0488" level="1">Example 420: 2-[6-(4-Fuoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1378" num="1436"><chemistry id="CHEM-US-00547" num="00547"><img id="EMI-C00547" he="33.61mm" wi="45.21mm" file="US20230000833A1-20230105-C00547.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1379" num="1437">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (4-fluoro-3-methylphenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>, 342.1; m/z found, 343.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.27 (d, J=1.9 Hz, 1H), 7.76 (d, J=1.9 Hz, 1H), 7.61-7.57 (m, 1H), 7.53-7.47 (m, 1H), 7.24 (t, J=9.1 Hz, 1H), 4.85 (s, 2H), 3.38 (s, 3H), 3.10 (s, 3H), 2.84 (s, 3H), 2.31 (d, J=1.9 Hz, 3H).</p><heading id="h-0489" level="1">Example 421: 2-[6-(3,4-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1380" num="1438"><chemistry id="CHEM-US-00548" num="00548"><img id="EMI-C00548" he="33.61mm" wi="45.21mm" file="US20230000833A1-20230105-C00548.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1381" num="1439">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (3,4-difluorophenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N402, 346.1; m/z found, 347.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (d, J=2.0 Hz, 1H), 7.84 (d, J=2.0 Hz, 1H), 7.83-7.75 (m, 1H), 7.60-7.50 (m, 2H), 4.84 (s, 2H), 3.39 (s, 3H), 3.11 (s, 3H), 2.85 (s, 3H).</p><heading id="h-0490" level="1">Example 422: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(3,4-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1382" num="1440"><chemistry id="CHEM-US-00549" num="00549"><img id="EMI-C00549" he="37.42mm" wi="45.21mm" file="US20230000833A1-20230105-C00549.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1383" num="1441">The title compound was prepared in a manner analogous to Example 34, using azetidine in Step A and (3,4-difluorophenyl)boronic acid in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 358.1; m/z found, 359.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (d, J=1.9 Hz, 1H), 7.84-7.76 (m, 2H), 7.61-7.52 (m, 2H), 4.60 (s, 2H), 4.29 (t, J=7.6 Hz, 2H), 3.91 (t, J=7.7 Hz, 2H), 3.38 (s, 3H), 2.35-2.23 (m, 2H).</p><heading id="h-0491" level="1">Example 423: 2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1384" num="1442"><chemistry id="CHEM-US-00550" num="00550"><img id="EMI-C00550" he="33.61mm" wi="45.21mm" file="US20230000833A1-20230105-C00550.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1385" num="1443">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (2,4-difluoro-3-methylphenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 360.1; m/z found, 361.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.11 (t, J=1.7 Hz, 1H), 7.64 (t, J=1.7 Hz, 1H), 7.43-7.35 (m, 1H), 7.19 (td, J=8.8, 1.4 Hz, 1H), 4.84 (s, 2H), 3.39 (s, 3H), 3.08 (s, 3H), 2.83 (s, 3H), 2.23 (t, J=1.9 Hz, 3H).</p><heading id="h-0492" level="1">Example 424: 2-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1386" num="1444"><chemistry id="CHEM-US-00551" num="00551"><img id="EMI-C00551" he="33.61mm" wi="39.79mm" file="US20230000833A1-20230105-C00551.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1387" num="1445">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (2-fluoro-3-(trifluoromethyl)phenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F4N402, 396.1; m/z found, 397.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.19 (t, J=1.6 Hz, 1H), 7.91-7.86 (m, 1H), 7.85-7.80 (m, 1H), 7.73 (t, J=1.7 Hz, 1H), 7.54 (t, J=7.8 Hz, 1H), 4.85 (s, 2H), 3.41 (s, 3H), 3.08 (s, 3H), 2.83 (s, 3H).</p><heading id="h-0493" level="1">Example 425: 2-[6-(2,3-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1388" num="1446"><chemistry id="CHEM-US-00552" num="00552"><img id="EMI-C00552" he="33.61mm" wi="39.79mm" file="US20230000833A1-20230105-C00552.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1389" num="1447">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (2,3-difluorophenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 346.1; m/z found, 347.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.19 (t, J=1.7 Hz, 1H), 7.71 (t, J=1.6 Hz, 1H), 7.51-7.43 (m, 1H), 7.39-7.29 (m, 2H), 4.84 (s, 2H), 3.40 (s, 3H), 3.09 (s, 3H), 2.83 (s, 3H).</p><heading id="h-0494" level="1">Example 426: 2-[6-[3-(Difluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide and its trifluoroacetic acid salt.</heading><p id="p-1390" num="1448"><chemistry id="CHEM-US-00553" num="00553"><img id="EMI-C00553" he="33.61mm" wi="40.39mm" file="US20230000833A1-20230105-C00553.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1391" num="1449">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (3-(difluoromethyl)phenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 360.1; m/z found, 361.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (d, J=1.9 Hz, 1H), 7.90-7.80 (m, 3H), 7.67-7.56 (m, 2H), 7.11 (t, J=55.8 Hz, 1H), 4.87 (s, 2H), 3.40 (s, 3H), 3.11 (s, 3H), 2.85 (s, 3H).</p><heading id="h-0495" level="1">Example 427: 2-[6-(2-Fluoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1392" num="1450"><chemistry id="CHEM-US-00554" num="00554"><img id="EMI-C00554" he="33.61mm" wi="39.79mm" file="US20230000833A1-20230105-C00554.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1393" num="1451">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (2-fluoro-3-methylphenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>, 342.1; m/z found, 343.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.14 (t, J=1.7 Hz, 1H), 7.65 (t, J=1.6 Hz, 1H), 7.36-7.29 (m, 2H), 7.22-7.18 (m, 1H), 4.84 (s, 2H), 3.40 (s, 3H), 3.08 (s, 3H), 2.83 (s, 3H), 2.31 (d, J=2.1 Hz, 3H).</p><heading id="h-0496" level="1">Example 428: 2-[6-(3,5-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1394" num="1452"><chemistry id="CHEM-US-00555" num="00555"><img id="EMI-C00555" he="33.61mm" wi="45.21mm" file="US20230000833A1-20230105-C00555.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1395" num="1453">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (3,5-difluorophenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 346.1; m/z found, 347.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.43 (d, J=1.9 Hz, 1H), 7.91 (d, J=2.0 Hz, 1H), 7.52-7.46 (m, 2H), 7.24 (tt, J=9.2, 2.3 Hz, 1H), 4.84 (s, 2H), 3.39 (s, 3H), 3.11 (s, 3H), 2.85 (s, 3H).</p><heading id="h-0497" level="1">Example 429: N,N-Dimethyl-2-[3-methyl-2-oxo-6-(3-pyridyl)imidazo[4,5-b]pyridin-1-yl]acetamide and its Trifluoroacetic Acid Salt</heading><p id="p-1396" num="1454"><chemistry id="CHEM-US-00556" num="00556"><img id="EMI-C00556" he="33.61mm" wi="39.79mm" file="US20230000833A1-20230105-C00556.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1397" num="1455">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and pyridin-3-ylboronic acid in step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>, 311.1; m/z found, 312.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.03 (d, J=2.3 Hz, 1H), 8.69 (dd, J=5.0, 1.6 Hz, 1H), 8.43 (d, J=1.9 Hz, 1H), 8.37-8.32 (m, 1H), 7.94 (d, J=2.0 Hz, 1H), 7.72 (dd, J=8.1, 5.0 Hz, 1H), 4.85 (s, 2H), 3.41 (s, 3H), 3.11 (s, 3H), 2.85 (s, 3H).</p><heading id="h-0498" level="1">Example 430: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one and its trifluoroacetic acid salt.</heading><p id="p-1398" num="1456"><chemistry id="CHEM-US-00557" num="00557"><img id="EMI-C00557" he="43.60mm" wi="47.41mm" file="US20230000833A1-20230105-C00557.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1399" num="1457">The title compound was prepared in a manner analogous to Example 34, using 3,3-difluoroazetidine hydrochloride in Step A and (5-(trifluoromethyl)thiophen-2-yl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>S, 432.1; m/z found, 433.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.43 (d, J=1.9 Hz, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.79-7.76 (m, 1H), 7.59-7.57 (m, 1H), 4.83 (t, J=12.4 Hz, 2H), 4.76 (s, 2H), 4.39 (t, J=12.4 Hz, 2H), 3.39 (s, 3H).</p><heading id="h-0499" level="1">Example 431: 2-[6-[3,4-Difluoro-5-(trifluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-1400" num="1458"><chemistry id="CHEM-US-00558" num="00558"><img id="EMI-C00558" he="33.61mm" wi="45.21mm" file="US20230000833A1-20230105-C00558.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1401" num="1459">The title compound was prepared in a manner analogous to Example 34, using dimethylamine hydrochloride in Step A and (3,4-difluoro-5-(trifluoromethyl)phenyl)boronic acid in step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F5N402, 414.1; m/z found, 414.9 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.44 (d, J=2.1 Hz, 1H), 8.23-8.17 (m, 1H), 7.92 (d, J=2.0 Hz, 1H), 7.88-7.85 (d, J=5.4 Hz, 1H), 4.85 (s, 2H), 3.40 (s, 3H), 3.12 (s, 3H), 2.85 (s, 3H).</p><p id="p-1402" num="1460">Examples 434-525 were prepared in a manner described in the Examples above.</p><heading id="h-0500" level="1">Example 432: 2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1403" num="1461"><chemistry id="CHEM-US-00559" num="00559"><img id="EMI-C00559" he="28.53mm" wi="39.79mm" file="US20230000833A1-20230105-C00559.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1404" num="1462">MS (ESI): mass calcd. for C<sub>15</sub>H<sub>11 </sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 336.1; m/z found, 337.1 [M+H]<sup>+</sup>.</p><heading id="h-0501" level="1">Example 433: 2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1405" num="1463"><chemistry id="CHEM-US-00560" num="00560"><img id="EMI-C00560" he="28.28mm" wi="45.21mm" file="US20230000833A1-20230105-C00560.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1406" num="1464">MS (ESI): mass calcd. for C<sub>15</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>3</sub>, 316.1; m/z found, 317.1 [M+H]<sup>+</sup>.</p><heading id="h-0502" level="1">Example 434: 2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1407" num="1465"><chemistry id="CHEM-US-00561" num="00561"><img id="EMI-C00561" he="28.45mm" wi="45.21mm" file="US20230000833A1-20230105-C00561.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1408" num="1466">MS (ESI): mass calcd. for C<sub>14</sub>H<sub>10</sub>ClFN<sub>4</sub>O<sub>2</sub>, 320.0; m/z found, 321.1 [M+H]<sup>+</sup>.</p><heading id="h-0503" level="1">Example 435: N-Methyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1409" num="1467"><chemistry id="CHEM-US-00562" num="00562"><img id="EMI-C00562" he="30.90mm" wi="39.79mm" file="US20230000833A1-20230105-C00562.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1410" num="1468">MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 350.1; m/z found, 351.1 [M+H]<sup>+</sup>.</p><heading id="h-0504" level="1">Example 436: 2-[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide</heading><p id="p-1411" num="1469"><chemistry id="CHEM-US-00563" num="00563"><img id="EMI-C00563" he="30.90mm" wi="46.57mm" file="US20230000833A1-20230105-C00563.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1412" num="1470">MS (ESI): mass calcd. for C<sub>15</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>2</sub>, 316.1; m/z found, 317.0 [M+H]<sup>+</sup>.</p><heading id="h-0505" level="1">Example 437: 2-[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide</heading><p id="p-1413" num="1471"><chemistry id="CHEM-US-00564" num="00564"><img id="EMI-C00564" he="30.90mm" wi="45.21mm" file="US20230000833A1-20230105-C00564.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1414" num="1472">MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>2</sub>, 314.1; m/z found, 315.1 [M+H]<sup>+</sup>.</p><heading id="h-0506" level="1">Example 438: 2-[6-(3,5-Dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide</heading><p id="p-1415" num="1473"><chemistry id="CHEM-US-00565" num="00565"><img id="EMI-C00565" he="30.90mm" wi="44.70mm" file="US20230000833A1-20230105-C00565.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1416" num="1474">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>, 310.1; m/z found, 311.1 [M+H]<sup>+</sup>.</p><heading id="h-0507" level="1">Example 439: 2-[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide</heading><p id="p-1417" num="1475"><chemistry id="CHEM-US-00566" num="00566"><img id="EMI-C00566" he="30.90mm" wi="48.77mm" file="US20230000833A1-20230105-C00566.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1418" num="1476">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>, 326.1; m/z found, 327.1 [M+H]<sup>+</sup>.</p><heading id="h-0508" level="1">Example 440: 2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide</heading><p id="p-1419" num="1477"><chemistry id="CHEM-US-00567" num="00567"><img id="EMI-C00567" he="30.90mm" wi="45.21mm" file="US20230000833A1-20230105-C00567.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1420" num="1478">MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>3</sub>, 330.1; m/z found, 331.1 [M+H]<sup>+</sup>.</p><heading id="h-0509" level="1">Example 441: 2-[6-(2-Ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide</heading><p id="p-1421" num="1479"><chemistry id="CHEM-US-00568" num="00568"><img id="EMI-C00568" he="31.07mm" wi="39.79mm" file="US20230000833A1-20230105-C00568.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1422" num="1480">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>, 326.1; m/z found, 327.1 [M+H]<sup>+</sup>.</p><heading id="h-0510" level="1">Example 442: N-(2-Methoxyethyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1423" num="1481"><chemistry id="CHEM-US-00569" num="00569"><img id="EMI-C00569" he="41.15mm" wi="39.79mm" file="US20230000833A1-20230105-C00569.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1424" num="1482">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 394.1; m/z found, 395.0 [M+H]<sup>+</sup>.</p><heading id="h-0511" level="1">Example 443: 2-[6-(2-Ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide</heading><p id="p-1425" num="1483"><chemistry id="CHEM-US-00570" num="00570"><img id="EMI-C00570" he="41.32mm" wi="45.21mm" file="US20230000833A1-20230105-C00570.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1426" num="1484">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>21</sub>FN<sub>4</sub>O<sub>4</sub>, 388.2; m/z found, 389.2 [M+H]<sup>+</sup>.</p><heading id="h-0512" level="1">Example 444: N-(2-Methoxyethyl)-246-(4-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)acetamide.</heading><p id="p-1427" num="1485"><chemistry id="CHEM-US-00571" num="00571"><img id="EMI-C00571" he="41.32mm" wi="48.77mm" file="US20230000833A1-20230105-C00571.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1428" num="1486">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>, 356.1; m/z found, 357.1 [M+H]<sup>+</sup>.</p><heading id="h-0513" level="1">Example 445: N-(2-Methoxyethyl)-2-[2-oxo-6-(3-pyridyl)-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1429" num="1487"><chemistry id="CHEM-US-00572" num="00572"><img id="EMI-C00572" he="41.32mm" wi="40.64mm" file="US20230000833A1-20230105-C00572.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1430" num="1488">MS (ESI): mass calcd. for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O<sub>3</sub>, 327.1; m/z found, 328.1 [M+H]<sup>+</sup>.</p><heading id="h-0514" level="1">Example 446: 2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide</heading><p id="p-1431" num="1489"><chemistry id="CHEM-US-00573" num="00573"><img id="EMI-C00573" he="41.32mm" wi="45.21mm" file="US20230000833A1-20230105-C00573.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1432" num="1490">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>4</sub>, 374.1; m/z found, 375.1 [M+H]<sup>+</sup>.</p><heading id="h-0515" level="1">Example 447: N-Cyclopropyl-2-[6-(3,5-difluorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1433" num="1491"><chemistry id="CHEM-US-00574" num="00574"><img id="EMI-C00574" he="36.58mm" wi="45.21mm" file="US20230000833A1-20230105-C00574.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1434" num="1492">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 344.1; m/z found, 345.0 [M+H]<sup>+</sup>.</p><heading id="h-0516" level="1">Example 448: 2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-acetamide</heading><p id="p-1435" num="1493"><chemistry id="CHEM-US-00575" num="00575"><img id="EMI-C00575" he="36.41mm" wi="45.21mm" file="US20230000833A1-20230105-C00575.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1436" num="1494">MS (ESI): mass calcd. for C<sub>17</sub>H14CIFN402, 360.1; m/z found, 361.1 [M+H]<sup>+</sup>.</p><heading id="h-0517" level="1">Example 449: N-Cyclopropyl-2-[6-(3-ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1437" num="1495"><chemistry id="CHEM-US-00576" num="00576"><img id="EMI-C00576" he="36.41mm" wi="39.79mm" file="US20230000833A1-20230105-C00576.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1438" num="1496">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>, 352.2; m/z found, 353.1 [M+H]<sup>+</sup>.</p><heading id="h-0518" level="1">Example 450: N-Cyclopropyl-2-[6-(3-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1439" num="1497"><chemistry id="CHEM-US-00577" num="00577"><img id="EMI-C00577" he="36.41mm" wi="39.79mm" file="US20230000833A1-20230105-C00577.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1440" num="1498">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>, 338.1; m/z found, 339.1 [M+H]<sup>+</sup>.</p><heading id="h-0519" level="1">Example 451: N-Cyclopropyl-2-[6-(4-methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide.</heading><p id="p-1441" num="1499"><chemistry id="CHEM-US-00578" num="00578"><img id="EMI-C00578" he="36.58mm" wi="48.77mm" file="US20230000833A1-20230105-C00578.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1442" num="1500">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>, 352.2; m/z found, 353.1 [M+H]<sup>+</sup>.</p><heading id="h-0520" level="1">Example 452: N-Cyclopropyl-2-[6-(4-fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1443" num="1501"><chemistry id="CHEM-US-00579" num="00579"><img id="EMI-C00579" he="36.58mm" wi="45.21mm" file="US20230000833A1-20230105-C00579.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1444" num="1502">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>3</sub>, 356.1; m/z found, 357.1 [M+H]<sup>+</sup>.</p><heading id="h-0521" level="1">Example 453: 2-[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-acetamide</heading><p id="p-1445" num="1503"><chemistry id="CHEM-US-00580" num="00580"><img id="EMI-C00580" he="36.58mm" wi="46.57mm" file="US20230000833A1-20230105-C00580.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1446" num="1504">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub>, 342.1; m/z found, 343.1 [M+H]<sup>+</sup>.</p><heading id="h-0522" level="1">Example 454: N-Cyclopropyl-2-[6-(2,4-dimethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1447" num="1505"><chemistry id="CHEM-US-00581" num="00581"><img id="EMI-C00581" he="36.41mm" wi="48.77mm" file="US20230000833A1-20230105-C00581.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1448" num="1506">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>, 368.1; m/z found, 369.2 [M+H]<sup>+</sup>.</p><heading id="h-0523" level="1">Example 455: N-Cyclopropyl-2-[6-(2-fluoro-6-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1449" num="1507"><chemistry id="CHEM-US-00582" num="00582"><img id="EMI-C00582" he="36.58mm" wi="39.79mm" file="US20230000833A1-20230105-C00582.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1450" num="1508">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>3</sub>, 356.1; m/z found, 357.1 [M+H]<sup>+</sup>.</p><heading id="h-0524" level="1">Example 456: N-Cyclopropyl-2-[6-(2-ethoxyphenyl)-2-oxo-3H-imidazo[4,5-1D]pyridin-1-yl]acetamide</heading><p id="p-1451" num="1509"><chemistry id="CHEM-US-00583" num="00583"><img id="EMI-C00583" he="36.58mm" wi="39.79mm" file="US20230000833A1-20230105-C00583.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1452" num="1510">MS (ESI): mass calcd. for C<sub>19</sub>H20N403, 352.2; m/z found, 353.1 [M+H]<sup>+</sup>.</p><p id="p-1453" num="1511">Example 457: 6-(3-Fluoro-4-methoxy-phenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one</p><p id="p-1454" num="0000"><chemistry id="CHEM-US-00584" num="00584"><img id="EMI-C00584" he="36.24mm" wi="48.77mm" file="US20230000833A1-20230105-C00584.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1455" num="1512">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>FN<sub>3</sub>O<sub>3</sub>S, 383.1; m/z found, 384.1 [M+H]<sup>+</sup>.</p><heading id="h-0525" level="1">Example 458: 6-(2-Ethoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1456" num="1513"><chemistry id="CHEM-US-00585" num="00585"><img id="EMI-C00585" he="36.24mm" wi="39.79mm" file="US20230000833A1-20230105-C00585.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1457" num="1514">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S, 379.1; m/z found, 380.1 [M+H]<sup>+</sup>.</p><heading id="h-0526" level="1">Example 459: 6-(4-Chlorophenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1458" num="1515"><chemistry id="CHEM-US-00586" num="00586"><img id="EMI-C00586" he="36.07mm" wi="46.57mm" file="US20230000833A1-20230105-C00586.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1459" num="1516">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>2</sub>S, 369.0; m/z found, 370.0 [M+H]<sup>+</sup>.</p><heading id="h-0527" level="1">Example 460: 6-(2-Ethoxy-5-fluoro-phenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1460" num="1517"><chemistry id="CHEM-US-00587" num="00587"><img id="EMI-C00587" he="36.07mm" wi="45.21mm" file="US20230000833A1-20230105-C00587.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1461" num="1518">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>3</sub>S, 397.1; m/z found, 398.1 [M+H]<sup>+</sup>.</p><heading id="h-0528" level="1">Example 461: 6-(4-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1462" num="1519"><chemistry id="CHEM-US-00588" num="00588"><img id="EMI-C00588" he="36.07mm" wi="48.77mm" file="US20230000833A1-20230105-C00588.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1463" num="1520">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S, 365.1; m/z found, 366.1 [M+H]<sup>+</sup>.</p><heading id="h-0529" level="1">Example 462: 6-(4-Fluoro-2-methoxy-phenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1464" num="1521"><chemistry id="CHEM-US-00589" num="00589"><img id="EMI-C00589" he="36.24mm" wi="45.21mm" file="US20230000833A1-20230105-C00589.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1465" num="1522">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>FN<sub>3</sub>O<sub>3</sub>S, 383.1; m/z found, 384.1 [M+H]<sup>+</sup>.</p><heading id="h-0530" level="1">Example 463: 6-(3-Ethoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1466" num="1523"><chemistry id="CHEM-US-00590" num="00590"><img id="EMI-C00590" he="36.24mm" wi="39.79mm" file="US20230000833A1-20230105-C00590.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1467" num="1524">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S, 379.1; m/z found, 380.1 [M+H]<sup>+</sup>.</p><heading id="h-0531" level="1">Example 464: 6-(3-Chloro-4-fluoro-phenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1468" num="1525"><chemistry id="CHEM-US-00591" num="00591"><img id="EMI-C00591" he="36.07mm" wi="45.21mm" file="US20230000833A1-20230105-C00591.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1469" num="1526">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>11</sub>ClFN<sub>3</sub>O<sub>2</sub>S, 387.0; m/z found, 388.0 [M+H]<sup>+</sup>.</p><heading id="h-0532" level="1">Example 465: 1-(Cyclopropylmethyl)-6-(2,4-dimethoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1470" num="1527"><chemistry id="CHEM-US-00592" num="00592"><img id="EMI-C00592" he="22.94mm" wi="51.48mm" file="US20230000833A1-20230105-C00592.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1471" num="1528">MS (ESI): mass calcd. for C<sub>18</sub>Fl<sub>19</sub>N<sub>3</sub>O<sub>3</sub>, 325.1; m/z found, 326.1 [M+H]<sup>+</sup>.</p><heading id="h-0533" level="1">Example 466: 1-(Cyclopropylmethyl)-6-(2-ethoxy-5-fluoro-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1472" num="1529"><chemistry id="CHEM-US-00593" num="00593"><img id="EMI-C00593" he="30.14mm" wi="47.92mm" file="US20230000833A1-20230105-C00593.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1473" num="1530">MS (ESI): mass calcd. for C<sub>18</sub>Fl<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 327.1; m/z found, 328.1 [M+H]<sup>+</sup>.</p><heading id="h-0534" level="1">Example 467: 1-(Cyclopropylmethyl)-6-(4-fluoro-2-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1474" num="1531"><chemistry id="CHEM-US-00594" num="00594"><img id="EMI-C00594" he="22.94mm" wi="47.92mm" file="US20230000833A1-20230105-C00594.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1475" num="1532">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>2</sub>, 313.1; m/z found, 314.1 [M+H]<sup>+</sup>.</p><heading id="h-0535" level="1">Example 468: 1-(Cyclopropylmethyl)-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1476" num="1533"><chemistry id="CHEM-US-00595" num="00595"><img id="EMI-C00595" he="27.26mm" wi="51.48mm" file="US20230000833A1-20230105-C00595.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1477" num="1534">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>, 309.1; m/z found, 310.1 [M+H]<sup>+</sup>.</p><heading id="h-0536" level="1">Example 469: 1-(Cyclopropylmethyl)-6-(3-fluoro-4-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1478" num="1535"><chemistry id="CHEM-US-00596" num="00596"><img id="EMI-C00596" he="28.11mm" wi="51.48mm" file="US20230000833A1-20230105-C00596.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1479" num="1536">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>2</sub>, 313.1; m/z found, 314.1 [M+H]<sup>+</sup>.</p><heading id="h-0537" level="1">Example 470: 1-(Cyclopropylmethyl)-6-(3,5-difluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1480" num="1537"><chemistry id="CHEM-US-00597" num="00597"><img id="EMI-C00597" he="28.11mm" wi="47.92mm" file="US20230000833A1-20230105-C00597.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1481" num="1538">MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>2</sub>N<sub>3</sub>O, 301.1; m/z found, 302.1 [M+H]<sup>+</sup>.</p><heading id="h-0538" level="1">Example 471: 1-(Cyclopropylmethyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1482" num="1539"><chemistry id="CHEM-US-00598" num="00598"><img id="EMI-C00598" he="22.94mm" wi="51.48mm" file="US20230000833A1-20230105-C00598.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1483" num="1540">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>, 295.1; m/z found, 296.1 [M+H]<sup>+</sup>.</p><heading id="h-0539" level="1">Example 472: 1-(Cyclopropylmethyl)-6-(2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1484" num="1541"><chemistry id="CHEM-US-00599" num="00599"><img id="EMI-C00599" he="23.11mm" wi="41.66mm" file="US20230000833A1-20230105-C00599.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1485" num="1542">MS (ESI): mass calcd. for C<sub>14</sub>H<sub>13</sub>N<sub>30</sub>S, 271.1; m/z found, 272.1 [M+H]<sup>+</sup>.</p><heading id="h-0540" level="1">Example 473: 1-(Cyclopropylmethyl)-6-[3-(dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1486" num="1543"><chemistry id="CHEM-US-00600" num="00600"><img id="EMI-C00600" he="30.14mm" wi="42.50mm" file="US20230000833A1-20230105-C00600.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1487" num="1544">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O, 308.2; m/z found, 309.2 [M+H]<sup>+</sup>.</p><heading id="h-0541" level="1">Example 474: 1-(Cyclopropylmethyl)-6-(3,5-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1488" num="1545"><chemistry id="CHEM-US-00601" num="00601"><img id="EMI-C00601" he="27.09mm" wi="47.33mm" file="US20230000833A1-20230105-C00601.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1489" num="1546">MS (ESI): mass calcd. for C<sub>18</sub>Fl<sub>19</sub>N<sub>3</sub>O, 293.2; m/z found, 294.2 [M+H]<sup>+</sup>.</p><heading id="h-0542" level="1">Example 475: 6-(3-Methoxyphenyl)-1-(tetrahydrofuran-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1490" num="1547"><chemistry id="CHEM-US-00602" num="00602"><img id="EMI-C00602" he="27.94mm" wi="46.06mm" file="US20230000833A1-20230105-C00602.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1491" num="1548">MS (ESI): mass calcd. for C<sub>18</sub>Fl<sub>19</sub>N<sub>3</sub>O<sub>3</sub>, 325.1; m/z found, 326.1 [M+H]<sup>+</sup>.</p><heading id="h-0543" level="1">Example 476: 4-[[6-(4-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1492" num="1549"><chemistry id="CHEM-US-00603" num="00603"><img id="EMI-C00603" he="25.82mm" wi="64.85mm" file="US20230000833A1-20230105-C00603.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1493" num="1550">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>, 356.1; m/z found, 357.1 [M+H]<sup>+</sup>.</p><heading id="h-0544" level="1">Example 477: 3-[[6-(4-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1494" num="1551"><chemistry id="CHEM-US-00604" num="00604"><img id="EMI-C00604" he="32.26mm" wi="56.90mm" file="US20230000833A1-20230105-C00604.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1495" num="1552">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>, 356.1; m/z found, 357.1 [M+H]<sup>+</sup>.</p><heading id="h-0545" level="1">Example 478: 3-[[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1496" num="1553"><chemistry id="CHEM-US-00605" num="00605"><img id="EMI-C00605" he="32.17mm" wi="53.34mm" file="US20230000833A1-20230105-C00605.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1497" num="1554">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>2</sub>, 374.1; m/z found, 375.1 [M+H]<sup>+</sup>.</p><heading id="h-0546" level="1">Example 479: 34[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl)benzonitrile</heading><p id="p-1498" num="1555"><chemistry id="CHEM-US-00606" num="00606"><img id="EMI-C00606" he="32.17mm" wi="53.34mm" file="US20230000833A1-20230105-C00606.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1499" num="1556">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>15</sub>FN<sub>4</sub>O, 358.1; m/z found, 359.1 [M+H]<sup>+</sup>.</p><heading id="h-0547" level="1">Example 480: 3-[[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1500" num="1557"><chemistry id="CHEM-US-00607" num="00607"><img id="EMI-C00607" he="32.00mm" wi="53.34mm" file="US20230000833A1-20230105-C00607.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1501" num="1558">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>12</sub>ClFN<sub>4</sub>O, 378.1; m/z found, 379.1 [M+H]<sup>+</sup>.</p><heading id="h-0548" level="1">Example 481: 2-[[6-(2-Fluoro-6-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1502" num="1559"><chemistry id="CHEM-US-00608" num="00608"><img id="EMI-C00608" he="29.13mm" wi="47.92mm" file="US20230000833A1-20230105-C00608.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1503" num="1560">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>2</sub>, 374.1; m/z found, 375.1 [M+H]<sup>+</sup>.</p><heading id="h-0549" level="1">Example 482: 2-[[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1504" num="1561"><chemistry id="CHEM-US-00609" num="00609"><img id="EMI-C00609" he="29.13mm" wi="54.69mm" file="US20230000833A1-20230105-C00609.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1505" num="1562">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>13</sub>ClN<sub>4</sub>O, 360.1; m/z found, 361.1 [M+H]<sup>+</sup>.</p><heading id="h-0550" level="1">Example 483: 2-[[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1506" num="1563"><chemistry id="CHEM-US-00610" num="00610"><img id="EMI-C00610" he="29.13mm" wi="53.34mm" file="US20230000833A1-20230105-C00610.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1507" num="1564">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>15</sub>FN<sub>4</sub>O, 358.1; m/z found, 359.2 [M+H]<sup>+</sup>.</p><heading id="h-0551" level="1">Example 484: 2-[[6-(2-Ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1508" num="1565"><chemistry id="CHEM-US-00611" num="00611"><img id="EMI-C00611" he="29.97mm" wi="47.92mm" file="US20230000833A1-20230105-C00611.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1509" num="1566">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>, 370.1; m/z found, 371.1 [M+H]<sup>+</sup>.</p><heading id="h-0552" level="1">Example 485: 2-[[6-(3-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1510" num="1567"><chemistry id="CHEM-US-00612" num="00612"><img id="EMI-C00612" he="29.13mm" wi="47.92mm" file="US20230000833A1-20230105-C00612.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1511" num="1568">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>, 356.1; m/z found, 357.1 [M+H]<sup>+</sup>.</p><heading id="h-0553" level="1">Example 486: 2-[[6-(3-Cyanophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1512" num="1569"><chemistry id="CHEM-US-00613" num="00613"><img id="EMI-C00613" he="29.29mm" wi="47.92mm" file="US20230000833A1-20230105-C00613.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1513" num="1570">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>13</sub>N<sub>5</sub>O, 351.1; m/z found, 352.1 [M+H]<sup>+</sup>.</p><heading id="h-0554" level="1">Example 487: 2-[[6-(2,4-Dimethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1514" num="1571"><chemistry id="CHEM-US-00614" num="00614"><img id="EMI-C00614" he="29.13mm" wi="56.90mm" file="US20230000833A1-20230105-C00614.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1515" num="1572">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>, 386.1; m/z found, 387.1 [M+H]<sup>+</sup>.</p><heading id="h-0555" level="1">Example 488: 2-[[6-(3,5-Dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1516" num="1573"><chemistry id="CHEM-US-00615" num="00615"><img id="EMI-C00615" he="29.13mm" wi="52.75mm" file="US20230000833A1-20230105-C00615.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1517" num="1574">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O, 354.1; m/z found, 355.2 [M+H]<sup>+</sup>.</p><heading id="h-0556" level="1">Example 489: 2-[[6-(2-Ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1518" num="1575"><chemistry id="CHEM-US-00616" num="00616"><img id="EMI-C00616" he="29.97mm" wi="53.34mm" file="US20230000833A1-20230105-C00616.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1519" num="1576">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>2</sub>, 388.1; m/z found, 389.1 [M+H]<sup>+</sup>.</p><heading id="h-0557" level="1">Example 490: 2-[[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1520" num="1577"><chemistry id="CHEM-US-00617" num="00617"><img id="EMI-C00617" he="29.13mm" wi="53.34mm" file="US20230000833A1-20230105-C00617.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1521" num="1578">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>2</sub>, 374.1; m/z found, 375.1 [M+H]<sup>+</sup>.</p><heading id="h-0558" level="1">Example 491: 2-[[6-(3-Fluoro-4-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1522" num="1579"><chemistry id="CHEM-US-00618" num="00618"><img id="EMI-C00618" he="29.29mm" wi="56.90mm" file="US20230000833A1-20230105-C00618.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1523" num="1580">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>2</sub>, 374.1; m/z found, 375.1 [M+H]<sup>+</sup>.</p><heading id="h-0559" level="1">Example 492: 6-(4-Fluoro-2-methyl-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1524" num="1581"><chemistry id="CHEM-US-00619" num="00619"><img id="EMI-C00619" he="25.99mm" wi="59.44mm" file="US20230000833A1-20230105-C00619.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1525" num="1582">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O, 351.1; m/z found, 352.1 [M+H]<sup>+</sup>.</p><heading id="h-0560" level="1">Example 493: 6-(2,3-Dimethoxyphenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1526" num="1583"><chemistry id="CHEM-US-00620" num="00620"><img id="EMI-C00620" he="25.99mm" wi="62.99mm" file="US20230000833A1-20230105-C00620.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1527" num="1584">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub>, 379.1; m/z found, 380.1 [M+H]<sup>+</sup>.</p><heading id="h-0561" level="1">Example 494: 6-(2-Ethoxy-5-fluoro-phenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1528" num="1585"><chemistry id="CHEM-US-00621" num="00621"><img id="EMI-C00621" he="32.17mm" wi="53.34mm" file="US20230000833A1-20230105-C00621.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1529" num="1586">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 381.1; m/z found, 382.1 [M+H]<sup>+</sup>.</p><heading id="h-0562" level="1">Example 495: 6-(3,5-Dimethylphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1530" num="1587"><chemistry id="CHEM-US-00622" num="00622"><img id="EMI-C00622" he="32.00mm" wi="52.75mm" file="US20230000833A1-20230105-C00622.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1531" num="1588">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O, 347.1; m/z found, 348.1 [M+H]<sup>+</sup>.</p><heading id="h-0563" level="1">Example 496: 6-(2,4-Dimethoxyphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1532" num="1589"><chemistry id="CHEM-US-00623" num="00623"><img id="EMI-C00623" he="32.00mm" wi="56.90mm" file="US20230000833A1-20230105-C00623.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1533" num="1590">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub>, 379.1; m/z found, 380.1 [M+H]<sup>+</sup>.</p><heading id="h-0564" level="1">Example 497: 6-(2-Ethoxyphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1534" num="1591"><chemistry id="CHEM-US-00624" num="00624"><img id="EMI-C00624" he="32.17mm" wi="47.92mm" file="US20230000833A1-20230105-C00624.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1535" num="1592">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, 364.1 [M+H]<sup>+</sup>.</p><heading id="h-0565" level="1">Example 498: 1-[(3-Fluorophenyl)methyl]-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1536" num="1593"><chemistry id="CHEM-US-00625" num="00625"><img id="EMI-C00625" he="32.17mm" wi="56.90mm" file="US20230000833A1-20230105-C00625.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1537" num="1594">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, 364.1 [M+H]<sup>+</sup>.</p><heading id="h-0566" level="1">Example 499: 6-(4-Fluoro-2-methoxy-phenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1538" num="1595"><chemistry id="CHEM-US-00626" num="00626"><img id="EMI-C00626" he="32.17mm" wi="53.34mm" file="US20230000833A1-20230105-C00626.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1539" num="1596">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 367.1; m/z found, 368.1 [M+H]<sup>+</sup>.</p><heading id="h-0567" level="1">Example 500: 6-[3-(Dimethylamino)phenyl]-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1540" num="1597"><chemistry id="CHEM-US-00627" num="00627"><img id="EMI-C00627" he="32.17mm" wi="47.92mm" file="US20230000833A1-20230105-C00627.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1541" num="1598">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>19</sub>FN<sub>4</sub>O, 362.2; m/z found, 363.1 [M+H]<sup>+</sup>.</p><heading id="h-0568" level="1">Example 501: 6-(4-Fluoro-2-methoxy-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1542" num="1599"><chemistry id="CHEM-US-00628" num="00628"><img id="EMI-C00628" he="25.99mm" wi="59.44mm" file="US20230000833A1-20230105-C00628.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1543" num="1600">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 367.1; m/z found, 368.1 [M+H]<sup>+</sup>.</p><heading id="h-0569" level="1">Example 502: 6-(3-Chloro-4-fluoro-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1544" num="1601"><chemistry id="CHEM-US-00629" num="00629"><img id="EMI-C00629" he="28.19mm" wi="59.44mm" file="US20230000833A1-20230105-C00629.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1545" num="1602">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>ClF<sub>2</sub>N<sub>3</sub>O, 371.1; m/z found, 372.1 [M+H]<sup>+</sup>.</p><heading id="h-0570" level="1">Example 503: 6-(2-Ethoxyphenyl)-1-[(2-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1546" num="1603"><chemistry id="CHEM-US-00630" num="00630"><img id="EMI-C00630" he="30.23mm" wi="47.92mm" file="US20230000833A1-20230105-C00630.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1547" num="1604">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, 364.1 [M+H]<sup>+</sup>.</p><heading id="h-0571" level="1">Example 504: 1-[(3-Chlorophenyl)methyl]-6-(3,5-difluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1548" num="1605"><chemistry id="CHEM-US-00631" num="00631"><img id="EMI-C00631" he="32.09mm" wi="53.34mm" file="US20230000833A1-20230105-C00631.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1549" num="1606">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>12</sub>ClF<sub>2</sub>N<sub>3</sub>O, 371.1; m/z found, 372.1 [M+H]<sup>+</sup>.</p><heading id="h-0572" level="1">Example 505: 6-(4-Fluoro-2-methoxy-phenyl)-1-[(3-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1550" num="1607"><chemistry id="CHEM-US-00632" num="00632"><img id="EMI-C00632" he="32.09mm" wi="54.86mm" file="US20230000833A1-20230105-C00632.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1551" num="1608">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub>, 379.1; m/z found, 380.1 [M+H]<sup>+</sup>.</p><heading id="h-0573" level="1">Example 506: 1-[(3-Methoxyphenyl)methyl]-6-(3-pyridyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1552" num="1609"><chemistry id="CHEM-US-00633" num="00633"><img id="EMI-C00633" he="32.26mm" wi="50.12mm" file="US20230000833A1-20230105-C00633.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1553" num="1610">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>, 332.1; m/z found, 333.1 [M+H]<sup>+</sup>.</p><heading id="h-0574" level="1">Example 507: 1-[(3-Methoxyphenyl)methyl]-6-(4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1554" num="1611"><chemistry id="CHEM-US-00634" num="00634"><img id="EMI-C00634" he="32.26mm" wi="48.60mm" file="US20230000833A1-20230105-C00634.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1555" num="1612">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S, 351.1; m/z found, 352.1 [M+H]<sup>+</sup>.</p><heading id="h-0575" level="1">Example 508: 6-(3,5-Difluorophenyl)-1-[(4-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1556" num="1613"><chemistry id="CHEM-US-00635" num="00635"><img id="EMI-C00635" he="28.11mm" wi="62.82mm" file="US20230000833A1-20230105-C00635.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1557" num="1614">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, 367.1; m/z found, 368.1 [M+H]<sup>+</sup>.</p><heading id="h-0576" level="1">Example 509: 1-[(3,5-Dimethoxyphenyl)methyl]-6-(2-fluoro-6-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1558" num="1615"><chemistry id="CHEM-US-00636" num="00636"><img id="EMI-C00636" he="32.26mm" wi="54.53mm" file="US20230000833A1-20230105-C00636.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1559" num="1616">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>, 409.1; m/z found, 410.1 [M+H]<sup>+</sup>.</p><heading id="h-0577" level="1">Example 510: 1-[(3,5-Dimethoxyphenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1560" num="1617"><chemistry id="CHEM-US-00637" num="00637"><img id="EMI-C00637" he="32.26mm" wi="54.53mm" file="US20230000833A1-20230105-C00637.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1561" num="1618">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>18</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 429.1; m/z found, 430.1 [M+H]<sup>+</sup>.</p><heading id="h-0578" level="1">Example 511: 6-(4-Chlorophenyl)-1-[(4-isopropylphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1562" num="1619"><chemistry id="CHEM-US-00638" num="00638"><img id="EMI-C00638" he="28.87mm" wi="64.09mm" file="US20230000833A1-20230105-C00638.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1563" num="1620">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>20</sub>ClN<sub>3</sub>O, 377.1; m/z found, 378.1 [M+H]<sup>+</sup>.</p><heading id="h-0579" level="1">Example 512: 6-(4-tert-Butylphenyl)-1-[(3,4-dimethoxy-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1564" num="1621"><chemistry id="CHEM-US-00639" num="00639"><img id="EMI-C00639" he="32.09mm" wi="59.18mm" file="US20230000833A1-20230105-C00639.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1565" num="1622">MS (ESI): mass calcd. for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub>, 418.2; m/z found, 419.2 [M+H]<sup>+</sup>.</p><heading id="h-0580" level="1">Example 513: 3-[1-[(3,5-Dimethylisoxazol-4-yl)methyl]-2-oxo-3H-imidazo[4,5-b]pyridin-6-yl]benzonitrile</heading><p id="p-1566" num="1623"><chemistry id="CHEM-US-00640" num="00640"><img id="EMI-C00640" he="29.13mm" wi="46.99mm" file="US20230000833A1-20230105-C00640.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1567" num="1624">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub>, 345.1; m/z found, 346.1 [M+H]<sup>+</sup>.</p><heading id="h-0581" level="1">Example 514: 1-[(3,5-Dimethylisoxazol-4-yl)methyl]-6-(2-ethoxy-5-fluoro-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1568" num="1625"><chemistry id="CHEM-US-00641" num="00641"><img id="EMI-C00641" he="29.97mm" wi="52.41mm" file="US20230000833A1-20230105-C00641.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1569" num="1626">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>3</sub>, 382.1; m/z found, 383.0 [M+H]<sup>+</sup>.</p><heading id="h-0582" level="1">Example 515: 6-(4-Methoxy-3-methyl-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1570" num="1627"><chemistry id="CHEM-US-00642" num="00642"><img id="EMI-C00642" he="28.02mm" wi="57.57mm" file="US20230000833A1-20230105-C00642.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1571" num="1628">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>, 350.1; m/z found, 351.1 [M+H]<sup>+</sup>.</p><heading id="h-0583" level="1">Example 516: 6-(3,5-Dimethylphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1572" num="1629"><chemistry id="CHEM-US-00643" num="00643"><img id="EMI-C00643" he="28.02mm" wi="53.51mm" file="US20230000833A1-20230105-C00643.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1573" num="1630">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>, 334.1; m/z found, 335.1 [M+H]<sup>+</sup>.</p><heading id="h-0584" level="1">Example 517: 6-(2-Ethoxyphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1574" num="1631"><chemistry id="CHEM-US-00644" num="00644"><img id="EMI-C00644" he="29.97mm" wi="48.60mm" file="US20230000833A1-20230105-C00644.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1575" num="1632">MS (ESI): mass calcd. for C<sub>19</sub>H18N<sub>4</sub>O<sub>3</sub>, 350.1; m/z found, 351.1 [M+H]<sup>+</sup>.</p><heading id="h-0585" level="1">Example 518: 6-(2,4-Dimethoxyphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1576" num="1633"><chemistry id="CHEM-US-00645" num="00645"><img id="EMI-C00645" he="27.86mm" wi="57.57mm" file="US20230000833A1-20230105-C00645.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1577" num="1634">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>O<sub>4</sub>, 366.1; m/z found, 367.1 [M+H]<sup>+</sup>.</p><heading id="h-0586" level="1">Example 519: 6-(3-Fluoro-4-methoxy-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1578" num="1635"><chemistry id="CHEM-US-00646" num="00646"><img id="EMI-C00646" he="28.11mm" wi="57.57mm" file="US20230000833A1-20230105-C00646.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1579" num="1636">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>3</sub>, 354.1; m/z found, 355.1 [M+H]<sup>+</sup>.</p><heading id="h-0587" level="1">Example 520: 6-(4-Fluoro-2-methoxy-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1580" num="1637"><chemistry id="CHEM-US-00647" num="00647"><img id="EMI-C00647" he="28.02mm" wi="54.02mm" file="US20230000833A1-20230105-C00647.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1581" num="1638">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>3</sub>, 354.1; m/z found, 355.1 [M+H]<sup>+</sup>.</p><heading id="h-0588" level="1">Example 521: 6-(2-Ethoxy-5-fluoro-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1582" num="1639"><chemistry id="CHEM-US-00648" num="00648"><img id="EMI-C00648" he="30.14mm" wi="54.02mm" file="US20230000833A1-20230105-C00648.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1583" num="1640">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>3</sub>, 368.1; m/z found, 369.1 [M+H]<sup>+</sup>.</p><heading id="h-0589" level="1">Example 522: 6-(4-Fluoro-2-methyl-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1584" num="1641"><chemistry id="CHEM-US-00649" num="00649"><img id="EMI-C00649" he="28.02mm" wi="54.02mm" file="US20230000833A1-20230105-C00649.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1585" num="1642">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>FN<sub>4</sub>O<sub>2</sub>, 338.1; m/z found, 339.1 [M+H]<sup>+</sup>.</p><heading id="h-0590" level="1">Example 523: 6-(3,5-Difluorophenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1586" num="1643"><chemistry id="CHEM-US-00650" num="00650"><img id="EMI-C00650" he="27.94mm" wi="54.02mm" file="US20230000833A1-20230105-C00650.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1587" num="1644">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 342.1.</p><p id="p-1588" num="1645">The following compounds may be prepared in a manner analogous to the methods as described above.</p><heading id="h-0591" level="1">Example 524: 1-(2-Oxo-2-(pyrrolidin-1-yl)ethyl)-6-(thiazol-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-1589" num="1646"><chemistry id="CHEM-US-00651" num="00651"><img id="EMI-C00651" he="33.36mm" wi="44.11mm" file="US20230000833A1-20230105-C00651.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1590" num="1647">MS (ESI): mass calcd. for C<sub>15</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub>S, 329.1</p><heading id="h-0592" level="1">Example 525: 1-(2-(3-hydroxy-3-methylazetidin-1-yl)-2-oxoethyl)-6-(5-methylpyridin-3-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-1591" num="1648"><chemistry id="CHEM-US-00652" num="00652"><img id="EMI-C00652" he="37.42mm" wi="47.84mm" file="US20230000833A1-20230105-C00652.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1592" num="1649">MS (ESI): mass calcd. for C<sub>18</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>, 353.2</p><heading id="h-0593" level="1">Example 526: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(6-fluoropyridin-3-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-1593" num="1650"><chemistry id="CHEM-US-00653" num="00653"><img id="EMI-C00653" he="32.09mm" wi="48.77mm" file="US20230000833A1-20230105-C00653.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1594" num="1651">MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>FN<sub>5</sub>O<sub>2</sub>, 327.1</p><heading id="h-0594" level="1">Example 527: 1-(2-(2-Oxo-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetyl)azetidine-3-carbonitrile</heading><p id="p-1595" num="1652"><chemistry id="CHEM-US-00654" num="00654"><img id="EMI-C00654" he="38.27mm" wi="44.53mm" file="US20230000833A1-20230105-C00654.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1596" num="1653">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 401.1</p><heading id="h-0595" level="1">Example 528: 1-Benzyl-6-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-1597" num="1654"><chemistry id="CHEM-US-00655" num="00655"><img id="EMI-C00655" he="28.53mm" wi="53.34mm" file="US20230000833A1-20230105-C00655.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1598" num="1655">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>13</sub>F<sub>4</sub>N<sub>3</sub>O, 387.1.</p><heading id="h-0596" level="1">Example 529: 1-(2-(3-Methylazetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-1599" num="1656"><chemistry id="CHEM-US-00656" num="00656"><img id="EMI-C00656" he="37.42mm" wi="43.35mm" file="US20230000833A1-20230105-C00656.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1600" num="1657">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1.</p><heading id="h-0597" level="1">Example 530: 1-(2-(3-(Methoxymethyl)azetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-1601" num="1658"><chemistry id="CHEM-US-00657" num="00657"><img id="EMI-C00657" he="46.91mm" wi="43.35mm" file="US20230000833A1-20230105-C00657.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1602" num="1659">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 420.1.</p><heading id="h-0598" level="1">Example 531: 6-(2-Fluoro-3-methylphenyl)-1-(2-oxo-2-(3-(trifluoromethyl)azetidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one</heading><p id="p-1603" num="1660"><chemistry id="CHEM-US-00658" num="00658"><img id="EMI-C00658" he="38.86mm" wi="45.04mm" file="US20230000833A1-20230105-C00658.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1604" num="1661">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 408.1.</p><heading id="h-0599" level="1">Example 532: N-(3-Chloropropyl)-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1605" num="1662"><chemistry id="CHEM-US-00659" num="00659"><img id="EMI-C00659" he="31.16mm" wi="56.90mm" file="US20230000833A1-20230105-C00659.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1606" num="1663">To a suspension of 2-(3-methyl-2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 67, 300 mg, 0.84 mmol) and benzotriazol- 1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (371.3 mg, 0.84 mmol) in DCM (3 mL) was added TEA (0.35 mL, 2.5 mmol) followed by 3-chloropropan-1-amine hydrochloride (218.3 mg, 1.67 mmol). The reaction mixture was stirred at room temperature overnight. To the reaction mixture was added water and the reaction mixture was extracted with DCM. The organics were separated, combined, dried, concentrated under reduced pressure. Purification (via HPLC Method A) afforded the title compound (140 mg, 38%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 432.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.43 (d, J=2.0 Hz, 1H), 8.27 (t, J=5.6 Hz, 1H), 7.91 (d, J=2.0 Hz, 1H), 7.77 (dq, J=3.7, 1.2 Hz, 1H), 7.60 (dt, J=3.8, 1.3 Hz, 1H), 4.56 (s, 2H), 3.64 (t, J=6.6 Hz, 2H), 3.41 (s, 3H), 3.21 (q, J=6.5 Hz, 2H), 1.87 (p, J=6.6 Hz, 2H).</p><heading id="h-0600" level="1">Example 533: 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-1607" num="1664"><chemistry id="CHEM-US-00660" num="00660"><img id="EMI-C00660" he="33.61mm" wi="45.21mm" file="US20230000833A1-20230105-C00660.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1608" num="1665">DIPEA (133 &#x3bc;L, 0.8 mmol) and HBtU (147 mg, 0.4 mmol) were added to a solution of 2-(6-(3-(difluoromethyl)-4-fluorophenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 59, 100 mg, 0.3 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred 10 minutes and dimethylamine was added (2M in THF, 130 &#x3bc;L, 0.3 mmol). The reaction was stirred at room temperature overnight. Saturated solution of NaHCO<sub>3 </sub>was added and the mixture was extracted with EtOAc (&#xd7;3). The organic layers were dried over MgSO<sub>4 </sub>and concentrated. The crude product was was purified (FCC, SiO<sub>2</sub>, 0-100% EtOAc in heptane) to provide the title compound (61.5 mg, 0.16 mmol, 61%). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 378.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.31 (s, 1H), 7.88 (d, J=6.1 Hz, 2H), 7.83 (s, 1H), 7.50 (t, J=9.7 Hz, 1H), 7.26 (t, J=54.2 Hz, 1H), 4.86 (s, 2H), 3.39 (s, 3H), 3.10 (s, 3H), 2.84 (s, 3H).</p><heading id="h-0601" level="1">Example 534: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1609" num="1666"><chemistry id="CHEM-US-00661" num="00661"><img id="EMI-C00661" he="39.71mm" wi="47.41mm" file="US20230000833A1-20230105-C00661.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1610" num="1667">To a mixture of 1-[2-(azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 323, 66 mg, 0.173 mmol) in DMF (3 mL) was added NaH (8 mg, 0.21 mmol). The solution was stirred at rt for 1.5 h then fluoroiodomethane was added (0.017 mL, 0.26 mmol). After stirring 2 h additional at rt, MeOH was added (0.5 mL) and the solution was loaded directly onto silica gel (24 g) and purified by FCC (0-10% (2N NH<sub>3</sub>-MeOH)/DCM gradient). The solvents were removed in vacuo. The residue was dissolved in MeCN/water (20 mL, 1:1) and solvents were removed by lyopholization to give the title compound as a white powder (24 mg, 34%). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 414.1; m/z found, 415.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>-d) &#x3b4; 8.34 (d, J=1.9 Hz, 1H), 7.51 (d, J=1.9 Hz, 1H), 7.42 (dq, J=3.4, 1.1 Hz, 1H), 7.22 (dq, J=3.6, 1.1 Hz, 1H), 6.08 (d, J=52.5 Hz, 2H), 4.49 (s, 2H), 4.35 (t, J=7.8 Hz, 2H), 4.10 (t, J=7.8 Hz, 2H), 2.42-2.35 (m, 2H).</p><heading id="h-0602" level="1">Example 535: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(2-fluoroethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1611" num="1668"><chemistry id="CHEM-US-00662" num="00662"><img id="EMI-C00662" he="45.13mm" wi="47.41mm" file="US20230000833A1-20230105-C00662.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1612" num="1669">To a solution of 1-[2-(azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 323, 7 mg, 0.018 mmol) in dry DMF (0.3 mL) at rt was added sodium hydride (60% dispersion in mineral oil, 3 mg, 0.073 mmol). The reaction mixture was stirred at rt for 10 min followed by addition of 1-fluoro-2-iodoethane (6.4 mg, 0.073 mmol). The reaction mixture was stirred at rt for 1 h. The reaction mixture was cooled to 0&#xb0; C. and quenched by adding two drops of methanol. The reaction mixture was diluted with EtOAc (10 mL) and washed with brine (20 mL). The organic phase was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Purification (reversed phase HPLC; TFA 0.05% buffered water/MeCN) afforded the title compound which was suspended in EtOAc and neutralized with saturated NaHCO<sub>3 </sub>solution. The compound was further dried under high vacuum to afford the tittle compound as a white solid. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 428.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) d 8.32 (d, J=1.8 Hz, 1H), 7.55 (d, J=1.9 Hz, 1H), 7.45 (dd, J=3.7, 1.2 Hz, 1H), 7.30-7.26 (m, 1H), 4.84 (t, J=5.0 Hz, 1H), 4.75 (t, J=5.0 Hz, 1H), 4.40-4.30 (m, 5H), 2.41 (dt, J=15.5, 7.8 Hz, 2H).</p><heading id="h-0603" level="1">Example 536: 1-[2-[3-(2-Fluoroethyl)azetidin-1-yl]-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1613" num="1670"><chemistry id="CHEM-US-00663" num="00663"><img id="EMI-C00663" he="47.67mm" wi="40.13mm" file="US20230000833A1-20230105-C00663.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1614" num="1671">Step A: 1-(2-(3-(2-Fluoroethyl)azetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a vial containing Pd(PPh<sub>3</sub>)<sub>4 </sub>(4.43 mg, 0.0038 mmol) and K<sub>2</sub>CO<sub>3 </sub>(15.9 mg, 0.115 mmol) was added 6-bromo-1-(2-(3-(2-fluoroethyl)azetidin-1-yl)-2-oxoethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 68, 23 mg, 0.038 mmol) and 3-(trifluoromethyl)phenylboronic acid (14.5 mg, 0.076 mmol) under nitrogen. DMF was added (0.15 mL) and the reaction mixture was heated to 110&#xb0; C. for 2 h. The reaction mixture was cooled, diluted with EtOAc and NaHCO<sub>3 </sub>(aq). The organic layer was separated, washed with brine, separated, dried, and concentrated under reduced pressure. The title compound was used crude in the next step without further purification.</p><p id="p-1615" num="1672">Step B: 1-[2-[3-(2-Fluoroethypazetidin-1-yl]-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 24, Step C using 1-(2-(3-(2-fluoroethyl)azetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>18</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 422.1; m/z found, 423.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.21 (d, J=1.9 Hz, 1H), 7.80-7.61 (m, 2H), 7.61-7.46 (m, 2H), 7.44 (d, J=1.9 Hz, 1H), 4.59-4.27 (m, 3H), 4.41 (s, 2H), 4.14 (t, J=9.5 Hz, 1H), 3.97 (dd, J=8.7, 5.8 Hz, 1H), 3.70 (dd, J=10.2, 5.9 Hz, 1H), 2.82 (t, J=7.9 Hz, 1H), 2.11-1.86 (m, 2H).</p><heading id="h-0604" level="1">Example 537: 6-(6-Fluoro-2-pyridyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1616" num="1673"><chemistry id="CHEM-US-00664" num="00664"><img id="EMI-C00664" he="27.94mm" wi="43.86mm" file="US20230000833A1-20230105-C00664.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1617" num="1674">Step A: 6-Bromo-1-(2-oxobutyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 330, Step A, using 1-chlorobutan-2-one instead of 1-bromo-2-butanone.</p><p id="p-1618" num="1675">Step B: 6-(6-fluoropyridin-2-yl)-1-(2-oxobutyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 330, Step B, using 6-bromo-1-(2-oxobutyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and using (6-fluoropyridin-2-yl)boronic acid instead of (3,4-difluorophenyl)boronic acid.</p><p id="p-1619" num="1676">Step C. 6-(6-Fluoro-2-pyridyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 11, Step C. MS (ESI): mass calcd. for C<sub>15</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>2</sub>, 300.1; m/z found, 301.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) &#x3b4; 8.66 (d, J=2.1 Hz, 1H), 8.11-7.91 (m, 1H), 7.87 (d, J=1.8 Hz, 1H), 7.79 (dd, J=7.5, 2.7 Hz, 1H), 7.01 (dd, J=8.0, 2.8 Hz, 1H), 4.78 (s, 2H), 2.65 (d, J=7.2 Hz, 2H), 1.09(t, J=7.3 Hz, 3H).</p><heading id="h-0605" level="1">Example 538: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1620" num="1677"><chemistry id="CHEM-US-00665" num="00665"><img id="EMI-C00665" he="36.41mm" wi="50.12mm" file="US20230000833A1-20230105-C00665.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1621" num="1678">Step A: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(4-hydroxy-3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 330, Steps A-B, using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 38) in Step A; and (4-hydroxy-3-(trifluoromethyl)phenyl)boronic acid, K<sub>2</sub>CO<sub>3 </sub>instead of Cs<sub>2</sub>CO<sub>3</sub>, and DMF instead of dioxane in Step B. MS (ESI): mass calcd. for C<sub>37</sub>H<sub>29</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 634.2 m/z found, 626.2 [M+Na]<sup>+</sup>.</p><p id="p-1622" num="1679">Step B: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a solution of 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-(4-hydroxy-3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (30 mg, 0.047 mmol) in DMF (0.073 mL) was added 1-fluoro-2-iodoethane (20.55 mg, 0.118 mmol) and potassium carbonate (13 mg, 0.09 mmol). The reaction mixture was stirred at rt for 5 h. The mixture was diluted with EtOAc (25 mL) and NaHCO<sub>3</sub>(aq. 20 mL). The organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4 </sub>and concentrated. The residue (20 mg, yield 62%) was used in next step directly. MS (ESI): mass calcd. for C<sub>39</sub>H<sub>32</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 680.2 m/z found, 703.2 [M+Na]<sup>+</sup>.</p><p id="p-1623" num="1680">Step C. 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one. To a solution of 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-(4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (20 mg, 0.029 mmol) in DCM (5.6 mL), was added the mixed solution of TFA and TIPS (20:1, 250 &#x3bc;L). The reaction mixture was stirred at rt overnight. The solvents were removed under vacuum. The residue was purified on a RP-HPLC (C18, MeCN in Water 35% to 60%) to afford the title compound (6.5 mg, yield 51%). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>18</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 438.1; m/z found, 439.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.16 (s, 1H), 7.68 (d, J=2.2 Hz, 1H), 7.61 (dd, J=8.7, 2.3 Hz, 1H), 7.39 (d, J=1.6 Hz, 1H), 7.03 (d, J=8.6 Hz, 1H), 5.23 (s, 1H), 4.90-4.59 (m, 2H), 4.45 (s, 2H), 4.40-4.20 (m, 3H), 4.10-3.95 (m, 3H), 2.30 (t, J=7.8 Hz, 2H).</p><heading id="h-0606" level="1">Example 539: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1624" num="1681"><chemistry id="CHEM-US-00666" num="00666"><img id="EMI-C00666" he="34.63mm" wi="59.94mm" file="US20230000833A1-20230105-C00666.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1625" num="1682">Step A: 1-Bromo-3-(2-fluoroethoxy)-5-(trifluoromethyl)benzene. To a solution of 3-bromo-5-(trifluoromethyl)phenol (500 mg, 2.1 mmol) in DMF (3.2 mL) was added potassium carbonate (573 mg, 4.1 mmol). 1-fluoro-2-iodoethane was added dropwise at rt. The reaction was stirred overnight. The reaction mixture was diluted with EtOAc (50 mL) and brine (30 mL). The organic layer was collected, dried over Na<sub>2</sub>SO<sub>4 </sub>and concentrated. The residue was purified (FCC EtOAc in Hexanes 0% to 50%) to afford colorless oil (380 mg, yield 64%) MS (ESI): mass calcd. for C<sub>9</sub>H<sub>7</sub>BrF<sub>4</sub>O, 286.0; m/z found, 287.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 7.43 (d, J=0.7 Hz, 1H), 7.38-7.24 (s, 1H), 7.15 (d, J=0.7 Hz, 1H), 4.92-4.69 (m, 2H), 4.37-4.24 (m, 2H).</p><p id="p-1626" num="1683">Step B: 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. To a vial charged with a stirring bar, 1-bromo-3-(2-fluoroethoxy)-5-(trifluoromethyl)benzene (250 mg, 0.87 mmol), bis(pinacolato)diboron (266 mg, 1.0 mmol), potassium acetate (256 mg, 2.6 mmol) and palladium acetate (10 mg, 0.04 mmol), was added DMF (10 mL). The mixture was degassed with nitrogen for 10 mins. The vial was sealed and heated at 90&#xb0; C. for 2 h. The reaction was allowed to rt, filtered. To the solution, were added intermediate 38 (240 mg, 0.44 mmol), Pd(PPh<sub>3</sub>)<sub>4 </sub>(25 mg, 0.04 mmol), and potassium carbonate (180 mmol). The mixture was heated overnight at 110&#xb0; C. The mixture was diluted with EtOAc and Brine after cooling down. The organic layer was collected, dried and concentrated. The residue was purified (FCC, EtOAc in Hexanes 10% to 80%) to afford the desired product (180 mg, yield 30%) MS (ESI): mass calcd. for C<sub>39</sub>H<sub>32</sub>F<sub>4</sub>ON<sub>4</sub>O<sub>3</sub>, 680.2; m/z found, 703.2 [M+H]<sup>+</sup>.</p><p id="p-1627" num="1684">Step C: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 24, Step C using 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-(3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. MS (ESI): mass calcd. for C<sub>20</sub>H<sub>18</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 438.1; m/z found, 439.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3b4; 11.83 (s, 1H), 8.42 (d, J=2.0 Hz, 1H), 7.90 (d, J=2.1 Hz, 1H), 7.64 (d, J=6.5 Hz, 2H), 7.35 (s, 1H), 4.85 (dt, J=47.9, 3.6 Hz, 2H), 4.70-4.41 (m, 4H), 4.33 (s, 2H), 3.96 (s, 2H), 2.34 (s, 2H).</p><heading id="h-0607" level="1">Example 540: 1-[2-(3-<sup>18</sup>F-Fluoranylazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1628" num="1685"><chemistry id="CHEM-US-00667" num="00667"><img id="EMI-C00667" he="44.11mm" wi="45.21mm" file="US20230000833A1-20230105-C00667.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1629" num="1686">Fluoride-18 ([<sup>18</sup>F]F<sup>&#x2212;</sup>) was purchased from PETNET Solutions(PETNET Solutions, USA). The process was performed in Synthra RNPlus (Synthra GmbH). The aqueous solution of [<sup>18</sup>F]fluoride ([<sup>18</sup>F]F<sup>&#x2212;</sup>) was trapped on a SepPak Light Accell plus QMA anion exchange cartridge (CO<sub>3</sub><sup>2&#x2212;</sup> form, Waters, Milford, Mass., U.S.A.) and eluted with a mixture of Kryptofix 2.2.2 (K-222, 7.2 mg) and KHCO<sub>3 </sub>(1.1 mg) dissolved in CH<sub>3</sub>CN/H<sub>2</sub>O (0.8 mL; 3:1 v/v). After evaporation of the solvent with a stream of nitrogen at 85&#xb0; C. and vacuum, anhydrous CH<sub>3</sub>CN (0.5 mL) was added, and [<sup>18</sup>F]F<sup>&#x2212;</sup> was further dried under the same conditions before drying temperature was changed to 110&#xb0; C. for 10 min. The reaction vial was then cooled to 70&#xb0; C. before a solution of 1-(2-(6-(4-fluoro-3-methylphenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetyl)azetidin-3-yl 4-methylbenzenesulfonate (1.50 mg) in anhydrous MeCN (0.7 mL) was added to the dried [<sup>18</sup>F]F<sup>&#x2212;</sup>/KHCO<sub>3</sub>/K-222 complex and the mixture was heated at 100&#xb0; C. for 10 min. The crude radiolabeling mixture was diluted with water (4.3 mL) and purified using reverse phase HPLC (RP-HPLC) on an Eclipse XDB-C<sub>18 </sub>column (5 &#x3bc;m, 9.4 mm&#xd7;250 mm; Agilent, Santa Clara, Calif., U.S.A.) eluted with a mixture of 10 mM NH<sub>4</sub>OAc and MeCN (62:38 v/v) at a flow rate of 4 mL/min and with UV detection at 254 nm. The purified radiotracer solution was diluted with water (30 mL) and passed through a SepPak Light C-18 cartridge. The C-18 cartridge was further washed by water (10 mL) before EtOH (0.5 mL) was used to elute the tracer and diluted by saline (4.5 mL) and formulated as an ethanol concentration 10%, suitable for intravenous injection (IV). Quality control was performed using RP-HPLC on an Eclipse XDB-C<sub>18 </sub>column (5 &#x3bc;m, 4.6 mm&#xd7;150 mm m, Agilent, Santa Clara, Calif, U.S.A.) eluted with a mixture of 0.05% TFA solution and MeCN at a flow rate of 1.0 mL/min. UV detection was performed at 254 nm.</p><heading id="h-0608" level="1">Example 541: 6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1630" num="1687"><chemistry id="CHEM-US-00668" num="00668"><img id="EMI-C00668" he="33.53mm" wi="53.34mm" file="US20230000833A1-20230105-C00668.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1631" num="1688">The title compound was prepared in a manner analogous to Example 6, using 6-(3-(difluoromethyl)-4-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 56) and 3-(chloromethyl)pyridazine (Intermediate 2, Method B). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O, 385.1; m/z found, 386 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.15 (s, 1H), 8.36 (s, 1H), 7.96-7.84 (m, 3H), 7.73-7.63 (m, 2H), 7.49 (t, J=9.8 Hz, 1H), 7.24 (t, J=54.2 Hz, 1H), 5.49 (s, 2H), 3.42 (s, 3H).</p><heading id="h-0609" level="1">Example 542: 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1632" num="1689"><chemistry id="CHEM-US-00669" num="00669"><img id="EMI-C00669" he="39.20mm" wi="53.34mm" file="US20230000833A1-20230105-C00669.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1633" num="1690">The title compound was prepared in a manner analogous to Example 6, using 6-(3-(difluoromethoxy)-4-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 58) and 3-(chloromethyl)pyridazine (Intermediate 2). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 401.1; m/z found 402 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.15 (s, 1H), 8.35 (s, 1H), 7.88 (s, 1H), 7.72-7.04 (m, 6H), 5.48 (s, 2H), 3.41 (s, 3H).</p><heading id="h-0610" level="1">Example 543: 6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1634" num="1691"><chemistry id="CHEM-US-00670" num="00670"><img id="EMI-C00670" he="39.20mm" wi="54.69mm" file="US20230000833A1-20230105-C00670.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1635" num="1692">The title compound was prepared in a manner analogous to Example 6, using 6-(4-chloro-3-(difluoromethoxy)phenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 57) and 3-(chloromethyl)pyridazine (Intermediate 2). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>14</sub>C<sub>1</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>, 417.1; m/z found, 418 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 9.15 (s, 1H), 8.39 (s, 1H), 7.90 (s, 1H), 7.72-7.10 (m, 6H), 5.48 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0611" level="1">Example 544: 6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1636" num="1693"><chemistry id="CHEM-US-00671" num="00671"><img id="EMI-C00671" he="39.20mm" wi="57.83mm" file="US20230000833A1-20230105-C00671.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1637" num="1694">The title compound was prepared in a manner analogous to Example 6, using 6-(4-chloro-3-(difluoromethoxy)phenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 57) and 3-(chloromethyl)-5-fluoropyridine (Intermediate 64). The halide was added as a solution of DMF (5 mL) and DIPEA (1 equivalent). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 434.1; m/z found, 435 [M+H]<sup>+</sup>.<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.53 (s, 1H), 8.50 (s, 1H), 8.38 (s, 1H), 7.97 (s, 1H), 7.77-7.11 (m, 5H), 5.24 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0612" level="1">Example 545: 6-(3,4-Difluorophenyl)-3-methyl-1-(thiadiazol-4-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1638" num="1695"><chemistry id="CHEM-US-00672" num="00672"><img id="EMI-C00672" he="30.73mm" wi="52.15mm" file="US20230000833A1-20230105-C00672.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1639" num="1696">The title compound was prepared in a manner analogous to Example 6, using 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 29) and 4-(chloromethyl)-1,2,3-thiadiazole. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>11</sub>F<sub>2</sub>N<sub>5</sub>OS, 359.1; m/z found, 360 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.66 (s, 1H), 8.21 (d, J=1.5 Hz, 1H), 7.61 (d, J=1.5 Hz, 1H), 7.34 (dd, J=11.0, 7.6 Hz, 1H), 7.23 (br s, 2H), 5.62 (s, 2H), 3.54 (s, 3H).</p><heading id="h-0613" level="1">Example 546: 6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1640" num="1697"><chemistry id="CHEM-US-00673" num="00673"><img id="EMI-C00673" he="33.53mm" wi="56.47mm" file="US20230000833A1-20230105-C00673.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1641" num="1698">The title compound was prepared in a manner analogous to Example 6, using 6-(3-(difluoromethyl)-4-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 56) and 3-(chloromethyl)-5-fluoropyridine (Intermediate 64). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O, 402.1; m/z found, 403 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.54 (s, 1H), 8.50 (d, J=2.0 Hz, 1H), 8.33 (s, 1H), 7.98 (s, 1H), 7.90 (d, J=4.4 Hz, 2H), 7.73 (d, J=9.6 Hz, 1H), 7.50 (t, J=9.7 Hz, 1H), 7.25 (t, J=54.2 Hz, 1H), 5.24 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0614" level="1">Example 547: 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1642" num="1699"><chemistry id="CHEM-US-00674" num="00674"><img id="EMI-C00674" he="39.20mm" wi="56.47mm" file="US20230000833A1-20230105-C00674.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1643" num="1700">The title compound was prepared in a manner analogous to Example 6, using 6-(3-(difluoromethoxy)-4-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 58) and 3-(chloromethyl)-5-fluoropyridine (Intermediate 64). The halide was added as a solution of DMF (5 mL) and DIPEA (1 equivalent). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 418.1; m/z found, 419 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.53 (s, 1H), 8.50 (d, J=2.2 Hz, 1H), 8.34 (s, 1H), 7.94 (s, 1H), 7.70 (dd, J=17.3, 8.6 Hz, 2H), 7.65-7.06 (m, 3H), 5.23 (s, 2H), 3.40 (s, 3H).</p><heading id="h-0615" level="1">Example 548: 3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1644" num="1701"><chemistry id="CHEM-US-00675" num="00675"><img id="EMI-C00675" he="31.33mm" wi="46.74mm" file="US20230000833A1-20230105-C00675.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1645" num="1702">The title compound was prepared in a manner analogous to Example 6, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and 4-(chloromethyl)-1,2,3-thiadiazole. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>N<sub>6</sub>OS, 391.1; m/z found 392 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.66 (s, 1H), 8.27 (d, J=1.5 Hz, 1H), 7.77 (s, 1H), 7.72 (d, J=7.4 Hz, 1H), 7.68-7.58 (m, 3H), 5.64 (s, 2H), 3.56 (s, 3H).</p><heading id="h-0616" level="1">Example 549: 6-(3,4-Difluorophenyl)-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1646" num="1703"><chemistry id="CHEM-US-00676" num="00676"><img id="EMI-C00676" he="30.73mm" wi="56.39mm" file="US20230000833A1-20230105-C00676.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1647" num="1704">The title compound was prepared in a manner analogous to Example 6, using 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 29) and 4-(chloromethyl)-1-methyl-1H-1,2,3 triazole hydrochloride. The halide was added as a solution of DMF (5 mL) and DIPEA (1 equivalent). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>2</sub>N<sub>6</sub>O, 356.1; m/z found, 357 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.34 (d, J=1.7 Hz, 1H), 8.05 (s, 1H), 7.93 (d, J=1.7 Hz, 1H), 7.86-7.76 (m, 1H), 7.59-7.51 (m, 2H), 5.19 (s, 2H), 3.97 (s, 3H), 3.38 (s, 3H).</p><heading id="h-0617" level="1">Example 550: 6-(3,4-Difluorophenyl)-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1648" num="1705"><chemistry id="CHEM-US-00677" num="00677"><img id="EMI-C00677" he="30.73mm" wi="54.02mm" file="US20230000833A1-20230105-C00677.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1649" num="1706">The title compound was prepared in a manner analogous to Example 6, using 6-(3,4-difluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 29) and 4-(chloromethyl)-1-methyl-1H-pyrazole hydrochloride. The halide was added as a solution of DMF (5 mL) and DIPEA (1 equivalent). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O, 355.1; m/z found, 356 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.17 (d, J=1.7 Hz, 1H), 7.49 (s, 1H), 7.41 (s, 1H), 7.36-7.28 (m, 1H), 7.25-7.17 (m, 3H), 4.98 (s, 2H), 3.85 (s, 3H), 3.53 (s, 3H).</p><heading id="h-0618" level="1">Example 551: 3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-(3-(trifluoromethyl)phenyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1650" num="1707"><chemistry id="CHEM-US-00678" num="00678"><img id="EMI-C00678" he="30.65mm" wi="58.93mm" file="US20230000833A1-20230105-C00678.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1651" num="1708">The title compound was prepared in a manner analogous to Example 6, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and 4-(chloromethyl)-1-methyl-1H-pyrazole hydrochloride. The halide was added as a solution of DMF (5 mL) and DIPEA (1 equivalent) at 0&#xb0; C. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>O, 387.1; m/z found, 388 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.23 (d, J=1.5 Hz, 1H), 7.73 (s, 1H), 7.72-7.54 (m, 3H), 7.50 (s, 1H), 7.42 (s, 1H), 7.29 (d, J=1.4 Hz, 1H), 4.99 (s, 2H), 3.84 (s, 3H), 3.54 (s, 3H).</p><heading id="h-0619" level="1">Example 552: 3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1652" num="1709"><chemistry id="CHEM-US-00679" num="00679"><img id="EMI-C00679" he="31.33mm" wi="50.97mm" file="US20230000833A1-20230105-C00679.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1653" num="1710">The title compound was prepared in a manner analogous to Example 6, using 3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 26) and 4-(chloromethyl)-1-methyl-1H-1,2,3 triazole hydrochloride. The halide was added as a solution of DMF (5 mL) and DIPEA (1 equivalent). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>6</sub>O, 388.1; m/z found, 389 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.24 (d, J=1.7 Hz, 1H), 7.78 (s, 1H), 7.76-7.67 (m, 2H), 7.67-7.53 (m, 3H), 5.23 (s, 2H), 4.05 (s, 3H), 3.53 (s, 3H).</p><heading id="h-0620" level="1">Example 553: 3-Methyl-6-(5-methyl-2-thienyl)-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1654" num="1711"><chemistry id="CHEM-US-00680" num="00680"><img id="EMI-C00680" he="27.77mm" wi="55.54mm" file="US20230000833A1-20230105-C00680.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1655" num="1712">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 50) in Step A; and 2-bromo-5-methylthiophene (Intermediate 48) in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>16</sub>N<sub>6</sub>OS, 340.1; m/z found, 341 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.23 (s, 1H), 7.59 (s, 2H), 7.06 (d, J=3.4 Hz, 1H), 6.73 (d, J=2.3 Hz, 1H), 5.19 (s, 2H), 4.05 (s, 3H), 3.50 (s, 3H), 2.51 (s, 3H).</p><heading id="h-0621" level="1">Example 554: 3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1656" num="1713"><chemistry id="CHEM-US-00681" num="00681"><img id="EMI-C00681" he="30.65mm" wi="53.17mm" file="US20230000833A1-20230105-C00681.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1657" num="1714">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 51) in Step A; and 2-bromo-5-methylthiophene (Intermediate 48) in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub>S, 341.1; m/z found, 342 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.28 (d, J=1.3 Hz, 1H), 7.41 (d, J=1.3 Hz, 1H), 7.04 (d, J=3.4 Hz, 1H), 6.74 (d, J=2.4 Hz, 1H), 5.30 (s, 2H), 3.53 (s, 3H), 2.51 (s, 6H).</p><heading id="h-0622" level="1">Example 555: 3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1658" num="1715"><chemistry id="CHEM-US-00682" num="00682"><img id="EMI-C00682" he="30.65mm" wi="53.17mm" file="US20230000833A1-20230105-C00682.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1659" num="1716">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((1-methyl-1H-pyrazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 52) in Step A; and 2-bromo-5-methylthiophene (Intermediate 48) in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>17</sub>N<sub>5</sub>OS, 339.1; m/z found, 340 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.23 (s, 1H), 7.50 (s, 1H), 7.40 (s, 1H), 7.25 (s, 1H), 7.01 (d, J=2.8 Hz, 1H), 6.75 (s, 1H), 4.95 (s, 2H), 3.84 (s, 3H), 3.50 (s, 3H), 2.52 (s, 3H).</p><heading id="h-0623" level="1">Example 556: 3-Methyl-6-(5-methyl-2-thienyl)-1-(thiadiazol-4-ylmethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-1660" num="1717"><chemistry id="CHEM-US-00683" num="00683"><img id="EMI-C00683" he="27.77mm" wi="51.22mm" file="US20230000833A1-20230105-C00683.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1661" num="1718">The title compound was prepared in a manner analogous to Example 8, using 1-((1,2,3-thiadiazol-4-yl)methyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 53) in Step A; and 2-bromo-5-methylthiophene (Intermediate 48) in Step B. MS (ESI): mass calcd. for C<sub>15</sub>H<sub>13</sub>N<sub>5</sub>OS<sub>2</sub>, 343.1; m/z found, 344 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.62 (s, 1H), 8.26 (d, J=1.5 Hz, 1H), 7.55 (d, J=1.5 Hz, 1H), 7.05 (d, J=3.4 Hz, 1H), 6.74 (d, J=2.3 Hz, 1H), 5.61 (s, 2H), 3.52 (s, 3H), 2.51 (s, 3H).</p><heading id="h-0624" level="1">Example 557: 3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1662" num="1719"><chemistry id="CHEM-US-00684" num="00684"><img id="EMI-C00684" he="27.77mm" wi="55.37mm" file="US20230000833A1-20230105-C00684.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1663" num="1720">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 55) in Step A; and 2-bromo-5-methylthiophene (Intermediate 48) in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub>S, 341.1; m/z found, 342 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.29 (d, J=1.4 Hz, 1H), 7.29 (d, J=1.5 Hz, 1H), 7.04 (d, J=3.4 Hz, 1H), 6.74 (d, J=2.5 Hz, 1H), 5.31 (s, 2H), 3.54 (s, 3H), 2.51 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0625" level="1">Example 558: 3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1664" num="1721"><chemistry id="CHEM-US-00685" num="00685"><img id="EMI-C00685" he="27.77mm" wi="55.54mm" file="US20230000833A1-20230105-C00685.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1665" num="1722">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 54) in Step A, and 2-bromo-5-methylthiophene (Intermediate 48) in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S, 340.1; m/z found, 341[M+H]<sup>+</sup>.<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.24 (s, 1H), 7.39 (s, 1H), 7.03 (s, 1H), 6.73 (s, 1H), 6.00 (s, 1H), 5.10 (s, 2H), 3.52 (s, 3H), 2.50 (s, 3H), 2.37 (s, 3H).</p><heading id="h-0626" level="1">Example 559: 6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1666" num="1723"><chemistry id="CHEM-US-00686" num="00686"><img id="EMI-C00686" he="27.77mm" wi="60.11mm" file="US20230000833A1-20230105-C00686.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1667" num="1724">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 50) in Step A; and 2-bromo-5-(difluoromethyl)thiophene (Intermediate 49) in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>F<sub>2</sub>N<sub>6</sub>OS, 376.1; m/z found, 377 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.34 (s, 1H), 7.74 (s, 1H), 7.67 (s, 1H), 7.31 (s, 2H), 6.89 (t, J=56.0 Hz, 1H), 5.26 (s, 2H), 4.11 (s, 3H), 3.56 (s, 3H).</p><heading id="h-0627" level="1">Example 560: 6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1668" num="1725"><chemistry id="CHEM-US-00687" num="00687"><img id="EMI-C00687" he="30.65mm" wi="57.74mm" file="US20230000833A1-20230105-C00687.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1669" num="1726">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 51) in Step A; using 2-bromo-5-(difluoromethyl)thiophene (Intermediate 49) in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S, 377.1; m/z found 378 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.33 (d, J=1.2 Hz, 1H), 7.47 (d, J=1.3 Hz, 1H), 7.18 (d, J=3.5 Hz, 1H), 6.83 (t, J=56.0 Hz, 1H), 5.32 (s, 2H), 3.55 (s, 3H), 2.52 (s, 3H).</p><heading id="h-0628" level="1">Example 561: 6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1670" num="1727"><chemistry id="CHEM-US-00688" num="00688"><img id="EMI-C00688" he="30.65mm" wi="57.74mm" file="US20230000833A1-20230105-C00688.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1671" num="1728">The title compound was prepared in a manner analogous to Example 8 , using 6-bromo-3-methyl-1-((1-methyl-1H-pyrazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 52) in Step A; and 2-bromo-5-(difluoromethyl)thiophene (Intermediate 49) in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>OS, 375.1; m/z found, 376 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.27 (s, 1H), 7.49 (s, 1H), 7.40 (s, 1H), 7.26 (s, 2H), 7.14 (s, 1H), 6.83 (t, J=56.0 Hz, 1H), 4.95 (s, 2H), 3.84 (s, 3H), 3.51 (s, 3H).</p><heading id="h-0629" level="1">Example 562: 6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-(thiadiazol-4-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1672" num="1729"><chemistry id="CHEM-US-00689" num="00689"><img id="EMI-C00689" he="27.77mm" wi="55.88mm" file="US20230000833A1-20230105-C00689.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1673" num="1730">The title compound was prepared in a manner analogous to Example 8, using 1-((1,2,3-thiadiazol-4-yl)methyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 53) in Step A; and 2-bromo-5-(difluoromethyl)thiophene (Intermediate 49) in Step B. MS (ESI): mass calcd. for C<sub>15</sub>H<sub>11</sub>F<sub>2</sub>N<sub>5</sub>OS<sub>2</sub>, 379.0; m/z found, 380 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.65 (s, 1H), 8.31 (s, 1H), 7.64 (s, 1H), 7.26 (s, 1H), 7.22-7.17 (m, 1H), 6.84 (t, J=56.0 Hz, 1H), 5.61 (s, 2H), 3.53 (s, 3H).</p><heading id="h-0630" level="1">Example 563: 6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1674" num="1731"><chemistry id="CHEM-US-00690" num="00690"><img id="EMI-C00690" he="27.77mm" wi="58.93mm" file="US20230000833A1-20230105-C00690.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1675" num="1732">The title compound was prepared in a manner analogous to Example 8, using bromo-3-methyl-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 55) in Step A and 2-bromo-5-(difluoromethyl)thiophene (Intermediate 49) in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S, 377.1; m/z found, 378 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.35 (d, J=1.4 Hz, 1H), 7.34 (d, J=1.4 Hz, 1H), 7.26-7.27 (m, 1H), 7.18 (d, J=3.5 Hz, 1H), 6.84 (t, J=56.0 Hz, 1H), 5.33 (s, 2H), 3.55 (s, 3H), 2.39 (s, 3H).</p><heading id="h-0631" level="1">Example 564: 6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1676" num="1733"><chemistry id="CHEM-US-00691" num="00691"><img id="EMI-C00691" he="27.77mm" wi="60.11mm" file="US20230000833A1-20230105-C00691.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1677" num="1734">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 54) in Step A; and 2-bromo-5-(difluoromethyl)thiophene (Intermediate 49) in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, 376.1; m/z found 377 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.30 (s, 1H), 7.45 (s, 1H), 7.18 (s, 1H), 6.83 (t, J=56.0 Hz, 1H), 6.02 (s, 1H), 5.12 (s, 2H), 3.54 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0632" level="1">Example 565: 3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1678" num="1735"><chemistry id="CHEM-US-00692" num="00692"><img id="EMI-C00692" he="30.65mm" wi="56.22mm" file="US20230000833A1-20230105-C00692.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1679" num="1736">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((1-methyl-1H-pyrazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 52) in Step A; and 2-bromo-5-trifluoromethylthiophene in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>OS, 393.1; m/z found, 394 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.28 (d, J=1.4 Hz, 1H), 7.50 (s, 1H), 7.41 (s, 2H), 7.26 (s, 1H), 7.15 (d, J=2.9 Hz, 1H), 4.97 (s, 2H), 3.85 (s, 3H), 3.52 (s, 3H).</p><heading id="h-0633" level="1">Example 566: 3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1680" num="1737"><chemistry id="CHEM-US-00693" num="00693"><img id="EMI-C00693" he="27.77mm" wi="58.59mm" file="US20230000833A1-20230105-C00693.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1681" num="1738">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 50) in Step A; and 2-bromo-5-trifluoromethylthiophene in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>3</sub>N<sub>6</sub>OS, 394.1; m/z found 395 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.27 (s, 1H), 7.69 (s, 1H), 7.62 (s, 1H), 7.41 (s, 1H), 7.21 (s, 1H), 5.20 (s, 2H), 4.06 (s, 3H), 3.51 (s, 3H).</p><heading id="h-0634" level="1">Example 567: 3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1682" num="1739"><chemistry id="CHEM-US-00694" num="00694"><img id="EMI-C00694" he="30.65mm" wi="56.22mm" file="US20230000833A1-20230105-C00694.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1683" num="1740">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 51) in Step A; and 2-bromo-5-trifluoromethylthiophene in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S, 395.1; m/z found, 396 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.33 (d, J=1.5 Hz, 1H), 7.47 (d, J=1.4 Hz, 1H), 7.42 (d, J=3.0 Hz, 1H), 7.19 (d, J=2.9 Hz, 1H), 5.32 (s, 2H), 3.55 (s, 3H), 2.52 (s, 3H).</p><p id="p-1684" num="1741">Example 568: 3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</p><p id="p-1685" num="0000"><chemistry id="CHEM-US-00695" num="00695"><img id="EMI-C00695" he="27.77mm" wi="54.36mm" file="US20230000833A1-20230105-C00695.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1686" num="1742">The title compound was prepared in a manner analogous to Example 8, using 1-((1,2,3-thiadiazol-4-yl)methyl)-6-bromo-3-methyl-1, 3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 53) in Step A; and 2-bromo-5-trifluoromethylthiophene in Step B. MS (ESI): mass calcd. for C<sub>15</sub>H<sub>10</sub>F<sub>3</sub>N<sub>5</sub>OS<sub>2</sub>, 397.0; m/z found, 398 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.66 (s, 1H), 8.31 (s, 1H), 7.65 (d, J=1.4 Hz, 1H), 7.43 (d, J=2.8 Hz, 1H), 7.21 (d, J=2.8 Hz, 1H), 5.61 (s, 2H), 3.53 (s, 3H).</p><heading id="h-0635" level="1">Example 569: 3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1687" num="1743"><chemistry id="CHEM-US-00696" num="00696"><img id="EMI-C00696" he="27.77mm" wi="58.59mm" file="US20230000833A1-20230105-C00696.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1688" num="1744">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 55) in Step A; and 2-bromo-5-trifluoromethylthiophene in Step B. MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S, 395.1; m/z found, 396 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.35 (s, 1H), 7.43 (s, 1H), 7.34 (s, 1H), 7.19 (s, 1H), 5.33 (s, 2H), 3.56 (s, 3H), 2.39 (s, 3H).</p><heading id="h-0636" level="1">Example 570: 3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1689" num="1745"><chemistry id="CHEM-US-00697" num="00697"><img id="EMI-C00697" he="27.77mm" wi="58.59mm" file="US20230000833A1-20230105-C00697.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1690" num="1746">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 54) in Step A, and 2-bromo-5-trifluoromethylthiophene in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 394.1; m/z found, 395 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.29 (s, 1H), 7.43 (d, J=8.6 Hz, 2H), 7.18 (s, 1H), 6.02 (s, 1H), 5.12 (s, 2H), 3.54 (s, 3H), 2.38 (s, 3H).</p><heading id="h-0637" level="1">Example 571: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1691" num="1747"><chemistry id="CHEM-US-00698" num="00698"><img id="EMI-C00698" he="29.89mm" wi="56.39mm" file="US20230000833A1-20230105-C00698.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1692" num="1748">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((5-methylisoxazol-3-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 54) in Step A, using 1-bromo-2,4-difluoro-3-methyl-benzene in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 370.1; m/z found, 371 [M+H]<sup>+</sup>.<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.14 (s, 1H), 7.40 (s, 1H), 7.21-7.10 (m, 1H), 6.99-6.87 (m, 1H), 6.02 (s, 1H), 5.12 (s, 2H), 3.55 (s, 3H), 2.37 (s, 3H), 2.26 (s, 3H).</p><heading id="h-0638" level="1">Example 572: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1693" num="1749"><chemistry id="CHEM-US-00699" num="00699"><img id="EMI-C00699" he="30.65mm" wi="54.02mm" file="US20230000833A1-20230105-C00699.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1694" num="1750">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((1-methyl-1H-pyrazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 52) in Step A; and 1-bromo-2,4-difluoro-3-methyl-benzene in Step B. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>2</sub>N<sub>5</sub>O, 369.1; m/z found, 370 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.11 (s, 1H), 7.49 (s, 1H), 7.41 (s, 1H), 7.30 (s, 1H), 7.17 (dd, J=15.1, 8.4 Hz, 1H), 6.94 (t, J=8.6 Hz, 1H), 4.96 (s, 2H), 3.84 (s, 3H), 3.53 (s, 3H), 2.27 (s, 3H).</p><heading id="h-0639" level="1">Example 573: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(3-methyl-1 ,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1695" num="1751"><chemistry id="CHEM-US-00700" num="00700"><img id="EMI-C00700" he="29.89mm" wi="56.39mm" file="US20230000833A1-20230105-C00700.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1696" num="1752">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 55) in Step A; and 1-bromo-2,4-difluoro-3-methyl-benzene in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>, 371.1; m/z found 372.1[M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.19 (s, 1H), 7.32 (s, 1H), 7.18 (dd, J=15.1, 8.5 Hz, 1H), 6.94 (t, J=9.0 Hz, 1H), 5.32 (s, 2H), 3.57 (s, 3H), 2.37 (s, 3H), 2.26 (s, 3H).</p><heading id="h-0640" level="1">Example 574: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1697" num="1753"><chemistry id="CHEM-US-00701" num="00701"><img id="EMI-C00701" he="29.89mm" wi="56.39mm" file="US20230000833A1-20230105-C00701.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1698" num="1754">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 50) in Step A; and 1-bromo-2,4-difluoro-3-methyl-benzene in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>2</sub>N<sub>6</sub>O, 370.1; m/z found, 371[M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.16 (s, 1H), 7.64 (d, J=3.0 Hz, 2H), 7.26-7.16 (m, 1H), 6.96 (t, J=8.3 Hz, 1H), 5.24 (s, 2H), 4.08 (s, 3H), 3.56 (s, 3H), 2.29 (s, 3H).</p><heading id="h-0641" level="1">Example 575: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1699" num="1755"><chemistry id="CHEM-US-00702" num="00702"><img id="EMI-C00702" he="30.65mm" wi="54.02mm" file="US20230000833A1-20230105-C00702.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1700" num="1756">The title compound was prepared in a manner analogous to Example 8, using 6-bromo-3-methyl-1-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 51) in Step A; and 1-bromo-2,4-difluoro-3-methyl-benzene in Step B. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>, 371.1; m/z found, 372, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.18 (s, 1H), 7.44 (s, 1H), 7.16 (dd, J=15.0, 8.4 Hz, 1H), 6.93 (t, J=8.4 Hz, 1H), 5.32 (s, 2H), 3.56 (s, 3H), 2.51 (s, 3H), 2.26 (s, 3H).</p><heading id="h-0642" level="1">Example 576: 6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(thiadiazol-4-ylmethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1701" num="1757"><chemistry id="CHEM-US-00703" num="00703"><img id="EMI-C00703" he="29.89mm" wi="52.15mm" file="US20230000833A1-20230105-C00703.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1702" num="1758">The title compound was prepared in a manner analogous to Example 8, using 1-((1,2,3-thiadiazol-4-yl)methyl)-6-bromo-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 53) in Step A; and 1-bromo-2,4-difluoro-3-methyl-benzene in Step B. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>2</sub>N<sub>5</sub>OS, 373.1; m/z found, 374 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.63 (s, 1H), 8.16 (s, 1H), 7.58 (s, 1H), 7.18 (dd, J=15.1, 8.4 Hz, 1H), 6.94 (t, J=8.5 Hz, 1H), 5.62 (s, 2H), 3.55 (s, 3H), 2.26 (s, 3H).</p><heading id="h-0643" level="1">Example 577: N-(2-Fluoroethyl)-N-methyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1703" num="1759"><chemistry id="CHEM-US-00704" num="00704"><img id="EMI-C00704" he="33.61mm" wi="52.15mm" file="US20230000833A1-20230105-C00704.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1704" num="1760">The title compound was prepared in a manner analogous to Example 11, Step B: using 2-(6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-N-(2-fluoroethyl)-N-methylacetamide (Intermediate 66) and 4,4,5,5-tetramethyl-2-(5-(trifluoromethyl)thiophen-2-yl)-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 416.1; m/z found, 417.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.24 (t, J=2.27 Hz, 1H), 7.34 (m, 1H), 7-29-7.23 (m, 1H), 7.11 (dt, J=1.17, 3.91 Hz, 1H), 5.23 (s, 2H), 4.62-4.52 (m, 2H), 3.81-3.57 (m, 2H), 3.50-3.40 (m, 3H), 3.21 (d, J=0.70 Hz, 3H).</p><heading id="h-0644" level="1">Example 578: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1705" num="1761"><chemistry id="CHEM-US-00705" num="00705"><img id="EMI-C00705" he="40.81mm" wi="47.41mm" file="US20230000833A1-20230105-C00705.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1706" num="1762">The title compound was prepared in a manner analogous to Example 25, using 1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 40) in place of 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 38) and (5-(trifluoromethyl)thiophen-2-yl)boronic acid in place of (3-(trifluoromethyl)phenyl)boronic acid in Step A . MS (ESI): mass calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 400.1; m/z found, 401.1 [M+H]<sup>+</sup>.</p><heading id="h-0645" level="1">Example 579: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1707" num="1763"><chemistry id="CHEM-US-00706" num="00706"><img id="EMI-C00706" he="34.63mm" wi="45.21mm" file="US20230000833A1-20230105-C00706.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1708" num="1764">The title compound was prepared in a manner analogous to Example 26, Method A, using (2,4-difluoro-3-methylphenyl)boronic acid instead of 4,4,5,5-tetramethyl-2-(5-(trifluoromethyl)thiophen-2-yl)-1,3,2-dioxaborolane in Step A; and azetidine instead of dimethylamine hydrochloride in Step C. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 358.1; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0646" level="1">Example 580: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1709" num="1765"><chemistry id="CHEM-US-00707" num="00707"><img id="EMI-C00707" he="40.81mm" wi="39.79mm" file="US20230000833A1-20230105-C00707.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1710" num="1766">Step A: 6-Bromo-1-(2-(3,3-difluoroazetidin-1-yl)-2-oxoethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one .The title compound was prepared in a manner analogous to Intermediate 38 using 3,3-difluoroazetidine in place of azetidine in Step B.</p><p id="p-1711" num="1767">Step B: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 25, using 6-bromo-1-(2-(3,3-difluoroazetidin-1-yl)-2-oxoethyl)-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one in place of intermediate 38. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 358.1; m/z found, 359.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 8.07 (d, J=2.0 Hz, 1H), 7.34-7.13 (m, 5H), 4.53 (s, 2H), 4.25 (t, J=12.0 Hz, 2H), 3.79 (t, J=11.6 Hz, 2H), 2.39 (s, 3H).</p><heading id="h-0647" level="1">Example 581: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(m-tolyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1712" num="1768"><chemistry id="CHEM-US-00708" num="00708"><img id="EMI-C00708" he="43.60mm" wi="39.79mm" file="US20230000833A1-20230105-C00708.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1713" num="1769">The title compound was prepared in a manner analogous to Example 14 Step B, using 1-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one (Example 580) in place of 1-((5-methylisoxazol-3-yl)methyl)-6-(4-methylthiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 372.1; m/z found, [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.29 (d, J=1.8 Hz, 1H), 7.44 (d, J=1.8 Hz, 1H), 7.42-7.39 (m, 1H), 7.36-7.31 (m, 2H), 7.22-7.17 (m, 1H), 4.59 (d, J=28.0 Hz, 4H), 4.43-4.33 (m, 2H), 3.54 (s, 3H), 2.42 (s, 3H).</p><heading id="h-0648" level="1">Example 582: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1714" num="1770"><chemistry id="CHEM-US-00709" num="00709"><img id="EMI-C00709" he="37.42mm" wi="59.94mm" file="US20230000833A1-20230105-C00709.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1715" num="1771">The title compound was prepared in a manner analogous to Example 14 Step B, using 1-[2-(azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 539). MS (ESI): mass calcd. for C<sub>20</sub>H<sub>18</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 438.1; m/z found, 439.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) &#x3b4; 8.37 (d, J=1.9 Hz, 1H), 7.59 (d, J=1.9 Hz, 2H), 7.48 (s, 1H), 7.27 (s, 1H), 4.98-4.66 (m, 1H), 4.52 (s, 2H), 4.48-4.25 (m, 4H), 3.99 (t, J=7.7 Hz, 2H), 3.45 (s, 3H), 2.35 (t, J=7.7 Hz, 2H).</p><heading id="h-0649" level="1">Example 583: N,N-Dimethyl-2-[3-methyl-6-(m-tolyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1716" num="1772"><chemistry id="CHEM-US-00710" num="00710"><img id="EMI-C00710" he="33.70mm" wi="39.79mm" file="US20230000833A1-20230105-C00710.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1717" num="1773">Step A: N,N-Dimethyl-2-(2-oxo-6-(m-tolyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetamide. The title compound was prepared in a manner analogous to Example 26 Method A using m-tolylboronic acid instead of 4,4,5,5-tetramethyl-2-(5-(trifluoromethyl)thiophen-2-yl)-1,3,2-dioxaborolane in Step A.</p><p id="p-1718" num="1774">Step B: N,N-Dimethyl-2-[3-methyl-6-(m-tolyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide. The title compound was prepared in a manner analogous to Example 14 Step B using N,N-dimethyl-2-(2-oxo-6-(m-tolyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetamide. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>, 324.2; m/z found, 325.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>-d) &#x3b4; 8.25 (d, J=1.9 Hz, 1H), 7.38-7.31 (m, 4H), 7.20-7.15 (m, 1H), 4.73 (s, 2H), 3.54 (s, 3H), 3.16 (s, 3H), 2.98 (s, 3H), 2.42 (s, 3H).</p><heading id="h-0650" level="1">Example 584: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethyl)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1719" num="1775"><chemistry id="CHEM-US-00711" num="00711"><img id="EMI-C00711" he="37.42mm" wi="45.21mm" file="US20230000833A1-20230105-C00711.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1720" num="1776">The title compound was prepared in a manner analogous to Example 533, using azetidine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found 391[M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.32 (s, 1H), 7.90 (d, J=6.1 Hz, 2H), 7.83 (s, 1H), 7.51 (t, J=9.7 Hz, 1H), 7.27 (t, J=54.2 Hz, 1H), 4.61 (s, 2H), 4.29 (t, J=7.5 Hz, 2H), 3.90 (t, J=7.6 Hz, 2H), 3.39 (s, 3H), 2.36-2.21 (m, 2H).</p><heading id="h-0651" level="1">Example 585: 6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1721" num="1777"><chemistry id="CHEM-US-00712" num="00712"><img id="EMI-C00712" he="43.60mm" wi="45.21mm" file="US20230000833A1-20230105-C00712.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1722" num="1778">The title compound was prepared in a manner analogous to Example 533, using 3-fluoroazetidine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 408.1; m/z found, 409 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.32 (s, 1H), 7.89 (d, J=6.2 Hz, 2H), 7.82 (s, 1H), 7.51 (t, J=9.7 Hz, 1H), 7.27 (t, J=54.2 Hz, 1H), 5.47 (d, J=57.1 Hz, 1H), 4.69 (s, 2H), 4.66-4.54 (m, 1H), 4.40 (dd, J=24.4, 10.6 Hz, 1H), 4.33-4.16 (m, 1H), 3.97 (dd, J=25.0, 11.5 Hz, 1H), 3.39 (s, 3H).</p><heading id="h-0652" level="1">Example 586: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethyl)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1723" num="1779"><chemistry id="CHEM-US-00713" num="00713"><img id="EMI-C00713" he="43.60mm" wi="45.21mm" file="US20230000833A1-20230105-C00713.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1724" num="1780">The title compound was prepared in a manner analogous to Example 533, using 3,3-difluoroazetidine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 426.1; m/z found, 427 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.32 (s, 1H), 7.88 (d, J=6.1 Hz, 2H), 7.82 (s, 1H), 7.52 (t, J=9.7 Hz, 1H), 7.27 (t, J=54.2 Hz, 1H), 4.90-4.72 (m, 4H), 4.37 (t, J=12.5 Hz, 2H), 3.40 (s, 3H).</p><heading id="h-0653" level="1">Example 587: 2-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-1725" num="1781"><chemistry id="CHEM-US-00714" num="00714"><img id="EMI-C00714" he="39.20mm" wi="45.21mm" file="US20230000833A1-20230105-C00714.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1726" num="1782">The title compound was prepared in a manner analogous to Example 533, using 2-(6-(3-(difluoromethoxy)-4-fluorophenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 60). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 394.1; m/z found, 395 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.32 (s, 1H), 7.80 (s, 1H), 7.69-7.08 (m, 4H), 4.85 (s, 2H), 3.39 (s, 3H), 3.11 (s, 3H), 2.84 (s, 3H).</p><heading id="h-0654" level="1">Example 588: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1727" num="1783"><chemistry id="CHEM-US-00715" num="00715"><img id="EMI-C00715" he="39.20mm" wi="45.21mm" file="US20230000833A1-20230105-C00715.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1728" num="1784">The title compound was prepared in a manner analogous to Example 533, using 2-(6-(3-(difluoromethoxy)-4-fluorophenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 60) and azetidine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 406.1; m/z found 407 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.24-8.16 (m, 1H), 7.44-7.32 (m, 3H), 7.29-7.19 (m, 1H), 6.61 (t, J=73.5 Hz, 1H), 4.50 (s, 2H), 4.34 (t, J=7.7 Hz, 2H), 4.09 (t, J=7.8 Hz, 2H), 3.54 (s, 3H), 2.44-2.28 (m, 2H).</p><heading id="h-0655" level="1">Example 589: 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1729" num="1785"><chemistry id="CHEM-US-00716" num="00716"><img id="EMI-C00716" he="43.60mm" wi="45.21mm" file="US20230000833A1-20230105-C00716.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1730" num="1786">The title compound was prepared in a manner analogous to Example 533, using 2-(6-(3-(difluoromethoxy)-4-fluorophenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 60) and 3-fluoroazetidine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 424.1; m/z found, 425 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.33 (s, 1H), 7.80 (s, 1H), 7.70-7.03 (m, 4H), 5.47 (d, J=57.1 Hz, 1H), 4.68 (s, 2H), 4.65-4.55 (m, 1H), 4.48-4.33 (m, 1H), 4.31-4.17 (m, 1H), 4.05-3.89 (m, 1H), 3.39 (s, 3H).</p><heading id="h-0656" level="1">Example 590: 1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1731" num="1787"><chemistry id="CHEM-US-00717" num="00717"><img id="EMI-C00717" he="43.60mm" wi="45.21mm" file="US20230000833A1-20230105-C00717.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1732" num="1788">The title compound was prepared in a manner analogous to Example 533, using 2-(6-(3-(difluoromethoxy)-4-fluorophenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 60) and 3,3-difluoroazetidine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>F<sub>5</sub>N<sub>4</sub>O<sub>3</sub>, 442.1; m/z found, 443 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.33 (s, 1H), 7.80 (s, 1H), 7.68-7.07 (m, 4H), 4.89-4.71 (m, 4H), 4.38 (t, J=12.4 Hz, 2H), 3.40 (s, 3H).</p><heading id="h-0657" level="1">Example 591: 2-[6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-1733" num="1789"><chemistry id="CHEM-US-00718" num="00718"><img id="EMI-C00718" he="39.20mm" wi="46.57mm" file="US20230000833A1-20230105-C00718.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1734" num="1790">The title compound was prepared in a manner analogous to Example 533, using 2-(6-(4-chloro-3-(difluoromethoxy)phenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 65). MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>3</sub>, 410.1; m/z found, 411[M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.21 (d, J=1.4 Hz, 1H), 7.51 (d, J=8.2 Hz, 1H), 7.39 (s, 1H), 7.38-7.32 (m, 1H), 7.30 (d, J=1.4 Hz, 1H), 6.59 (t, J=73.5 Hz, 1H), 4.74 (s, 2H), 3.54 (s, 3H), 3.18 (s, 3H), 2.99 (s, 3H).</p><heading id="h-0658" level="1">Example 592: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-chloro-3-(difluoromethoxy)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1735" num="1791"><chemistry id="CHEM-US-00719" num="00719"><img id="EMI-C00719" he="39.20mm" wi="46.57mm" file="US20230000833A1-20230105-C00719.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1736" num="1792">The title compound was prepared in a manner analogous to Example 533, using 2-(6-(4-chloro-3-(difluoromethoxy)phenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 65) and azetidine. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>3</sub>, 422.1; m/z found, 423 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.35 (s, 1H), 7.81 (s, 1H), 7.71 (d, J=8.3 Hz, 1H), 7.68-7.59 (m, 2H), 7.37 (t, J=65.6 Hz, 1H), 4.60 (s, 2H), 4.28 (t, J=7.5 Hz, 2H), 3.90 (t, J=7.6 Hz, 2H), 3.38 (s, 3H), 2.35-2.22 (m, 2H).</p><heading id="h-0659" level="1">Example 593: 6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1737" num="1793"><chemistry id="CHEM-US-00720" num="00720"><img id="EMI-C00720" he="43.60mm" wi="46.57mm" file="US20230000833A1-20230105-C00720.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1738" num="1794">The title compound was prepared in a manner analogous to Example 533, using 2-(6-(4-chloro-3-(difluoromethoxy)phenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 65) and 3-fluoroazetidine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 440.1; m/z found, 441[M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.36 (s, 1H), 7.82 (s, 1H), 7.71 (d, J=8.3 Hz, 1H), 7.62 (d, J=12.5 Hz, 2H), 7.36 (t, J=65.2 Hz, 1H), 5.46 (d, J=56.8 Hz, 1H), 4.76-4.53 (m, 3H), 4.40 (dd, J=24.4, 10.7 Hz, 1H), 4.33-4.16 (m, 1H), 3.96 (dd, J=24.9, 11.5 Hz, 1H), 3.39 (s, 3H).</p><heading id="h-0660" level="1">Example 594: 6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1739" num="1795"><chemistry id="CHEM-US-00721" num="00721"><img id="EMI-C00721" he="43.60mm" wi="46.57mm" file="US20230000833A1-20230105-C00721.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1740" num="1796">The title compound was prepared in a manner analogous to Example 533, using 2-(6-(4-chloro-3-(difluoromethoxy)phenyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetic acid (Intermediate 65) and 3,3-difluoroazetidine hydrochloride. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>ClF<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 458.1; m/z found, 459 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.36 (s, 1H), 7.82 (s, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.67-7.59 (m, 2H), 7.37 (t, J=64.7 Hz, 1H), 4.91-4.70 (m, 4H), 4.37 (t, J=12.4 Hz, 2H), 3.40 (s, 3H).</p><heading id="h-0661" level="1">Example 595: 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-(fluoromethyl)imidazo[4,5-b]pyridin-2-one</heading><p id="p-1741" num="1797"><chemistry id="CHEM-US-00722" num="00722"><img id="EMI-C00722" he="39.62mm" wi="45.21mm" file="US20230000833A1-20230105-C00722.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1742" num="1798">The title compound was prepared in a manner analogous to Example 534, using 1-[2-(azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one (Example 579). MS (ESI): mass calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 390.1; m/z found, 391.2 [M+H]<sup>+</sup>.</p><heading id="h-0662" level="1">Example 596: 2-(3-(Fluoromethyl)-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl1-N,N-dimethyl-acetamide</heading><p id="p-1743" num="1799"><chemistry id="CHEM-US-00723" num="00723"><img id="EMI-C00723" he="35.90mm" wi="47.41mm" file="US20230000833A1-20230105-C00723.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1744" num="1800">The title compound was prepared in a manner analogous to Example 534 using N,N-dimethyl-2-[2-oxo-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide (Example 26) in place of 1-[2-(azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 323). MS (ESI): mass calcd. for C<sub>16</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 402.1; m/z found, 403.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>-d) &#x3b4; 8.36 (d, J=1.9 Hz, 1H), 7.46-7.42 (m, 1H), 7.41 (d, J=1.9 Hz, 1H), 7.24-7.20 (m, 1H), 6.11 (d, J=52.6 Hz, 2H), 4.75 (s, 2H), 3.20 (s, 3H), 3.02 (s, 3H).</p><heading id="h-0663" level="1">Example 597: 1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1745" num="1801"><chemistry id="CHEM-US-00724" num="00724"><img id="EMI-C00724" he="45.80mm" wi="47.41mm" file="US20230000833A1-20230105-C00724.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1746" num="1802">The title compound was prepared in a manner analogous to Example 534, using 1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one (Example 578). MS (ESI): mass calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>S, 432.1; m/z found, 433.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.49 (d, J=1.9 Hz, 1H), 7.97 (d, J=2.0 Hz, 1H), 7.80-7.78 (m, 1H), 7.65-7.62 (m, 1H), 6.03 (d, J=53.3 Hz, 2H), 5.57-5.51 (m, 0.5H), 5.47-5.41 (m, 0.5H), 4.79-4.61 (m, 3H), 4.49-4.37 (m, 1H), 4.34-4.23 (m, 1H), 4.05-3.94 (m, 1H).</p><heading id="h-0664" level="1">Example 598: 3-(Fluoromethyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one</heading><p id="p-1747" num="1803"><chemistry id="CHEM-US-00725" num="00725"><img id="EMI-C00725" he="40.98mm" wi="47.41mm" file="US20230000833A1-20230105-C00725.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1748" num="1804">Step A: 1-(2-Oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 26, Method A, using pyrrolidine in place of dimethylamine hydrochloride in Step C. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 396.1; m/z found, 397.1 [M+H]<sup>+</sup>.</p><p id="p-1749" num="1805">Step B: 3-(Fluoromethyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 534 using 1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 428.1; m/z found, 429.1 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.35 (d, J=1.9 Hz, 1H), 7.46 (d, J=1.9 Hz, 1H), 7.45-7.42 (m, 1H), 7.24-7.21 (m, 1H), 6.11 (d, J=52.5 Hz, 2H), 4.68 (s, 2H), 3.64 (t, J=6.8 Hz, 2H), 3.53 (t, J=7.0 Hz, 2H), 2.09 (p, J=6.9 Hz, 2H), 1.94 (p, J=6.9 Hz, 2H).</p><heading id="h-0665" level="1">Example 599: 2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-(fluoromethyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide</heading><p id="p-1750" num="1806"><chemistry id="CHEM-US-00726" num="00726"><img id="EMI-C00726" he="35.90mm" wi="45.21mm" file="US20230000833A1-20230105-C00726.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1751" num="1807">Step A: 2-[6-(2,4-Difluoro-3-methyl-phenyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide. The title compound was prepared in a manner analogous to Example 26 using (2,4-difluoro-3-methylphenyl)boronic acid in Step A. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, 346.1; m/z found, 347.2 [M+H]<sup>+</sup>.</p><p id="p-1752" num="1808">Step B: 2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-(fluoromethyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide. The title compound was prepared in a manner analogous to Example 534. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 378.1; m/z found, 379.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; 8.20-8.17 (m, 1H), 7.79-7.76 (m, 1H), 7.47-7.39 (m, 1H), 7.25-7.18 (m, 1H), 6.05 (d, J=53.3 Hz, 2H), 4.89 (s, 2H), 3.09 (s, 3H), 2.84 (s, 3H), 2.25-2.22 (m, 3H).</p><heading id="h-0666" level="1">Example 600: 6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethypimidazo[4,5-b]pyridin-2-one</heading><p id="p-1753" num="1809"><chemistry id="CHEM-US-00727" num="00727"><img id="EMI-C00727" he="45.80mm" wi="45.21mm" file="US20230000833A1-20230105-C00727.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1754" num="1810">Step A: 6-(2,4-Difluoro-3-methylphenyl)-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 25, using 1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 40) in place of 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (Intermediate 38) and (2,4-difluoro-3-methylphenyl)boronic acid in place of (3-(trifluoromethyl)phenyl)boronic acid in Step A.</p><p id="p-1755" num="1811">Step B: 6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)imidazo[4,5-b]pyridin-2-one. The title compound was prepared in a manner analogous to Example 534. MS (ESI): mass calcd. for C<sub>19</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 408.1; m/z found, 409.2 [M+H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3b4; 8.24-8.21 (m, 1H), 7.51-7.49 (m, 1H), 7.25-7.19 (m, 1H), 6.99-6.93 (m, 1H), 6.12 (d, J=52.7 Hz, 2H), 5.47-5.41 (m, 0.5H), 5.36-5.29 (m, 0.5H), 4.69-4.57 (m, 2H), 4.53-4.32 (m, 3H), 4.26-4.15 (m, 1H), 2.30-2.27 (m, 3H).</p><p id="p-1756" num="1812">Examples 601-612 were prepared in a manner described in the Examples above.</p><heading id="h-0667" level="1">Example 601: 1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1757" num="1813"><chemistry id="CHEM-US-00728" num="00728"><img id="EMI-C00728" he="28.36mm" wi="53.85mm" file="US20230000833A1-20230105-C00728.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1758" num="1814">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>, 339.2; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0668" level="1">Example 602: 6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1759" num="1815"><chemistry id="CHEM-US-00729" num="00729"><img id="EMI-C00729" he="33.53mm" wi="44.37mm" file="US20230000833A1-20230105-C00729.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1760" num="1816">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S, 365.1; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0669" level="1">Example 603: 1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1761" num="1817"><chemistry id="CHEM-US-00730" num="00730"><img id="EMI-C00730" he="28.36mm" wi="53.85mm" file="US20230000833A1-20230105-C00730.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1762" num="1818">MS (ESI): mass calcd. for C<sub>20</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>, 353.2; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0670" level="1">Example 604: 1-Isobutyl-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1763" num="1819"><chemistry id="CHEM-US-00731" num="00731"><img id="EMI-C00731" he="24.30mm" wi="50.97mm" file="US20230000833A1-20230105-C00731.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1764" num="1820">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>, 297.1; m/z found, 39676416 [M+H]<sup>+</sup>.</p><heading id="h-0671" level="1">Example 605: 6-(2-Ethoxyphenyl)-1-[(3-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1765" num="1821"><chemistry id="CHEM-US-00732" num="00732"><img id="EMI-C00732" he="32.68mm" wi="50.46mm" file="US20230000833A1-20230105-C00732.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1766" num="1822">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>, 375.2; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0672" level="1">Example 606: 6-(2-Ethoxyphenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1767" num="1823"><chemistry id="CHEM-US-00733" num="00733"><img id="EMI-C00733" he="29.97mm" wi="54.02mm" file="US20230000833A1-20230105-C00733.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1768" num="1824">MS (ESI): mass calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>, 363.1; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0673" level="1">Example 607: N-Cyclopropyl-2-[6-(2-ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide</heading><p id="p-1769" num="1825"><chemistry id="CHEM-US-00734" num="00734"><img id="EMI-C00734" he="36.41mm" wi="45.21mm" file="US20230000833A1-20230105-C00734.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1770" num="1826">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>3</sub>, 370.1; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0674" level="1">Example 608: 2-[[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile</heading><p id="p-1771" num="1827"><chemistry id="CHEM-US-00735" num="00735"><img id="EMI-C00735" he="29.21mm" wi="57.91mm" file="US20230000833A1-20230105-C00735.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1772" num="1828">MS (ESI): mass calcd. for C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>, 370.1; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0675" level="1">Example 609: 1-(3,3-Dimethyl-2-oxo-butyl)-6-(3-fluoro-4-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1773" num="1829"><chemistry id="CHEM-US-00736" num="00736"><img id="EMI-C00736" he="28.36mm" wi="53.85mm" file="US20230000833A1-20230105-C00736.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1774" num="1830">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>3</sub>, 357.1; m/z found, 39686582 [M+H]<sup>+</sup>.</p><heading id="h-0676" level="1">Example 610: 2-[6-(3,5-Difluorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide</heading><p id="p-1775" num="1831"><chemistry id="CHEM-US-00737" num="00737"><img id="EMI-C00737" he="45.80mm" wi="45.21mm" file="US20230000833A1-20230105-C00737.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1776" num="1832">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub>, 362.1; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0677" level="1">Example 611: 1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one</heading><p id="p-1777" num="1833"><chemistry id="CHEM-US-00738" num="00738"><img id="EMI-C00738" he="28.62mm" wi="43.86mm" file="US20230000833A1-20230105-C00738.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1778" num="1834">MS (ESI): mass calcd. for C<sub>19</sub>H<sub>18</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>, 377.1; m/z found, [M+H]<sup>+</sup>.</p><heading id="h-0678" level="1">Example 612: 2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide</heading><p id="p-1779" num="1835"><chemistry id="CHEM-US-00739" num="00739"><img id="EMI-C00739" he="45.80mm" wi="45.21mm" file="US20230000833A1-20230105-C00739.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1780" num="1836">MS (ESI): mass calcd. for C<sub>17</sub>H<sub>16</sub>ClFN<sub>4</sub>O<sub>3</sub>, 378.1; m/z found, [M+H]<sup>+</sup>.</p><p id="p-1781" num="1837">Biological Assays</p><p id="p-1782" num="1838">Effects of Test Articles on Cloned Human NR1/NR2B Ion Channels Expressed in Mammalian Cells</p><p id="p-1783" num="1839">NMDA receptors are ion channels that are highly permeable to Ca<sup>2+</sup> ions, rendering it possible to monitor NMDA receptor function using cell-based calcium flux assay. In this assay, co-agonists glutamate and glycine are added to cells heterologously expressing human GluN1/GluN2B NMDA receptors to initiate cellular Ca<sup>2+</sup> influx. The time course of the changes in intracellular calcium is measured using a fluorescent dye and a FLIPR (Fluorometric Imaging Plate Reader) device.</p><p id="p-1784" num="1840">Twenty four hours before measurements, the expression of the NMDA receptors in the stable cell line is induced with Tet-On inducible system in the presence of a non-selective NMDA receptor blocker. On the day of the experiment, cell culture media is carefully washed and the cells are loaded with Calcium 5 Dye Kit (Molecular Devices) in dye loading buffer containing 137 mM NaCl, 4 mM KCl, 2 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2 </sub>(standard assay) or 1.5 mM MgCl<sub>2 </sub>(HTS assay), 10 mM HEPES and 5 mM D-glucose; pH 7.4. After 1 h incubation at the room temperature, the dye is washed away with the assay buffer (137 mM NaCl (standard assay) or 150 mM (HTS assay), 4 mM KCl (standard assay) or 3 mM (HTS assay), 2 mM CaCl<sub>2</sub>, 0.01 mM EDTA, 10 mM HEPES and 5 mM D-glucose; pH 7.4) In the FLIPR TETRA reader, various concentrations of the test compounds are added to the cells for 5 min while fluorescence is monitored to detect potential agonist activity. Next, co-agonists, glutamate and glycine are added for another 5 minutes. The concentration of glutamate corresponding to &#x2dc;EC<sub>40 </sub>(standard assay) or EC<sub>40 </sub>(HTS assay) is used to maximize the assay's signal window and ability to detect NMDA receptor antagonists and negative allosteric modulators. A saturating concentration (10 &#x3bc;M) of glycine is also present in the assay. A non-selective NMDA receptor antagonist, (+)MK-801 is used as a positive control for antagonist activity. The fluorescent signal in the presence of test compounds is quantified and normalized to the signal defined by the appropriate control wells.</p><p id="p-1785" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="21pt" align="center"/><colspec colname="2" colwidth="161pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 3</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry/><entry>NR2B</entry><entry>NR2B</entry></row><row><entry/><entry/><entry>IC<sub>50</sub></entry><entry>IC<sub>50</sub></entry></row><row><entry/><entry/><entry>(&#x3bc;M)</entry><entry>(&#x3bc;M)</entry></row><row><entry/><entry/><entry>standard</entry><entry>HTS</entry></row><row><entry>Ex #</entry><entry>Compound Name</entry><entry>assay</entry><entry>assay</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="21pt" align="char" char="."/><colspec colname="2" colwidth="161pt" align="left"/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry>1</entry><entry>6-(4-Methoxyphenyl)-1-(2-morpholino-2-oxo-</entry><entry>2.740</entry><entry/></row><row><entry/><entry>ethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>2</entry><entry>6-(4-Fluoro-2-methyl-phenyl)-1-(2-methoxyethyl)-</entry><entry/><entry>2.062</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>3</entry><entry>N-Ethyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-</entry><entry>0.088</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>4</entry><entry>(S*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-</entry><entry>0.320</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>5</entry><entry>(R*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-</entry><entry>NT</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>6</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(2-</entry><entry>0.048</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>7</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-4-</entry><entry>6.770</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>8</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(5-</entry><entry>0.104</entry><entry/></row><row><entry/><entry>methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>9</entry><entry>2-[6-(5-Chloro-2-thienyl)-3-methyl-2-oxo-</entry><entry>0.005</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>10</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-1-[2-(3-</entry><entry>0.010</entry><entry/></row><row><entry/><entry>fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>11</entry><entry>1-[(5-Methylisoxazol-3-yl)methyl]-6-phenyl-3H-</entry><entry>0.088</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>12</entry><entry>6-(4-Fluorophenyl)-1-[(5-methylisoxazol-3-</entry><entry>0.029</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>13</entry><entry>6-(4-Fluorophenyl)-1-[(5-methyl-1,3,4-oxadiazol-2-</entry><entry>0.076</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>14</entry><entry>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(4-</entry><entry>0.097</entry><entry/></row><row><entry/><entry>methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>15</entry><entry>6-(4-Fluorophenyl)-1-[(1-methylpyrazol-4-</entry><entry>0.204</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>16</entry><entry>1-[(1,5-Dimethylpyrazol-3-yl)methyl]-6-(4-</entry><entry>8.900</entry><entry/></row><row><entry/><entry>fluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>17</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[3-</entry><entry>0.146</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>18</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-3-methyl-6-[3-</entry><entry>0.700</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>19</entry><entry>1-[(5-Methylisoxazol-3-yl)methyl]-6-[3-</entry><entry>0.124</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>20</entry><entry>N-Cyclopropyl-2-[2-oxo-6-[3-</entry><entry>0.022</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>21</entry><entry>1-[(3-Chlorophenyl)methyl]-6-[3-</entry><entry>1.340</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>22</entry><entry>1-[(2-Methoxy-3-pyridyl)methyl]-6-[3-</entry><entry>26.699</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>23</entry><entry>1-(Pyrimidin-4-ylmethyl)-6-[3-</entry><entry>0.220</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>24</entry><entry>(R/S)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3-</entry><entry>0.127</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>25</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-</entry><entry>0.070</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>26</entry><entry>N,N-Dimethyl-2-[2-oxo-6-[5-(trifluoromethyl)-2-</entry><entry>0.012</entry><entry/></row><row><entry/><entry>thienyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>27</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-</entry><entry>0.031</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>28</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetamide;</entry><entry/><entry/></row><row><entry>29</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-5-</entry><entry>0.396</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>30</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-oxobutyl)-</entry><entry>0.011</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>31</entry><entry>(R/S)-1-(2-Cyclopropyl-2-hydroxy-ethyl)-6-[3-</entry><entry>0.151</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>32</entry><entry>1-[(2-Oxo-1H-pyridin-3-yl)methyl]-6-[3-</entry><entry>8.329</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>33</entry><entry>(R/S)-6-(4-Fluoro-2-methyl-phenyl)-3-methyl-1-</entry><entry>1.230</entry><entry/></row><row><entry/><entry>(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>34</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>0.065</entry><entry/></row><row><entry/><entry>6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>35</entry><entry>6-(4-Methoxyphenyl)-1-(2-oxo-2-pyrrolidin-1-yl-</entry><entry/><entry>2.139</entry></row><row><entry/><entry>ethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>36</entry><entry>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-</entry><entry>0.159</entry><entry/></row><row><entry/><entry>oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>37</entry><entry>2-[6-(2-Chloro-4-methoxy-phenyl)-2-oxo-3H-</entry><entry/><entry>1.376</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>38</entry><entry>N-Cyclopropyl-2-[6-(4-methoxyphenyl)-2-oxo-3H-</entry><entry/><entry>1.013</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>39</entry><entry>N-Cyclopropyl-2-[6-(3,5-dimethylphenyl)-2-oxo-</entry><entry/><entry>1.026</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>40</entry><entry>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-</entry><entry/><entry>1.822</entry></row><row><entry/><entry>oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>41</entry><entry>N-Cyclopropyl-2-[6-(4-methoxyphenyl)-2-oxo-3H-</entry><entry/><entry>8.718</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</entry><entry/><entry/></row><row><entry>42</entry><entry>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-3-</entry><entry/><entry>2.707</entry></row><row><entry/><entry>methyl-2-oxo-imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetamide;</entry><entry/><entry/></row><row><entry>43</entry><entry>(R*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-</entry><entry/><entry>3.487</entry></row><row><entry/><entry>hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>44</entry><entry>(S*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-</entry><entry/><entry>0.325</entry></row><row><entry/><entry>hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>45</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(3-</entry><entry>0.038</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>46</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(4-</entry><entry>0.600</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>47</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrazin-</entry><entry>0.113</entry><entry/></row><row><entry/><entry>2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>48</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.072</entry><entry/></row><row><entry/><entry>(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>49</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.486</entry><entry/></row><row><entry/><entry>(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>50</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.009</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>51</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(3-</entry><entry>22.600</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>52</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(4-</entry><entry>3.330</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>53</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(2-</entry><entry>1.400</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>54</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-5-</entry><entry>0.610</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>55</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyrazin-2-</entry><entry>3.030</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>56</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-2-</entry><entry>8.710</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>57</entry><entry>6-(3-Fluorophenyl)-3-methyl-1-(pyridazin-3-</entry><entry>0.200</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>58</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(4-</entry><entry>1.900</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>59</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(3-</entry><entry>0.246</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>60</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-5-</entry><entry>0.450</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>61</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyridazin-3-</entry><entry>0.223</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>62</entry><entry>6-(3,4-difluorophenyl)-3-methyl-1-(2-</entry><entry>2.000</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>63</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrazin-2-</entry><entry>2.300</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>64</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-2-</entry><entry>3.590</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>65</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.810</entry><entry/></row><row><entry/><entry>(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>66</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(4-</entry><entry>0.725</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>67</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.009</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>68</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(2-</entry><entry>0.310</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>69</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.033</entry><entry/></row><row><entry/><entry>(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>70</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-4-</entry><entry>2.210</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>71</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.278</entry><entry/></row><row><entry/><entry>(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>72</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.482</entry><entry/></row><row><entry/><entry>(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>73</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(5-methyl-</entry><entry>0.314</entry><entry/></row><row><entry/><entry>1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>74</entry><entry>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[3-</entry><entry>0.057</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>75</entry><entry>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-</entry><entry>0.093</entry><entry/></row><row><entry/><entry>yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>76</entry><entry>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-</entry><entry>0.218</entry><entry/></row><row><entry/><entry>yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>77</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(3-methyl-</entry><entry>0.457</entry><entry/></row><row><entry/><entry>1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>78</entry><entry>N,N-Dimethyl-2-[3-methyl-6-(5-methyl-2-thienyl)-2-</entry><entry>0.043</entry><entry/></row><row><entry/><entry>oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>79</entry><entry>2-[6-(5-Ethyl-2-thienyl)-3-methyl-2-oxo-</entry><entry>0.031</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>80</entry><entry>N,N-Dimethyl-2-[3-methyl-6-(4-methyl-2-thienyl)-2-</entry><entry>0.030</entry><entry/></row><row><entry/><entry>oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>81</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-fluoro-2-</entry><entry>0.031</entry><entry/></row><row><entry/><entry>thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>82</entry><entry>2-[6-(5-Fluoro-2-thienyl)-3-methyl-2-oxo-</entry><entry>0.154</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>83</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(5-</entry><entry>0.033</entry><entry/></row><row><entry/><entry>fluoro-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>84</entry><entry>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[5-</entry><entry>0.030</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>85</entry><entry>6-(5-Fluoro-2-thienyl)-3-methyl-1-(pyridazin-3-</entry><entry>0.157</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>86</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>1.600</entry><entry/></row><row><entry/><entry>6-(4-methylthiazol-2-yl)imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>87</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-ethyl-2-</entry><entry>0.021</entry><entry/></row><row><entry/><entry>thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>88</entry><entry>6-(5-Ethyl-2-thienyl)-1-[2-(3-fluoroazetidin-1-yl)-2-</entry><entry>0.020</entry><entry/></row><row><entry/><entry>oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>89</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-</entry><entry>0.549</entry><entry/></row><row><entry/><entry>(hydroxymethyl)-2-thienyl]-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>90</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-</entry><entry>0.915</entry><entry/></row><row><entry/><entry>(hydroxymethyl)-2-thienyl]-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>91</entry><entry>2-[6-[5-(Hydroxymethyl)-2-thienyl]-3-methyl-2-oxo-</entry><entry>1.700</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>92</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>0.249</entry><entry/></row><row><entry/><entry>6-[2-(trifluoromethyl)-3-thienyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>93</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-</entry><entry>0.006</entry><entry/></row><row><entry/><entry>(difluoromethyl)-2-thienyl]-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>94</entry><entry>2-[6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-2-oxo-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>95</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-</entry><entry>0.096</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>96</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-</entry><entry>0.522</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetamide;</entry><entry/><entry/></row><row><entry>97</entry><entry>2-[6-[5-(Difluoromethyl)-3-thienyl]-3-methyl-2-oxo-</entry><entry>0.015</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>98</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-</entry><entry>0.013</entry><entry/></row><row><entry/><entry>(difluoromethyl)-3-thienyl]-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>99</entry><entry>6-[5-(Difluoromethyl)-3-thienyl]-1-[2-(3-</entry><entry>0.007</entry><entry/></row><row><entry/><entry>fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>100</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-</entry><entry>0.033</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>101</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-</entry><entry>0.019</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetamide;</entry><entry/><entry/></row><row><entry>102</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-</entry><entry>0.018</entry><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>103</entry><entry>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[5-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>104</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-</entry><entry>0.048</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>105</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-cyclopropyl-</entry><entry>0.081</entry><entry/></row><row><entry/><entry>2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>106</entry><entry>6-(5-Cyclopropyl-2-thienyl)-1-[2-(3-fluoroazetidin-</entry><entry>0.039</entry><entry/></row><row><entry/><entry>1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>107</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-</entry><entry>0.087</entry><entry/></row><row><entry/><entry>(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>108</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-</entry><entry>0.047</entry><entry/></row><row><entry/><entry>(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>109</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>0.040</entry><entry/></row><row><entry/><entry>6-[2-(trifluoromethyl)thiazol-4-yl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>110</entry><entry>2-[6-(5-Cyclopropyl-2-thienyl)-3-methyl-2-oxo-</entry><entry>0.040</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>111</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-</entry><entry>0.037</entry><entry/></row><row><entry/><entry>(1,1,2,2,2-pentafluoroethyl)-2-thienyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>112</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(2-</entry><entry>5.104</entry><entry/></row><row><entry/><entry>methylthiazol-5-yl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>113</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>5.359</entry><entry/></row><row><entry/><entry>6-(2-methylthiazol-5-yl)imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>114</entry><entry>N,N-Dimethyl-2-[3-methyl-6-(2-methylthiazol-5-yl)-</entry><entry>11.700</entry><entry/></row><row><entry/><entry>2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>115</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-</entry><entry>0.820</entry><entry/></row><row><entry/><entry>(trifluoromethyl)thiazol-5-yl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>116</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>0.705</entry><entry/></row><row><entry/><entry>6-[2-(trifluoromethyl)thiazol-5-yl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>117</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-</entry><entry>0.038</entry><entry/></row><row><entry/><entry>(difluoromethyl)-2-thienyl]-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>118</entry><entry>6-[4-(Difluoromethyl)-2-thienyl]-1-[2-(3-</entry><entry>0.020</entry><entry/></row><row><entry/><entry>fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>119</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-</entry><entry>NT</entry><entry/></row><row><entry/><entry>(trifluoromethyl)thiazol-5-yl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>120</entry><entry>1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-</entry><entry>0.010</entry><entry/></row><row><entry/><entry>(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one-7-D;</entry><entry/><entry/></row><row><entry>121</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-</entry><entry>2.960</entry><entry/></row><row><entry/><entry>(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>122</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-</entry><entry>1.220</entry><entry/></row><row><entry/><entry>(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>123</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>1.820</entry><entry/></row><row><entry/><entry>6-[5-(trideuteriomethoxymethyl)-2-</entry><entry/><entry/></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>124</entry><entry>1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-</entry><entry>NT</entry><entry/></row><row><entry/><entry>(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one-7-T;</entry><entry/><entry/></row><row><entry>125</entry><entry>1-[(5-Methylisoxazol-3-yl)methyl]-6-(4-methyl-2-</entry><entry>0.082</entry><entry/></row><row><entry/><entry>thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>126</entry><entry>1-[(5-Methylisoxazol-3-yl)methyl]-6-(o-tolyl)-3H-</entry><entry>0.038</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>127</entry><entry>1-[(3-Methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(4-</entry><entry>0.095</entry><entry/></row><row><entry/><entry>methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>128</entry><entry>6-(4-Fluorophenyl)-1-[(1-methylpyrazol-3-</entry><entry>5.159</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>129</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(1-methylpyrazol-</entry><entry>0.394</entry><entry/></row><row><entry/><entry>3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>130</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-1-[(1-methylpyrazol-</entry><entry>4.726</entry><entry/></row><row><entry/><entry>3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>131</entry><entry>6-(3,4-Difluorophenyl)-1-[(1-methylpyrazol-3-</entry><entry>3.560</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>132</entry><entry>6-(2,4-Difluorophenyl)-1-[(1-methylpyrazol-3-</entry><entry>6.759</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>133</entry><entry>(R/S)-3-methyl-1-(oxetan-2-ylmethyl)-6-[3-</entry><entry>0.211</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>134</entry><entry>Ethyl 2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-</entry><entry>0.035</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetate;</entry><entry/><entry/></row><row><entry>135</entry><entry>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-</entry><entry>5.999</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetic acid;</entry><entry/><entry/></row><row><entry>136</entry><entry>Ethyl 2-[3-methyl-2-oxo-6-[3-</entry><entry>0.159</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetate;</entry><entry/><entry/></row><row><entry>137</entry><entry>2-[3-Methyl-2-oxo-6-[3-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetic acid;</entry><entry/><entry/></row><row><entry>138</entry><entry>1-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry><entry>0.089</entry><entry/></row><row><entry/><entry>methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>139</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.084</entry><entry/></row><row><entry/><entry>(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>140</entry><entry>6-(4-Fluorophenyl)-1-[(3-methyl-1,2,4-oxadiazol-5-</entry><entry>0.105</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>141</entry><entry>6-(4-Fluorophenyl)-1-[(1-methyl-1,2,4-triazol-3-</entry><entry>1.181</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>142</entry><entry>6-(4-Fluorophenyl)-1-[(1-methyltriazol-4-yl)methyl]-</entry><entry>0.208</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>143</entry><entry>6-(3,4-Difluorophenyl)-1-[(3-methyl-1,2,4-</entry><entry>0.075</entry><entry/></row><row><entry/><entry>oxadiazol-5-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>144</entry><entry>6-(3,4-Difluorophenyl)-1-[(5-methyl-1,2,4-</entry><entry>0.107</entry><entry/></row><row><entry/><entry>oxadiazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>145</entry><entry>6-(3,4-Difluorophenyl)-1-[[3-(methoxymethyl)-</entry><entry>1.310</entry><entry/></row><row><entry/><entry>1,2,4-oxadiazol-5-yl]methyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>146</entry><entry>1-(2-Pyrrolidin-1-ylethyl)-6-[3-</entry><entry>0.506</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>147</entry><entry>1-[2-(3-Hydroxyazetidin-1-yl)ethyl]-6-[3-</entry><entry>0.365</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>148</entry><entry>1-[2-(Cyclopropylamino)ethyl]-6-[3-</entry><entry>0.505</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>149</entry><entry>1-[2-(3-Methoxyazetidin-1-yl)ethyl]-6-[3-</entry><entry>0.756</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>150</entry><entry>1-[2-(Cyclobutylamino)ethyl]-6-[3-</entry><entry>0.277</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>151</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-2-methyl-</entry><entry>0.115</entry><entry/></row><row><entry/><entry>phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>152</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(o-tolyl)-3H-</entry><entry>0.127</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>153</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-phenyl-3H-imidazo[4,5-</entry><entry>0.283</entry><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>154</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(m-tolyl)-3H-</entry><entry>0.077</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>155</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[2-(trifluoromethyl)-4-</entry><entry>1.750</entry><entry/></row><row><entry/><entry>pyridyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>156</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-3-methyl-</entry><entry>0.039</entry><entry/></row><row><entry/><entry>phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>157</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(2,6-dimethylphenyl)-</entry><entry>1.970</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>158</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(3-chlorophenyl)-3H-</entry><entry>0.201</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>159</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(3,5-difluorophenyl)-</entry><entry>0.211</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>160</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[3-</entry><entry>0.311</entry><entry/></row><row><entry/><entry>(trifluoromethoxy)phenyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>161</entry><entry>1-[2-(1-Piperidyl)ethyl]-6-[3-</entry><entry>1.430</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>162</entry><entry>1-[2-(4-Fluoro-1-piperidyl)ethyl]-6-[3-</entry><entry>1.100</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>163</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[3-</entry><entry>0.246</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>164</entry><entry>1-[2-(3-Methylpyrrolidin-1-yl)ethyl]-6-[3-</entry><entry>1.220</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>165</entry><entry>1-[2-(4-Hydroxy-1-piperidyl)ethyl]-6-[3-</entry><entry>NT</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>166</entry><entry>1-[2-[3-(Trifluoromethyl)azetidin-1-yl]ethyl]-6-[3-</entry><entry>3.480</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>167</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)ethyl]-6-[3-</entry><entry>0.158</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>168</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[2-methyl-3-</entry><entry>4.230</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>169</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(2,3-dimethylphenyl)-</entry><entry>0.217</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>170</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(3,5-dimethylphenyl)-</entry><entry>0.581</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>171</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-2,3-dimethyl-</entry><entry>0.210</entry><entry/></row><row><entry/><entry>phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>172</entry><entry>1-[2-(Azetidin-1-yl)ethyl]-6-[2-methyl-5-</entry><entry>0.326</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>173</entry><entry>6-(3,5-Difluorophenyl)-1-[2-(2-</entry><entry>4.260</entry><entry/></row><row><entry/><entry>hydroxyethylamino)ethyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>174</entry><entry>6-(3,5-Difluorophenyl)-1-(2-pyrrolidin-1-ylethyl)-</entry><entry>1.248</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>175</entry><entry>6-(3,5-Difluorophenyl)-1-[2-(3-hydroxypyrrolidin-1-</entry><entry>2.108</entry><entry/></row><row><entry/><entry>yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>176</entry><entry>6-(3,5-Difluorophenyl)-1-[2-(3-methoxypyrrolidin-1-</entry><entry>4.368</entry><entry/></row><row><entry/><entry>yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>177</entry><entry>6-(4-Fluoro-2-methyl-phenyl)-1-(2-pyrrolidin-1-</entry><entry>0.502</entry><entry/></row><row><entry/><entry>ylethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>178</entry><entry>6-(2,6-Dimethylphenyl)-1-(2-pyrrolidin-1-ylethyl)-</entry><entry>20.701</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>179</entry><entry>6-(o-Tolyl)-1-(2-pyrrolidin-1-ylethyl)-3H-</entry><entry>0.707</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>180</entry><entry>6-Phenyl-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-</entry><entry>0.539</entry><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>181</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[2-methyl-3-</entry><entry>9.350</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>182</entry><entry>6-(2,3-Dimethylphenyl)-1-[2-(3-fluoroazetidin-1-</entry><entry>1.740</entry><entry/></row><row><entry/><entry>yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>183</entry><entry>6-(3,5-Dimethylphenyl)-1-[2-(3-fluoroazetidin-1-</entry><entry>2.080</entry><entry/></row><row><entry/><entry>yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>184</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(4-fluoro-2,3-</entry><entry>2.570</entry><entry/></row><row><entry/><entry>dimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>185</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[2-methyl-5-</entry><entry>2.130</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>186</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(o-tolyl)-3H-</entry><entry>1.340</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>187</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(4-fluoro-2-</entry><entry>1.190</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>188</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-phenyl-3H-</entry><entry>1.435</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>189</entry><entry>6-(3,5-Difluorophenyl)-1-[2-(propylamino)ethyl]-</entry><entry>2.570</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>190</entry><entry>N-Cyclobutyl-2-[2-oxo-6-[3-</entry><entry>0.070</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>191</entry><entry>1-[2-(3-Methoxyazetidin-1-yl)-2-oxo-ethyl]-6-[3-</entry><entry>0.132</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>192</entry><entry>N-(Oxetan-3-yl)-2-[2-oxo-6-[3-</entry><entry>0.052</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>193</entry><entry>1-[2-(4-Methylpiperazin-1-yl)-2-oxo-ethyl]-6-[3-</entry><entry>0.587</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>194</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-</entry><entry>0.047</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>195</entry><entry>N-(3,3-Difluorocyclobutyl)-2-[2-oxo-6-[3-</entry><entry>0.007</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>196</entry><entry>1-[2-(3,3-Difluoropyrrolidin-1-yl)-2-oxo-ethyl]-3-</entry><entry>0.182</entry><entry/></row><row><entry/><entry>methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>197</entry><entry>3-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[3-</entry><entry>0.205</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>198</entry><entry>N-(3,3-Difluoro-1-methyl-cyclobutyl)-2-[3-methyl-2-</entry><entry>5.010</entry><entry/></row><row><entry/><entry>oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>199</entry><entry>N-(3-Methyloxetan-3-yl)-2-[3-methyl-2-oxo-6-[3-</entry><entry>2.660</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetamide;</entry><entry/><entry/></row><row><entry>200</entry><entry>N-(3,3-Difluorocyclobutyl)-2-[3-methyl-2-oxo-6-[3-</entry><entry>0.174</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetamide;</entry><entry/><entry/></row><row><entry>201</entry><entry>1-(2-Oxo-2-pyrrolidin-1-yl-ethyl)-6-[3-</entry><entry>0.033</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>202</entry><entry>(R/S)-N-Cyclopropyl-2-[2-oxo-6-[3-</entry><entry>7.318</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]propanamide;</entry><entry/><entry/></row><row><entry>203</entry><entry>(R/S)-1-[2-(Azetidin-1-yl)-1-methyl-2-oxo-ethyl]-6-</entry><entry>1.102</entry><entry/></row><row><entry/><entry>[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>204</entry><entry>1-(2-Morpholino-2-oxo-ethyl)-6-[3-</entry><entry>0.037</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>205</entry><entry>N-Cyclopentyl-2-[2-oxo-6-[3-</entry><entry>0.523</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>206</entry><entry>1-[2-Oxo-2-(1-piperidyl)ethyl]-6-[3-</entry><entry>0.163</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>207</entry><entry>1-[2-(2,6-Diazaspiro[3.3]heptan-6-yl)-2-oxo-ethyl]-</entry><entry>0.453</entry><entry/></row><row><entry/><entry>6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>208</entry><entry>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-(2-pyridyl)acetamide;</entry><entry/><entry/></row><row><entry>209</entry><entry>N-(3,3-Difluoro-1-methyl-cyclobutyl)-2-[2-oxo-6-[3-</entry><entry>0.443</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>210</entry><entry>1-[(6-Methoxy-3-pyridyl)methyl]-6-[3-</entry><entry>1.620</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>211</entry><entry>1-(Cyclopropylmethyl)-6-[3-</entry><entry>0.115</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>212</entry><entry>3-[[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-</entry><entry>0.123</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>213</entry><entry>2-[[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-</entry><entry>0.375</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>214</entry><entry>1-[2-Oxo-2-(2-thienyl)ethyl]-6-[3-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>215</entry><entry>1-(2-Oxo-2-thiazol-2-yl-ethyl)-6-[3-</entry><entry>0.365</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>216</entry><entry>(R/S)-1-(Oxetan-2-ylmethyl)-6-[3-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>217</entry><entry>(R/S)-1-(Morpholin-2-ylmethyl)-6-[3-</entry><entry>6.489</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>218</entry><entry>(R/S)-1-(Tetrahydropyran-2-ylmethyl)-6-[3-</entry><entry>0.552</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>219</entry><entry>6-[3-(Trifluoromethyl)phenyl]-1-[[4-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]methyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>220</entry><entry>1-[(3-Fluoro-4-methoxy-phenyl)methyl]-6-[3-</entry><entry>1.650</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>221</entry><entry>1-[(4-Fluoro-3-methyl-phenyl)methyl]-6-[3-</entry><entry>8.714</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>222</entry><entry>1-[(3-Fluorophenyl)methyl]-6-[3-</entry><entry>0.479</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>223</entry><entry>(R*)-1-(Oxetan-2-ylmethyl)-6-[3-</entry><entry>0.036</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>224</entry><entry>(S*)-1-(Oxetan-2-ylmethyl)-6-[3-</entry><entry>0.054</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>225</entry><entry>(R/S)-1-[(2,2-Difluorocyclopropyl)methyl]-6-[3-</entry><entry>0.400</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>226</entry><entry>1-[(3-Fluorooxetan-3-yl)methyl]-6-[3-</entry><entry>0.800</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>227</entry><entry>1-(Pyrimidin-2-ylmethyl)-6-[3-</entry><entry>0.096</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>228</entry><entry>1-(2-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-</entry><entry>0.083</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>229</entry><entry>1-(4-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-</entry><entry>0.194</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>230</entry><entry>1-(3-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>231</entry><entry>1-[(2-Methylpyrimidin-5-yl)methyl]-6-[3-</entry><entry>0.094</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>232</entry><entry>1-(Pyridazin-3-ylmethyl)-6-[3-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>233</entry><entry>1-[(3-Methoxy-2-pyridyl)methyl]-6-[3-</entry><entry>2.825</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>234</entry><entry>1-[(3-Fluoro-5-methyl-2-pyridyl)methyl]-6-[3-</entry><entry>1.980</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>235</entry><entry>1-[(6-Methyl-3-pyridyl)methyl]-6-[3-</entry><entry>0.256</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>236</entry><entry>1-(2H-Tetrazol-5-ylmethyl)-6-[3-</entry><entry>&#x3e;5</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>237</entry><entry>1-[Difluoro(3-pyridyl)methyl]-6-[3-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>238</entry><entry>1-[(6-Fluoro-3-pyridyl)methyl]-6-[3-</entry><entry>0.088</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>239</entry><entry>1-(2-Cyclopropyl-2-oxo-ethyl)-6-[3-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>240</entry><entry>1-(2-Oxobutyl)-6-[3-(trifluoromethyl)phenyl]-3H-</entry><entry>0.022</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>241</entry><entry>1-(3-Methyl-2-oxo-butyl)-6-[3-</entry><entry>0.093</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>242</entry><entry>1-[(5-Methyl-3-pyridyl)methyl]-6-[3-</entry><entry>0.150</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>243</entry><entry>1-(Thiadiazol-4-ylmethyl)-6-[3-</entry><entry>0.065</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>244</entry><entry>1-[(6-Oxo-1H-pyridin-3-yl)methyl]-6-[3-</entry><entry>1.890</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>245</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-3-methyl-6-[3-</entry><entry>0.409</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>246</entry><entry>3-Methyl-1-(pyrimidin-4-ylmethyl)-6-[3-</entry><entry>0.349</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>247</entry><entry>3-Methyl-1-(pyrimidin-5-ylmethyl)-6-[3-</entry><entry>0.133</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>248</entry><entry>3-Methyl-1-[(2-methylpyrimidin-4-yl)methyl]-6-[3-</entry><entry>2.050</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>249</entry><entry>3-Methyl-1-(pyrazin-2-ylmethyl)-6-[3-</entry><entry>0.253</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>250</entry><entry>3-Methyl-1-(4-pyridylmethyl)-6-[3-</entry><entry>1.999</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>251</entry><entry>3-Methyl-1-(2-pyridylmethyl)-6-[3-</entry><entry>0.800</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>252</entry><entry>1-[(6-Methoxypyridazin-3-yl)methyl]-6-[3-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>253</entry><entry>1-(Pyrazin-2-ylmethyl)-6-[3-</entry><entry>0.066</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>254</entry><entry>1-[(2-Methylpyrimidin-4-yl)methyl]-6-[3-</entry><entry>0.824</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>255</entry><entry>1-(Pyrimidin-5-ylmethyl)-6-[3-</entry><entry>0.043</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>256</entry><entry>1-[(5-Fluoropyrimidin-2-yl)methyl]-6-[3-</entry><entry>0.134</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>257</entry><entry>6-[3-(Trifluoromethyl)phenyl]-1-[[6-</entry><entry>1.460</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-3-pyridyl]methyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>258</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-6-[3-</entry><entry>0.077</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>259</entry><entry>6-[3-(Trifluoromethyl)phenyl]-1-[[5-</entry><entry>1.030</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-3-pyridyl]methyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>260</entry><entry>6-[3-(Trifluoromethyl)phenyl]-1-[[4-</entry><entry>2.860</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-3-pyridyl]methyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>261</entry><entry>3-Methyl-1-(pyrimidin-2-ylmethyl)-6-[3-</entry><entry>0.573</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>262</entry><entry>1-(2-cyclobutyl-2-oxo-ethyl)-6-[3-</entry><entry>0.308</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>263</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-[3-</entry><entry>0.063</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>264</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-[2-fluoro-3-</entry><entry>0.044</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>265</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-phenyl-3H-</entry><entry>0.397</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>266</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-(4-fluorophenyl)-</entry><entry>0.173</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>267</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-[4-fluoro-3-</entry><entry>0.442</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>268</entry><entry>(R/S)-1-(Azetidin-2-ylmethyl)-6-(2,3-</entry><entry>0.041</entry><entry/></row><row><entry/><entry>dichlorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>269</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-methyl-3-</entry><entry>0.128</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>270</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-methyl-3-</entry><entry>0.115</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>271</entry><entry>(R/S)-6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-</entry><entry>0.046</entry><entry/></row><row><entry/><entry>(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>272</entry><entry>6-(3,4-Difluorophenyl)-1-[(5-methyl-3-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>273</entry><entry>6-(3-Chlorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-</entry><entry>0.096</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>274</entry><entry>6-(3-Fluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-</entry><entry>0.057</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>275</entry><entry>6-(3,4-Difluorophenyl)-1-[(4-methyl-3-</entry><entry>0.009</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>276</entry><entry>6-(3-Fluorophenyl)-1-[(4-methyl-3-pyridyl)methyl]-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>277</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(4-methyl-3-</entry><entry>0.077</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>278</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(4-methyl-3-</entry><entry>0.111</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>279</entry><entry>6-(3,4-Difluorophenyl)-1-(2-pyridylmethyl)-3H-</entry><entry>5.030</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>280</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-</entry><entry>0.576</entry><entry/></row><row><entry/><entry>pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>281</entry><entry>6-(3-Fluorophenyl)-1-(2-pyridylmethyl)-3H-</entry><entry>0.932</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>282</entry><entry>6-(3-Chlorophenyl)-1-(2-pyridylmethyl)-3H-</entry><entry>2.610</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>283</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-(2-pyridylmethyl)-</entry><entry>0.079</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>284</entry><entry>6-(3,4-Difluorophenyl)-1-[(3-methyl-2-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>285</entry><entry>6-(3-Fluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>286</entry><entry>6-(4-Fluorophenyl)-1-(2-pyridylmethyl)-3H-</entry><entry>1.980</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>287</entry><entry>6-[3-(Difluoromethyl)phenyl]-1-(2-pyridylmethyl)-</entry><entry>0.107</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>288</entry><entry>6-(3-Methoxyphenyl)-1-(2-pyridylmethyl)-3H-</entry><entry>4.050</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>289</entry><entry>6-(p-Tolyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-</entry><entry>7.079</entry><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>290</entry><entry>6-(3-fluorophenyl)-1-(3-pyridylmethyl)-3H-</entry><entry>0.065</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>291</entry><entry>6-[3-(Difluoromethyl)phenyl]-1-(3-pyridylmethyl)-</entry><entry>0.022</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>292</entry><entry>6-(3,4-Difluorophenyl)-1-(3-pyridylmethyl)-3H-</entry><entry>0.060</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>293</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-(3-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>294</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-(3-pyridylmethyl)-</entry><entry>0.023</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>295</entry><entry>6-(4-Fluorophenyl)-1-(3-pyridylmethyl)-3H-</entry><entry>0.098</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>296</entry><entry>6-(3-Chlorophenyl)-1-(3-pyridylmethyl)-3H-</entry><entry>0.029</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>297</entry><entry>6-(m-Tolyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-</entry><entry>0.027</entry><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>298</entry><entry>6-(3,4-Difluorophenyl)-1-[(5-fluoro-3-</entry><entry>0.032</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>299</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-</entry><entry>0.019</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>300</entry><entry>6-[3-(Difluoromethoxy)phenyl]-1-(3-pyridylmethyl)-</entry><entry>0.030</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>301</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-fluoro-3-</entry><entry>0.045</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>302</entry><entry>6-[3-(Difluoromethyl)phenyl]-1-[(5-fluoro-3-</entry><entry>0.022</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>303</entry><entry>6-(2,3-Difluorophenyl)-1-[(5-fluoro-3-</entry><entry>0.030</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>304</entry><entry>6-[3-(Difluoromethoxy)phenyl]-1-[(5-fluoro-3-</entry><entry>0.021</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>305</entry><entry>6-(3-Chlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-</entry><entry>0.013</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>306</entry><entry>6-(4-Chloro-3-methyl-phenyl)-1-[(5-fluoro-3-</entry><entry>0.086</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>307</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-6-[3-</entry><entry>0.088</entry><entry/></row><row><entry/><entry>(trifluoromethoxy)phenyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>308</entry><entry>1-[(5-Methyl-3-pyridyl)methyl]-6-(3,4,5-</entry><entry>0.030</entry><entry/></row><row><entry/><entry>trifluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>309</entry><entry>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[(5-methyl-</entry><entry>0.316</entry><entry/></row><row><entry/><entry>3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>310</entry><entry>6-(2,3-Difluorophenyl)-1-[(5-methyl-3-</entry><entry>0.088</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>311</entry><entry>6-(3,5-Difluorophenyl)-1-[(5-methyl-3-</entry><entry>0.028</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>312</entry><entry>1-[(4-Methyl-3-pyridyl)methyl]-6-(3,4,5-</entry><entry>0.002</entry><entry/></row><row><entry/><entry>trifluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>313</entry><entry>1-[(4-Methyl-3-pyridyl)methyl]-6-[3-</entry><entry>0.018</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>314</entry><entry>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[(4-methyl-</entry><entry>0.049</entry><entry/></row><row><entry/><entry>3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>315</entry><entry>1-[(3-Methyl-2-pyridyl)methyl]-6-[3-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>316</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(3-methyl-2-</entry><entry>0.114</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>317</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(3-methyl-2-</entry><entry>0.046</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>318</entry><entry>6-(3,5-Difluorophenyl)-1-[(3-methyl-2-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>319</entry><entry>6-(2,3-Difluorophenyl)-1-[(3-methyl-2-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>320</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-2-</entry><entry>0.075</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>321</entry><entry>2-[6-(5-Chloro-4-methyl-2-thienyl)-2-oxo-3H-</entry><entry>0.014</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>322</entry><entry>2-[6-(5-Chloro-4-methyl-2-thienyl)-3-methyl-2-oxo-</entry><entry>0.023</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>323</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-</entry><entry>0.041</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>324</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-</entry><entry>0.015</entry><entry/></row><row><entry/><entry>methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>325</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-</entry><entry>NT</entry><entry/></row><row><entry/><entry>methyl-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>326</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(5-</entry><entry>0.022</entry><entry/></row><row><entry/><entry>methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>327</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>0.071</entry><entry/></row><row><entry/><entry>6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>328</entry><entry>3-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-</entry><entry>0.079</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>329</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-3-</entry><entry>0.750</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>330</entry><entry>6-(3,4-Difluorophenyl)-1-(2-oxobutyl)-3H-</entry><entry>0.004</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>331</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-</entry><entry>0.012</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>332</entry><entry>6-(m-Tolyl)-1-(2-oxobutyl)-3H-imidazo[4,5-</entry><entry>0.036</entry><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>333</entry><entry>(R/S)-6-(3,4-Difluorophenyl)-1-(2-hydroxybutyl)-3-</entry><entry>1.900</entry><entry/></row><row><entry/><entry>methyl-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>334</entry><entry>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-1-(2-</entry><entry>0.031</entry><entry/></row><row><entry/><entry>hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>335</entry><entry>(R/S)-1-(2-Hydroxybutyl)-6-(m-tolyl)-3H-</entry><entry>0.054</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>336</entry><entry>(R/S)-6-(2,4-difluoro-3-methyl-phenyl)-1-(2-</entry><entry>0.015</entry><entry/></row><row><entry/><entry>hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>337</entry><entry>(R/S)-1-(2-Hydroxybutyl)-6-[3-</entry><entry>0.119</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>338</entry><entry>(R/S)-1-(2-Hydroxy-3-methyl-butyl)-6-[3-</entry><entry>0.687</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>339</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(3-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>340</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-</entry><entry>0.052</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>341</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-fluoro-3-</entry><entry>0.081</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>342</entry><entry>6-[3-(Difluoromethoxy)phenyl]-1-[(5-fluoro-3-</entry><entry>0.138</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>343</entry><entry>6-(3,4-Difluorophenyl)-1-[(5-fluoro-3-</entry><entry>0.256</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>344</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(3,4,5-</entry><entry>0.518</entry><entry/></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>345</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-[3-</entry><entry>0.778</entry><entry/></row><row><entry/><entry>(trifluoromethoxy)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>346</entry><entry>6-(2,3-Difluorophenyl)-1-[(5-fluoro-3-</entry><entry>0.225</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>347</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(2,3,4-</entry><entry>0.621</entry><entry/></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>348</entry><entry>6-(3-Chlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-</entry><entry>0.213</entry><entry/></row><row><entry/><entry>3-methyl-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>349</entry><entry>6-(3-Chloro-2-fluoro-phenyl)-1-[(5-fluoro-3-</entry><entry>0.107</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>350</entry><entry>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(m-</entry><entry>0.029</entry><entry/></row><row><entry/><entry>tolyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>351</entry><entry>6-(3,4-Dichlorophenyl)-1-[(5-fluoro-3-</entry><entry>0.251</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>352</entry><entry>6-(2-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-</entry><entry>0.052</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>353</entry><entry>3-Methyl-1-(3-pyridylmethyl)-6-(3,4,5-</entry><entry>0.144</entry><entry/></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>354</entry><entry>6-(3,5-Difluorophenyl)-3-methyl-1-(3-</entry><entry>1.030</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>355</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-3-methyl-1-(3-</entry><entry>0.044</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>356</entry><entry>3-Methyl-6-(m-tolyl)-1-(3-</entry><entry>0.070</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>357</entry><entry>6-(2-Fluoro-3-methyl-phenyl)-3-methyl-1-(3-</entry><entry>0.118</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>358</entry><entry>6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-</entry><entry>0.049</entry><entry/></row><row><entry/><entry>(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>359</entry><entry>6-(3-Chloro-2-fluoro-phenyl)-3-methyl-1-(3-</entry><entry>0.096</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>360</entry><entry>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>361</entry><entry>3-Methyl-1-(3-pyridylmethyl)-6-(2,3,4-</entry><entry>1.540</entry><entry/></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>362</entry><entry>3-Methyl-1-(3-pyridylmethyl)-6-[3-</entry><entry>0.105</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>363</entry><entry>6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(3-</entry><entry>0.053</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>364</entry><entry>3-Methyl-1-(3-pyridylmethyl)-6-[5-(trifluoromethyl)-</entry><entry>0.168</entry><entry/></row><row><entry/><entry>2-thienyl]imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>365</entry><entry>6-(5-Chloro-4-methyl-2-thienyl)-3-methyl-1-(3-</entry><entry>0.063</entry><entry/></row><row><entry/><entry>pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>366</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-[3-</entry><entry>0.433</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>367</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(4-fluoro-3-</entry><entry>0.117</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>368</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(2,4-difluoro-3-</entry><entry>0.356</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>369</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(3,4-</entry><entry>0.096</entry><entry/></row><row><entry/><entry>difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>370</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-(3,4,5-</entry><entry>0.131</entry><entry/></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>371</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(2-fluoro-3-</entry><entry>0.190</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>372</entry><entry>6-(5-Chloro-4-methyl-2-thienyl)-1-[(5-chloro-3-</entry><entry>6.640</entry><entry/></row><row><entry/><entry>pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>373</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-[5-</entry><entry>9.721</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>374</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-(m-</entry><entry>0.416</entry><entry/></row><row><entry/><entry>tolyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>375</entry><entry>1-[(5-Chloro-3-pyridyl)methyl]-6-(2,3-</entry><entry>1.510</entry><entry/></row><row><entry/><entry>difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>376</entry><entry>6-(3-Chlorophenyl)-3-methyl-1-(pyridazin-3-</entry><entry>0.056</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>377</entry><entry>6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(pyridazin-</entry><entry>0.030</entry><entry/></row><row><entry/><entry>3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>378</entry><entry>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[3-</entry><entry>0.031</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>379</entry><entry>3-Methyl-6-(m-tolyl)-1-(pyridazin-3-</entry><entry>0.033</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>380</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-3-methyl-1-</entry><entry>0.016</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>381</entry><entry>6-(3-Fluoro-5-methyl-phenyl)-3-methyl-1-</entry><entry>0.037</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>382</entry><entry>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-</entry><entry>0.016</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>383</entry><entry>6-[3-Fluoro-5-(trifluoromethyl)phenyl]-3-methyl-1-</entry><entry>0.041</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>384</entry><entry>6-[4-Chloro-3-(trifluoromethyl)phenyl]-3-methyl-1-</entry><entry>0.206</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>385</entry><entry>6-(5-(Difluoromethyl)-2-fluorophenyl)-3-methyl-1-</entry><entry>0.653</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>386</entry><entry>6-(5-(Difluoromethyl)-2-fluorophenyl)-3-methyl-1-</entry><entry>1.110</entry><entry/></row><row><entry/><entry>(pyridin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>387</entry><entry>6-[3,4-Difluoro-5-(trifluoromethyl)phenyl]-3-methyl-</entry><entry>0.022</entry><entry/></row><row><entry/><entry>1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>388</entry><entry>3-Methyl-1-(2-oxobutyl)-6-[3-</entry><entry>0.050</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>389</entry><entry>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(2-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>oxobutyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>390</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(2-</entry><entry>0.019</entry><entry/></row><row><entry/><entry>oxobutyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>391</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(2-</entry><entry>0.026</entry><entry/></row><row><entry/><entry>oxobutyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>392</entry><entry>6-(3-Cyclopropylphenyl)-3-methyl-1-(2-</entry><entry>0.324</entry><entry/></row><row><entry/><entry>oxobutyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>393</entry><entry>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-1-(2-hydroxy-</entry><entry>0.486</entry><entry/></row><row><entry/><entry>4-methoxy-butyl)-3-methyl-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>394</entry><entry>(R/S)-6-[3-(Difluoromethyl)phenyl]-3-methyl-1-</entry><entry>0.128</entry><entry/></row><row><entry/><entry>(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>395</entry><entry>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>1.200</entry><entry/></row><row><entry/><entry>(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>396</entry><entry>(R/S)-6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-</entry><entry>0.135</entry><entry/></row><row><entry/><entry>methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>397</entry><entry>(R/S)-6-(3-Chlorophenyl)-3-methyl-1-(oxetan-2-</entry><entry>0.228</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>398</entry><entry>(R/S)-3-Methyl-6-[2-methyl-3-</entry><entry>2.840</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-1-(oxetan-2-</entry><entry/><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>399</entry><entry>(R/S)-1-(2,4-Dihydroxybutyl)-3-methyl-6-[2-methyl-</entry><entry>5.100</entry><entry/></row><row><entry/><entry>3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>400</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>401</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(4-</entry><entry>0.016</entry><entry/></row><row><entry/><entry>fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>402</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>0.016</entry><entry/></row><row><entry/><entry>6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>403</entry><entry>6-(3,4-Difluorophenyl)-1-[2-(3-fluoroazetidin-1-yl)-</entry><entry>0.042</entry><entry/></row><row><entry/><entry>2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>404</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry>0.050</entry><entry/></row><row><entry/><entry>6-(m-tolyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>405</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2-</entry><entry>0.022</entry><entry/></row><row><entry/><entry>fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>406</entry><entry>6-(3-Chlorophenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-</entry><entry>0.016</entry><entry/></row><row><entry/><entry>oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>407</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[4-</entry><entry>0.031</entry><entry/></row><row><entry/><entry>fluoro-3-(trifluoromethyl)phenyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>408</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-</entry><entry>0.042</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>409</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-</entry><entry>0.008</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>410</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-</entry><entry/><entry/></row><row><entry/><entry>methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry>0.013</entry><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>411</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(3,4,5-</entry><entry>0.014</entry><entry/></row><row><entry/><entry>trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>412</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(3,5-</entry><entry>0.027</entry><entry/></row><row><entry/><entry>difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>413</entry><entry>1-(2-(3,3-Difluoroazetidin-1-yl)-2-oxoethyl)-6-(4-</entry><entry>0.009</entry><entry/></row><row><entry/><entry>fluoro-3-methylphenyl)-3-methyl-1H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2(3H)-one;</entry><entry/><entry/></row><row><entry>414</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2,4-</entry><entry>0.013</entry><entry/></row><row><entry/><entry>difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>415</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[2-</entry><entry>0.015</entry><entry/></row><row><entry/><entry>fluoro-3-(trifluoromethyl)phenyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>416</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(3,4-</entry><entry>0.010</entry><entry/></row><row><entry/><entry>difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>417</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(3-</entry><entry>0.031</entry><entry/></row><row><entry/><entry>fluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>418</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2-</entry><entry>0.019</entry><entry/></row><row><entry/><entry>fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>419</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[3-</entry><entry>0.047</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetamide;</entry><entry/><entry/></row><row><entry>420</entry><entry>2-[6-(4-Fuoro-3-methyl-phenyl)-3-methyl-2-oxo-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>421</entry><entry>2-[6-(3,4-Difluorophenyl)-3-methyl-2-oxo-</entry><entry>0.053</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>422</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(3,4-</entry><entry>0.010</entry><entry/></row><row><entry/><entry>difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>423</entry><entry>2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-2-</entry><entry>0.006</entry><entry/></row><row><entry/><entry>oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>424</entry><entry>2-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-</entry><entry>0.028</entry><entry/></row><row><entry/><entry>2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>425</entry><entry>2-[6-(2,3-Difluorophenyl)-3-methyl-2-oxo-</entry><entry>0.408</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>426</entry><entry>2-[6-[3-(Difluoromethyl)phenyl]-3-methyl-2-oxo-</entry><entry>0.019</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>427</entry><entry>2-[6-(2-Fluoro-3-methyl-phenyl)-3-methyl-2-oxo-</entry><entry>0.041</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>428</entry><entry>2-[6-(3,5-Difluorophenyl)-3-methyl-2-oxo-</entry><entry>0.126</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>429</entry><entry>N,N-Dimethyl-2-[3-methyl-2-oxo-6-(3-</entry><entry>&#x3e;10</entry><entry/></row><row><entry/><entry>pyridyl)imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>430</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry><entry>0.028</entry><entry/></row><row><entry/><entry>methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>431</entry><entry>2-[6-[3,4-Difluoro-5-(trifluoromethyl)phenyl]-3-</entry><entry>0.095</entry><entry/></row><row><entry/><entry>methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry><entry/><entry/></row><row><entry/><entry>dimethyl-acetamide;</entry><entry/><entry/></row><row><entry>432</entry><entry>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-</entry><entry>0.962</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>433</entry><entry>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-</entry><entry/><entry>0.867</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>434</entry><entry>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-</entry><entry>0.583</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>435</entry><entry>N-Methyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-</entry><entry>0.264</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>436</entry><entry>2-[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>4.700</entry></row><row><entry/><entry>b]pyridin-1-yl]-N-methyl-acetamide;</entry><entry/><entry/></row><row><entry>437</entry><entry>2-[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-</entry><entry>0.219</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</entry><entry/><entry/></row><row><entry>438</entry><entry>2-[6-(3,5-Dimethylphenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>0.394</entry></row><row><entry/><entry>b]pyridin-1-yl]-N-methyl-acetamide;</entry><entry/><entry/></row><row><entry>439</entry><entry>2-[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-</entry><entry/><entry>3.371</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</entry><entry/><entry/></row><row><entry>440</entry><entry>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-</entry><entry>0.358</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</entry><entry/><entry/></row><row><entry>441</entry><entry>2-[6-(2-Ethoxyphenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>2.444</entry></row><row><entry/><entry>b]pyridin-1-yl]-N-methyl-acetamide;</entry><entry/><entry/></row><row><entry>442</entry><entry>N-(2-Methoxyethyl)-2-[2-oxo-6-[3-</entry><entry/><entry>0.197</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>443</entry><entry>2-[6-(2-Ethoxy-5-fluoro-phenyl)-2-oxo-3H-</entry><entry/><entry>1.322</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-(2-</entry><entry/><entry/></row><row><entry/><entry>methoxyethyl)acetamide;</entry><entry/><entry/></row><row><entry>444</entry><entry>N-(2-Methoxyethyl)-2-[6-(4-methoxyphenyl)-2-oxo-</entry><entry/><entry>0.747</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>445</entry><entry>N-(2-Methoxyethyl)-2-[2-oxo-6-(3-pyridyl)-3H-</entry><entry/><entry>&#x3e;29.0001</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>446</entry><entry>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-</entry><entry>0.204</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-(2-</entry><entry/><entry/></row><row><entry/><entry>methoxyethyl)acetamide;</entry><entry/><entry/></row><row><entry>447</entry><entry>N-Cyclopropyl-2-[6-(3,5-difluorophenyl)-2-oxo-3H-</entry><entry>0.184</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>448</entry><entry>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-</entry><entry>0.008</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>449</entry><entry>N-Cyclopropyl-2-[6-(3-ethoxyphenyl)-2-oxo-3H-</entry><entry/><entry>0.638</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>450</entry><entry>N-Cyclopropyl-2-[6-(3-methoxyphenyl)-2-oxo-3H-</entry><entry/><entry>1.763</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>451</entry><entry>N-Cyclopropyl-2-[6-(4-methoxy-3-methyl-phenyl)-</entry><entry/><entry>1.031</entry></row><row><entry/><entry>2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>452</entry><entry>N-Cyclopropyl-2-[6-(4-fluoro-2-methoxy-phenyl)-2-</entry><entry/><entry>0.071</entry></row><row><entry/><entry>oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>453</entry><entry>2-[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>0.100</entry></row><row><entry/><entry>b]pyridin-1-yl]-N-cyclopropyl-acetamide;</entry><entry/><entry/></row><row><entry>454</entry><entry>N-Cyclopropyl-2-[6-(2,4-dimethoxyphenyl)-2-oxo-</entry><entry/><entry>1.938</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>455</entry><entry>N-Cyclopropyl-2-[6-(2-fluoro-6-methoxy-phenyl)-2-</entry><entry>0.416</entry><entry/></row><row><entry/><entry>oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>456</entry><entry>N-Cyclopropyl-2-[6-(2-ethoxyphenyl)-2-oxo-3H-</entry><entry>0.146</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>457</entry><entry>6-(3-Fluoro-4-methoxy-phenyl)-1-[2-oxo-2-(2-</entry><entry>0.330</entry><entry/></row><row><entry/><entry>thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>458</entry><entry>6-(2-Ethoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-</entry><entry>0.135</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>459</entry><entry>6-(4-Chlorophenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-</entry><entry/><entry>1.422</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>460</entry><entry>6-(2-Ethoxy-5-fluoro-phenyl)-1-[2-oxo-2-(2-</entry><entry/><entry>1.770</entry></row><row><entry/><entry>thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>461</entry><entry>6-(4-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-</entry><entry>0.054</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>462</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[2-oxo-2-(2-</entry><entry>0.255</entry><entry/></row><row><entry/><entry>thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>463</entry><entry>6-(3-Ethoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-</entry><entry/><entry>0.360</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>464</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-1-[2-oxo-2-(2-</entry><entry>0.359</entry><entry/></row><row><entry/><entry>thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>465</entry><entry>1-(Cyclopropylmethyl)-6-(2,4-dimethoxyphenyl)-</entry><entry/><entry>14.401</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>466</entry><entry>1-(Cyclopropylmethyl)-6-(2-ethoxy-5-fluoro-</entry><entry/><entry>15.754</entry></row><row><entry/><entry>phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>467</entry><entry>1-(Cyclopropylmethyl)-6-(4-fluoro-2-methoxy-</entry><entry/><entry>0.305</entry></row><row><entry/><entry>phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>468</entry><entry>1-(Cyclopropylmethyl)-6-(4-methoxy-3-methyl-</entry><entry/><entry>4.174</entry></row><row><entry/><entry>phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>469</entry><entry>1-(Cyclopropylmethyl)-6-(3-fluoro-4-methoxy-</entry><entry/><entry>0.944</entry></row><row><entry/><entry>phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>470</entry><entry>1-(Cyclopropylmethyl)-6-(3,5-difluorophenyl)-3H-</entry><entry/><entry>0.509</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>471</entry><entry>1-(Cyclopropylmethyl)-6-(4-methoxyphenyl)-3H-</entry><entry>1.803</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>472</entry><entry>1-(Cyclopropylmethyl)-6-(2-thienyl)-3H-</entry><entry>1.556</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>473</entry><entry>1-(Cyclopropylmethyl)-6-[3-</entry><entry/><entry>15.668</entry></row><row><entry/><entry>(dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>474</entry><entry>1-(Cyclopropylmethyl)-6-(3,5-dimethylphenyl)-3H-</entry><entry>3.570</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>475</entry><entry>6-(3-Methoxyphenyl)-1-(tetrahydrofuran-2-</entry><entry/><entry>0.157</entry></row><row><entry/><entry>ylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>476</entry><entry>4-[[6-(4-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>4.534</entry></row><row><entry/><entry>b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>477</entry><entry>3-[[6-(4-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>3.156</entry></row><row><entry/><entry>b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>478</entry><entry>3-[[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-</entry><entry/><entry>3.044</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>479</entry><entry>3-[[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-</entry><entry>0.778</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>480</entry><entry>3-[[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-</entry><entry/><entry>4.222</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>481</entry><entry>2-[[6-(2-Fluoro-6-methoxy-phenyl)-2-oxo-3H-</entry><entry>2.250</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>482</entry><entry>2-[[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>1.410</entry></row><row><entry/><entry>b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>483</entry><entry>2-[[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-</entry><entry/><entry>1.801</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>484</entry><entry>2-[[6-(2-Ethoxyphenyl)-2-oxo-3H-imidazo[4,5-</entry><entry>1.390</entry><entry/></row><row><entry/><entry>b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>485</entry><entry>2-[[6-(3-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-</entry><entry>0.031</entry><entry/></row><row><entry/><entry>b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>486</entry><entry>2-[[6-(3-Cyanophenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>3.839</entry></row><row><entry/><entry>b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>487</entry><entry>2-[[6-(2,4-Dimethoxyphenyl)-2-oxo-3H-</entry><entry/><entry>2.566</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>488</entry><entry>2-[[6-(3,5-Dimethylphenyl)-2-oxo-3H-imidazo[4,5-</entry><entry/><entry>4.949</entry></row><row><entry/><entry>b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>489</entry><entry>2-[[6-(2-Ethoxy-5-fluoro-phenyl)-2-oxo-3H-</entry><entry/><entry>1.283</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>490</entry><entry>2-[[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-</entry><entry>0.046</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>491</entry><entry>2-[[6-(3-Fluoro-4-methoxy-phenyl)-2-oxo-3H-</entry><entry>0.053</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>492</entry><entry>6-(4-Fluoro-2-methyl-phenyl)-1-[(4-</entry><entry/><entry>6.121</entry></row><row><entry/><entry>fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>493</entry><entry>6-(2,3-Dimethoxyphenyl)-1-[(4-</entry><entry/><entry>1.012</entry></row><row><entry/><entry>fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>494</entry><entry>6-(2-Ethoxy-5-fluoro-phenyl)-1-[(3-</entry><entry/><entry>5.643</entry></row><row><entry/><entry>fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>495</entry><entry>6-(3,5-Dimethylphenyl)-1-[(3-fluorophenyl)methyl]-</entry><entry/><entry>2.813</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>496</entry><entry>6-(2,4-Dimethoxyphenyl)-1-[(3-</entry><entry/><entry>2.795</entry></row><row><entry/><entry>fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>497</entry><entry>6-(2-Ethoxyphenyl)-1-[(3-fluorophenyl)methyl]-3H-</entry><entry/><entry>1.946</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>498</entry><entry>1-[(3-Fluorophenyl)methyl]-6-(4-methoxy-3-</entry><entry>2.220</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>499</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[(3-</entry><entry>0.090</entry><entry/></row><row><entry/><entry>fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>500</entry><entry>6-[3-(Dimethylamino)phenyl]-1-[(3-</entry><entry>6.080</entry><entry/></row><row><entry/><entry>fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>501</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[(4-</entry><entry/><entry>0.790</entry></row><row><entry/><entry>fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>502</entry><entry>6-(3-Chloro-4-fluoro-phenyl)-1-[(4-</entry><entry/><entry>4.858</entry></row><row><entry/><entry>fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>503</entry><entry>6-(2-Ethoxyphenyl)-1-[(2-fluorophenyl)methyl]-3H-</entry><entry/><entry>5.492</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>504</entry><entry>1-[(3-Chlorophenyl)methyl]-6-(3,5-difluorophenyl)-</entry><entry/><entry>4.132</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>505</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[(3-</entry><entry>1.640</entry><entry/></row><row><entry/><entry>methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>506</entry><entry>1-[(3-Methoxyphenyl)methyl]-6-(3-pyridyl)-3H-</entry><entry/><entry>&#x3e;29</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>507</entry><entry>1-[(3-Methoxyphenyl)methyl]-6-(4-methyl-2-</entry><entry/><entry>8.100</entry></row><row><entry/><entry>thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>508</entry><entry>6-(3,5-Difluorophenyl)-1-[(4-</entry><entry/><entry>0.463</entry></row><row><entry/><entry>methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>509</entry><entry>1-[(3,5-Dimethoxyphenyl)methyl]-6-(2-fluoro-6-</entry><entry/><entry>0.884</entry></row><row><entry/><entry>methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>510</entry><entry>1-[(3,5-Dimethoxyphenyl)methyl]-6-[3-</entry><entry/><entry>17.434</entry></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>511</entry><entry>6-(4-Chlorophenyl)-1-[(4-isopropylphenyl)methyl]-</entry><entry/><entry>&#x3e;29</entry></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>512</entry><entry>6-(4-tert-Butylphenyl)-1-[(3,4-dimethoxy-2-</entry><entry/><entry>&#x3e;29</entry></row><row><entry/><entry>pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>513</entry><entry>3-[1-[(3,5-Dimethylisoxazol-4-yl)methyl]-2-oxo-3H-</entry><entry/><entry>&#x3e;29</entry></row><row><entry/><entry>imidazo[4,5-b]pyridin-6-yl]benzonitrile;</entry><entry/><entry/></row><row><entry>514</entry><entry>1-[(3,5-Dimethylisoxazol-4-yl)methyl]-6-(2-ethoxy-</entry><entry/><entry>&#x3e;29</entry></row><row><entry/><entry>5-fluoro-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>515</entry><entry>6-(4-Methoxy-3-methyl-phenyl)-1-[(5-</entry><entry/><entry>0.156</entry></row><row><entry/><entry>methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>516</entry><entry>6-(3,5-Dimethylphenyl)-1-[(5-methylisoxazol-3-</entry><entry>0.491</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>517</entry><entry>6-(2-Ethoxyphenyl)-1-[(5-methylisoxazol-3-</entry><entry>0.709</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>518</entry><entry>6-(2,4-Dimethoxyphenyl)-1-[(5-methylisoxazol-3-</entry><entry>0.808</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>519</entry><entry>6-(3-Fluoro-4-methoxy-phenyl)-1-[(5-</entry><entry>0.139</entry><entry/></row><row><entry/><entry>methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>520</entry><entry>6-(4-Fluoro-2-methoxy-phenyl)-1-[(5-</entry><entry>0.019</entry><entry/></row><row><entry/><entry>methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>521</entry><entry>6-(2-Ethoxy-5-fluoro-phenyl)-1-[(5-methylisoxazol-</entry><entry>0.132</entry><entry/></row><row><entry/><entry>3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>522</entry><entry>6-(4-Fluoro-2-methyl-phenyl)-1-[(5-methylisoxazol-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>523</entry><entry>6-(3,5-Difluorophenyl)-1-[(5-methylisoxazol-3-</entry><entry>0.133</entry><entry/></row><row><entry/><entry>yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>532</entry><entry>N-(3-Chloropropyl)-2-[3-methyl-2-oxo-6-[5-</entry><entry>0.862</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-</entry><entry/><entry/></row><row><entry/><entry>yl]acetamide;</entry><entry/><entry/></row><row><entry>533</entry><entry>2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-</entry><entry>0.025</entry><entry/></row><row><entry/><entry>2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>534</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)-6-</entry><entry>0.036</entry><entry/></row><row><entry/><entry>[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>535</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(2-fluoroethyl)-6-</entry><entry>0.106</entry><entry/></row><row><entry/><entry>[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>536</entry><entry>1-[2-[3-(2-Fluoroethyl)azetidin-1-yl]-2-oxo-ethyl]-6-</entry><entry>0.163</entry><entry/></row><row><entry/><entry>[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>537</entry><entry>6-(6-Fluoro-2-pyridyl)-1-(2-oxobutyl)-3H-</entry><entry>0.273</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>538</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-(2-</entry><entry>0.240</entry><entry/></row><row><entry/><entry>fluoroethoxy)-3-(trifluoromethyl)phenyl]-3H-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>539</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-</entry><entry>0.333</entry><entry/></row><row><entry/><entry>fluoroethoxy)-5-(trifluoromethyl)phenyl]-3H-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>541</entry><entry>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-1-</entry><entry>0.022</entry><entry/></row><row><entry/><entry>(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>542</entry><entry>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-</entry><entry>0.016</entry><entry/></row><row><entry/><entry>1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>543</entry><entry>6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-</entry><entry>0.028</entry><entry/></row><row><entry/><entry>1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>544</entry><entry>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-</entry><entry>0.090</entry><entry/></row><row><entry/><entry>fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>545</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-(thiadiazol-4-</entry><entry>0.512</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>546</entry><entry>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(5-fluoro-</entry><entry>0.024</entry><entry/></row><row><entry/><entry>3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>547</entry><entry>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[(5-</entry><entry>0.036</entry><entry/></row><row><entry/><entry>fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>548</entry><entry>3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[3-</entry><entry>0.185</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>549</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(1-</entry><entry>0.467</entry><entry/></row><row><entry/><entry>methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>550</entry><entry>6-(3,4-Difluorophenyl)-3-methyl-1-[(1-</entry><entry>0.697</entry><entry/></row><row><entry/><entry>methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>551</entry><entry>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[3-</entry><entry>0.190</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>552</entry><entry>3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[3-</entry><entry>0.130</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>553</entry><entry>3-Methyl-6-(5-methyl-2-thienyl)-1-[(1-methyltriazol-</entry><entry>0.726</entry><entry/></row><row><entry/><entry>4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>554</entry><entry>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-</entry><entry>0.533</entry><entry/></row><row><entry/><entry>yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>555</entry><entry>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-(5-</entry><entry>1.310</entry><entry/></row><row><entry/><entry>methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>556</entry><entry>3-Methyl-6-(5-methyl-2-thienyl)-1-(thiadiazol-4-</entry><entry>0.363</entry><entry/></row><row><entry/><entry>ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>557</entry><entry>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-</entry><entry>0.671</entry><entry/></row><row><entry/><entry>yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>558</entry><entry>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(5-</entry><entry>0.216</entry><entry/></row><row><entry/><entry>methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>559</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-</entry><entry>0.280</entry><entry/></row><row><entry/><entry>methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>560</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-</entry><entry>0.304</entry><entry/></row><row><entry/><entry>methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>561</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-</entry><entry>0.354</entry><entry/></row><row><entry/><entry>methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>562</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-</entry><entry>0.166</entry><entry/></row><row><entry/><entry>(thiadiazol-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>563</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(3-</entry><entry>0.316</entry><entry/></row><row><entry/><entry>methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>564</entry><entry>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-</entry><entry>0.087</entry><entry/></row><row><entry/><entry>methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>565</entry><entry>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[5-</entry><entry>0.374</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>566</entry><entry>3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[5-</entry><entry>0.349</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>567</entry><entry>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-</entry><entry>0.146</entry><entry/></row><row><entry/><entry>yl)methyl]-6-[5-(trifluoromethyl)-2-</entry><entry/><entry/></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>568</entry><entry>3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[5-</entry><entry>0.305</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>569</entry><entry>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-</entry><entry>0.412</entry><entry/></row><row><entry/><entry>yl)methyl]-6-[5-(trifluoromethyl)-2-</entry><entry/><entry/></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>570</entry><entry>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[5-</entry><entry>0.139</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>571</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-</entry><entry>0.037</entry><entry/></row><row><entry/><entry>methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one;</entry><entry/><entry/></row><row><entry>572</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-</entry><entry>0.150</entry><entry/></row><row><entry/><entry>methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>573</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(3-</entry><entry>0.043</entry><entry/></row><row><entry/><entry>methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>574</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-</entry><entry>0.046</entry><entry/></row><row><entry/><entry>methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-</entry><entry/><entry/></row><row><entry/><entry>one;</entry><entry/><entry/></row><row><entry>575</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-</entry><entry>0.028</entry><entry/></row><row><entry/><entry>methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>576</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-</entry><entry>0.050</entry><entry/></row><row><entry/><entry>(thiadiazol-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>577</entry><entry>N-(2-Fluoroethyl)-N-methyl-2-[3-methyl-2-oxo-6-</entry><entry>0.064</entry><entry/></row><row><entry/><entry>[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>1-yl]acetamide;</entry><entry/><entry/></row><row><entry>578</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-</entry><entry>0.014</entry><entry/></row><row><entry/><entry>(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>579</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-</entry><entry>0.015</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>580</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(m-</entry><entry>0.026</entry><entry/></row><row><entry/><entry>tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>581</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry><entry>0.032</entry><entry/></row><row><entry/><entry>methyl-6-(m-tolyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>582</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-</entry><entry>1.290</entry><entry/></row><row><entry/><entry>fluoroethoxy)-5-(trifluoromethyl)phenyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>583</entry><entry>N,N-Dimethyl-2-[3-methyl-6-(m-tolyl)-2-oxo-</entry><entry>0.051</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>584</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-</entry><entry>0.024</entry><entry/></row><row><entry/><entry>(difluoromethyl)-4-fluoro-phenyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>585</entry><entry>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[2-(3-</entry><entry>0.018</entry><entry/></row><row><entry/><entry>fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>586</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-</entry><entry>0.051</entry><entry/></row><row><entry/><entry>(difluoromethyl)-4-fluoro-phenyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>587</entry><entry>2-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-</entry><entry>0.035</entry><entry/></row><row><entry/><entry>methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry><entry/><entry/></row><row><entry/><entry>dimethyl-acetamide;</entry><entry/><entry/></row><row><entry>588</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-</entry><entry>0.023</entry><entry/></row><row><entry/><entry>(difluoromethoxy)-4-fluoro-phenyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>589</entry><entry>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[2-(3-</entry><entry>0.028</entry><entry/></row><row><entry/><entry>fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>590</entry><entry>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-</entry><entry>0.025</entry><entry/></row><row><entry/><entry>(difluoromethoxy)-4-fluoro-phenyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>591</entry><entry>2-[6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-</entry><entry>0.034</entry><entry/></row><row><entry/><entry>methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-</entry><entry/><entry/></row><row><entry/><entry>dimethyl-acetamide;</entry><entry/><entry/></row><row><entry>592</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-chloro-3-</entry><entry>0.071</entry><entry/></row><row><entry/><entry>(difluoromethoxy)phenyl]-3-methyl-imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>593</entry><entry>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3-</entry><entry>0.053</entry><entry/></row><row><entry/><entry>fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>594</entry><entry>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3,3-</entry><entry>0.082</entry><entry/></row><row><entry/><entry>difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-</entry><entry/><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>595</entry><entry>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-</entry><entry>0.974</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3-(fluoromethyl)imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>596</entry><entry>2-[3-(Fluoromethyl)-2-oxo-6-[5-(trifluoromethyl)-2-</entry><entry>0.066</entry><entry/></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-</entry><entry/><entry/></row><row><entry/><entry>acetamide;</entry><entry/><entry/></row><row><entry>597</entry><entry>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry><entry>0.063</entry><entry/></row><row><entry/><entry>(fluoromethyl)-6-[5-(trifluoromethyl)-2-</entry><entry/><entry/></row><row><entry/><entry>thienyl]imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>598</entry><entry>3-(Fluoromethyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-</entry><entry>0.173</entry><entry/></row><row><entry/><entry>6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-</entry><entry/><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>599</entry><entry>2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-</entry><entry>0.025</entry><entry/></row><row><entry/><entry>(fluoromethyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]-</entry><entry/><entry/></row><row><entry/><entry>N,N-dimethyl-acetamide;</entry><entry/><entry/></row><row><entry>600</entry><entry>6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-</entry><entry>0.017</entry><entry/></row><row><entry/><entry>fluoroazetidin-1-yl)-2-oxo-ethyl]-3-</entry><entry/><entry/></row><row><entry/><entry>(fluoromethyl)imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>601</entry><entry>1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxyphenyl)-</entry><entry>1.634</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>602</entry><entry>6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-</entry><entry>0.204</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>603</entry><entry>1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxy-3-</entry><entry>1.290</entry><entry/></row><row><entry/><entry>methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>604</entry><entry>1-Isobutyl-6-(4-methoxyphenyl)-3H-imidazo[4,5-</entry><entry>1.824</entry><entry/></row><row><entry/><entry>b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>605</entry><entry>6-(2-Ethoxyphenyl)-1-[(3-methoxyphenyl)methyl]-</entry><entry>2.090</entry><entry/></row><row><entry/><entry>3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>606</entry><entry>6-(2-Ethoxyphenyl)-1-[(4-fluorophenyl)methyl]-3H-</entry><entry>2.180</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>607</entry><entry>N-Cyclopropyl-2-[6-(2-ethoxy-5-fluoro-phenyl)-2-</entry><entry>0.336</entry><entry/></row><row><entry/><entry>oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</entry><entry/><entry/></row><row><entry>608</entry><entry>2-[[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-</entry><entry>1.020</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</entry><entry/><entry/></row><row><entry>609</entry><entry>1-(3,3-Dimethyl-2-oxo-butyl)-6-(3-fluoro-4-</entry><entry>0.263</entry><entry/></row><row><entry/><entry>methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</entry><entry/><entry/></row><row><entry>610</entry><entry>2-[6-(3,5-Difluorophenyl)-2-oxo-3H-imidazo[4,5-</entry><entry>1.790</entry><entry/></row><row><entry/><entry>b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide;</entry><entry/><entry/></row><row><entry>611</entry><entry>1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-</entry><entry>0.204</entry><entry/></row><row><entry/><entry>(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-</entry><entry/><entry/></row><row><entry/><entry>2-one; and</entry><entry/><entry/></row><row><entry>612</entry><entry>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-</entry><entry>0.116</entry><entry/></row><row><entry/><entry>imidazo[4,5-b]pyridin-1-yl]-N-(2-</entry><entry/><entry/></row><row><entry/><entry>methoxyethyl)acetamide.</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><?detailed-description description="Detailed Description" end="tail"?></description><us-chemistry idref="CHEM-US-00001" cdx-file="US20230000833A1-20230105-C00001.CDX" mol-file="US20230000833A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230000833A1-20230105-C00002.CDX" mol-file="US20230000833A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230000833A1-20230105-C00003.CDX" mol-file="US20230000833A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230000833A1-20230105-C00004.CDX" mol-file="US20230000833A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230000833A1-20230105-C00005.CDX" mol-file="US20230000833A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230000833A1-20230105-C00006.CDX" mol-file="US20230000833A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230000833A1-20230105-C00007.CDX" mol-file="US20230000833A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230000833A1-20230105-C00008.CDX" mol-file="US20230000833A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230000833A1-20230105-C00009.CDX" mol-file="US20230000833A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230000833A1-20230105-C00010.CDX" mol-file="US20230000833A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230000833A1-20230105-C00011.CDX" mol-file="US20230000833A1-20230105-C00011.MOL"/><us-chemistry idref="CHEM-US-00012" cdx-file="US20230000833A1-20230105-C00012.CDX" mol-file="US20230000833A1-20230105-C00012.MOL"/><us-chemistry idref="CHEM-US-00013" cdx-file="US20230000833A1-20230105-C00013.CDX" mol-file="US20230000833A1-20230105-C00013.MOL"/><us-chemistry idref="CHEM-US-00014" cdx-file="US20230000833A1-20230105-C00014.CDX" mol-file="US20230000833A1-20230105-C00014.MOL"/><us-chemistry idref="CHEM-US-00015" cdx-file="US20230000833A1-20230105-C00015.CDX" mol-file="US20230000833A1-20230105-C00015.MOL"/><us-chemistry idref="CHEM-US-00016" cdx-file="US20230000833A1-20230105-C00016.CDX" mol-file="US20230000833A1-20230105-C00016.MOL"/><us-chemistry idref="CHEM-US-00017" cdx-file="US20230000833A1-20230105-C00017.CDX" mol-file="US20230000833A1-20230105-C00017.MOL"/><us-chemistry idref="CHEM-US-00018" cdx-file="US20230000833A1-20230105-C00018.CDX" mol-file="US20230000833A1-20230105-C00018.MOL"/><us-chemistry idref="CHEM-US-00019" cdx-file="US20230000833A1-20230105-C00019.CDX" mol-file="US20230000833A1-20230105-C00019.MOL"/><us-chemistry idref="CHEM-US-00020" cdx-file="US20230000833A1-20230105-C00020.CDX" mol-file="US20230000833A1-20230105-C00020.MOL"/><us-chemistry idref="CHEM-US-00021" cdx-file="US20230000833A1-20230105-C00021.CDX" mol-file="US20230000833A1-20230105-C00021.MOL"/><us-chemistry idref="CHEM-US-00022" cdx-file="US20230000833A1-20230105-C00022.CDX" mol-file="US20230000833A1-20230105-C00022.MOL"/><us-chemistry idref="CHEM-US-00023" cdx-file="US20230000833A1-20230105-C00023.CDX" mol-file="US20230000833A1-20230105-C00023.MOL"/><us-chemistry idref="CHEM-US-00024" cdx-file="US20230000833A1-20230105-C00024.CDX" mol-file="US20230000833A1-20230105-C00024.MOL"/><us-chemistry idref="CHEM-US-00025" cdx-file="US20230000833A1-20230105-C00025.CDX" mol-file="US20230000833A1-20230105-C00025.MOL"/><us-chemistry idref="CHEM-US-00026" cdx-file="US20230000833A1-20230105-C00026.CDX" mol-file="US20230000833A1-20230105-C00026.MOL"/><us-chemistry idref="CHEM-US-00027" cdx-file="US20230000833A1-20230105-C00027.CDX" mol-file="US20230000833A1-20230105-C00027.MOL"/><us-chemistry idref="CHEM-US-00028" cdx-file="US20230000833A1-20230105-C00028.CDX" mol-file="US20230000833A1-20230105-C00028.MOL"/><us-chemistry idref="CHEM-US-00029" cdx-file="US20230000833A1-20230105-C00029.CDX" mol-file="US20230000833A1-20230105-C00029.MOL"/><us-chemistry idref="CHEM-US-00030" cdx-file="US20230000833A1-20230105-C00030.CDX" mol-file="US20230000833A1-20230105-C00030.MOL"/><us-chemistry idref="CHEM-US-00031" cdx-file="US20230000833A1-20230105-C00031.CDX" mol-file="US20230000833A1-20230105-C00031.MOL"/><us-chemistry idref="CHEM-US-00032" cdx-file="US20230000833A1-20230105-C00032.CDX" mol-file="US20230000833A1-20230105-C00032.MOL"/><us-chemistry idref="CHEM-US-00033" cdx-file="US20230000833A1-20230105-C00033.CDX" mol-file="US20230000833A1-20230105-C00033.MOL"/><us-chemistry idref="CHEM-US-00034" cdx-file="US20230000833A1-20230105-C00034.CDX" mol-file="US20230000833A1-20230105-C00034.MOL"/><us-chemistry idref="CHEM-US-00035" cdx-file="US20230000833A1-20230105-C00035.CDX" mol-file="US20230000833A1-20230105-C00035.MOL"/><us-chemistry idref="CHEM-US-00036" cdx-file="US20230000833A1-20230105-C00036.CDX" mol-file="US20230000833A1-20230105-C00036.MOL"/><us-chemistry idref="CHEM-US-00037" cdx-file="US20230000833A1-20230105-C00037.CDX" mol-file="US20230000833A1-20230105-C00037.MOL"/><us-chemistry idref="CHEM-US-00038" cdx-file="US20230000833A1-20230105-C00038.CDX" mol-file="US20230000833A1-20230105-C00038.MOL"/><us-chemistry idref="CHEM-US-00039" cdx-file="US20230000833A1-20230105-C00039.CDX" mol-file="US20230000833A1-20230105-C00039.MOL"/><us-chemistry idref="CHEM-US-00040" cdx-file="US20230000833A1-20230105-C00040.CDX" mol-file="US20230000833A1-20230105-C00040.MOL"/><us-chemistry idref="CHEM-US-00041" cdx-file="US20230000833A1-20230105-C00041.CDX" mol-file="US20230000833A1-20230105-C00041.MOL"/><us-chemistry idref="CHEM-US-00042" cdx-file="US20230000833A1-20230105-C00042.CDX" mol-file="US20230000833A1-20230105-C00042.MOL"/><us-chemistry idref="CHEM-US-00043" cdx-file="US20230000833A1-20230105-C00043.CDX" mol-file="US20230000833A1-20230105-C00043.MOL"/><us-chemistry idref="CHEM-US-00044" cdx-file="US20230000833A1-20230105-C00044.CDX" mol-file="US20230000833A1-20230105-C00044.MOL"/><us-chemistry idref="CHEM-US-00045" cdx-file="US20230000833A1-20230105-C00045.CDX" mol-file="US20230000833A1-20230105-C00045.MOL"/><us-chemistry idref="CHEM-US-00046" cdx-file="US20230000833A1-20230105-C00046.CDX" mol-file="US20230000833A1-20230105-C00046.MOL"/><us-chemistry idref="CHEM-US-00047" cdx-file="US20230000833A1-20230105-C00047.CDX" mol-file="US20230000833A1-20230105-C00047.MOL"/><us-chemistry idref="CHEM-US-00048" cdx-file="US20230000833A1-20230105-C00048.CDX" mol-file="US20230000833A1-20230105-C00048.MOL"/><us-chemistry idref="CHEM-US-00049" cdx-file="US20230000833A1-20230105-C00049.CDX" mol-file="US20230000833A1-20230105-C00049.MOL"/><us-chemistry idref="CHEM-US-00050" cdx-file="US20230000833A1-20230105-C00050.CDX" mol-file="US20230000833A1-20230105-C00050.MOL"/><us-chemistry idref="CHEM-US-00051" cdx-file="US20230000833A1-20230105-C00051.CDX" mol-file="US20230000833A1-20230105-C00051.MOL"/><us-chemistry idref="CHEM-US-00052" cdx-file="US20230000833A1-20230105-C00052.CDX" mol-file="US20230000833A1-20230105-C00052.MOL"/><us-chemistry idref="CHEM-US-00053" cdx-file="US20230000833A1-20230105-C00053.CDX" mol-file="US20230000833A1-20230105-C00053.MOL"/><us-chemistry idref="CHEM-US-00054" cdx-file="US20230000833A1-20230105-C00054.CDX" mol-file="US20230000833A1-20230105-C00054.MOL"/><us-chemistry idref="CHEM-US-00055" cdx-file="US20230000833A1-20230105-C00055.CDX" mol-file="US20230000833A1-20230105-C00055.MOL"/><us-chemistry idref="CHEM-US-00056" cdx-file="US20230000833A1-20230105-C00056.CDX" mol-file="US20230000833A1-20230105-C00056.MOL"/><us-chemistry idref="CHEM-US-00057" cdx-file="US20230000833A1-20230105-C00057.CDX" mol-file="US20230000833A1-20230105-C00057.MOL"/><us-chemistry idref="CHEM-US-00058" cdx-file="US20230000833A1-20230105-C00058.CDX" mol-file="US20230000833A1-20230105-C00058.MOL"/><us-chemistry idref="CHEM-US-00059" cdx-file="US20230000833A1-20230105-C00059.CDX" mol-file="US20230000833A1-20230105-C00059.MOL"/><us-chemistry idref="CHEM-US-00060" cdx-file="US20230000833A1-20230105-C00060.CDX" mol-file="US20230000833A1-20230105-C00060.MOL"/><us-chemistry idref="CHEM-US-00061" cdx-file="US20230000833A1-20230105-C00061.CDX" mol-file="US20230000833A1-20230105-C00061.MOL"/><us-chemistry idref="CHEM-US-00062" cdx-file="US20230000833A1-20230105-C00062.CDX" mol-file="US20230000833A1-20230105-C00062.MOL"/><us-chemistry idref="CHEM-US-00063" cdx-file="US20230000833A1-20230105-C00063.CDX" mol-file="US20230000833A1-20230105-C00063.MOL"/><us-chemistry idref="CHEM-US-00064" cdx-file="US20230000833A1-20230105-C00064.CDX" mol-file="US20230000833A1-20230105-C00064.MOL"/><us-chemistry idref="CHEM-US-00065" cdx-file="US20230000833A1-20230105-C00065.CDX" mol-file="US20230000833A1-20230105-C00065.MOL"/><us-chemistry idref="CHEM-US-00066" cdx-file="US20230000833A1-20230105-C00066.CDX" mol-file="US20230000833A1-20230105-C00066.MOL"/><us-chemistry idref="CHEM-US-00067" cdx-file="US20230000833A1-20230105-C00067.CDX" mol-file="US20230000833A1-20230105-C00067.MOL"/><us-chemistry idref="CHEM-US-00068" cdx-file="US20230000833A1-20230105-C00068.CDX" mol-file="US20230000833A1-20230105-C00068.MOL"/><us-chemistry idref="CHEM-US-00069" cdx-file="US20230000833A1-20230105-C00069.CDX" mol-file="US20230000833A1-20230105-C00069.MOL"/><us-chemistry idref="CHEM-US-00070" cdx-file="US20230000833A1-20230105-C00070.CDX" mol-file="US20230000833A1-20230105-C00070.MOL"/><us-chemistry idref="CHEM-US-00071" cdx-file="US20230000833A1-20230105-C00071.CDX" mol-file="US20230000833A1-20230105-C00071.MOL"/><us-chemistry idref="CHEM-US-00072" cdx-file="US20230000833A1-20230105-C00072.CDX" mol-file="US20230000833A1-20230105-C00072.MOL"/><us-chemistry idref="CHEM-US-00073" cdx-file="US20230000833A1-20230105-C00073.CDX" mol-file="US20230000833A1-20230105-C00073.MOL"/><us-chemistry idref="CHEM-US-00074" cdx-file="US20230000833A1-20230105-C00074.CDX" mol-file="US20230000833A1-20230105-C00074.MOL"/><us-chemistry idref="CHEM-US-00075" cdx-file="US20230000833A1-20230105-C00075.CDX" mol-file="US20230000833A1-20230105-C00075.MOL"/><us-chemistry idref="CHEM-US-00076" cdx-file="US20230000833A1-20230105-C00076.CDX" mol-file="US20230000833A1-20230105-C00076.MOL"/><us-chemistry idref="CHEM-US-00077" cdx-file="US20230000833A1-20230105-C00077.CDX" mol-file="US20230000833A1-20230105-C00077.MOL"/><us-chemistry idref="CHEM-US-00078" cdx-file="US20230000833A1-20230105-C00078.CDX" mol-file="US20230000833A1-20230105-C00078.MOL"/><us-chemistry idref="CHEM-US-00079" cdx-file="US20230000833A1-20230105-C00079.CDX" mol-file="US20230000833A1-20230105-C00079.MOL"/><us-chemistry idref="CHEM-US-00080" cdx-file="US20230000833A1-20230105-C00080.CDX" mol-file="US20230000833A1-20230105-C00080.MOL"/><us-chemistry idref="CHEM-US-00081" cdx-file="US20230000833A1-20230105-C00081.CDX" mol-file="US20230000833A1-20230105-C00081.MOL"/><us-chemistry idref="CHEM-US-00082" cdx-file="US20230000833A1-20230105-C00082.CDX" mol-file="US20230000833A1-20230105-C00082.MOL"/><us-chemistry idref="CHEM-US-00083" cdx-file="US20230000833A1-20230105-C00083.CDX" mol-file="US20230000833A1-20230105-C00083.MOL"/><us-chemistry idref="CHEM-US-00084" cdx-file="US20230000833A1-20230105-C00084.CDX" mol-file="US20230000833A1-20230105-C00084.MOL"/><us-chemistry idref="CHEM-US-00085" cdx-file="US20230000833A1-20230105-C00085.CDX" mol-file="US20230000833A1-20230105-C00085.MOL"/><us-chemistry idref="CHEM-US-00086" cdx-file="US20230000833A1-20230105-C00086.CDX" mol-file="US20230000833A1-20230105-C00086.MOL"/><us-chemistry idref="CHEM-US-00087" cdx-file="US20230000833A1-20230105-C00087.CDX" mol-file="US20230000833A1-20230105-C00087.MOL"/><us-chemistry idref="CHEM-US-00088" cdx-file="US20230000833A1-20230105-C00088.CDX" mol-file="US20230000833A1-20230105-C00088.MOL"/><us-chemistry idref="CHEM-US-00089" cdx-file="US20230000833A1-20230105-C00089.CDX" mol-file="US20230000833A1-20230105-C00089.MOL"/><us-chemistry idref="CHEM-US-00090" cdx-file="US20230000833A1-20230105-C00090.CDX" mol-file="US20230000833A1-20230105-C00090.MOL"/><us-chemistry idref="CHEM-US-00091" cdx-file="US20230000833A1-20230105-C00091.CDX" mol-file="US20230000833A1-20230105-C00091.MOL"/><us-chemistry idref="CHEM-US-00092" cdx-file="US20230000833A1-20230105-C00092.CDX" mol-file="US20230000833A1-20230105-C00092.MOL"/><us-chemistry idref="CHEM-US-00093" cdx-file="US20230000833A1-20230105-C00093.CDX" mol-file="US20230000833A1-20230105-C00093.MOL"/><us-chemistry idref="CHEM-US-00094" cdx-file="US20230000833A1-20230105-C00094.CDX" mol-file="US20230000833A1-20230105-C00094.MOL"/><us-chemistry idref="CHEM-US-00095" cdx-file="US20230000833A1-20230105-C00095.CDX" mol-file="US20230000833A1-20230105-C00095.MOL"/><us-chemistry idref="CHEM-US-00096" cdx-file="US20230000833A1-20230105-C00096.CDX" mol-file="US20230000833A1-20230105-C00096.MOL"/><us-chemistry idref="CHEM-US-00097" cdx-file="US20230000833A1-20230105-C00097.CDX" mol-file="US20230000833A1-20230105-C00097.MOL"/><us-chemistry idref="CHEM-US-00098" cdx-file="US20230000833A1-20230105-C00098.CDX" mol-file="US20230000833A1-20230105-C00098.MOL"/><us-chemistry idref="CHEM-US-00099" cdx-file="US20230000833A1-20230105-C00099.CDX" mol-file="US20230000833A1-20230105-C00099.MOL"/><us-chemistry idref="CHEM-US-00100" cdx-file="US20230000833A1-20230105-C00100.CDX" mol-file="US20230000833A1-20230105-C00100.MOL"/><us-chemistry idref="CHEM-US-00101" cdx-file="US20230000833A1-20230105-C00101.CDX" mol-file="US20230000833A1-20230105-C00101.MOL"/><us-chemistry idref="CHEM-US-00102" cdx-file="US20230000833A1-20230105-C00102.CDX" mol-file="US20230000833A1-20230105-C00102.MOL"/><us-chemistry idref="CHEM-US-00103" cdx-file="US20230000833A1-20230105-C00103.CDX" mol-file="US20230000833A1-20230105-C00103.MOL"/><us-chemistry idref="CHEM-US-00104" cdx-file="US20230000833A1-20230105-C00104.CDX" mol-file="US20230000833A1-20230105-C00104.MOL"/><us-chemistry idref="CHEM-US-00105" cdx-file="US20230000833A1-20230105-C00105.CDX" mol-file="US20230000833A1-20230105-C00105.MOL"/><us-chemistry idref="CHEM-US-00106" cdx-file="US20230000833A1-20230105-C00106.CDX" mol-file="US20230000833A1-20230105-C00106.MOL"/><us-chemistry idref="CHEM-US-00107" cdx-file="US20230000833A1-20230105-C00107.CDX" mol-file="US20230000833A1-20230105-C00107.MOL"/><us-chemistry idref="CHEM-US-00108" cdx-file="US20230000833A1-20230105-C00108.CDX" mol-file="US20230000833A1-20230105-C00108.MOL"/><us-chemistry idref="CHEM-US-00109" cdx-file="US20230000833A1-20230105-C00109.CDX" mol-file="US20230000833A1-20230105-C00109.MOL"/><us-chemistry idref="CHEM-US-00110" cdx-file="US20230000833A1-20230105-C00110.CDX" mol-file="US20230000833A1-20230105-C00110.MOL"/><us-chemistry idref="CHEM-US-00111" cdx-file="US20230000833A1-20230105-C00111.CDX" mol-file="US20230000833A1-20230105-C00111.MOL"/><us-chemistry idref="CHEM-US-00112" cdx-file="US20230000833A1-20230105-C00112.CDX" mol-file="US20230000833A1-20230105-C00112.MOL"/><us-chemistry idref="CHEM-US-00113" cdx-file="US20230000833A1-20230105-C00113.CDX" mol-file="US20230000833A1-20230105-C00113.MOL"/><us-chemistry idref="CHEM-US-00114" cdx-file="US20230000833A1-20230105-C00114.CDX" mol-file="US20230000833A1-20230105-C00114.MOL"/><us-chemistry idref="CHEM-US-00115" cdx-file="US20230000833A1-20230105-C00115.CDX" mol-file="US20230000833A1-20230105-C00115.MOL"/><us-chemistry idref="CHEM-US-00116" cdx-file="US20230000833A1-20230105-C00116.CDX" mol-file="US20230000833A1-20230105-C00116.MOL"/><us-chemistry idref="CHEM-US-00117" cdx-file="US20230000833A1-20230105-C00117.CDX" mol-file="US20230000833A1-20230105-C00117.MOL"/><us-chemistry idref="CHEM-US-00118" cdx-file="US20230000833A1-20230105-C00118.CDX" mol-file="US20230000833A1-20230105-C00118.MOL"/><us-chemistry idref="CHEM-US-00119" cdx-file="US20230000833A1-20230105-C00119.CDX" mol-file="US20230000833A1-20230105-C00119.MOL"/><us-chemistry idref="CHEM-US-00120" cdx-file="US20230000833A1-20230105-C00120.CDX" mol-file="US20230000833A1-20230105-C00120.MOL"/><us-chemistry idref="CHEM-US-00121" cdx-file="US20230000833A1-20230105-C00121.CDX" mol-file="US20230000833A1-20230105-C00121.MOL"/><us-chemistry idref="CHEM-US-00122" cdx-file="US20230000833A1-20230105-C00122.CDX" mol-file="US20230000833A1-20230105-C00122.MOL"/><us-chemistry idref="CHEM-US-00123" cdx-file="US20230000833A1-20230105-C00123.CDX" mol-file="US20230000833A1-20230105-C00123.MOL"/><us-chemistry idref="CHEM-US-00124" cdx-file="US20230000833A1-20230105-C00124.CDX" mol-file="US20230000833A1-20230105-C00124.MOL"/><us-chemistry idref="CHEM-US-00125" cdx-file="US20230000833A1-20230105-C00125.CDX" mol-file="US20230000833A1-20230105-C00125.MOL"/><us-chemistry idref="CHEM-US-00126" cdx-file="US20230000833A1-20230105-C00126.CDX" mol-file="US20230000833A1-20230105-C00126.MOL"/><us-chemistry idref="CHEM-US-00127" cdx-file="US20230000833A1-20230105-C00127.CDX" mol-file="US20230000833A1-20230105-C00127.MOL"/><us-chemistry idref="CHEM-US-00128" cdx-file="US20230000833A1-20230105-C00128.CDX" mol-file="US20230000833A1-20230105-C00128.MOL"/><us-chemistry idref="CHEM-US-00129" cdx-file="US20230000833A1-20230105-C00129.CDX" mol-file="US20230000833A1-20230105-C00129.MOL"/><us-chemistry idref="CHEM-US-00130" cdx-file="US20230000833A1-20230105-C00130.CDX" mol-file="US20230000833A1-20230105-C00130.MOL"/><us-chemistry idref="CHEM-US-00131" cdx-file="US20230000833A1-20230105-C00131.CDX" mol-file="US20230000833A1-20230105-C00131.MOL"/><us-chemistry idref="CHEM-US-00132" cdx-file="US20230000833A1-20230105-C00132.CDX" mol-file="US20230000833A1-20230105-C00132.MOL"/><us-chemistry idref="CHEM-US-00133" cdx-file="US20230000833A1-20230105-C00133.CDX" mol-file="US20230000833A1-20230105-C00133.MOL"/><us-chemistry idref="CHEM-US-00134" cdx-file="US20230000833A1-20230105-C00134.CDX" mol-file="US20230000833A1-20230105-C00134.MOL"/><us-chemistry idref="CHEM-US-00135" cdx-file="US20230000833A1-20230105-C00135.CDX" mol-file="US20230000833A1-20230105-C00135.MOL"/><us-chemistry idref="CHEM-US-00136" cdx-file="US20230000833A1-20230105-C00136.CDX" mol-file="US20230000833A1-20230105-C00136.MOL"/><us-chemistry idref="CHEM-US-00137" cdx-file="US20230000833A1-20230105-C00137.CDX" mol-file="US20230000833A1-20230105-C00137.MOL"/><us-chemistry idref="CHEM-US-00138" cdx-file="US20230000833A1-20230105-C00138.CDX" mol-file="US20230000833A1-20230105-C00138.MOL"/><us-chemistry idref="CHEM-US-00139" cdx-file="US20230000833A1-20230105-C00139.CDX" mol-file="US20230000833A1-20230105-C00139.MOL"/><us-chemistry idref="CHEM-US-00140" cdx-file="US20230000833A1-20230105-C00140.CDX" mol-file="US20230000833A1-20230105-C00140.MOL"/><us-chemistry idref="CHEM-US-00141" cdx-file="US20230000833A1-20230105-C00141.CDX" mol-file="US20230000833A1-20230105-C00141.MOL"/><us-chemistry idref="CHEM-US-00142" cdx-file="US20230000833A1-20230105-C00142.CDX" mol-file="US20230000833A1-20230105-C00142.MOL"/><us-chemistry idref="CHEM-US-00143" cdx-file="US20230000833A1-20230105-C00143.CDX" mol-file="US20230000833A1-20230105-C00143.MOL"/><us-chemistry idref="CHEM-US-00144" cdx-file="US20230000833A1-20230105-C00144.CDX" mol-file="US20230000833A1-20230105-C00144.MOL"/><us-chemistry idref="CHEM-US-00145" cdx-file="US20230000833A1-20230105-C00145.CDX" mol-file="US20230000833A1-20230105-C00145.MOL"/><us-chemistry idref="CHEM-US-00146" cdx-file="US20230000833A1-20230105-C00146.CDX" mol-file="US20230000833A1-20230105-C00146.MOL"/><us-chemistry idref="CHEM-US-00147" cdx-file="US20230000833A1-20230105-C00147.CDX" mol-file="US20230000833A1-20230105-C00147.MOL"/><us-chemistry idref="CHEM-US-00148" cdx-file="US20230000833A1-20230105-C00148.CDX" mol-file="US20230000833A1-20230105-C00148.MOL"/><us-chemistry idref="CHEM-US-00149" cdx-file="US20230000833A1-20230105-C00149.CDX" mol-file="US20230000833A1-20230105-C00149.MOL"/><us-chemistry idref="CHEM-US-00150" cdx-file="US20230000833A1-20230105-C00150.CDX" mol-file="US20230000833A1-20230105-C00150.MOL"/><us-chemistry idref="CHEM-US-00151" cdx-file="US20230000833A1-20230105-C00151.CDX" mol-file="US20230000833A1-20230105-C00151.MOL"/><us-chemistry idref="CHEM-US-00152" cdx-file="US20230000833A1-20230105-C00152.CDX" mol-file="US20230000833A1-20230105-C00152.MOL"/><us-chemistry idref="CHEM-US-00153" cdx-file="US20230000833A1-20230105-C00153.CDX" mol-file="US20230000833A1-20230105-C00153.MOL"/><us-chemistry idref="CHEM-US-00154" cdx-file="US20230000833A1-20230105-C00154.CDX" mol-file="US20230000833A1-20230105-C00154.MOL"/><us-chemistry idref="CHEM-US-00155" cdx-file="US20230000833A1-20230105-C00155.CDX" mol-file="US20230000833A1-20230105-C00155.MOL"/><us-chemistry idref="CHEM-US-00156" cdx-file="US20230000833A1-20230105-C00156.CDX" mol-file="US20230000833A1-20230105-C00156.MOL"/><us-chemistry idref="CHEM-US-00157" cdx-file="US20230000833A1-20230105-C00157.CDX" mol-file="US20230000833A1-20230105-C00157.MOL"/><us-chemistry idref="CHEM-US-00158" cdx-file="US20230000833A1-20230105-C00158.CDX" mol-file="US20230000833A1-20230105-C00158.MOL"/><us-chemistry idref="CHEM-US-00159" cdx-file="US20230000833A1-20230105-C00159.CDX" mol-file="US20230000833A1-20230105-C00159.MOL"/><us-chemistry idref="CHEM-US-00160" cdx-file="US20230000833A1-20230105-C00160.CDX" mol-file="US20230000833A1-20230105-C00160.MOL"/><us-chemistry idref="CHEM-US-00161" cdx-file="US20230000833A1-20230105-C00161.CDX" mol-file="US20230000833A1-20230105-C00161.MOL"/><us-chemistry idref="CHEM-US-00162" cdx-file="US20230000833A1-20230105-C00162.CDX" mol-file="US20230000833A1-20230105-C00162.MOL"/><us-chemistry idref="CHEM-US-00163" cdx-file="US20230000833A1-20230105-C00163.CDX" mol-file="US20230000833A1-20230105-C00163.MOL"/><us-chemistry idref="CHEM-US-00164" cdx-file="US20230000833A1-20230105-C00164.CDX" mol-file="US20230000833A1-20230105-C00164.MOL"/><us-chemistry idref="CHEM-US-00165" cdx-file="US20230000833A1-20230105-C00165.CDX" mol-file="US20230000833A1-20230105-C00165.MOL"/><us-chemistry idref="CHEM-US-00166" cdx-file="US20230000833A1-20230105-C00166.CDX" mol-file="US20230000833A1-20230105-C00166.MOL"/><us-chemistry idref="CHEM-US-00167" cdx-file="US20230000833A1-20230105-C00167.CDX" mol-file="US20230000833A1-20230105-C00167.MOL"/><us-chemistry idref="CHEM-US-00168" cdx-file="US20230000833A1-20230105-C00168.CDX" mol-file="US20230000833A1-20230105-C00168.MOL"/><us-chemistry idref="CHEM-US-00169" cdx-file="US20230000833A1-20230105-C00169.CDX" mol-file="US20230000833A1-20230105-C00169.MOL"/><us-chemistry idref="CHEM-US-00170" cdx-file="US20230000833A1-20230105-C00170.CDX" mol-file="US20230000833A1-20230105-C00170.MOL"/><us-chemistry idref="CHEM-US-00171" cdx-file="US20230000833A1-20230105-C00171.CDX" mol-file="US20230000833A1-20230105-C00171.MOL"/><us-chemistry idref="CHEM-US-00172" cdx-file="US20230000833A1-20230105-C00172.CDX" mol-file="US20230000833A1-20230105-C00172.MOL"/><us-chemistry idref="CHEM-US-00173" cdx-file="US20230000833A1-20230105-C00173.CDX" mol-file="US20230000833A1-20230105-C00173.MOL"/><us-chemistry idref="CHEM-US-00174" cdx-file="US20230000833A1-20230105-C00174.CDX" mol-file="US20230000833A1-20230105-C00174.MOL"/><us-chemistry idref="CHEM-US-00175" cdx-file="US20230000833A1-20230105-C00175.CDX" mol-file="US20230000833A1-20230105-C00175.MOL"/><us-chemistry idref="CHEM-US-00176" cdx-file="US20230000833A1-20230105-C00176.CDX" mol-file="US20230000833A1-20230105-C00176.MOL"/><us-chemistry idref="CHEM-US-00177" cdx-file="US20230000833A1-20230105-C00177.CDX" mol-file="US20230000833A1-20230105-C00177.MOL"/><us-chemistry idref="CHEM-US-00178" cdx-file="US20230000833A1-20230105-C00178.CDX" mol-file="US20230000833A1-20230105-C00178.MOL"/><us-chemistry idref="CHEM-US-00179" cdx-file="US20230000833A1-20230105-C00179.CDX" mol-file="US20230000833A1-20230105-C00179.MOL"/><us-chemistry idref="CHEM-US-00180" cdx-file="US20230000833A1-20230105-C00180.CDX" mol-file="US20230000833A1-20230105-C00180.MOL"/><us-chemistry idref="CHEM-US-00181" cdx-file="US20230000833A1-20230105-C00181.CDX" mol-file="US20230000833A1-20230105-C00181.MOL"/><us-chemistry idref="CHEM-US-00182" cdx-file="US20230000833A1-20230105-C00182.CDX" mol-file="US20230000833A1-20230105-C00182.MOL"/><us-chemistry idref="CHEM-US-00183" cdx-file="US20230000833A1-20230105-C00183.CDX" mol-file="US20230000833A1-20230105-C00183.MOL"/><us-chemistry idref="CHEM-US-00184" cdx-file="US20230000833A1-20230105-C00184.CDX" mol-file="US20230000833A1-20230105-C00184.MOL"/><us-chemistry idref="CHEM-US-00185" cdx-file="US20230000833A1-20230105-C00185.CDX" mol-file="US20230000833A1-20230105-C00185.MOL"/><us-chemistry idref="CHEM-US-00186" cdx-file="US20230000833A1-20230105-C00186.CDX" mol-file="US20230000833A1-20230105-C00186.MOL"/><us-chemistry idref="CHEM-US-00187" cdx-file="US20230000833A1-20230105-C00187.CDX" mol-file="US20230000833A1-20230105-C00187.MOL"/><us-chemistry idref="CHEM-US-00188" cdx-file="US20230000833A1-20230105-C00188.CDX" mol-file="US20230000833A1-20230105-C00188.MOL"/><us-chemistry idref="CHEM-US-00189" cdx-file="US20230000833A1-20230105-C00189.CDX" mol-file="US20230000833A1-20230105-C00189.MOL"/><us-chemistry idref="CHEM-US-00190" cdx-file="US20230000833A1-20230105-C00190.CDX" mol-file="US20230000833A1-20230105-C00190.MOL"/><us-chemistry idref="CHEM-US-00191" cdx-file="US20230000833A1-20230105-C00191.CDX" mol-file="US20230000833A1-20230105-C00191.MOL"/><us-chemistry idref="CHEM-US-00192" cdx-file="US20230000833A1-20230105-C00192.CDX" mol-file="US20230000833A1-20230105-C00192.MOL"/><us-chemistry idref="CHEM-US-00193" cdx-file="US20230000833A1-20230105-C00193.CDX" mol-file="US20230000833A1-20230105-C00193.MOL"/><us-chemistry idref="CHEM-US-00194" cdx-file="US20230000833A1-20230105-C00194.CDX" mol-file="US20230000833A1-20230105-C00194.MOL"/><us-chemistry idref="CHEM-US-00195" cdx-file="US20230000833A1-20230105-C00195.CDX" mol-file="US20230000833A1-20230105-C00195.MOL"/><us-chemistry idref="CHEM-US-00196" cdx-file="US20230000833A1-20230105-C00196.CDX" mol-file="US20230000833A1-20230105-C00196.MOL"/><us-chemistry idref="CHEM-US-00197" cdx-file="US20230000833A1-20230105-C00197.CDX" mol-file="US20230000833A1-20230105-C00197.MOL"/><us-chemistry idref="CHEM-US-00198" cdx-file="US20230000833A1-20230105-C00198.CDX" mol-file="US20230000833A1-20230105-C00198.MOL"/><us-chemistry idref="CHEM-US-00199" cdx-file="US20230000833A1-20230105-C00199.CDX" mol-file="US20230000833A1-20230105-C00199.MOL"/><us-chemistry idref="CHEM-US-00200" cdx-file="US20230000833A1-20230105-C00200.CDX" mol-file="US20230000833A1-20230105-C00200.MOL"/><us-chemistry idref="CHEM-US-00201" cdx-file="US20230000833A1-20230105-C00201.CDX" mol-file="US20230000833A1-20230105-C00201.MOL"/><us-chemistry idref="CHEM-US-00202" cdx-file="US20230000833A1-20230105-C00202.CDX" mol-file="US20230000833A1-20230105-C00202.MOL"/><us-chemistry idref="CHEM-US-00203" cdx-file="US20230000833A1-20230105-C00203.CDX" mol-file="US20230000833A1-20230105-C00203.MOL"/><us-chemistry idref="CHEM-US-00204" cdx-file="US20230000833A1-20230105-C00204.CDX" mol-file="US20230000833A1-20230105-C00204.MOL"/><us-chemistry idref="CHEM-US-00205" cdx-file="US20230000833A1-20230105-C00205.CDX" mol-file="US20230000833A1-20230105-C00205.MOL"/><us-chemistry idref="CHEM-US-00206" cdx-file="US20230000833A1-20230105-C00206.CDX" mol-file="US20230000833A1-20230105-C00206.MOL"/><us-chemistry idref="CHEM-US-00207" cdx-file="US20230000833A1-20230105-C00207.CDX" mol-file="US20230000833A1-20230105-C00207.MOL"/><us-chemistry idref="CHEM-US-00208" cdx-file="US20230000833A1-20230105-C00208.CDX" mol-file="US20230000833A1-20230105-C00208.MOL"/><us-chemistry idref="CHEM-US-00209" cdx-file="US20230000833A1-20230105-C00209.CDX" mol-file="US20230000833A1-20230105-C00209.MOL"/><us-chemistry idref="CHEM-US-00210" cdx-file="US20230000833A1-20230105-C00210.CDX" mol-file="US20230000833A1-20230105-C00210.MOL"/><us-chemistry idref="CHEM-US-00211" cdx-file="US20230000833A1-20230105-C00211.CDX" mol-file="US20230000833A1-20230105-C00211.MOL"/><us-chemistry idref="CHEM-US-00212" cdx-file="US20230000833A1-20230105-C00212.CDX" mol-file="US20230000833A1-20230105-C00212.MOL"/><us-chemistry idref="CHEM-US-00213" cdx-file="US20230000833A1-20230105-C00213.CDX" mol-file="US20230000833A1-20230105-C00213.MOL"/><us-chemistry idref="CHEM-US-00214" cdx-file="US20230000833A1-20230105-C00214.CDX" mol-file="US20230000833A1-20230105-C00214.MOL"/><us-chemistry idref="CHEM-US-00215" cdx-file="US20230000833A1-20230105-C00215.CDX" mol-file="US20230000833A1-20230105-C00215.MOL"/><us-chemistry idref="CHEM-US-00216" cdx-file="US20230000833A1-20230105-C00216.CDX" mol-file="US20230000833A1-20230105-C00216.MOL"/><us-chemistry idref="CHEM-US-00217" cdx-file="US20230000833A1-20230105-C00217.CDX" mol-file="US20230000833A1-20230105-C00217.MOL"/><us-chemistry idref="CHEM-US-00218" cdx-file="US20230000833A1-20230105-C00218.CDX" mol-file="US20230000833A1-20230105-C00218.MOL"/><us-chemistry idref="CHEM-US-00219" cdx-file="US20230000833A1-20230105-C00219.CDX" mol-file="US20230000833A1-20230105-C00219.MOL"/><us-chemistry idref="CHEM-US-00220" cdx-file="US20230000833A1-20230105-C00220.CDX" mol-file="US20230000833A1-20230105-C00220.MOL"/><us-chemistry idref="CHEM-US-00221" cdx-file="US20230000833A1-20230105-C00221.CDX" mol-file="US20230000833A1-20230105-C00221.MOL"/><us-chemistry idref="CHEM-US-00222" cdx-file="US20230000833A1-20230105-C00222.CDX" mol-file="US20230000833A1-20230105-C00222.MOL"/><us-chemistry idref="CHEM-US-00223" cdx-file="US20230000833A1-20230105-C00223.CDX" mol-file="US20230000833A1-20230105-C00223.MOL"/><us-chemistry idref="CHEM-US-00224" cdx-file="US20230000833A1-20230105-C00224.CDX" mol-file="US20230000833A1-20230105-C00224.MOL"/><us-chemistry idref="CHEM-US-00225" cdx-file="US20230000833A1-20230105-C00225.CDX" mol-file="US20230000833A1-20230105-C00225.MOL"/><us-chemistry idref="CHEM-US-00226" cdx-file="US20230000833A1-20230105-C00226.CDX" mol-file="US20230000833A1-20230105-C00226.MOL"/><us-chemistry idref="CHEM-US-00227" cdx-file="US20230000833A1-20230105-C00227.CDX" mol-file="US20230000833A1-20230105-C00227.MOL"/><us-chemistry idref="CHEM-US-00228" cdx-file="US20230000833A1-20230105-C00228.CDX" mol-file="US20230000833A1-20230105-C00228.MOL"/><us-chemistry idref="CHEM-US-00229" cdx-file="US20230000833A1-20230105-C00229.CDX" mol-file="US20230000833A1-20230105-C00229.MOL"/><us-chemistry idref="CHEM-US-00230" cdx-file="US20230000833A1-20230105-C00230.CDX" mol-file="US20230000833A1-20230105-C00230.MOL"/><us-chemistry idref="CHEM-US-00231" cdx-file="US20230000833A1-20230105-C00231.CDX" mol-file="US20230000833A1-20230105-C00231.MOL"/><us-chemistry idref="CHEM-US-00232" cdx-file="US20230000833A1-20230105-C00232.CDX" mol-file="US20230000833A1-20230105-C00232.MOL"/><us-chemistry idref="CHEM-US-00233" cdx-file="US20230000833A1-20230105-C00233.CDX" mol-file="US20230000833A1-20230105-C00233.MOL"/><us-chemistry idref="CHEM-US-00234" cdx-file="US20230000833A1-20230105-C00234.CDX" mol-file="US20230000833A1-20230105-C00234.MOL"/><us-chemistry idref="CHEM-US-00235" cdx-file="US20230000833A1-20230105-C00235.CDX" mol-file="US20230000833A1-20230105-C00235.MOL"/><us-chemistry idref="CHEM-US-00236" cdx-file="US20230000833A1-20230105-C00236.CDX" mol-file="US20230000833A1-20230105-C00236.MOL"/><us-chemistry idref="CHEM-US-00237" cdx-file="US20230000833A1-20230105-C00237.CDX" mol-file="US20230000833A1-20230105-C00237.MOL"/><us-chemistry idref="CHEM-US-00238" cdx-file="US20230000833A1-20230105-C00238.CDX" mol-file="US20230000833A1-20230105-C00238.MOL"/><us-chemistry idref="CHEM-US-00239" cdx-file="US20230000833A1-20230105-C00239.CDX" mol-file="US20230000833A1-20230105-C00239.MOL"/><us-chemistry idref="CHEM-US-00240" cdx-file="US20230000833A1-20230105-C00240.CDX" mol-file="US20230000833A1-20230105-C00240.MOL"/><us-chemistry idref="CHEM-US-00241" cdx-file="US20230000833A1-20230105-C00241.CDX" mol-file="US20230000833A1-20230105-C00241.MOL"/><us-chemistry idref="CHEM-US-00242" cdx-file="US20230000833A1-20230105-C00242.CDX" mol-file="US20230000833A1-20230105-C00242.MOL"/><us-chemistry idref="CHEM-US-00243" cdx-file="US20230000833A1-20230105-C00243.CDX" mol-file="US20230000833A1-20230105-C00243.MOL"/><us-chemistry idref="CHEM-US-00244" cdx-file="US20230000833A1-20230105-C00244.CDX" mol-file="US20230000833A1-20230105-C00244.MOL"/><us-chemistry idref="CHEM-US-00245" cdx-file="US20230000833A1-20230105-C00245.CDX" mol-file="US20230000833A1-20230105-C00245.MOL"/><us-chemistry idref="CHEM-US-00246" cdx-file="US20230000833A1-20230105-C00246.CDX" mol-file="US20230000833A1-20230105-C00246.MOL"/><us-chemistry idref="CHEM-US-00247" cdx-file="US20230000833A1-20230105-C00247.CDX" mol-file="US20230000833A1-20230105-C00247.MOL"/><us-chemistry idref="CHEM-US-00248" cdx-file="US20230000833A1-20230105-C00248.CDX" mol-file="US20230000833A1-20230105-C00248.MOL"/><us-chemistry idref="CHEM-US-00249" cdx-file="US20230000833A1-20230105-C00249.CDX" mol-file="US20230000833A1-20230105-C00249.MOL"/><us-chemistry idref="CHEM-US-00250" cdx-file="US20230000833A1-20230105-C00250.CDX" mol-file="US20230000833A1-20230105-C00250.MOL"/><us-chemistry idref="CHEM-US-00251" cdx-file="US20230000833A1-20230105-C00251.CDX" mol-file="US20230000833A1-20230105-C00251.MOL"/><us-chemistry idref="CHEM-US-00252" cdx-file="US20230000833A1-20230105-C00252.CDX" mol-file="US20230000833A1-20230105-C00252.MOL"/><us-chemistry idref="CHEM-US-00253" cdx-file="US20230000833A1-20230105-C00253.CDX" mol-file="US20230000833A1-20230105-C00253.MOL"/><us-chemistry idref="CHEM-US-00254" cdx-file="US20230000833A1-20230105-C00254.CDX" mol-file="US20230000833A1-20230105-C00254.MOL"/><us-chemistry idref="CHEM-US-00255" cdx-file="US20230000833A1-20230105-C00255.CDX" mol-file="US20230000833A1-20230105-C00255.MOL"/><us-chemistry idref="CHEM-US-00256" cdx-file="US20230000833A1-20230105-C00256.CDX" mol-file="US20230000833A1-20230105-C00256.MOL"/><us-chemistry idref="CHEM-US-00257" cdx-file="US20230000833A1-20230105-C00257.CDX" mol-file="US20230000833A1-20230105-C00257.MOL"/><us-chemistry idref="CHEM-US-00258" cdx-file="US20230000833A1-20230105-C00258.CDX" mol-file="US20230000833A1-20230105-C00258.MOL"/><us-chemistry idref="CHEM-US-00259" cdx-file="US20230000833A1-20230105-C00259.CDX" mol-file="US20230000833A1-20230105-C00259.MOL"/><us-chemistry idref="CHEM-US-00260" cdx-file="US20230000833A1-20230105-C00260.CDX" mol-file="US20230000833A1-20230105-C00260.MOL"/><us-chemistry idref="CHEM-US-00261" cdx-file="US20230000833A1-20230105-C00261.CDX" mol-file="US20230000833A1-20230105-C00261.MOL"/><us-chemistry idref="CHEM-US-00262" cdx-file="US20230000833A1-20230105-C00262.CDX" mol-file="US20230000833A1-20230105-C00262.MOL"/><us-chemistry idref="CHEM-US-00263" cdx-file="US20230000833A1-20230105-C00263.CDX" mol-file="US20230000833A1-20230105-C00263.MOL"/><us-chemistry idref="CHEM-US-00264" cdx-file="US20230000833A1-20230105-C00264.CDX" mol-file="US20230000833A1-20230105-C00264.MOL"/><us-chemistry idref="CHEM-US-00265" cdx-file="US20230000833A1-20230105-C00265.CDX" mol-file="US20230000833A1-20230105-C00265.MOL"/><us-chemistry idref="CHEM-US-00266" cdx-file="US20230000833A1-20230105-C00266.CDX" mol-file="US20230000833A1-20230105-C00266.MOL"/><us-chemistry idref="CHEM-US-00267" cdx-file="US20230000833A1-20230105-C00267.CDX" mol-file="US20230000833A1-20230105-C00267.MOL"/><us-chemistry idref="CHEM-US-00268" cdx-file="US20230000833A1-20230105-C00268.CDX" mol-file="US20230000833A1-20230105-C00268.MOL"/><us-chemistry idref="CHEM-US-00269" cdx-file="US20230000833A1-20230105-C00269.CDX" mol-file="US20230000833A1-20230105-C00269.MOL"/><us-chemistry idref="CHEM-US-00270" cdx-file="US20230000833A1-20230105-C00270.CDX" mol-file="US20230000833A1-20230105-C00270.MOL"/><us-chemistry idref="CHEM-US-00271" cdx-file="US20230000833A1-20230105-C00271.CDX" mol-file="US20230000833A1-20230105-C00271.MOL"/><us-chemistry idref="CHEM-US-00272" cdx-file="US20230000833A1-20230105-C00272.CDX" mol-file="US20230000833A1-20230105-C00272.MOL"/><us-chemistry idref="CHEM-US-00273" cdx-file="US20230000833A1-20230105-C00273.CDX" mol-file="US20230000833A1-20230105-C00273.MOL"/><us-chemistry idref="CHEM-US-00274" cdx-file="US20230000833A1-20230105-C00274.CDX" mol-file="US20230000833A1-20230105-C00274.MOL"/><us-chemistry idref="CHEM-US-00275" cdx-file="US20230000833A1-20230105-C00275.CDX" mol-file="US20230000833A1-20230105-C00275.MOL"/><us-chemistry idref="CHEM-US-00276" cdx-file="US20230000833A1-20230105-C00276.CDX" mol-file="US20230000833A1-20230105-C00276.MOL"/><us-chemistry idref="CHEM-US-00277" cdx-file="US20230000833A1-20230105-C00277.CDX" mol-file="US20230000833A1-20230105-C00277.MOL"/><us-chemistry idref="CHEM-US-00278" cdx-file="US20230000833A1-20230105-C00278.CDX" mol-file="US20230000833A1-20230105-C00278.MOL"/><us-chemistry idref="CHEM-US-00279" cdx-file="US20230000833A1-20230105-C00279.CDX" mol-file="US20230000833A1-20230105-C00279.MOL"/><us-chemistry idref="CHEM-US-00280" cdx-file="US20230000833A1-20230105-C00280.CDX" mol-file="US20230000833A1-20230105-C00280.MOL"/><us-chemistry idref="CHEM-US-00281" cdx-file="US20230000833A1-20230105-C00281.CDX" mol-file="US20230000833A1-20230105-C00281.MOL"/><us-chemistry idref="CHEM-US-00282" cdx-file="US20230000833A1-20230105-C00282.CDX" mol-file="US20230000833A1-20230105-C00282.MOL"/><us-chemistry idref="CHEM-US-00283" cdx-file="US20230000833A1-20230105-C00283.CDX" mol-file="US20230000833A1-20230105-C00283.MOL"/><us-chemistry idref="CHEM-US-00284" cdx-file="US20230000833A1-20230105-C00284.CDX" mol-file="US20230000833A1-20230105-C00284.MOL"/><us-chemistry idref="CHEM-US-00285" cdx-file="US20230000833A1-20230105-C00285.CDX" mol-file="US20230000833A1-20230105-C00285.MOL"/><us-chemistry idref="CHEM-US-00286" cdx-file="US20230000833A1-20230105-C00286.CDX" mol-file="US20230000833A1-20230105-C00286.MOL"/><us-chemistry idref="CHEM-US-00287" cdx-file="US20230000833A1-20230105-C00287.CDX" mol-file="US20230000833A1-20230105-C00287.MOL"/><us-chemistry idref="CHEM-US-00288" cdx-file="US20230000833A1-20230105-C00288.CDX" mol-file="US20230000833A1-20230105-C00288.MOL"/><us-chemistry idref="CHEM-US-00289" cdx-file="US20230000833A1-20230105-C00289.CDX" mol-file="US20230000833A1-20230105-C00289.MOL"/><us-chemistry idref="CHEM-US-00290" cdx-file="US20230000833A1-20230105-C00290.CDX" mol-file="US20230000833A1-20230105-C00290.MOL"/><us-chemistry idref="CHEM-US-00291" cdx-file="US20230000833A1-20230105-C00291.CDX" mol-file="US20230000833A1-20230105-C00291.MOL"/><us-chemistry idref="CHEM-US-00292" cdx-file="US20230000833A1-20230105-C00292.CDX" mol-file="US20230000833A1-20230105-C00292.MOL"/><us-chemistry idref="CHEM-US-00293" cdx-file="US20230000833A1-20230105-C00293.CDX" mol-file="US20230000833A1-20230105-C00293.MOL"/><us-chemistry idref="CHEM-US-00294" cdx-file="US20230000833A1-20230105-C00294.CDX" mol-file="US20230000833A1-20230105-C00294.MOL"/><us-chemistry idref="CHEM-US-00295" cdx-file="US20230000833A1-20230105-C00295.CDX" mol-file="US20230000833A1-20230105-C00295.MOL"/><us-chemistry idref="CHEM-US-00296" cdx-file="US20230000833A1-20230105-C00296.CDX" mol-file="US20230000833A1-20230105-C00296.MOL"/><us-chemistry idref="CHEM-US-00297" cdx-file="US20230000833A1-20230105-C00297.CDX" mol-file="US20230000833A1-20230105-C00297.MOL"/><us-chemistry idref="CHEM-US-00298" cdx-file="US20230000833A1-20230105-C00298.CDX" mol-file="US20230000833A1-20230105-C00298.MOL"/><us-chemistry idref="CHEM-US-00299" cdx-file="US20230000833A1-20230105-C00299.CDX" mol-file="US20230000833A1-20230105-C00299.MOL"/><us-chemistry idref="CHEM-US-00300" cdx-file="US20230000833A1-20230105-C00300.CDX" mol-file="US20230000833A1-20230105-C00300.MOL"/><us-chemistry idref="CHEM-US-00301" cdx-file="US20230000833A1-20230105-C00301.CDX" mol-file="US20230000833A1-20230105-C00301.MOL"/><us-chemistry idref="CHEM-US-00302" cdx-file="US20230000833A1-20230105-C00302.CDX" mol-file="US20230000833A1-20230105-C00302.MOL"/><us-chemistry idref="CHEM-US-00303" cdx-file="US20230000833A1-20230105-C00303.CDX" mol-file="US20230000833A1-20230105-C00303.MOL"/><us-chemistry idref="CHEM-US-00304" cdx-file="US20230000833A1-20230105-C00304.CDX" mol-file="US20230000833A1-20230105-C00304.MOL"/><us-chemistry idref="CHEM-US-00305" cdx-file="US20230000833A1-20230105-C00305.CDX" mol-file="US20230000833A1-20230105-C00305.MOL"/><us-chemistry idref="CHEM-US-00306" cdx-file="US20230000833A1-20230105-C00306.CDX" mol-file="US20230000833A1-20230105-C00306.MOL"/><us-chemistry idref="CHEM-US-00307" cdx-file="US20230000833A1-20230105-C00307.CDX" mol-file="US20230000833A1-20230105-C00307.MOL"/><us-chemistry idref="CHEM-US-00308" cdx-file="US20230000833A1-20230105-C00308.CDX" mol-file="US20230000833A1-20230105-C00308.MOL"/><us-chemistry idref="CHEM-US-00309" cdx-file="US20230000833A1-20230105-C00309.CDX" mol-file="US20230000833A1-20230105-C00309.MOL"/><us-chemistry idref="CHEM-US-00310" cdx-file="US20230000833A1-20230105-C00310.CDX" mol-file="US20230000833A1-20230105-C00310.MOL"/><us-chemistry idref="CHEM-US-00311" cdx-file="US20230000833A1-20230105-C00311.CDX" mol-file="US20230000833A1-20230105-C00311.MOL"/><us-chemistry idref="CHEM-US-00312" cdx-file="US20230000833A1-20230105-C00312.CDX" mol-file="US20230000833A1-20230105-C00312.MOL"/><us-chemistry idref="CHEM-US-00313" cdx-file="US20230000833A1-20230105-C00313.CDX" mol-file="US20230000833A1-20230105-C00313.MOL"/><us-chemistry idref="CHEM-US-00314" cdx-file="US20230000833A1-20230105-C00314.CDX" mol-file="US20230000833A1-20230105-C00314.MOL"/><us-chemistry idref="CHEM-US-00315" cdx-file="US20230000833A1-20230105-C00315.CDX" mol-file="US20230000833A1-20230105-C00315.MOL"/><us-chemistry idref="CHEM-US-00316" cdx-file="US20230000833A1-20230105-C00316.CDX" mol-file="US20230000833A1-20230105-C00316.MOL"/><us-chemistry idref="CHEM-US-00317" cdx-file="US20230000833A1-20230105-C00317.CDX" mol-file="US20230000833A1-20230105-C00317.MOL"/><us-chemistry idref="CHEM-US-00318" cdx-file="US20230000833A1-20230105-C00318.CDX" mol-file="US20230000833A1-20230105-C00318.MOL"/><us-chemistry idref="CHEM-US-00319" cdx-file="US20230000833A1-20230105-C00319.CDX" mol-file="US20230000833A1-20230105-C00319.MOL"/><us-chemistry idref="CHEM-US-00320" cdx-file="US20230000833A1-20230105-C00320.CDX" mol-file="US20230000833A1-20230105-C00320.MOL"/><us-chemistry idref="CHEM-US-00321" cdx-file="US20230000833A1-20230105-C00321.CDX" mol-file="US20230000833A1-20230105-C00321.MOL"/><us-chemistry idref="CHEM-US-00322" cdx-file="US20230000833A1-20230105-C00322.CDX" mol-file="US20230000833A1-20230105-C00322.MOL"/><us-chemistry idref="CHEM-US-00323" cdx-file="US20230000833A1-20230105-C00323.CDX" mol-file="US20230000833A1-20230105-C00323.MOL"/><us-chemistry idref="CHEM-US-00324" cdx-file="US20230000833A1-20230105-C00324.CDX" mol-file="US20230000833A1-20230105-C00324.MOL"/><us-chemistry idref="CHEM-US-00325" cdx-file="US20230000833A1-20230105-C00325.CDX" mol-file="US20230000833A1-20230105-C00325.MOL"/><us-chemistry idref="CHEM-US-00326" cdx-file="US20230000833A1-20230105-C00326.CDX" mol-file="US20230000833A1-20230105-C00326.MOL"/><us-chemistry idref="CHEM-US-00327" cdx-file="US20230000833A1-20230105-C00327.CDX" mol-file="US20230000833A1-20230105-C00327.MOL"/><us-chemistry idref="CHEM-US-00328" cdx-file="US20230000833A1-20230105-C00328.CDX" mol-file="US20230000833A1-20230105-C00328.MOL"/><us-chemistry idref="CHEM-US-00329" cdx-file="US20230000833A1-20230105-C00329.CDX" mol-file="US20230000833A1-20230105-C00329.MOL"/><us-chemistry idref="CHEM-US-00330" cdx-file="US20230000833A1-20230105-C00330.CDX" mol-file="US20230000833A1-20230105-C00330.MOL"/><us-chemistry idref="CHEM-US-00331" cdx-file="US20230000833A1-20230105-C00331.CDX" mol-file="US20230000833A1-20230105-C00331.MOL"/><us-chemistry idref="CHEM-US-00332" cdx-file="US20230000833A1-20230105-C00332.CDX" mol-file="US20230000833A1-20230105-C00332.MOL"/><us-chemistry idref="CHEM-US-00333" cdx-file="US20230000833A1-20230105-C00333.CDX" mol-file="US20230000833A1-20230105-C00333.MOL"/><us-chemistry idref="CHEM-US-00334" cdx-file="US20230000833A1-20230105-C00334.CDX" mol-file="US20230000833A1-20230105-C00334.MOL"/><us-chemistry idref="CHEM-US-00335" cdx-file="US20230000833A1-20230105-C00335.CDX" mol-file="US20230000833A1-20230105-C00335.MOL"/><us-chemistry idref="CHEM-US-00336" cdx-file="US20230000833A1-20230105-C00336.CDX" mol-file="US20230000833A1-20230105-C00336.MOL"/><us-chemistry idref="CHEM-US-00337" cdx-file="US20230000833A1-20230105-C00337.CDX" mol-file="US20230000833A1-20230105-C00337.MOL"/><us-chemistry idref="CHEM-US-00338" cdx-file="US20230000833A1-20230105-C00338.CDX" mol-file="US20230000833A1-20230105-C00338.MOL"/><us-chemistry idref="CHEM-US-00339" cdx-file="US20230000833A1-20230105-C00339.CDX" mol-file="US20230000833A1-20230105-C00339.MOL"/><us-chemistry idref="CHEM-US-00340" cdx-file="US20230000833A1-20230105-C00340.CDX" mol-file="US20230000833A1-20230105-C00340.MOL"/><us-chemistry idref="CHEM-US-00341" cdx-file="US20230000833A1-20230105-C00341.CDX" mol-file="US20230000833A1-20230105-C00341.MOL"/><us-chemistry idref="CHEM-US-00342" cdx-file="US20230000833A1-20230105-C00342.CDX" mol-file="US20230000833A1-20230105-C00342.MOL"/><us-chemistry idref="CHEM-US-00343" cdx-file="US20230000833A1-20230105-C00343.CDX" mol-file="US20230000833A1-20230105-C00343.MOL"/><us-chemistry idref="CHEM-US-00344" cdx-file="US20230000833A1-20230105-C00344.CDX" mol-file="US20230000833A1-20230105-C00344.MOL"/><us-chemistry idref="CHEM-US-00345" cdx-file="US20230000833A1-20230105-C00345.CDX" mol-file="US20230000833A1-20230105-C00345.MOL"/><us-chemistry idref="CHEM-US-00346" cdx-file="US20230000833A1-20230105-C00346.CDX" mol-file="US20230000833A1-20230105-C00346.MOL"/><us-chemistry idref="CHEM-US-00347" cdx-file="US20230000833A1-20230105-C00347.CDX" mol-file="US20230000833A1-20230105-C00347.MOL"/><us-chemistry idref="CHEM-US-00348" cdx-file="US20230000833A1-20230105-C00348.CDX" mol-file="US20230000833A1-20230105-C00348.MOL"/><us-chemistry idref="CHEM-US-00349" cdx-file="US20230000833A1-20230105-C00349.CDX" mol-file="US20230000833A1-20230105-C00349.MOL"/><us-chemistry idref="CHEM-US-00350" cdx-file="US20230000833A1-20230105-C00350.CDX" mol-file="US20230000833A1-20230105-C00350.MOL"/><us-chemistry idref="CHEM-US-00351" cdx-file="US20230000833A1-20230105-C00351.CDX" mol-file="US20230000833A1-20230105-C00351.MOL"/><us-chemistry idref="CHEM-US-00352" cdx-file="US20230000833A1-20230105-C00352.CDX" mol-file="US20230000833A1-20230105-C00352.MOL"/><us-chemistry idref="CHEM-US-00353" cdx-file="US20230000833A1-20230105-C00353.CDX" mol-file="US20230000833A1-20230105-C00353.MOL"/><us-chemistry idref="CHEM-US-00354" cdx-file="US20230000833A1-20230105-C00354.CDX" mol-file="US20230000833A1-20230105-C00354.MOL"/><us-chemistry idref="CHEM-US-00355" cdx-file="US20230000833A1-20230105-C00355.CDX" mol-file="US20230000833A1-20230105-C00355.MOL"/><us-chemistry idref="CHEM-US-00356" cdx-file="US20230000833A1-20230105-C00356.CDX" mol-file="US20230000833A1-20230105-C00356.MOL"/><us-chemistry idref="CHEM-US-00357" cdx-file="US20230000833A1-20230105-C00357.CDX" mol-file="US20230000833A1-20230105-C00357.MOL"/><us-chemistry idref="CHEM-US-00358" cdx-file="US20230000833A1-20230105-C00358.CDX" mol-file="US20230000833A1-20230105-C00358.MOL"/><us-chemistry idref="CHEM-US-00359" cdx-file="US20230000833A1-20230105-C00359.CDX" mol-file="US20230000833A1-20230105-C00359.MOL"/><us-chemistry idref="CHEM-US-00360" cdx-file="US20230000833A1-20230105-C00360.CDX" mol-file="US20230000833A1-20230105-C00360.MOL"/><us-chemistry idref="CHEM-US-00361" cdx-file="US20230000833A1-20230105-C00361.CDX" mol-file="US20230000833A1-20230105-C00361.MOL"/><us-chemistry idref="CHEM-US-00362" cdx-file="US20230000833A1-20230105-C00362.CDX" mol-file="US20230000833A1-20230105-C00362.MOL"/><us-chemistry idref="CHEM-US-00363" cdx-file="US20230000833A1-20230105-C00363.CDX" mol-file="US20230000833A1-20230105-C00363.MOL"/><us-chemistry idref="CHEM-US-00364" cdx-file="US20230000833A1-20230105-C00364.CDX" mol-file="US20230000833A1-20230105-C00364.MOL"/><us-chemistry idref="CHEM-US-00365" cdx-file="US20230000833A1-20230105-C00365.CDX" mol-file="US20230000833A1-20230105-C00365.MOL"/><us-chemistry idref="CHEM-US-00366" cdx-file="US20230000833A1-20230105-C00366.CDX" mol-file="US20230000833A1-20230105-C00366.MOL"/><us-chemistry idref="CHEM-US-00367" cdx-file="US20230000833A1-20230105-C00367.CDX" mol-file="US20230000833A1-20230105-C00367.MOL"/><us-chemistry idref="CHEM-US-00368" cdx-file="US20230000833A1-20230105-C00368.CDX" mol-file="US20230000833A1-20230105-C00368.MOL"/><us-chemistry idref="CHEM-US-00369" cdx-file="US20230000833A1-20230105-C00369.CDX" mol-file="US20230000833A1-20230105-C00369.MOL"/><us-chemistry idref="CHEM-US-00370" cdx-file="US20230000833A1-20230105-C00370.CDX" mol-file="US20230000833A1-20230105-C00370.MOL"/><us-chemistry idref="CHEM-US-00371" cdx-file="US20230000833A1-20230105-C00371.CDX" mol-file="US20230000833A1-20230105-C00371.MOL"/><us-chemistry idref="CHEM-US-00372" cdx-file="US20230000833A1-20230105-C00372.CDX" mol-file="US20230000833A1-20230105-C00372.MOL"/><us-chemistry idref="CHEM-US-00373" cdx-file="US20230000833A1-20230105-C00373.CDX" mol-file="US20230000833A1-20230105-C00373.MOL"/><us-chemistry idref="CHEM-US-00374" cdx-file="US20230000833A1-20230105-C00374.CDX" mol-file="US20230000833A1-20230105-C00374.MOL"/><us-chemistry idref="CHEM-US-00375" cdx-file="US20230000833A1-20230105-C00375.CDX" mol-file="US20230000833A1-20230105-C00375.MOL"/><us-chemistry idref="CHEM-US-00376" cdx-file="US20230000833A1-20230105-C00376.CDX" mol-file="US20230000833A1-20230105-C00376.MOL"/><us-chemistry idref="CHEM-US-00377" cdx-file="US20230000833A1-20230105-C00377.CDX" mol-file="US20230000833A1-20230105-C00377.MOL"/><us-chemistry idref="CHEM-US-00378" cdx-file="US20230000833A1-20230105-C00378.CDX" mol-file="US20230000833A1-20230105-C00378.MOL"/><us-chemistry idref="CHEM-US-00379" cdx-file="US20230000833A1-20230105-C00379.CDX" mol-file="US20230000833A1-20230105-C00379.MOL"/><us-chemistry idref="CHEM-US-00380" cdx-file="US20230000833A1-20230105-C00380.CDX" mol-file="US20230000833A1-20230105-C00380.MOL"/><us-chemistry idref="CHEM-US-00381" cdx-file="US20230000833A1-20230105-C00381.CDX" mol-file="US20230000833A1-20230105-C00381.MOL"/><us-chemistry idref="CHEM-US-00382" cdx-file="US20230000833A1-20230105-C00382.CDX" mol-file="US20230000833A1-20230105-C00382.MOL"/><us-chemistry idref="CHEM-US-00383" cdx-file="US20230000833A1-20230105-C00383.CDX" mol-file="US20230000833A1-20230105-C00383.MOL"/><us-chemistry idref="CHEM-US-00384" cdx-file="US20230000833A1-20230105-C00384.CDX" mol-file="US20230000833A1-20230105-C00384.MOL"/><us-chemistry idref="CHEM-US-00385" cdx-file="US20230000833A1-20230105-C00385.CDX" mol-file="US20230000833A1-20230105-C00385.MOL"/><us-chemistry idref="CHEM-US-00386" cdx-file="US20230000833A1-20230105-C00386.CDX" mol-file="US20230000833A1-20230105-C00386.MOL"/><us-chemistry idref="CHEM-US-00387" cdx-file="US20230000833A1-20230105-C00387.CDX" mol-file="US20230000833A1-20230105-C00387.MOL"/><us-chemistry idref="CHEM-US-00388" cdx-file="US20230000833A1-20230105-C00388.CDX" mol-file="US20230000833A1-20230105-C00388.MOL"/><us-chemistry idref="CHEM-US-00389" cdx-file="US20230000833A1-20230105-C00389.CDX" mol-file="US20230000833A1-20230105-C00389.MOL"/><us-chemistry idref="CHEM-US-00390" cdx-file="US20230000833A1-20230105-C00390.CDX" mol-file="US20230000833A1-20230105-C00390.MOL"/><us-chemistry idref="CHEM-US-00391" cdx-file="US20230000833A1-20230105-C00391.CDX" mol-file="US20230000833A1-20230105-C00391.MOL"/><us-chemistry idref="CHEM-US-00392" cdx-file="US20230000833A1-20230105-C00392.CDX" mol-file="US20230000833A1-20230105-C00392.MOL"/><us-chemistry idref="CHEM-US-00393" cdx-file="US20230000833A1-20230105-C00393.CDX" mol-file="US20230000833A1-20230105-C00393.MOL"/><us-chemistry idref="CHEM-US-00394" cdx-file="US20230000833A1-20230105-C00394.CDX" mol-file="US20230000833A1-20230105-C00394.MOL"/><us-chemistry idref="CHEM-US-00395" cdx-file="US20230000833A1-20230105-C00395.CDX" mol-file="US20230000833A1-20230105-C00395.MOL"/><us-chemistry idref="CHEM-US-00396" cdx-file="US20230000833A1-20230105-C00396.CDX" mol-file="US20230000833A1-20230105-C00396.MOL"/><us-chemistry idref="CHEM-US-00397" cdx-file="US20230000833A1-20230105-C00397.CDX" mol-file="US20230000833A1-20230105-C00397.MOL"/><us-chemistry idref="CHEM-US-00398" cdx-file="US20230000833A1-20230105-C00398.CDX" mol-file="US20230000833A1-20230105-C00398.MOL"/><us-chemistry idref="CHEM-US-00399" cdx-file="US20230000833A1-20230105-C00399.CDX" mol-file="US20230000833A1-20230105-C00399.MOL"/><us-chemistry idref="CHEM-US-00400" cdx-file="US20230000833A1-20230105-C00400.CDX" mol-file="US20230000833A1-20230105-C00400.MOL"/><us-chemistry idref="CHEM-US-00401" cdx-file="US20230000833A1-20230105-C00401.CDX" mol-file="US20230000833A1-20230105-C00401.MOL"/><us-chemistry idref="CHEM-US-00402" cdx-file="US20230000833A1-20230105-C00402.CDX" mol-file="US20230000833A1-20230105-C00402.MOL"/><us-chemistry idref="CHEM-US-00403" cdx-file="US20230000833A1-20230105-C00403.CDX" mol-file="US20230000833A1-20230105-C00403.MOL"/><us-chemistry idref="CHEM-US-00404" cdx-file="US20230000833A1-20230105-C00404.CDX" mol-file="US20230000833A1-20230105-C00404.MOL"/><us-chemistry idref="CHEM-US-00405" cdx-file="US20230000833A1-20230105-C00405.CDX" mol-file="US20230000833A1-20230105-C00405.MOL"/><us-chemistry idref="CHEM-US-00406" cdx-file="US20230000833A1-20230105-C00406.CDX" mol-file="US20230000833A1-20230105-C00406.MOL"/><us-chemistry idref="CHEM-US-00407" cdx-file="US20230000833A1-20230105-C00407.CDX" mol-file="US20230000833A1-20230105-C00407.MOL"/><us-chemistry idref="CHEM-US-00408" cdx-file="US20230000833A1-20230105-C00408.CDX" mol-file="US20230000833A1-20230105-C00408.MOL"/><us-chemistry idref="CHEM-US-00409" cdx-file="US20230000833A1-20230105-C00409.CDX" mol-file="US20230000833A1-20230105-C00409.MOL"/><us-chemistry idref="CHEM-US-00410" cdx-file="US20230000833A1-20230105-C00410.CDX" mol-file="US20230000833A1-20230105-C00410.MOL"/><us-chemistry idref="CHEM-US-00411" cdx-file="US20230000833A1-20230105-C00411.CDX" mol-file="US20230000833A1-20230105-C00411.MOL"/><us-chemistry idref="CHEM-US-00412" cdx-file="US20230000833A1-20230105-C00412.CDX" mol-file="US20230000833A1-20230105-C00412.MOL"/><us-chemistry idref="CHEM-US-00413" cdx-file="US20230000833A1-20230105-C00413.CDX" mol-file="US20230000833A1-20230105-C00413.MOL"/><us-chemistry idref="CHEM-US-00414" cdx-file="US20230000833A1-20230105-C00414.CDX" mol-file="US20230000833A1-20230105-C00414.MOL"/><us-chemistry idref="CHEM-US-00415" cdx-file="US20230000833A1-20230105-C00415.CDX" mol-file="US20230000833A1-20230105-C00415.MOL"/><us-chemistry idref="CHEM-US-00416" cdx-file="US20230000833A1-20230105-C00416.CDX" mol-file="US20230000833A1-20230105-C00416.MOL"/><us-chemistry idref="CHEM-US-00417" cdx-file="US20230000833A1-20230105-C00417.CDX" mol-file="US20230000833A1-20230105-C00417.MOL"/><us-chemistry idref="CHEM-US-00418" cdx-file="US20230000833A1-20230105-C00418.CDX" mol-file="US20230000833A1-20230105-C00418.MOL"/><us-chemistry idref="CHEM-US-00419" cdx-file="US20230000833A1-20230105-C00419.CDX" mol-file="US20230000833A1-20230105-C00419.MOL"/><us-chemistry idref="CHEM-US-00420" cdx-file="US20230000833A1-20230105-C00420.CDX" mol-file="US20230000833A1-20230105-C00420.MOL"/><us-chemistry idref="CHEM-US-00421" cdx-file="US20230000833A1-20230105-C00421.CDX" mol-file="US20230000833A1-20230105-C00421.MOL"/><us-chemistry idref="CHEM-US-00422" cdx-file="US20230000833A1-20230105-C00422.CDX" mol-file="US20230000833A1-20230105-C00422.MOL"/><us-chemistry idref="CHEM-US-00423" cdx-file="US20230000833A1-20230105-C00423.CDX" mol-file="US20230000833A1-20230105-C00423.MOL"/><us-chemistry idref="CHEM-US-00424" cdx-file="US20230000833A1-20230105-C00424.CDX" mol-file="US20230000833A1-20230105-C00424.MOL"/><us-chemistry idref="CHEM-US-00425" cdx-file="US20230000833A1-20230105-C00425.CDX" mol-file="US20230000833A1-20230105-C00425.MOL"/><us-chemistry idref="CHEM-US-00426" cdx-file="US20230000833A1-20230105-C00426.CDX" mol-file="US20230000833A1-20230105-C00426.MOL"/><us-chemistry idref="CHEM-US-00427" cdx-file="US20230000833A1-20230105-C00427.CDX" mol-file="US20230000833A1-20230105-C00427.MOL"/><us-chemistry idref="CHEM-US-00428" cdx-file="US20230000833A1-20230105-C00428.CDX" mol-file="US20230000833A1-20230105-C00428.MOL"/><us-chemistry idref="CHEM-US-00429" cdx-file="US20230000833A1-20230105-C00429.CDX" mol-file="US20230000833A1-20230105-C00429.MOL"/><us-chemistry idref="CHEM-US-00430" cdx-file="US20230000833A1-20230105-C00430.CDX" mol-file="US20230000833A1-20230105-C00430.MOL"/><us-chemistry idref="CHEM-US-00431" cdx-file="US20230000833A1-20230105-C00431.CDX" mol-file="US20230000833A1-20230105-C00431.MOL"/><us-chemistry idref="CHEM-US-00432" cdx-file="US20230000833A1-20230105-C00432.CDX" mol-file="US20230000833A1-20230105-C00432.MOL"/><us-chemistry idref="CHEM-US-00433" cdx-file="US20230000833A1-20230105-C00433.CDX" mol-file="US20230000833A1-20230105-C00433.MOL"/><us-chemistry idref="CHEM-US-00434" cdx-file="US20230000833A1-20230105-C00434.CDX" mol-file="US20230000833A1-20230105-C00434.MOL"/><us-chemistry idref="CHEM-US-00435" cdx-file="US20230000833A1-20230105-C00435.CDX" mol-file="US20230000833A1-20230105-C00435.MOL"/><us-chemistry idref="CHEM-US-00436" cdx-file="US20230000833A1-20230105-C00436.CDX" mol-file="US20230000833A1-20230105-C00436.MOL"/><us-chemistry idref="CHEM-US-00437" cdx-file="US20230000833A1-20230105-C00437.CDX" mol-file="US20230000833A1-20230105-C00437.MOL"/><us-chemistry idref="CHEM-US-00438" cdx-file="US20230000833A1-20230105-C00438.CDX" mol-file="US20230000833A1-20230105-C00438.MOL"/><us-chemistry idref="CHEM-US-00439" cdx-file="US20230000833A1-20230105-C00439.CDX" mol-file="US20230000833A1-20230105-C00439.MOL"/><us-chemistry idref="CHEM-US-00440" cdx-file="US20230000833A1-20230105-C00440.CDX" mol-file="US20230000833A1-20230105-C00440.MOL"/><us-chemistry idref="CHEM-US-00441" cdx-file="US20230000833A1-20230105-C00441.CDX" mol-file="US20230000833A1-20230105-C00441.MOL"/><us-chemistry idref="CHEM-US-00442" cdx-file="US20230000833A1-20230105-C00442.CDX" mol-file="US20230000833A1-20230105-C00442.MOL"/><us-chemistry idref="CHEM-US-00443" cdx-file="US20230000833A1-20230105-C00443.CDX" mol-file="US20230000833A1-20230105-C00443.MOL"/><us-chemistry idref="CHEM-US-00444" cdx-file="US20230000833A1-20230105-C00444.CDX" mol-file="US20230000833A1-20230105-C00444.MOL"/><us-chemistry idref="CHEM-US-00445" cdx-file="US20230000833A1-20230105-C00445.CDX" mol-file="US20230000833A1-20230105-C00445.MOL"/><us-chemistry idref="CHEM-US-00446" cdx-file="US20230000833A1-20230105-C00446.CDX" mol-file="US20230000833A1-20230105-C00446.MOL"/><us-chemistry idref="CHEM-US-00447" cdx-file="US20230000833A1-20230105-C00447.CDX" mol-file="US20230000833A1-20230105-C00447.MOL"/><us-chemistry idref="CHEM-US-00448" cdx-file="US20230000833A1-20230105-C00448.CDX" mol-file="US20230000833A1-20230105-C00448.MOL"/><us-chemistry idref="CHEM-US-00449" cdx-file="US20230000833A1-20230105-C00449.CDX" mol-file="US20230000833A1-20230105-C00449.MOL"/><us-chemistry idref="CHEM-US-00450" cdx-file="US20230000833A1-20230105-C00450.CDX" mol-file="US20230000833A1-20230105-C00450.MOL"/><us-chemistry idref="CHEM-US-00451" cdx-file="US20230000833A1-20230105-C00451.CDX" mol-file="US20230000833A1-20230105-C00451.MOL"/><us-chemistry idref="CHEM-US-00452" cdx-file="US20230000833A1-20230105-C00452.CDX" mol-file="US20230000833A1-20230105-C00452.MOL"/><us-chemistry idref="CHEM-US-00453" cdx-file="US20230000833A1-20230105-C00453.CDX" mol-file="US20230000833A1-20230105-C00453.MOL"/><us-chemistry idref="CHEM-US-00454" cdx-file="US20230000833A1-20230105-C00454.CDX" mol-file="US20230000833A1-20230105-C00454.MOL"/><us-chemistry idref="CHEM-US-00455" cdx-file="US20230000833A1-20230105-C00455.CDX" mol-file="US20230000833A1-20230105-C00455.MOL"/><us-chemistry idref="CHEM-US-00456" cdx-file="US20230000833A1-20230105-C00456.CDX" mol-file="US20230000833A1-20230105-C00456.MOL"/><us-chemistry idref="CHEM-US-00457" cdx-file="US20230000833A1-20230105-C00457.CDX" mol-file="US20230000833A1-20230105-C00457.MOL"/><us-chemistry idref="CHEM-US-00458" cdx-file="US20230000833A1-20230105-C00458.CDX" mol-file="US20230000833A1-20230105-C00458.MOL"/><us-chemistry idref="CHEM-US-00459" cdx-file="US20230000833A1-20230105-C00459.CDX" mol-file="US20230000833A1-20230105-C00459.MOL"/><us-chemistry idref="CHEM-US-00460" cdx-file="US20230000833A1-20230105-C00460.CDX" mol-file="US20230000833A1-20230105-C00460.MOL"/><us-chemistry idref="CHEM-US-00461" cdx-file="US20230000833A1-20230105-C00461.CDX" mol-file="US20230000833A1-20230105-C00461.MOL"/><us-chemistry idref="CHEM-US-00462" cdx-file="US20230000833A1-20230105-C00462.CDX" mol-file="US20230000833A1-20230105-C00462.MOL"/><us-chemistry idref="CHEM-US-00463" cdx-file="US20230000833A1-20230105-C00463.CDX" mol-file="US20230000833A1-20230105-C00463.MOL"/><us-chemistry idref="CHEM-US-00464" cdx-file="US20230000833A1-20230105-C00464.CDX" mol-file="US20230000833A1-20230105-C00464.MOL"/><us-chemistry idref="CHEM-US-00465" cdx-file="US20230000833A1-20230105-C00465.CDX" mol-file="US20230000833A1-20230105-C00465.MOL"/><us-chemistry idref="CHEM-US-00466" cdx-file="US20230000833A1-20230105-C00466.CDX" mol-file="US20230000833A1-20230105-C00466.MOL"/><us-chemistry idref="CHEM-US-00467" cdx-file="US20230000833A1-20230105-C00467.CDX" mol-file="US20230000833A1-20230105-C00467.MOL"/><us-chemistry idref="CHEM-US-00468" cdx-file="US20230000833A1-20230105-C00468.CDX" mol-file="US20230000833A1-20230105-C00468.MOL"/><us-chemistry idref="CHEM-US-00469" cdx-file="US20230000833A1-20230105-C00469.CDX" mol-file="US20230000833A1-20230105-C00469.MOL"/><us-chemistry idref="CHEM-US-00470" cdx-file="US20230000833A1-20230105-C00470.CDX" mol-file="US20230000833A1-20230105-C00470.MOL"/><us-chemistry idref="CHEM-US-00471" cdx-file="US20230000833A1-20230105-C00471.CDX" mol-file="US20230000833A1-20230105-C00471.MOL"/><us-chemistry idref="CHEM-US-00472" cdx-file="US20230000833A1-20230105-C00472.CDX" mol-file="US20230000833A1-20230105-C00472.MOL"/><us-chemistry idref="CHEM-US-00473" cdx-file="US20230000833A1-20230105-C00473.CDX" mol-file="US20230000833A1-20230105-C00473.MOL"/><us-chemistry idref="CHEM-US-00474" cdx-file="US20230000833A1-20230105-C00474.CDX" mol-file="US20230000833A1-20230105-C00474.MOL"/><us-chemistry idref="CHEM-US-00475" cdx-file="US20230000833A1-20230105-C00475.CDX" mol-file="US20230000833A1-20230105-C00475.MOL"/><us-chemistry idref="CHEM-US-00476" cdx-file="US20230000833A1-20230105-C00476.CDX" mol-file="US20230000833A1-20230105-C00476.MOL"/><us-chemistry idref="CHEM-US-00477" cdx-file="US20230000833A1-20230105-C00477.CDX" mol-file="US20230000833A1-20230105-C00477.MOL"/><us-chemistry idref="CHEM-US-00478" cdx-file="US20230000833A1-20230105-C00478.CDX" mol-file="US20230000833A1-20230105-C00478.MOL"/><us-chemistry idref="CHEM-US-00479" cdx-file="US20230000833A1-20230105-C00479.CDX" mol-file="US20230000833A1-20230105-C00479.MOL"/><us-chemistry idref="CHEM-US-00480" cdx-file="US20230000833A1-20230105-C00480.CDX" mol-file="US20230000833A1-20230105-C00480.MOL"/><us-chemistry idref="CHEM-US-00481" cdx-file="US20230000833A1-20230105-C00481.CDX" mol-file="US20230000833A1-20230105-C00481.MOL"/><us-chemistry idref="CHEM-US-00482" cdx-file="US20230000833A1-20230105-C00482.CDX" mol-file="US20230000833A1-20230105-C00482.MOL"/><us-chemistry idref="CHEM-US-00483" cdx-file="US20230000833A1-20230105-C00483.CDX" mol-file="US20230000833A1-20230105-C00483.MOL"/><us-chemistry idref="CHEM-US-00484" cdx-file="US20230000833A1-20230105-C00484.CDX" mol-file="US20230000833A1-20230105-C00484.MOL"/><us-chemistry idref="CHEM-US-00485" cdx-file="US20230000833A1-20230105-C00485.CDX" mol-file="US20230000833A1-20230105-C00485.MOL"/><us-chemistry idref="CHEM-US-00486" cdx-file="US20230000833A1-20230105-C00486.CDX" mol-file="US20230000833A1-20230105-C00486.MOL"/><us-chemistry idref="CHEM-US-00487" cdx-file="US20230000833A1-20230105-C00487.CDX" mol-file="US20230000833A1-20230105-C00487.MOL"/><us-chemistry idref="CHEM-US-00488" cdx-file="US20230000833A1-20230105-C00488.CDX" mol-file="US20230000833A1-20230105-C00488.MOL"/><us-chemistry idref="CHEM-US-00489" cdx-file="US20230000833A1-20230105-C00489.CDX" mol-file="US20230000833A1-20230105-C00489.MOL"/><us-chemistry idref="CHEM-US-00490" cdx-file="US20230000833A1-20230105-C00490.CDX" mol-file="US20230000833A1-20230105-C00490.MOL"/><us-chemistry idref="CHEM-US-00491" cdx-file="US20230000833A1-20230105-C00491.CDX" mol-file="US20230000833A1-20230105-C00491.MOL"/><us-chemistry idref="CHEM-US-00492" cdx-file="US20230000833A1-20230105-C00492.CDX" mol-file="US20230000833A1-20230105-C00492.MOL"/><us-chemistry idref="CHEM-US-00493" cdx-file="US20230000833A1-20230105-C00493.CDX" mol-file="US20230000833A1-20230105-C00493.MOL"/><us-chemistry idref="CHEM-US-00494" cdx-file="US20230000833A1-20230105-C00494.CDX" mol-file="US20230000833A1-20230105-C00494.MOL"/><us-chemistry idref="CHEM-US-00495" cdx-file="US20230000833A1-20230105-C00495.CDX" mol-file="US20230000833A1-20230105-C00495.MOL"/><us-chemistry idref="CHEM-US-00496" cdx-file="US20230000833A1-20230105-C00496.CDX" mol-file="US20230000833A1-20230105-C00496.MOL"/><us-chemistry idref="CHEM-US-00497" cdx-file="US20230000833A1-20230105-C00497.CDX" mol-file="US20230000833A1-20230105-C00497.MOL"/><us-chemistry idref="CHEM-US-00498" cdx-file="US20230000833A1-20230105-C00498.CDX" mol-file="US20230000833A1-20230105-C00498.MOL"/><us-chemistry idref="CHEM-US-00499" cdx-file="US20230000833A1-20230105-C00499.CDX" mol-file="US20230000833A1-20230105-C00499.MOL"/><us-chemistry idref="CHEM-US-00500" cdx-file="US20230000833A1-20230105-C00500.CDX" mol-file="US20230000833A1-20230105-C00500.MOL"/><us-chemistry idref="CHEM-US-00501" cdx-file="US20230000833A1-20230105-C00501.CDX" mol-file="US20230000833A1-20230105-C00501.MOL"/><us-chemistry idref="CHEM-US-00502" cdx-file="US20230000833A1-20230105-C00502.CDX" mol-file="US20230000833A1-20230105-C00502.MOL"/><us-chemistry idref="CHEM-US-00503" cdx-file="US20230000833A1-20230105-C00503.CDX" mol-file="US20230000833A1-20230105-C00503.MOL"/><us-chemistry idref="CHEM-US-00504" cdx-file="US20230000833A1-20230105-C00504.CDX" mol-file="US20230000833A1-20230105-C00504.MOL"/><us-chemistry idref="CHEM-US-00505" cdx-file="US20230000833A1-20230105-C00505.CDX" mol-file="US20230000833A1-20230105-C00505.MOL"/><us-chemistry idref="CHEM-US-00506" cdx-file="US20230000833A1-20230105-C00506.CDX" mol-file="US20230000833A1-20230105-C00506.MOL"/><us-chemistry idref="CHEM-US-00507" cdx-file="US20230000833A1-20230105-C00507.CDX" mol-file="US20230000833A1-20230105-C00507.MOL"/><us-chemistry idref="CHEM-US-00508" cdx-file="US20230000833A1-20230105-C00508.CDX" mol-file="US20230000833A1-20230105-C00508.MOL"/><us-chemistry idref="CHEM-US-00509" cdx-file="US20230000833A1-20230105-C00509.CDX" mol-file="US20230000833A1-20230105-C00509.MOL"/><us-chemistry idref="CHEM-US-00510" cdx-file="US20230000833A1-20230105-C00510.CDX" mol-file="US20230000833A1-20230105-C00510.MOL"/><us-chemistry idref="CHEM-US-00511" cdx-file="US20230000833A1-20230105-C00511.CDX" mol-file="US20230000833A1-20230105-C00511.MOL"/><us-chemistry idref="CHEM-US-00512" cdx-file="US20230000833A1-20230105-C00512.CDX" mol-file="US20230000833A1-20230105-C00512.MOL"/><us-chemistry idref="CHEM-US-00513" cdx-file="US20230000833A1-20230105-C00513.CDX" mol-file="US20230000833A1-20230105-C00513.MOL"/><us-chemistry idref="CHEM-US-00514" cdx-file="US20230000833A1-20230105-C00514.CDX" mol-file="US20230000833A1-20230105-C00514.MOL"/><us-chemistry idref="CHEM-US-00515" cdx-file="US20230000833A1-20230105-C00515.CDX" mol-file="US20230000833A1-20230105-C00515.MOL"/><us-chemistry idref="CHEM-US-00516" cdx-file="US20230000833A1-20230105-C00516.CDX" mol-file="US20230000833A1-20230105-C00516.MOL"/><us-chemistry idref="CHEM-US-00517" cdx-file="US20230000833A1-20230105-C00517.CDX" mol-file="US20230000833A1-20230105-C00517.MOL"/><us-chemistry idref="CHEM-US-00518" cdx-file="US20230000833A1-20230105-C00518.CDX" mol-file="US20230000833A1-20230105-C00518.MOL"/><us-chemistry idref="CHEM-US-00519" cdx-file="US20230000833A1-20230105-C00519.CDX" mol-file="US20230000833A1-20230105-C00519.MOL"/><us-chemistry idref="CHEM-US-00520" cdx-file="US20230000833A1-20230105-C00520.CDX" mol-file="US20230000833A1-20230105-C00520.MOL"/><us-chemistry idref="CHEM-US-00521" cdx-file="US20230000833A1-20230105-C00521.CDX" mol-file="US20230000833A1-20230105-C00521.MOL"/><us-chemistry idref="CHEM-US-00522" cdx-file="US20230000833A1-20230105-C00522.CDX" mol-file="US20230000833A1-20230105-C00522.MOL"/><us-chemistry idref="CHEM-US-00523" cdx-file="US20230000833A1-20230105-C00523.CDX" mol-file="US20230000833A1-20230105-C00523.MOL"/><us-chemistry idref="CHEM-US-00524" cdx-file="US20230000833A1-20230105-C00524.CDX" mol-file="US20230000833A1-20230105-C00524.MOL"/><us-chemistry idref="CHEM-US-00525" cdx-file="US20230000833A1-20230105-C00525.CDX" mol-file="US20230000833A1-20230105-C00525.MOL"/><us-chemistry idref="CHEM-US-00526" cdx-file="US20230000833A1-20230105-C00526.CDX" mol-file="US20230000833A1-20230105-C00526.MOL"/><us-chemistry idref="CHEM-US-00527" cdx-file="US20230000833A1-20230105-C00527.CDX" mol-file="US20230000833A1-20230105-C00527.MOL"/><us-chemistry idref="CHEM-US-00528" cdx-file="US20230000833A1-20230105-C00528.CDX" mol-file="US20230000833A1-20230105-C00528.MOL"/><us-chemistry idref="CHEM-US-00529" cdx-file="US20230000833A1-20230105-C00529.CDX" mol-file="US20230000833A1-20230105-C00529.MOL"/><us-chemistry idref="CHEM-US-00530" cdx-file="US20230000833A1-20230105-C00530.CDX" mol-file="US20230000833A1-20230105-C00530.MOL"/><us-chemistry idref="CHEM-US-00531" cdx-file="US20230000833A1-20230105-C00531.CDX" mol-file="US20230000833A1-20230105-C00531.MOL"/><us-chemistry idref="CHEM-US-00532" cdx-file="US20230000833A1-20230105-C00532.CDX" mol-file="US20230000833A1-20230105-C00532.MOL"/><us-chemistry idref="CHEM-US-00533" cdx-file="US20230000833A1-20230105-C00533.CDX" mol-file="US20230000833A1-20230105-C00533.MOL"/><us-chemistry idref="CHEM-US-00534" cdx-file="US20230000833A1-20230105-C00534.CDX" mol-file="US20230000833A1-20230105-C00534.MOL"/><us-chemistry idref="CHEM-US-00535" cdx-file="US20230000833A1-20230105-C00535.CDX" mol-file="US20230000833A1-20230105-C00535.MOL"/><us-chemistry idref="CHEM-US-00536" cdx-file="US20230000833A1-20230105-C00536.CDX" mol-file="US20230000833A1-20230105-C00536.MOL"/><us-chemistry idref="CHEM-US-00537" cdx-file="US20230000833A1-20230105-C00537.CDX" mol-file="US20230000833A1-20230105-C00537.MOL"/><us-chemistry idref="CHEM-US-00538" cdx-file="US20230000833A1-20230105-C00538.CDX" mol-file="US20230000833A1-20230105-C00538.MOL"/><us-chemistry idref="CHEM-US-00539" cdx-file="US20230000833A1-20230105-C00539.CDX" mol-file="US20230000833A1-20230105-C00539.MOL"/><us-chemistry idref="CHEM-US-00540" cdx-file="US20230000833A1-20230105-C00540.CDX" mol-file="US20230000833A1-20230105-C00540.MOL"/><us-chemistry idref="CHEM-US-00541" cdx-file="US20230000833A1-20230105-C00541.CDX" mol-file="US20230000833A1-20230105-C00541.MOL"/><us-chemistry idref="CHEM-US-00542" cdx-file="US20230000833A1-20230105-C00542.CDX" mol-file="US20230000833A1-20230105-C00542.MOL"/><us-chemistry idref="CHEM-US-00543" cdx-file="US20230000833A1-20230105-C00543.CDX" mol-file="US20230000833A1-20230105-C00543.MOL"/><us-chemistry idref="CHEM-US-00544" cdx-file="US20230000833A1-20230105-C00544.CDX" mol-file="US20230000833A1-20230105-C00544.MOL"/><us-chemistry idref="CHEM-US-00545" cdx-file="US20230000833A1-20230105-C00545.CDX" mol-file="US20230000833A1-20230105-C00545.MOL"/><us-chemistry idref="CHEM-US-00546" cdx-file="US20230000833A1-20230105-C00546.CDX" mol-file="US20230000833A1-20230105-C00546.MOL"/><us-chemistry idref="CHEM-US-00547" cdx-file="US20230000833A1-20230105-C00547.CDX" mol-file="US20230000833A1-20230105-C00547.MOL"/><us-chemistry idref="CHEM-US-00548" cdx-file="US20230000833A1-20230105-C00548.CDX" mol-file="US20230000833A1-20230105-C00548.MOL"/><us-chemistry idref="CHEM-US-00549" cdx-file="US20230000833A1-20230105-C00549.CDX" mol-file="US20230000833A1-20230105-C00549.MOL"/><us-chemistry idref="CHEM-US-00550" cdx-file="US20230000833A1-20230105-C00550.CDX" mol-file="US20230000833A1-20230105-C00550.MOL"/><us-chemistry idref="CHEM-US-00551" cdx-file="US20230000833A1-20230105-C00551.CDX" mol-file="US20230000833A1-20230105-C00551.MOL"/><us-chemistry idref="CHEM-US-00552" cdx-file="US20230000833A1-20230105-C00552.CDX" mol-file="US20230000833A1-20230105-C00552.MOL"/><us-chemistry idref="CHEM-US-00553" cdx-file="US20230000833A1-20230105-C00553.CDX" mol-file="US20230000833A1-20230105-C00553.MOL"/><us-chemistry idref="CHEM-US-00554" cdx-file="US20230000833A1-20230105-C00554.CDX" mol-file="US20230000833A1-20230105-C00554.MOL"/><us-chemistry idref="CHEM-US-00555" cdx-file="US20230000833A1-20230105-C00555.CDX" mol-file="US20230000833A1-20230105-C00555.MOL"/><us-chemistry idref="CHEM-US-00556" cdx-file="US20230000833A1-20230105-C00556.CDX" mol-file="US20230000833A1-20230105-C00556.MOL"/><us-chemistry idref="CHEM-US-00557" cdx-file="US20230000833A1-20230105-C00557.CDX" mol-file="US20230000833A1-20230105-C00557.MOL"/><us-chemistry idref="CHEM-US-00558" cdx-file="US20230000833A1-20230105-C00558.CDX" mol-file="US20230000833A1-20230105-C00558.MOL"/><us-chemistry idref="CHEM-US-00559" cdx-file="US20230000833A1-20230105-C00559.CDX" mol-file="US20230000833A1-20230105-C00559.MOL"/><us-chemistry idref="CHEM-US-00560" cdx-file="US20230000833A1-20230105-C00560.CDX" mol-file="US20230000833A1-20230105-C00560.MOL"/><us-chemistry idref="CHEM-US-00561" cdx-file="US20230000833A1-20230105-C00561.CDX" mol-file="US20230000833A1-20230105-C00561.MOL"/><us-chemistry idref="CHEM-US-00562" cdx-file="US20230000833A1-20230105-C00562.CDX" mol-file="US20230000833A1-20230105-C00562.MOL"/><us-chemistry idref="CHEM-US-00563" cdx-file="US20230000833A1-20230105-C00563.CDX" mol-file="US20230000833A1-20230105-C00563.MOL"/><us-chemistry idref="CHEM-US-00564" cdx-file="US20230000833A1-20230105-C00564.CDX" mol-file="US20230000833A1-20230105-C00564.MOL"/><us-chemistry idref="CHEM-US-00565" cdx-file="US20230000833A1-20230105-C00565.CDX" mol-file="US20230000833A1-20230105-C00565.MOL"/><us-chemistry idref="CHEM-US-00566" cdx-file="US20230000833A1-20230105-C00566.CDX" mol-file="US20230000833A1-20230105-C00566.MOL"/><us-chemistry idref="CHEM-US-00567" cdx-file="US20230000833A1-20230105-C00567.CDX" mol-file="US20230000833A1-20230105-C00567.MOL"/><us-chemistry idref="CHEM-US-00568" cdx-file="US20230000833A1-20230105-C00568.CDX" mol-file="US20230000833A1-20230105-C00568.MOL"/><us-chemistry idref="CHEM-US-00569" cdx-file="US20230000833A1-20230105-C00569.CDX" mol-file="US20230000833A1-20230105-C00569.MOL"/><us-chemistry idref="CHEM-US-00570" cdx-file="US20230000833A1-20230105-C00570.CDX" mol-file="US20230000833A1-20230105-C00570.MOL"/><us-chemistry idref="CHEM-US-00571" cdx-file="US20230000833A1-20230105-C00571.CDX" mol-file="US20230000833A1-20230105-C00571.MOL"/><us-chemistry idref="CHEM-US-00572" cdx-file="US20230000833A1-20230105-C00572.CDX" mol-file="US20230000833A1-20230105-C00572.MOL"/><us-chemistry idref="CHEM-US-00573" cdx-file="US20230000833A1-20230105-C00573.CDX" mol-file="US20230000833A1-20230105-C00573.MOL"/><us-chemistry idref="CHEM-US-00574" cdx-file="US20230000833A1-20230105-C00574.CDX" mol-file="US20230000833A1-20230105-C00574.MOL"/><us-chemistry idref="CHEM-US-00575" cdx-file="US20230000833A1-20230105-C00575.CDX" mol-file="US20230000833A1-20230105-C00575.MOL"/><us-chemistry idref="CHEM-US-00576" cdx-file="US20230000833A1-20230105-C00576.CDX" mol-file="US20230000833A1-20230105-C00576.MOL"/><us-chemistry idref="CHEM-US-00577" cdx-file="US20230000833A1-20230105-C00577.CDX" mol-file="US20230000833A1-20230105-C00577.MOL"/><us-chemistry idref="CHEM-US-00578" cdx-file="US20230000833A1-20230105-C00578.CDX" mol-file="US20230000833A1-20230105-C00578.MOL"/><us-chemistry idref="CHEM-US-00579" cdx-file="US20230000833A1-20230105-C00579.CDX" mol-file="US20230000833A1-20230105-C00579.MOL"/><us-chemistry idref="CHEM-US-00580" cdx-file="US20230000833A1-20230105-C00580.CDX" mol-file="US20230000833A1-20230105-C00580.MOL"/><us-chemistry idref="CHEM-US-00581" cdx-file="US20230000833A1-20230105-C00581.CDX" mol-file="US20230000833A1-20230105-C00581.MOL"/><us-chemistry idref="CHEM-US-00582" cdx-file="US20230000833A1-20230105-C00582.CDX" mol-file="US20230000833A1-20230105-C00582.MOL"/><us-chemistry idref="CHEM-US-00583" cdx-file="US20230000833A1-20230105-C00583.CDX" mol-file="US20230000833A1-20230105-C00583.MOL"/><us-chemistry idref="CHEM-US-00584" cdx-file="US20230000833A1-20230105-C00584.CDX" mol-file="US20230000833A1-20230105-C00584.MOL"/><us-chemistry idref="CHEM-US-00585" cdx-file="US20230000833A1-20230105-C00585.CDX" mol-file="US20230000833A1-20230105-C00585.MOL"/><us-chemistry idref="CHEM-US-00586" cdx-file="US20230000833A1-20230105-C00586.CDX" mol-file="US20230000833A1-20230105-C00586.MOL"/><us-chemistry idref="CHEM-US-00587" cdx-file="US20230000833A1-20230105-C00587.CDX" mol-file="US20230000833A1-20230105-C00587.MOL"/><us-chemistry idref="CHEM-US-00588" cdx-file="US20230000833A1-20230105-C00588.CDX" mol-file="US20230000833A1-20230105-C00588.MOL"/><us-chemistry idref="CHEM-US-00589" cdx-file="US20230000833A1-20230105-C00589.CDX" mol-file="US20230000833A1-20230105-C00589.MOL"/><us-chemistry idref="CHEM-US-00590" cdx-file="US20230000833A1-20230105-C00590.CDX" mol-file="US20230000833A1-20230105-C00590.MOL"/><us-chemistry idref="CHEM-US-00591" cdx-file="US20230000833A1-20230105-C00591.CDX" mol-file="US20230000833A1-20230105-C00591.MOL"/><us-chemistry idref="CHEM-US-00592" cdx-file="US20230000833A1-20230105-C00592.CDX" mol-file="US20230000833A1-20230105-C00592.MOL"/><us-chemistry idref="CHEM-US-00593" cdx-file="US20230000833A1-20230105-C00593.CDX" mol-file="US20230000833A1-20230105-C00593.MOL"/><us-chemistry idref="CHEM-US-00594" cdx-file="US20230000833A1-20230105-C00594.CDX" mol-file="US20230000833A1-20230105-C00594.MOL"/><us-chemistry idref="CHEM-US-00595" cdx-file="US20230000833A1-20230105-C00595.CDX" mol-file="US20230000833A1-20230105-C00595.MOL"/><us-chemistry idref="CHEM-US-00596" cdx-file="US20230000833A1-20230105-C00596.CDX" mol-file="US20230000833A1-20230105-C00596.MOL"/><us-chemistry idref="CHEM-US-00597" cdx-file="US20230000833A1-20230105-C00597.CDX" mol-file="US20230000833A1-20230105-C00597.MOL"/><us-chemistry idref="CHEM-US-00598" cdx-file="US20230000833A1-20230105-C00598.CDX" mol-file="US20230000833A1-20230105-C00598.MOL"/><us-chemistry idref="CHEM-US-00599" cdx-file="US20230000833A1-20230105-C00599.CDX" mol-file="US20230000833A1-20230105-C00599.MOL"/><us-chemistry idref="CHEM-US-00600" cdx-file="US20230000833A1-20230105-C00600.CDX" mol-file="US20230000833A1-20230105-C00600.MOL"/><us-chemistry idref="CHEM-US-00601" cdx-file="US20230000833A1-20230105-C00601.CDX" mol-file="US20230000833A1-20230105-C00601.MOL"/><us-chemistry idref="CHEM-US-00602" cdx-file="US20230000833A1-20230105-C00602.CDX" mol-file="US20230000833A1-20230105-C00602.MOL"/><us-chemistry idref="CHEM-US-00603" cdx-file="US20230000833A1-20230105-C00603.CDX" mol-file="US20230000833A1-20230105-C00603.MOL"/><us-chemistry idref="CHEM-US-00604" cdx-file="US20230000833A1-20230105-C00604.CDX" mol-file="US20230000833A1-20230105-C00604.MOL"/><us-chemistry idref="CHEM-US-00605" cdx-file="US20230000833A1-20230105-C00605.CDX" mol-file="US20230000833A1-20230105-C00605.MOL"/><us-chemistry idref="CHEM-US-00606" cdx-file="US20230000833A1-20230105-C00606.CDX" mol-file="US20230000833A1-20230105-C00606.MOL"/><us-chemistry idref="CHEM-US-00607" cdx-file="US20230000833A1-20230105-C00607.CDX" mol-file="US20230000833A1-20230105-C00607.MOL"/><us-chemistry idref="CHEM-US-00608" cdx-file="US20230000833A1-20230105-C00608.CDX" mol-file="US20230000833A1-20230105-C00608.MOL"/><us-chemistry idref="CHEM-US-00609" cdx-file="US20230000833A1-20230105-C00609.CDX" mol-file="US20230000833A1-20230105-C00609.MOL"/><us-chemistry idref="CHEM-US-00610" cdx-file="US20230000833A1-20230105-C00610.CDX" mol-file="US20230000833A1-20230105-C00610.MOL"/><us-chemistry idref="CHEM-US-00611" cdx-file="US20230000833A1-20230105-C00611.CDX" mol-file="US20230000833A1-20230105-C00611.MOL"/><us-chemistry idref="CHEM-US-00612" cdx-file="US20230000833A1-20230105-C00612.CDX" mol-file="US20230000833A1-20230105-C00612.MOL"/><us-chemistry idref="CHEM-US-00613" cdx-file="US20230000833A1-20230105-C00613.CDX" mol-file="US20230000833A1-20230105-C00613.MOL"/><us-chemistry idref="CHEM-US-00614" cdx-file="US20230000833A1-20230105-C00614.CDX" mol-file="US20230000833A1-20230105-C00614.MOL"/><us-chemistry idref="CHEM-US-00615" cdx-file="US20230000833A1-20230105-C00615.CDX" mol-file="US20230000833A1-20230105-C00615.MOL"/><us-chemistry idref="CHEM-US-00616" cdx-file="US20230000833A1-20230105-C00616.CDX" mol-file="US20230000833A1-20230105-C00616.MOL"/><us-chemistry idref="CHEM-US-00617" cdx-file="US20230000833A1-20230105-C00617.CDX" mol-file="US20230000833A1-20230105-C00617.MOL"/><us-chemistry idref="CHEM-US-00618" cdx-file="US20230000833A1-20230105-C00618.CDX" mol-file="US20230000833A1-20230105-C00618.MOL"/><us-chemistry idref="CHEM-US-00619" cdx-file="US20230000833A1-20230105-C00619.CDX" mol-file="US20230000833A1-20230105-C00619.MOL"/><us-chemistry idref="CHEM-US-00620" cdx-file="US20230000833A1-20230105-C00620.CDX" mol-file="US20230000833A1-20230105-C00620.MOL"/><us-chemistry idref="CHEM-US-00621" cdx-file="US20230000833A1-20230105-C00621.CDX" mol-file="US20230000833A1-20230105-C00621.MOL"/><us-chemistry idref="CHEM-US-00622" cdx-file="US20230000833A1-20230105-C00622.CDX" mol-file="US20230000833A1-20230105-C00622.MOL"/><us-chemistry idref="CHEM-US-00623" cdx-file="US20230000833A1-20230105-C00623.CDX" mol-file="US20230000833A1-20230105-C00623.MOL"/><us-chemistry idref="CHEM-US-00624" cdx-file="US20230000833A1-20230105-C00624.CDX" mol-file="US20230000833A1-20230105-C00624.MOL"/><us-chemistry idref="CHEM-US-00625" cdx-file="US20230000833A1-20230105-C00625.CDX" mol-file="US20230000833A1-20230105-C00625.MOL"/><us-chemistry idref="CHEM-US-00626" cdx-file="US20230000833A1-20230105-C00626.CDX" mol-file="US20230000833A1-20230105-C00626.MOL"/><us-chemistry idref="CHEM-US-00627" cdx-file="US20230000833A1-20230105-C00627.CDX" mol-file="US20230000833A1-20230105-C00627.MOL"/><us-chemistry idref="CHEM-US-00628" cdx-file="US20230000833A1-20230105-C00628.CDX" mol-file="US20230000833A1-20230105-C00628.MOL"/><us-chemistry idref="CHEM-US-00629" cdx-file="US20230000833A1-20230105-C00629.CDX" mol-file="US20230000833A1-20230105-C00629.MOL"/><us-chemistry idref="CHEM-US-00630" cdx-file="US20230000833A1-20230105-C00630.CDX" mol-file="US20230000833A1-20230105-C00630.MOL"/><us-chemistry idref="CHEM-US-00631" cdx-file="US20230000833A1-20230105-C00631.CDX" mol-file="US20230000833A1-20230105-C00631.MOL"/><us-chemistry idref="CHEM-US-00632" cdx-file="US20230000833A1-20230105-C00632.CDX" mol-file="US20230000833A1-20230105-C00632.MOL"/><us-chemistry idref="CHEM-US-00633" cdx-file="US20230000833A1-20230105-C00633.CDX" mol-file="US20230000833A1-20230105-C00633.MOL"/><us-chemistry idref="CHEM-US-00634" cdx-file="US20230000833A1-20230105-C00634.CDX" mol-file="US20230000833A1-20230105-C00634.MOL"/><us-chemistry idref="CHEM-US-00635" cdx-file="US20230000833A1-20230105-C00635.CDX" mol-file="US20230000833A1-20230105-C00635.MOL"/><us-chemistry idref="CHEM-US-00636" cdx-file="US20230000833A1-20230105-C00636.CDX" mol-file="US20230000833A1-20230105-C00636.MOL"/><us-chemistry idref="CHEM-US-00637" cdx-file="US20230000833A1-20230105-C00637.CDX" mol-file="US20230000833A1-20230105-C00637.MOL"/><us-chemistry idref="CHEM-US-00638" cdx-file="US20230000833A1-20230105-C00638.CDX" mol-file="US20230000833A1-20230105-C00638.MOL"/><us-chemistry idref="CHEM-US-00639" cdx-file="US20230000833A1-20230105-C00639.CDX" mol-file="US20230000833A1-20230105-C00639.MOL"/><us-chemistry idref="CHEM-US-00640" cdx-file="US20230000833A1-20230105-C00640.CDX" mol-file="US20230000833A1-20230105-C00640.MOL"/><us-chemistry idref="CHEM-US-00641" cdx-file="US20230000833A1-20230105-C00641.CDX" mol-file="US20230000833A1-20230105-C00641.MOL"/><us-chemistry idref="CHEM-US-00642" cdx-file="US20230000833A1-20230105-C00642.CDX" mol-file="US20230000833A1-20230105-C00642.MOL"/><us-chemistry idref="CHEM-US-00643" cdx-file="US20230000833A1-20230105-C00643.CDX" mol-file="US20230000833A1-20230105-C00643.MOL"/><us-chemistry idref="CHEM-US-00644" cdx-file="US20230000833A1-20230105-C00644.CDX" mol-file="US20230000833A1-20230105-C00644.MOL"/><us-chemistry idref="CHEM-US-00645" cdx-file="US20230000833A1-20230105-C00645.CDX" mol-file="US20230000833A1-20230105-C00645.MOL"/><us-chemistry idref="CHEM-US-00646" cdx-file="US20230000833A1-20230105-C00646.CDX" mol-file="US20230000833A1-20230105-C00646.MOL"/><us-chemistry idref="CHEM-US-00647" cdx-file="US20230000833A1-20230105-C00647.CDX" mol-file="US20230000833A1-20230105-C00647.MOL"/><us-chemistry idref="CHEM-US-00648" cdx-file="US20230000833A1-20230105-C00648.CDX" mol-file="US20230000833A1-20230105-C00648.MOL"/><us-chemistry idref="CHEM-US-00649" cdx-file="US20230000833A1-20230105-C00649.CDX" mol-file="US20230000833A1-20230105-C00649.MOL"/><us-chemistry idref="CHEM-US-00650" cdx-file="US20230000833A1-20230105-C00650.CDX" mol-file="US20230000833A1-20230105-C00650.MOL"/><us-chemistry idref="CHEM-US-00651" cdx-file="US20230000833A1-20230105-C00651.CDX" mol-file="US20230000833A1-20230105-C00651.MOL"/><us-chemistry idref="CHEM-US-00652" cdx-file="US20230000833A1-20230105-C00652.CDX" mol-file="US20230000833A1-20230105-C00652.MOL"/><us-chemistry idref="CHEM-US-00653" cdx-file="US20230000833A1-20230105-C00653.CDX" mol-file="US20230000833A1-20230105-C00653.MOL"/><us-chemistry idref="CHEM-US-00654" cdx-file="US20230000833A1-20230105-C00654.CDX" mol-file="US20230000833A1-20230105-C00654.MOL"/><us-chemistry idref="CHEM-US-00655" cdx-file="US20230000833A1-20230105-C00655.CDX" mol-file="US20230000833A1-20230105-C00655.MOL"/><us-chemistry idref="CHEM-US-00656" cdx-file="US20230000833A1-20230105-C00656.CDX" mol-file="US20230000833A1-20230105-C00656.MOL"/><us-chemistry idref="CHEM-US-00657" cdx-file="US20230000833A1-20230105-C00657.CDX" mol-file="US20230000833A1-20230105-C00657.MOL"/><us-chemistry idref="CHEM-US-00658" cdx-file="US20230000833A1-20230105-C00658.CDX" mol-file="US20230000833A1-20230105-C00658.MOL"/><us-chemistry idref="CHEM-US-00659" cdx-file="US20230000833A1-20230105-C00659.CDX" mol-file="US20230000833A1-20230105-C00659.MOL"/><us-chemistry idref="CHEM-US-00660" cdx-file="US20230000833A1-20230105-C00660.CDX" mol-file="US20230000833A1-20230105-C00660.MOL"/><us-chemistry idref="CHEM-US-00661" cdx-file="US20230000833A1-20230105-C00661.CDX" mol-file="US20230000833A1-20230105-C00661.MOL"/><us-chemistry idref="CHEM-US-00662" cdx-file="US20230000833A1-20230105-C00662.CDX" mol-file="US20230000833A1-20230105-C00662.MOL"/><us-chemistry idref="CHEM-US-00663" cdx-file="US20230000833A1-20230105-C00663.CDX" mol-file="US20230000833A1-20230105-C00663.MOL"/><us-chemistry idref="CHEM-US-00664" cdx-file="US20230000833A1-20230105-C00664.CDX" mol-file="US20230000833A1-20230105-C00664.MOL"/><us-chemistry idref="CHEM-US-00665" cdx-file="US20230000833A1-20230105-C00665.CDX" mol-file="US20230000833A1-20230105-C00665.MOL"/><us-chemistry idref="CHEM-US-00666" cdx-file="US20230000833A1-20230105-C00666.CDX" mol-file="US20230000833A1-20230105-C00666.MOL"/><us-chemistry idref="CHEM-US-00667" cdx-file="US20230000833A1-20230105-C00667.CDX" mol-file="US20230000833A1-20230105-C00667.MOL"/><us-chemistry idref="CHEM-US-00668" cdx-file="US20230000833A1-20230105-C00668.CDX" mol-file="US20230000833A1-20230105-C00668.MOL"/><us-chemistry idref="CHEM-US-00669" cdx-file="US20230000833A1-20230105-C00669.CDX" mol-file="US20230000833A1-20230105-C00669.MOL"/><us-chemistry idref="CHEM-US-00670" cdx-file="US20230000833A1-20230105-C00670.CDX" mol-file="US20230000833A1-20230105-C00670.MOL"/><us-chemistry idref="CHEM-US-00671" cdx-file="US20230000833A1-20230105-C00671.CDX" mol-file="US20230000833A1-20230105-C00671.MOL"/><us-chemistry idref="CHEM-US-00672" cdx-file="US20230000833A1-20230105-C00672.CDX" mol-file="US20230000833A1-20230105-C00672.MOL"/><us-chemistry idref="CHEM-US-00673" cdx-file="US20230000833A1-20230105-C00673.CDX" mol-file="US20230000833A1-20230105-C00673.MOL"/><us-chemistry idref="CHEM-US-00674" cdx-file="US20230000833A1-20230105-C00674.CDX" mol-file="US20230000833A1-20230105-C00674.MOL"/><us-chemistry idref="CHEM-US-00675" cdx-file="US20230000833A1-20230105-C00675.CDX" mol-file="US20230000833A1-20230105-C00675.MOL"/><us-chemistry idref="CHEM-US-00676" cdx-file="US20230000833A1-20230105-C00676.CDX" mol-file="US20230000833A1-20230105-C00676.MOL"/><us-chemistry idref="CHEM-US-00677" cdx-file="US20230000833A1-20230105-C00677.CDX" mol-file="US20230000833A1-20230105-C00677.MOL"/><us-chemistry idref="CHEM-US-00678" cdx-file="US20230000833A1-20230105-C00678.CDX" mol-file="US20230000833A1-20230105-C00678.MOL"/><us-chemistry idref="CHEM-US-00679" cdx-file="US20230000833A1-20230105-C00679.CDX" mol-file="US20230000833A1-20230105-C00679.MOL"/><us-chemistry idref="CHEM-US-00680" cdx-file="US20230000833A1-20230105-C00680.CDX" mol-file="US20230000833A1-20230105-C00680.MOL"/><us-chemistry idref="CHEM-US-00681" cdx-file="US20230000833A1-20230105-C00681.CDX" mol-file="US20230000833A1-20230105-C00681.MOL"/><us-chemistry idref="CHEM-US-00682" cdx-file="US20230000833A1-20230105-C00682.CDX" mol-file="US20230000833A1-20230105-C00682.MOL"/><us-chemistry idref="CHEM-US-00683" cdx-file="US20230000833A1-20230105-C00683.CDX" mol-file="US20230000833A1-20230105-C00683.MOL"/><us-chemistry idref="CHEM-US-00684" cdx-file="US20230000833A1-20230105-C00684.CDX" mol-file="US20230000833A1-20230105-C00684.MOL"/><us-chemistry idref="CHEM-US-00685" cdx-file="US20230000833A1-20230105-C00685.CDX" mol-file="US20230000833A1-20230105-C00685.MOL"/><us-chemistry idref="CHEM-US-00686" cdx-file="US20230000833A1-20230105-C00686.CDX" mol-file="US20230000833A1-20230105-C00686.MOL"/><us-chemistry idref="CHEM-US-00687" cdx-file="US20230000833A1-20230105-C00687.CDX" mol-file="US20230000833A1-20230105-C00687.MOL"/><us-chemistry idref="CHEM-US-00688" cdx-file="US20230000833A1-20230105-C00688.CDX" mol-file="US20230000833A1-20230105-C00688.MOL"/><us-chemistry idref="CHEM-US-00689" cdx-file="US20230000833A1-20230105-C00689.CDX" mol-file="US20230000833A1-20230105-C00689.MOL"/><us-chemistry idref="CHEM-US-00690" cdx-file="US20230000833A1-20230105-C00690.CDX" mol-file="US20230000833A1-20230105-C00690.MOL"/><us-chemistry idref="CHEM-US-00691" cdx-file="US20230000833A1-20230105-C00691.CDX" mol-file="US20230000833A1-20230105-C00691.MOL"/><us-chemistry idref="CHEM-US-00692" cdx-file="US20230000833A1-20230105-C00692.CDX" mol-file="US20230000833A1-20230105-C00692.MOL"/><us-chemistry idref="CHEM-US-00693" cdx-file="US20230000833A1-20230105-C00693.CDX" mol-file="US20230000833A1-20230105-C00693.MOL"/><us-chemistry idref="CHEM-US-00694" cdx-file="US20230000833A1-20230105-C00694.CDX" mol-file="US20230000833A1-20230105-C00694.MOL"/><us-chemistry idref="CHEM-US-00695" cdx-file="US20230000833A1-20230105-C00695.CDX" mol-file="US20230000833A1-20230105-C00695.MOL"/><us-chemistry idref="CHEM-US-00696" cdx-file="US20230000833A1-20230105-C00696.CDX" mol-file="US20230000833A1-20230105-C00696.MOL"/><us-chemistry idref="CHEM-US-00697" cdx-file="US20230000833A1-20230105-C00697.CDX" mol-file="US20230000833A1-20230105-C00697.MOL"/><us-chemistry idref="CHEM-US-00698" cdx-file="US20230000833A1-20230105-C00698.CDX" mol-file="US20230000833A1-20230105-C00698.MOL"/><us-chemistry idref="CHEM-US-00699" cdx-file="US20230000833A1-20230105-C00699.CDX" mol-file="US20230000833A1-20230105-C00699.MOL"/><us-chemistry idref="CHEM-US-00700" cdx-file="US20230000833A1-20230105-C00700.CDX" mol-file="US20230000833A1-20230105-C00700.MOL"/><us-chemistry idref="CHEM-US-00701" cdx-file="US20230000833A1-20230105-C00701.CDX" mol-file="US20230000833A1-20230105-C00701.MOL"/><us-chemistry idref="CHEM-US-00702" cdx-file="US20230000833A1-20230105-C00702.CDX" mol-file="US20230000833A1-20230105-C00702.MOL"/><us-chemistry idref="CHEM-US-00703" cdx-file="US20230000833A1-20230105-C00703.CDX" mol-file="US20230000833A1-20230105-C00703.MOL"/><us-chemistry idref="CHEM-US-00704" cdx-file="US20230000833A1-20230105-C00704.CDX" mol-file="US20230000833A1-20230105-C00704.MOL"/><us-chemistry idref="CHEM-US-00705" cdx-file="US20230000833A1-20230105-C00705.CDX" mol-file="US20230000833A1-20230105-C00705.MOL"/><us-chemistry idref="CHEM-US-00706" cdx-file="US20230000833A1-20230105-C00706.CDX" mol-file="US20230000833A1-20230105-C00706.MOL"/><us-chemistry idref="CHEM-US-00707" cdx-file="US20230000833A1-20230105-C00707.CDX" mol-file="US20230000833A1-20230105-C00707.MOL"/><us-chemistry idref="CHEM-US-00708" cdx-file="US20230000833A1-20230105-C00708.CDX" mol-file="US20230000833A1-20230105-C00708.MOL"/><us-chemistry idref="CHEM-US-00709" cdx-file="US20230000833A1-20230105-C00709.CDX" mol-file="US20230000833A1-20230105-C00709.MOL"/><us-chemistry idref="CHEM-US-00710" cdx-file="US20230000833A1-20230105-C00710.CDX" mol-file="US20230000833A1-20230105-C00710.MOL"/><us-chemistry idref="CHEM-US-00711" cdx-file="US20230000833A1-20230105-C00711.CDX" mol-file="US20230000833A1-20230105-C00711.MOL"/><us-chemistry idref="CHEM-US-00712" cdx-file="US20230000833A1-20230105-C00712.CDX" mol-file="US20230000833A1-20230105-C00712.MOL"/><us-chemistry idref="CHEM-US-00713" cdx-file="US20230000833A1-20230105-C00713.CDX" mol-file="US20230000833A1-20230105-C00713.MOL"/><us-chemistry idref="CHEM-US-00714" cdx-file="US20230000833A1-20230105-C00714.CDX" mol-file="US20230000833A1-20230105-C00714.MOL"/><us-chemistry idref="CHEM-US-00715" cdx-file="US20230000833A1-20230105-C00715.CDX" mol-file="US20230000833A1-20230105-C00715.MOL"/><us-chemistry idref="CHEM-US-00716" cdx-file="US20230000833A1-20230105-C00716.CDX" mol-file="US20230000833A1-20230105-C00716.MOL"/><us-chemistry idref="CHEM-US-00717" cdx-file="US20230000833A1-20230105-C00717.CDX" mol-file="US20230000833A1-20230105-C00717.MOL"/><us-chemistry idref="CHEM-US-00718" cdx-file="US20230000833A1-20230105-C00718.CDX" mol-file="US20230000833A1-20230105-C00718.MOL"/><us-chemistry idref="CHEM-US-00719" cdx-file="US20230000833A1-20230105-C00719.CDX" mol-file="US20230000833A1-20230105-C00719.MOL"/><us-chemistry idref="CHEM-US-00720" cdx-file="US20230000833A1-20230105-C00720.CDX" mol-file="US20230000833A1-20230105-C00720.MOL"/><us-chemistry idref="CHEM-US-00721" cdx-file="US20230000833A1-20230105-C00721.CDX" mol-file="US20230000833A1-20230105-C00721.MOL"/><us-chemistry idref="CHEM-US-00722" cdx-file="US20230000833A1-20230105-C00722.CDX" mol-file="US20230000833A1-20230105-C00722.MOL"/><us-chemistry idref="CHEM-US-00723" cdx-file="US20230000833A1-20230105-C00723.CDX" mol-file="US20230000833A1-20230105-C00723.MOL"/><us-chemistry idref="CHEM-US-00724" cdx-file="US20230000833A1-20230105-C00724.CDX" mol-file="US20230000833A1-20230105-C00724.MOL"/><us-chemistry idref="CHEM-US-00725" cdx-file="US20230000833A1-20230105-C00725.CDX" mol-file="US20230000833A1-20230105-C00725.MOL"/><us-chemistry idref="CHEM-US-00726" cdx-file="US20230000833A1-20230105-C00726.CDX" mol-file="US20230000833A1-20230105-C00726.MOL"/><us-chemistry idref="CHEM-US-00727" cdx-file="US20230000833A1-20230105-C00727.CDX" mol-file="US20230000833A1-20230105-C00727.MOL"/><us-chemistry idref="CHEM-US-00728" cdx-file="US20230000833A1-20230105-C00728.CDX" mol-file="US20230000833A1-20230105-C00728.MOL"/><us-chemistry idref="CHEM-US-00729" cdx-file="US20230000833A1-20230105-C00729.CDX" mol-file="US20230000833A1-20230105-C00729.MOL"/><us-chemistry idref="CHEM-US-00730" cdx-file="US20230000833A1-20230105-C00730.CDX" mol-file="US20230000833A1-20230105-C00730.MOL"/><us-chemistry idref="CHEM-US-00731" cdx-file="US20230000833A1-20230105-C00731.CDX" mol-file="US20230000833A1-20230105-C00731.MOL"/><us-chemistry idref="CHEM-US-00732" cdx-file="US20230000833A1-20230105-C00732.CDX" mol-file="US20230000833A1-20230105-C00732.MOL"/><us-chemistry idref="CHEM-US-00733" cdx-file="US20230000833A1-20230105-C00733.CDX" mol-file="US20230000833A1-20230105-C00733.MOL"/><us-chemistry idref="CHEM-US-00734" cdx-file="US20230000833A1-20230105-C00734.CDX" mol-file="US20230000833A1-20230105-C00734.MOL"/><us-chemistry idref="CHEM-US-00735" cdx-file="US20230000833A1-20230105-C00735.CDX" mol-file="US20230000833A1-20230105-C00735.MOL"/><us-chemistry idref="CHEM-US-00736" cdx-file="US20230000833A1-20230105-C00736.CDX" mol-file="US20230000833A1-20230105-C00736.MOL"/><us-chemistry idref="CHEM-US-00737" cdx-file="US20230000833A1-20230105-C00737.CDX" mol-file="US20230000833A1-20230105-C00737.MOL"/><us-chemistry idref="CHEM-US-00738" cdx-file="US20230000833A1-20230105-C00738.CDX" mol-file="US20230000833A1-20230105-C00738.MOL"/><us-chemistry idref="CHEM-US-00739" cdx-file="US20230000833A1-20230105-C00739.CDX" mol-file="US20230000833A1-20230105-C00739.MOL"/><us-chemistry idref="CHEM-US-00740" cdx-file="US20230000833A1-20230105-C00740.CDX" mol-file="US20230000833A1-20230105-C00740.MOL"/><us-chemistry idref="CHEM-US-00741" cdx-file="US20230000833A1-20230105-C00741.CDX" mol-file="US20230000833A1-20230105-C00741.MOL"/><us-chemistry idref="CHEM-US-00742" cdx-file="US20230000833A1-20230105-C00742.CDX" mol-file="US20230000833A1-20230105-C00742.MOL"/><us-chemistry idref="CHEM-US-00743" cdx-file="US20230000833A1-20230105-C00743.CDX" mol-file="US20230000833A1-20230105-C00743.MOL"/><us-chemistry idref="CHEM-US-00744" cdx-file="US20230000833A1-20230105-C00744.CDX" mol-file="US20230000833A1-20230105-C00744.MOL"/><us-chemistry idref="CHEM-US-00745" cdx-file="US20230000833A1-20230105-C00745.CDX" mol-file="US20230000833A1-20230105-C00745.MOL"/><us-chemistry idref="CHEM-US-00746" cdx-file="US20230000833A1-20230105-C00746.CDX" mol-file="US20230000833A1-20230105-C00746.MOL"/><us-chemistry idref="CHEM-US-00747" cdx-file="US20230000833A1-20230105-C00747.CDX" mol-file="US20230000833A1-20230105-C00747.MOL"/><us-chemistry idref="CHEM-US-00748" cdx-file="US20230000833A1-20230105-C00748.CDX" mol-file="US20230000833A1-20230105-C00748.MOL"/><us-chemistry idref="CHEM-US-00749" cdx-file="US20230000833A1-20230105-C00749.CDX" mol-file="US20230000833A1-20230105-C00749.MOL"/><us-chemistry idref="CHEM-US-00750" cdx-file="US20230000833A1-20230105-C00750.CDX" mol-file="US20230000833A1-20230105-C00750.MOL"/><us-chemistry idref="CHEM-US-00751" cdx-file="US20230000833A1-20230105-C00751.CDX" mol-file="US20230000833A1-20230105-C00751.MOL"/><us-chemistry idref="CHEM-US-00752" cdx-file="US20230000833A1-20230105-C00752.CDX" mol-file="US20230000833A1-20230105-C00752.MOL"/><us-chemistry idref="CHEM-US-00753" cdx-file="US20230000833A1-20230105-C00753.CDX" mol-file="US20230000833A1-20230105-C00753.MOL"/><us-chemistry idref="CHEM-US-00754" cdx-file="US20230000833A1-20230105-C00754.CDX" mol-file="US20230000833A1-20230105-C00754.MOL"/><us-chemistry idref="CHEM-US-00755" cdx-file="US20230000833A1-20230105-C00755.CDX" mol-file="US20230000833A1-20230105-C00755.MOL"/><us-chemistry idref="CHEM-US-00756" cdx-file="US20230000833A1-20230105-C00756.CDX" mol-file="US20230000833A1-20230105-C00756.MOL"/><us-chemistry idref="CHEM-US-00757" cdx-file="US20230000833A1-20230105-C00757.CDX" mol-file="US20230000833A1-20230105-C00757.MOL"/><us-chemistry idref="CHEM-US-00758" cdx-file="US20230000833A1-20230105-C00758.CDX" mol-file="US20230000833A1-20230105-C00758.MOL"/><us-chemistry idref="CHEM-US-00759" cdx-file="US20230000833A1-20230105-C00759.CDX" mol-file="US20230000833A1-20230105-C00759.MOL"/><us-chemistry idref="CHEM-US-00760" cdx-file="US20230000833A1-20230105-C00760.CDX" mol-file="US20230000833A1-20230105-C00760.MOL"/><us-chemistry idref="CHEM-US-00761" cdx-file="US20230000833A1-20230105-C00761.CDX" mol-file="US20230000833A1-20230105-C00761.MOL"/><us-chemistry idref="CHEM-US-00762" cdx-file="US20230000833A1-20230105-C00762.CDX" mol-file="US20230000833A1-20230105-C00762.MOL"/><us-chemistry idref="CHEM-US-00763" cdx-file="US20230000833A1-20230105-C00763.CDX" mol-file="US20230000833A1-20230105-C00763.MOL"/><us-chemistry idref="CHEM-US-00764" cdx-file="US20230000833A1-20230105-C00764.CDX" mol-file="US20230000833A1-20230105-C00764.MOL"/><us-chemistry idref="CHEM-US-00765" cdx-file="US20230000833A1-20230105-C00765.CDX" mol-file="US20230000833A1-20230105-C00765.MOL"/><us-chemistry idref="CHEM-US-00766" cdx-file="US20230000833A1-20230105-C00766.CDX" mol-file="US20230000833A1-20230105-C00766.MOL"/><us-chemistry idref="CHEM-US-00767" cdx-file="US20230000833A1-20230105-C00767.CDX" mol-file="US20230000833A1-20230105-C00767.MOL"/><us-chemistry idref="CHEM-US-00768" cdx-file="US20230000833A1-20230105-C00768.CDX" mol-file="US20230000833A1-20230105-C00768.MOL"/><us-claim-statement>What is claimed:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A compound, and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof, having the structure of Formula (I):</claim-text><claim-text><chemistry id="CHEM-US-00740" num="00740"><img id="EMI-C00740" he="26.50mm" wi="55.29mm" file="US20230000833A1-20230105-C00740.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein<claim-text>R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</claim-text><claim-text>R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; pyridinyl substituted with F, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>haloalkyl; thiazolyl; thiazolyl substituted with C<sub>1-6</sub>alkyl or C<sub>1-6</sub>haloalkyl; thienyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>3</sub>, and cyclopropyl;</claim-text><claim-text>R<sup>3 </sup>is H;</claim-text><claim-text>R<sup>4 </sup>is selected from the group consisting of:<claim-text>(a)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00741" num="00741"><img id="EMI-C00741" he="21.00mm" wi="20.83mm" file="US20230000833A1-20230105-C00741.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein ring A is a 4-6 membered heterocycle optionally containing an additional oxygen heteroatom selected from the group consisting of: azetidinyl; azetidinyl substituted with one or two members independently selected from the group consisting of: F, OH, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>haloalkyl, CH<sub>2</sub>OCH<sub>3</sub>, CN, and OCH<sub>3</sub>; pyrrolidinyl; pyrrolidinyl substituted two F members; morpholinyl; piperidinyl; piperazinyl substituted with C<sub>1-6</sub>alkyl; and (2,6-diazaspiro[3.3]heptan-6-yl);<claim-text><claim-text>(b)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00742" num="00742"><img id="EMI-C00742" he="20.66mm" wi="25.23mm" file="US20230000833A1-20230105-C00742.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>4b </sup>is selected from the group consisting of: H; C<sub>1-6</sub>alkyl; CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>; C<sub>3-6</sub>cycloalkyl; C<sub>3-6</sub>cycloalkyl substituted with two or three members independently selected from the group consisting of F or CH<sub>3</sub>; oxetanyl; oxetanyl substituted with CH<sub>3</sub>; and pyridinyl;<claim-text><claim-text>(c)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00743" num="00743"><img id="EMI-C00743" he="10.75mm" wi="16.00mm" file="US20230000833A1-20230105-C00743.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;<claim-text><claim-text>(d)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00744" num="00744"><img id="EMI-C00744" he="15.66mm" wi="19.05mm" file="US20230000833A1-20230105-C00744.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>4d </sup>is selected from the group consisting of: OH, C<sub>1-6</sub>alkyl, O&#x2014;C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, thienyl, and thiazolyl; and<claim-text><claim-text>(e) C<sub>2-6</sub>alkyl substituted with one or two members independently selected from OH, OC<sub>1-6</sub>alkyl, or cyclopropyl; CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-6</sub>alkyl); CH<sub>2</sub>CH<sub>2</sub>NH(CH<sub>2</sub>CH<sub>2</sub>OH); CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>3-6</sub>cycloalkyl); and difluoro(3-pyridyl)methyl; and</claim-text></claim-text><claim-text>R<sup>1a </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>1 </sup>is H.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>1 </sup>is CH<sub>3 </sub>or CH<sub>2</sub>F.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>1a </sup>is H.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>2 </sup>is phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: CI, F, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>alkyl, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; or pyridinyl substituted with CF<sub>3</sub>.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>2 </sup>is thiazolyl substituted with C<sub>1-6</sub>alkyl or CF<sub>3</sub>; thienyl; or thienyl substituted with one or two members each independently selected from the group consisting of: Cl, F, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCD<sub>3</sub>, and cyclopropyl.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>1 </sup>is H or CH<sub>3</sub>, R<sup>2 </sup>is phenyl, wherein the phenyl is optionally substituted with one, two, or three members independently selected from: halo, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>haloalkyl; or thienyl, wherein the thienyl is optionally substituted with one or two members independently selected from: halo, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>haloalkyl; R<sup>3 </sup>is H, and R<sup>4 </sup>is</claim-text><claim-text><chemistry id="CHEM-US-00745" num="00745"><img id="EMI-C00745" he="73.15mm" wi="67.39mm" file="US20230000833A1-20230105-C00745.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>2 </sup>is phenyl; o-tolyl; m-tolyl; p-tolyl; 4-tert-butylphenyl; 3-(trifluoromethyl)phenyl; 4-fluorophenyl; 3-fluorophenyl; 3-cyanophenyl; 3-chlorophenyl; 4-chlorophenyl; 3-(difluoromethyl)phenyl; 3-methoxyphenyl; 3-(difluoromethoxy)phenyl; 4-methoxyphenyl; 3-(trifluoromethoxy)phenyl; 2-ethoxyphenyl; 3-ethoxyphenyl; 3-cyclopropylphenyl; 3-(dimethylamino)phenyl; 2,3-dichlorophenyl; 2,3-difluorophenyl; 2,3-dimethylphenyl; 2-fluoro-3-(trifluoromethyl)phenyl; 2,4-dimethoxyphenyl; 2,3-dimethoxyphenyl; 2,4-difluorophenyl; 3,4-difluorophenyl; 3,4-dichlorophenyl; 3-(difluoromethyl)-4-fluoro-phenyl; 5-(difluoromethyl)-2-fluorophenyl; 2,6-dimethylphenyl; 3,5-dimethylphenyl; 3,5-difluorophenyl; 3-fluoro-5-(trifluoromethyl)phenyl; 2-methyl-5-(trifluoromethyl)phenyl; 2-methyl-3-(trifluoromethyl)phenyl; 4-chloro-3-methyl-phenyl; 4-fluoro-3-(trifluoromethyl)phenyl; 4-chloro-3-(trifluoromethyl)phenyl; 2-ethoxy-5-fluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 2-chloro-4-methoxy-phenyl; 4-fluoro-2-methyl-phenyl; 4-fluoro-2-methoxy-phenyl; 2-fluoro-6-methoxy-phenyl; 3-fluoro-4-methoxy-phenyl; 3-fluoro-5-methyl-phenyl; 2-fluoro-3-methyl-phenyl; 4-fluoro-3-methyl-phenyl; 4-methoxy-3-methyl-phenyl; 4-fluoro-2,3-dimethyl-phenyl; 2,4-difluoro-3-methyl-phenyl; 2,3,4-trifluorophenyl; 3,4,5-trifluorophenyl; 3,4-difluoro-5-(trifluoromethyl)phenyl; 3-pyridyl; 2-(trifluoromethyl)-4-pyridyl; 2-thienyl; 5-methyl-2-thienyl; 5-ethyl-2-thienyl; 4-methyl-2-thienyl; 5-(trideuteriomethoxymethyl; 5-(hydroxymethyl)-2-thienyl; 5-fluoro-2-thienyl; 5-chloro-2-thienyl; 5-cyclopropyl-2-thienyl; 5-chloro-4-methyl-2-thienyl; 5-(difluoromethyl)-2-thienyl; 5-(difluoromethyl)-3-thienyl; 5-(trifluoromethyl)-2-thienyl; 5-(trifluoromethyl)-3-thienyl; 2-(trifluoromethyl)-3-thienyl; 4-(difluoromethyl)-2-thienyl; 5-(1,1,2,2,2-pentafluoroethyl)-2-thienyl; 4-methylthiazol-2-yl; 2-methylthiazol-5-yl; 2-(trifluoromethyl)thiazol-5-yl; or 2-(trifluoromethyl)thiazol-4-yl.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>3 </sup>is H.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>3 </sup>is D or T.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>4 </sup>is</claim-text><claim-text><chemistry id="CHEM-US-00746" num="00746"><img id="EMI-C00746" he="21.00mm" wi="21.67mm" file="US20230000833A1-20230105-C00746.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein ring A is</claim-text><claim-text><chemistry id="CHEM-US-00747" num="00747"><img id="EMI-C00747" he="101.09mm" wi="75.61mm" file="US20230000833A1-20230105-C00747.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>4 </sup>is</claim-text><claim-text><chemistry id="CHEM-US-00748" num="00748"><img id="EMI-C00748" he="185.25mm" wi="75.18mm" file="US20230000833A1-20230105-C00748.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>4 </sup>is</claim-text><claim-text><chemistry id="CHEM-US-00749" num="00749"><img id="EMI-C00749" he="255.95mm" wi="73.41mm" file="US20230000833A1-20230105-C00749.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>4 </sup>is</claim-text><claim-text><chemistry id="CHEM-US-00750" num="00750"><img id="EMI-C00750" he="220.47mm" wi="62.23mm" file="US20230000833A1-20230105-C00750.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>4 </sup>is</claim-text><claim-text><chemistry id="CHEM-US-00751" num="00751"><img id="EMI-C00751" he="156.72mm" wi="63.58mm" file="US20230000833A1-20230105-C00751.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein<claim-text>R<sup>a </sup>is independently selected from: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;</claim-text><claim-text>R<sup>b </sup>is independently selected from: CI, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>;</claim-text><claim-text>Re is For CH<sub>3</sub>;</claim-text><claim-text>Rd is OCH<sub>3</sub>;</claim-text><claim-text>m is 0 or 1; and</claim-text><claim-text>n is 0, 1, or 2.</claim-text></claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein<claim-text>R<sup>1 </sup>is H or CH<sub>3</sub>;</claim-text><claim-text>R<sup>2 </sup>is phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, and OC<sub>1</sub>-6alkyl;</claim-text><claim-text>R<sup>3 </sup>is H; and</claim-text><claim-text>R<sup>4 </sup>is</claim-text></claim-text><claim-text><chemistry id="CHEM-US-00752" num="00752"><img id="EMI-C00752" he="92.20mm" wi="75.69mm" file="US20230000833A1-20230105-C00752.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof, having the structure of Formula (IA):</claim-text><claim-text><chemistry id="CHEM-US-00753" num="00753"><img id="EMI-C00753" he="34.97mm" wi="58.93mm" file="US20230000833A1-20230105-C00753.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;<claim-text>R<sup>2 </sup>is phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, OC<sub>1-6</sub>alkyl; thiazolyl substituted with C<sub>1-6</sub>alkyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>3</sub>, and cyclopropyl;</claim-text><claim-text>R<sup>3 </sup>is H or T; and</claim-text><claim-text>ring A is</claim-text></claim-text><claim-text><chemistry id="CHEM-US-00754" num="00754"><img id="EMI-C00754" he="101.09mm" wi="70.27mm" file="US20230000833A1-20230105-C00754.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The compound of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein<claim-text>R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</claim-text><claim-text>R<sup>2 </sup>is 3-(trifluoromethyl)phenyl, 4-fluoro-3-methyl-phenyl, 2,4-difluoro-3-methyl-phenyl, 5-(trifluoromethyl)-2-thienyl, 5-(difluoromethyl)-2-thienyl, or 5-chloro-4-methyl-2-thienyl;</claim-text><claim-text>R<sup>3 </sup>is H; and</claim-text></claim-text><claim-text><chemistry id="CHEM-US-00755" num="00755"><img id="EMI-C00755" he="25.91mm" wi="70.95mm" file="US20230000833A1-20230105-C00755.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>ring A is</claim-text></claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The compound of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein R<sup>2 </sup>is m-tolyl, 3-fluorophenyl, 3-chlorophenyl, 3-(trifluoromethyl)phenyl, 5-methyl-2-thienyl, 5-ethyl-2-thienyl, 5-(hydroxymethyl)-2-thienyl, 5-cyclopropyl-2-thienyl, 5-(trideuteriomethoxymethyl)-2-thienyl, 5-(trifluoromethyl)-2-thienyl, 5-(trifluoromethyl)-3-thienyl, 2-(trifluoromethyl)-3-thienyl, 5-(1,1,2,2,2-pentafluoroethyl)-2-thienyl, 5-(trifluoromethyl)thiophen-2-yl, 5-fluoro-2-thienyl, 5-chloro-4-methyl-2-thienyl, 5-(difluoromethyl)-2-thienyl, 4-(difluoromethyl)-2-thienyl, 5-(difluoromethyl)-3-thienyl, 4-methylthiazol-2-yl, 2-methylthiazol-5-yl, 4-methoxyphenyl, 4-fluoro-2-methyl-phenyl, 2-fluoro-3-methyl-phenyl, 4-fluoro-3-methyl-phenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 2,4-difluoro-3-methyl-phenyl, 3,4,5-trifluorophenyl, 2-(trifluoromethyl)thiazol-5-yl, 2-(trifluoromethyl)thiazol-4-yl, 2-methyl-5-(trifluoromethyl)phenyl, 2-methyl-3-(trifluoromethyl)phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, or 4-fluoro-3-(trifluoromethyl)phenyl.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof, having the structure of Formula (IB):</claim-text><claim-text><chemistry id="CHEM-US-00756" num="00756"><img id="EMI-C00756" he="33.61mm" wi="60.28mm" file="US20230000833A1-20230105-C00756.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein R<sup>1 </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>;<claim-text>R<sup>2 </sup>is selected from the group consisting of: phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6 </sub>alkyl, C<sub>1-6</sub>haloalkyl, OC<sub>1-6</sub>alkyl; pyridinyl; thiazolyl substituted with C<sub>1-6</sub>alkyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, and cyclopropyl;</claim-text></claim-text><claim-text>R<sup>3 </sup>is H; and</claim-text><claim-text>R<sup>4b </sup>is H, C<sub>1-6</sub>alkyl, 2-methoxyethyl, C<sub>3-6</sub>cycloalkyl, 3,3-difluorocyclobutyl, 3,3-difluoro-1-methyl-cyclobutyl, cyclopentyl, oxetan-3-yl, 3-methyloxetan-3-yl, or 2-pyridyl.</claim-text></claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The compound of <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein<claim-text>R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</claim-text><claim-text>R<sup>1b </sup>is CH<sub>3</sub>;</claim-text><claim-text>R<sup>2 </sup>is 3-(trifluoromethyl)phenyl, 4-fluoro-3-methyl-phenyl, 2,4-difluoro-3-methyl-phenyl, 5-(trifluoromethyl)-2-thienyl, 5-(difluoromethyl)-2-thienyl, or 5-chloro-4-methyl-2-thienyl;</claim-text><claim-text>R<sup>3 </sup>is H; and</claim-text><claim-text>R<sup>4b </sup>is CH<sub>3</sub>.</claim-text></claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The compound of <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein R<sup>2 </sup>is 3-pyridyl, 5-methyl-2-thienyl, 4-methyl-2-thienyl, 5-cyclopropyl-2-thienyl, 5-ethyl-2-thienyl, 5-chloro-2-thienyl, 5-(hydroxymethyl)-2-thienyl, 5-(trifluoromethyl)-2-thienyl, 5-(trifluoromethyl)-3-thienyl, 2-(trifluoromethyl)-3-thienyl, 5-(difluoromethyl)-2-thienyl, 5-(difluoromethyl)-3-thienyl, 5-chloro-4-methyl-2-thienyl, 5-fluoro-2-thienyl, 5-fluoro-2-thienyl, 2-methylthiazol-5-yl, 3,5-dimethylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-fluoro-2-methyl-phenyl, 2-fluoro-3-methyl-phenyl, 4-fuoro-3-methyl-phenyl, 4-chlorophenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-methoxy-3-methyl-phenyl, 4-fluoro-2-methoxy-phenyl, 2-fluoro-6-methoxy-phenyl, 2,4-difluoro-3-methyl-phenyl, 3-(difluoromethyl)phenyl, 3-chloro-4-fluoro-phenyl, 2,4-dimethoxyphenyl, 2-ethoxy-5-fluoro-phenyl, 2-chloro-4-methoxy-phenyl, 3-(trifluoromethyl)phenyl, 2-(trifluoromethyl)thiazol-5-yl, 2-(trifluoromethyl)thiazol-4-yl, 2-fluoro-3-(trifluoromethyl)phenyl, or 3,4-difluoro-5-(trifluoromethyl)phenyl.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof, having the structure of Formula (IC):</claim-text><claim-text><chemistry id="CHEM-US-00757" num="00757"><img id="EMI-C00757" he="25.15mm" wi="55.88mm" file="US20230000833A1-20230105-C00757.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>1 </sup>is H or CH<sub>3; </sub><claim-text>R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>alkyl, OC<sub>1-6</sub>haloalkyl, and N(CH<sub>3</sub>)<sub>2</sub>; pyridinyl substituted with CF<sub>3</sub>; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>haloalkyl; and</claim-text><claim-text>R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>.</claim-text></claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. The compound of <claim-ref idref="CLM-00001">claim 1</claim-ref>, and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof, having the structure of Formula (ID):</claim-text><claim-text><chemistry id="CHEM-US-00758" num="00758"><img id="EMI-C00758" he="30.06mm" wi="57.49mm" file="US20230000833A1-20230105-C00758.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>1 </sup>is H or CH<sub>3</sub>;<claim-text>R<sup>2 </sup>is m-tolyl, 3-(trifluoromethyl)phenyl, 4-chlorophenyl, 2,4-difluoro-3-methyl-phenyl, 3,4-difluorophenyl, 4-fuoro-3-methyl-phenyl, 3-cyclopropylphenyl, 3-fluoro-4-methoxy-phenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-methoxyphenyl, 2-ethoxy-5-fluoro-phenyl, 4-fluoro-2-methoxy-phenyl, or 3-chloro-4-fluoro-phenyl; and</claim-text><claim-text>R<sup>4d </sup>is OH, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, 2-thienyl, or thiazol-2-yl.</claim-text></claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A compound selected from the group consisting of:<claim-text>6-(4-Methoxyphenyl)-1-(2-morpholino-2-oxo-ethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-2-methyl-phenyl)-1-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-Ethyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>(S*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R*)-1-(2-Hydroxybutyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-(5-Chloro-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>6-[5-(Difluoromethyl)-2-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Methylisoxazol-3-yl)methyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(4-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-[(1-methylpyrazol-4-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(1,5-Dimethylpyrazol-3-yl)methyl]-6-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Methylisoxazol-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-Cyclopropyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[(3-Chlorophenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(2-Methoxy-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Pyrimidin-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[2-oxo-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(2-Cyclopropyl-2-hydroxy-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(2-Oxo-1H-pyridin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-(4-Fluoro-2-methyl-phenyl)-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Methoxyphenyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(2-Chloro-4-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(4-methoxyphenyl)-2-oxo-3H-imidazo[4, 5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(3,5-dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(4-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>(R*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(S*)-6-(4-Fluoro-2-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-difluorophenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(4-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(2-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-5-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrimidin-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-6-(5-methyl-2-thienyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(5-Ethyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-6-(4-methyl-2-thienyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-fluoro-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-(5-Fluoro-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(5-fluoro-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(5-Fluoro-2-thienyl)-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(4-methylthiazol-2-yl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-ethyl-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(5-Ethyl-2-thienyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(hydroxymethyl)-2-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-(hydroxymethyl)-2-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-[5-(Hydroxymethyl)-2-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(difluoromethyl)-2-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-[5-(Difluoromethyl)-3-thienyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(difluoromethyl)-3-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[5-(Difluoromethyl)-3-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-3-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-cyclopropyl-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(5-Cyclopropyl-2-thienyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-4-yl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-(5-Cyclopropyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(1,1,2,2,2-pentafluoroethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(2-methylthiazol-5-yl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(2-methylthiazol-5-yl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-6-(2-methylthiazol-5-yl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-5-yl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[2-(trifluoromethyl)thiazol-5-yl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-(difluoromethyl)-2-thienyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[4-(Difluoromethyl)-2-thienyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[2-(trifluoromethyl)thiazol-5-yl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one-7-D;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trideuteriomethoxymethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one-7-T;</claim-text><claim-text>1-[(5-Methylisoxazol-3-yl)methyl]-6-(4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Methylisoxazol-3-yl)methyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chloro-4-fluoro-phenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluorophenyl)-1-[(1-methylpyrazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-3-methyl-1-(oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>Ethyl 2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetate;</claim-text><claim-text>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetic acid;</claim-text><claim-text>Ethyl 2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetate;</claim-text><claim-text>2-[3-Methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetic acid;</claim-text><claim-text>1-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(pyrazin-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-[(1-methyl-1,2,4-triazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-[(1-methyltriazol-4-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-Pyrrolidin-1-ylethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Hydroxyazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Cyclopropylamino)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Methoxyazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Cyclobutylamino)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-[2-(trifluoromethyl)-4-pyridyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(2,6-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(3-chlorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(3,5-difluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-[3-(trifluoromethoxy)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(1-Piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(4-Fluoro-1-piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Methylpyrrolidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(4-Hydroxy-1-piperidyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-[3-(Trifluoromethyl)azetidin-1-yl]ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(2,3-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(3,5-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-(4-fluoro-2,3-dimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)ethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-[2-(2-hydroxyethylamino)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-[2-(3-hydroxypyrrolidin-1-ypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-[2-(3-methoxypyrrolidin-1-yl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-2-methyl-phenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,6-Dimethylphenyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(o-Tolyl)-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-Phenyl-1-(2-pyrrolidin-1-ylethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-ypethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,3-Dimethylphenyl)-1-[2-(3-fluoroazetidin-1-ypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Dimethylphenyl)-1-[2-(3-fluoroazetidin-1-ypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(4-fluoro-2,3-dimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-ypethyl]-6-[2-methyl-5-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(o-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-[2-(propylamino)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-Cyclobutyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(3-Methoxyazetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-(Oxetan-3-yl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(4-Methylpiperazin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>N-(3,3-Difluorocyclobutyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(3,3-Difluoropyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-(3,3-Difluoro-1-methyl-cyclobutyl)-2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-(3-Methyloxetan-3-yl)-2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-(3,3-Difluorocyclobutyl)-2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-(2-Oxo-2-pyrrolidin-1-yl-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)&#x2014;N-Cyclopropyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]propanamide;</claim-text><claim-text>(R/S)-1-[2-(Azetidin-1-yl)-1-methyl-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-Morpholino-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-Cyclopentyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-Oxo-2-(1-piperidypethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(2,6-Diazaspiro[3.3]heptan-6-yl)-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-pyridyl)acetamide;</claim-text><claim-text>N-(3,3-Difluoro-1-methyl-cyclobutyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[(6-Methoxy-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-[[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>1-[2-Oxo-2-(2-thienyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-Oxo-2-thiazol-2-yl-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Morpholin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Tetrahydropyran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Trifluoromethyl)phenyl]-1-[[4-(trifluoromethyl)phenyl]methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Fluoro-4-methoxy-phenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(4-Fluoro-3-methyl-phenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Fluorophenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R*)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(S*)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-[(2,2-Difluorocyclopropyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Fluorooxetan-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Pyrimidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(4-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(3-Pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(2-Methylpyrimidin-5-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Pyridazin-3-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Methoxy-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Fluoro-5-methyl-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(6-Methyl-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2H-Tetrazol-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[Difluoro(3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(6-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-Cyclopropyl-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-Oxobutyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(3-Methyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Methyl-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Thiadiazol-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(6-Oxo-1H-pyridin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Azetidin-2-ylmethyl)-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(pyrimidin-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(pyrimidin-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(2-methylpyrimidin-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(pyrazin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(4-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(2-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(6-Methoxypyridazin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Pyrazin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(2-Methylpyrimidin-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Pyrimidin-5-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Fluoropyrimidin-2-yl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Trifluoromethyl)phenyl]-1-[6-(trifluoromethyl)-3-pyridyl]methyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Trifluoromethyl)phenyl]-[[5-(trifluoromethyl)-3-pyridyl]methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Trifluoromethyl)phenyl]-[[4-(trifluoromethyl)-3-pyridyl]methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(pyrimidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-cyclobutyl-2-oxo-ethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Azetidin-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Azetidin-2-ylmethyl)-6-[2-fluoro-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Azetidin-2-ylmethyl)-6-phenyl-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Azetidin-2-ylmethyl)-6-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Azetidin-2-ylmethyl)-6-[4-fluoro-3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(Azetidin-2-ylmethyl)-6-(2,3-dichlorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chlorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chlorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethyl)phenyl]-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Methoxyphenyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(p-Tolyl)-1-(2-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-fluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethyl)phenyl]-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chlorophenyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(m-Tolyl)-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethoxy)phenyl]-1-(3-pyridylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethyl)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,3-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Chloro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Fluoro-3-pyridyl)methyl]-6-[3-(trifluoromethoxy)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Methyl-3-pyridyl)methyl]-6-(3,4,5-trifluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,3-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-[(5-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(4-Methyl-3-pyridyl)methyl]-6-(3,4,5-trifluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(4-Methyl-3-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[(4-methyl-3-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Methyl-2-pyridyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,3-Difluorophenyl)-1-[(3-methyl-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-2-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-(5-Chloro-4-methyl-2-thienyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>2-[6-(5-Chloro-4-methyl-2-thienyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[2-methyl-3-(trifluoromethyl)phenyl]-3H-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(m-Tolyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-(3,4-Difluorophenyl)-1-(2-hydroxybutyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(2-Hydroxybutyl)-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-(2,4-difluoro-3-methyl-phenyl)-1-(2-hydroxybutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(2-Hydroxybutyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(2-Hydroxy-3-methyl-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-[3-(trifluoromethoxy)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,3-Difluorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(2,3,4-trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chloro-2-fluoro-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Fluoro-3-pyridyl)methyl]-3-methyl-6-(m-tolyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Dichlorophenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Fluoro-3-methyl-phenyl)-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(3-pyridylmethyl)-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-3-methyl-1-(3-pyridylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chloro-4-fluoro-phenyl)-3-methyl-1-(3-pyridylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-6-(m-tolyl)-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Fluoro-3-methyl-phenyl)-3-methyl-1-(3-pyridylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(3-pyridylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chloro-2-fluoro-phenyl)-3-methyl-1-(3-pyridylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(3-pyridylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(3-pyridylmethyl)-6-(2,3,4-trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(3-pyridylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(3-pyridylmethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(5-Chloro-4-methyl-2-thienyl)-3-methyl-1-(3-pyridylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-6-(3,4-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-6-(2-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(5-Chloro-4-methyl-2-thienyl)-1-[(5-chloro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-3-methyl-6-(m-tolyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(5-Chloro-3-pyridyl)methyl]-6-(2,3-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chlorophenyl)-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(pyridazin-3-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-6-(m-tolyl)-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chloro-4-fluoro-phenyl)-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluoro-5-methyl-phenyl)-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-Fluoro-5-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Chloro-3-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3,4-Difluoro-5-(trifluoromethyl)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(2-oxobutyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Cyclopropylphenyl)-3-methyl-1-(2-oxobutyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-1-(2-hydroxy-4-methoxy-butyl)-3-methyl-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-[3-(Difluoromethyl)phenyl]-3-methyl-1-(oxetan-2-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-(4-Fluoro-3-methyl-phenyl)-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-6-(3-Chlorophenyl)-3-methyl-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-3-Methyl-6-[2-methyl-3-(trifluoromethyl)phenyl]-1-(oxetan-2-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>(R/S)-1-(2,4-Dihydroxybutyl)-3-methyl-6-[2-methyl-3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(m-tolyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chlorophenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[4-fluoro-3-(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(3,4,5-trifluorophenyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(3,5-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-(3,3-Difluoroazetidin-1-yl)-2-oxoethyl)-6-(4-fluoro-3-methylphenyl)-3-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[2-fluoro-3-(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(3,4-difluorophenyl)-3-methyl-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(3-fluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(4-Fuoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>2-[6-(3,4-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(3,4-difluorophenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>2-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>2-[6-(2,3-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>2-[6-[3-(Difluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>2-[6-(2-Fluoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>2-[6-(3,5-Difluorophenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N, N-dimethyl-acetamide;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-(3-pyridyl)imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-[3,4-Difluoro-5-(trifluoromethyl)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>2-[2-Oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-Methyl-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</claim-text><claim-text>2-[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</claim-text><claim-text>2-[6-(3,5-Dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</claim-text><claim-text>2-[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</claim-text><claim-text>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</claim-text><claim-text>2-[6-(2-Ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-methyl-acetamide;</claim-text><claim-text>N-(2-Methoxyethyl)-2-[2-oxo-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(2-Ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide;</claim-text><claim-text>N-(2-Methoxyethyl)-2-[6-(4-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-(2-Methoxyethyl)-2-[2-oxo-6-(3-pyridyl)-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(3,5-difluorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(3-ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(3-methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(4-methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(4-fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-cyclopropyl-acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(2,4-dimethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(2-fluoro-6-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>N-Cyclopropyl-2-[6-(2-ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>6-(3-Fluoro-4-methoxy-phenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxyphenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Chlorophenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxy-5-fluoro-phenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Methoxyphenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one; 6-(4-Fluoro-2-methoxy-phenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Ethoxyphenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chloro-4-fluoro-phenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(2,4-dimethoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(2-ethoxy-5-fluoro-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(4-fluoro-2-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(3-fluoro-4-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(3,5-difluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-[3-(dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(Cyclopropylmethyl)-6-(3,5-dimethylphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Methoxyphenyl)-1-(tetrahydrofuran-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>4-[[6-(4-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>3-[[6-(4-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>3-[[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>3-[[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>3-[[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(2-Fluoro-6-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(4-Chlorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(4-Fluoro-2-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(2-Ethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitnle;</claim-text><claim-text>2-[[6-(3-Methoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(3-Cyanophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(2,4-Dimethoxyphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(3,5-Dimethylphenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(2-Ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(4-Fluoro-2-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>2-[[6-(3-Fluoro-4-methoxy-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>6-(4-Fluoro-2-methyl-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,3-Dimethoxyphenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxy-5-fluoro-phenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Dimethylphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Dimethoxyphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxyphenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Fluorophenyl)methyl]-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-2-methoxy-phenyl)-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Dimethylamino)phenyl]-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-2-methoxy-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Chloro-4-fluoro-phenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxyphenyl)-1-[(2-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Chlorophenyl)methyl]-6-(3,5-difluorophenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-2-methoxy-phenyl)-1-[(3-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Methoxyphenyl)methyl]-6-(3-pyridyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3-Methoxyphenyl)methyl]-6-(4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-[(4-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3,5-Dimethoxyphenyl)methyl]-6-(2-fluoro-6-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[(3,5-Dimethoxyphenyl)methyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Chlorophenyl)-1-[(4-isopropylphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-tert-Butylphenyl)-1-[(3,4-dimethoxy-2-pyridyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-[1-[(3,5-Dimethylisoxazol-4-yl)methyl]-2-oxo-3H-imidazo[4,5-b]pyridin-6-yl]benzonitrile;</claim-text><claim-text>1-[(3,5-Dimethylisoxazol-4-yl)methyl]-6-(2-ethoxy-5-fluoro-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Methoxy-3-methyl-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,5-Dimethylphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxyphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Dimethoxyphenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Fluoro-4-methoxy-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-2-methoxy-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxy-5-fluoro-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(4-Fluoro-2-methyl-phenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one; and</claim-text><claim-text>6-(3,5-Difluorophenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text></claim-text><claim-text>and pharmaceutically acceptable salts, solvates, or N-oxides or N-oxides thereof.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. A compound selected from the group consisting of:<claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(5-chloro-4-methyl-2-thienyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(2-(3,3-Difluoroazetidin-1-yl)-2-oxoethyl)-6-(4-fluoro-3-methylphenyl)-3-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one; and</claim-text><claim-text>2-[6-(4-Fuoro-3-methyl-phenyl)-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text></claim-text><claim-text>and pharmaceutically acceptable salts, solvates, or N-oxides thereof.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. A compound selected from the group consisting of:<claim-text>1-(2-Oxo-2-(pyrrolidin-1-yl)ethyl)-6-(thiazol-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</claim-text><claim-text>1-(2-(3-hydroxy-3-methylazetidin-1-yl)-2-oxoethyl)-6-(5-methylpyridin-3-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</claim-text><claim-text>1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(6-fluoropyridin-3-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</claim-text><claim-text>1-(2-(2-Oxo-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)acetyl)azetidine-3-carbonitrile;</claim-text><claim-text>1-Benzyl-6-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</claim-text><claim-text>1-(2-(3-Methylazetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;</claim-text><claim-text>1-(2-(3-(Methoxymethypazetidin-1-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; and</claim-text><claim-text>6-(2-Fluoro-3-methylphenyl)-1-(2-oxo-2-(3-(trifluoromethypazetidin-1-ypethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; and</claim-text><claim-text>pharmaceutically acceptable salts, solvates, or N-oxides thereof.</claim-text></claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. A pharmaceutical composition comprising:<claim-text>(A) an effective amount of at least one compound selected from compounds of Formula (I) wherein:</claim-text></claim-text><claim-text><chemistry id="CHEM-US-00759" num="00759"><img id="EMI-C00759" he="26.50mm" wi="55.29mm" file="US20230000833A1-20230105-C00759.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein<claim-text>R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</claim-text><claim-text>R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; pyridinyl substituted with F, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>haloalkyl; thiazolyl; thiazolyl substituted with C<sub>1-6</sub>alkyl or C<sub>1-6</sub>haloalkyl; thienyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>3</sub>, and cyclopropyl;</claim-text><claim-text>R<sup>3 </sup>is H;</claim-text><claim-text>R<sup>4 </sup>is selected from the group consisting of:<claim-text>(a)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00760" num="00760"><img id="EMI-C00760" he="20.83mm" wi="21.17mm" file="US20230000833A1-20230105-C00760.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein ring A is a 4-6 membered heterocycle optionally containing an additional oxygen heteroatom selected from the group consisting of: azetidinyl; azetidinyl substituted with one or two members independently selected from the group consisting of: F, OH, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>haloalkyl, CH<sub>2</sub>OCH<sub>3</sub>, CN, and OCH<sub>3</sub>; pyrrolidinyl; pyrrolidinyl substituted two F members; morpholinyl; piperidinyl; piperazinyl substituted with C<sub>1-6</sub>alkyl; and (2,6-diazaspiro[3.3]heptan-6-yl);<claim-text><claim-text>(b)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00761" num="00761"><img id="EMI-C00761" he="20.57mm" wi="25.40mm" file="US20230000833A1-20230105-C00761.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>4b </sup>is selected from the group consisting of: H; C<sub>1-6</sub>alkyl; CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>; C<sub>3-6</sub>cycloalkyl; C<sub>3-6</sub>cycloalkyl substituted substituted with two or three members independently selected from the group consisting of F or CH<sub>3</sub>; oxetanyl; oxetanyl substituted with CH<sub>3</sub>; and pyridinyl;<claim-text><claim-text>(c)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00762" num="00762"><img id="EMI-C00762" he="10.67mm" wi="16.17mm" file="US20230000833A1-20230105-C00762.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF<sub>3</sub>; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1-6</sub>alkyl, and CF<sub>3</sub>;</claim-text><claim-text>(d)</claim-text><claim-text><chemistry id="CHEM-US-00763" num="00763"><img id="EMI-C00763" he="16.76mm" wi="19.22mm" file="US20230000833A1-20230105-C00763.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>4d </sup>is selected from the group consisting of: OH, C<sub>1-6</sub>alkyl, O&#x2014;C<sub>3-6</sub>cycloalkyl, thienyl, and thiazolyl; and<claim-text><claim-text>(e) C<sub>2-6</sub>alkyl substituted with one or two members independently selected from OH, OC<sub>1-6</sub>alkyl, or cyclopropyl; CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-6</sub>alkyl); CH<sub>2</sub>CH<sub>2</sub>NH(CH<sub>2</sub>CH<sub>2</sub>OH); CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>3-6</sub>cycloalkyl); and difluoro(3-pyridyl)methyl; and</claim-text></claim-text><claim-text>R<sup>1a </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>;</claim-text></claim-text><claim-text>and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides of compounds of Formula (I); and<claim-text>(B) at least one pharmaceutically acceptable excipient.</claim-text></claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. A pharmaceutical composition comprising an effective amount of at least one compound of <claim-ref idref="CLM-00025">claim 25</claim-ref> and at least one pharmaceutically acceptable excipient.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I):</claim-text><claim-text><chemistry id="CHEM-US-00764" num="00764"><img id="EMI-C00764" he="26.50mm" wi="55.29mm" file="US20230000833A1-20230105-C00764.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein<claim-text>R<sup>1 </sup>is H; CH<sub>2</sub>F; or CH<sub>3</sub>;</claim-text><claim-text>R<sup>2 </sup>is selected from the group consisting of: phenyl; phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CN, OC<sub>1-6</sub>haloalkyl, N(CH<sub>3</sub>)<sub>2</sub>, and cyclopropyl; pyridinyl; pyridinyl substituted with F, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>haloalkyl; thiazolyl; thiazolyl substituted with C<sub>1-6</sub>alkyl or C<sub>1-6</sub>haloalkyl; thienyl; and thienyl substituted with one or two members each independently selected from the group consisting of: halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>3</sub>, and cyclopropyl;</claim-text><claim-text>R<sup>3 </sup>is H;</claim-text><claim-text>R<sup>4 </sup>is selected from the group consisting of:<claim-text>(a)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00765" num="00765"><img id="EMI-C00765" he="20.83mm" wi="21.17mm" file="US20230000833A1-20230105-C00765.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein ring A is a 4-6 membered heterocycle optionally containing an additional oxygen heteroatom selected from the group consisting of: azetidinyl; azetidinyl substituted with one or two members independently selected from the group consisting of: F, OH, C<sub>1-4</sub>alkyl, C<sub>1</sub>-4haloalkyl, CH<sub>2</sub>OCH<sub>3</sub>, CN, and OCH<sub>3</sub>; pyrrolidinyl; pyrrolidinyl substituted two F members;<claim-text>morpholinyl; piperidinyl; piperazinyl substituted with C<sub>1-6</sub>alkyl; and (2,6-diazaspiro[3. 3]heptan-6-yl);</claim-text></claim-text><claim-text><chemistry id="CHEM-US-00766" num="00766"><img id="EMI-C00766" he="20.57mm" wi="25.40mm" file="US20230000833A1-20230105-C00766.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>(b) wherein Rob is selected from the group consisting of: H; C<sub>1-6</sub>alkyl;</claim-text><claim-text>CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>; C<sub>3-6</sub>cycloalkyl; C<sub>3-6</sub>cycloalkyl substituted substituted with two or three members independently selected from the group consisting of F or CH<sub>3</sub>; oxetanyl; oxetanyl substituted with CH<sub>3</sub>; and pyridinyl;<claim-text>(c)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00767" num="00767"><img id="EMI-C00767" he="10.67mm" wi="16.17mm" file="US20230000833A1-20230105-C00767.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>4c </sup>is selected from the group consisting of: cyclopropyl; cyclopropyl substituted with one or two F members; CH(OH)cyclopropyl; azetidinyl; CH<sub>2</sub>-azetidinyl; CH<sub>2</sub>-azetidinyl substituted with one or two members independently selected from: F, OH, OCH<sub>3</sub>, and CF<sub>3</sub>; oxetanyl; oxetanyl substituted with F or CH<sub>3</sub>; tetrahydrofuranyl; tetrahydropyranyl; CH<sub>2</sub>pyrrolidinyl; CH<sub>2</sub>pyrrolidinyl substituted with CH<sub>3</sub>, OH, or OCH<sub>3</sub>; CH<sub>2</sub>piperidinyl; CH<sub>2</sub>piperidinyl substituted with OH, or F; morpholinyl; pyrazolyl substituted with one or two CH<sub>3 </sub>members; triazolyl substituted with CH<sub>3</sub>; tetrazolyl; isoxazolyl substituted with one or two CH<sub>3 </sub>members; oxadiazolyl substituted with CH<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>; thiadiazolyl; pyridinyl; pyridinyl substituted with one or two members independently selected from the group consisting of: CI, F, CH<sub>3</sub>, OCH<sub>3</sub>, and CF3; (2-oxo-1H-pyridin-3-yl); 6-oxo-1H-pyridin-3-yl; pyrimidinyl; pyrimidinyl substituted with F or CH<sub>3</sub>; pyrazinyl; pyridazinyl; pyridazinyl substituted with OCH<sub>3</sub>; phenyl; phenyl substituted with one or two members independently selected from the group consisting of: halo, CN, OCH<sub>3</sub>, C<sub>1</sub>-6alkyl, and CF3;<claim-text><claim-text>(d)</claim-text></claim-text></claim-text><claim-text><chemistry id="CHEM-US-00768" num="00768"><img id="EMI-C00768" he="16.76mm" wi="19.22mm" file="US20230000833A1-20230105-C00768.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sup>4d </sup>is selected from the group consisting of: OH, C<sub>1-6</sub>alkyl, O&#x2014;C<sub>3-6</sub>cycloalkyl, thienyl, and thiazolyl; and<claim-text><claim-text>(e) C<sub>2-6</sub>alkyl substituted with one or two members independently selected from OH, OC<sub>1-6</sub>alkyl, or cyclopropyl; CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-6</sub>alkyl); CH<sub>2</sub>CH<sub>2</sub>NH(CH<sub>2</sub>CH<sub>2</sub>OH); CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>3-6</sub>cycloalkyl); and difluoro(3-pyridyl)methyl; and</claim-text></claim-text><claim-text>R<sup>1a </sup>and R<sup>1b </sup>are each independently H or CH<sub>3</sub>;</claim-text></claim-text><claim-text>and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides of compounds of Formula (I).</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The method of <claim-ref idref="CLM-00030">claim 30</claim-ref>, wherein the disorder, disease or condition mediated by the NR2B receptor is selected from the group consisting of: bipolar disorder, major depressive disorder, treatment-resistant depression, post-partum depression, seasonal affective disorder, Alzheimer's disease, Parkinson's disease, Huntington's chorea, multiple sclerosis, cognitive impairment, head injury, spinal cord injury, stroke, epilepsy, dyskinesias, amyotrophic lateral sclerosis, neurodegeneration associated with bacterial or chronic infections, pain, diabetic neuropathy, migraine, cerebral ischemia, schizophrenia, encephalitis, autism and autism spectrum disorders, memory and learning disorders, obsessive compulsive disorder, attention deficit hyperactivity disorder (ADHD) and addictive illnesses.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. The method of <claim-ref idref="CLM-00031">claim 31</claim-ref>, wherein the disorder, disease or condition is selected from the group consisting of treatment-resistant depression, major depressive disorder and bipolar disorder.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. A compound selected from the group consisting of:<claim-text>6-(5-(Difluoromethyl)-2-fluorophenyl)-3-methyl-1-(pyridazin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(5-(Difluoromethyl)-2-fluorophenyl)-3-methyl-1-(pyridin-3-ylmethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-(3-Chloropropyl)-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(fluorom ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-(2-fluoroethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-[3-(2-Fluoroethyl)azetidin-1-yl]-2-oxo-ethyl]-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>6-(6-Fluoro-2-pyridyl)-1-(2-oxobutyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl]-3H-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl]-3H-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3-<sup>18</sup>F-Fluoranylazetidin-1-yl)-2-oxo-ethyl]-6-(4-fluoro-3-methyl-phenyl)-3-methyl-imidazo[4,5-b]pyridin-2-one</claim-text><claim-text>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-3-methyl-1-(pyridazin-3-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-1-(pyridazin-3-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-(thiadiazol-4-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[(5-fluoro-3-pyridyl)methyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3,4-Difluorophenyl)-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[3-(trifluoromethyl)phenyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-6-(5-methyl-2-thienyl)-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-6-(5-methyl-2-thienyl)-1-(thiadiazol-4-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-(5-methyl-2-thienyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-(thiadiazol-4-ylmethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[5-(Difluoromethyl)-2-thienyl]-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(1-methylpyrazol-4-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(1-methyltriazol-4-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-(thiadiazol-4-ylmethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-Methyl-1-[(5-methylisoxazol-3-yl)methyl]-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-methylisoxazol-3-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-methylpyrazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(1-methyltriazol-4-yl)methyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-1-(thiadiazol-4-ylmethypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-(2-Fluoroethyl)-N-methyl-2-[3-methyl-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-6-[5-(trifluoromethyl)-2-thienyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-(m-tolyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-(m-tolypimidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(2-fluoroethoxy)-5-(trifluoromethyl)phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N,N-Dimethyl-2-[3-methyl-6-(m-tolyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethyl)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethyl)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(3,3-Difluoroazetidin-1-yl)-2-oxo-ethyl]-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-3-methyl-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>2-[6-[4-Chloro-3-(difluoromethoxy)phenyl]-3-methyl-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-[4-chloro-3-(difluoromethoxy)phenyl]-3-methyl-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4, 5-b]pyridin-2-one;</claim-text><claim-text>6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-3-methyl-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-6-(2,4-difluoro-3-methyl-phenyl)-3-(fluoromethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[3-(Fluoromethyl)-2-oxo-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>1-[2-(3-Fluoroazetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>3-(Fluoromethyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-(fluoromethyl)-2-oxo-imidazo[4,5-b]pyridin-1-yl]-N,N-dimethyl-acetamide;</claim-text><claim-text>6-(2,4-Difluoro-3-methyl-phenyl)-1-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethyl]-3-(fluoromethyl)imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienypethyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-(3,3-Dimethyl-2-oxo-butyl)-6-(4-methoxy-3-methyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>1-Isobutyl-6-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxyphenyl)-1-[(3-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>6-(2-Ethoxyphenyl)-1-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>N-Cyclopropyl-2-[6-(2-ethoxy-5-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]acetamide;</claim-text><claim-text>2-[[6-(4-Methoxy-3-methyl-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile;</claim-text><claim-text>1-(3,3-Dimethyl-2-oxo-butyl)-6-(3-fluoro-4-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-one;</claim-text><claim-text>2-[6-(3,5-Difluorophenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide;</claim-text><claim-text>1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one; and</claim-text><claim-text>2-[6-(3-Chloro-4-fluoro-phenyl)-2-oxo-3H-imidazo[4,5-b]pyridin-1-yl]-N-(2-methoxyethyl)acetamide;</claim-text></claim-text><claim-text>and pharmaceutically acceptable salts, solvates, or N-oxides thereof.</claim-text></claim></claims></us-patent-application>